Clustering O 0 8.278385939775035e-05
of O 0 7.598897582283826e-07
missense O 0 0.00011956219532294199
mutations O 0 5.497219899552874e-05
in O 0 7.211872343759751e-08
the O 0 1.427072902515647e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999982118606567
telangiectasia I-Disease 1 1.0
gene O 0 4.868746327701956e-05
in O 0 4.6160209876688896e-08
a O 0 1.2811047156446875e-07
sporadic B-Disease 0 0.0010512437438592315
T I-Disease 1 0.9541327357292175
- I-Disease 0 0.017968548461794853
cell I-Disease 0 0.0005068184691481292
leukaemia I-Disease 0 0.008581877686083317
. O 0 6.863998009976058e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 1 0.952970027923584
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.6434336558290852e-08
is O 0 1.4502662404325406e-09
a O 0 7.179739913709682e-09
recessive B-Disease 0 4.1293755202787e-05
multi I-Disease 0 0.0001770433591445908
- I-Disease 1 0.5059009194374084
system I-Disease 0 0.00023779711045790464
disorder I-Disease 0 0.4088567793369293
caused O 0 1.6337909869434952e-07
by O 0 2.764036999280961e-09
mutations O 0 1.8025957615463994e-07
in O 0 1.651199843522022e-09
the O 0 5.917664580579185e-09
ATM O 0 2.0958041204721667e-06
gene O 0 5.048146931585507e-07
at O 0 2.161741292638908e-07
11q22 O 0 2.6496211376070278e-06
- O 0 9.332068657386117e-06
q23 O 0 3.630725586845074e-06
( O 0 1.2338111332610424e-07
ref O 0 1.1554418051673565e-05
. O 0 2.3862339659785903e-08
3 O 0 1.2952136785315815e-07
) O 0 5.451798301692179e-08
. O 0 1.285054622712778e-07

The O 0 2.131406290573068e-06
risk O 0 7.583226306451252e-06
of O 0 4.453669433246432e-08
cancer B-Disease 0 5.287916064844467e-05
, O 0 8.333315371089611e-09
especially O 0 5.245103196216405e-08
lymphoid B-Disease 0 6.67745416649268e-06
neoplasias I-Disease 0 1.0468744221725501e-05
, O 0 7.318080363916124e-09
is O 0 3.6502829647844237e-09
substantially O 0 2.302263624187617e-07
elevated O 0 1.2086801461919094e-06
in O 0 3.416597138539146e-08
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 3.723233749042265e-05
and O 0 3.138494619747689e-08
has O 0 5.4266092064381155e-08
long O 0 3.138153772397345e-07
been O 0 1.6459000562463189e-07
associated O 0 1.4558814598331082e-07
with O 0 3.560161303539644e-07
chromosomal O 1 1.0
instability O 1 0.999998927116394
. O 0 2.0519541976682376e-06

By O 0 4.906002686766442e-06
analysing O 0 7.079936767695472e-05
tumour B-Disease 1 0.9999784231185913
DNA O 0 2.2439473923441255e-06
from O 0 1.3555637679019128e-07
patients O 0 9.549320338919642e-07
with O 0 2.9165292403376952e-08
sporadic B-Disease 0 0.0002375222247792408
T I-Disease 1 0.5440165996551514
- I-Disease 0 0.000362560705980286
cell I-Disease 0 0.00018116396677214652
prolymphocytic I-Disease 0 0.0005580529104918242
leukaemia I-Disease 0 0.3185034394264221
( O 0 5.600479653367074e-07
T B-Disease 0 0.00016795915144030005
- I-Disease 0 1.5829138646950014e-05
PLL I-Disease 0 1.6478568795719184e-05
) O 0 1.1873116712024512e-08
, O 0 1.2609291388798738e-09
a O 0 3.030806494663807e-09
rare O 0 2.7874230923430332e-08
clonal B-Disease 0 2.7547705485631013e-06
malignancy I-Disease 0 5.740171036450192e-05
with O 0 4.144707688169547e-09
similarities O 0 4.360319749707742e-08
to O 0 5.670310887495589e-09
a O 0 6.400281193919e-08
mature B-Disease 0 3.868471196710743e-07
T I-Disease 0 1.4614914107369259e-05
- I-Disease 0 4.918567356071435e-06
cell I-Disease 0 8.385427463508677e-06
leukaemia I-Disease 0 8.14542145235464e-05
seen O 0 6.805959174016607e-07
in O 0 2.582438440867918e-08
A B-Disease 1 0.9999936819076538
- I-Disease 1 0.9999929666519165
T I-Disease 1 1.0
, O 0 1.2509119962089699e-08
we O 0 4.341644821437285e-09
demonstrate O 0 6.781375461173411e-09
a O 0 2.4386308528079326e-09
high O 0 9.107671949948326e-09
frequency O 0 4.0194283457140045e-08
of O 0 5.960699933638125e-09
ATM O 0 8.853950930642895e-06
mutations O 0 6.933566055522533e-06
in O 0 2.0709003933916392e-07
T B-Disease 0 0.0003065959899686277
- I-Disease 0 3.245094194426201e-05
PLL I-Disease 0 0.0001527246495243162
. O 0 1.14223792024859e-06

In O 0 1.0665528407116653e-06
marked O 0 4.2060628402396105e-07
contrast O 0 6.858541468091062e-08
to O 0 4.8920871797975e-09
the O 0 6.682151276748982e-09
ATM O 0 3.6343840292829555e-06
mutation O 0 9.428530916011368e-07
pattern O 0 4.989700528312824e-07
in O 0 4.908473627551757e-08
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
, O 0 6.349599068755651e-09
the O 0 1.2904004531577584e-09
most O 0 1.0718321785674334e-09
frequent O 0 3.274422866184068e-08
nucleotide O 0 1.2798676607417292e-07
changes O 0 1.2942340532617891e-08
in O 0 4.671090181318505e-09
this O 0 1.0838963504511412e-08
leukaemia B-Disease 0 0.00020620273426175117
were O 0 3.6854467566627136e-07
missense O 0 3.847899643005803e-05
mutations O 0 3.927103171008639e-05
. O 0 8.340567774212104e-07

These O 0 2.841113200702239e-06
clustered O 0 8.984653504739981e-06
in O 0 3.135951232025036e-08
the O 0 1.031534502260456e-08
region O 0 1.300765006817528e-08
corresponding O 0 9.175707305075775e-09
to O 0 2.207696025990913e-09
the O 0 1.6534628111131155e-09
kinase O 0 2.881105558572017e-07
domain O 0 3.1253165388989146e-08
, O 0 2.1190020849104485e-09
which O 0 1.3077896543478573e-09
is O 0 6.23926632581373e-10
highly O 0 2.7879429875810047e-09
conserved O 0 9.776455200949385e-09
in O 0 1.3517478247848658e-09
ATM O 0 8.259371497842949e-07
- O 0 4.1017239027496544e-07
related O 0 3.3502267626772664e-08
proteins O 0 1.4000708148387275e-08
in O 0 3.853827923450126e-09
mouse O 0 6.61570140891854e-07
, O 0 7.85072007403187e-09
yeast O 0 2.69418194420723e-07
and O 0 4.537345432709117e-08
Drosophila O 0 2.06677827918611e-06
. O 0 3.155656145281682e-07

The O 0 1.9167787286278326e-06
resulting O 0 2.0475793007790344e-06
amino O 0 1.13091755338246e-06
- O 0 2.5809322323766537e-06
acid O 0 2.1115820914019423e-07
substitutions O 0 1.0057711108402145e-07
are O 0 8.243835836196922e-09
predicted O 0 4.4850228420045823e-08
to O 0 5.2417403750837366e-09
interfere O 0 2.460108703417063e-07
with O 0 3.4456540731753194e-08
ATP O 0 1.489903638685064e-06
binding O 0 6.511141350529215e-07
or O 0 1.766045585327447e-07
substrate O 0 4.77275762023055e-06
recognition O 0 1.380089884150948e-06
. O 0 5.667242817253282e-07

Two O 0 2.0829086224694038e-06
of O 0 8.982016197478515e-08
seventeen O 0 1.9999984033347573e-06
mutated O 0 1.3175694220990408e-05
T B-Disease 0 9.173415310215205e-05
- I-Disease 0 6.008042419125559e-06
PLL I-Disease 0 1.9112763766315766e-05
samples O 0 1.0984858818119392e-06
had O 0 6.735313604622206e-07
a O 0 7.827771497659342e-08
previously O 0 5.278752723825164e-06
reported O 0 7.578541499242419e-06
A B-Disease 1 0.9995025396347046
- I-Disease 1 0.9993515610694885
T I-Disease 1 0.9999996423721313
allele O 0 2.949759436887689e-05
. O 0 5.047833724347583e-07

In O 0 9.520376806904096e-07
contrast O 0 1.2295442957110936e-06
, O 0 6.676510366787625e-08
no O 0 1.0347173429181566e-07
mutations O 0 1.5219981150949025e-06
were O 0 2.3398217763315188e-07
detected O 0 2.016663955828335e-07
in O 0 1.1138150401990288e-09
the O 0 1.40178280094716e-09
p53 O 0 3.064628018023541e-08
gene O 0 4.097938344216345e-08
, O 0 1.4564840444819538e-09
suggesting O 0 1.822334461110131e-08
that O 0 1.3786084496203443e-09
this O 0 4.548182719332772e-09
tumour B-Disease 1 0.9999959468841553
suppressor O 0 8.724650228941755e-07
is O 0 9.064553552207144e-09
not O 0 1.1335069771689632e-08
frequently O 0 1.9749197122109763e-07
altered O 0 2.480716432273766e-07
in O 0 5.489442678197065e-09
this O 0 2.058730252940677e-08
leukaemia B-Disease 0 0.00027738860808312893
. O 0 2.413688093838573e-07

Occasional O 0 0.0002688088861759752
missense O 0 0.000686070357915014
mutations O 0 5.47761628695298e-05
in O 0 1.0911693237858344e-07
ATM O 0 1.0782160643429961e-05
were O 0 3.543016191542847e-06
also O 0 7.480118568992111e-08
found O 0 5.922296963944973e-08
in O 0 2.0600149142069313e-08
tumour B-Disease 1 0.9999926090240479
DNA O 0 3.2323643495146825e-07
from O 0 1.9747437463024653e-08
patients O 0 1.4313975782442867e-07
with O 0 1.4281122950876579e-08
B B-Disease 0 0.00019596991478465497
- I-Disease 0 1.534034890937619e-05
cell I-Disease 0 2.3362383217317984e-05
non I-Disease 0 2.871584911190439e-05
- I-Disease 0 0.01624908298254013
Hodgkins I-Disease 1 0.9999887943267822
lymphomas I-Disease 0 0.27694380283355713
( O 0 5.555211828323081e-07
B B-Disease 0 6.988330278545618e-05
- I-Disease 0 3.260602170485072e-06
NHL I-Disease 0 6.689996325803804e-07
) O 0 5.551618720289753e-09
and O 0 1.0492026802921828e-08
a O 0 8.552834884767435e-08
B B-Disease 0 0.0009132630657404661
- I-Disease 0 6.076381851016777e-06
NHL I-Disease 0 3.4562262953841127e-06
cell O 0 3.361295057402458e-06
line O 0 1.3980893527332228e-05
. O 0 4.1455959376435203e-07

The O 0 7.764624569972511e-07
evidence O 0 6.788871331764312e-08
of O 0 1.8369731291656421e-09
a O 0 8.831668729669673e-09
significant O 0 1.0776092018716099e-08
proportion O 0 5.0117428429530264e-08
of O 0 4.522819008201395e-09
loss O 0 2.665390184120042e-07
- O 0 5.761266947956756e-07
of O 0 1.2956517636553144e-08
- O 0 6.638037575612543e-06
function O 0 4.179401003057137e-07
mutations O 0 1.1631236702669412e-06
and O 0 1.4387751434696838e-08
a O 0 1.7021148934759367e-08
complete O 0 8.231396009250602e-08
absence O 0 5.332245933686863e-08
of O 0 1.4186610775013264e-09
the O 0 3.97338650870438e-09
normal O 0 2.1396306948417987e-08
copy O 0 1.4542252735338934e-08
of O 0 6.927558526825806e-10
ATM O 0 1.932234425794377e-07
in O 0 1.9243824311843127e-09
the O 0 1.7643234651032458e-09
majority O 0 1.0182731102759135e-08
of O 0 1.1364944541014665e-08
mutated O 0 7.35797657398507e-05
tumours B-Disease 1 0.9999984502792358
establishes O 0 9.067891824088292e-07
somatic O 0 1.9028509541385574e-06
inactivation O 0 1.0178923730563838e-06
of O 0 3.849684127033015e-09
this O 0 3.310821172775036e-09
gene O 0 6.531895024863843e-08
in O 0 3.210230969941108e-09
the O 0 3.302042195230115e-09
pathogenesis O 0 6.684971509685056e-08
of O 0 4.427073818646932e-09
sporadic B-Disease 0 2.495442640793044e-05
T I-Disease 0 0.0078011564910411835
- I-Disease 0 1.1915610230062157e-05
PLL I-Disease 0 9.907446838042233e-06
and O 0 4.063404190901565e-08
suggests O 0 4.4851766745068744e-08
that O 0 3.6255671798102185e-09
ATM O 0 6.937096941328491e-07
acts O 0 9.296346803466804e-08
as O 0 2.4757691008403526e-08
a O 0 5.276198749015748e-07
tumour B-Disease 1 0.9999988079071045
suppressor O 0 5.5986700317589566e-05
. O 0 1.0985362450810499e-06

As O 0 1.5354252127508516e-06
constitutional O 0 2.41809573253704e-07
DNA O 0 7.05164438841166e-07
was O 0 2.4274208954011556e-07
not O 0 6.570578303666252e-09
available O 0 7.694145764958193e-09
, O 0 3.416282590151809e-09
a O 0 1.8342536378668228e-08
putative O 0 8.986427019408438e-06
hereditary O 0 0.03286013752222061
predisposition O 0 9.416654211236164e-05
to O 0 5.131596481078304e-07
T B-Disease 0 0.15539789199829102
- I-Disease 0 1.79701983142877e-05
PLL I-Disease 0 7.403862127830507e-06
will O 0 1.5998553593021825e-08
require O 0 1.7578280164798343e-08
further O 0 9.031608350085207e-09
investigation O 0 4.974457823436751e-08
. O 0 1.4295703287814376e-08
. O 0 1.0135454431292601e-07

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
protein O 0 0.0002168043574783951
kinase O 0 7.313303649425507e-05
is O 0 1.307921735360651e-07
involved O 0 2.6282942044986157e-08
in O 0 1.835015583928623e-09
the O 0 8.651037108897697e-10
modulation O 0 1.3023861100691647e-08
of O 0 9.740137585367847e-10
the O 0 1.1482210737767673e-08
Ca2 O 0 9.246977583643456e-07
+ O 0 1.7522849020679132e-06
homeostasis O 0 8.175127732101828e-06
in O 0 5.034861771946453e-08
skeletal O 0 4.906026879325509e-05
muscle O 0 3.739826934179291e-05
cells O 0 2.9846733013982885e-06
. O 0 3.1816017553865095e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9998492002487183
DM B-Disease 1 1.0
) O 0 1.4188925661073881e-06
, O 0 6.111488648485874e-09
the O 0 2.113423658300917e-09
most O 0 4.752773730132276e-09
prevalent O 0 2.0371840037114453e-06
muscular B-Disease 0 0.030598990619182587
disorder I-Disease 0 0.059433337301015854
in O 0 1.4248147550688373e-08
adults O 0 5.195035100769019e-06
, O 0 1.3206518545416657e-08
is O 0 9.972606740404899e-09
caused O 0 1.5706110900737258e-07
by O 0 1.159918205928534e-08
( O 0 3.137734339020426e-08
CTG O 0 1.4763536455575377e-06
) O 0 1.4067977005538523e-08
n O 0 5.411001779975777e-07
- O 0 2.707779458432924e-06
repeat O 0 6.447772875617375e-07
expansion O 0 2.229574924683675e-08
in O 0 2.512909436092059e-09
a O 0 2.8046420741389966e-09
gene O 0 3.249517632752941e-08
encoding O 0 3.266837111937093e-08
a O 0 2.611543870045807e-08
protein O 0 2.856962453279266e-07
kinase O 0 1.640991285967175e-05
( O 0 6.76911383834522e-07
DM B-Disease 1 0.9999988079071045
protein O 0 2.071340304610203e-06
kinase O 0 8.855150554154534e-06
; O 0 1.09727182007191e-07
DMPK O 0 5.600065378530417e-06
) O 0 4.696353972377665e-09
and O 0 1.3996108716440858e-09
involves O 0 8.234972703746735e-09
changes O 0 1.1670728383705864e-08
in O 0 2.7504791777488435e-09
cytoarchitecture O 0 9.461724062020949e-07
and O 0 8.042893995252598e-08
ion O 0 4.616149453795515e-06
homeostasis O 0 8.568998600821942e-05
. O 0 4.1365800029780075e-07

To O 0 4.125493830997584e-07
obtain O 0 5.642446012643632e-07
clues O 0 4.898420229437761e-07
to O 0 2.6838259614692106e-08
the O 0 2.561178469306924e-08
normal O 0 2.3290242268103611e-07
biological O 0 3.2098719771056494e-07
role O 0 3.5387266450470634e-08
of O 0 2.8657796136144498e-09
DMPK O 0 7.390490281977691e-07
in O 0 3.920913371757706e-09
cellular O 0 1.7515669981094106e-07
ion O 0 3.705839048961934e-07
homeostasis O 0 3.6819583328906447e-06
, O 0 9.469612649581904e-09
we O 0 1.3592980074861316e-08
have O 0 4.590407609583735e-09
compared O 0 5.990504092778792e-09
the O 0 6.171192445947327e-09
resting O 0 3.0155595709402405e-07
[ O 0 3.883300436768877e-08
Ca2 O 0 1.6011946968319535e-07
+ O 0 1.7936272911356355e-07
] O 0 1.7584994793651276e-07
i O 0 2.231196276625269e-07
, O 0 1.5485306370521812e-09
the O 0 1.0832943431182684e-09
amplitude O 0 1.4858064112388547e-08
and O 0 5.75276537517766e-09
shape O 0 1.1532213051168583e-07
of O 0 3.0254234673066094e-09
depolarization O 0 2.655462481016002e-07
- O 0 5.154170594323659e-06
induced O 0 4.09473841500585e-06
Ca2 O 0 1.1542317679413827e-06
+ O 0 9.57375846155628e-07
transients O 0 1.714014729259361e-06
, O 0 1.0766477487322845e-08
and O 0 3.6803933234352826e-09
the O 0 1.0894671831351843e-09
content O 0 6.776617489379078e-09
of O 0 1.1279185363477495e-09
ATP O 0 8.581087485026728e-08
- O 0 3.2621244372421643e-07
driven O 0 2.234390450439605e-07
ion O 0 2.3392304626668192e-07
pumps O 0 4.419854064963147e-07
in O 0 7.957181580309225e-09
cultured O 0 2.701244170566497e-07
skeletal O 0 1.459181476093363e-06
muscle O 0 6.489759698524722e-07
cells O 0 3.726194464093169e-08
of O 0 3.4322187314472785e-09
wild O 0 8.947083784960341e-08
- O 0 6.164472665659559e-07
type O 0 5.1255638027214445e-06
and O 0 1.2535539894997783e-07
DMPK O 0 1.4593802006857004e-05
[ O 0 5.884278948542487e-07
- O 0 3.2732732506701723e-06
/ O 0 1.6966465409495868e-05
- O 0 2.091548958560452e-05
] O 0 1.5706156091255252e-06
knockout O 0 0.0005162208108231425
mice O 0 0.00016605033306404948
. O 0 6.036190143277054e-07

In O 0 2.625994966365397e-06
vitro O 0 8.769754640525207e-05
- O 0 4.1752013203222305e-05
differentiated O 0 1.0789699445012957e-05
DMPK O 0 2.4899749405449256e-05
[ O 0 1.3675282843905734e-06
- O 0 3.7738557239208603e-06
/ O 0 1.9853747289744206e-05
- O 0 1.7552103599882685e-05
] O 0 1.0245246357953874e-06
myotubes O 0 1.6210084368140087e-06
exhibit O 0 1.026719971264356e-07
a O 0 2.2426002388442612e-08
higher O 0 1.2762743040184432e-07
resting O 0 6.967104582145112e-07
[ O 0 8.013554975150328e-08
Ca2 O 0 1.5816921461464517e-07
+ O 0 2.753969852165028e-07
] O 0 1.1817901679478382e-07
i O 0 1.1680999989494012e-07
than O 0 6.664687912660838e-09
do O 0 3.717477170539496e-08
wild O 0 2.4670015363881248e-08
- O 0 4.758463774123811e-07
type O 0 8.997412805911154e-06
myotubes O 0 3.6965914205211448e-06
because O 0 9.77632552690011e-09
of O 0 1.1411248612702707e-09
an O 0 2.2980719549536843e-09
altered O 0 1.8072259422297066e-07
open O 0 4.552811105895671e-08
probability O 0 1.7836377708135842e-08
of O 0 3.5671121612068646e-09
voltage O 0 4.670986527344212e-06
- O 0 5.843544840899995e-06
dependent O 0 8.311807846439478e-07
l O 0 1.0798723906191299e-06
- O 0 1.6346075426554307e-07
type O 0 3.889386448463483e-07
Ca2 O 0 5.32403987563157e-07
+ O 0 3.6447127627070586e-07
and O 0 6.135609709190248e-08
Na O 0 7.428347089444287e-06
+ O 0 2.798664354486391e-06
channels O 0 3.696326757562929e-06
. O 0 8.040698276090552e-07

The O 0 1.4706678257425665e-06
mutant O 0 9.48835804592818e-06
myotubes O 0 4.39104678662261e-06
exhibit O 0 1.8245573585318198e-07
smaller O 0 9.486465302188662e-08
and O 0 1.2534747462211726e-08
slower O 0 6.213809911059798e-07
Ca2 O 0 1.0263230478813057e-06
+ O 0 3.511550517032447e-07
responses O 0 1.8417107128243515e-07
upon O 0 2.1105163838797125e-08
triggering O 0 1.375514386836585e-07
by O 0 9.98459714907085e-09
acetylcholine O 0 3.216402149064379e-07
or O 0 7.685686398417602e-08
high O 0 1.8554970893092104e-07
external O 0 8.776910362939816e-06
K O 0 1.4763627405045554e-05
+ O 0 3.1896026939648436e-06
. O 0 4.6511161144735524e-07

In O 0 7.981123530953482e-07
addition O 0 2.043877032065211e-07
, O 0 2.221204553620737e-08
we O 0 6.1975677922987416e-09
observed O 0 5.3676005862257625e-09
that O 0 2.8390001460820713e-10
these O 0 2.9833742143381414e-09
Ca2 O 0 2.177601317043809e-07
+ O 0 1.1132007102787611e-06
transients O 0 8.584804163547233e-06
partially O 0 9.999416761274915e-06
result O 0 3.053763109051033e-08
from O 0 1.7106934757649128e-09
an O 0 6.963246645952381e-10
influx O 0 4.1671559536382574e-09
of O 0 1.019879958263914e-09
extracellular O 0 5.1050079719061614e-08
Ca2 O 0 2.493379724910483e-07
+ O 0 1.317130511324649e-07
through O 0 1.142310068757979e-08
the O 0 1.2600210652635724e-08
l O 0 8.95997402494686e-07
- O 0 2.0568489844663418e-07
type O 0 5.850057505085715e-07
Ca2 O 0 2.1339710656320676e-06
+ O 0 1.4254419511416927e-06
channel O 0 4.881305358139798e-06
. O 0 5.401550993155979e-07

Neither O 0 3.5436252801446244e-05
the O 0 9.089054486821624e-08
content O 0 1.429804115105071e-07
nor O 0 7.039960792099009e-08
the O 0 3.7915479644823336e-09
activity O 0 1.8720051286891248e-08
of O 0 3.558352945631782e-09
Na O 0 1.3175493904782343e-06
+ O 0 8.016709216462914e-07
/ O 0 1.2543246157292742e-06
K O 0 2.609339162518154e-06
+ O 0 1.0637593277351698e-06
ATPase O 0 7.942543561512139e-06
and O 0 2.1649680093105417e-07
sarcoplasmic O 0 2.6528943635639735e-05
reticulum O 0 7.424755949614337e-06
Ca2 O 0 5.685426913260017e-06
+ O 0 4.478535629459657e-06
- O 0 1.9348560726939468e-06
ATPase O 0 8.665726454637479e-06
are O 0 5.9147335917941746e-08
affected O 0 1.3309977475728374e-07
by O 0 2.14566266976135e-08
DMPK O 0 1.2862153198511805e-05
absence O 0 1.0718335943238344e-06
. O 0 3.4180186503363075e-07

In O 0 9.100561442210164e-07
conclusion O 0 2.7896498977497686e-07
, O 0 1.0899249502926978e-08
our O 0 1.6847891970428464e-08
data O 0 4.961646737910996e-08
suggest O 0 4.114134455335261e-08
that O 0 4.267084463549509e-09
DMPK O 0 1.3893259165342897e-06
is O 0 1.8016697023170991e-09
involved O 0 3.0446654086802027e-09
in O 0 9.013070290109226e-10
modulating O 0 9.998836958402535e-08
the O 0 1.9230321779417636e-09
initial O 0 1.1987848935746115e-08
events O 0 8.370751203301552e-09
of O 0 2.5461270869442387e-09
excitation O 0 1.0591331829346018e-06
- O 0 9.664130629971623e-05
contraction O 0 2.026167931035161e-05
coupling O 0 4.647755758924177e-06
in O 0 5.920783507917804e-08
skeletal O 0 4.064958557137288e-05
muscle O 0 6.820866019552341e-06
. O 0 4.062699332507691e-08
. O 0 1.1358783069681522e-07

Constitutional O 0 0.00010450927948113531
RB1 O 0 0.0021355757489800453
- O 0 3.901838499587029e-05
gene O 0 1.1331694622640498e-05
mutations O 0 9.380231858813204e-06
in O 0 2.0362090680237088e-08
patients O 0 1.3244606407170068e-06
with O 0 3.742605159118284e-08
isolated O 0 1.455105211789487e-05
unilateral B-Disease 0 2.6032195819425397e-05
retinoblastoma I-Disease 0 0.0003684961993712932
. O 0 1.0590100600893493e-06

In O 0 1.1827728485513944e-06
most O 0 2.6040936518256785e-07
patients O 0 3.1449596917809686e-06
with O 0 2.7353298293064654e-08
isolated O 0 6.222726824489655e-06
unilateral B-Disease 0 1.130061355070211e-05
retinoblastoma I-Disease 0 6.005892646498978e-05
, O 0 1.0165230435177364e-07
tumor B-Disease 0 1.8660571186046582e-06
development O 0 4.194140146296377e-09
is O 0 1.5422995103264725e-09
initiated O 0 6.294456955657779e-09
by O 0 1.5481674831008263e-09
somatic O 0 1.5721411728009116e-07
inactivation O 0 4.793283210346999e-07
of O 0 2.4336404003122425e-09
both O 0 1.1387337295332145e-08
alleles O 0 1.2538075111478975e-07
of O 0 6.961205389899305e-09
the O 0 1.3315258229340543e-07
RB1 O 0 8.346666436409578e-05
gene O 0 5.64675929126679e-06
. O 0 7.159871415751695e-07

However O 0 3.012652996403631e-06
, O 0 1.4955302773955736e-08
some O 0 1.3508509866255736e-09
of O 0 5.583931650399165e-10
these O 0 9.463870576098543e-09
patients O 0 1.397414166603994e-07
can O 0 2.7778487066143498e-08
transmit O 0 0.00014721402840223163
retinoblastoma B-Disease 0 0.0003589622210711241
predisposition O 0 0.00010610115714371204
to O 0 9.28571424196889e-08
their O 0 2.4444168502668617e-06
offspring O 0 7.745086804789025e-06
. O 0 2.622205954594392e-07

To O 0 1.0294431831425754e-06
determine O 0 4.5672231863136403e-07
the O 0 1.1556627654840668e-08
frequency O 0 3.1515841669715883e-07
and O 0 2.9479773289153854e-08
nature O 0 1.6432018412615434e-08
of O 0 3.069177356707087e-09
constitutional O 0 2.202579025833984e-07
RB1 O 0 2.503740142856259e-05
- O 0 1.8349923038840643e-06
gene O 0 1.1661092003123485e-06
mutations O 0 1.61689229116746e-06
in O 0 1.6224477761284106e-08
patients O 0 3.724908594904264e-07
with O 0 1.0563512731209812e-08
isolated O 0 1.4400676491277409e-06
unilateral B-Disease 0 1.1009001354977954e-06
retinoblastoma I-Disease 0 5.559501460083993e-06
, O 0 1.401144622548145e-08
we O 0 1.5132744835000267e-08
analyzed O 0 8.349929458972838e-08
DNA O 0 7.190541140289497e-08
from O 0 6.464764723546068e-09
peripheral O 0 4.654808890336426e-06
blood O 0 3.841585112240864e-06
and O 0 2.5739899101040464e-08
from O 0 6.804881991229195e-08
tumor B-Disease 0 2.223882074758876e-05
tissue O 0 8.136805263347924e-06
. O 0 3.408419502193283e-07

The O 0 2.0458383005461656e-06
analysis O 0 7.053366175568954e-07
of O 0 2.070296289957696e-07
tumors B-Disease 1 1.0
from O 0 7.105142429963962e-08
54 O 0 2.94172650683322e-07
( O 0 1.505400959445069e-08
71 O 0 9.12504560801608e-08
% O 0 6.927297402370414e-09
) O 0 7.032572857390562e-10
of O 0 8.850618016253975e-10
76 O 0 9.304080350602817e-08
informative O 0 9.507710387879342e-07
patients O 0 1.907192199723795e-05
showed O 0 5.073468855698593e-06
loss O 0 1.1246434894474078e-07
of O 0 3.1666882449599143e-09
constitutional O 0 5.065618893240753e-07
heterozygosity O 0 0.00012071442324668169
( O 0 1.8688103864406003e-06
LOH O 1 0.9999988079071045
) O 0 2.9094960041220475e-07
at O 0 1.0090691375808092e-06
intragenic O 0 5.277256423141807e-05
loci O 0 7.564699899376137e-06
. O 0 6.294009153862135e-07

Three O 0 2.8329502583801514e-06
of O 0 9.170673109792915e-08
13 O 0 1.2223388239362976e-06
uninformative O 0 0.001549289096146822
patients O 0 0.00039667499368079007
had O 0 1.1674111419779365e-06
constitutional O 0 4.192582707673864e-07
deletions O 0 2.3322489141719416e-05
. O 0 1.23326935863588e-06

For O 0 1.694427169240953e-06
39 O 0 7.227264177345205e-06
randomly O 0 5.508877620741259e-06
selected O 0 7.81534345151158e-06
tumors B-Disease 1 1.0
, O 0 1.5155960397805757e-07
SSCP O 0 1.241228892467916e-05
, O 0 5.8940795355511e-08
hetero O 0 5.820291335112415e-06
- O 0 6.88392617576028e-07
duplex O 0 1.9852593595715007e-06
analysis O 0 4.8285883735843527e-08
, O 0 2.1457804422198024e-09
sequencing O 0 2.5010569615346867e-08
, O 0 4.7857486862312726e-09
and O 0 8.191641143184825e-09
Southern O 0 3.7645630612814784e-08
blot O 0 8.484894351568073e-06
analysis O 0 9.247430909908871e-08
were O 0 2.1407537076356675e-07
used O 0 5.798307967097571e-08
to O 0 3.30356222377759e-08
identify O 0 2.956402749987319e-05
mutations O 0 1.2921178495162167e-05
. O 0 4.618090940766706e-07

Mutations O 0 0.0014720449689775705
were O 0 7.880028533691075e-06
detected O 0 4.052069016324822e-06
in O 0 4.192622427012793e-08
21 O 0 1.3867322934402182e-07
( O 0 1.90589659609941e-08
91 O 0 8.78414638805225e-08
% O 0 3.189335728848164e-08
) O 0 6.904675053931442e-09
of O 0 1.822518669314377e-08
23 O 0 0.0004494437307585031
tumors B-Disease 1 1.0
with O 0 1.4435835510084871e-05
LOH O 1 0.999998927116394
. O 0 5.042203156335745e-06

In O 0 2.327366473764414e-06
6 O 0 9.591615253157215e-07
( O 0 5.6356814326363747e-08
38 O 0 1.0927980298447437e-07
% O 0 1.3696403122764877e-08
) O 0 1.8048683658733466e-09
of O 0 3.828975358999287e-09
16 O 0 4.064818858751096e-05
tumors B-Disease 1 1.0
without O 0 2.9084549169056118e-05
LOH O 1 0.999981164932251
, O 0 4.02499793494826e-08
one O 0 2.116438224675221e-08
mutation O 0 5.885114546799741e-07
was O 0 1.8921892319667677e-07
detected O 0 2.831651784163114e-07
, O 0 2.9902331721842756e-09
and O 0 4.13696721324186e-09
in O 0 1.5366206085332124e-09
9 O 0 4.853342971955499e-08
( O 0 5.9508624694615264e-09
56 O 0 4.323104008108203e-08
% O 0 8.00262967004528e-09
) O 0 1.393011261896504e-09
of O 0 1.771009339179841e-09
the O 0 7.092900887073483e-06
tumors B-Disease 1 1.0
without O 0 2.2503534637507983e-05
LOH O 1 0.9999850988388062
, O 0 4.589578495028945e-08
both O 0 4.505394457510192e-08
mutations O 0 5.907330887566786e-06
were O 0 1.956635742317303e-07
found O 0 1.2686487593782658e-07
. O 0 1.353121348302011e-07

Thus O 0 1.1134268788737245e-05
, O 0 2.9037128257414224e-08
a O 0 7.4475998701473145e-09
total O 0 6.337898650343732e-09
of O 0 1.2110703551115876e-09
45 O 0 5.1469708495233135e-08
mutations O 0 7.051106649669237e-07
were O 0 1.1093170826370624e-07
identified O 0 4.150366805788508e-07
in O 0 4.1294960340110265e-08
tumors B-Disease 1 1.0
of O 0 2.5701240247144597e-08
36 O 0 2.6437630822329083e-06
patients O 0 4.53643860964803e-06
. O 0 2.1604674316222372e-07

Thirty O 0 0.00011047266161767766
- O 0 3.6299887142376974e-05
nine O 0 2.0717497761779669e-07
of O 0 2.1136978833879994e-09
the O 0 5.2375228598577905e-09
mutations O 0 3.6403358194547764e-07
- O 0 1.3937008702669118e-07
including O 0 5.634560817924239e-09
34 O 0 4.340794390600422e-08
small O 0 1.0742641443073353e-08
mutations O 0 1.341129063803237e-06
, O 0 2.049401093273673e-09
2 O 0 4.062216341083058e-09
large O 0 4.661584451781664e-09
structural O 0 1.6907532653931412e-06
alterations O 0 1.6698351146260393e-06
, O 0 1.3706857870943168e-08
and O 0 1.08899405049101e-08
hypermethylation O 0 1.230745624525298e-06
in O 0 1.9412306428989723e-08
3 O 0 3.3311766856058966e-06
tumors O 1 1.0
- O 0 0.005627251695841551
were O 0 2.3099046302377246e-06
not O 0 1.706509777932297e-08
detected O 0 1.5068162895204296e-07
in O 0 1.7878569735785277e-09
the O 0 4.2717585024831806e-09
corresponding O 0 1.0956969731523714e-07
peripheral O 0 3.429712887736969e-05
blood O 0 9.36060769163305e-06
DNA O 0 2.6680759219743777e-06
. O 0 4.736450875952869e-07

In O 0 8.841420253702381e-07
6 O 0 6.471638585026085e-07
( O 0 5.639767763909731e-08
17 O 0 1.0394826688298053e-07
% O 0 7.971597604239378e-09
) O 0 5.978356143465646e-10
of O 0 2.352635586344576e-10
the O 0 1.0996116905914732e-08
36 O 0 2.3308753327455634e-07
patients O 0 6.690302711831464e-08
, O 0 9.386994515026004e-10
a O 0 6.136800845268908e-09
mutation O 0 1.0783318202811643e-06
was O 0 1.2696291662450676e-07
detected O 0 1.3725097858241497e-07
in O 0 1.8053227801573257e-09
constitutional O 0 7.020876324759229e-09
DNA O 0 1.1211609773909004e-07
, O 0 5.780582235104248e-09
and O 0 8.161167741604913e-09
1 O 0 2.091831818873402e-09
of O 0 2.911962615481656e-10
these O 0 4.9919250955099415e-09
mutations O 0 2.7717734951693274e-07
is O 0 1.264580440363261e-09
known O 0 4.4735721793642824e-09
to O 0 6.90355550503341e-09
be O 0 2.4004995324844458e-08
associated O 0 4.109303475274828e-08
with O 0 1.9868336309514234e-08
reduced O 0 1.3689361821889179e-06
expressivity O 0 9.801469423109666e-05
. O 0 5.000676424060657e-07

The O 0 2.1301841002241417e-07
presence O 0 7.594581319381177e-08
of O 0 2.4220356831250456e-09
a O 0 8.324101408163642e-09
constitutional O 0 3.452034391671077e-08
mutation O 0 2.4835928797983797e-06
was O 0 2.7109038569506083e-07
not O 0 6.333765956156867e-09
associated O 0 5.734634545007111e-09
with O 0 1.3920630204111717e-09
an O 0 3.4775682333787472e-09
early O 0 1.0150272800046878e-07
age O 0 5.994033358547313e-07
at O 0 1.8603429907670943e-07
treatment O 0 3.746684171801462e-07
. O 0 1.2200452204069734e-07

In O 0 1.1568225772862206e-06
1 O 0 9.458232170800329e-07
patient O 0 2.1759478840976954e-06
, O 0 1.173071773052925e-08
somatic O 0 1.3650187611347064e-06
mosaicism O 0 1.4485658539342694e-05
was O 0 5.645051146530022e-07
demonstrated O 0 1.9614141422152898e-08
by O 0 9.357605801341151e-10
molecular O 0 2.5997604069516456e-08
analysis O 0 1.682778716372013e-08
of O 0 2.7316424677792384e-09
DNA O 0 2.1594767929400405e-07
and O 0 3.029212791716418e-08
RNA O 0 2.6511506234783155e-07
from O 0 4.600972758339594e-08
peripheral O 0 6.584510992979631e-05
blood O 0 5.671763574355282e-05
. O 0 5.398187568061985e-07

In O 0 2.027073833232862e-06
2 O 0 3.6870815165457316e-06
patients O 0 7.86904274718836e-06
without O 0 7.223808040635049e-08
a O 0 6.576837563443405e-08
detectable O 0 6.359456165228039e-05
mutation O 0 1.4800145891058492e-06
in O 0 1.671263660796285e-08
peripheral O 0 5.585556573350914e-05
blood O 0 6.179563933983445e-05
, O 0 2.5462107089424535e-08
mosaicism O 0 3.848361757263774e-06
was O 0 4.2727143068077567e-07
suggested O 0 4.148648358182072e-08
because O 0 3.2654403625542727e-09
1 O 0 1.629542945025264e-09
of O 0 3.8741818086940327e-10
the O 0 2.076092364688975e-08
patients O 0 1.6830873619255726e-06
showed O 0 1.2398045328154694e-05
multifocal O 1 0.9981324076652527
tumors B-Disease 1 1.0
and O 0 2.707601822748984e-07
the O 0 1.3065611703666491e-08
other O 0 5.093023780489148e-09
later O 0 3.5047243329699995e-08
developed O 0 1.5553878540686128e-07
bilateral B-Disease 0 1.1126190884169773e-06
retinoblastoma I-Disease 0 5.028119630878791e-05
. O 0 6.335242233035387e-07

In O 0 7.998449973456445e-07
conclusion O 0 2.4509526497240586e-07
, O 0 1.969958773884173e-08
our O 0 5.154614513003253e-08
results O 0 2.982750046953697e-08
emphasize O 0 8.409321594626817e-08
that O 0 3.382656821315777e-09
the O 0 2.1984389864115883e-09
manifestation O 0 3.163701478570147e-08
and O 0 6.26323526375927e-09
transmissibility O 0 1.776415388121677e-07
of O 0 5.0165316345385236e-09
retinoblastoma B-Disease 0 6.382671813298657e-07
depend O 0 6.871989199908057e-08
on O 0 2.1279134898577468e-08
the O 0 5.2706332631657915e-09
nature O 0 7.393307299707885e-09
of O 0 9.157030689266321e-10
the O 0 3.538630499733131e-09
first O 0 3.282176308516682e-08
mutation O 0 7.962498926872286e-08
, O 0 1.4115382196422388e-09
its O 0 7.773546806255638e-10
time O 0 5.259295665638319e-09
in O 0 6.847059585979309e-10
development O 0 1.4997398878335844e-09
, O 0 1.0825982332818285e-09
and O 0 1.4100312029086126e-09
the O 0 6.588797285544956e-10
number O 0 1.6713201933526989e-09
and O 0 9.56687951081392e-10
types O 0 7.909366495084669e-09
of O 0 7.336762308796096e-10
cells O 0 1.181898046098695e-08
that O 0 8.722780275860487e-10
are O 0 7.1019963243657e-09
affected O 0 6.756280157560468e-08
. O 0 1.165113339141044e-08
. O 0 9.105729503744442e-08

Hereditary B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999213218688965
of I-Disease 0 1.239726259427698e-07
the I-Disease 0 7.975586413522251e-08
fifth I-Disease 0 5.613441658169904e-07
component I-Disease 0 1.3297695033998025e-07
of I-Disease 0 3.2902229829545604e-09
complement I-Disease 0 1.772181690284924e-07
in O 0 3.831943118370873e-08
man O 0 2.5151894078589976e-06
. O 0 1.2247444658441964e-07

I O 0 0.0032938229851424694
. O 0 1.7657857824815437e-05

Clinical O 0 0.025760263204574585
, O 0 7.514365734095918e-07
immunochemical O 0 1.3814007616019808e-05
, O 0 2.696525491785451e-08
and O 0 3.440255724740382e-08
family O 0 2.401599203949445e-07
studies O 0 3.1690285595686873e-07
. O 0 1.7758885917373846e-07

The O 0 6.538539309985936e-07
first O 0 1.3793290065677866e-07
recognized O 0 1.2984725117348717e-07
human O 0 4.2143820877527105e-08
kindred O 0 1.6926441048781271e-06
with O 0 2.6722827328740095e-07
hereditary B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.8818981051445007
of I-Disease 0 3.956114991154891e-09
the I-Disease 0 2.358195061447077e-08
fifth I-Disease 0 1.357991550321458e-06
component I-Disease 0 2.0642713138840918e-07
of I-Disease 0 5.239601197359889e-09
complement I-Disease 0 5.690247917300439e-07
( O 0 8.737941925573978e-08
C5 O 0 3.5010148167202715e-06
) O 0 2.3291212514209292e-08
is O 0 1.950925998528419e-08
described O 0 4.871967007602507e-07
. O 0 2.404862868843338e-07

The O 0 2.3893185243650805e-06
proband O 0 1.6667530871927738e-05
, O 0 3.305282803012233e-08
a O 0 1.8416891123251844e-08
20 O 0 2.8398261520123924e-08
- O 0 4.436712686128885e-07
year O 0 1.0524817461998737e-08
- O 0 8.520657956978539e-07
old O 0 7.991588404365757e-07
black O 0 1.8424800884986325e-07
female O 0 8.340632007275417e-07
with O 0 3.092751967415097e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999943971633911
erythematosus I-Disease 1 0.9999998807907104
since O 0 1.43928230045276e-06
age O 0 7.572803042421583e-07
11 O 0 4.668563136078774e-08
, O 0 1.7431840859671865e-08
lacked O 0 4.522718882071786e-06
serum O 0 2.027089794864878e-05
hemolytic O 0 8.042788977036253e-05
complement O 0 5.020918365516991e-07
activity O 0 4.957825012752437e-07
, O 0 1.7780264371936028e-08
even O 0 9.262134881282691e-08
during O 0 3.769363274841453e-07
remission O 0 6.56209795124596e-06
. O 0 2.6045853473988245e-07

C5 O 0 0.00398128479719162
was O 0 6.431328802136704e-05
undetectable O 0 6.25503744231537e-05
in O 0 6.989413492419772e-08
her O 0 5.558349016610009e-07
serum O 0 1.303727799495391e-06
by O 0 7.598156770427522e-09
both O 0 6.524734885715588e-08
immunodiffusion O 0 1.4778814147575758e-05
and O 0 3.1063709116097016e-07
hemolytic O 0 0.000715594447683543
assays O 0 7.303129677893594e-05
. O 0 1.5513983271375764e-06

Other O 0 1.0268291816828423e-06
complement O 0 2.5292392820119858e-06
components O 0 1.98552834262955e-06
were O 0 2.558772109750862e-07
normal O 0 1.3159203149371024e-07
during O 0 4.381336182746054e-08
remission O 0 2.2711574843015114e-07
of O 0 6.5006964256042465e-09
lupus O 0 4.903464287053794e-05
, O 0 2.663509413025622e-08
but O 0 2.1839960950842396e-08
C1 O 0 0.00014430029841605574
, O 0 2.5138310988381818e-08
C4 O 0 1.1505600241434877e-06
, O 0 2.620915218187747e-08
C2 O 0 2.2513473595608957e-05
, O 0 1.0041281583994532e-08
and O 0 2.990850944684098e-08
C3 O 0 4.359495869721286e-05
levels O 0 5.386265456763795e-06
fell O 0 5.3167834266787395e-05
during O 0 3.4659692005334364e-07
exacerbations O 0 0.0001896807225421071
. O 0 6.221007993190142e-07

A O 0 9.732429134601261e-06
younger O 0 5.499067356140586e-06
half O 0 1.1335931731082383e-06
- O 0 7.669389560760465e-06
sister O 0 6.396780918294098e-06
, O 0 1.2289747886029545e-08
who O 0 9.048596183447444e-08
had O 0 6.600224082831119e-07
no O 0 3.185785431014665e-07
underlying O 0 0.0005361074581742287
disease O 0 0.002471903571859002
, O 0 3.5216694005413274e-09
was O 0 1.9085106828242715e-07
also O 0 1.439121000146315e-08
found O 0 1.4825451977173998e-08
to O 0 8.782952143349121e-09
lack O 0 8.71347481279372e-07
immunochemically O 0 8.023874397622421e-05
detectable O 0 0.0010683403816074133
C5 O 0 4.696089308708906e-05
. O 0 8.74129796102352e-07

By O 0 3.5038403893850045e-06
hemolytic O 0 0.0013846257934346795
assay O 0 2.6474657715880312e-05
, O 0 2.551155375840608e-07
she O 0 3.867939994961489e-07
exhibited O 0 1.179724449684727e-06
1 O 0 5.401082603384566e-08
- O 0 9.727389169711387e-07
2 O 0 3.216521093918345e-08
% O 0 4.316625723532752e-09
of O 0 7.295569148801917e-10
the O 0 6.492840487481999e-09
normal O 0 2.6064464009323274e-07
serum O 0 8.382136797990825e-07
C5 O 0 1.1660335985652637e-06
level O 0 1.3322370762125502e-07
and O 0 2.9762825093371248e-08
normal O 0 7.09804552911919e-08
concentrations O 0 7.610822194692446e-08
of O 0 6.307192546017859e-10
other O 0 2.439686896948956e-09
complement O 0 1.2274828975478158e-07
components O 0 2.140413926099427e-06
. O 0 2.340962339530961e-07

C5 O 0 0.0006391435745172203
levels O 0 3.7771246752527077e-06
of O 0 1.56863304567878e-08
other O 0 9.528187128182708e-09
family O 0 2.866901915865583e-08
members O 0 7.597026119299244e-09
were O 0 1.4337625486859906e-07
either O 0 3.805598325357096e-08
normal O 0 4.991413860011562e-08
or O 0 4.778491202728219e-08
approximately O 0 2.4570272927348924e-08
half O 0 8.742926382865335e-08
- O 0 6.574939561687643e-06
normal O 0 2.565736281212594e-07
, O 0 3.912531187921786e-09
consistent O 0 9.674824497096779e-08
with O 0 1.651679504277581e-08
autosomal O 0 4.57806236227043e-05
codominant O 0 2.0233114810253028e-06
inheritance O 0 1.9712749121936213e-07
of O 0 3.1959472845954906e-09
the O 0 3.0254998506507036e-08
gene O 0 2.4302742531290278e-05
determining O 0 0.00041332058026455343
C5 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 1.8647816659722594e-06

Normal O 0 0.001347081270068884
hemolytic O 0 0.18581634759902954
titers O 0 0.0010001613991335034
were O 0 7.295224349945784e-06
restored O 0 5.522383048628399e-07
to O 0 2.7602716556884843e-08
both O 0 7.427387345160241e-07
homozygous O 1 0.9977272152900696
C5 B-Disease 1 1.0
- I-Disease 1 0.9999973773956299
deficient I-Disease 1 1.0
( O 0 1.0166923857468646e-05
C5D B-Disease 1 1.0
) O 0 7.664561962883454e-08
sera O 0 5.160792397873593e-07
by O 0 1.472219901543781e-09
addition O 0 2.6190949409254927e-09
of O 0 1.070551203241621e-09
highly O 0 1.4244267276808387e-07
purified O 0 1.2577503412103397e-06
human O 0 2.3759886857988022e-07
C5 O 0 2.0811290596611798e-05
. O 0 7.512244906138221e-07

In O 0 1.356755319648073e-06
specific O 0 1.1131518249385408e-06
C5 O 0 2.578630119387526e-05
titrations O 0 1.9744480596273206e-05
, O 0 4.552785171085816e-08
however O 0 1.3097873008405259e-08
, O 0 1.8629426890015566e-09
it O 0 2.6419788579090664e-09
was O 0 5.766687394270775e-08
noted O 0 6.0441482929718404e-09
that O 0 5.14476738988634e-10
when O 0 1.7328073420586065e-09
limited O 0 1.342861599695766e-09
amounts O 0 1.5656551610732095e-09
of O 0 1.7622382442183948e-09
C5 O 0 1.1893718010469456e-06
were O 0 1.0350529322522561e-07
assayed O 0 5.739823336625705e-07
in O 0 2.3423918360521157e-09
the O 0 2.320946990153061e-09
presence O 0 4.830529309884923e-09
of O 0 1.1466796401293777e-09
low O 0 3.9886364788799256e-07
dilutions O 0 7.785719731145946e-07
of O 0 2.2778030128733917e-08
either O 0 6.179632691782899e-06
C5D B-Disease 1 1.0
serum O 0 3.039957482542377e-05
, O 0 1.8484389130435375e-08
curving O 0 3.283579701474082e-07
rather O 0 1.8437628312995002e-08
than O 0 1.4201311238082326e-09
linear O 0 1.9566574138707438e-08
dose O 0 4.4488345452009526e-07
- O 0 7.723113526481029e-07
response O 0 6.506752470158972e-08
plots O 0 4.1125855432255776e-07
were O 0 2.5848733002931112e-06
consistently O 0 2.962451844723546e-06
obtained O 0 1.8381516753152027e-08
, O 0 4.7479442599751565e-09
suggesting O 0 3.327865982782896e-08
some O 0 3.633230383215391e-09
inhibitory O 0 2.2743805061509192e-07
effect O 0 1.801272588863867e-07
. O 0 1.1277872147275048e-07

Further O 0 3.897022907040082e-06
studies O 0 9.828066822592518e-07
suggested O 0 6.313644007605035e-07
that O 0 1.6235064848046932e-08
low O 0 2.9885839012422366e-06
dilutions O 0 9.513165423413739e-06
of O 0 2.2095301233093778e-07
C5D B-Disease 1 1.0
serum O 0 3.966116128140129e-05
contain O 0 3.116513198619941e-07
a O 0 3.863426911721035e-08
factor O 0 1.1706090674579173e-07
( O 0 1.2712993324726085e-08
or O 0 2.614998173555705e-08
factors O 0 2.2228149987313373e-08
) O 0 3.0015359087087745e-09
interfering O 0 3.4519622715833975e-08
at O 0 2.4314516622325755e-08
some O 0 1.5637957595515672e-09
step O 0 1.7468785529217712e-08
in O 0 2.095649431765878e-09
the O 0 2.7185507178728585e-08
hemolytic O 0 7.950000508571975e-06
assay O 0 8.199990588764194e-07
of O 0 1.4147408577969145e-08
C5 O 0 5.946581040916499e-06
, O 0 1.9231064740665715e-08
rather O 0 9.781995657931475e-09
than O 0 2.2211017469686567e-09
a O 0 1.7943282415444628e-08
true O 0 1.0408753325918951e-07
C5 O 0 4.118957804166712e-06
inhibitor O 0 1.0400294740975369e-06
or O 0 4.4082605654693907e-07
inactivator O 0 2.758068330876995e-05
. O 0 9.226638439940871e-07

Of O 0 7.585271077914513e-07
clinical O 0 4.271536090527661e-05
interest O 0 4.528319266228209e-07
are O 0 1.5646685369574698e-07
( O 0 9.336217132727143e-09
a O 0 7.0704642141095064e-09
) O 0 1.2962813045191979e-09
the O 0 1.2985282848987367e-09
documentation O 0 4.434918920992459e-08
of O 0 2.5772715517291545e-08
membranous O 1 0.8352634906768799
glomerulonephritis B-Disease 1 1.0
, O 0 1.649610021559056e-05
vasculitis B-Disease 1 1.0
, O 0 1.7803411083150422e-06
and O 0 0.0007184589630924165
arthritis B-Disease 1 1.0
in O 0 1.2799366899685083e-08
an O 0 7.89988341409753e-09
individual O 0 1.0242143844152451e-07
lacking O 0 3.1278743790608132e-06
C5 O 0 5.860466444573831e-06
( O 0 1.2649573832845817e-08
and O 0 6.5546315042297465e-09
its O 0 3.845134433078101e-09
biologic O 0 8.890505398539972e-08
functions O 0 3.1795689636737734e-08
) O 0 4.1475067824592315e-09
, O 0 1.0878724587826127e-09
and O 0 1.9671013262723136e-08
( O 0 1.6545108394439012e-08
b O 0 1.4288868896983331e-06
) O 0 8.539525198081321e-10
a O 0 2.619144900961601e-09
remarkable O 0 2.9513190114016652e-08
propensity O 0 1.5515596487603034e-06
to O 0 3.4344347454862145e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.328443222092801e-08
the O 0 1.3722683434025384e-08
proband O 0 1.1142393532281858e-06
, O 0 3.761640332555771e-09
even O 0 5.55595125462105e-09
during O 0 1.8050069883202013e-08
periods O 0 5.793764401573753e-08
of O 0 3.914412349814711e-09
low O 0 2.8217118597240187e-05
- O 0 1.1791726137744263e-05
dose O 0 1.1095705758634722e-06
or O 0 8.07267852565019e-08
alternate O 0 1.7187946355079475e-07
- O 0 7.053124136291444e-06
day O 0 3.504755454741826e-07
corticosteroid O 0 7.898115291027352e-05
therapy O 0 3.628864578786306e-05
. O 0 8.237967108470912e-07

Other O 0 1.183567292173393e-06
observations O 0 3.0758533284824807e-06
indicate O 0 2.967241698570433e-06
that O 0 1.5457960245157665e-08
the O 0 4.005530129802537e-08
C5D B-Disease 1 0.9999998807907104
state O 0 1.4242659496233046e-08
is O 0 3.382540914032006e-09
compatible O 0 3.133326842430506e-08
with O 0 7.17784987003256e-09
normal O 0 1.0825785778934005e-07
coagulation O 0 1.6277272152365185e-07
function O 0 8.114761840261053e-08
and O 0 8.967051989827723e-09
the O 0 2.26426122296175e-09
capacity O 0 5.597220908981626e-09
to O 0 5.456632479194923e-09
mount O 0 1.175593638436112e-06
a O 0 4.680296399328654e-07
neutrophilic O 0 0.004828168079257011
leukocytosis O 0 0.0003651194565463811
during O 0 5.127959411765914e-06
pyogenic B-Disease 1 0.530282735824585
infection I-Disease 1 0.8309389352798462
. O 0 3.174651794779493e-07
. O 0 6.411871140699077e-07

Susceptibility O 0 0.004969291854649782
to O 0 8.87798669282347e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 5.143024827702902e-05
twins O 0 0.0006417327676899731
: O 0 7.743185648223516e-09
the O 0 2.4993485059354725e-09
role O 0 1.1086631168666372e-08
of O 0 1.9939925266498904e-09
genes O 0 5.185875195934386e-08
, O 0 5.6715765417436614e-09
HLA O 0 3.8700429172422446e-07
, O 0 6.17698647786824e-09
and O 0 6.612077996237531e-09
the O 0 2.0220902285927878e-08
environment O 0 5.158125873094832e-07
. O 0 7.894042397538215e-08

OBJECTIVE O 0 2.7775797207141295e-05
To O 0 1.4843567441857886e-07
determine O 0 2.4077291982393945e-07
the O 0 1.1473804129025211e-08
relative O 0 7.111420075034403e-08
effects O 0 5.824311415381089e-07
of O 0 2.1131738581203763e-09
genetic O 0 5.28367138485919e-07
and O 0 7.769163090642905e-09
environmental O 0 4.317929125363662e-08
factors O 0 3.3740366944812195e-08
in O 0 8.68269811604705e-09
susceptibility O 0 3.33892458002083e-05
to O 0 1.6476620658067986e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.00840375479310751
AS B-Disease 1 0.9999892711639404
) O 0 1.3536480025777564e-07
. O 0 1.4377332036019652e-07

METHODS O 0 0.00044610927579924464
Twins O 0 0.21970869600772858
with O 0 2.252299395877344e-07
AS B-Disease 1 0.999980092048645
were O 0 2.5504891709715594e-06
identified O 0 8.929848149819009e-08
from O 0 3.2365077284879362e-09
the O 0 8.186549216304684e-09
Royal O 0 3.8040093386371154e-07
National O 0 3.8259406665019924e-07
Hospital O 0 4.054837063449668e-06
for O 0 1.0114712978293028e-07
Rheumatic B-Disease 1 0.9616726636886597
Diseases I-Disease 0 0.000496579275932163
database O 0 1.089096826945024e-06
. O 0 2.8068359370081453e-07

Clinical O 0 0.004075309261679649
and O 0 1.7705630170894437e-06
radiographic O 0 0.00019294917001388967
examinations O 0 0.00916051585227251
were O 0 1.5470663129235618e-05
performed O 0 1.2876666914962698e-06
to O 0 1.4318954022485286e-08
establish O 0 7.288474535016576e-07
diagnoses O 0 0.03671487420797348
, O 0 1.1265434807228303e-07
and O 0 5.136402705829823e-06
disease O 1 0.7088654637336731
severity O 0 0.00015301660459954292
was O 0 2.8026706786477007e-06
assessed O 0 1.3736961079757748e-07
using O 0 2.594653025767002e-08
a O 0 1.3616386240755673e-08
combination O 0 9.829204827838112e-08
of O 0 7.79870834577423e-09
validated O 0 5.198080543777905e-07
scoring O 0 4.145866569160717e-06
systems O 0 7.588645530631766e-06
. O 0 3.546281277522212e-07

HLA O 0 0.001180951134301722
typing O 0 0.00014920993999112397
for O 0 1.2174747325843782e-06
HLA O 0 3.67086504411418e-05
- O 0 1.178749789687572e-05
B27 O 0 4.189843366475543e-06
, O 0 3.9302296528376246e-08
HLA O 0 1.0630575388859143e-06
- O 0 6.516669941447617e-07
B60 O 0 5.764629804616561e-07
, O 0 1.0251423709917162e-08
and O 0 2.9601983086990913e-08
HLA O 0 2.768624199234182e-06
- O 0 5.523828349396354e-06
DR1 O 0 0.0007834025891497731
was O 0 6.737350304319989e-07
performed O 0 1.3859046532616048e-07
by O 0 3.65198249419052e-09
polymerase O 0 2.3660801673486276e-07
chain O 0 3.404043695809378e-07
reaction O 0 1.8057644268765216e-08
with O 0 1.958919471078957e-09
sequence O 0 5.268485026022063e-08
- O 0 1.484564791098819e-07
specific O 0 2.0118495314136453e-08
primers O 0 2.2807780624134466e-06
, O 0 2.3030709783711245e-08
and O 0 3.8404749602705124e-08
zygosity O 0 5.811527444166131e-06
was O 0 1.368677260416007e-07
assessed O 0 2.5078503540498787e-07
using O 0 2.1151089413251611e-07
microsatellite O 0 5.376554327085614e-05
markers O 0 3.37759884132538e-05
. O 0 7.804155757185072e-07

Genetic O 0 0.00024077759007923305
and O 0 1.108715878217481e-06
environmental O 0 7.120920599845704e-07
variance O 0 2.0166851300018607e-07
components O 0 4.3022623685828876e-06
were O 0 1.6268299987132195e-06
assessed O 0 1.4011519056111865e-07
with O 0 4.18725809581133e-09
the O 0 6.502606453295812e-09
program O 0 2.6670067043710333e-08
Mx O 0 1.3759724879491841e-06
, O 0 3.1675460032687397e-09
using O 0 1.807762384231637e-09
data O 0 3.364384681958654e-08
from O 0 1.0416330020746045e-09
this O 0 3.951452498540675e-10
and O 0 2.273877752756448e-09
previous O 0 1.9049188892950042e-08
studies O 0 1.460067355907313e-08
of O 0 5.7962155075586e-09
twins O 0 4.485350291361101e-05
with O 0 9.339604645219879e-08
AS B-Disease 1 0.9998877048492432
. O 0 2.5697573846628075e-07

RESULTS O 0 9.017069533001631e-05
Six O 0 8.012528383005701e-07
of O 0 3.842922424723838e-08
8 O 0 7.977500899869483e-07
monozygotic O 0 4.141403405810706e-05
( O 0 8.638066901767161e-07
MZ O 1 0.9887169599533081
) O 0 2.1867518285034748e-07
twin O 0 9.796590893529356e-05
pairs O 0 2.451751242915634e-05
were O 0 3.223888052161783e-05
disease O 0 0.00010618233500281349
concordant O 0 1.827916776164784e-06
, O 0 2.4292637235134862e-08
compared O 0 5.599519781185336e-08
with O 0 7.507014565533154e-09
4 O 0 3.372036161408687e-08
of O 0 5.707376349306514e-09
15 O 0 1.285023927266593e-07
B27 O 0 4.624023404176114e-06
- O 0 7.2735360845399555e-06
positive O 0 4.4339040528029727e-07
dizygotic O 0 1.4714237295265775e-05
( O 0 1.8190134198903252e-07
DZ O 0 0.00019721114949788898
) O 0 6.654198614342022e-08
twin O 0 2.108706576109398e-05
pairs O 0 1.0354769983678125e-06
( O 0 2.3536699700343888e-08
27 O 0 7.744164065570658e-08
% O 0 1.0325679866696191e-08
) O 0 1.286942108436051e-09
and O 0 3.1612084061549695e-09
4 O 0 4.460629643432412e-09
of O 0 2.4696176215144305e-09
32 O 0 1.0542196378082735e-06
DZ O 0 0.05599544942378998
twin O 0 0.0001574900234118104
pairs O 0 2.5978972644224996e-06
overall O 0 1.3028627563471673e-06
( O 0 2.4279389165826615e-08
12 O 0 1.9256685135360385e-08
. O 0 1.5533851982496572e-09
5 O 0 1.62242610457497e-08
% O 0 2.975340507305191e-08
) O 0 2.6987841295067483e-08
. O 0 9.873492246015303e-08

Nonsignificant O 0 0.000616752018686384
increases O 0 8.723471182747744e-06
in O 0 2.5587958418782364e-08
similarity O 0 7.950176694748734e-08
with O 0 2.313919056362579e-09
regard O 0 2.216972028179498e-08
to O 0 1.695103790666508e-08
age O 0 3.3538440220581833e-06
at O 0 6.057230621081544e-06
disease O 0 0.0007928012637421489
onset O 0 3.708575604832731e-06
and O 0 9.416606161494201e-09
all O 0 1.892041412432377e-09
of O 0 1.235390123532909e-09
the O 0 2.1875527522752236e-07
disease O 0 0.001532178488560021
severity O 0 6.621952252316987e-06
scores O 0 2.801019491016632e-06
assessed O 0 7.196728688541043e-07
were O 0 2.537107377520442e-07
noted O 0 5.241492928576008e-08
in O 0 6.64464820943067e-08
disease O 0 0.009600126184523106
- O 0 0.00019213478663004935
concordant O 0 0.0015183737268671393
MZ O 1 0.9999715089797974
twins O 0 0.0008852505125105381
compared O 0 1.5398142068079324e-06
with O 0 4.33194060178721e-07
concordant O 0 0.0006214387249201536
DZ O 1 0.9978318810462952
twins O 0 0.0006022519082762301
. O 0 2.0772984044015175e-06

HLA O 0 0.005888513755053282
- O 0 0.00026333771529607475
B27 O 0 1.7626041881158017e-05
and O 0 2.649947248301032e-07
B60 O 0 2.379510988248512e-06
were O 0 1.9232831505178183e-07
associated O 0 2.4579271951097326e-08
with O 0 9.295456848690264e-09
the O 0 1.83484033300374e-07
disease O 0 2.7560203307075426e-05
in O 0 1.9363484149437227e-09
probands O 0 1.0007735227191006e-06
, O 0 2.3346709010496625e-09
and O 0 2.5628776878505732e-09
the O 0 2.272082966214839e-09
rate O 0 1.7269771035444137e-07
of O 0 4.014645504923919e-09
disease O 0 2.3442066776624415e-06
concordance O 0 1.6113278888951754e-07
was O 0 1.0654920146180302e-07
significantly O 0 8.310350807505529e-08
increased O 0 6.069820557286221e-08
among O 0 1.0350944279480245e-07
DZ O 0 0.0007104923133738339
twin O 0 4.0051923861028627e-05
pairs O 0 5.061215233581606e-07
in O 0 5.796878532748906e-09
which O 0 1.3834136503021455e-08
the O 0 4.9089702969240534e-08
co O 0 2.036928344750777e-05
- O 0 2.0289562598918565e-05
twin O 0 0.0012396088568493724
was O 0 3.950726181756181e-07
positive O 0 1.2749369560083323e-08
for O 0 1.684827055647986e-09
both O 0 4.451529278526323e-08
B27 O 0 1.9651233742479235e-06
and O 0 2.1090482960062218e-07
DR1 O 0 0.001249715336598456
. O 0 1.0098768825628213e-06

Additive O 0 4.56580200989265e-05
genetic O 0 1.634811815165449e-05
effects O 0 5.436747869680403e-06
were O 0 3.851838812352071e-07
estimated O 0 1.2092153056642019e-08
to O 0 1.7993412315675528e-09
contribute O 0 2.2955717327022285e-08
97 O 0 5.0069559165422106e-08
% O 0 1.0393116589568763e-08
of O 0 7.822048009309412e-10
the O 0 6.374183403323741e-09
population O 0 1.8136343982178005e-08
variance O 0 2.0828439062370308e-07
. O 0 1.9400339112962683e-07

CONCLUSION O 0 2.1175916117499582e-05
Susceptibility O 0 3.3685751986922696e-05
to O 0 5.609059030575736e-07
AS B-Disease 1 0.9996095299720764
is O 0 3.524311864566698e-08
largely O 0 2.7330457896823646e-08
genetically O 0 3.34976029137124e-08
determined O 0 5.078068809893921e-08
, O 0 2.447335001320994e-09
and O 0 2.833148604608482e-09
the O 0 3.894855105102124e-09
environmental O 0 2.987942693266632e-08
trigger O 0 4.549334562398144e-07
for O 0 5.848174833289477e-09
the O 0 3.3764968065952417e-07
disease O 0 0.00038860103813931346
is O 0 8.386476402222343e-09
probably O 0 1.1699996349534558e-07
ubiquitous O 0 1.7040725879269303e-06
. O 0 2.857207448414556e-07

HLA O 0 0.0024169243406504393
- O 0 0.0002660377067513764
B27 O 0 1.0837643458216917e-05
accounts O 0 3.2739114885771414e-07
for O 0 6.238579874917605e-09
a O 0 5.3104520780777875e-09
minority O 0 1.3640691243210767e-08
of O 0 3.7904757110851506e-10
the O 0 4.759205474158534e-09
overall O 0 4.883740984951146e-07
genetic O 0 3.0649782729597064e-06
susceptibility O 0 2.8424058200471336e-06
to O 0 3.2932294402598927e-07
AS B-Disease 1 0.9999924898147583
. O 0 4.346751723005582e-07

Cell O 0 0.00030780379893258214
cycle O 0 2.9517485018004663e-05
- O 0 1.52267784869764e-05
dependent O 0 1.5253040146490093e-06
colocalization O 0 1.892511704681965e-06
of O 0 9.387948196604157e-09
BARD1 O 0 4.845462171942927e-06
and O 0 5.4837101970406366e-08
BRCA1 O 0 7.818064659659285e-06
proteins O 0 6.857037249119458e-08
in O 0 4.826413046998823e-09
discrete O 0 3.575049731807667e-07
nuclear O 0 6.061281510483241e-06
domains O 0 2.5946983441826887e-06
. O 0 4.356770091362705e-07

Germ O 0 0.01384879183024168
- O 0 0.005354148801416159
line O 0 2.0602034055627882e-05
mutations O 0 1.1802330845966935e-06
of O 0 6.740008995365088e-09
the O 0 2.3640406965341754e-08
BRCA1 O 0 1.4418760656553786e-05
gene O 0 8.254985459643649e-07
predispose O 0 1.1803793995568412e-06
women O 0 6.935364638138708e-08
to O 0 3.859808472839177e-09
early O 0 2.7374915134714684e-07
- O 0 0.05217102915048599
onset O 1 0.9934131503105164
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9999593496322632
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 2.859005654443081e-08
compromising O 0 2.005747774092015e-06
the O 0 1.752180978087381e-08
genes O 0 5.042916200181935e-07
presumptive O 0 1.4138679034658708e-05
function O 0 1.3282119937230163e-07
as O 0 2.1288553142539968e-08
a O 0 9.249106369679794e-08
tumor B-Disease 0 1.5566354704787955e-05
suppressor O 0 1.0544575161475223e-05
. O 0 3.584232501907536e-07

Although O 0 2.7935445814364357e-06
the O 0 7.169342097768094e-08
biochemical O 0 9.376514071846032e-07
properties O 0 1.4417287275136914e-07
of O 0 6.100971727818205e-09
BRCA1 O 0 1.788113331713248e-05
polypeptides O 0 3.474040681794577e-07
are O 0 1.3677398769118554e-08
not O 0 9.122449462495297e-09
understood O 0 2.456741476919433e-08
, O 0 7.822092418230397e-10
their O 0 4.2021794932622925e-09
expression O 0 1.0402477990112402e-08
pattern O 0 9.058110350679272e-08
and O 0 8.796985362380383e-09
subcellular O 0 2.6618033643899253e-06
localization O 0 9.676610943643027e-07
suggest O 0 1.065595611748904e-07
a O 0 7.119750122797086e-09
role O 0 4.454824775734778e-08
in O 0 9.646296206256011e-09
cell O 0 7.800331331964117e-07
- O 0 1.8733300748863257e-05
cycle O 0 4.118773176742252e-06
regulation O 0 1.3051335372438189e-06
. O 0 2.1689378115752334e-07

When O 0 1.768001493474003e-05
resting O 0 1.41646323754685e-05
cells O 0 9.756302006280748e-07
are O 0 3.2124866322646994e-08
induced O 0 4.050359052598651e-07
to O 0 1.2787897851751495e-08
proliferate O 0 1.0686012501537334e-06
, O 0 8.05280642168782e-09
the O 0 6.85521639454123e-09
steady O 0 2.59924547663104e-07
- O 0 4.372278539221952e-08
state O 0 1.295833884640274e-09
levels O 0 5.009971992819828e-09
of O 0 5.322902119075934e-10
BRCA1 O 0 3.1002684863778995e-07
increase O 0 7.254125744537987e-09
in O 0 2.951779265458754e-09
late O 0 3.56101601539649e-08
G1 O 0 7.310165415219672e-07
and O 0 3.6153490867718574e-08
reach O 0 8.000542806030353e-08
a O 0 2.3052596276329496e-08
maximum O 0 9.543104795284307e-08
during O 0 1.9864022249294067e-07
S O 0 2.1596410078927875e-05
phase O 0 5.631447379528254e-07
. O 0 2.4792097974568605e-07

Moreover O 0 2.2554455426870845e-05
, O 0 2.4052278035924246e-07
in O 0 3.918343338682462e-08
S O 0 5.6492590374546126e-06
phase O 0 6.632062081735057e-07
cells O 0 2.751588681348949e-07
, O 0 1.4534709436020421e-08
BRCA1 O 0 3.2242407996818656e-06
polypeptides O 0 4.1301504438706615e-07
are O 0 2.4230397244195956e-08
hyperphosphorylated O 0 1.4008569451107178e-06
and O 0 3.2017819506791056e-08
accumulate O 0 5.34048524514219e-07
into O 0 9.565424896607055e-09
discrete O 0 9.601691317584482e-07
subnuclear O 0 1.9015747966477647e-05
foci O 0 1.467810488975374e-05
termed O 0 2.9448663099174155e-06
" O 0 4.004629374776414e-07
BRCA1 O 0 2.644288724695798e-05
nuclear O 0 6.98701296641957e-06
dots O 0 4.989615626982413e-05
. O 0 1.2677962786256103e-06

" O 0 2.754065462795552e-05
BRCA1 O 0 0.0008751277346163988
associates O 0 2.207213947258424e-05
in O 0 1.3033756829372578e-07
vivo O 0 6.5511367211001925e-06
with O 0 2.87840791202143e-08
a O 0 1.001477514250837e-07
structurally O 0 2.238888555439189e-05
related O 0 1.328175187609304e-07
protein O 0 6.166154093989462e-07
termed O 0 8.723329301574267e-06
BARD1 O 0 0.00014542913413606584
. O 0 1.3390075537245139e-06

Here O 0 4.935355718771461e-06
we O 0 2.2064895688345132e-07
show O 0 7.086222808538878e-08
that O 0 1.4077390364519715e-09
the O 0 2.8290769726879716e-09
steady O 0 1.2404677818267373e-07
- O 0 1.0627904600823967e-07
state O 0 1.5108281292697257e-09
levels O 0 8.648038729575092e-09
of O 0 5.735943942042354e-10
BARD1 O 0 3.83091361300103e-07
, O 0 6.914516181844022e-10
unlike O 0 2.791875175489622e-09
those O 0 8.712205401550932e-10
of O 0 1.0480620815656039e-09
BRCA1 O 0 5.3998642215447035e-06
, O 0 1.4813609894304136e-08
remain O 0 7.886818309543742e-08
relatively O 0 3.165856554687707e-08
constant O 0 7.430774218164515e-08
during O 0 1.6005976988253678e-07
cell O 0 7.0334695010387804e-06
cycle O 0 6.70136478220229e-06
progression O 0 6.603840574825881e-06
. O 0 4.5092892264619877e-07

However O 0 1.3991776540933643e-05
, O 0 3.9118771155699505e-07
immunostaining O 0 1.1771736353693996e-05
revealed O 0 1.809352170312195e-06
that O 0 3.793039837773904e-08
BARD1 O 0 7.886712410254404e-06
resides O 0 5.153562483428686e-07
within O 0 1.1301074209768558e-07
BRCA1 O 0 1.173661894426914e-05
nuclear O 0 8.807933795651479e-07
dots O 0 1.9524468370946124e-06
during O 0 2.0720422355680057e-07
S O 0 1.0459547183927498e-06
phase O 0 2.4313218105476153e-08
of O 0 1.2893376366562848e-09
the O 0 9.582005411346017e-09
cell O 0 3.947245943436428e-07
cycle O 0 2.665049692041066e-07
, O 0 5.914121636863001e-09
but O 0 3.976858842236197e-09
not O 0 3.356518618602422e-09
during O 0 8.749111657380126e-09
the O 0 1.6423932436282485e-08
G1 O 0 4.996994903194718e-06
phase O 0 6.131749046289769e-07
. O 0 2.853618639164779e-07

Nevertheless O 0 5.965798845863901e-05
, O 0 7.354302624662523e-07
BARD1 O 0 8.180399163393304e-06
polypeptides O 0 9.529369435767876e-07
are O 0 4.386478735796118e-08
found O 0 1.683668138241501e-08
exclusively O 0 1.8696640680104792e-08
in O 0 8.615798074984582e-10
the O 0 2.140351895718595e-09
nuclear O 0 3.793285685560477e-08
fractions O 0 1.1624408102761663e-08
of O 0 2.0937878097981866e-09
both O 0 2.395034393032347e-08
G1 O 0 2.823100658133626e-06
- O 0 1.7628160549065797e-06
and O 0 2.181837857051505e-07
S O 0 1.3326020962267648e-05
- O 0 1.013587507259217e-06
phase O 0 4.6950310661486583e-07
cells O 0 5.544668510992778e-07
. O 0 1.1636425512051574e-07

Therefore O 0 9.700554983282927e-06
, O 0 1.4699736539114383e-07
progression O 0 9.507646723250218e-07
to O 0 1.0847199405361607e-07
S O 0 2.584898356872145e-05
phase O 0 2.4623150807201455e-07
is O 0 1.2861624654192383e-08
accompanied O 0 2.1124979099340635e-08
by O 0 8.900116754695375e-10
the O 0 1.2908656366050764e-09
aggregation O 0 2.009862676288776e-08
of O 0 3.054868580321113e-09
nuclear O 0 1.6251412944257027e-06
BARD1 O 0 3.3806898045440903e-06
polypeptides O 0 4.175735739408992e-07
into O 0 7.405066781984715e-08
BRCA1 O 0 4.388393790577538e-05
nuclear O 0 5.309221251081908e-06
dots O 0 2.4922532247728668e-05
. O 0 7.379081239378138e-07

This O 0 1.4199009683579789e-06
cell O 0 8.368235285161063e-06
cycle O 0 7.743092282908037e-06
- O 0 6.332708835543599e-06
dependent O 0 7.095783871591266e-07
colocalization O 0 1.4509193988487823e-06
of O 0 8.960418185210983e-09
BARD1 O 0 5.030752618040424e-06
and O 0 1.1721071047077203e-07
BRCA1 O 0 0.000154107779962942
indicates O 0 2.17028073734582e-07
a O 0 1.441313024486135e-08
role O 0 2.5572882478286374e-08
for O 0 7.922789535541597e-09
BARD1 O 0 7.140231900848448e-06
in O 0 4.370552630916791e-08
BRCA1 O 0 0.0005604647449217737
- O 0 0.00010133525938726962
mediated O 0 0.00029365657246671617
tumor B-Disease 0 0.0001043207012116909
suppression O 0 2.7338489871908678e-06
. O 0 5.876629529666388e-07

Ethnic O 0 2.738108923949767e-05
differences O 0 7.0461182986036874e-06
in O 0 1.592379135217925e-07
the O 0 2.194414605583006e-07
HFE O 0 0.00018291219021193683
codon O 0 1.2151815099059604e-05
282 O 0 6.171822860778775e-06
( O 0 1.40671386361646e-06
Cys O 0 0.000886318099219352
/ O 0 0.00012559235619846731
Tyr O 0 0.00010752013622550294
) O 0 2.9822467695339583e-07
polymorphism O 0 1.7589736671652645e-05
. O 0 1.2054775879732915e-06

Recent O 0 2.37652170653746e-06
studies O 0 6.524761033688264e-07
have O 0 2.1455218757182593e-07
shown O 0 3.69822032553202e-07
that O 0 1.6320107079081936e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.007247841451317072
HH B-Disease 1 0.9978364109992981
) O 0 2.3624133760336008e-08
is O 0 5.307981165714182e-09
likely O 0 3.9520138273019256e-08
to O 0 1.0591333143850079e-08
be O 0 1.6682420778124651e-07
caused O 0 1.5507104933476512e-07
by O 0 4.611847348456877e-09
homozygosity O 0 3.342233014791418e-07
for O 0 2.3956634453980996e-09
a O 0 3.3508783303659584e-08
Cys282Tyr O 0 3.483822183625307e-06
mutation O 0 3.6461662489273294e-07
in O 0 3.0126630079507777e-09
the O 0 8.041417309812005e-09
HFE O 0 8.694559255673084e-06
gene O 0 4.6705935119462083e-07
located O 0 2.5959457161661703e-07
4 O 0 3.916095181466517e-07
. O 0 5.02926184253738e-07

5 O 0 4.065354005433619e-05
Mb O 0 0.00010714685777202249
telomeric O 0 0.00018816323427017778
to O 0 2.5770486900000833e-06
HLA O 0 0.00019763546879403293
- O 0 8.46572729642503e-05
A O 0 1.454635366826551e-06
. O 0 3.805616586305405e-07

Population O 0 3.8128860069264192e-06
studies O 0 2.2913424402304372e-07
of O 0 7.536539392560826e-09
this O 0 2.6114130857735063e-09
polymorphism O 0 8.172447678589378e-07
are O 0 1.4552519189692248e-08
facilitated O 0 4.1039534437459224e-08
by O 0 3.751329913370682e-09
the O 0 4.522465069101145e-09
fact O 0 7.626759668255545e-09
that O 0 1.4206945619932299e-09
the O 0 7.490080555783152e-09
Cys282Tyr O 0 3.0917051390133565e-06
mutation O 0 4.151958137299516e-07
creates O 0 9.392518762751934e-08
a O 0 4.0361300079894136e-08
Rsal O 0 1.5809140450073755e-06
restriction O 0 1.1145853306970821e-07
site O 0 5.176309514354216e-07
. O 0 2.587554490673938e-07

We O 0 3.0665854865219444e-05
have O 0 2.0363417263524752e-07
studied O 0 2.1892225277042598e-07
the O 0 3.2839675867535334e-08
codon O 0 2.1612188447761582e-06
282 O 0 1.1327363154123304e-06
( O 0 1.8241642862903973e-07
Cys O 0 0.0001797417353373021
/ O 0 2.7680283892550506e-05
Tyr O 0 9.153997780231293e-06
) O 0 2.2064090998696884e-08
polymorphism O 0 4.007246161563671e-07
in O 0 6.138392905086221e-09
different O 0 6.703610555547357e-09
ethnic O 0 4.2491215879181254e-08
groups O 0 8.12329403743206e-08
. O 0 2.0400388223151822e-07

In O 0 2.007148395932745e-06
agreement O 0 1.4773689827052294e-07
with O 0 1.8726726835893714e-08
previous O 0 1.3192878611789638e-07
observations O 0 3.173053642058221e-07
the O 0 5.627915200534517e-08
Tyr O 0 2.798963350869599e-06
allele O 0 1.0008565141106374e-06
appeared O 0 2.520793884741579e-07
to O 0 1.2097366663965659e-08
be O 0 1.426030049600513e-08
rare O 0 1.2466769838681557e-08
or O 0 3.0528377692462527e-07
absent O 0 3.931954495328682e-07
in O 0 4.8793666884705544e-09
Asiatic O 0 1.101356374988427e-07
( O 0 2.6105764217021488e-09
Indian O 0 2.8672118013162162e-09
, O 0 2.07117922812472e-09
Chinese O 0 3.155967265300319e-09
) O 0 5.85841286593336e-09
populations O 0 1.352561440626232e-07
. O 0 1.0399605798738776e-07

The O 0 1.9336755485710455e-06
highest O 0 1.7275270920436014e-06
allele O 0 1.9361814338481054e-06
frequency O 0 7.992906603249139e-07
( O 0 3.5301784606645015e-08
7 O 0 2.3804108906233523e-08
. O 0 1.4744004905864472e-09
5 O 0 1.4766695421997156e-08
% O 0 1.8722907668689004e-08
) O 0 6.708714028746954e-09
was O 0 2.7684819770001923e-07
found O 0 2.1038367492565158e-08
in O 0 1.3031862700074726e-08
Swedes O 0 9.975613465940114e-06
. O 0 2.2765244978018018e-07

Saamis O 0 0.0009150319965556264
( O 0 3.921973075193819e-06
2 O 0 1.1542615538928658e-06
% O 0 1.1865741100791638e-07
) O 0 1.6661584112398486e-08
and O 0 2.74774372144293e-08
Mordvinians O 0 1.5855569017730886e-06
( O 0 5.3759610096904e-09
1 O 0 4.296976552353726e-09
. O 0 1.4924235181013046e-09
8 O 0 2.073219640408297e-08
% O 0 7.866893803054609e-09
) O 0 3.3714622205138767e-09
had O 0 4.005461207157168e-08
significantly O 0 3.769484635540721e-08
lower O 0 3.750151122972056e-08
frequencies O 0 7.620176489808728e-08
of O 0 7.768807819275025e-09
the O 0 5.990118268073275e-08
Tyr O 0 6.430305347748799e-06
allele O 0 3.692828158818884e-06
. O 0 2.0299354730468622e-07

Comparisons O 0 3.288855623395648e-06
with O 0 1.0365089053721022e-07
allele O 0 1.1690779047057731e-06
frequencies O 0 2.519303734516143e-07
based O 0 1.124402793095669e-08
on O 0 2.429059797748323e-08
prevalence O 0 2.0083796243852703e-06
estimates O 0 6.57529497516407e-08
of O 0 1.2973877971944603e-08
HH B-Disease 1 0.9742564558982849
showed O 0 8.55057623994071e-06
some O 0 6.106024130758669e-09
disagreements O 0 3.216215134216327e-07
with O 0 5.627214694214899e-09
the O 0 7.249423283894885e-09
RFLP O 0 2.5904753329086816e-06
data O 0 3.4369773516118585e-07
, O 0 6.853987155608365e-09
particularly O 0 3.045236240950544e-08
in O 0 1.463680909807863e-08
Finns O 0 7.573556558782002e-06
. O 0 3.592527946238988e-07

The O 0 3.115347453785944e-06
newly O 0 6.531137387355557e-06
described O 0 1.4661559362139087e-06
HFE O 0 3.974089486291632e-05
marker O 0 1.7014127706715954e-06
provides O 0 4.6072781145767294e-08
a O 0 1.1202542005150917e-08
new O 0 3.3189264669886143e-09
approach O 0 1.7749803404853992e-08
to O 0 2.222703576748586e-09
the O 0 1.2453928999178743e-09
screening O 0 2.665745491015059e-08
of O 0 6.8932397567778025e-09
HH B-Disease 0 0.012338075786828995
as O 0 1.7444746092110108e-08
well O 0 1.2380704461634195e-08
as O 0 1.7809174135408057e-09
studies O 0 3.155028238666091e-09
of O 0 6.745998759605243e-10
the O 0 5.030942773487368e-09
relationship O 0 4.4009599520222764e-08
between O 0 1.1151058743053e-08
the O 0 2.815706423575648e-08
HFE O 0 0.00011181525042047724
Tyr O 0 3.5213297451264225e-06
allele O 0 1.0575990927463863e-06
and O 0 3.870802700589593e-08
different O 0 2.550622468788788e-07
disorders O 1 0.8643885254859924
including O 0 3.3984881611104356e-06
cancer B-Disease 0 0.07778958231210709

Autosomal B-Disease 1 0.9999685287475586
dominant I-Disease 1 0.9988395571708679
neurohypophyseal I-Disease 1 0.9998425245285034
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999008178710938
associated O 0 7.368016667896882e-05
with O 0 1.361466388516419e-07
a O 0 1.818619637106167e-07
missense O 0 2.7518388378666714e-05
mutation O 0 3.7193858588580042e-06
encoding O 0 3.503529796944349e-06
Gly23 O 0 0.00015838636318221688
- O 0 0.00023852147569414228
- O 0 0.00012158617028035223
> O 0 7.738744898233563e-06
Val O 0 0.00044219967094250023
in O 0 2.871192918973975e-07
neurophysin O 0 0.00011337029718561098
II O 0 6.633689918089658e-05
. O 0 7.538770887549617e-07

Autosomal B-Disease 1 0.999966025352478
dominant I-Disease 1 0.997322142124176
neurohypophyseal I-Disease 1 0.9999279975891113
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999786615371704
( O 0 2.5708193788887e-05
ADNDI B-Disease 0 0.002070461167022586
) O 0 6.972383204129073e-08
is O 0 1.913538305586826e-08
an O 0 2.6294183044228703e-06
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 4.018388608528767e-06
by O 0 1.497859791754763e-08
progressive O 0 1.1921782061108388e-05
degeneration O 0 1.359673206025036e-05
of O 0 3.4149991723353423e-09
the O 0 1.809936911456589e-08
magnocellular O 0 2.660902509887819e-06
neurons O 0 1.1499398056002974e-07
of O 0 2.9245603716532287e-09
the O 0 9.213447782485673e-09
hypothalamus O 0 5.050458184996387e-07
leading O 0 1.2924215297971386e-07
to O 0 9.644125498198264e-09
decreased O 0 4.177185530807037e-07
ability O 0 6.594838453111151e-08
to O 0 8.573083576379759e-09
produce O 0 6.07097874194551e-08
the O 0 7.598377038675608e-08
hormone O 0 2.0491224859142676e-06
arginine O 0 1.2136133591411635e-06
vasopressin O 0 1.1042775440728292e-06
( O 0 8.112656502134996e-08
AVP O 0 2.9823315799148986e-06
) O 0 1.1741321515046366e-07
. O 0 1.592913747572311e-07

Affected O 0 8.46862603793852e-05
individuals O 0 6.544066195601772e-07
are O 0 2.6908789863000493e-08
not O 0 2.6485041715318403e-08
symptomatic O 0 5.818492923026497e-07
at O 0 1.7348676806250296e-07
birth O 0 6.8239432948757894e-06
, O 0 6.2078249207786484e-09
but O 0 6.306053013105384e-09
usually O 0 2.2188804393863393e-07
develop O 0 3.7453202821779996e-05
diabetes B-Disease 1 0.9775760173797607
insipidus I-Disease 0 0.005147797521203756
at O 0 1.3100742535243626e-06
1 O 0 4.514426450441533e-07
- O 0 8.022726979106665e-05
6 O 0 9.919803005686845e-07
yr O 0 9.425673488294706e-05
of O 0 2.2474131000649322e-08
age O 0 7.532332233495254e-07
. O 0 1.3238680196536734e-07

The O 0 1.0796304650284583e-06
genetic O 0 4.374920990812825e-06
locus O 0 2.828420292644296e-06
of O 0 2.758424422211192e-08
the O 0 5.747081104345853e-07
disease O 0 0.00623907707631588
is O 0 2.8210482838630924e-09
the O 0 9.249332855176817e-09
AVP O 0 3.498203295748681e-05
- O 0 5.483543282025494e-05
neurophysin O 0 2.4065309844445437e-05
II O 0 1.0763411410152912e-05
( O 0 6.197712565381153e-08
NPII O 0 1.1817738823083346e-06
) O 0 4.813799581171452e-09
gene O 0 3.47450708204633e-08
, O 0 1.2893056622331756e-09
and O 0 4.9566497573039214e-09
mutations O 0 4.2235399178025546e-07
that O 0 3.2383602466268258e-09
cause O 0 6.945743535879956e-08
ADNDI B-Disease 0 7.071875188557897e-06
have O 0 4.011961323158175e-07
been O 0 1.2037253327434883e-07
found O 0 1.1020661716543145e-08
in O 0 1.011810080164821e-09
both O 0 3.044874574698042e-09
the O 0 2.1082542378536573e-09
signal O 0 4.7415937842743006e-08
peptide O 0 1.570090724101192e-08
of O 0 6.561908794111559e-10
the O 0 8.93631835197084e-09
prepro O 0 3.29622844219557e-06
- O 0 2.6980590064340504e-06
AVP O 0 8.234854249167256e-06
- O 0 3.7710276501456974e-06
NPII O 0 3.6512712995317997e-06
precursor O 0 2.427981087294029e-07
and O 0 3.039561136120028e-08
within O 0 7.866056961347567e-08
NPII O 0 9.905235856422223e-06
itself O 0 3.660995560039737e-07
. O 0 1.2498820467499172e-07

An O 0 3.1085394311958225e-06
affected O 0 9.928009603754617e-06
girl O 0 5.415063787950203e-05
who O 0 1.6418177040122828e-07
presented O 0 3.384271707318476e-08
at O 0 1.210277105201385e-07
9 O 0 5.969109651005056e-08
months O 0 8.578513899237805e-09
of O 0 1.6172997385766053e-09
age O 0 2.0147416535110096e-07
and O 0 1.642311886485004e-08
her O 0 1.6722256646062306e-07
similarly O 0 2.532746066208347e-07
affected O 0 8.16793033209251e-08
younger O 0 1.3821087918586272e-07
brother O 0 1.6045531481267972e-07
and O 0 3.121545688600236e-08
father O 0 5.058773240307346e-07
were O 0 2.5399035052942054e-07
all O 0 2.045277280871005e-09
found O 0 6.8578840384248e-09
to O 0 3.425508765531049e-09
have O 0 2.4153385069780597e-08
a O 0 2.7979005778888677e-08
novel O 0 1.946037713196347e-07
missense O 0 3.7236300158838276e-06
mutation O 0 2.0093775674467906e-06
( O 0 6.07122174756114e-08
G1758 O 0 1.7181176872327342e-06
- O 0 1.4947459021641407e-05
- O 0 3.8743182813050225e-05
> O 0 3.024273837581859e-06
T O 0 6.077552370697958e-06
) O 0 9.327389527413743e-09
encoding O 0 7.64058114555155e-08
the O 0 2.30235528420053e-08
amino O 0 1.3657253816745651e-07
acid O 0 5.937475933137648e-08
substitution O 0 4.4750080974154116e-08
Gly23 O 0 2.4885434868338052e-06
- O 0 7.006402938714018e-06
- O 0 1.1587302651605569e-05
> O 0 2.867240937121096e-06
Val O 0 0.00011345215170877054
within O 0 1.628731638447789e-06
NPII O 0 4.992828326066956e-05
. O 0 6.860437906652805e-07

The O 0 4.36343270848738e-06
mutation O 0 4.163654739386402e-05
was O 0 6.883433911752945e-07
confirmed O 0 1.2140735350385512e-07
by O 0 6.659655937824027e-09
restriction O 0 1.1216658180046579e-07
endonuclease O 0 1.1505981092341244e-05
analysis O 0 1.8205682863481343e-06
. O 0 9.2012089680793e-07

A O 0 2.360663165745791e-05
T1 O 0 0.00022210249153431505
- O 0 5.875705028302036e-06
weighted O 0 5.994049843138782e-07
magnetic O 0 1.962219187134906e-07
resonance O 0 4.319420270348928e-07
imaging O 0 1.751939271343872e-05
of O 0 2.6055486657128313e-08
the O 0 5.878394517822016e-07
fathers O 0 0.0023481526877731085
pituitary O 0 0.00017726361693348736
gland O 0 6.874453447380802e-06
demonstrates O 0 4.119399648061517e-07
an O 0 9.460733707555846e-08
attenuated O 0 0.00012476241681724787
posterior O 0 0.09289587289094925
pituitary O 0 0.014728516340255737
bright O 0 3.905489938915707e-05
spot O 0 6.460945587605238e-05
. O 0 2.250968918815488e-06

This O 0 5.652340178130544e-07
mutation O 0 5.933676220593043e-06
may O 0 1.532831390704814e-07
be O 0 2.864730230811574e-09
valuable O 0 3.6642275880183206e-09
for O 0 8.996307587771923e-10
developing O 0 1.547660488654401e-08
models O 0 5.967948624174824e-08
of O 0 5.494721566634553e-09
dominantly B-Disease 0 0.006215736735612154
inherited I-Disease 1 0.8871764540672302
neurodegeneration I-Disease 1 0.9999998807907104
, O 0 1.8120299927204542e-08
as O 0 2.3827442241497465e-09
the O 0 9.37064426054235e-10
early O 0 4.974312961536498e-09
age O 0 1.539622473956115e-08
of O 0 8.160915276889114e-10
onset O 0 3.027127604582347e-06
of O 0 1.7519637296459223e-08
symptoms O 0 0.0005361670046113431
suggests O 0 2.276356703134752e-08
that O 0 1.2345092725851714e-09
this O 0 2.3226343071058864e-09
mutation O 0 1.5821568695173482e-06
may O 0 8.16746279497238e-08
be O 0 3.4357161560194527e-09
particularly O 0 7.278074587446781e-09
deleterious O 0 8.227140142480494e-07
to O 0 1.9127320172174223e-08
the O 0 3.324604946897125e-08
magnocellular O 0 1.030988642014563e-05
neuron O 0 1.9867520677507855e-06
. O 0 6.964235410578112e-08
. O 0 2.4970773893073783e-07

Frequent O 0 0.0002577610139269382
inactivation O 0 0.00019651700858958066
of O 0 8.878318453753309e-07
PTEN O 0 0.00025082300999201834
/ O 0 0.00019405415514484048
MMAC1 O 0 0.00025133005692623556
in O 0 1.2951819599038572e-06
primary O 1 0.9999920129776001
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.6170779367239447e-06

Sporadic B-Disease 1 0.999994158744812
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 4.672206443956384e-07
the O 0 8.349352320635717e-09
most O 0 6.6893179884175424e-09
common O 0 1.8214628028090374e-07
male B-Disease 0 9.27355868043378e-05
cancer I-Disease 0 4.3677296162059065e-06
in O 0 2.3939277227214006e-09
the O 0 3.800352033067611e-09
Western O 0 1.4039563289713897e-08
world O 0 3.0890359425939096e-07
, O 0 2.8846773858504093e-09
yet O 0 1.4876658793738784e-09
many O 0 1.4898061950763264e-10
of O 0 8.118743871632361e-11
the O 0 6.270045593836926e-10
major O 0 7.502548804438902e-09
genetic O 0 5.292839588832976e-08
events O 0 1.1897554053064141e-08
involved O 0 1.9764884839901242e-08
in O 0 1.3570539136864568e-09
the O 0 2.8641073956947594e-09
progression O 0 5.229180999322125e-08
of O 0 5.894860710675687e-10
this O 0 1.9339714274480002e-09
often O 0 7.358235052379314e-06
fatal O 1 0.9154031276702881
cancer B-Disease 0 0.08657438308000565
remain O 0 2.380441088689622e-07
to O 0 1.9529140971030756e-08
be O 0 2.7552175652090227e-07
elucidated O 0 1.0866123375308234e-05
. O 0 2.836846704212803e-07

Numerous O 0 1.807997250580229e-05
cytogenetic O 0 0.00031864471384324133
and O 0 1.2916541436425177e-06
allelotype O 0 1.749284638208337e-05
studies O 0 4.507891731009295e-07
have O 0 2.822888802711532e-07
reported O 0 3.4234537338306836e-07
frequent O 0 1.279501816497941e-06
loss O 0 9.21983939861093e-07
of O 0 1.85991133605512e-08
heterozygosity O 0 9.661980584496632e-06
on O 0 6.10653955845919e-07
chromosomal O 0 0.07131674140691757
arm O 0 0.010142362676560879
10q O 0 1.3625055544252973e-05
in O 0 5.601452244263783e-07
sporadic B-Disease 1 0.9999561309814453
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9864678506564815e-06

Deletion O 0 0.00039282700163312256
mapping O 0 3.973949424107559e-05
studies O 0 4.474710749491351e-06
have O 0 1.2560867617139593e-06
unambiguously O 0 2.3821652575861663e-05
identified O 0 6.915405492691207e-07
a O 0 1.4155830285744742e-08
region O 0 3.8753384501433175e-08
of O 0 4.812973131151921e-09
chromosome O 0 1.3824393136019353e-05
10q23 O 0 3.1487661544815637e-07
to O 0 1.4259294189855609e-08
be O 0 8.773559656560792e-09
the O 0 4.918686791199889e-09
minimal O 0 3.824525265372358e-07
area O 0 1.2464599308259494e-07
of O 0 1.2040232810761609e-08
loss O 0 1.2828435274059302e-06
. O 0 1.731591652287534e-07

A O 0 5.140538632986136e-06
new O 0 4.3616091716103256e-07
tumor B-Disease 0 1.3787894204142503e-05
suppressor O 0 5.23001654073596e-06
gene O 0 1.2432597031875048e-06
, O 0 4.532303066184795e-08
PTEN O 0 2.3328630049945787e-05
/ O 0 1.7705862774164416e-05
MMAC1 O 0 3.307584847789258e-05
, O 0 4.277435294852694e-08
was O 0 2.734363135914464e-07
isolated O 0 3.082144246491225e-07
recently O 0 9.523812138922949e-08
at O 0 1.075354827406727e-08
this O 0 5.64294666549614e-10
region O 0 3.386000591021343e-09
of O 0 5.141490566629159e-10
chromosome O 0 5.342316399037372e-06
10q23 O 0 2.730490678004571e-07
and O 0 3.6166248662539147e-08
found O 0 2.791972697480105e-08
to O 0 4.190286340133298e-09
be O 0 1.2057928877595714e-08
inactivated O 0 1.062188630385208e-07
by O 0 1.5317309642881582e-09
mutation O 0 7.363377108049463e-08
in O 0 1.3905776974354467e-08
three O 0 0.00018048088531941175
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 2.566961120464839e-05
lines O 0 3.987638046965003e-05
. O 0 7.816475431354775e-07

We O 0 4.5043907448416576e-05
screened O 0 0.00018407359311822802
80 O 0 5.8421206631464884e-05
prostate B-Disease 1 0.9999908208847046
tumors I-Disease 1 1.0
by O 0 5.546192483052437e-08
microsatellite O 0 2.5073268261621706e-06
analysis O 0 1.559632920589138e-07
and O 0 1.414431238799807e-07
found O 0 3.7999484447936993e-07
chromosome O 0 1.7818136257119477e-05
10q23 O 0 7.750619488433586e-07
to O 0 2.7775888256087455e-08
be O 0 4.182590629397964e-08
deleted O 0 9.71333520283224e-07
in O 0 1.706076879770535e-08
23 O 0 1.4775324075344543e-07
cases O 0 6.556559384307548e-08
. O 0 1.2464705889669858e-07

We O 0 1.669048288022168e-05
then O 0 1.591571390235913e-07
proceeded O 0 1.411192158684571e-07
with O 0 4.1869467892752255e-09
sequence O 0 2.1721353604675642e-08
analysis O 0 1.1288832979516883e-08
of O 0 2.774998231203085e-09
the O 0 1.5481180781762305e-08
entire O 0 5.868245693818608e-07
PTEN O 0 1.5565537978545763e-05
/ O 0 2.121079205608112e-06
MMAC1 O 0 6.3995753407652956e-06
coding O 0 3.086278411501553e-06
region O 0 4.296094004985207e-07
and O 0 1.409920855621749e-07
tested O 0 4.3448430915304925e-06
for O 0 6.0249267797019e-09
homozygous O 0 1.3150036011211341e-06
deletion O 0 2.2086895512529736e-07
with O 0 6.017828901860867e-09
new O 0 7.716734806706427e-09
intragenic O 0 2.22786752601678e-06
markers O 0 3.1271049465431133e-06
in O 0 5.297846161766984e-09
these O 0 6.182455880576754e-09
23 O 0 3.547058824437954e-08
cases O 0 4.717451762559222e-09
with O 0 1.4853926977309584e-08
10q23 O 0 5.650896582665155e-06
loss O 0 4.96334109811869e-07
of O 0 3.0954108609648756e-08
heterozygosity O 0 2.3491760657634586e-05
. O 0 4.6201611780816165e-07

The O 0 3.0514669902004243e-07
identification O 0 1.894664762858156e-07
of O 0 8.120299987979251e-09
the O 0 2.3315214647823268e-08
second O 0 2.3045723196446488e-07
mutational O 0 5.402212991612032e-06
event O 0 3.7525842344621196e-07
in O 0 8.358864711510705e-09
10 O 0 1.703485352777534e-08
( O 0 9.678326584605657e-09
43 O 0 1.4187489227879269e-07
% O 0 1.7953163933270844e-07
) O 0 4.133669619932334e-07
tumors B-Disease 1 1.0
establishes O 0 7.05062893757713e-06
PTEN O 0 4.634202196029946e-05
/ O 0 2.8728614779538475e-05
MMAC1 O 0 3.0750750738661736e-05
as O 0 5.5285646283209644e-08
a O 0 1.9019925190377762e-08
main O 0 1.445820885237481e-07
inactivation O 0 9.85144197329646e-07
target O 0 1.957221797965758e-07
of O 0 8.66202132243643e-09
10q O 0 2.3813588541088393e-06
loss O 0 7.194238378360751e-07
in O 0 1.283281250152868e-07
sporadic B-Disease 1 0.9997411370277405
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5088366467352898e-07
. O 0 2.4061728254309855e-07

Risk O 0 0.0008495693327859044
reversals O 0 1.0377654689364135e-05
in O 0 1.333215777776786e-07
predictive O 0 6.353724074870115e-06
testing O 0 1.693048579909373e-05
for O 0 4.265863935870584e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 7.108042723302788e-07

The O 0 4.809382971870946e-07
first O 0 1.5960156929395453e-07
predictive O 0 2.1893945358897327e-06
testing O 0 3.4273089113412425e-06
for O 0 7.524355396526516e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 5.941259217934203e-08
HD B-Disease 0 3.723255213117227e-05
) O 0 2.667780130138908e-08
was O 0 8.71400871460537e-08
based O 0 3.647728785693971e-09
on O 0 3.784553559427195e-09
analysis O 0 1.7702232568694853e-08
of O 0 5.903347588542829e-09
linked O 0 1.049337697622832e-06
polymorphic O 0 7.021936312412436e-07
DNA O 0 4.1473319356555294e-07
markers O 0 6.353296839733957e-07
to O 0 1.4913570822727706e-08
estimate O 0 1.1174249436862738e-07
the O 0 1.1977518532546583e-08
likelihood O 0 5.515967060887306e-08
of O 0 1.9620456370716965e-09
inheriting O 0 5.117379373587028e-07
the O 0 2.676669019763267e-08
mutation O 0 7.031378004285216e-07
for O 0 3.631888390032145e-08
HD B-Disease 0 8.132164657581598e-05
. O 0 9.905838851409499e-07

Limits O 0 1.1520288353494834e-05
to O 0 1.6602460561898624e-07
accuracy O 0 7.529314984822122e-07
included O 0 2.8319236733409525e-08
recombination O 0 7.892597153613679e-08
between O 0 2.5461572406015875e-08
the O 0 1.6797901736254062e-08
DNA O 0 3.0148808605190425e-07
markers O 0 3.4339407193328952e-06
and O 0 5.3821402445919375e-08
the O 0 1.966096085936897e-08
mutation O 0 1.6413337107223924e-06
, O 0 7.850943894993634e-09
pedigree O 0 5.81859808335139e-07
structure O 0 1.5520627982823498e-07
, O 0 3.7688070442243315e-09
and O 0 5.450308648846658e-09
whether O 0 6.022077059242292e-09
DNA O 0 6.259726603730087e-08
samples O 0 6.235179483837783e-08
were O 0 9.389115263047643e-08
available O 0 6.390788342969245e-09
from O 0 6.8959353782815924e-09
family O 0 4.9096723131469844e-08
members O 0 1.6642717426407216e-08
. O 0 4.9391744028071116e-08

With O 0 3.4304412110941485e-07
direct O 0 3.1263007826964895e-07
tests O 0 8.866861662681913e-07
for O 0 3.46035222698049e-09
the O 0 1.3651231256517349e-08
HD B-Disease 0 2.7646912712953053e-05
mutation O 0 3.6455193708206934e-07
, O 0 6.3195511046387765e-09
we O 0 8.18039946892668e-09
have O 0 5.492814647567457e-09
assessed O 0 2.070915527951911e-08
the O 0 2.88928103664432e-09
accuracy O 0 3.5265117048766115e-07
of O 0 6.950339415112694e-09
results O 0 2.498740343526151e-07
obtained O 0 3.335949827487639e-08
by O 0 3.754579758208365e-09
linkage O 0 2.1036485975400865e-07
approaches O 0 4.807727549405172e-08
when O 0 1.0472913203329881e-08
requested O 0 3.2237055247463786e-09
to O 0 6.3321592413956296e-09
do O 0 1.973569681013032e-07
so O 0 4.3227230683839934e-09
by O 0 1.3573802082333941e-09
the O 0 6.629796267532129e-09
test O 0 3.06050424114801e-07
individuals O 0 4.7822837245803385e-08
. O 0 8.933493944596194e-08

For O 0 6.412488460227905e-07
six O 0 9.789427934947526e-08
such O 0 6.050631107257232e-09
individuals O 0 1.4242386825458198e-08
, O 0 6.983307265784333e-09
there O 0 6.15012396565362e-09
was O 0 4.9563595894142054e-08
significant O 0 1.0726405541561235e-08
disparity O 0 4.9056943396408315e-08
between O 0 1.9416454222209723e-08
the O 0 5.978110806381665e-08
tests O 0 2.519131385270157e-06
. O 0 2.337105371452708e-07

Three O 0 1.762466308719013e-05
went O 0 2.639941158122383e-06
from O 0 1.7881545133491272e-08
a O 0 3.215422950120228e-08
decreased O 0 2.5618587642384227e-06
risk O 0 3.290269319222716e-07
to O 0 2.941841881209939e-09
an O 0 2.274268107171906e-09
increased O 0 2.3537199922429863e-07
risk O 0 7.3189526119676884e-06
, O 0 5.1100514930624286e-09
while O 0 5.723903573340294e-09
in O 0 9.247351773211676e-10
another O 0 5.4849840225301705e-09
three O 0 8.964999409499796e-09
the O 0 3.85094942600972e-08
risk O 0 3.285012326159631e-06
was O 0 2.693069518500124e-07
decreased O 0 1.611630295883515e-06
. O 0 8.170469811830117e-08

Knowledge O 0 1.132527813751949e-06
of O 0 2.1589181997683227e-08
the O 0 1.5575217560126475e-08
potential O 0 2.3227197942787825e-08
reasons O 0 4.526443220242982e-09
for O 0 5.915201106709844e-10
these O 0 1.4831017525196444e-09
changes O 0 3.7475751391014e-09
in O 0 4.002076448017533e-09
results O 0 2.3876458499216824e-07
and O 0 1.502489332949608e-08
impact O 0 2.0350132245994246e-08
of O 0 6.799426577330792e-10
these O 0 4.177310497510689e-09
risk O 0 4.190735580777982e-08
reversals O 0 3.2780910430574295e-08
on O 0 1.7516496697567163e-08
both O 0 2.3181705444130785e-07
patients O 0 1.9847756504987046e-07
and O 0 4.9947725955235e-09
the O 0 2.744651839137191e-09
counseling O 0 7.869748941402577e-08
team O 0 4.398576436415169e-08
can O 0 8.62876170515392e-09
assist O 0 1.1317182746495291e-08
in O 0 1.0865037758378548e-09
the O 0 7.786575828561126e-10
development O 0 4.6139389531241193e-10
of O 0 3.1683841661411805e-10
strategies O 0 9.454129035191272e-09
for O 0 6.519517148362297e-10
the O 0 2.968349788190494e-09
prevention O 0 7.843494387316241e-08
and O 0 9.69795088678893e-09
, O 0 1.8276766766689434e-09
where O 0 1.1662534271650316e-09
necessary O 0 3.775627810398419e-09
, O 0 1.0635924363455729e-09
management O 0 1.1126387589044384e-09
of O 0 1.605193616915912e-10
a O 0 7.865063267331607e-09
risk O 0 2.231049478496061e-07
reversal O 0 1.7543948516163255e-08
in O 0 1.160470719518969e-09
any O 0 2.2028840973575825e-09
predictive O 0 3.0703154152433854e-07
testing O 0 3.25911429399639e-07
program O 0 8.768996906383109e-08
. O 0 3.244445423433717e-08
. O 0 1.1234107688551376e-07

A O 0 1.1373746019671671e-05
novel O 0 2.901595280491165e-06
common O 0 5.531538818104309e-07
missense O 0 3.527865555952303e-05
mutation O 0 7.446505151165184e-06
G301C O 0 2.642001390995574e-06
in O 0 1.957669226726466e-08
the O 0 3.648871782502283e-08
N O 0 3.206915789633058e-05
- O 0 2.252743433928117e-05
acetylgalactosamine O 0 9.821602725423872e-05
- O 0 3.599677802412771e-05
6 O 0 1.7097244153774227e-06
- O 0 1.7360425772494636e-05
sulfate O 0 8.026249815884512e-06
sulfatase O 0 3.0310588044812903e-05
gene O 0 2.3356624296866357e-06
in O 0 2.5048458951459907e-07
mucopolysaccharidosis B-Disease 0 7.550475129391998e-05
IVA I-Disease 0 0.00021956406999379396
. O 0 1.6204335224756505e-06

Mucopolysaccharidosis B-Disease 1 0.8824288845062256
IVA I-Disease 1 0.9994896650314331
( O 0 0.029712779447436333
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 6.217947543518676e-07
is O 0 1.4178258567199009e-08
an O 0 4.4472351135027566e-08
autosomal B-Disease 1 0.9991017580032349
recessive I-Disease 1 0.9999922513961792
lysosomal I-Disease 1 0.9999864101409912
storage I-Disease 1 0.9999936819076538
disorder I-Disease 1 0.9999998807907104
caused O 0 1.9662555132526904e-05
by O 0 1.9437093712326714e-08
a O 0 4.975018441655266e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.0851130838318568e-07
N O 0 0.00018691099830903113
- O 0 0.00011808437557192519
acetylgalactosamine O 0 0.0006910022348165512
- O 0 0.0005954064545221627
6 O 0 1.0115808436239604e-05
- O 0 0.0008491315529681742
sulfate O 0 6.976837175898254e-05
sulfatase O 0 9.096116264117882e-05
( O 0 3.126479839465901e-07
GALNS O 0 1.3088631021673791e-05
) O 0 9.32027859334994e-08
. O 0 1.117533656724845e-07

In O 0 1.0995844377248432e-06
previous O 0 3.5980139045932447e-07
studies O 0 8.65721929699248e-08
, O 0 1.91652986814006e-08
we O 0 3.593137165580629e-08
have O 0 7.282976000055896e-09
found O 0 3.934712999864587e-09
two O 0 1.928803117223765e-09
common O 0 2.2812812972006213e-08
mutations O 0 3.038312286207656e-07
in O 0 3.7174257006000744e-09
Caucasians O 0 2.1395943861080013e-07
and O 0 5.6751392918386045e-08
Japanese O 0 7.040765694910078e-07
, O 0 2.7307475392035485e-08
respectively O 0 7.188627932919189e-07
. O 0 1.060866381408232e-07

To O 0 1.570049676047347e-06
characterize O 0 4.13470070270705e-06
the O 0 7.36179046612051e-08
mutational O 0 6.993925580900395e-06
spectrum O 0 3.9802728224458406e-07
in O 0 4.804626474452789e-09
various O 0 4.875841064233555e-09
ethnic O 0 1.4020027805372592e-08
groups O 0 1.0559603857984712e-08
, O 0 5.579909867492461e-09
mutations O 0 1.568478182889521e-07
in O 0 1.0781884274280173e-09
the O 0 3.963668060436021e-09
GALNS O 0 1.388809209856845e-06
gene O 0 1.2116075254198222e-07
in O 0 8.519713823318398e-09
Colombian O 0 2.764365945040481e-06
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 0.9999998807907104
patients O 0 0.0001228238397743553
were O 0 6.03639193741401e-07
investigated O 0 3.278169913301099e-07
, O 0 5.809906777898277e-09
and O 0 7.684569425236987e-09
genetic O 0 5.873866939509753e-07
backgrounds O 0 5.346585680854332e-07
were O 0 1.2691315021129412e-07
extensively O 0 8.726116362822722e-08
analyzed O 0 8.883148439053912e-08
to O 0 1.0073777367836101e-08
identify O 0 7.590365385112818e-07
racial O 0 7.296736725947994e-07
origin O 0 6.330301971502195e-08
, O 0 4.329893776855442e-09
based O 0 4.861178570791935e-09
on O 0 1.09973958828391e-08
mitochondrial O 0 4.835809477299335e-07
DNA O 0 4.1050816435017623e-07
( O 0 1.956970940852898e-08
mtDNA O 0 6.317877705441788e-07
) O 0 4.1876514700334155e-08
lineages O 0 5.931323698860069e-07
. O 0 3.3007916044880403e-07

Three O 0 1.2572368177643511e-05
novel O 0 5.722029072785517e-06
missense O 0 6.110136746428907e-05
mutations O 0 0.00014345177623908967
never O 0 1.3056877833150793e-05
identified O 0 8.595623057772173e-07
previously O 0 3.494579345897364e-07
in O 0 2.8505424687352843e-09
other O 0 2.5256383651139913e-09
populations O 0 2.3192933795712634e-08
and O 0 1.3490774719571164e-08
found O 0 3.0299869280270286e-08
in O 0 1.9472448098412087e-09
16 O 0 2.4404000598110542e-08
out O 0 7.21697457350956e-09
of O 0 1.1848090286648016e-09
19 O 0 1.4611070753289823e-07
Colombian O 0 1.553463675918465e-06
MPS B-Disease 1 0.9999953508377075
IVA I-Disease 1 0.998760461807251
unrelated O 0 5.44875149444124e-07
alleles O 0 6.030700774317665e-07
account O 0 1.732045831204232e-07
for O 0 2.3098634116536232e-08
84 O 0 1.2530703088486916e-06
. O 0 2.595552075490559e-07

2 O 0 1.1604707651713397e-05
% O 0 3.8381026001843566e-07
of O 0 5.747062381544765e-09
the O 0 7.4158905682963905e-09
alleles O 0 1.1982653802533605e-07
in O 0 4.660073216200544e-09
this O 0 2.6872053471294066e-09
study O 0 4.7412683557013224e-08
. O 0 1.1608924666006715e-07

The O 0 2.8651445518335095e-06
G301C O 0 1.983425499929581e-05
and O 0 4.0317758021046757e-07
S162F O 0 8.892241567082237e-06
mutations O 0 6.120279522292549e-06
account O 0 2.3374754221094918e-07
for O 0 2.7660741253043852e-08
68 O 0 2.407729880360421e-06
. O 0 2.990009875247779e-07

4 O 0 5.071876512374729e-05
% O 0 2.5655012905190233e-06
and O 0 1.768983679539815e-07
10 O 0 2.683560467175994e-07
. O 0 1.3268332565985475e-07

5 O 0 7.934556379041169e-06
% O 0 3.7677745012842934e-07
of O 0 1.4771682543823772e-08
mutations O 0 1.7724196368362755e-06
, O 0 1.0328890631683407e-08
respectively O 0 2.2176831748765835e-07
, O 0 9.891791385996385e-09
whereas O 0 3.841705620288849e-08
the O 0 1.3017055877639905e-08
remaining O 0 1.216445895124707e-07
F69V O 0 3.078773488596198e-06
is O 0 5.0891975078570795e-09
limited O 0 8.683012531207623e-09
to O 0 6.5564824680564016e-09
a O 0 5.242592848730965e-08
single O 0 2.3754409994580783e-06
allele O 0 4.78418178317952e-06
. O 0 2.548767099597171e-07

The O 0 2.3822788079996826e-06
skewed O 0 1.0846018085430842e-05
prevalence O 0 2.1922609448665753e-05
of O 0 2.5402101755389594e-08
G301C O 0 4.7036175487846776e-07
in O 0 7.591651751681638e-09
only O 0 1.277268779631413e-08
Colombian O 0 4.0115978094945604e-07
patients O 0 1.3733529158344027e-07
and O 0 3.638376044889924e-09
haplotype O 0 1.2345103073130304e-07
analysis O 0 2.0564502989373068e-08
by O 0 4.04266176090573e-09
restriction O 0 3.190643838024698e-08
fragment O 0 2.4608175408502575e-07
length O 0 4.819810328626772e-07
polymorphisms O 0 1.0054419362859335e-05
in O 0 5.217601017903917e-09
the O 0 6.6946403975975954e-09
GALNS O 0 1.132988018071046e-06
gene O 0 1.6864811414052383e-07
suggest O 0 4.63787230842172e-08
that O 0 3.2937201854821296e-09
G301C O 0 1.733896795030887e-07
originated O 0 3.298858430866858e-08
from O 0 4.168340783650137e-09
a O 0 1.3995073544492698e-08
common O 0 1.1382662279402211e-07
ancestor O 0 9.7331417237001e-07
. O 0 2.4976111490104813e-07

Investigation O 0 2.0519855752354488e-06
of O 0 3.812478155396093e-08
the O 0 3.19604644971605e-08
genetic O 0 1.0926662525889697e-06
background O 0 2.4326584480149904e-07
by O 0 6.146347875102265e-09
means O 0 1.0454252574731981e-08
of O 0 9.244230381177942e-10
mtDNA O 0 3.4630815548553073e-07
lineages O 0 1.21702257160905e-07
indicate O 0 7.101538557208187e-08
that O 0 2.143800248433081e-09
all O 0 3.5115814700503734e-09
our O 0 1.4768477285542758e-07
patients O 0 1.1157700896546885e-07
are O 0 2.5873276854326832e-09
probably O 0 1.7521106343565407e-08
of O 0 2.02860239717495e-09
native O 0 7.150674008471469e-08
American O 0 1.27256055293401e-06
descent O 0 0.0002595992118585855

Low O 0 7.355099660344422e-05
frequency O 0 9.086131285584997e-06
of O 0 2.897169224524987e-07
BRCA1 O 0 0.0004348514194134623
germline O 0 2.1006882889196277e-05
mutations O 0 2.933380301328725e-06
in O 0 3.715166130291436e-08
45 O 0 7.633165637344064e-07
German O 1 0.9999954700469971
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.78667254053289e-06
. O 0 8.219031428779999e-07

In O 0 3.848207370538148e-07
this O 0 1.2158620776858697e-08
study O 0 4.836699574184422e-08
we O 0 4.4763059037222774e-08
investigated O 0 2.8970640642000944e-07
45 O 0 2.443805726670689e-07
German O 1 0.9999369382858276
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.631065960187698e-07
for O 0 1.7473784197363784e-08
germline O 0 3.316716174595058e-05
mutations O 0 7.981527232914232e-06
in O 0 1.480047640001203e-08
the O 0 1.1302614666419686e-07
BRCA1 O 0 0.00013992877211421728
gene O 0 1.2842726391681936e-05
. O 0 9.654855830376619e-07

We O 0 1.5435738532687537e-05
identified O 0 3.1980546282284195e-06
four O 0 1.9849819921091694e-07
germline O 0 8.228809747379273e-06
mutations O 0 2.0609088551282184e-06
in O 0 2.5293902083944886e-08
three O 0 2.3337186121352715e-06
breast B-Disease 1 0.9999901056289673
cancer I-Disease 0 0.00775401433929801
families O 0 1.4951402249607781e-07
and O 0 2.37856365714606e-08
in O 0 2.273371357830456e-08
one O 0 0.0004740724980365485
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.3915877161707613e-07
. O 0 1.6018819604113332e-09
among O 0 2.811583632578163e-09
these O 0 3.6345821907701747e-09
were O 0 1.387477226444389e-07
one O 0 2.6326690161226907e-08
frameshift O 0 1.0796070455398876e-05
mutation O 0 2.0394700186443515e-06
, O 0 1.0929727345398987e-08
one O 0 2.488171979564413e-08
nonsense O 0 2.5642441414674977e-06
mutation O 0 6.762957696082594e-07
, O 0 6.7880532306219266e-09
one O 0 7.4773192082489e-09
novel O 0 5.515199319461317e-08
splice O 0 3.5353215935174376e-05
site O 0 1.3715639397560153e-06
mutation O 0 3.2846114663698245e-06
, O 0 1.22057661755548e-08
and O 0 2.7738776608998705e-08
one O 0 1.3537358256598964e-07
missense O 0 5.045334546593949e-05
mutation O 0 2.1256322725093924e-05
. O 0 8.32938383155124e-07

The O 0 1.981695731956279e-06
missense O 0 7.593307236675173e-05
mutation O 0 5.2591505664167926e-05
was O 0 1.658033852436347e-06
also O 0 8.293233833001068e-08
found O 0 8.186646738295167e-08
in O 0 2.264746079561064e-08
2 O 0 3.103889412159333e-07
. O 0 3.5470765169520746e-07

8 O 0 8.092756615951657e-06
% O 0 1.8615480712469434e-07
of O 0 1.729894782975805e-09
the O 0 2.4568012069181577e-09
general O 0 5.307535744236702e-09
population O 0 3.688770844334499e-09
, O 0 8.691027342244695e-10
suggesting O 0 5.749485776362917e-09
that O 0 3.6503580713720396e-10
it O 0 1.0695122565351767e-09
is O 0 3.3477274286042302e-09
not O 0 1.1344947381530801e-07
disease O 0 1.2539773706521373e-05
associated O 0 2.008782615803284e-07
. O 0 1.63067610969847e-07

The O 0 7.309099601116031e-07
average O 0 2.577635996203753e-06
age O 0 2.107910006543534e-07
of O 0 2.4787647490143172e-08
disease O 0 0.008379763923585415
onset O 0 2.6974315915140323e-05
in O 0 6.637489224914361e-09
those O 0 3.097797218742926e-08
families O 0 7.456244333070572e-08
harbouring O 0 4.729490683530457e-05
causative O 0 3.709419252118096e-05
mutations O 0 1.0028707038145512e-05
was O 0 2.7496579946273414e-07
between O 0 7.928975520599124e-08
32 O 0 1.9501749193295836e-06
. O 0 4.4508846031021676e-07

3 O 0 4.653178257285617e-05
and O 0 1.9486446944938507e-06
37 O 0 7.180246484495001e-06
. O 0 1.655265805311501e-06

4 O 0 3.208671842003241e-05
years O 0 4.8982286671162e-07
, O 0 2.148885869246442e-08
whereas O 0 4.8916788841779635e-08
the O 0 9.436329939660482e-09
family O 0 1.3807623133743618e-07
harbouring O 0 3.3319677186227636e-06
the O 0 2.698331336148385e-08
missense O 0 3.7073768908157945e-06
mutation O 0 1.521223225608992e-06
had O 0 1.1736350558066988e-07
an O 0 5.058268914837072e-09
average O 0 9.89590603239776e-07
age O 0 5.651537549056229e-08
of O 0 3.2538389760361497e-09
onset O 0 9.93705543805845e-06
of O 0 4.876568482359289e-08
51 O 0 7.516232017223956e-06
. O 0 4.544300509223831e-07

2 O 0 5.6166805734392256e-05
years O 0 3.895997451763833e-06
. O 0 1.7034193433573819e-06

These O 0 1.2286487844903604e-06
findings O 0 7.485005539820122e-07
show O 0 5.343908924260177e-07
that O 0 1.485698764014387e-08
BRCA1 O 0 8.158512355294079e-05
is O 0 2.8353394299074353e-08
implicated O 0 3.290830932201061e-07
in O 0 1.5787625651242365e-09
a O 0 2.5723199126304053e-09
small O 0 4.087834515331679e-09
fraction O 0 3.281638072394344e-08
of O 0 1.2723089071187133e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.750595164499828e-07
suggesting O 0 2.6750822712529043e-07
the O 0 9.322088878604973e-09
involvement O 0 6.416562570166207e-08
of O 0 3.114051017050201e-09
another O 0 5.916550449569513e-08
susceptibility O 0 1.2928229807585012e-05
gene O 0 7.088721304171486e-06
( O 0 4.4314819547253137e-07
s O 0 7.687658944632858e-05
) O 0 1.889761279016966e-06

Paternal O 1 0.7890104055404663
transmission O 1 0.8495888710021973
of O 0 4.96115317218937e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 3.8501570088556036e-05

We O 0 2.076387136185076e-05
report O 0 1.7684894260128203e-07
a O 0 1.885090128439515e-08
rare O 0 1.651040015815397e-08
case O 0 2.289371536789986e-08
of O 0 6.633340632333784e-08
paternally O 1 0.9945535659790039
transmitted O 1 0.999998927116394
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.09027551114559174
DM B-Disease 1 1.0
) O 0 6.421474608941935e-06
. O 0 1.639207880543836e-06

The O 0 4.514733518590219e-06
proband O 0 4.002786590717733e-05
is O 0 3.819953775519025e-08
a O 0 1.3599412262976784e-08
23 O 0 5.731729046942746e-08
year O 0 3.626694500269423e-09
old O 0 1.1566185094125103e-06
, O 0 7.617560271455659e-08
mentally B-Disease 1 0.9999997615814209
retarded I-Disease 1 0.9996457099914551
male O 0 1.9058885300182737e-05
who O 0 3.263893631810788e-06
suffers O 0 0.3246782720088959
severe O 1 0.7074419856071472
muscular B-Disease 1 0.989297091960907
weakness I-Disease 1 0.5909944772720337
. O 0 1.694131469776039e-06

He O 0 8.466020517516881e-06
presented O 0 4.080872884060227e-07
with O 0 1.6953971737621032e-07
respiratory O 1 0.5870663523674011
and O 0 5.937735636507568e-07
feeding O 0 6.390686030499637e-05
difficulties O 0 1.691618854238186e-05
at O 0 1.1185630910404143e-06
birth O 0 1.3531303920899518e-05
. O 0 3.5222629435338604e-07

His O 0 2.834127917594742e-05
two O 0 5.674939529853873e-06
sibs O 1 0.8625383377075195
suffer O 0 0.014117228798568249
from O 0 5.551382855628617e-07
childhood O 0 0.07445960491895676
onset O 1 0.9998936653137207
DM B-Disease 1 1.0
. O 0 9.029714419739321e-06

Their O 0 4.049627932545263e-06
late O 0 8.64454420934635e-07
father O 0 5.674522185472597e-07
had O 0 2.7869926810808465e-08
the O 0 1.8380595934175403e-09
adult O 0 4.25285122673813e-08
type O 0 3.33858537260312e-07
of O 0 2.8992522160820045e-08
DM B-Disease 1 1.0
, O 0 1.3271824172989e-07
with O 0 5.9463154400418716e-08
onset O 0 0.00014859484508633614
around O 0 6.572887514266768e-07
30 O 0 1.1563754043208974e-07
years O 0 7.954014336064574e-08
. O 0 1.479026821016305e-07

Only O 0 1.1603815437410958e-06
six O 0 7.88636782544927e-08
other O 0 3.877909549032665e-09
cases O 0 5.1667381484321595e-09
of O 0 4.637197736911958e-09
paternal O 0 0.045252058655023575
transmission O 1 0.5915799140930176
of O 0 3.8844441405672114e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0018551297252997756
been O 0 8.68008555698907e-06
reported O 0 3.095983174716821e-06
recently O 0 1.1865915894304635e-06
. O 0 3.4730035736174614e-07

We O 0 1.8075739944833913e-06
review O 0 4.129275410491573e-08
the O 0 8.48798809016671e-09
sex O 0 8.609662671688056e-08
related O 0 3.263872727643502e-08
effects O 0 1.3198080068832496e-06
on O 0 1.148730746081128e-07
transmission O 0 0.004679394420236349
of O 0 1.682015636106371e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 3.971157184423646e-06

Decreased O 0 0.0013866869267076254
fertility O 0 5.924327706452459e-05
of O 0 7.162836368479475e-08
males O 0 6.251362947296002e-07
with O 0 2.9010056579181764e-08
adult O 0 4.837192682316527e-05
onset O 1 0.983583390712738
DM B-Disease 1 1.0
and O 0 3.100214371443144e-06
contraction O 0 4.102939328731736e-06
of O 0 2.6887434501077223e-09
the O 0 9.603046358108713e-09
repeat O 0 2.328733330614341e-07
upon O 0 1.032132868061808e-08
male O 0 1.8138355528662942e-07
transmission O 0 9.51375966451451e-07
contribute O 0 2.208771121559039e-08
to O 0 4.931979713518331e-09
the O 0 5.249264134477016e-09
almost O 0 3.800107251095142e-08
absent O 0 9.078710405674428e-08
occurrence O 0 7.972514026732824e-08
of O 0 4.689479471409186e-09
paternal O 0 0.0010199017124250531
transmission O 0 0.03956710174679756
of O 0 4.140501005167607e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.1150546924909577e-05

Also O 0 2.2388107936421875e-06
the O 0 7.262546120045954e-08
fathers O 0 5.61470528737118e-07
of O 0 3.1396603095146247e-09
the O 0 1.7910286587152768e-08
reported O 0 5.167367476133222e-07
congenitally O 0 1.2800358490494546e-05
affected O 0 3.659026788227493e-07
children O 0 2.6337522740504937e-07
showed O 0 4.5599114173455746e-07
, O 0 1.9007442286778087e-09
on O 0 8.084786173867542e-09
average O 0 1.873307553523773e-07
, O 0 7.957652314871666e-09
shorter O 0 2.344808081033989e-06
CTG O 0 1.3508792108041234e-05
repeat O 0 2.1421885776362615e-06
lengths O 0 9.06917284737574e-06
and O 0 7.515040323369249e-08
hence O 0 1.7490897619154566e-07
less O 0 1.2514088609805185e-07
severe O 0 0.0059387944638729095
clinical O 0 0.19380861520767212
symptoms O 0 0.03234376385807991
than O 0 1.4412800730667641e-08
the O 0 2.85421624113269e-08
mothers O 0 4.04312140744878e-06
of O 0 3.869501608022574e-09
children O 0 8.066427881203708e-07
with O 0 7.26932694306015e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 8.83830216480419e-06

We O 0 7.650096449651755e-06
conclude O 0 7.633616974089819e-07
that O 0 2.235451113108411e-08
paternal O 0 6.274944462347776e-05
transmission O 0 0.006719626951962709
of O 0 1.748147269609035e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 3.369564751665166e-07
rare O 0 5.094434740726683e-08
and O 0 4.428883215723545e-08
preferentially O 0 4.2830438928831427e-07
occurs O 0 1.689996764753232e-08
with O 0 4.569381761854174e-09
onset O 0 6.1952641772222705e-06
of O 0 5.750563758510907e-08
DM B-Disease 1 1.0
past O 0 1.4811944311077241e-05
30 O 0 2.3388112424527208e-07
years O 0 1.0877402090159194e-08
in O 0 2.4403012943707836e-09
the O 0 7.325831052895637e-09
father O 0 1.7955971998162568e-07
. O 0 5.9647944361529426e-09
. O 0 5.0439165732996116e-08

The O 0 3.8006332943041343e-06
RB1 O 0 0.0002811105805449188
gene O 0 5.0253106564923655e-06
mutation O 0 1.7119906488005654e-06
in O 0 1.8226716136382493e-08
a O 0 7.559145842606085e-08
child O 0 1.3469377336150501e-05
with O 0 2.1822634153068066e-06
ectopic B-Disease 1 0.9999997615814209
intracranial I-Disease 1 0.999996542930603
retinoblastoma I-Disease 1 0.8383173942565918
. O 0 8.055256330408156e-06

The O 0 4.577921117743244e-06
RB1 O 0 0.00033930467907339334
gene O 0 8.480016731482465e-06
mutation O 0 7.990475751284976e-06
was O 0 3.549671987457259e-07
investigated O 0 2.0574709935772262e-07
in O 0 5.8507523270634465e-09
a O 0 2.567860413194012e-08
child O 0 6.687280801997986e-06
with O 0 3.6206424169904494e-07
ectopic B-Disease 1 0.9999961853027344
intracranial I-Disease 1 0.9373838901519775
retinoblastoma I-Disease 0 8.681564941070974e-05
using O 0 6.860686880827416e-07
DNA O 0 1.0169879942623083e-06
obtained O 0 5.1660514088780474e-08
from O 0 4.786798957212568e-09
both O 0 8.835004727814066e-09
the O 0 1.1246945597065405e-08
pineal B-Disease 0 9.045737101587292e-07
and I-Disease 0 2.6257293939124793e-07
retinal I-Disease 0 4.1274619434261695e-05
tumours I-Disease 1 1.0
of O 0 1.9073912227440815e-08
the O 0 1.7405518804025633e-07
patient O 0 8.728096872800961e-06
. O 0 1.5448667056716658e-07

A O 0 1.0252507308905479e-05
nonsense O 0 1.612767118785996e-05
mutation O 0 2.4627549919387093e-06
in O 0 2.2414711864371384e-08
exon O 0 2.4203252451115986e-06
17 O 0 3.178026588557259e-07
( O 0 2.4635312456666725e-08
codon O 0 2.9496291631403437e-07
556 O 0 1.3858333147709345e-07
) O 0 1.9441646070816887e-09
of O 0 5.545900960690631e-10
the O 0 1.0469856981387693e-08
RB1 O 0 1.9819206045212923e-06
gene O 0 1.2551450367936923e-07
was O 0 7.042566352311042e-08
found O 0 5.031307814817865e-09
to O 0 3.0735534117809493e-09
be O 0 7.879928709542128e-09
present O 0 7.824066727835088e-09
homozygously O 0 4.2356529661446984e-07
in O 0 1.6645472777909731e-09
both O 0 5.697446070485057e-09
the O 0 7.0911139182783245e-09
retinal B-Disease 0 1.9207369916784955e-07
and I-Disease 0 8.734609480143263e-08
the I-Disease 0 5.075101512375113e-07
pineal I-Disease 0 0.0008970845374278724
tumours I-Disease 1 0.9999997615814209
. O 0 1.3573817341239192e-06

The O 0 1.2829598290409194e-06
same O 0 2.4129792564053787e-07
mutation O 0 8.508348514624231e-07
was O 0 8.055820899244281e-08
present O 0 1.0296847818835886e-08
heterozygously O 0 5.792250590275216e-07
in O 0 5.6988591623508e-09
the O 0 2.8408866370455144e-09
DNA O 0 2.9422812630741646e-08
from O 0 1.3270902154971509e-09
the O 0 1.591138887313548e-09
constitutional O 0 7.717146921493168e-09
cells O 0 5.9549614128684425e-09
of O 0 5.475113695752043e-10
the O 0 9.856310434486204e-09
patient O 0 3.810486930433399e-07
, O 0 3.80974318758831e-09
proving O 0 1.4481751975381485e-07
it O 0 1.7892863857227326e-09
to O 0 5.26865351346828e-09
be O 0 5.7307092404812465e-09
of O 0 3.0920697113856477e-09
germline O 0 5.825149855809286e-06
origin O 0 3.1876274420028494e-07
. O 0 2.9703571158279374e-07

The O 0 1.0589180874376325e-06
initial O 0 8.090719916253875e-07
mutation O 0 2.46529975811427e-06
was O 0 2.5768395062186755e-07
shown O 0 3.5750556293123736e-08
to O 0 9.335754391770479e-09
have O 0 6.457422330186091e-08
occurred O 0 9.233789199925013e-08
in O 0 2.022205070062455e-09
the O 0 1.6676844794005774e-08
paternally O 0 6.871556252008304e-06
derived O 0 1.0817772135851556e-06
RB1 O 0 2.5973771698772907e-05
allele O 0 1.1704416465363465e-05
. O 0 8.081927944658673e-07

The O 0 3.460695097601274e-06
mutation O 0 7.33200886315899e-06
is O 0 3.23832480830788e-08
in O 0 1.3096043138816071e-09
an O 0 8.80739037256717e-10
area O 0 1.8853347327763004e-08
of O 0 4.2936890154443574e-10
the O 0 2.40882735980108e-09
gene O 0 3.102888612716015e-08
that O 0 5.760393273490649e-10
encodes O 0 8.943479734568882e-09
the O 0 2.9082618535625215e-09
protein O 0 3.612832699673163e-08
- O 0 9.964815461671606e-08
binding O 0 3.3670232824078994e-08
region O 0 1.7336610369511618e-08
known O 0 1.5706538292192818e-08
as O 0 3.986701635483314e-09
the O 0 2.111465668974688e-09
pocket O 0 1.4295314940682147e-06
region O 0 3.8544399671991414e-08
and O 0 2.7391202195303777e-08
has O 0 8.922335759109501e-09
been O 0 1.0730969002281654e-08
detected O 0 3.2059737975487224e-08
in O 0 2.793237585674291e-10
other O 0 6.246267947318529e-10
cases O 0 2.746458394042861e-09
of O 0 3.457277797380698e-09
retinoblastoma B-Disease 0 2.955704530904768e-06
. O 0 6.409259611928064e-08
. O 0 2.2546483080532198e-07

Low O 0 0.0015643106307834387
levels O 0 5.743559540860588e-06
of O 0 2.9315202709767618e-08
beta O 0 2.2718204206739756e-07
hexosaminidase O 0 9.0651769824035e-07
A O 0 2.947999711011562e-08
in O 0 9.101906783826053e-09
healthy O 0 1.149952950640909e-07
individuals O 0 4.16113588030953e-09
with O 0 7.262197065927012e-09
apparent O 0 8.249275560956448e-05
deficiency O 0 6.130635301815346e-05
of O 0 1.2627342504956118e-09
this O 0 3.9308876154109385e-09
enzyme O 0 1.452524088563223e-06
. O 0 2.4700011636014096e-07

Appreciable O 0 0.0006744799902662635
beta O 0 4.65715529571753e-05
hexosaminidase O 0 0.00012779074313584715
A O 0 1.0891538977375603e-06
( O 0 7.355698983246839e-08
hex O 0 2.960685208108771e-07
A O 0 1.82113559787922e-08
) O 0 1.575303443246412e-09
activity O 0 1.6264880997596265e-08
has O 0 8.915650440144418e-09
been O 0 1.0597860367056455e-08
detected O 0 1.1139201916421371e-07
in O 0 3.111949142819981e-09
cultured O 0 6.572937536475365e-07
skin O 0 0.0001961183297680691
fibroblasts O 0 1.3181991107558133e-06
and O 0 1.958713255589828e-06
melanoma B-Disease 0 0.32061293721199036
tissue O 0 2.040225444943644e-05
from O 0 4.70722554268832e-08
healthy O 0 5.859113798578619e-07
individuals O 0 2.4795969721935762e-08
previously O 0 5.11949792780797e-07
reported O 0 6.754231094419083e-07
as O 0 1.3488593708643748e-07
having O 0 0.00017138253315351903
deficiency B-Disease 0 2.0749263057950884e-05
of I-Disease 0 1.1666805299626049e-09
hex I-Disease 0 2.408879709037137e-07
A I-Disease 0 2.2479275330056225e-08
activity O 0 2.4241769480681796e-08
indistinguishable O 0 6.162890286987022e-08
from O 0 5.278638637307154e-10
that O 0 2.484366323773912e-10
of O 0 1.051014830721897e-09
patients O 0 4.2078642081833095e-07
with O 0 1.0814577763085254e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9976848363876343
( O 0 2.041412869857595e-07
TSD B-Disease 0 6.84583792462945e-05
) O 0 3.260898893131525e-07
. O 0 1.7601556123736373e-07

Identification O 0 1.612152118468657e-05
and O 0 1.5752628996779094e-06
quantitation O 0 2.2388650904758833e-05
of O 0 7.276342728346208e-08
hex O 0 4.2988663153664675e-06
A O 0 2.415011977063841e-07
, O 0 1.0634105152007578e-08
amounting O 0 6.794039819624231e-08
to O 0 3.270216097917e-08
3 O 0 5.087089789412857e-07
. O 0 2.4129931830429996e-07

5 O 0 3.0655795853817835e-05
% O 0 5.282514848659048e-06
- O 0 5.219489321461879e-05
6 O 0 2.2613676264882088e-06
. O 0 6.657867288595298e-07

9 O 0 2.678107557585463e-05
% O 0 3.925315468222834e-07
of O 0 8.667424999941886e-09
total O 0 2.4958056954460517e-08
beta O 0 7.906851351435762e-08
hexosaminidase O 0 6.566884849235066e-07
activity O 0 9.809689061057725e-08
, O 0 4.716354418121682e-09
has O 0 5.506640476937719e-09
been O 0 1.7806803143116667e-08
obtained O 0 3.956961691642391e-08
by O 0 2.332068582688862e-08
cellulose O 0 1.0256801033392549e-05
acetate O 0 1.1647171049844474e-05
gel O 0 5.3145067795412615e-05
electrophoresis O 0 7.044377980491845e-06
, O 0 9.401122014196517e-08
DEAE O 0 7.2761031333357096e-06
- O 0 1.8206479808213771e-06
cellulose O 0 2.3452598725270946e-06
ion O 0 1.1876986718561966e-06
- O 0 2.4563980787206674e-06
exchange O 0 1.3913661689457513e-07
chromatography O 0 7.088465849847125e-07
, O 0 1.74997989432768e-08
radial O 0 2.077246790577192e-06
immunodiffusion O 0 4.675033324019751e-06
, O 0 2.2756447393135204e-08
and O 0 1.0134893813074086e-07
radioimmunoassay O 0 1.258403790416196e-05
. O 0 2.859841004010377e-07

Previous O 0 2.0835021132370457e-05
family O 0 7.31689624444698e-07
studies O 0 1.23266559626245e-07
suggested O 0 5.766863253597876e-08
that O 0 1.952592754150828e-09
these O 0 2.2830997092881944e-09
individuals O 0 8.534254192227309e-09
may O 0 4.868139669156335e-08
be O 0 5.24635179743882e-09
compound O 0 1.647966207940499e-08
heterozygotes O 0 6.192949797423353e-08
for O 0 5.05979091958153e-10
the O 0 1.0476743916854048e-09
common O 0 1.1575357561355304e-08
mutant O 0 4.3010049921576865e-07
TSD B-Disease 0 1.3786034287477378e-06
gene O 0 2.444206756990752e-07
and O 0 1.5603673020336828e-08
a O 0 1.8199378004624123e-08
rare O 0 4.134129838462286e-08
( O 0 2.33629791068779e-08
allelic O 0 1.4155284588923678e-06
) O 0 4.260271424527673e-08
mutant O 0 2.6325647013436537e-06
gene O 0 3.946872766391607e-06
. O 0 4.092674430467014e-07

Thus O 0 1.1871339665958658e-05
, O 0 9.599423833606124e-08
the O 0 2.2415738598624557e-08
postulated O 0 3.6488549426394457e-07
rate O 0 1.9692473074428563e-07
mutant O 0 6.617026429012185e-07
gene O 0 2.0453376237128396e-07
appears O 0 3.622728073082726e-08
to O 0 1.8039391092017354e-09
code O 0 5.2659507865371324e-09
for O 0 9.320519911426572e-10
the O 0 1.839894125943431e-09
expression O 0 5.5170903401347005e-09
of O 0 1.5306153011707124e-09
low O 0 2.3865402454248397e-06
amounts O 0 2.7346830577812398e-08
of O 0 9.547526325093258e-09
hex O 0 4.113073828193592e-06
A O 0 3.3221144235540123e-07
. O 0 1.749566962416793e-07

Heterozygotes O 0 0.00039427989395335317
for O 0 2.2674437616387877e-07
the O 0 5.869309305239767e-08
rare O 0 7.301463966769006e-08
mutant O 0 2.6189047730440507e-06
may O 0 2.9471067364283954e-07
be O 0 1.362116552883208e-08
indistinguishable O 0 3.038883278350113e-07
from O 0 7.818814928839402e-09
heterozygotes O 0 3.3096424090217624e-07
for O 0 2.654662711876199e-09
the O 0 1.0609713108067353e-08
common O 0 2.912966579060594e-07
TSD B-Disease 0 5.536154640140012e-05
mutant O 0 1.5730494851595722e-05
. O 0 5.644205884891562e-07

However O 0 2.046730060101254e-06
, O 0 5.097069077919514e-08
direct O 0 8.9038941553099e-08
visualization O 0 2.0341440176707692e-06
and O 0 4.7581096396243083e-07
quantitation O 0 1.7737484085955657e-05
of O 0 1.548623096425672e-08
hex O 0 1.5449286365765147e-06
A O 0 2.7212898601192137e-08
by O 0 8.284357644328111e-10
the O 0 1.3871808146603826e-09
methods O 0 6.024618670608106e-08
described O 0 1.7713976774302864e-07
may O 0 6.748012282287164e-08
prevent O 0 3.0879283485774067e-07
false O 0 3.3467335924797226e-07
- O 0 7.3693872764124535e-06
positive O 0 4.280083771845966e-07
prenatal O 1 0.8025146126747131
diagnosis O 0 0.04044443741440773
of O 0 3.813671156649434e-08
TSD B-Disease 0 3.931539322366007e-05
in O 0 2.0697434877092746e-07
fetuses O 0 0.00034718672395683825
having O 0 3.847536049761402e-07
the O 0 6.552557163530537e-09
incomplete O 0 7.483592412427242e-07
hex B-Disease 0 1.7510486713945284e-06
A I-Disease 0 7.036067017907044e-07
deficiency I-Disease 0 2.219894486188423e-05
of O 0 9.211932883168572e-10
the O 0 6.313635392274364e-09
type O 0 6.5314989114995115e-06
described O 0 2.385019683970313e-07
in O 0 3.3793938758464037e-09
the O 0 1.2288294826134916e-08
four O 0 2.385586128639261e-07
healthy O 0 1.0759517863334622e-06
individuals O 0 3.1496793440055626e-07

The O 0 6.081396350055002e-06
tumor B-Disease 0 0.00010807171202031896
suppressor O 0 2.9358761821640655e-05
gene O 0 8.592741323809605e-06
Smad4 O 0 2.3625143512617797e-05
/ O 0 2.3064019842422567e-05
Dpc4 O 0 7.999412446224596e-06
is O 0 2.0686691470928054e-08
required O 0 1.0466522759600139e-08
for O 0 2.368760521065383e-09
gastrulation O 0 4.2217479290229676e-07
and O 0 5.598889529778717e-08
later O 0 3.009884608218272e-08
for O 0 5.513913325927433e-09
anterior O 0 2.309857700311113e-05
development O 0 1.6384634093924433e-08
of O 0 2.0692285662704535e-09
the O 0 3.134319115360995e-08
mouse O 0 4.356908902991563e-06
embryo O 0 2.097583774229861e-06
. O 0 2.9160014491935726e-07

Mutations O 0 0.00039550356450490654
in O 0 2.2493263429623767e-07
the O 0 4.5246588342706673e-07
SMAD4 O 0 0.00017025298438966274
/ O 0 0.00013403080811258405
DPC4 O 0 0.0003665818367153406
tumor B-Disease 0 4.3184492824366316e-05
suppressor O 0 4.706768322648713e-06
gene O 0 1.1829533832496963e-06
, O 0 7.526111289735127e-09
a O 0 1.022196016720045e-08
key O 0 1.6048760187459266e-07
signal O 0 2.112830799205767e-07
transducer O 0 5.031665750721004e-07
in O 0 8.02034083591252e-09
most O 0 1.0635768710187676e-08
TGFbeta O 0 1.2656399803745444e-06
- O 0 5.865313710273767e-07
related O 0 2.6503636618713244e-08
pathways O 0 9.764811892409853e-08
, O 0 3.1213656104256415e-09
are O 0 1.6765691057685217e-09
involved O 0 3.371712908872837e-09
in O 0 9.311387216826006e-10
50 O 0 1.2389350878549976e-08
% O 0 1.562961671197627e-08
of O 0 3.5927261166079916e-08
pancreatic B-Disease 1 0.869445264339447
cancers I-Disease 1 0.9108284711837769
. O 0 7.969121043061023e-07

Homozygous O 0 0.014520915225148201
Smad4 O 0 0.0008400800288654864
mutant O 0 0.00031922824564389884
mice O 0 0.2031901478767395
die O 0 0.003185239154845476
before O 0 2.0090220687052351e-07
day O 0 1.293304308092047e-07
7 O 0 4.1886343637997925e-07
. O 0 1.985917350566524e-07

5 O 0 1.282622542930767e-05
of O 0 7.453868988704926e-07
embryogenesis O 0 4.067622285219841e-05
. O 0 2.9150082809792366e-06

Mutant O 0 0.0002088617766276002
embryos O 0 2.5206758436979726e-05
have O 0 2.387095037192921e-07
reduced O 0 1.3486869931966794e-07
size O 0 1.2715265995666414e-07
, O 0 3.5056338276717725e-08
fail O 0 2.4144303552020574e-06
to O 0 3.471843967872701e-08
gastrulate O 0 5.0412749260431156e-05
or O 0 2.889762811264518e-07
express O 0 7.618723429914098e-08
a O 0 2.800805276592655e-08
mesodermal O 0 2.2316951344691915e-06
marker O 0 4.123320650251117e-06
, O 0 1.8437205540067225e-08
and O 0 1.6771936728332548e-08
show O 0 7.172186542447889e-07
abnormal O 0 7.580970304843504e-06
visceral O 0 5.67510232940549e-06
endoderm O 0 7.42747142794542e-05
development O 0 6.592882755285245e-07
. O 0 7.511786179748015e-07

Growth B-Disease 1 0.999996542930603
retardation I-Disease 1 0.9999997615814209
of O 0 1.1899079765953502e-07
the O 0 1.6091011900698504e-07
Smad4 O 0 8.096670353552327e-05
- O 0 0.00016642999253235757
deficient O 0 7.287316839210689e-05
embryos O 0 7.405610062960477e-07
results O 0 7.051221473375335e-08
from O 0 1.1986865722235507e-08
reduced O 0 1.286258708432797e-07
cell O 0 3.3977420343944686e-07
proliferation O 0 2.348610053104494e-07
rather O 0 9.646958787357107e-09
than O 0 4.600706926538578e-09
increased O 0 7.625236264630075e-08
apoptosis O 0 1.0902908798016142e-06
. O 0 2.5759675281733507e-07

Aggregation O 0 3.019245014002081e-05
of O 0 5.730077532462019e-07
mutant O 0 2.6127450837520882e-05
Smad4 O 0 7.739043940091506e-05
ES O 0 2.5936295060091652e-05
cells O 0 3.441700471285003e-07
with O 0 1.808432337213617e-08
wild O 0 3.3394260867680714e-07
- O 0 4.113881459488766e-06
type O 0 2.812464845192153e-05
tetraploid O 0 3.2325664506061e-05
morulae O 0 3.282765828771517e-05
rescues O 0 1.5282264939742163e-05
the O 0 4.422877282195259e-07
gastrulation B-Disease 0 5.9291145589668304e-05
defect I-Disease 0 0.0001776067219907418
. O 0 1.5697411299697706e-06

These O 0 4.725081907963613e-06
results O 0 1.3471459396896535e-06
indicate O 0 4.915168005936721e-07
that O 0 1.1504592833944116e-08
Smad4 O 0 8.103097570710815e-07
is O 0 3.0978308807050325e-09
initially O 0 1.0306731468290309e-08
required O 0 1.6144980907739637e-09
for O 0 1.978138486347092e-10
the O 0 6.188882184510192e-10
differentiation O 0 3.2932430116261457e-09
of O 0 3.32556593374278e-10
the O 0 3.2156972640251524e-09
visceral O 0 1.6157979132458422e-07
endoderm O 0 2.589916903161793e-06
and O 0 4.128235886469156e-08
that O 0 3.5713534352055376e-09
the O 0 1.34273419050146e-08
gastrulation B-Disease 0 1.2610088333531166e-06
defect I-Disease 0 2.6159841581829824e-06
in O 0 8.684221342036835e-09
the O 0 1.5894290328333227e-08
epiblast O 0 1.7324913414995535e-06
is O 0 7.735303064748678e-09
secondary O 0 1.0782675019527233e-07
and O 0 5.9133125063226544e-08
non O 0 4.088319656148087e-06
- O 0 2.7003423383575864e-05
cell O 0 2.7533681077329675e-06
autonomous O 0 1.0222096307188622e-06
. O 0 2.76365994977823e-07

Rescued O 0 0.0015248334966599941
embryos O 0 0.0001478345220675692
show O 0 6.453827518271282e-05
severe O 0 0.029223589226603508
anterior O 0 0.2618458569049835
truncations O 0 0.00010847572411876172
, O 0 6.021758167662483e-07
indicating O 0 2.4543517156416783e-06
a O 0 2.74692091295492e-08
second O 0 2.1530567551053537e-07
important O 0 1.4404500703335543e-08
role O 0 3.446324114975141e-08
for O 0 1.0611048040232163e-08
Smad4 O 0 3.57897306457744e-06
in O 0 3.7174341827039825e-08
anterior O 0 7.83096402301453e-05
patterning O 0 1.5019403690530453e-05
during O 0 1.2650220924115274e-06
embryogenesis O 0 1.0582715731288772e-05
. O 0 7.581250542898488e-07

Prevalence O 0 0.003404471091926098
of O 0 9.82105007096834e-07
p16 O 0 1.8948518118122593e-05
and O 0 3.105585903995234e-07
CDK4 O 0 5.314020381774753e-05
germline O 0 3.8317513826768845e-05
mutations O 0 4.611542408383684e-06
in O 0 3.452943531101482e-08
48 O 0 2.9059483495075256e-06
melanoma B-Disease 0 0.34577491879463196
- O 0 0.003859691321849823
prone O 1 0.5302945971488953
families O 0 8.052976454564487e-07
in O 0 8.031243936557075e-08
France O 0 8.38831692817621e-05
. O 0 4.95784433951485e-07

The O 0 5.627261543850182e-06
French O 0 0.00030789387528784573
Familial B-Disease 1 0.9885663390159607
Melanoma I-Disease 1 0.9994487166404724
Study O 0 4.955167241860181e-06
Group O 0 3.4229221910209162e-06
. O 0 4.2360932184237754e-07

Germline O 0 0.002042500302195549
mutations O 0 0.00016678393876645714
in O 0 8.52306598631003e-08
the O 0 3.039561136120028e-08
p16 O 0 1.1070466143792146e-06
and O 0 5.886462517423752e-08
CDK4 O 0 5.315787348081358e-06
genes O 0 7.085059223754797e-07
have O 0 1.9822087438114977e-07
been O 0 2.1534140159928938e-07
reported O 0 5.23435019772478e-08
in O 0 4.778221707191221e-10
a O 0 1.3485725869344378e-09
subset O 0 2.3615529087805953e-08
of O 0 7.256118372822584e-09
melanoma B-Disease 0 8.110047201626003e-05
pedigrees O 0 3.813209559666575e-06
, O 0 1.4911408996454156e-08
but O 0 6.883885017572311e-09
their O 0 6.090102999678493e-08
prevalence O 0 1.71905558090657e-05
is O 0 7.51321671543792e-09
not O 0 1.1498384466790412e-08
well O 0 5.005227521337474e-08
known O 0 2.4883317450985487e-07
. O 0 1.370095503716584e-07

We O 0 3.6784977055503987e-06
searched O 0 1.6062264194260933e-06
for O 0 1.0098709424255503e-08
such O 0 1.5348785353808125e-08
germline O 0 4.963642822986003e-06
mutations O 0 1.5575490124319913e-06
in O 0 1.3332103421248576e-08
48 O 0 4.1936263528441486e-07
French O 0 0.00036412960616871715
melanoma B-Disease 1 0.8513684868812561
- O 0 0.0021721343509852886
prone O 0 0.02965579740703106
families O 0 7.440277016712571e-08
selected O 0 9.483096086171372e-09
according O 0 2.185099212681507e-09
to O 0 2.558023570742307e-09
two O 0 1.2141749827776493e-08
major O 0 4.3644050151669944e-08
criteria O 0 2.611529623663955e-07
families O 0 1.3721060732052592e-08
with O 0 4.5498835810064975e-09
at O 0 2.1131069161128835e-07
least O 0 1.5895775362650966e-08
three O 0 1.0201158140432653e-08
affected O 0 2.361701589848053e-08
members O 0 3.88686993701981e-09
( O 0 5.01132912944513e-09
n O 0 9.224086738868209e-07
= O 0 3.5749617381952703e-06
20 O 0 1.5011316634172545e-08
) O 0 1.9513566318352105e-09
or O 0 1.7697201926125672e-08
families O 0 7.45762207543521e-09
with O 0 1.813176941922734e-09
two O 0 2.555654710079125e-08
affected O 0 5.270806724411159e-08
members O 0 1.712828656685872e-09
, O 0 1.2476659705384918e-09
one O 0 9.511350596014267e-10
of O 0 3.6629541066979243e-10
them O 0 3.674880177939599e-09
affected O 0 1.992343712231559e-08
before O 0 3.0959881325287597e-09
the O 0 1.2947074523594893e-09
age O 0 9.84462378283979e-09
of O 0 7.725420303472674e-10
50 O 0 9.983874171837215e-09
( O 0 6.210809644358051e-09
n O 0 2.3168145162344445e-06
= O 0 1.3128222235536668e-05
28 O 0 3.0736171652279154e-07
) O 0 4.2831320712366505e-09
, O 0 2.510078367379265e-09
and O 0 4.406307763105133e-09
one O 0 6.4437997160382565e-09
additional O 0 2.114803976382973e-08
minor O 0 2.456109996273881e-06
criterion O 0 2.3111715563572943e-06
. O 0 3.1332166372521897e-07

Sixteen O 0 3.153229408781044e-05
different O 0 2.117544227075996e-06
p16 O 0 2.126459548890125e-05
germline O 0 1.6304291420965455e-05
mutations O 0 8.534713742847089e-06
were O 0 7.192941779976536e-07
found O 0 9.985173221593868e-08
in O 0 1.0202209743681578e-08
21 O 0 7.990325201490123e-08
families O 0 2.8784244321400365e-08
, O 0 5.814174919294146e-09
while O 0 1.5273702302920356e-08
one O 0 1.8578337090957575e-08
germline O 0 1.071270617103437e-06
mutation O 0 3.3735165061443695e-07
, O 0 6.802413743400848e-09
Arg24His O 0 8.979983476820053e-07
, O 0 6.7889596166992305e-09
was O 0 7.739187424249394e-08
detected O 0 2.8425202458493004e-07
in O 0 4.090330296691036e-09
the O 0 2.0627041408260993e-08
CDK4 O 0 9.778986168385018e-06
gene O 0 2.495383114364813e-06
. O 0 4.2294084323657444e-07

The O 0 3.914642547897529e-07
frequency O 0 5.651547212437436e-07
of O 0 3.734903941676748e-08
p16 O 0 2.9354873731790576e-06
gene O 0 9.608304480934748e-07
mutation O 0 5.116442594044202e-07
in O 0 1.135151261877354e-08
our O 0 2.7248736600427037e-08
sample O 0 7.148914704657727e-08
( O 0 1.8691116210334258e-08
44 O 0 3.37236407688124e-08
% O 0 9.07081432188761e-09
) O 0 9.001559497789913e-10
is O 0 8.973686238533674e-10
among O 0 1.1328449289749187e-09
the O 0 4.177517887171689e-09
highest O 0 1.805665164056336e-07
rates O 0 1.4984960898800637e-06
yet O 0 8.677685769953314e-08
reported O 0 7.720316119730342e-08
and O 0 5.056455254504044e-09
the O 0 9.135752598865565e-09
CDK4 O 0 3.1357176339952275e-06
mutation O 0 1.310377513163985e-07
is O 0 1.477660660498259e-09
the O 0 3.926601266357466e-09
second O 0 2.500022731055651e-07
mutation O 0 9.170888688458945e-07
detected O 0 4.756059297505999e-07
in O 0 4.7608486042349796e-09
this O 0 2.465969872744722e-09
gene O 0 4.1762930891309225e-07
worldwide O 0 2.9593809358630097e-07
. O 0 2.805479084599938e-07

In O 0 7.001007134022075e-07
summary O 0 1.5393003423014306e-06
, O 0 6.229331717122477e-08
our O 0 7.120704026419844e-08
results O 0 6.551871933879738e-08
show O 0 9.530608480190494e-08
frequent O 0 7.742878693761668e-08
involvement O 0 6.136148300583955e-08
of O 0 1.066139510008668e-09
the O 0 5.1251034527410866e-09
p16 O 0 1.711690487127271e-07
gene O 0 8.403260665090784e-08
in O 0 7.244889577151525e-09
familial B-Disease 0 0.0009812648640945554
melanoma I-Disease 0 0.4029494822025299
and O 0 1.8651341804343247e-07
confirm O 0 8.241707405431953e-07
the O 0 6.9761445509186615e-09
role O 0 2.2364277540987132e-08
of O 0 9.170961767779318e-10
the O 0 1.2968632390197854e-08
CDK4 O 0 1.3147064237273298e-06
gene O 0 1.0267062577895558e-07
as O 0 7.370076549051419e-09
a O 0 9.378967291695517e-08
melanoma B-Disease 0 0.0005181684391573071
- O 0 5.577200681727845e-06
predisposing O 0 1.126644838223001e-05
gene O 0 9.445387831874541e-07
. O 0 3.8086554354777036e-08
. O 0 1.1932522170354787e-07

Progression O 0 0.00035993920755572617
of O 0 9.74956719801412e-07
somatic O 0 7.225772424135357e-05
CTG O 0 0.0001873179426183924
repeat O 0 1.2725636224786285e-05
length O 0 1.0811152151291026e-06
heterogeneity O 0 1.0306150670658099e-06
in O 0 1.5263072583593384e-08
the O 0 5.507021327844086e-08
blood O 0 5.609248091786867e-06
cells O 0 2.882611624954734e-07
of O 0 2.1123433668890357e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9849026799201965
. O 0 1.3887894283470814e-06

The O 0 8.251758458754921e-07
genetic O 0 3.0181222427927423e-06
basis O 0 2.572982111814781e-07
of O 0 3.703994764236995e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.025815963745117188
DM B-Disease 1 1.0
) O 0 1.0373831571541814e-07
is O 0 3.4339342480649293e-09
the O 0 9.86531412117131e-10
expansion O 0 3.2519031911704133e-09
of O 0 1.5332859426564482e-09
an O 0 2.5855730001467236e-08
unstable O 0 5.185916234040633e-05
CTG O 0 8.723071914573666e-06
repeat O 0 7.089770406309981e-07
in O 0 4.8043697908894956e-09
the O 0 7.635711618547703e-09
34 O 0 5.098108957213299e-08
UTR O 0 4.10491708180416e-07
of O 0 6.516736039685611e-09
the O 0 1.4768069434012432e-07
DM B-Disease 1 0.9999953508377075
protein O 0 9.620774790164432e-07
kinase O 0 4.470032308745431e-06
gene O 0 1.5385445522042573e-06
on O 0 2.071350877486111e-07
chromosome O 0 5.900270116399042e-05
19 O 0 2.2807691948401043e-06
. O 0 4.1317423438158585e-07

One O 0 1.378295792164863e-06
of O 0 1.3512432062157131e-08
the O 0 1.5542632070264517e-08
principal O 0 3.7214711312572035e-08
features O 0 1.2824977524417136e-08
of O 0 6.00395644312357e-09
the O 0 7.078602379806398e-07
DM B-Disease 1 1.0
mutation O 0 2.07479370146757e-05
is O 0 7.457379602726633e-09
an O 0 3.8111167555143766e-09
extraordinarily O 0 3.5947215337728267e-07
high O 0 1.928177510990281e-07
level O 0 1.3300105194957723e-07
of O 0 4.0345424778820416e-09
somatic O 0 1.5784222568981932e-06
mosaicism O 0 6.773416316718794e-06
, O 0 9.022087077426022e-09
due O 0 2.0052027593919775e-08
to O 0 3.716241758766614e-09
an O 0 2.21836660152519e-09
extremely O 0 6.148519560156274e-08
high O 0 2.6299389332962164e-08
degree O 0 6.17997963914263e-09
of O 0 1.465736421124575e-09
somatic O 0 6.490719215435092e-07
instability O 0 3.53630525751214e-07
both O 0 3.004241122539497e-08
within O 0 9.888659668888522e-09
and O 0 1.4309042839499853e-08
between O 0 1.1996907467448636e-08
different O 0 7.597218143473583e-08
tissues O 0 7.273661140061449e-06
. O 0 2.5111003765232454e-07

This O 0 7.812749345248449e-07
instability O 0 2.5869176170090213e-06
appears O 0 1.3946794297226006e-07
to O 0 7.660276857279769e-09
be O 0 5.975897110488404e-09
biased O 0 4.8994383661238317e-08
towards O 0 5.212358988870847e-09
further O 0 2.938583820721874e-09
expansion O 0 5.3083049067481625e-09
and O 0 2.935704346285206e-09
continuous O 0 3.5819155641547695e-08
throughout O 0 1.4485364019378721e-08
the O 0 3.2689924100992584e-09
life O 0 3.4481897337457212e-09
of O 0 1.664111487498232e-10
an O 0 7.306416582864017e-10
individual O 0 2.0096777575417946e-09
, O 0 1.4740546561142764e-09
features O 0 5.315927253946029e-08
that O 0 1.4688155580699913e-08
could O 0 2.40487224800745e-07
be O 0 6.251956730096708e-09
associated O 0 5.530238489370731e-09
with O 0 8.022982833644221e-10
the O 0 3.6402574288274536e-09
progressive O 0 1.244179657078348e-07
nature O 0 2.0021110103130013e-08
of O 0 4.108619666709501e-09
the O 0 3.821149334726215e-07
disease O 0 0.00015734563930891454
. O 0 1.6151231818639644e-07

Although O 0 7.2865332185756415e-06
increasing O 0 6.875817462059786e-07
measured O 0 2.7840337679663207e-06
allele O 0 8.924260441744991e-07
size O 0 6.437893063093725e-08
between O 0 6.035556054939661e-08
patients O 0 5.362146566767478e-06
clearly O 0 4.7737540143089063e-08
correlates O 0 5.1081055829627076e-08
with O 0 3.0335476353116064e-09
an O 0 2.9788254085616472e-09
increased O 0 8.840132892373731e-08
severity O 0 5.4135180107550696e-06
of O 0 1.4042241147649293e-08
symptoms O 0 0.0002441401593387127
and O 0 8.757893965594121e-09
an O 0 3.2534603899847525e-09
earlier O 0 3.613576993188872e-08
age O 0 7.022124037803223e-08
of O 0 1.5687728893709618e-09
onset O 0 4.31962826041854e-06
, O 0 2.72214495389278e-09
this O 0 4.2772108077571147e-10
correlation O 0 1.721394795595188e-07
is O 0 4.91427032400793e-09
not O 0 6.1058491596099884e-09
precise O 0 1.3143968544682139e-06
and O 0 1.8061577122807648e-07
measured O 0 8.672299372847192e-06
allele O 0 1.0631305258357315e-06
length O 0 9.03520174233563e-07
cannot O 0 1.0749107559604454e-06
be O 0 1.2007666860824884e-08
used O 0 4.322378543974992e-08
as O 0 6.820836340182268e-09
an O 0 2.5796405012101786e-09
accurate O 0 1.1608836757659446e-05
predictor O 0 4.621086554834619e-05
of O 0 7.0306720445501014e-09
age O 0 2.0279017576285696e-07
of O 0 2.499130502542357e-08
onset O 0 0.00014732453564647585
. O 0 7.627227773809864e-07

In O 0 1.0723039167714887e-06
order O 0 1.1291496093690512e-07
to O 0 7.141579771996476e-09
further O 0 1.455301834596412e-08
characterize O 0 4.379323002012825e-07
the O 0 1.6591783946751093e-08
dynamics O 0 6.288891540862096e-07
of O 0 1.321584761626582e-07
DM B-Disease 1 1.0
CTG O 0 0.0001445709349354729
repeat O 0 3.122057023574598e-06
somatic O 0 3.6445114801608725e-06
instability O 0 1.296833147534926e-06
, O 0 2.1099367586430162e-08
we O 0 2.3083307709725887e-08
have O 0 9.773788889333446e-09
studied O 0 7.91987631032498e-08
repeat O 0 5.26399560385471e-07
length O 0 1.1907241059816442e-07
changes O 0 8.024058750777385e-09
over O 0 3.7099667782314327e-09
time O 0 2.208910210299564e-08
in O 0 1.1190348203626854e-08
111 O 0 4.538117536867503e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00024087769270408899
with O 0 1.8581172156473258e-08
varying O 0 7.907572694421106e-07
clinical O 0 7.473197183571756e-05
severity O 0 0.00018433826335240155
and O 0 6.705710120513686e-07
CTG O 0 1.1285427717666607e-05
repeat O 0 7.193449391706963e-07
size O 0 6.347749348378784e-08
over O 0 2.499020901325366e-08
time O 0 3.236972645481728e-08
intervals O 0 1.4881752008477633e-07
of O 0 2.396257636760879e-09
1 O 0 7.538211121982386e-08
- O 0 7.918508345028386e-06
7 O 0 4.088909406618768e-07
years O 0 1.135522040840442e-07
. O 0 1.1349211348488097e-07

We O 0 2.1583540728897788e-05
have O 0 1.9897315439720842e-07
found O 0 3.3301009949582294e-08
a O 0 6.902502125427645e-09
direct O 0 7.395765777573615e-08
progression O 0 1.3605323374576983e-06
of O 0 4.85503459657366e-09
the O 0 7.91940557576254e-09
size O 0 2.8901862236807574e-08
heterogeneity O 0 9.350227259119492e-08
over O 0 1.3018099487283052e-08
time O 0 1.9072782464490956e-08
related O 0 6.1599734202388845e-09
to O 0 4.911496098713997e-09
initial O 0 1.5769779793117777e-07
CTG O 0 3.2074285627459176e-06
repeat O 0 4.753854909722577e-07
size O 0 6.828310716855412e-08
and O 0 1.4508728440887353e-08
the O 0 6.62197363610062e-09
time O 0 2.4579458468565463e-08
interval O 0 2.3265690174412157e-07
and O 0 2.2358690898727218e-08
always O 0 7.218381625762049e-08
biased O 0 1.4647260115907557e-07
towards O 0 4.231393191389543e-08
further O 0 5.031022354273773e-08
expansion O 0 2.9758041364402743e-07
. O 0 2.20528619365723e-07

Attempts O 0 9.041054909175728e-06
to O 0 1.7684708097931434e-07
mathematically O 0 1.4455329164775321e-06
model O 0 1.064319974375394e-07
the O 0 8.142292173829446e-09
dynamics O 0 2.9152815272937005e-07
have O 0 1.789379950878356e-07
proved O 0 7.25800362033624e-07
only O 0 1.6287357240685196e-08
partially O 0 1.4300388784249662e-06
successful O 0 2.195104897850797e-08
suggesting O 0 2.1692372342840827e-08
that O 0 8.0089018750229e-10
individual O 0 8.10103650827898e-10
specific O 0 3.2253906212531547e-09
genetic O 0 2.626470632094424e-07
and O 0 8.759100467159442e-08
/ O 0 3.465880217845552e-05
or O 0 7.374015922323451e-07
environmental O 0 1.7557948694957304e-07
factors O 0 1.4566965944595722e-07
also O 0 2.709755264618252e-08
play O 0 6.456289014522554e-08
a O 0 1.2212659328270092e-08
role O 0 3.236694468000678e-08
in O 0 5.085840193430613e-09
somatic O 0 9.449730669075507e-07
mosaicism O 0 5.426005373010412e-06
. O 0 5.2717020082582167e-08
. O 0 1.7303452182204637e-07

Aspartylglucosaminuria B-Disease 1 0.9999759197235107
among O 0 1.544666156405583e-05
Palestinian O 0 4.9457485147286206e-05
Arabs O 0 9.359840078104753e-06
. O 0 8.085913805189193e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.7399030327796936
AGU B-Disease 1 0.9999998807907104
) O 0 1.2979776329302695e-06
is O 0 1.3672182497259655e-08
a O 0 1.8448675476179233e-08
rare O 0 1.9102023429695691e-07
disorder B-Disease 0 0.008482563309371471
of I-Disease 0 6.946800912288609e-09
glycoprotein I-Disease 0 1.403503574692877e-05
metabolism I-Disease 0 0.0004333847900852561
caused O 0 9.60964371188311e-07
by O 0 5.055664331621301e-09
the O 0 1.2976555296972947e-07
deficiency B-Disease 0 2.528927507228218e-05
of I-Disease 0 2.147499733595737e-09
the I-Disease 0 3.4102622947784766e-08
lysosomal I-Disease 0 3.402965376153588e-05
enzyme I-Disease 0 1.127366067521507e-05
aspartylglucosaminidase I-Disease 0 1.4371987163031008e-05
( O 0 1.1496393170773445e-07
AGA O 0 1.7618898482396617e-06
) O 0 9.281889390422293e-08
. O 0 1.4648783519533026e-07

AGU B-Disease 1 0.9999994039535522
is O 0 2.547672738728579e-05
inherited O 0 0.00030839568353258073
as O 0 4.470034653536459e-08
an O 0 3.388315050756319e-08
autosomal O 0 0.32730382680892944
recessive O 1 0.5721938014030457
trait O 0 2.9705757697229274e-05
and O 0 8.228726500192352e-08
occurs O 0 2.6848807621604465e-08
with O 0 4.856924196161572e-09
a O 0 1.9090288461143246e-08
high O 0 7.258176424329577e-07
frequency O 0 4.469789473660057e-06
in O 0 2.437311330538705e-08
Finland O 0 1.1834445103886537e-05
because O 0 3.227595612997902e-08
of O 0 2.3492512379874597e-09
a O 0 3.540954907066407e-08
founder O 0 7.995514010872284e-07
effect O 0 2.6590581114760425e-07
. O 0 9.921593147055319e-08

While O 0 9.88422198133776e-06
very O 0 3.0892360314282996e-07
few O 0 2.0720204929602914e-07
patients O 0 1.0793977480716421e-06
with O 0 7.019579584266467e-08
AGU B-Disease 1 1.0
have O 0 3.5254258818895323e-06
been O 0 3.395231544800481e-07
reported O 0 1.6171838979062159e-07
from O 0 9.615399143569903e-09
non O 0 3.6015913451592496e-07
- O 0 7.573648304060043e-07
Finnish O 0 2.8027748157910537e-06
origin O 0 3.861990194309328e-08
, O 0 5.723357787701389e-09
we O 0 3.6983433915338537e-07
diagnosed O 0 5.617869828711264e-05
the O 0 1.1885782136289436e-08
disorder O 0 6.448923522839323e-05
in O 0 4.386836227610047e-09
8 O 0 1.1109177933121828e-07
patients O 0 9.23528631346926e-08
originating O 0 2.601000481661231e-08
from O 0 5.435826011535028e-09
3 O 0 3.0890998203858544e-08
unrelated O 0 4.402555120464058e-08
families O 0 3.696400341368644e-08
, O 0 2.948763233590057e-09
all O 0 3.8593443996148835e-09
Palestinian O 0 3.0077700330366497e-07
Arabs O 0 2.3909446866809958e-08
from O 0 1.487501344321629e-09
the O 0 1.968267548946301e-09
region O 0 7.854868755430289e-09
of O 0 3.1691229640529173e-09
Jerusalem O 0 1.6216486073972192e-06
. O 0 1.8332154638756037e-07

The O 0 5.3334838412411045e-06
clinical O 0 0.004417709074914455
diagnosis O 1 0.9943260550498962
of O 0 7.099344543348707e-07
AGU B-Disease 1 1.0
is O 0 5.873900477126881e-07
often O 0 8.389901609007211e-07
difficult O 0 5.127754320710665e-06
, O 0 9.133644063297197e-09
in O 0 6.88690160455252e-10
particular O 0 2.9901363607365283e-09
early O 0 9.712723070265383e-09
in O 0 6.044467704136025e-10
the O 0 1.904478352798833e-09
course O 0 2.2189137638406464e-08
of O 0 5.762800237008037e-10
the O 0 7.009759173115526e-08
disease O 0 9.667344784247689e-06
, O 0 7.989799932772712e-10
and O 0 1.4837892026164923e-09
most O 0 7.205087637629504e-10
of O 0 4.385646290572254e-10
the O 0 4.280267162926066e-08
patients O 0 8.279371854769124e-07
are O 0 2.8871102131233783e-07
diagnosed O 0 0.00015365028230007738
after O 0 7.079504982243634e-09
the O 0 3.4583329533433016e-09
age O 0 5.243173006874713e-08
of O 0 1.4959118388446768e-09
5 O 0 3.199870945991279e-08
years O 0 6.556984999406268e-08
. O 0 9.502075215550576e-08

However O 0 6.076636964280624e-06
, O 0 7.69234489439441e-08
since O 0 2.0147910007040082e-08
these O 0 8.346040303308655e-09
patients O 0 1.1766643126520648e-07
excrete O 0 1.1252786435989037e-07
early O 0 6.661739604396644e-09
large O 0 3.4509797242066043e-09
amounts O 0 5.773155731247925e-09
of O 0 2.3949326966032913e-09
aspartylglucosamine O 0 1.1921266604986158e-06
in O 0 1.0719349852195137e-08
urine O 0 4.1573625253477076e-07
, O 0 1.924565840027981e-09
biochemical O 0 9.574664971978564e-08
screening O 0 1.808493124144661e-07
is O 0 7.108338806460779e-09
easy O 0 2.661359133071528e-07
by O 0 5.964284355286509e-08
urine O 0 2.626540890560136e-06
chromatography O 0 3.653946578197065e-06
. O 0 6.04947913984688e-08
. O 0 1.747362574633371e-07

Detection O 0 3.1431631214218214e-05
of O 0 2.5773854872568336e-07
heterozygous O 0 9.552021765557583e-06
carriers O 0 6.181798539728334e-07
of O 0 1.624661827293039e-08
the O 0 2.0650995793403126e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 9.223805363944848e-07
ATM O 0 5.3236149142321665e-06
) O 0 2.3870988741236943e-08
gene O 0 1.4423090988202603e-07
by O 0 1.2435421581358241e-08
G2 O 0 2.3777845399308717e-06
phase O 0 1.0264745924359886e-06
chromosomal O 0 0.00011338997137499973
radiosensitivity O 0 1.523081573395757e-05
of O 0 1.0380996684489219e-07
peripheral O 0 0.0020720374304801226
blood O 0 0.004977097734808922
lymphocytes O 0 7.680449198232964e-05
. O 0 8.267772386716388e-07

In O 0 0.0002125520841218531
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
( O 0 0.015756582841277122
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 1.4760381361611508e-07
patients O 0 6.694361900372314e-07
, O 0 1.9661363648282304e-09
mutations O 0 8.67598046738749e-08
in O 0 8.539753348912882e-10
a O 0 4.724367119735007e-09
single O 0 3.1064567451721814e-07
gene O 0 8.226702874480907e-08
, O 0 1.8096458775929136e-09
ATM O 0 8.416692480750498e-07
, O 0 8.27651192025769e-09
result O 0 1.157367890414207e-08
in O 0 5.147852366604866e-09
an O 0 9.846428838500287e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 5.126396729338012e-08
embraces O 0 1.5553968069070834e-07
a O 0 1.079584244223497e-08
variety O 0 1.3815916410919726e-08
of O 0 3.530324699241305e-09
clinical O 0 1.6278308976325206e-06
features O 0 9.551132507112925e-07
and O 0 4.1434535091866564e-07
manifests O 0 6.54974769531691e-07
extreme O 0 2.7938349376199767e-06
radiosensitivity O 0 2.030245195783209e-05
and O 0 6.445989697567711e-08
a O 0 5.1526875211038714e-08
strong O 0 4.931164312438341e-07
pre O 0 0.00013198432861827314
- O 0 6.381283310474828e-05
disposition O 0 2.502090865164064e-06
to O 0 1.8795169864915806e-07
malignancy B-Disease 0 0.00019265340233687311
. O 0 4.223374787670764e-07

Heterozygotes O 0 0.0005586041952483356
for O 0 2.7292384174870676e-07
the O 0 3.760307620837011e-08
ATM O 0 2.020010470005218e-06
gene O 0 1.0680358855097438e-06
have O 0 3.630772837937002e-08
no O 0 4.958921806519356e-08
clinical O 0 7.332872655751999e-07
expression O 0 8.372830961889122e-08
of O 0 4.602350500704233e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
but O 0 2.705706947381259e-07
may O 0 4.631154126855108e-07
be O 0 1.9574960674617614e-07
cancer B-Disease 0 5.36351217306219e-06
prone O 0 4.927374902763404e-06
with O 0 9.994410632430117e-09
a O 0 3.2576036090858906e-08
moderate O 0 2.043478843916091e-06
increase O 0 7.123420431298655e-08
in O 0 9.516709198464923e-09
in O 0 1.3552207356326562e-08
vitro O 0 2.8829970688093454e-05
radiosensitivity O 0 2.6471780074643902e-05
. O 0 1.7603083790618257e-07

We O 0 5.0710252253338695e-05
performed O 0 7.055095011310186e-06
a O 0 1.1976850089467916e-07
blind O 0 2.6764221274788724e-06
chromosomal O 0 4.216998149786377e-06
analysis O 0 2.420432849703502e-07
on O 0 1.1355804474533215e-07
G2 O 0 2.1319958705134923e-06
- O 0 1.0978659474858432e-06
phase O 0 4.794248411599256e-07
lymphocytes O 0 5.744357736148231e-07
from O 0 1.3617892591355485e-08
7 O 0 1.1776050712342112e-07
unrelated O 0 6.19664888290572e-07
A B-Disease 1 0.9999992847442627
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.00013823706831317395
, O 0 8.396592754422727e-09
13 O 0 5.3356338014509674e-08
obligate O 0 6.983336220400815e-07
A B-Disease 1 0.9999964237213135
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
heterozygotes O 0 2.2685935618937947e-05
( O 0 1.2239779856315636e-08
parents O 0 1.830622231580037e-08
of O 0 4.270387932159281e-10
the O 0 2.178678748521179e-08
patients O 0 1.7445485411826667e-07
) O 0 1.6532103463973158e-09
, O 0 1.5293721844500396e-09
and O 0 1.1539909472446652e-08
14 O 0 2.5165991957010192e-08
normal O 0 2.737955284715099e-08
controls O 0 1.2665368842590397e-07
following O 0 2.0295011893267656e-08
X O 0 4.658716534322593e-06
- O 0 4.5644972601621703e-07
irradiation O 0 1.5031979216928448e-07
with O 0 2.0285336077563443e-08
1 O 0 3.113090940587426e-08
Gy O 0 3.931511400878662e-06
in O 0 4.147380661123634e-09
order O 0 4.650998253197258e-09
to O 0 2.6575401879114224e-09
evaluate O 0 6.22890397039555e-08
this O 0 1.3996989123299386e-09
cytogenetic O 0 9.007146672956878e-07
method O 0 5.084154963697074e-08
as O 0 4.865436054046768e-09
a O 0 4.5039483254072366e-09
tool O 0 2.478325882293575e-07
for O 0 3.0144906570939156e-09
detection O 0 2.2914012731689581e-07
of O 0 1.6407964764653116e-08
ATM O 0 2.672928530955687e-05
carriers O 0 7.751264092803467e-06
. O 0 4.0329254602511355e-07

Both O 0 0.00010787804058054462
A B-Disease 1 0.9999788999557495
- I-Disease 1 0.9999696016311646
T I-Disease 1 0.9999998807907104
homozygotes O 0 8.604798495071009e-05
and O 0 8.170859899792049e-08
heterozygotes O 0 2.7191474600840593e-06
showed O 0 5.715102133763139e-07
significantly O 0 6.868425117545485e-08
increased O 0 3.682150762074343e-08
levels O 0 7.54469766661714e-08
of O 0 8.473268309217019e-09
radiation O 0 0.0012369961477816105
- O 0 0.00026619803975336254
induced O 0 6.255108746699989e-05
chromatid O 0 0.00014004571130499244
damage O 0 4.793050720763858e-06
relative O 0 1.3985126656734792e-07
to O 0 1.2032013607665704e-08
that O 0 2.6743660619388265e-09
of O 0 4.938842224078144e-09
normal O 0 5.702362386728055e-07
controls O 0 1.6380143279093318e-05
. O 0 5.204489639254462e-07

These O 0 2.0035454326716717e-06
results O 0 7.462176654371433e-07
show O 0 1.6984057538138586e-07
that O 0 4.741419701304039e-09
the O 0 1.4598167119572736e-08
G2 O 0 1.4255616633818136e-06
- O 0 1.3535553762267227e-06
phase O 0 2.82312839772203e-07
chromosomal O 0 5.083036739961244e-05
radiosensitivity O 0 3.5496689179126406e-06
assay O 0 1.5005068689788459e-06
can O 0 2.9542573543039907e-07
be O 0 1.2455504183606081e-08
used O 0 1.5552476639868473e-08
for O 0 1.228421031562732e-09
the O 0 2.6186453006005195e-09
detection O 0 3.5037896850553807e-07
of O 0 3.46364252834519e-08
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
heterozygotes O 0 5.596107803285122e-05
. O 0 3.932644858650747e-07

In O 0 1.5265743513737107e-06
combination O 0 1.1787661833295715e-06
with O 0 2.3970908813453207e-08
molecular O 0 1.5535777038166998e-06
genetic O 0 4.4027078729413915e-06
analyses O 0 2.588052666396834e-06
, O 0 1.9257896610724856e-08
this O 0 3.200302689521095e-09
test O 0 1.425781988473318e-06
may O 0 2.515301957828342e-07
be O 0 1.3046678182249138e-09
of O 0 1.5151328802698316e-10
value O 0 1.236243440949636e-09
in O 0 3.229833622775402e-10
studies O 0 3.0700790798476874e-09
of O 0 9.867384687112235e-10
familial B-Disease 0 1.075892669177847e-05
and I-Disease 0 1.145847136285738e-06
sporadic I-Disease 0 0.0026363127399235964
cancers I-Disease 1 0.9334291219711304
aimed O 0 2.0376114662212785e-06
at O 0 1.6791149448636133e-07
determination O 0 3.645727275625177e-08
of O 0 4.458849678368182e-10
the O 0 1.1837247848589527e-09
potential O 0 5.502293731751706e-09
involvement O 0 1.5378324391690512e-08
of O 0 1.4931467173795454e-09
ATM O 0 1.1841061677841935e-05
mutations O 0 5.4814327086205594e-06
in O 0 3.5267664344473815e-08
tumor B-Disease 0 1.983703623409383e-05
risk O 0 2.044219627350685e-06
or O 0 3.140841897675273e-08
development O 0 1.9462468969777547e-08
. O 0 1.267263716187017e-08
. O 0 1.0289176088917884e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
: O 0 8.947550327320641e-07
identification O 0 4.328075533521769e-07
and O 0 4.491306526688277e-08
detection O 0 3.3896279205691826e-07
of O 0 9.722436189463224e-09
founder O 0 4.176683603418496e-07
- O 0 2.192947249568533e-06
effect O 0 1.2511748082033591e-07
mutations O 0 2.491615873623232e-07
in O 0 1.5109606898988659e-09
the O 0 2.888647321341864e-09
ATM O 0 5.318842681845126e-07
gene O 0 2.4202665827033343e-07
in O 0 1.3301470147553118e-08
ethnic O 0 1.6171900085737434e-07
populations O 0 1.1452385706434143e-06
. O 0 2.70561656634527e-07

To O 0 5.319497518030403e-07
facilitate O 0 3.40560887934771e-07
the O 0 1.7067572244400253e-08
evaluation O 0 6.253844020420729e-08
of O 0 5.518710821661443e-09
ATM O 0 4.713694579550065e-06
heterozygotes O 0 1.5194717661870527e-06
for O 0 3.9603960111378456e-09
susceptibility O 0 2.904433813455398e-07
to O 0 9.614629092880023e-09
other O 0 3.79195448374503e-08
diseases O 0 0.0001482228108216077
, O 0 1.5781242979073795e-09
such O 0 2.36786590335214e-09
as O 0 2.5772626486286754e-06
breast B-Disease 1 0.9999586343765259
cancer I-Disease 0 0.002247251570224762
, O 0 1.2743680777305144e-08
we O 0 2.2606375438272153e-08
have O 0 5.752545995107994e-09
attempted O 0 5.8518605072777063e-08
to O 0 2.823486999758984e-09
define O 0 2.071121656399555e-07
the O 0 1.9031021203375076e-09
most O 0 2.0079689022622915e-09
common O 0 1.3399685805381978e-08
mutations O 0 1.5696468835812993e-07
and O 0 4.754269422591051e-09
their O 0 1.7971196086818964e-08
frequencies O 0 5.668870926456293e-06
in O 0 1.643163045628171e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
( O 0 0.00032483137329109013
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 7.533783730195864e-08
homozygotes O 0 2.709921091081924e-06
from O 0 1.1717077086359495e-08
10 O 0 1.3447949420708483e-08
ethnic O 0 4.537518805136642e-08
populations O 0 5.502044473360002e-07
. O 0 1.139873901934152e-07

Both O 0 6.593287253053859e-06
genomic O 0 2.60476390394615e-05
mutations O 0 4.535787957138382e-05
and O 0 1.9514141058607493e-07
their O 0 9.294289782246778e-08
effects O 0 1.287384407078207e-06
on O 0 4.0074866092254524e-08
cDNA O 0 3.6106700918026036e-07
were O 0 4.2887134554803197e-07
characterized O 0 1.1296629054413643e-06
. O 0 2.2147388278881408e-07

Protein O 0 2.302347456861753e-05
- O 0 1.2819280527764931e-05
truncation O 0 4.628876922652125e-06
testing O 0 1.280942569792387e-06
of O 0 1.0000970718238023e-08
the O 0 1.150988282461185e-08
entire O 0 5.677987147123531e-08
ATM O 0 1.1636508361334563e-06
cDNA O 0 1.0600023188089835e-06
detected O 0 2.0888041944999713e-06
92 O 0 6.142313395685051e-07
( O 0 6.11948109963123e-08
66 O 0 2.997750243594055e-07
% O 0 4.581724155627853e-08
) O 0 1.171347907558129e-08
truncating O 0 8.474111155010178e-07
mutations O 0 7.626732667631586e-07
in O 0 7.146076175246208e-09
140 O 0 8.878219404095944e-08
mutant O 0 5.479430910781957e-06
alleles O 0 7.5269126682542264e-06
screened O 0 2.6519484890741296e-05
. O 0 9.078933089767816e-07

The O 0 1.0641915650921874e-06
haplotyping O 0 4.812113274965668e-06
of O 0 2.8684169706139073e-08
patients O 0 2.319171017006738e-06
with O 0 2.142011190642279e-08
identical O 0 0.0003338375245220959
mutations O 0 6.884580216137692e-05
indicates O 0 2.3427691075994517e-07
that O 0 3.4839418017185153e-09
almost O 0 2.0316701210276733e-08
all O 0 7.729561990466038e-10
of O 0 2.5726032415462896e-10
these O 0 1.0132894523451341e-09
represent O 0 1.0909773529022004e-08
common O 0 3.33863603430018e-08
ancestry O 0 4.727240593638271e-06
and O 0 5.766555588593292e-08
that O 0 4.49671233582194e-09
very O 0 2.1515353054724073e-08
few O 0 4.7457557883490153e-08
spontaneously O 0 5.600624035650981e-07
recurring O 0 4.066454494022764e-06
ATM O 0 8.484209683956578e-05
mutations O 0 4.5220796891953796e-05
exist O 0 1.479749244026607e-06
. O 0 4.0789663557916356e-07

Assays O 0 6.8799672590103e-05
requiring O 0 5.513744781637797e-06
minimal O 0 2.1086227661726298e-06
amounts O 0 6.899898608025978e-08
of O 0 3.220632427414216e-09
genomic O 0 3.0798551620137005e-07
DNA O 0 7.908394650257833e-07
were O 0 9.897740227415852e-08
designed O 0 1.2841211116665363e-07
to O 0 4.062480574162919e-09
allow O 0 8.873001888787257e-09
rapid O 0 5.263543556566219e-08
screening O 0 1.5186866164640378e-07
for O 0 4.511678142193887e-09
common O 0 2.8245601413345867e-08
ethnic O 0 1.816608943272513e-07
mutations O 0 1.5303734471672215e-05
. O 0 2.968963883631659e-07

These O 0 1.3970931149742682e-06
rapid O 0 6.1434416238626e-06
assays O 0 1.7060845493688248e-05
detected O 0 1.0576964996289462e-05
mutations O 0 3.836423275060952e-06
in O 0 1.747625155701371e-08
76 O 0 3.7989482848388434e-07
% O 0 3.259480507722401e-08
of O 0 5.414530157565878e-09
Costa O 0 2.5616586754040327e-06
Rican O 0 9.441377187613398e-06
patients O 0 1.2312962098803837e-06
( O 0 4.315456880732427e-09
3 O 0 8.43994474308829e-09
) O 0 2.8699806975396314e-09
, O 0 2.613575578180871e-09
50 O 0 8.42273717438502e-09
% O 0 5.584935625080334e-09
of O 0 2.1242587688874437e-09
Norwegian O 1 0.8914374113082886
patients O 0 2.1946163542452268e-05
( O 0 4.854646018515041e-09
1 O 0 7.050627193194714e-09
) O 0 2.47604625691622e-09
, O 0 1.5622216853472537e-09
25 O 0 4.762519711931645e-09
% O 0 2.730100590042639e-09
of O 0 7.614822106205565e-10
Polish O 0 0.0017565966118127108
patients O 0 3.7306003832782153e-06
( O 0 4.807788833716131e-09
4 O 0 1.2960917672444339e-08
) O 0 4.027338462719854e-09
, O 0 2.0673824874251068e-09
and O 0 1.0166351316343025e-08
14 O 0 1.9923133365296053e-08
% O 0 3.2338420830058112e-09
of O 0 1.5589594060116951e-09
Italian O 0 0.025751853361725807
patients O 0 3.967250904679531e-06
( O 0 6.797641116662589e-09
1 O 0 7.371594890059896e-09
) O 0 1.7295649357151888e-09
, O 0 5.608267739098949e-10
as O 0 1.3917604846369613e-09
well O 0 5.5005937582564e-09
as O 0 2.416821187622986e-09
in O 0 2.3021828887692664e-09
patients O 0 1.3282811295312058e-08
of O 0 9.381733168112305e-10
Amish O 0 1.6493992234245525e-06
/ O 0 1.8288915271114092e-06
Mennonite O 0 1.504016836406663e-06
and O 0 3.103800452208816e-07
Irish O 0 3.6004378216603072e-06
English O 0 2.165466867154464e-06
backgrounds O 0 4.145491402596235e-06
. O 0 3.959031005251745e-07

Additional O 0 6.642280368396314e-06
mutations O 0 3.59166442649439e-05
were O 0 8.294845770251413e-07
observed O 0 1.083615686070516e-07
in O 0 4.59353444171029e-09
Japanese O 0 5.690965565463557e-08
, O 0 2.4919892815944422e-09
Utah O 0 5.262557056795458e-09
Mormon O 0 1.3840180557167514e-08
, O 0 2.1709580799722517e-09
and O 0 3.6507634693094815e-09
African O 0 3.381323310236439e-08
American O 0 2.3196567155991943e-07
patients O 0 4.4590245806830353e-07
. O 0 7.824427683544855e-08

These O 0 8.531667958777689e-07
assays O 0 2.1645810193149373e-06
should O 0 1.0766440539100586e-07
facilitate O 0 7.128816292834017e-08
screening O 0 5.514646659321443e-07
for O 0 2.0547649626223574e-07
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
heterozygotes O 0 5.957127086730907e-06
in O 0 3.6193628094594033e-09
the O 0 9.965039460269054e-09
populations O 0 4.0746581220219014e-08
studied O 0 9.882101892344508e-08
. O 0 1.842433938747945e-08
. O 0 1.0633825553441056e-07

The O 0 2.388664688623976e-05
von B-Disease 1 0.9471718072891235
Hippel I-Disease 1 0.9960390329360962
- I-Disease 1 0.9009446501731873
Lindau I-Disease 1 0.9961976408958435
tumor I-Disease 0 0.000994861125946045
suppressor O 0 1.2743294973915908e-05
gene O 0 1.216017267324787e-06
is O 0 1.3054576086801717e-08
required O 0 2.0027375313702578e-08
for O 0 7.797072321125142e-09
cell O 0 1.7268781675738865e-06
cycle O 0 1.0564397143753013e-06
exit O 0 1.257437361346092e-06
upon O 0 1.8595146400457452e-07
serum O 0 6.6903935476148035e-06
withdrawal O 0 1.926888444359065e-06
. O 0 3.1463167715628515e-07

The O 0 1.1176758789588348e-06
inactivation O 0 1.1077055205532815e-05
of O 0 9.494574726431892e-08
the O 0 5.152702442501322e-07
von B-Disease 1 0.996559202671051
Hippel I-Disease 1 0.9999796152114868
- I-Disease 1 0.9997977614402771
Lindau I-Disease 1 0.9999380111694336
( I-Disease 0 5.233364845480537e-06
VHL I-Disease 0 0.0015397606184706092
) I-Disease 0 2.1767334601463517e-07
tumor I-Disease 0 8.080192856141366e-06
suppressor O 0 4.913105385639938e-06
gene O 0 1.3875330751034198e-06
predisposes O 0 3.6755873225047253e-06
affected O 0 3.534871950705565e-07
individuals O 0 1.0374341385954722e-08
to O 0 4.021742050497323e-09
the O 0 1.0165715025323152e-07
human O 0 3.491530515020713e-05
VHL B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
and O 0 4.9759194098442094e-08
is O 0 9.449982130149692e-09
associated O 0 9.606750239754547e-08
with O 0 6.852395983969473e-08
sporadic B-Disease 1 0.9964907765388489
renal I-Disease 1 1.0
cell I-Disease 1 0.9999985694885254
carcinomas I-Disease 1 1.0
( O 0 1.8688870113692246e-05
RCC B-Disease 0 0.009217065759003162
) O 0 1.1600491234275978e-07
and O 0 6.470342555076058e-07
brain B-Disease 0 0.03689681738615036
hemangioblastomas I-Disease 0 0.00038603044231422246
. O 0 1.1032628890461638e-06

VHL O 0 0.0396537110209465
- O 0 0.0005169910145923495
negative O 0 2.3530348698841408e-05
786 O 0 1.96851251530461e-05
- O 0 6.249301804928109e-05
0 O 0 2.114109747708426e-06
RCC B-Disease 0 2.1797239242005162e-05
cells O 0 6.102335987634433e-07
are O 0 2.4964815992234435e-08
tumorigenic O 0 1.4928732525731903e-06
in O 0 2.8042691724294855e-08
nude O 0 0.13852965831756592
mice O 0 3.705374547280371e-05
which O 0 9.031281500426758e-09
is O 0 3.526515524043816e-09
suppressed O 0 1.1624319284919693e-08
by O 0 1.205231248135874e-09
the O 0 3.2437510455451957e-09
reintroduction O 0 1.27022133256105e-07
of O 0 2.8789514772142866e-08
VHL B-Disease 0 0.00010699871927499771
. O 0 1.1421431054259301e-06

Remarkably O 0 0.004695231094956398
, O 0 2.9673023504983576e-07
this O 0 1.0273208950195567e-08
occurs O 0 1.6435652838708847e-08
without O 0 1.0324360033564517e-08
affecting O 0 2.5532477465617376e-08
the O 0 6.199128321782155e-09
growth O 0 3.892681021966382e-08
rate O 0 1.0064293576306227e-07
and O 0 1.1373597175179384e-08
cell O 0 1.1132171096051025e-07
cycle O 0 9.021677982445908e-08
profile O 0 1.9286899188841744e-08
of O 0 1.108334757304874e-09
these O 0 7.142873847953979e-09
cells O 0 2.509399976702298e-08
in O 0 3.3737972415792683e-09
culture O 0 1.1085683127021184e-07
. O 0 1.0258175109356671e-07

The O 0 2.389753717579879e-06
786 O 0 2.847481118806172e-05
- O 0 2.4735216356930323e-05
0 O 0 1.6681798342688126e-06
cell O 0 1.0683913842512993e-06
line O 0 2.059804728560266e-06
, O 0 2.6676567621564118e-09
like O 0 4.790863705750326e-09
many O 0 4.786461005323872e-09
cancer B-Disease 0 1.950942987605231e-06
cells O 0 4.267322495365988e-08
, O 0 2.6025916977090446e-09
fails O 0 2.992642578192317e-08
to O 0 4.203758674492519e-09
exit O 0 1.0712532230172656e-06
the O 0 3.525878611299049e-08
cell O 0 1.2885008118246333e-06
cycle O 0 4.660698209590919e-07
upon O 0 5.479360964955049e-08
serum O 0 2.93140010398929e-06
withdrawal O 0 2.2474018805951346e-06
. O 0 3.0731919764548365e-07

Here O 0 7.856451702537015e-06
, O 0 1.3769226825388614e-07
it O 0 1.28227757301147e-08
is O 0 2.1176123077282227e-09
shown O 0 5.067983810391752e-09
that O 0 3.0884253487961644e-10
reintroduction O 0 4.598811997880148e-09
of O 0 3.995134223444552e-10
the O 0 3.556670069571055e-09
wild O 0 3.546104920815196e-08
- O 0 1.037014726534835e-06
type O 0 1.5429939594469033e-05
VHL B-Disease 0 7.550438749603927e-05
gene O 0 1.8541398958404898e-06
restores O 0 8.728752618480939e-07
the O 0 2.3710898133799674e-08
ability O 0 1.8744923124813795e-07
of O 0 3.351741284518539e-08
VHL O 0 0.00011763707880163565
- O 0 1.404251997882966e-05
negative O 0 1.809810237318743e-05
RCC B-Disease 0 0.0006390726193785667
cancer I-Disease 0 1.9983657693956047e-05
cells O 0 6.396619767201628e-08
to O 0 3.868483311464388e-09
exit O 0 1.8428210069032502e-07
the O 0 2.0454189453289473e-08
cell O 0 4.389140428884275e-07
cycle O 0 2.2492277196306532e-07
and O 0 1.8618173669437965e-08
enter O 0 3.1810557743483514e-07
G0 O 0 1.0158927580050658e-05
/ O 0 2.871318201869144e-06
quiescence O 0 4.939631253364496e-06
in O 0 9.529481559411579e-08
low O 0 0.0001802411425160244
serum O 0 6.985937943682075e-05
. O 0 1.0970527455356205e-06

Both O 0 6.054513141862117e-05
VHL O 0 0.003602731740102172
- O 0 0.00019835094281006604
positive O 0 1.4662679177490645e-06
and O 0 3.984180807492521e-07
VHL O 0 0.00017418091010767967
- O 0 1.1793457815656438e-05
negative O 0 3.7732329474238213e-06
RCC B-Disease 0 2.5077668396988884e-05
cells O 0 7.417265805997886e-07
exit O 0 4.565132769585034e-07
the O 0 2.9560514036575114e-08
cell O 0 6.089360340411076e-07
cycle O 0 3.848512051263242e-07
by O 0 9.301238002024093e-09
contact O 0 1.404597242071759e-06
inhibition O 0 4.202536729280837e-06
. O 0 4.2574816916385316e-07

The O 0 5.142343070474453e-06
cyclin O 0 0.00018615562294144183
- O 0 3.672440925583942e-06
dependent O 0 2.120581712006242e-06
kinase O 0 3.5508810469764285e-06
inhibitor O 0 1.2163907285867026e-06
, O 0 2.0742637829584964e-08
p27 O 0 8.972946829999273e-07
, O 0 1.1428199719887289e-08
accumulates O 0 7.924167988448971e-08
upon O 0 1.2377658897833044e-08
serum O 0 1.6784328238372836e-07
withdrawal O 0 1.0342378686800657e-07
, O 0 3.011456417567615e-09
only O 0 1.5317718204954645e-09
in O 0 1.1678827904759714e-09
the O 0 2.7391919843466894e-09
presence O 0 5.543228098758846e-09
of O 0 2.0446844217758553e-09
VHL B-Disease 0 2.360101916565327e-06
, O 0 3.3194582638174097e-09
as O 0 2.310003299754726e-09
a O 0 2.3016821781851604e-09
result O 0 5.213184550711958e-09
of O 0 2.796377296387931e-10
the O 0 1.3199712434186495e-09
stabilization O 0 1.0171238962186635e-08
of O 0 7.579379346367432e-10
the O 0 5.923966206466957e-09
protein O 0 9.462575434326936e-08
. O 0 7.631346932157612e-08

We O 0 3.825155999948038e-06
propose O 0 3.7639136962752673e-07
that O 0 6.906743177381713e-09
the O 0 5.277151604587971e-09
loss O 0 2.1026654195566152e-08
of O 0 1.4051182439800414e-09
wild O 0 5.534726099654108e-08
- O 0 1.1429132428020239e-05
type O 0 9.572686394676566e-05
VHL B-Disease 0 0.00023776399029884487
gene O 0 1.3142525858711451e-06
results O 0 2.6560218202575925e-07
in O 0 2.1019184170967264e-09
a O 0 5.528677959887318e-09
specific O 0 4.810570786162316e-08
cellular O 0 8.19014894659631e-06
defect O 0 1.4460140846495051e-05
in O 0 2.5472358444744714e-08
serum O 0 2.6302234346076148e-06
- O 0 5.759383839176735e-06
dependent O 0 1.1187230484210886e-06
growth O 0 1.1838839242273025e-07
control O 0 3.097165404142288e-07
, O 0 4.123937191735649e-09
which O 0 3.460721709203085e-09
may O 0 3.017345306943753e-08
initiate O 0 3.2812383210512053e-07
tumor B-Disease 0 5.9641133702825755e-06
formation O 0 5.643587428494357e-07
. O 0 2.595970443053375e-07

This O 0 5.985070856695529e-07
is O 0 1.5850429235797492e-07
corrected O 0 6.910565844009398e-07
by O 0 2.327730008744311e-09
the O 0 1.5725984958692152e-09
reintroduction O 0 2.7149752668265137e-08
of O 0 2.453850678207914e-09
wild O 0 1.1306959635248859e-07
- O 0 1.5332976545323618e-05
type O 0 0.0009065942140296102
VHL B-Disease 0 0.0009845701279118657
, O 0 3.467330600415153e-08
implicating O 0 5.0029170779453125e-06
VHL B-Disease 0 3.3618103771004826e-05
as O 0 3.02244878014335e-08
the O 0 5.413352877070565e-09
first O 0 3.000289794385935e-08
tumor B-Disease 0 2.6164357791458315e-07
suppressor O 0 1.2084548473012546e-07
involved O 0 1.7125355356029104e-08
in O 0 1.4370520329265446e-09
the O 0 3.1750584383871683e-09
regulation O 0 2.915789210078401e-08
of O 0 2.150114752907939e-09
cell O 0 2.053509149391175e-07
cycle O 0 2.0072236850410263e-07
exit O 0 8.593729603489919e-07
, O 0 1.2852355624204392e-08
which O 0 7.755956765720384e-09
is O 0 1.9071755286148573e-09
consistent O 0 4.365353944990602e-08
with O 0 2.552369871011706e-09
its O 0 7.4206023548129e-09
gatekeeper O 0 5.218450382926676e-07
function O 0 5.4923145142993235e-08
in O 0 3.283251670538334e-09
the O 0 2.9488658626064534e-08
kidney O 0 4.358267688076012e-06
. O 0 1.3226434170121593e-08
. O 0 7.056011241957094e-08

Piebaldism B-Disease 1 1.0
with O 0 0.02022227831184864
deafness B-Disease 1 1.0
: O 0 6.91210857439728e-07
molecular O 0 1.7525538851259626e-06
evidence O 0 8.508123983119731e-08
for O 0 1.1110996567254006e-08
an O 0 1.078016680367e-07
expanded O 0 0.013152278028428555
syndrome O 1 0.9999986886978149
. O 0 6.163531907077413e-07

In O 0 9.722093636810314e-07
a O 0 2.797122249376116e-07
South O 0 2.0412532819591434e-07
African O 0 9.527864364144989e-08
girl O 0 4.956350494467188e-07
of O 0 1.7079286873666888e-09
Xhosa O 0 9.227024747815449e-06
stock O 0 2.379369732352643e-07
with O 0 1.5916768347778998e-08
severe O 0 7.768189971102402e-05
piebaldism B-Disease 0 4.0493119740858674e-05
and O 0 2.1580665077181038e-07
profound O 0 7.758787251077592e-05
congenital O 1 1.0
sensorineural B-Disease 1 0.9999964237213135
deafness I-Disease 1 1.0
we O 0 0.0028078665491193533
identified O 0 3.95303550249082e-06
a O 0 2.6544361375613335e-08
novel O 0 9.258602773343227e-08
missense O 0 9.146197044174187e-07
substitution O 0 4.700084588193931e-08
at O 0 7.899705423142223e-08
a O 0 1.3795245834558045e-08
highly O 0 3.064458198309694e-08
conserved O 0 5.106702616330949e-08
residue O 0 1.6239872024925717e-07
in O 0 1.486242129367099e-09
the O 0 2.8934832307925262e-09
intracellular O 0 1.9091697822659626e-07
kinase O 0 3.229236824608961e-07
domain O 0 3.2783162851046654e-08
of O 0 3.3360627593737036e-09
the O 0 2.7646606781672745e-08
KIT O 0 1.095373954740353e-05
proto O 0 0.00026651471853256226
- O 0 4.403720595291816e-05
oncogene O 0 1.8856258975574747e-05
, O 0 1.1889981266222094e-07
R796G O 0 4.51272308055195e-06
. O 0 4.5770687506774266e-07

Though O 0 1.1878100849571638e-05
auditory B-Disease 0 5.90424970141612e-05
anomalies I-Disease 0 0.00031977012986317277
have O 0 1.3403133607425843e-06
been O 0 1.0572465214409021e-07
observed O 0 5.778291978231209e-08
in O 0 5.715852235965713e-09
mice O 0 2.1544710762100294e-06
with O 0 1.9018729702224846e-08
dominant O 0 6.449950888054445e-05
white O 0 1.5932463384160656e-06
spotting O 0 5.74805962969549e-05
( O 0 2.788631263683783e-07
W O 0 0.06752268970012665
) O 0 8.29902191412657e-09
due O 0 1.6771330990650313e-08
to O 0 2.9725043759754044e-08
KIT O 0 0.048347849398851395
mutations O 0 0.01860777661204338
, O 0 5.833806540067599e-07
deafness B-Disease 1 1.0
is O 0 6.898845583691582e-08
not O 0 1.4749132581926006e-08
typical O 0 8.239987892011413e-08
in O 0 1.3836353396357026e-08
human O 0 1.6836126803809748e-07
piebaldism B-Disease 0 1.1369331332389265e-05
. O 0 2.8657763095907285e-07

Thus O 0 7.627862942172214e-06
, O 0 7.32107068301957e-08
the O 0 1.025596141346341e-08
occurrence O 0 2.2821240008852328e-07
of O 0 4.2552851908794764e-08
sensorineural B-Disease 1 0.9649725556373596
deafness I-Disease 1 1.0
in O 0 1.9276846785487578e-07
this O 0 2.694345546672139e-08
patient O 0 7.663866199436598e-07
extends O 0 5.6552355687244926e-08
considerably O 0 1.0679436712734969e-07
the O 0 4.98914554114549e-09
phenotypic O 0 6.588828114217904e-07
range O 0 2.3836825846501597e-07
of O 0 7.2033734532794824e-09
piebaldism B-Disease 0 1.7723079963616328e-06
due O 0 5.8871588493047966e-08
to O 0 1.0590343713090533e-08
KIT O 0 4.701896159531316e-06
gene O 0 6.162144359223021e-07
mutation O 0 2.48274460545872e-07
in O 0 4.229034900049555e-09
humans O 0 3.28834879326223e-08
and O 0 1.3296981293819954e-08
tightens O 0 8.771973625698593e-06
the O 0 4.6080600668574334e-08
clinical O 0 7.260218808369245e-07
similarity O 0 1.0497836910872138e-07
between O 0 4.227424099667587e-08
piebaldism B-Disease 0 6.528372523462167e-06
and O 0 1.0983058018609881e-08
the O 0 1.5512119366789534e-09
various O 0 2.1649870785012126e-09
forms O 0 7.01618034781859e-08
of O 0 1.0096130154124694e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
. O 0 1.8249158983962843e-07
. O 0 3.581242822292552e-07

Cycloheximide O 0 0.00012304210395086557
facilitates O 0 2.8910244509461336e-06
the O 0 4.075023340988082e-08
identification O 0 6.330157731326835e-08
of O 0 6.0219162989483266e-09
aberrant O 0 2.311958724021679e-06
transcripts O 0 2.576883844085387e-06
resulting O 0 9.78458956524264e-07
from O 0 2.561569445447276e-08
a O 0 2.5775074519174268e-08
novel O 0 1.1172330971476185e-07
splice O 0 0.00018029200145974755
- O 0 6.122396735008806e-05
site O 0 1.1401961046431097e-06
mutation O 0 2.301320364495041e-06
in O 0 2.3767768198013073e-08
COL17A1 O 0 3.1856566238275263e-06
in O 0 1.4631897471417687e-08
a O 0 1.0617631573950348e-07
patient O 0 4.625963811122347e-06
with O 0 1.4544296789154032e-07
generalized O 0 0.0007742904708720744
atrophic B-Disease 1 0.9998489618301392
benign I-Disease 1 0.9986556768417358
epidermolysis I-Disease 1 0.9987083673477173
bullosa I-Disease 1 0.9943512678146362
. O 0 1.0935526006505825e-05

Patients O 1 0.9987019300460815
with O 0 6.431157999031711e-06
generalized O 0 0.0014246267965063453
atrophic B-Disease 1 0.9996359348297119
benign I-Disease 1 0.9988511800765991
epidermolysis I-Disease 1 0.997542142868042
bullosa I-Disease 1 0.9640266299247742
often O 0 4.6361430577235296e-05
show O 0 2.4958828817034373e-06
decreased O 0 4.263785285729682e-06
expression O 0 6.852056344541779e-08
of O 0 8.755772107349458e-09
type O 0 3.310433748993091e-05
XVII O 0 0.00011328060645610094
collagen O 0 2.424201511530555e-06
, O 0 2.252683195536065e-08
a O 0 3.959317140811436e-08
transmembrane O 0 2.1708324311475735e-06
hemidesmosomal O 0 3.743962679436663e-06
protein O 0 2.276357378150351e-07
encoded O 0 2.448628038109746e-07
by O 0 1.1279722400558967e-07
COL17A1 O 0 3.5091390600427985e-05
. O 0 9.104702485274174e-07

This O 0 8.437097562818963e-07
report O 0 3.7029386135145614e-07
documents O 0 6.267396912562617e-08
a O 0 2.8438481791681625e-08
novel O 0 1.1328093307838571e-07
splice O 0 0.0002101459976984188
- O 0 4.7676552640041336e-05
site O 0 6.817489293098333e-07
mutation O 0 1.9393528418731876e-06
in O 0 1.431242768745733e-08
COL17A1 O 0 3.7403401620395016e-06
in O 0 8.511658045051718e-09
a O 0 4.453134394566405e-08
patient O 0 2.1994608232489554e-06
with O 0 7.297955306739823e-08
generalized O 0 0.00014886545250192285
atrophic B-Disease 1 0.9988396763801575
benign I-Disease 1 0.9623596668243408
epidermolysis I-Disease 1 0.8861632943153381
bullosa I-Disease 1 0.5451422333717346
, O 0 4.18393909740189e-07
and O 0 1.334660471030702e-08
applies O 0 8.876692270121112e-09
a O 0 2.2436001945180806e-09
new O 0 6.886218817392376e-10
methodology O 0 1.7393313456182113e-08
to O 0 1.869185473069024e-09
define O 0 1.6643677724914596e-07
and O 0 1.8620625041876337e-08
characterize O 0 5.220690013629792e-07
the O 0 1.1272888400526426e-08
resulting O 0 1.2832786921990191e-07
mRNA O 0 4.239326187871484e-07
splice O 0 7.344145706156269e-05
variants O 0 1.8942753740702756e-05
. O 0 1.4497575193672674e-06

Mutational O 0 0.0007135719060897827
analysis O 0 6.340347226796439e-06
of O 0 2.978492545935296e-07
COL17A1 O 0 0.00012003136362181976
identified O 0 2.3682073333475273e-06
a O 0 1.2669451621150074e-07
maternally O 0 1.7845835827756673e-05
inherited O 0 1.886543213913683e-05
G O 0 3.0338035230670357e-06
- O 0 1.7670458873908501e-06
to O 0 1.685455259803348e-07
- O 0 0.0001794181007426232
T O 0 5.890707325306721e-05
transversion O 0 8.453559985355241e-07
at O 0 2.732117820869462e-08
the O 0 5.659182455985956e-09
- O 0 1.7091230120058754e-07
1 O 0 8.045928368005661e-09
position O 0 4.3746975819658473e-08
of O 0 4.13273237853673e-09
exon O 0 1.8018358787230682e-06
32 O 0 1.4214645034371642e-06
. O 0 2.6835246558221115e-07

This O 0 1.9041143559661577e-06
acceptor O 0 7.52355435906793e-06
splice O 0 0.00010546817793510854
- O 0 2.7488569685374387e-05
site O 0 6.803077212680364e-07
mutation O 0 1.0150636171601946e-06
led O 0 2.2594131010578167e-08
to O 0 3.748046761842261e-09
the O 0 2.556560296795851e-09
formation O 0 1.1350776318863609e-08
of O 0 1.487847511860707e-09
aberrant O 0 1.9271460871550516e-07
transcripts O 0 1.1280044986961002e-07
present O 0 3.176780438707283e-08
at O 0 1.1576344149943907e-07
extremely O 0 8.744358410694986e-07
low O 0 0.00010439712787047029
levels O 0 4.663250820158282e-06
. O 0 1.2926531667289964e-07

Based O 0 1.2133598374930443e-06
on O 0 1.8585465966225456e-07
our O 0 5.7504649930706364e-08
recent O 0 2.9161453696247008e-08
finding O 0 4.3928920945290884e-08
that O 0 5.794292157190739e-09
cycloheximide O 0 3.6782171264349017e-06
stabilized O 0 1.9436040020082146e-05
mutant O 0 3.195125145794009e-06
COL17A1 O 0 2.333166776224971e-06
transcripts O 0 5.808901164527924e-07
in O 0 3.276203486279883e-08
keratinocytes O 0 1.282291918869305e-06
homozygous O 0 2.3033317120280117e-06
for O 0 4.230551464701193e-09
a O 0 1.3528292264197717e-08
frameshift O 0 1.0236329217150342e-05
mutation O 0 1.118059685722983e-06
, O 0 2.2236790186980215e-09
the O 0 2.1798622906743503e-09
effects O 0 1.0381788229096856e-07
of O 0 7.59460216936958e-10
the O 0 8.297249110000848e-09
splice O 0 0.00030125153716653585
- O 0 1.5899700883892365e-05
site O 0 2.4123235675688193e-07
mutation O 0 2.827277683081775e-07
on O 0 6.820966458320754e-09
splicing O 0 1.5893992610926944e-07
of O 0 5.383739232200924e-09
COL17A1 O 0 1.3966588312541717e-06
transcripts O 0 4.048663413414033e-07
were O 0 2.2039216673874762e-07
determined O 0 5.670097635857019e-08
using O 0 4.4677843646923066e-08
reverse O 0 7.592103088427393e-07
transcriptase O 0 3.4222791782667628e-06
polymerase O 0 7.201919629551412e-07
chain O 0 1.0110525181517005e-06
reaction O 0 2.501009177535707e-08
of O 0 2.7308870720332834e-09
total O 0 1.2643207369933407e-08
RNA O 0 1.0129425476179676e-07
from O 0 1.7277292485573525e-08
keratinocytes O 0 3.9995305201045994e-07
incubated O 0 2.944272239346901e-07
for O 0 8.180336408258881e-09
2 O 0 1.8764706055662828e-07
. O 0 2.2375633079718682e-07

5 O 0 1.466976391384378e-05
h O 0 2.3545495423604734e-05
in O 0 2.652346076104095e-08
the O 0 1.030545426772278e-08
presence O 0 2.43242119779552e-08
or O 0 2.6161105282085373e-08
absence O 0 2.5417030258267914e-08
of O 0 2.4055171188308577e-09
10 O 0 3.575151552581701e-08
microg O 0 1.77143442670058e-06
cycloheximide O 0 2.713748699534335e-06
per O 0 2.8439899324439466e-07
ml O 0 1.1198599167983048e-05
. O 0 2.759690858056274e-07

Using O 0 2.3676473119849106e-06
this O 0 3.350418253944554e-08
approach O 0 2.0844414905241138e-07
, O 0 1.6938368929686476e-08
an O 0 1.370466140571125e-08
abnormally O 0 3.7408935895655304e-05
spliced O 0 6.76183553878218e-05
transcript O 0 1.0116580597241409e-05
was O 0 4.560251909424551e-06
identified O 0 2.539818808600103e-07
that O 0 7.886284958402712e-10
contains O 0 1.1719528680842473e-09
an O 0 9.191923888707265e-10
extra O 0 2.0379108178758543e-08
264 O 0 9.809913592562225e-08
bases O 0 1.1883475536933474e-07
upstream O 0 5.5347371130665124e-08
from O 0 6.318550571648984e-09
exon O 0 1.999242158490233e-07
32 O 0 1.68502452879693e-07
, O 0 7.735390994412228e-09
resulting O 0 3.238683277118071e-08
in O 0 3.82544218524572e-09
a O 0 5.639391176259778e-08
premature O 0 2.0736567876156187e-06
termination O 0 8.879961228558386e-07
codon O 0 2.2869769509270554e-06
27 O 0 5.534657248063013e-07
bp O 0 2.2593694666284136e-06
downstream O 0 2.640849743329454e-07
from O 0 8.346581203966252e-09
the O 0 1.8429892278959414e-08
cryptic O 0 1.3353603662835667e-06
splice O 0 6.603200017707422e-05
site O 0 8.305283699883148e-06
. O 0 1.0218177521892358e-06

Three O 0 1.8437912103763665e-06
other O 0 5.002564762435213e-08
splice O 0 8.441737008979544e-06
variants O 0 1.998907691813656e-06
, O 0 1.9152363250896087e-08
including O 0 7.028164716871288e-09
one O 0 1.2181113895337603e-08
derived O 0 1.8813331337241834e-08
from O 0 2.535484489030182e-09
the O 0 1.4810352944039096e-09
skipping O 0 2.614574334813824e-08
of O 0 9.22619314280837e-10
exon O 0 2.2351490258643025e-07
32 O 0 2.502737288523349e-07
, O 0 1.48775747277341e-08
were O 0 8.161856612787233e-08
also O 0 3.35611680668535e-08
identified O 0 8.603396963735577e-07
. O 0 1.7258000184483535e-07

These O 0 2.939142632385483e-06
results O 0 9.070417377188278e-07
indicate O 0 2.2557493650765537e-07
the O 0 2.573674384720448e-09
usefulness O 0 4.3925570736291775e-08
of O 0 2.8749111979919917e-09
cycloheximide O 0 2.1615196601487696e-06
treatment O 0 1.0609412726125811e-07
in O 0 1.6019430226776876e-09
evaluating O 0 3.527324921037689e-08
the O 0 6.830939813795567e-09
abnormal O 0 1.1422494594626187e-07
processing O 0 1.6609103425935245e-08
of O 0 1.7984698175155245e-09
mRNA O 0 4.161201516694746e-08
due O 0 1.6763269883313114e-08
to O 0 1.0467361200028336e-08
splice O 0 0.00020508666057139635
- O 0 2.121719444403425e-05
site O 0 8.357368415090605e-07
mutations O 0 2.762481699392083e-06
, O 0 8.02274247035939e-09
because O 0 8.766066095233782e-09
( O 0 1.2597639376110692e-08
i O 0 9.562600666868093e-08
) O 0 2.7500490773491038e-09
aberrant O 0 1.331708716634239e-07
splicing O 0 7.249294071698387e-07
often O 0 1.2780051861227548e-07
generates O 0 4.124403574223834e-08
a O 0 6.073445746324069e-08
premature O 0 1.594112745806342e-06
termination O 0 3.788470621657325e-07
codon O 0 7.672151696169749e-07
, O 0 1.6269007474534192e-08
( O 0 9.842971770979148e-09
ii O 0 2.605621318707563e-07
) O 0 9.067804285223247e-09
transcripts O 0 1.744894717603529e-07
with O 0 1.048061051278637e-07
premature O 0 4.435614300746238e-06
termination O 0 6.878925660203095e-07
codons O 0 4.5664828007829783e-07
can O 0 4.230860639609091e-08
occur O 0 7.779443222943883e-08
at O 0 1.9565349873573723e-07
low O 0 0.001226738910190761
or O 0 8.202906428778078e-06
undetectable O 0 0.00019543843518476933
levels O 0 2.979356281684886e-07
due O 0 2.1368004254895823e-08
to O 0 1.2198760224180205e-08
nonsense O 0 1.322566049566376e-06
- O 0 8.045883532759035e-07
mediated O 0 5.810175593978784e-07
mRNA O 0 1.3498554096713633e-07
decay O 0 1.8375405375081755e-07
, O 0 4.849296963982397e-09
and O 0 5.434021677075407e-09
( O 0 4.55064697035823e-09
iii O 0 3.0677803408707405e-08
) O 0 1.5221288673927802e-09
the O 0 1.1681813294472931e-09
levels O 0 2.0282126200754647e-08
of O 0 2.913918273339533e-10
these O 0 1.379634295695098e-09
transcripts O 0 6.948141617613146e-08
can O 0 6.489920423291551e-08
be O 0 1.3823060029949374e-08
increased O 0 2.912098828744547e-08
by O 0 2.3455495323787545e-08
cycloheximide O 0 5.533635885512922e-06
. O 0 1.5106667206055135e-07

A O 0 8.733592949283775e-06
deletion O 0 0.00017063748964574188
mutation O 0 2.7280693757347763e-05
in O 0 1.0407244843690933e-07
COL17A1 O 0 1.6578598660998978e-05
in O 0 2.10377653075966e-08
five O 0 5.162791083535012e-08
Austrian O 0 2.2554884708370082e-05
families O 0 2.6945104991682456e-07
with O 0 1.4115892099653138e-07
generalized O 0 0.0005333359003998339
atrophic B-Disease 1 0.9999113082885742
benign I-Disease 1 0.988324761390686
epidermolysis I-Disease 1 0.9596545100212097
bullosa I-Disease 0 0.06572724133729935
represents O 0 8.715934427527827e-07
propagation O 0 4.659596015699208e-07
of O 0 1.788202297348107e-08
an O 0 3.8496057896963976e-08
ancestral O 0 4.525864369497867e-06
allele O 0 1.5851888747420162e-05
. O 0 3.9520597283626557e-07

Patients O 1 0.998746395111084
with O 0 9.028044587466866e-06
generalized O 0 0.004088316112756729
atrophic B-Disease 1 0.9999597072601318
benign I-Disease 1 0.9999045133590698
epidermolysis I-Disease 1 0.9997422099113464
bullosa I-Disease 1 0.9981802701950073
, O 0 7.542826665485336e-07
a O 0 6.809036534605184e-08
usually O 0 1.1057428395133684e-07
nonlethal O 0 6.480371439465671e-07
form O 0 2.1935693439445458e-07
of O 0 2.278559776414113e-07
junctional B-Disease 1 0.7693926692008972
epidermolysis I-Disease 1 0.9910539984703064
bullosa I-Disease 1 0.8724596500396729
, O 0 1.9807725948339794e-07
have O 0 4.5677108317931925e-08
generalized O 0 1.3016531283938093e-06
blistering B-Disease 0 0.00029901109519414604
, O 0 5.969093308522133e-07
nail B-Disease 1 0.9999970197677612
dystrophy I-Disease 1 0.9994261264801025
, O 0 4.823898507311242e-07
patchy B-Disease 1 0.9222761392593384
alopecia I-Disease 1 0.999998927116394
, O 0 3.893873383731261e-07
and O 0 2.0715535811177688e-06
dental B-Disease 1 0.9998675584793091
abnormalities I-Disease 1 0.999995231628418
. O 0 1.8360707372266916e-06

Skin B-Disease 1 0.9999982118606567
fragility I-Disease 0 0.003492851508781314
in O 0 1.0223875079873324e-07
most O 0 1.7513022143589296e-08
cases O 0 1.2997705134409898e-08
is O 0 2.506571616933684e-09
due O 0 1.1856641002339074e-08
to O 0 9.823877711312434e-09
mutations O 0 8.951024028647225e-07
in O 0 1.5478722747985785e-09
the O 0 3.0594751176948876e-09
gene O 0 1.2974378194030578e-07
encoding O 0 3.9533830431537353e-07
type O 0 0.0001062903247657232
XVII O 0 0.00014567424659617245
collagen O 0 1.3095836038701236e-05
( O 0 5.211268785387801e-07
COL17A1 O 0 4.518441710388288e-05
) O 0 2.1340943590075767e-07
. O 0 3.738153964150115e-07

Recently O 0 8.050332689890638e-05
, O 0 5.361536068448913e-07
we O 0 2.058707480045996e-07
reported O 0 1.0615262624469324e-07
five O 0 1.7301992727425386e-08
Austrian O 0 6.453355581470532e-06
families O 0 2.29767934456504e-07
with O 0 9.610928941583552e-08
generalized O 0 0.00022465763322543353
atrophic B-Disease 1 0.9992853999137878
benign I-Disease 1 0.9552929401397705
epidermolysis I-Disease 1 0.932532787322998
bullosa I-Disease 1 0.9243070483207703
who O 0 2.8909396860399283e-05
share O 0 4.808979383597034e-07
the O 0 8.089895686680393e-08
same O 0 5.368503366298683e-07
COL17A1 O 0 0.00010422008926980197
mutation O 0 1.8684771930566058e-05
. O 0 4.1512376469654555e-07

Affected O 0 0.0002718719479162246
individuals O 0 1.5621769762219628e-06
in O 0 2.547230693039637e-08
three O 0 4.011555176930415e-08
families O 0 3.833610051628966e-08
are O 0 7.148747815932666e-09
homozygous O 0 8.150731218847795e-07
for O 0 2.6386399731848087e-09
4003delTC O 0 2.4611438220745185e-07
, O 0 3.10705017270152e-09
whereas O 0 1.2630576584626851e-08
those O 0 2.7812350200662195e-09
in O 0 1.149399353472802e-09
two O 0 1.9827224306823155e-08
others O 0 6.134696661774797e-08
are O 0 1.0494549229633776e-08
compound O 0 1.89696635288783e-07
heterozygotes O 0 3.047123982469202e-06
. O 0 1.353209171384151e-07

To O 0 2.2440308384830132e-06
determine O 0 1.5557794768028543e-06
if O 0 4.839006706447435e-08
the O 0 8.212824198494673e-09
occurrence O 0 1.3451429481392552e-07
of O 0 5.630349519947231e-09
4003delTC O 0 4.828952455682156e-07
in O 0 3.4908327339877587e-09
these O 0 1.0174071363167059e-08
unrelated O 0 6.915155381648219e-08
families O 0 1.701562979405935e-08
signifies O 0 6.96972124458739e-09
propagation O 0 2.8428285503423467e-08
of O 0 2.869312565323412e-09
an O 0 1.0306534292681135e-08
ancestral O 0 1.0655890037014615e-06
allele O 0 4.173779416305479e-06
or O 0 2.130326350879841e-07
a O 0 4.048635915410159e-08
mutational O 0 2.262643101857975e-05
hot O 0 5.0725626351777464e-05
spot O 0 6.0916125221410766e-05
, O 0 3.0506544845820827e-08
haplotypes O 0 5.775636395810579e-07
were O 0 4.051058226650639e-07
determined O 0 2.09537134310267e-07
for O 0 8.475434576382668e-09
polymorphisms O 0 1.2060883818776347e-05
both O 0 4.720892476939298e-08
within O 0 2.1804330785357706e-08
and O 0 7.054826767216582e-08
flanking O 0 0.00021456179092638195
COL17A1 O 0 0.0008320520864799619
. O 0 8.012116268218961e-07

Five O 0 2.3301083274418488e-05
intragenic O 0 0.00013771608064416796
polymorphisms O 0 0.0004532019083853811
were O 0 4.035586243844591e-06
chosen O 0 1.1682236333854235e-07
based O 0 8.698478382029862e-09
on O 0 2.7894868637190484e-08
their O 0 1.6346091058494494e-07
informativeness O 0 7.637085218448192e-06
. O 0 2.1875402467230742e-07

One O 0 9.286967497246224e-07
of O 0 8.721553257373671e-09
these O 0 9.860295691055398e-09
, O 0 7.998312234747118e-09
not O 0 2.5229432765172533e-08
previously O 0 7.739540706097614e-07
reported O 0 3.934981975817209e-07
, O 0 6.209897485121019e-09
was O 0 1.2593800136073696e-07
2988 O 0 1.1817541434311352e-07
A O 0 4.1072972578604094e-08
or O 0 1.1666126198406346e-07
C O 0 1.3748746141573065e-06
that O 0 1.6380438117025165e-09
introduces O 0 9.934826294966115e-09
a O 0 3.1930835753257725e-09
new O 0 3.0255620231400826e-09
restriction O 0 1.18751088962199e-08
site O 0 2.3764187062624842e-08
for O 0 8.233244308541998e-09
Eco0109 O 0 1.7643970977587742e-06
I O 0 3.931376340915449e-06
. O 0 2.510425360924273e-07

All O 0 7.67673327572993e-07
the O 0 1.4094490552452044e-07
4003delTC O 0 2.8225838377693435e-06
alleles O 0 1.2803856179743889e-06
showed O 0 5.6575117923785e-07
the O 0 4.882280357776381e-09
same O 0 5.509193101715937e-09
haplotype O 0 1.0861484867064064e-07
for O 0 1.5859940027951325e-09
these O 0 5.288921300916627e-09
five O 0 3.8247801370516754e-08
polymorphic O 0 5.5403947953891475e-06
markers O 0 4.4032542064087465e-05
. O 0 6.31672094186797e-07

Fourteen O 0 7.61719566071406e-05
microsatellite O 0 0.0001412220299243927
polymorphisms O 0 0.0004468941770028323
were O 0 1.0024967878052848e-06
selected O 0 4.065001135700186e-08
based O 0 8.382414762309054e-09
on O 0 1.8766703746564417e-08
their O 0 2.800944010061812e-08
high O 0 1.558877613661025e-07
heterozygosity O 0 5.909275841986528e-07
and O 0 2.3852646080513296e-08
their O 0 3.306064755292937e-08
location O 0 1.6699689808774565e-07
within O 0 6.518329342952711e-08
10q23 O 0 3.2891723549255403e-06
- O 0 5.864715603820514e-06
q25 O 0 8.384291504626162e-06
near O 0 4.82520044897683e-06
COL17A1 O 0 4.762683965964243e-05
. O 0 5.871806365576049e-07

Three O 0 1.5614261428709142e-05
families O 0 1.954224217115552e-06
shared O 0 1.8215703221358126e-06
microsatellite O 0 3.812382055912167e-05
polymorphisms O 0 0.0002860955719370395
covering O 0 2.057576239167247e-05
at O 0 8.844236845106934e-07
most O 0 2.384878072803076e-08
19 O 0 6.451291056919217e-08
cM O 0 3.069530691846012e-07
, O 0 6.36699004630259e-09
whereas O 0 2.2289922796403516e-08
the O 0 1.177478825553635e-08
others O 0 6.636656735281576e-08
shared O 0 5.308490358402196e-08
smaller O 0 9.234334896746077e-08
regions O 0 1.36961219254772e-07
consistent O 0 6.614704375351721e-07
with O 0 1.0787012172386312e-08
cross O 0 8.201122909667902e-06
- O 0 4.9259747356700245e-06
over O 0 2.212452088201644e-08
events O 0 3.381729740681294e-08
during O 0 3.298242035043586e-08
passage O 0 1.2826592232784151e-08
of O 0 1.207437705375014e-09
this O 0 1.7675233499048204e-09
mutation O 0 7.680294089595918e-08
through O 0 1.0172771958139037e-08
several O 0 3.3773719820828774e-08
generations O 0 4.3727294496420654e-07
. O 0 2.2542785416135303e-07

These O 0 2.0118743577768328e-06
results O 0 1.5065547813719604e-06
indicate O 0 6.257960194488987e-07
that O 0 3.120188551974934e-08
4003delTC O 0 1.529733822280832e-06
occurs O 0 1.2860593479047111e-08
on O 0 5.492458488021157e-09
a O 0 1.3941257037686228e-08
single O 0 5.341009909898276e-07
ancestral O 0 8.780876328273735e-07
allele O 0 2.6095929115399485e-06
. O 0 3.749206811676231e-08
. O 0 1.60982722263725e-07

The O 0 5.741582299378933e-06
haptoglobin O 0 9.51994297793135e-05
- O 0 1.890535895654466e-05
gene O 0 5.646404133585747e-06
deletion O 0 5.936245997872902e-06
responsible O 0 1.178456045636267e-06
for O 0 4.67467557996315e-08
anhaptoglobinemia B-Disease 0 3.766732334042899e-05
. O 0 6.385070037140395e-07

We O 0 2.1075949916848913e-05
have O 0 1.8173227545048576e-07
found O 0 3.359511069334076e-08
an O 0 2.377763985705883e-09
allelic O 0 3.8500942878272326e-07
deletion O 0 1.556784241074638e-06
of O 0 8.009547691756325e-09
the O 0 3.188447550428464e-08
haptoglobin O 0 4.81726465295651e-06
( O 0 2.6482211978873238e-08
Hp O 0 5.709056338787377e-08
) O 0 4.0300198733689285e-09
gene O 0 6.899977478269648e-08
from O 0 5.1894537556052e-09
an O 0 4.5253214508989e-09
individual O 0 5.754601062335496e-08
with O 0 1.1399239241427495e-07
anhaptoglobinemia B-Disease 0 8.426905696978793e-05
. O 0 4.303499565594393e-07

The O 0 3.042042862944072e-06
Hp O 0 7.28235136193689e-06
gene O 0 3.782813337238622e-06
cluster O 0 4.6780738216511963e-07
consists O 0 2.6539652253632084e-08
of O 0 1.9698449538196883e-09
coding O 0 2.091681636784415e-07
regions O 0 5.80991006415843e-08
of O 0 2.9895432795967736e-09
the O 0 1.172888275391415e-08
alpha O 0 6.423566389912594e-08
chain O 0 4.009769725143997e-07
and O 0 2.0906004039034087e-08
beta O 0 2.549928801443002e-08
chain O 0 1.6349598297438206e-07
of O 0 2.5005739701100538e-09
the O 0 9.295633596195785e-09
haptoglobin O 0 8.443472552244202e-07
gene O 0 1.3013064403821772e-07
( O 0 7.643579991167826e-09
Hp O 0 2.9226210784827344e-08
) O 0 2.5039386120084828e-09
and O 0 3.150217864344995e-09
of O 0 8.085630498477769e-10
the O 0 4.463489133854637e-09
alpha O 0 1.5434448386031363e-08
chain O 0 1.006940095749087e-07
and O 0 9.770117159746405e-09
beta O 0 9.697766145677633e-09
chain O 0 5.3129671329088524e-08
of O 0 6.043384126463991e-10
the O 0 4.064464320663319e-09
haptoglobin O 0 7.991618531377753e-07
- O 0 2.5318138341390295e-07
related O 0 3.546808358123599e-08
gene O 0 2.186238816648256e-07
( O 0 2.0343923878840542e-08
Hpr O 0 7.063995894895925e-07
) O 0 6.908718930276336e-09
, O 0 2.2976118785322797e-09
in O 0 2.035648760667641e-09
tandem O 0 8.494355370203266e-07
from O 0 1.4485777910522302e-08
the O 0 2.488338246564581e-08
5 O 0 1.2072649724359508e-07
side O 0 3.343107891851105e-06
. O 0 2.455807361911866e-07

Southern O 0 2.412627509329468e-05
blot O 0 0.00012227389379404485
and O 0 2.0522034560599423e-07
PCR O 0 6.259963356569642e-06
analyses O 0 2.766612851701211e-06
have O 0 2.7841056748911797e-07
indicated O 0 1.930854836018625e-07
that O 0 2.1288379947748126e-09
the O 0 2.1611048506287034e-09
individual O 0 6.375545424930351e-09
with O 0 1.2032358220892547e-08
anhaptoglobinemia B-Disease 0 9.457174201088492e-06
was O 0 2.0302451275711064e-07
homozygous O 0 2.2306771541025228e-07
for O 0 9.051298044404632e-10
the O 0 1.2715266617391308e-09
gene O 0 3.764412426221497e-08
deletion O 0 2.5558381366863614e-07
and O 0 1.4169769357863515e-08
that O 0 1.763004742194596e-09
the O 0 2.1828330254436423e-09
gene O 0 5.695634541780237e-08
deletion O 0 5.06931598920346e-07
was O 0 1.738960691000102e-07
included O 0 1.577198283087e-08
at O 0 9.704800874033026e-08
least O 0 7.601041573934708e-09
from O 0 3.3360754159161843e-09
the O 0 3.2936260385696414e-09
promoter O 0 6.198303026394569e-08
region O 0 1.1687524725800813e-08
of O 0 2.305619251075086e-09
Hp O 0 8.764749281908735e-08
to O 0 2.5557424621069913e-08
Hpr O 0 2.2002118384989444e-06
alpha O 0 9.102326714582887e-08
but O 0 1.528014337282002e-08
not O 0 9.311569293402044e-09
to O 0 2.5061378750024232e-08
Hpr O 0 1.1643727702903561e-05
beta O 0 8.170163710019551e-07
( O 0 1.454431242109422e-07
Hpdel O 0 5.370053258957341e-06
) O 0 1.350079372741675e-07
. O 0 2.6668928398976277e-07

In O 0 8.895438554645807e-07
addition O 0 3.6612257758861233e-07
, O 0 5.877072339899314e-08
we O 0 3.914608015520571e-08
found O 0 1.3810883991993705e-08
seven O 0 1.8489785702513473e-08
individuals O 0 2.8805813290233573e-09
with O 0 1.193577792157896e-09
hypohaptoglobinemia B-Disease 0 5.529629447664774e-07
in O 0 3.75178021982947e-09
three O 0 3.568876394410836e-08
families O 0 1.793045178999364e-08
, O 0 1.6821907200537112e-09
and O 0 2.400910359412478e-09
the O 0 2.1810435679725515e-09
genotypes O 0 1.0184171372884521e-07
of O 0 6.329161639229142e-10
six O 0 5.507312383912222e-09
of O 0 4.75174732894601e-10
the O 0 5.635054645125592e-09
seven O 0 2.4698875833450984e-08
individuals O 0 2.14824558142368e-09
were O 0 3.117428093446506e-08
found O 0 6.9949046554995675e-09
to O 0 8.619583269364739e-09
be O 0 2.0314034543389425e-07
Hp2 O 0 2.0899398805340752e-05
/ O 0 1.3201969522924628e-05
Hpdel O 0 4.4374915887601674e-05
. O 0 6.960629548302677e-07

The O 0 3.0442022307397565e-06
phenotypes O 0 1.3622793630929664e-05
and O 0 1.5480537740586442e-07
genotypes O 0 2.342586412851233e-06
in O 0 7.173210470057256e-09
one O 0 3.516199553743604e-09
of O 0 3.8117034528717397e-10
these O 0 1.2969763041326132e-09
three O 0 9.029937686477751e-09
families O 0 2.5290235683428364e-08
showed O 0 2.7268890789855504e-07
the O 0 6.066994018283367e-09
father O 0 1.0132439598464771e-07
to O 0 5.314931161848335e-09
be O 0 8.132982998176885e-08
hypohaptoglobinemic B-Disease 0 2.4261071303044446e-06
( O 0 2.326346404402102e-08
Hp2 O 0 5.54532959995413e-07
) O 0 8.427846864833555e-09
and O 0 2.9015644997798518e-08
Hp2 O 0 3.1439763006346766e-06
/ O 0 1.2955772490386153e-06
Hpdel O 0 2.8710117021546466e-06
, O 0 1.6099939159630594e-08
the O 0 1.215917677654943e-08
mother O 0 1.9380718185857404e-07
to O 0 5.219472853923435e-09
be O 0 2.1937612615374746e-08
Hp2 O 0 7.834520943106327e-07
- O 0 7.169437594711781e-07
1 O 0 3.9365467330299e-08
and O 0 3.482083243966372e-08
Hp1 O 0 2.9860111681045964e-06
/ O 0 9.279655159843969e-07
Hp2 O 0 1.5009304661361966e-06
, O 0 5.027489979880784e-09
one O 0 2.930462317252136e-09
of O 0 4.702895295416454e-10
the O 0 3.5406961806927484e-09
two O 0 2.04904253564564e-08
children O 0 5.674316838621962e-08
to O 0 4.579991941255912e-09
be O 0 3.081379418290453e-08
hypohaptoglobinemic B-Disease 0 5.299360736898961e-07
( O 0 6.435177279939808e-09
Hp2 O 0 2.9563091175077716e-07
) O 0 2.9620608188452024e-09
and O 0 7.664572976295858e-09
Hp2 O 0 1.1374538644304266e-06
/ O 0 8.951229233389313e-07
Hpdel O 0 1.17340721317305e-06
, O 0 5.777098799342184e-09
and O 0 2.983203684081559e-09
the O 0 1.4107145451802694e-09
other O 0 2.4885884464254104e-09
child O 0 6.77729161679963e-08
to O 0 4.307365131239749e-09
be O 0 1.6991565487955995e-08
Hp1 O 0 3.91207123584536e-07
and O 0 2.6355831295177268e-08
Hp1 O 0 4.592074674292235e-06
/ O 0 2.581783974164864e-06
Hpdel O 0 3.3642743346717907e-06
, O 0 1.618590417251653e-08
showing O 0 7.621412123626214e-08
an O 0 1.8496687514968357e-09
anomalous O 0 1.6238757893916045e-07
inheritance O 0 1.5363789884759171e-07
of O 0 3.894105038426687e-09
Hp O 0 5.298425094224513e-07
phenotypes O 0 3.778198561121826e-06
in O 0 6.353427561833769e-09
the O 0 2.0603842187938426e-08
child O 0 1.2632306152227102e-06
with O 0 6.694272514096156e-08
Hp1 O 0 4.1502356907585636e-05
. O 0 3.48634387137281e-07

The O 0 5.114411578688305e-06
Hp2 O 0 9.941460302798077e-05
/ O 0 5.3426894737640396e-05
Hpdel O 0 2.5788735001697205e-05
individuals O 0 2.4707600232432014e-07
had O 0 2.715012215048773e-07
an O 0 7.28335125543822e-09
extremely O 0 4.70544819108909e-07
low O 0 1.3339627003006171e-05
level O 0 6.603365818591556e-07
of O 0 4.153650312588297e-09
Hp O 0 1.3859312275599223e-07
( O 0 1.4282212745797551e-08
mean O 0 9.032697079192076e-08
+ O 0 1.377680547420823e-07
/ O 0 6.26440339601686e-07
- O 0 2.3374716420221375e-06
SD O 0 0.0005630927626043558
= O 0 1.5054610230436083e-05
0 O 0 2.925042394963384e-07
. O 0 2.5028130679061178e-08
049 O 0 1.7622528503125068e-06
+ O 0 4.81963581933087e-07
/ O 0 7.456592356902547e-07
- O 0 1.6277440408885013e-06
0 O 0 2.2439529345774645e-07
. O 0 1.4255378211203151e-08
043 O 0 2.7787473300122656e-06
mg O 0 1.5444394421137986e-06
/ O 0 1.2027904858769034e-06
ml O 0 3.3156998142658267e-06
; O 0 6.006180797157867e-08
n O 0 1.9476879060675856e-06
= O 0 3.412219029996777e-06
6 O 0 1.112817997750426e-07
) O 0 5.667932345687632e-09
, O 0 2.6204540759522388e-09
compared O 0 1.1139133171411686e-08
with O 0 1.7934342899650346e-09
the O 0 5.208791176158911e-09
level O 0 1.0883881174095222e-07
( O 0 2.5557751470728363e-09
1 O 0 1.9428301190060893e-09
. O 0 6.577697275744754e-10
64 O 0 1.2736196985940751e-08
+ O 0 4.352924065642583e-08
/ O 0 2.4188199176933267e-07
- O 0 3.0407559847844823e-07
1 O 0 1.6742180974915755e-08
. O 0 3.24006554919265e-09
07 O 0 6.148754323476169e-07
mg O 0 5.407452476902108e-07
/ O 0 4.59856465795383e-07
ml O 0 6.740807521055103e-07
) O 0 9.600225503447746e-09
obtained O 0 1.580613329110747e-08
from O 0 8.279795515875321e-09
52 O 0 3.5316540447638545e-07
healthy O 0 2.4850353952388105e-07
volunteers O 0 9.442886295119024e-08
having O 0 1.4048609386918542e-07
phenotype O 0 1.2863558822573395e-06
Hp2 O 0 7.03720786532358e-07
, O 0 5.378751222195888e-09
whereas O 0 1.6029586547006147e-08
the O 0 3.977943752175861e-09
serum O 0 2.584664002824866e-07
Hp O 0 4.27966320160067e-08
level O 0 4.111326035172169e-08
of O 0 9.9846308998508e-10
an O 0 2.5347930421304454e-09
individual O 0 1.22949757042079e-08
with O 0 4.100620287772472e-08
Hp1 O 0 3.5895343899028376e-05
/ O 0 1.3828426745021716e-05
Hpdel O 0 2.0218114514136687e-05
was O 0 7.468000262633723e-07
0 O 0 9.396189284416323e-07
. O 0 1.8945436863759824e-07

50 O 0 3.921859388356097e-05
mg O 0 4.670066118706018e-05
/ O 0 3.197906698915176e-05
ml O 0 2.831993333529681e-05
, O 0 4.7182279416801975e-08
which O 0 1.9972061338080493e-08
was O 0 5.4514238456704334e-08
approximately O 0 5.669910763117514e-09
half O 0 3.5757703464867063e-09
the O 0 1.1327845328423791e-09
level O 0 9.04928310063724e-09
of O 0 1.0441135733785245e-09
Hp O 0 6.46977511564728e-08
in O 0 8.816823715562805e-09
control O 0 2.024037030423642e-06
sera O 0 1.3761194850303582e-06
from O 0 7.321542483396115e-09
the O 0 1.3366322271224362e-08
Hp1 O 0 1.1859884807563503e-06
phenotype O 0 3.342775016790256e-07
( O 0 5.7228013439214465e-09
1 O 0 7.873904195321302e-09
. O 0 2.069718174624313e-09
26 O 0 4.73275711954102e-08
+ O 0 8.433093512394407e-08
/ O 0 5.011480084249342e-07
- O 0 6.898871447447164e-07
0 O 0 9.994070637731056e-08
. O 0 3.1941433942250796e-09
33 O 0 7.949449098987316e-08
mg O 0 4.3061436372227035e-07
/ O 0 5.690340572073183e-07
ml O 0 1.6233212818406173e-06
; O 0 4.3026211926644464e-08
n O 0 3.5656355521496153e-06
= O 0 4.4962444007978775e-06
9 O 0 1.5256399876761861e-07
) O 0 6.312117939444306e-09
, O 0 3.6027707484009852e-09
showing O 0 8.858310707182682e-08
a O 0 2.762594419891684e-08
gene O 0 8.567347435928241e-07
- O 0 2.9032089514657855e-06
dosage O 0 1.1650604392343666e-05
effect O 0 1.3675960417458555e-06
. O 0 4.153221766500792e-07

The O 0 4.4288287881499855e-07
other O 0 3.9024566689249696e-08
allele O 0 1.125516291722306e-06
( O 0 3.304375084667299e-08
Hp2 O 0 5.51375762825046e-07
) O 0 3.876704290917132e-09
of O 0 1.2388161607645998e-09
individuals O 0 8.652064842351592e-09
with O 0 1.1538368482888472e-08
Hp2 O 0 1.939221692737192e-05
/ O 0 1.0161737009184435e-05
Hpdel O 0 1.0280754395353142e-05
was O 0 1.1949039162573172e-06
found O 0 1.761886281315128e-08
to O 0 5.148725890080641e-09
have O 0 1.2708950691830978e-07
, O 0 1.9734665013260155e-09
in O 0 3.4749542132672673e-10
all O 0 1.183650177871698e-09
exons O 0 1.4531653391713917e-07
, O 0 8.235066850659223e-09
no O 0 2.6786608486872865e-08
mutation O 0 1.6593214979820914e-07
, O 0 2.713637980988892e-09
by O 0 2.51452036970079e-09
DNA O 0 1.7340835256618448e-07
sequencing O 0 1.0984125538016087e-06
. O 0 2.771366496290284e-07

On O 0 5.968575464976311e-07
the O 0 1.1768726437821897e-08
basis O 0 6.256418050298862e-09
of O 0 4.2462650062802254e-10
the O 0 2.023555545349609e-09
present O 0 3.3106568597673913e-09
study O 0 4.088708038807454e-09
, O 0 1.2713472496983513e-09
the O 0 1.0191215649157925e-09
mechanism O 0 1.3289551681339162e-08
of O 0 2.0778265774623605e-09
anhaptoglobinemia B-Disease 0 1.3461135495163035e-06
and O 0 2.0016221569107984e-08
the O 0 5.8832494431726445e-09
mechanism O 0 2.5039685880301477e-08
of O 0 1.838150742727862e-09
anomalous O 0 1.1305040459319571e-07
inheritance O 0 1.4392615810265852e-07
of O 0 6.717702394354319e-09
Hp O 0 6.618541306124825e-07
phenotypes O 0 9.262200364901219e-06
were O 0 3.160607775498647e-07
well O 0 1.2554970396649878e-07
explained O 0 1.4929373719496652e-06
. O 0 2.7788510692516866e-07

However O 0 3.10095356326201e-06
, O 0 4.691306898507719e-08
the O 0 1.0590242460750687e-08
mechanism O 0 1.129371511865429e-07
of O 0 2.0721602211892787e-08
hypohaptoglobinemia B-Disease 0 6.30354043096304e-05
remains O 0 1.4107927199802361e-06
unknown O 0 4.439982149051502e-06

ATM O 0 0.0010911407880485058
mutations O 0 0.0006205500103533268
and O 0 1.5897570619927137e-06
phenotypes O 0 0.00018970710516441613
in O 0 2.2664112293568905e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
families O 0 7.420314068440348e-05
in O 0 1.7874555169328232e-08
the O 0 2.8282691744152544e-08
British O 0 3.1168601708486676e-06
Isles O 0 8.740731232137477e-07
: O 0 3.5802061315592937e-09
expression O 0 5.067800401548084e-09
of O 0 6.426943421899978e-10
mutant O 0 1.2480002453685302e-07
ATM O 0 3.040889566818805e-07
and O 0 1.0223013546806214e-08
the O 0 2.026944123656449e-08
risk O 0 4.829670388062368e-07
of O 0 1.280767047973086e-08
leukemia B-Disease 1 0.5886703729629517
, O 0 3.001345703523839e-06
lymphoma B-Disease 1 1.0
, O 0 2.6849915002458147e-07
and O 0 3.6474710213951766e-05
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.7046442627906799
. O 0 6.842286666142172e-07

We O 0 8.716552656551357e-06
report O 0 1.058194740721774e-07
the O 0 4.63177007858917e-09
spectrum O 0 3.231457768038126e-08
of O 0 3.24899551706892e-09
59 O 0 2.395971705482225e-07
ATM O 0 9.852412404143251e-06
mutations O 0 1.4687248949485365e-05
observed O 0 4.5549654714704957e-07
in O 0 2.2557709655757208e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0017210778314620256
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4474655074536713e-07
patients O 0 3.1218380058817274e-07
in O 0 2.55626764200656e-09
the O 0 1.165424468041465e-08
British O 0 2.5314327558589866e-06
Isles O 0 1.4953833670006134e-05
. O 0 3.303748314920085e-07

Of O 0 1.4798324627918191e-06
51 O 0 9.226812835549936e-06
ATM O 0 2.999723619723227e-05
mutations O 0 3.116426523774862e-05
identified O 0 8.357926049029629e-07
in O 0 1.0393632621230608e-08
families O 0 2.9632714060312537e-08
native O 0 5.059851204691768e-09
to O 0 4.687011667670049e-09
the O 0 2.3420804851070898e-08
British O 0 3.775781351578189e-06
Isles O 0 2.275872020618408e-06
, O 0 1.226218859784467e-08
11 O 0 2.4275498944348328e-08
were O 0 6.507944050326842e-08
founder O 0 3.091446032499334e-08
mutations O 0 1.1917396847138662e-07
, O 0 1.6331522800783205e-09
and O 0 1.3586026748058089e-09
2 O 0 2.330733384070527e-09
of O 0 2.3195385889795972e-10
these O 0 2.4227195805082147e-09
11 O 0 1.902108692775073e-08
conferred O 0 2.426124368071214e-08
a O 0 1.3704400281255857e-08
milder O 0 3.6492172057478456e-06
clinical O 0 1.787521796359215e-05
phenotype O 0 1.9018004877580097e-06
with O 0 5.89890181146302e-09
respect O 0 5.655092394363237e-09
to O 0 5.63378721452068e-09
both O 0 3.5987690694128105e-07
cerebellar B-Disease 0 0.00033780289231799543
degeneration I-Disease 0 0.0002514786901883781
and O 0 5.506905864649525e-08
cellular O 0 2.4275952910102205e-06
features O 0 2.8966271656827303e-06
. O 0 5.301902774590417e-07

We O 0 1.8123491827282123e-05
report O 0 3.109921919985936e-07
, O 0 1.0563129038132502e-08
in O 0 4.079266702206041e-09
two O 0 2.609005491649441e-07
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
families O 0 1.6257631330063305e-07
, O 0 1.4252053981422819e-09
an O 0 2.251359099147976e-09
ATM O 0 3.974722858401947e-06
mutation O 0 6.592712793462852e-07
( O 0 1.5216450321986486e-08
7271T O 0 3.69602332739305e-07
- O 0 3.6222179460310144e-06
- O 0 8.057362720137462e-06
> O 0 5.084698386781383e-07
G O 0 2.8002102681057295e-06
) O 0 2.4961470668216634e-09
that O 0 1.9419148511445883e-09
may O 0 3.6890540400236205e-08
be O 0 2.9416065139287184e-09
associated O 0 2.437142709865725e-09
with O 0 3.252639546591496e-10
an O 0 1.7039785138450725e-09
increased O 0 4.238816586621397e-08
risk O 0 2.7265562607681204e-07
of O 0 8.054496625220509e-09
breast B-Disease 1 0.9990372657775879
cancer I-Disease 0 1.8218139302916825e-05
in O 0 3.7487262183333314e-09
both O 0 4.6313129331565506e-08
homozygotes O 0 1.247774162038695e-05
and O 0 1.498617621109588e-07
heterozygotes O 0 3.198548938598833e-06
( O 0 3.1784836096449e-08
relative O 0 2.281508244550423e-07
risk O 0 8.058385105869093e-07
12 O 0 9.312314475096173e-09
. O 0 1.4345106214008752e-09
7 O 0 4.7730164709491874e-08
; O 0 2.2908915653374606e-08
P O 0 0.0004949642461724579
= O 0 6.70860299578635e-06
. O 0 8.922047101123098e-09
0025 O 0 3.033930852325284e-06
) O 0 1.0487946511261725e-08
, O 0 2.3532469306530857e-09
although O 0 2.748344885006304e-09
there O 0 2.8372044713620426e-09
is O 0 1.7379112593474133e-09
a O 0 1.356130852059323e-08
less O 0 3.9758415937285463e-07
severe O 0 0.1646811068058014
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
phenotype O 0 4.061137133248849e-06
in O 0 2.8606024216060177e-09
terms O 0 4.672640940839301e-09
of O 0 1.8845777716158807e-10
the O 0 1.5803020003701818e-09
degree O 0 2.58693440002844e-08
of O 0 4.083207727489935e-08
cerebellar B-Disease 0 0.00270608882419765
degeneration I-Disease 0 0.005386184435337782
. O 0 1.507189949734311e-06

This O 0 1.1186110668859328e-06
mutation O 0 9.341043551103212e-06
( O 0 2.0972825609533174e-07
7271T O 0 3.068464366151602e-06
- O 0 9.993143066822086e-06
- O 0 1.3028891771682538e-05
> O 0 1.2660287893595523e-06
G O 0 1.7427705643058289e-06
) O 0 4.5162669159992674e-09
also O 0 2.918836949916681e-09
allows O 0 2.259347375854759e-09
expression O 0 7.88732634759981e-09
of O 0 1.0022428442724163e-09
full O 0 3.4767143830549685e-08
- O 0 4.2020414525723027e-07
length O 0 1.255080377404738e-07
ATM O 0 6.616691621275095e-07
protein O 0 5.042781481279235e-08
at O 0 1.558142770363702e-08
a O 0 5.298452787627639e-09
level O 0 4.806058839790239e-08
comparable O 0 1.2578196617596404e-07
with O 0 7.868274032318823e-09
that O 0 6.569688792978923e-09
in O 0 1.78300503250739e-08
unaffected O 0 2.7463636342872633e-06
individuals O 0 6.07379249117912e-08
. O 0 6.88000270088196e-08

In O 0 7.647643656127912e-07
addition O 0 1.395557518435453e-07
, O 0 2.408676991194625e-08
we O 0 2.2750848316377414e-08
have O 0 8.50839487753774e-09
studied O 0 3.361649874022987e-07
18 O 0 1.9693704871315276e-06
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 7.864803592383396e-06
, O 0 1.0567778874204237e-09
in O 0 4.670696052144763e-10
15 O 0 2.959976708183376e-09
families O 0 3.4017568761868233e-09
, O 0 2.1178383491360364e-09
who O 0 3.3116688058498767e-08
developed O 0 1.9052105926675722e-05
leukemia B-Disease 1 0.9725679755210876
, O 0 1.3628853139380226e-06
lymphoma B-Disease 1 1.0
, O 0 9.704578474156733e-08
preleukemic O 0 3.5991284676129e-05
T O 0 0.00010097527410835028
- O 0 5.740186225011712e-06
cell O 0 6.058039616618771e-06
proliferation O 0 1.7297210206379532e-06
, O 0 4.163424449643571e-08
or O 0 0.0006930351373739541
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 5.4748898747902786e-08
mostly O 0 3.474891485666376e-08
in O 0 3.259032865798872e-08
childhood O 0 3.404074959689751e-05
. O 0 3.8882146213836677e-07

A O 0 4.081070073880255e-06
wide O 0 7.496171292586951e-07
variety O 0 4.012457921476198e-08
of O 0 1.071066346725047e-08
ATM O 0 1.792805596778635e-05
mutation O 0 2.9655925573024433e-06
types O 0 1.1857425619155038e-07
, O 0 3.458755504226474e-09
including O 0 1.1306567238023035e-08
missense O 0 1.4538818504661322e-05
mutations O 0 9.389504157297779e-06
and O 0 5.440102057718832e-08
in O 0 2.5870329878330267e-08
- O 0 8.139691999531351e-06
frame O 0 3.121962072327733e-05
deletions O 0 5.0243093028257135e-06
, O 0 1.0066961664279006e-07
were O 0 3.0733590961062873e-07
seen O 0 1.0041495102086628e-07
in O 0 4.1750403134699354e-09
these O 0 4.60803377677621e-08
patients O 0 9.276859032070206e-07
. O 0 1.0122182914074074e-07

We O 0 5.26737767359009e-06
also O 0 1.2129625304169167e-07
show O 0 1.781540817091809e-07
that O 0 2.418347522237241e-09
25 O 0 7.750809771778222e-09
% O 0 3.794079717067689e-09
of O 0 1.0925343962853162e-09
all O 0 1.3219994343671715e-07
A B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.3024344298173673e-05
carried O 0 2.0270569223157509e-07
in O 0 4.8654547057935815e-09
- O 0 1.4309882772067795e-06
frame O 0 7.668329089938197e-06
deletions O 0 1.4441660596276051e-06
or O 0 1.8602524676225585e-07
missense O 0 4.094441464985721e-06
mutations O 0 1.692105115580489e-06
, O 0 3.49909234920176e-09
many O 0 6.682862041529347e-10
of O 0 9.423375413319945e-10
which O 0 5.3053522464097114e-08
were O 0 1.9064510752286878e-06
also O 0 3.5487843774717476e-08
associated O 0 1.2016555750449243e-08
with O 0 1.418349881987524e-09
expression O 0 1.2109648395153272e-08
of O 0 2.117798159062545e-09
mutant O 0 5.905951638851548e-07
ATM O 0 3.6414160149433883e-06
protein O 0 1.2678071925620316e-06
. O 0 4.984160000276461e-07

The O 0 3.3939636523427907e-06
DMPK O 0 4.369651651359163e-05
gene O 0 2.662206952663837e-06
of O 0 1.7881652070173004e-07
severely O 0 0.04118460416793823
affected O 0 0.0004949358990415931
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9991347193717957
is O 0 1.0552722073953191e-07
hypermethylated O 0 4.9156969907926396e-06
proximal O 0 5.772013537352905e-06
to O 0 6.418447640044178e-08
the O 0 1.106114098092803e-07
largely O 0 5.237955633674574e-07
expanded O 0 1.6700358855814557e-06
CTG O 0 4.545929914456792e-05
repeat O 0 1.093415903596906e-05
. O 0 7.761537403894181e-07

Using O 0 1.4127977010502946e-05
methylation O 0 1.7592941730981693e-05
- O 0 1.1731157428584993e-05
sensitive O 0 3.4518354823376285e-06
restriction O 0 3.968049782088201e-07
enzymes O 0 4.628857936950226e-07
, O 0 1.782658287652339e-08
we O 0 1.998059673269381e-08
characterized O 0 2.6588496737645073e-08
the O 0 2.5675797044044657e-09
methylation O 0 8.204216328522307e-08
pattern O 0 3.192717201727646e-07
on O 0 2.345773353340519e-08
the O 0 9.158293678979135e-09
5 O 0 1.9530631334419013e-08
side O 0 1.3160232015252404e-07
of O 0 1.7737610269463744e-09
the O 0 2.4847668811389667e-08
CTG O 0 3.2882439882087056e-06
repeat O 0 1.6461888208141318e-07
in O 0 1.8476413732315677e-09
the O 0 4.290106048188136e-09
DMPK O 0 3.3251507147724624e-07
gene O 0 2.388515341067432e-08
of O 0 1.134501270705357e-09
normal O 0 2.7033177474322656e-08
individuals O 0 2.829514178515069e-09
and O 0 1.7843854172028273e-09
of O 0 3.903303458230312e-09
patients O 0 6.935959504517086e-07
affected O 0 3.776278845180059e-07
with O 0 9.242102123607765e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.7076501990231918e-07
showing O 0 6.062462603040331e-07
expansions O 0 1.7891120762669743e-07
of O 0 9.659644639725684e-09
the O 0 4.525150743006634e-08
repetitive O 0 4.014737351099029e-05
sequence O 0 2.3554946437798208e-06
. O 0 4.266215967163589e-07

The O 0 1.9530464214767562e-06
gene O 0 6.56161591905402e-06
segment O 0 1.8024495602730894e-06
analyzed O 0 8.487116360811342e-07
corresponds O 0 1.9758634550726129e-07
to O 0 2.7186128903622375e-08
the O 0 5.3158661472707536e-08
genomic O 0 1.1140153219457716e-05
SacI O 0 0.00017841430963017046
- O 0 3.2866937544895336e-05
HindIII O 0 1.8954660845338367e-05
fragment O 0 1.2726163731713314e-06
carrying O 0 4.316471802212618e-07
exons O 0 3.0634148515673587e-06
11 O 0 6.631998985540122e-07
- O 0 2.3455820610251976e-06
15 O 0 2.8826448783547676e-07
. O 0 1.419788446810344e-07

There O 0 4.346239620645065e-06
is O 0 1.4097260248036037e-07
constitutive O 0 5.781510594715655e-07
methylation O 0 6.544003667841025e-07
in O 0 3.786100677416471e-08
intron O 0 1.2451472684915643e-05
12 O 0 3.8145446978887776e-07
at O 0 3.721712360515994e-08
restriction O 0 7.665918566601704e-09
sites O 0 1.2349408606837642e-08
of O 0 3.7040559508483284e-09
SacII O 0 8.799101465228887e-07
and O 0 2.9716312965888392e-08
HhaI O 0 6.430566941162397e-07
, O 0 2.9849906990619957e-09
localized O 0 1.358536536599786e-07
1 O 0 2.515385055801289e-08
, O 0 5.431483263151904e-09
159 O 0 5.780661993526337e-08
- O 0 3.2206747846430517e-07
1 O 0 2.8981739674804885e-08
, O 0 1.9798795936054603e-09
232 O 0 3.25129079215003e-08
bp O 0 2.0354893592866574e-07
upstream O 0 3.536898063316585e-08
of O 0 1.747860856049499e-09
the O 0 9.81453318615877e-09
CTG O 0 1.5227647054416593e-06
repeat O 0 1.2291158668631397e-07
, O 0 3.2918547887561544e-09
whereas O 0 9.243494858424128e-09
most O 0 1.9496007030994633e-09
, O 0 2.020439371364091e-09
if O 0 9.387353117062958e-10
not O 0 9.93741755550559e-10
all O 0 2.4993854208510413e-10
, O 0 1.651425801663109e-10
of O 0 7.195937595794177e-11
the O 0 5.588875473527821e-10
other O 0 4.952357413046116e-10
sites O 0 6.131605889692082e-09
of O 0 1.1967967727954942e-09
SacII O 0 5.020526145926851e-07
, O 0 7.144277169857105e-09
HhaI O 0 2.0051842852808477e-07
, O 0 3.991647457013414e-09
and O 0 6.253042084125582e-09
HpaII O 0 2.1360774837830832e-07
in O 0 7.433957338598418e-10
this O 0 4.1870723554993106e-10
region O 0 7.551546943318499e-09
are O 0 2.701038503971631e-09
unmethylated O 0 2.3618957811777364e-07
, O 0 1.3984874369654676e-09
in O 0 4.184501356530035e-10
normal O 0 8.728109790467897e-09
individuals O 0 9.554406155132256e-10
and O 0 9.057705141479744e-10
most O 0 7.531420487261187e-10
of O 0 9.330071160107423e-10
the O 0 6.926428142151053e-08
patients O 0 1.2099786772523657e-06
. O 0 1.0006449713273469e-07

In O 0 6.478776981566625e-07
a O 0 4.127432973177747e-08
number O 0 8.361847214644058e-09
of O 0 2.751434191594626e-09
young O 0 8.05499169587165e-08
and O 0 4.270555109542329e-08
severely O 0 0.00027394958306103945
affected O 0 7.523407816734107e-07
patients O 0 2.5919803192664403e-07
, O 0 1.9357797587105097e-09
however O 0 3.867893116904497e-09
, O 0 9.884734142318052e-10
complete O 0 2.35101271783833e-09
methylation O 0 8.224863456973708e-09
of O 0 3.564654960097613e-10
these O 0 1.1501142260783581e-09
restriction O 0 8.840331133797008e-09
sites O 0 5.856851714725053e-08
was O 0 2.828869014592783e-07
found O 0 1.3482131855369062e-08
in O 0 2.726587844392725e-09
the O 0 1.617180167556853e-08
mutated O 0 1.8222773405796033e-06
allele O 0 6.786554877180606e-06
. O 0 4.164497227066022e-07

In O 0 1.7299393562097976e-07
most O 0 7.758294451321035e-09
of O 0 2.1271495675989627e-09
these O 0 1.328144350054572e-08
patients O 0 8.925590577746334e-08
, O 0 7.143374225471177e-10
the O 0 3.066801479434389e-09
onset O 0 2.198569518441218e-06
of O 0 5.4843352081945795e-09
the O 0 3.999334239779273e-06
disease O 1 0.9706026315689087
was O 0 3.199200000381097e-05
congenital O 1 0.9998346567153931
. O 0 5.474972795127542e-07

Preliminary O 0 3.2796149753266945e-05
in O 0 8.890248750503815e-07
vivo O 0 2.8612739697564393e-05
footprinting O 0 5.790526847704314e-05
data O 0 5.688945634574338e-07
gave O 0 1.411324035416328e-07
evidence O 0 2.0883167195506758e-08
for O 0 5.7729243607695935e-09
protein O 0 6.696290455465714e-08
- O 0 8.207892960854224e-07
DNA O 0 3.207607619515329e-07
contact O 0 7.792449991939066e-07
in O 0 1.784668945958856e-08
normal O 0 2.4556740640946373e-07
genes O 0 2.3166434459653829e-07
at O 0 3.2053012688493254e-08
an O 0 6.0944698176967904e-09
Sp1 O 0 2.3103069679564214e-07
consensus O 0 1.3673956189563796e-08
binding O 0 2.986586977726802e-08
site O 0 3.041161633632328e-08
upstream O 0 1.8466911555492516e-08
of O 0 1.4759817812404208e-09
the O 0 1.2404577809377315e-08
CTG O 0 2.346183919144096e-06
repeat O 0 3.903871856891783e-07
and O 0 9.630082509204385e-09
for O 0 8.4685786161387e-10
a O 0 2.4220128125307383e-09
significant O 0 4.318454038809705e-09
reduction O 0 3.828128036786893e-09
of O 0 2.899636364350755e-10
this O 0 2.752482686219082e-10
interaction O 0 7.488194952998128e-09
in O 0 7.21558457428273e-09
cells O 0 3.8214622577470436e-08
with O 0 2.595681225514568e-09
a O 0 4.4801151233286873e-08
hypermethylated O 0 5.714367489417782e-06
DMPK O 0 5.584891368926037e-06
gene O 0 5.457654879137408e-07
. O 0 2.2392320886410744e-08
. O 0 1.0668076555475636e-07

The O 0 9.78149546426721e-06
hemochromatosis B-Disease 1 0.9999840259552002
gene O 0 1.9523688024492003e-05
product O 0 9.527969950795523e-07
complexes O 0 4.977229650648951e-07
with O 0 2.0030736180842723e-08
the O 0 1.8770284881952648e-08
transferrin O 0 9.92736431726371e-07
receptor O 0 5.247715080258786e-07
and O 0 4.8170438304850904e-08
lowers O 0 6.205412432791491e-07
its O 0 5.23856202860884e-09
affinity O 0 2.608422633443297e-08
for O 0 2.8859212797271994e-09
ligand O 0 1.2222264444972097e-07
binding O 0 5.526597988136928e-07
. O 0 1.7330553703232e-07

We O 0 2.755071545834653e-05
recently O 0 1.6980879991024267e-06
reported O 0 2.949440442989726e-07
the O 0 6.182432343848632e-09
positional O 0 4.1181860410688387e-07
cloning O 0 1.0467964273175312e-07
of O 0 2.1908914682455816e-09
a O 0 2.1465591970581954e-08
candidate O 0 5.730913699153461e-07
gene O 0 5.032437002228107e-06
for O 0 3.0239305033319397e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.00494350166991353
HFE O 1 0.8205794095993042
. O 0 4.411694135342259e-06

The O 0 1.2145684422648628e-06
gene O 0 1.923746822285466e-06
product O 0 2.622783767947112e-07
, O 0 7.902023035910588e-09
a O 0 4.606379278015993e-09
member O 0 4.2213303963478666e-09
of O 0 6.29864493895127e-10
the O 0 3.5277671894817786e-09
major O 0 1.4562125727479724e-08
histocompatibility O 0 7.075808525769389e-07
complex O 0 4.521285745795467e-08
class O 0 9.569789938268514e-08
I O 0 4.7163925955828745e-06
- O 0 6.520555757560942e-07
like O 0 7.226647369407146e-08
family O 0 6.230329319123484e-08
, O 0 6.255380213815442e-09
was O 0 1.2911451108266192e-07
found O 0 5.278349757276146e-09
to O 0 2.6731066249396918e-09
have O 0 1.057201881593528e-08
a O 0 7.456753436940744e-09
mutation O 0 3.6759865906788036e-07
, O 0 9.999538974625466e-09
Cys O 0 4.378890480438713e-06
- O 0 1.2844656112065422e-06
282 O 0 1.2585135209519649e-06
- O 0 9.617017894925084e-06
- O 0 5.150210199644789e-06
> O 0 1.0912801826634677e-06
Tyr O 0 3.895454938174225e-06
( O 0 3.877113030625878e-08
C282Y O 0 1.631352830600008e-07
) O 0 4.5459884745469026e-09
, O 0 1.964209905835901e-09
in O 0 1.8606983731572768e-09
85 O 0 1.4179070362274615e-08
% O 0 9.42798195069372e-09
of O 0 6.0713585270377735e-09
patient O 0 1.492742285336135e-06
chromosomes O 0 4.322537279222161e-06
. O 0 4.0319409322364663e-07

This O 0 1.0098422080773162e-06
mutation O 0 7.058379651425639e-06
eliminates O 0 1.7015263438224792e-06
the O 0 2.560582679222989e-08
ability O 0 8.289596564736712e-08
of O 0 6.112502948241172e-09
HFE O 0 1.6421714462921955e-05
to O 0 3.030374173818018e-08
associate O 0 1.818522576968462e-07
with O 0 4.609589510096157e-08
beta2 O 0 0.0001699671702226624
- O 0 9.267759014619514e-05
microglobulin O 0 9.60128272708971e-06
( O 0 4.2275210887510184e-08
beta2m O 0 7.651561304555798e-07
) O 0 7.567682480669191e-09
and O 0 8.951842822568779e-09
prevents O 0 8.562171416315323e-08
cell O 0 6.166347930047777e-07
- O 0 5.929377493885113e-06
surface O 0 1.2975016034033615e-05
expression O 0 2.508352963559446e-06
. O 0 4.0298920112036285e-07

A O 0 1.6195055650314316e-05
second O 0 1.9585431800805964e-06
mutation O 0 1.4975347539802897e-06
that O 0 8.049827471268145e-09
has O 0 1.771023683261319e-08
no O 0 2.5395030078811942e-08
effect O 0 1.2186992748297598e-08
on O 0 2.825228229141885e-08
beta2m O 0 2.364894271522644e-06
association O 0 3.22347339931639e-08
, O 0 1.134828675475319e-08
H63D O 0 1.266435674551758e-06
, O 0 5.6389901637032835e-09
was O 0 1.5122812158097076e-07
found O 0 7.538495161441006e-09
in O 0 9.924462363031239e-10
eight O 0 1.3738213233693841e-08
out O 0 6.477749003863664e-09
of O 0 5.406673997399025e-10
nine O 0 1.6505212840911554e-07
patients O 0 6.836625487949277e-08
heterozygous O 0 1.0740186695556986e-07
for O 0 1.855849585119529e-09
the O 0 1.687130257721492e-08
C282Y O 0 1.6780837768237689e-06
mutant O 0 2.959619678222225e-06
. O 0 2.3566039430988894e-07

In O 0 6.572699362550338e-07
this O 0 2.1673885797213188e-08
report O 0 3.5386996444231045e-08
, O 0 4.254487873112112e-09
we O 0 5.4683120254139794e-09
demonstrate O 0 7.81467068833308e-09
in O 0 2.5410182846741236e-09
cultured O 0 1.377453315853927e-07
293 O 0 2.558159621912637e-07
cells O 0 9.545489376705518e-08
overexpressing O 0 2.5480044314463157e-06
wild O 0 1.7934151230747375e-07
- O 0 6.658736992903869e-07
type O 0 4.080661256011808e-06
or O 0 2.2113304964932468e-07
mutant O 0 2.787628318401403e-06
HFE O 0 8.425346095464192e-06
proteins O 0 7.658029943513611e-08
that O 0 2.497418494229464e-09
both O 0 6.548821041008068e-09
the O 0 1.1006838995797352e-08
wild O 0 4.083597104909131e-08
- O 0 9.92503601082717e-07
type O 0 1.0654229299689177e-05
and O 0 1.637539241983177e-07
H63D O 0 1.8594362700241618e-05
HFE O 0 1.707101910142228e-05
proteins O 0 2.0979388182240655e-07
form O 0 1.614553468698432e-07
stable O 0 1.1150696082040668e-06
complexes O 0 1.10645380857477e-07
with O 0 9.413032131533328e-09
the O 0 4.4948198052452426e-08
transferrin O 0 6.012266567267943e-06
receptor O 0 3.3787687243602704e-06
( O 0 1.2391198822570004e-07
TfR O 0 1.0529382052482106e-05
) O 0 1.1494288543190123e-07
. O 0 2.1497166358130926e-07

The O 0 5.760608928540023e-06
C282Y O 0 5.588108251686208e-05
mutation O 0 1.4837590242677834e-05
nearly O 0 6.939962418073264e-07
completely O 0 1.2019555697406759e-06
prevents O 0 4.904646289105585e-08
the O 0 4.852128032695191e-09
association O 0 9.282805635280056e-09
of O 0 1.184160547396118e-09
the O 0 1.7013162434409423e-08
mutant O 0 3.3116737085947534e-06
HFE O 0 1.4348569493449759e-05
protein O 0 1.8099028409324092e-07
with O 0 2.667576559645113e-08
the O 0 1.727876650647886e-07
TfR O 0 0.0001017781178234145
. O 0 5.449811624202994e-07

Studies O 0 1.1586616892600432e-05
on O 0 4.1045413468054903e-07
cell O 0 1.7348390883853426e-06
- O 0 2.0148504518147092e-06
associated O 0 8.658638961378529e-08
transferrin O 0 3.4449382724233146e-07
at O 0 6.990852341459686e-08
37 O 0 5.2646981885118294e-08
degrees O 0 2.4424869593531184e-07
C O 0 2.131880864908453e-05
suggest O 0 4.858928193129941e-08
that O 0 1.8411403512885727e-09
the O 0 3.408641369162524e-09
overexpressed O 0 6.702468340336054e-07
wild O 0 5.672812619650358e-08
- O 0 2.508374166154681e-07
type O 0 1.8983773770742118e-06
HFE O 0 2.9471557354554534e-05
protein O 0 1.8355333963882003e-07
decreases O 0 1.517092869107728e-07
the O 0 8.825858266447995e-09
affinity O 0 4.708680023668421e-08
of O 0 6.8012719900423235e-09
the O 0 6.705428745590325e-08
TfR O 0 9.073757610167377e-06
for O 0 4.8000305952200506e-08
transferrin O 0 9.288490218750667e-06
. O 0 4.350185349721869e-07

The O 0 4.535374500846956e-06
overexpressed O 0 4.997001451556571e-05
H63D O 0 1.5256197912094649e-05
protein O 0 5.552087145588303e-07
does O 0 5.6802075931727813e-08
not O 0 1.9761905889481568e-08
have O 0 4.810054576864786e-09
this O 0 2.871347881683306e-10
effect O 0 4.58728299790323e-09
, O 0 7.917528299650201e-10
providing O 0 1.5184925539202254e-09
the O 0 6.260569285210238e-10
first O 0 3.4480847066475917e-09
direct O 0 6.166415822406179e-09
evidence O 0 1.4753801735878369e-08
for O 0 1.9679371465741724e-09
a O 0 1.3247540842087346e-08
functional O 0 6.652624051639577e-07
consequence O 0 1.2467262422433123e-07
of O 0 2.4238566709300358e-09
the O 0 5.3826227031095186e-08
H63D O 0 4.0680064557818696e-05
mutation O 0 5.8467280723562e-06
. O 0 2.1055433307992644e-07

Addition O 0 4.512624400376808e-06
of O 0 2.3165705442806939e-07
soluble O 0 3.6466010442381958e-06
wild O 0 5.634578883473296e-07
- O 0 1.642625647946261e-05
type O 0 0.0001754743279889226
HFE O 0 0.006348906550556421
/ O 0 8.259365858975798e-05
beta2m O 0 2.3372946088784374e-05
heterodimers O 0 1.6369087461498566e-05
to O 0 1.135382277084318e-07
cultured O 0 1.9447904833214125e-06
cells O 0 5.450451112665178e-07
also O 0 4.2484728624003765e-08
decreased O 0 2.6916032425106096e-07
the O 0 7.41488603850371e-09
apparent O 0 2.93566664311129e-08
affinity O 0 2.07706687405107e-08
of O 0 4.402082698362619e-09
the O 0 3.021607142272842e-08
TfR O 0 1.684733433648944e-06
for O 0 1.9063863820889537e-09
its O 0 1.3793501896230964e-09
ligand O 0 1.9958962482746756e-08
under O 0 2.736989479501517e-08
steady O 0 2.955747788746521e-07
- O 0 2.0099150788155384e-07
state O 0 3.2009679351574505e-09
conditions O 0 3.4812398297390246e-08
, O 0 5.748583276066199e-10
both O 0 8.050989874774928e-10
in O 0 1.0189641352909007e-09
293 O 0 3.64193262214485e-08
cells O 0 1.8399054724227426e-08
and O 0 4.152794552680916e-09
in O 0 9.732862515932084e-09
HeLa O 0 4.272015758033376e-06
cells O 0 4.4929001319360395e-07
. O 0 1.1193213111937439e-07

Furthermore O 0 8.382480882573873e-05
, O 0 6.409382535821351e-07
at O 0 1.3549589539252338e-07
4 O 0 1.1407069422375571e-07
degrees O 0 1.5123733874133904e-06
C O 0 0.00034966436214745045
, O 0 1.4325537200932104e-08
the O 0 1.4731418751523506e-08
added O 0 1.6961864446329855e-07
soluble O 0 4.825163557597989e-08
complex O 0 1.6137352787382042e-08
of O 0 1.055569764929487e-08
HFE O 0 0.00013443360512610525
/ O 0 6.489861334557645e-06
beta2m O 0 5.013309873902472e-06
inhibited O 0 7.265489898600208e-07
binding O 0 8.28311641498658e-08
of O 0 9.19094667040099e-09
transferrin O 0 5.315967541719147e-07
to O 0 4.409572085251057e-08
HeLa O 0 9.545974535285495e-06
cell O 0 1.6350752503058175e-06
TfR O 0 5.275049261399545e-06
in O 0 1.0934440020093916e-08
a O 0 4.3156319406989496e-08
concentration O 0 5.2698796935146675e-06
- O 0 1.3132067579135764e-05
dependent O 0 2.54055544246512e-06
manner O 0 2.546102450651233e-06
. O 0 2.2253672682381875e-07

Scatchard O 0 0.00029091539909131825
plots O 0 6.624819889111677e-06
of O 0 6.483400483148216e-08
these O 0 3.008438298479632e-08
data O 0 2.1538167516155227e-07
indicate O 0 4.303827836338314e-07
that O 0 5.6391620262274955e-09
the O 0 7.46375405924482e-09
added O 0 5.825811300042005e-08
heterodimer O 0 2.321081922218582e-07
substantially O 0 2.4720938540667703e-07
reduced O 0 2.7934801138940202e-08
the O 0 2.72383293697942e-09
affinity O 0 2.6609702885593833e-08
of O 0 1.036551999789026e-08
TfR O 0 4.5849860725866165e-06
for O 0 3.423746974817732e-08
transferrin O 0 1.3341318663151469e-05
. O 0 5.427674523161841e-07

These O 0 4.140284090681234e-06
results O 0 9.069664770322561e-07
establish O 0 2.3024809081562125e-07
a O 0 2.2215266071157203e-08
molecular O 0 2.1357494972562563e-07
link O 0 1.4268224504121463e-06
between O 0 2.2758733564387512e-07
HFE O 0 0.0017764398362487555
and O 0 1.5594456215239916e-07
a O 0 2.173362112500854e-08
key O 0 1.2086415779322124e-07
protein O 0 2.8188983591803662e-08
involved O 0 1.3892866412845706e-08
in O 0 5.485674581251487e-09
iron O 0 2.1834812287124805e-06
transport O 0 1.6617951814623666e-07
, O 0 3.5271747744758386e-09
the O 0 3.685620031390613e-09
TfR O 0 5.573976409323222e-07
, O 0 2.4132651432751118e-09
and O 0 3.6023308780386287e-09
raise O 0 7.0534924567766666e-09
the O 0 1.9752250945970218e-09
possibility O 0 3.435237871940444e-09
that O 0 5.134219160929376e-10
alterations O 0 2.3855514896808927e-08
in O 0 9.369716114093762e-10
this O 0 4.898227934369004e-10
regulatory O 0 3.694060168868418e-08
mechanism O 0 2.0488008090069343e-07
may O 0 6.992439693931374e-08
play O 0 1.646828806656231e-08
a O 0 3.361663392098535e-09
role O 0 1.1509662556363764e-08
in O 0 1.1623004780858537e-09
the O 0 5.572273309439879e-09
pathogenesis O 0 2.0614186269085621e-07
of O 0 7.28035445263231e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.9536576019163476e-06
. O 0 7.57820714625268e-07

Genomic O 0 8.06165553512983e-05
organization O 0 1.6464916825498221e-06
of O 0 5.893382848398687e-08
the O 0 2.075182550242971e-07
UBE3A O 0 0.00010035430750576779
/ O 0 1.1263494343438651e-05
E6 O 0 1.2129596143495291e-05
- O 0 2.0568993932101876e-05
AP O 0 3.998521788162179e-05
gene O 0 2.015480731643038e-06
and O 0 5.991078211309286e-08
related O 0 3.7790238138768473e-07
pseudogenes O 0 6.257164841372287e-06
. O 0 4.430898741247802e-07

The O 0 5.98801079831901e-06
UBE3A O 0 0.00014031304453965276
gene O 0 4.150372660660651e-06
encodes O 0 1.0704821988838376e-06
the O 0 1.3404483922840882e-07
E6 O 0 2.7476287414174294e-06
- O 0 6.503999884444056e-06
AP O 0 7.557323442597408e-06
ubiquitin O 0 1.4623520883105812e-06
- O 0 8.691746415934176e-07
protein O 0 7.450658046082026e-08
ligase O 0 5.4427484741381704e-08
and O 0 2.179348079778265e-08
has O 0 1.5116819795935044e-08
recently O 0 4.68668304165476e-08
been O 0 7.312805916370735e-09
shown O 0 2.7796969170879038e-09
to O 0 1.847014208244957e-09
be O 0 1.438188057534262e-08
mutated O 0 2.662321321622585e-06
in O 0 1.7689189917291515e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.24822096526622772
who O 0 5.85780639994482e-07
lack O 0 6.136429533398768e-07
15q11 O 0 1.3050106645096093e-05
- O 0 1.6686139133526012e-05
q13 O 0 6.9400489337567706e-06
deletions O 0 9.315102943219244e-06
or O 0 2.769353159237653e-06
chromosome O 0 0.0004839410539716482
15 O 0 2.8044726150255883e-06
paternal O 0 0.0011638656724244356
uniparental B-Disease 0 0.2980760931968689
disomy I-Disease 0 0.0016864124918356538
. O 0 3.0096491627773503e-06

Previous O 0 2.6605204766383395e-05
UBE3A O 0 0.00021046563051640987
cDNA O 0 4.47374577561277e-06
analysis O 0 5.78210062940343e-07
has O 0 6.853363032632842e-08
shown O 0 5.214350906612708e-08
a O 0 9.807103573677978e-09
coding O 0 8.266503073173226e-07
region O 0 5.1121993749347894e-08
of O 0 5.307495332118606e-09
approximately O 0 8.535039341950323e-08
2 O 0 1.21283761700397e-07
. O 0 1.8217893682503927e-07

6 O 0 4.069655915373005e-05
kb O 0 4.4588243326870725e-05
and O 0 7.87196825058345e-07
a O 0 1.316186342137371e-07
3 O 0 4.1907836134669196e-07
- O 0 6.725481853209203e-06
untranslated O 0 4.5623586629517376e-05
region O 0 8.224786256505467e-07
( O 0 3.361498102094629e-08
UTR O 0 8.20765762910014e-07
) O 0 7.692370296297213e-09
of O 0 2.7640791877558968e-09
< O 0 5.36580103016604e-07
50 O 0 9.939189027363682e-08
bp O 0 1.1385162679289351e-06
, O 0 4.8509805061769384e-09
whereas O 0 1.5545655429605176e-08
Northern O 0 7.229456588930816e-09
analysis O 0 3.2974494246218455e-08
has O 0 1.2438197138919804e-08
indicated O 0 2.0878347939401465e-08
mRNA O 0 2.0996514749072048e-08
sizes O 0 7.901333276549849e-08
of O 0 9.267662193224169e-09
5 O 0 1.562193432391723e-07
- O 0 3.60948320121679e-06
8 O 0 5.427161795523716e-07
kb O 0 1.70229614013806e-05
. O 0 3.524736200688494e-07

We O 0 7.219831786642317e-06
have O 0 7.127049173050182e-08
analyzed O 0 1.7436703103612672e-07
additional O 0 1.0240616354906251e-08
cDNA O 0 4.905816126665741e-07
clones O 0 5.141422434462584e-07
and O 0 1.8370512222531943e-08
provide O 0 2.0119799160056573e-08
evidence O 0 1.2047078890020657e-08
for O 0 1.204819799482948e-09
an O 0 3.5109855023307546e-09
additional O 0 4.0095358144753845e-08
0 O 0 1.5600674032612005e-06
. O 0 4.0999600514624035e-07

5 O 0 9.70738437899854e-06
kb O 0 1.1037343028874602e-05
of O 0 6.554909504075113e-08
5 O 0 1.5047183410388243e-07
- O 0 1.9932197119487682e-06
UTR O 0 3.5500684134603944e-06
and O 0 6.991172796233514e-08
> O 0 2.6856420731746766e-07
2 O 0 7.920828437590899e-08
kb O 0 2.2857559542899253e-06
of O 0 2.935470710951904e-08
3 O 0 7.38013000045612e-07
- O 0 1.9992921806988306e-05
UTR O 0 8.646583592053503e-05
. O 0 1.2097157195967156e-06

We O 0 1.0695345736166928e-05
have O 0 1.4530670000567625e-07
established O 0 2.3144412608644416e-08
the O 0 3.1594364902076677e-09
genomic O 0 1.4385699387275963e-07
organization O 0 3.468362663738844e-08
of O 0 3.1323033056196437e-09
UBE3A O 0 3.8194693843252026e-06
and O 0 1.2207419075593862e-08
the O 0 5.139699332801229e-09
sequence O 0 4.681081477997395e-08
of O 0 1.8362383613634847e-08
intron O 0 4.262343645677902e-05
- O 0 2.6767187591758557e-05
exon O 0 3.0519397114403546e-05
borders O 0 1.3633451089845039e-05
. O 0 9.904327953336178e-07

We O 0 5.294122456689365e-05
have O 0 2.3422596484579117e-07
also O 0 3.273779825008205e-08
mapped O 0 1.4208478660293622e-06
two O 0 7.360442566550773e-08
highly O 0 1.381895344820805e-07
homologous O 0 6.597260266971716e-07
processed O 0 4.548722927211202e-07
pseudogenes O 0 1.2964522966285585e-06
, O 0 3.755390665105551e-08
UBE3AP1 O 0 3.450765689194668e-06
and O 0 8.416413521672439e-08
UBE3AP2 O 0 6.42948998574866e-06
, O 0 6.388205076035547e-09
to O 0 2.8706046428794707e-09
chromosomes O 0 2.981561522119591e-07
2 O 0 4.1350290302943904e-08
and O 0 4.922697272036203e-08
21 O 0 4.722855706518203e-08
, O 0 2.4718325164485577e-09
respectively O 0 1.0556667717764867e-07
, O 0 4.781205209525297e-09
and O 0 1.4709996776218759e-08
determined O 0 1.437703076589969e-07
their O 0 2.957856182206342e-08
genomic O 0 1.2438978274076362e-06
organization O 0 3.408357827083819e-07
. O 0 2.48292224114266e-07

These O 0 3.9566639316035435e-06
results O 0 1.2354906857581227e-06
will O 0 1.897043588883207e-08
form O 0 5.43404299335748e-09
the O 0 1.1455866255616343e-09
basis O 0 3.935944015154291e-09
for O 0 1.0042846554370044e-09
studies O 0 7.899220832996434e-09
of O 0 2.9100539755688715e-09
mutation O 0 4.23685293071685e-07
and O 0 2.4933836328955294e-08
imprinting O 0 2.423202886348008e-06
of O 0 1.7258132345432387e-07
UBE3A O 0 0.00023101805709302425
. O 0 1.1954977026107372e-06

Mutation O 0 0.00019786247867159545
spectrum O 0 1.0173674127145205e-05
and O 0 3.0269836770457914e-07
genotype O 0 0.0006774378125555813
- O 0 5.2410363423405215e-05
phenotype O 0 2.6421312213642523e-05
analyses O 0 2.4763273813732667e-06
in O 0 1.231943969060012e-07
Cowden B-Disease 0 0.037156447768211365
disease I-Disease 1 0.5038188695907593
and O 0 4.022059556518798e-07
Bannayan B-Disease 1 0.9857702255249023
- I-Disease 1 0.9999897480010986
Zonana I-Disease 1 0.9999988079071045
syndrome I-Disease 1 1.0
, O 0 6.79200553577175e-08
two O 0 3.4120847658414277e-07
hamartoma B-Disease 1 0.8893498778343201
syndromes I-Disease 0 0.45653441548347473
with O 0 4.1938784534067963e-07
germline O 0 0.0019320419523864985
PTEN O 0 0.001816432224586606
mutation O 0 0.00012243805394973606
. O 0 2.608309159768396e-06

The O 0 3.087042205152102e-05
tumour B-Disease 1 0.9999667406082153
suppressor O 0 0.00013010649126954377
gene O 0 2.6377909307484515e-05
PTEN O 0 4.4261269067646936e-05
, O 0 3.5620214333675904e-08
which O 0 8.93178597749511e-09
maps O 0 3.251576572438353e-07
to O 0 1.482367792959849e-07
10q23 O 0 1.9504666852299124e-05
. O 0 3.8823822023914545e-07

3 O 0 1.0575391570455395e-05
and O 0 2.965774399399379e-07
encodes O 0 1.2978451877643238e-06
a O 0 9.460553940243699e-08
403 O 0 3.9050931377460074e-07
amino O 0 4.1849847320918343e-07
acid O 0 1.9744167900626053e-07
dual O 0 9.561330216456554e-07
specificity O 0 5.75661624679924e-06
phosphatase O 0 0.02563137747347355
( O 0 2.16099721228602e-07
protein O 0 5.787733243778348e-07
tyrosine O 0 6.579838554898743e-06
phosphatase O 0 0.0003101855400018394
; O 0 8.471413792676685e-08
PTPase O 0 1.5094569789653178e-06
) O 0 7.4262094251764665e-09
, O 0 2.9311721938540813e-09
was O 0 5.187359164438021e-08
shown O 0 7.361562914809383e-09
recently O 0 1.691022077920934e-08
to O 0 2.381140618012978e-09
play O 0 2.967677659171386e-08
a O 0 2.7988493744857124e-09
broad O 0 7.918592359601462e-08
role O 0 9.811672185833231e-08
in O 0 8.46914804952803e-09
human O 0 1.9631326608759991e-07
malignancy B-Disease 0 1.572646215208806e-05
. O 0 2.1274554740102758e-07

Somatic O 0 0.00224075629375875
PTEN O 0 0.0009373829234391451
deletions O 0 0.00012368860188871622
and O 0 4.547787739284104e-06
mutations O 0 6.594766455236822e-05
were O 0 6.191096417751396e-07
observed O 0 1.7286529896409775e-07
in O 0 1.8127490619690434e-08
sporadic B-Disease 0 0.00018390199693385512
breast I-Disease 1 0.9998065829277039
, I-Disease 0 3.046407357487624e-07
brain I-Disease 0 0.02136825956404209
, I-Disease 0 2.3690152772815054e-07
prostate I-Disease 1 0.8971255421638489
and I-Disease 0 4.529390935203992e-05
kidney I-Disease 1 0.9916313290596008
cancer I-Disease 1 0.5761410593986511
cell O 0 1.2701290870609228e-05
lines O 0 0.00014943888527341187
and O 0 4.63419382867869e-08
in O 0 1.3214423999485803e-09
several O 0 3.895969769018848e-09
primary O 0 0.007592265959829092
tumours B-Disease 1 1.0
such O 0 1.7855235512342915e-08
as O 0 5.666351626132382e-06
endometrial B-Disease 1 0.999994158744812
carcinomas I-Disease 1 1.0
, O 0 0.05876961722970009
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 0 0.44697147607803345
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 4.9002323976310436e-06

In O 0 5.598119514615973e-07
addition O 0 2.1744905609466514e-07
, O 0 5.102944555801514e-08
PTEN O 0 7.300778634089511e-06
was O 0 2.554288585088216e-07
identified O 0 7.458137218918637e-08
as O 0 2.156233858130463e-09
the O 0 1.3659924302800164e-09
susceptibility O 0 2.3070924726198427e-07
gene O 0 1.3074914306798746e-07
for O 0 8.199878998027543e-09
two O 0 1.8711644997893018e-06
hamartoma B-Disease 1 0.9999382495880127
syndromes I-Disease 1 0.9999629259109497
Cowden B-Disease 1 0.9970190525054932
disease I-Disease 1 0.9999732971191406
( O 0 3.060233098040044e-07
CD B-Disease 0 1.0649170690157916e-05
; O 0 3.0039203124943015e-07
MIM O 0 0.00020866152772214264
158350 O 0 7.551092039648211e-06
) O 0 6.863278656510374e-08
and O 0 6.01762479846002e-08
Bannayan B-Disease 0 7.17914299457334e-05
- I-Disease 0 0.00012678369239438325
Zonana I-Disease 0 0.00021462072618305683
( I-Disease 0 1.4384765734121174e-07
BZS I-Disease 0 1.1076484952354804e-05
) I-Disease 0 6.336994573530319e-08
or I-Disease 0 2.639039848872926e-07
Ruvalcaba I-Disease 0 2.6160812922171317e-05
- I-Disease 0 5.8156176237389445e-05
Riley I-Disease 0 3.939454836654477e-05
- I-Disease 0 0.1333969384431839
Smith I-Disease 0 0.06796108931303024
syndrome I-Disease 1 0.9998924732208252
( O 0 3.9565250631312665e-07
MIM O 0 9.304338891524822e-05
153480 O 0 1.4902765542501584e-05
) O 0 3.3102293173215003e-07
. O 0 3.793749385749834e-07

Constitutive O 0 3.733110861503519e-05
DNA O 0 7.486421509383945e-06
from O 0 2.039165565292933e-07
37 O 0 4.462721676645742e-07
CD B-Disease 0 2.1102503069414524e-06
families O 0 1.4097582834438072e-07
and O 0 2.7262252899618034e-08
seven O 0 9.230619468780787e-08
BZS B-Disease 0 1.178837464976823e-05
families O 0 1.216546792193185e-07
was O 0 2.566769126133295e-07
screened O 0 2.4165151444321964e-06
for O 0 1.4166356265832292e-07
germline O 0 0.00016991887241601944
PTEN O 0 0.00018616362649481744
mutations O 0 6.297267827903852e-05
. O 0 2.4899250092857983e-06

PTEN O 0 0.002127707004547119
mutations O 0 0.00031157027115114033
were O 0 4.564220034808386e-06
identified O 0 4.544750993318303e-07
in O 0 8.611728219420911e-09
30 O 0 1.299621832373532e-08
of O 0 3.0569553555181983e-09
37 O 0 2.187573784340202e-07
( O 0 1.0753158363741022e-08
81 O 0 1.346188867046294e-07
% O 0 3.650500701724013e-08
) O 0 7.9608097891537e-09
CD B-Disease 0 4.4657056719188404e-07
families O 0 6.279146447241146e-08
, O 0 2.559975786908808e-09
including O 0 4.0505336862395325e-09
missense O 0 1.055246571013413e-06
and O 0 6.897241178194236e-08
nonsense O 0 2.1820824258611538e-06
point O 0 3.342341585721442e-07
mutations O 0 1.403511305397842e-06
, O 0 5.265528901787775e-09
deletions O 0 3.964191819250118e-07
, O 0 2.1132796845790836e-08
insertions O 0 1.2003221172562917e-06
, O 0 1.767517510131711e-08
a O 0 3.0819201413123665e-08
deletion O 0 2.086470885842573e-05
/ O 0 3.792826419157791e-06
insertion O 0 1.835298689911724e-06
and O 0 2.504451686036191e-07
splice O 0 0.0010637894738465548
site O 0 1.0206052138528321e-05
mutations O 0 3.820389247266576e-05
. O 0 4.6049191837482795e-07

These O 0 2.988888809341006e-06
mutations O 0 1.606341902515851e-05
were O 0 6.817730309194303e-07
scattered O 0 1.671135265723933e-07
over O 0 2.2934273147257045e-08
the O 0 1.3593448144888498e-08
entire O 0 3.29443210489444e-08
length O 0 2.3614763478008172e-08
of O 0 1.2014602646104322e-09
PTEN O 0 7.49093999274919e-07
, O 0 2.694046319362542e-09
with O 0 1.3384481301059736e-09
the O 0 2.4903357154215655e-09
exception O 0 3.71829789180822e-09
of O 0 5.590304330560514e-10
the O 0 2.179970426396949e-09
first O 0 5.5282061595107734e-08
, O 0 6.8814696163599365e-09
fourth O 0 5.289408591124811e-07
and O 0 2.269269039345545e-08
last O 0 7.255844991505e-08
exons O 0 3.5349701192899374e-06
. O 0 6.932567089279473e-07

A O 0 2.314351331733633e-05
hot O 0 4.47695711045526e-05
spot O 0 1.2181425518065225e-05
for O 0 6.013391384840361e-08
PTEN O 0 2.22787512029754e-05
mutation O 0 1.960408326340257e-06
in O 0 1.8338793594807612e-08
CD B-Disease 0 1.8209119616585667e-06
was O 0 8.644346394248714e-07
identified O 0 1.0050845844489231e-07
in O 0 1.781223057939485e-09
exon O 0 1.2560875006784045e-07
5 O 0 1.9698910946885917e-08
that O 0 1.8632340115232182e-09
contains O 0 3.0262545802628438e-09
the O 0 7.568837112614801e-09
PTPase O 0 5.870518293704663e-07
core O 0 1.4672370696189319e-07
motif O 0 7.59498632874056e-08
, O 0 2.164545209737412e-09
with O 0 7.99132371387401e-10
13 O 0 4.121829544345701e-09
of O 0 3.3050209791163354e-10
30 O 0 4.669558073544522e-09
( O 0 1.972096708158233e-09
43 O 0 2.7142451841655202e-08
% O 0 1.717560138558838e-08
) O 0 6.663696261455243e-09
CD B-Disease 0 1.050884975484223e-06
mutations O 0 2.7284963834972586e-06
identified O 0 2.0599762251549691e-07
in O 0 4.8392809759434385e-09
this O 0 8.624647662713869e-09
exon O 0 6.028462394169765e-06
. O 0 6.912794106028741e-07

Seven O 0 5.588024123426294e-06
of O 0 4.435697320559484e-08
30 O 0 7.139974655956394e-08
( O 0 1.3979600588243102e-08
23 O 0 3.219332000981012e-08
% O 0 7.671842716661104e-09
) O 0 2.571633128667372e-09
were O 0 5.641230771402661e-08
within O 0 1.794902448892799e-09
the O 0 1.4229617484318169e-09
core O 0 6.944087971305635e-08
motif O 0 4.0064470852030354e-08
, O 0 1.592213583201385e-09
the O 0 1.1110821152016115e-09
majority O 0 5.9882196978833235e-09
( O 0 1.6764156729465185e-09
five O 0 1.9230981251894264e-09
of O 0 3.595094499875273e-10
seven O 0 8.4556708301875e-09
) O 0 4.5946976778843407e-10
of O 0 2.033932466893873e-10
which O 0 4.303842171538008e-09
were O 0 6.160904320040572e-08
missense O 0 1.0330840041206102e-06
mutations O 0 6.810009836044628e-07
, O 0 6.016864784186282e-09
possibly O 0 4.299438316479609e-08
pointing O 0 1.1177958469943405e-07
to O 0 2.4250541574843965e-09
the O 0 2.344354266270443e-09
functional O 0 5.701047456341257e-08
significance O 0 1.0541292283505754e-08
of O 0 1.0345467815753295e-09
this O 0 2.5994466579248865e-09
region O 0 1.0017793528049879e-07
. O 0 1.0487249824109313e-07

Germline O 0 0.0017461135284975171
PTEN O 0 0.0006529175443574786
mutations O 0 0.000234675346291624
were O 0 4.733213245344814e-06
identified O 0 5.830524401062576e-07
in O 0 5.835683936084024e-09
four O 0 1.6356219489921386e-08
of O 0 2.1712314168809144e-09
seven O 0 1.545923282719741e-07
( O 0 1.9862802957959502e-08
57 O 0 1.375875200437804e-07
% O 0 3.38482735173784e-08
) O 0 1.682323080842707e-08
BZS B-Disease 0 1.0405957254988607e-05
families O 0 2.1402678385129548e-07
studied O 0 1.603642772352032e-06
. O 0 4.941205133945914e-07

Interestingly O 0 5.4016643844079226e-05
, O 0 3.6783467294299044e-07
none O 0 1.9181888433195127e-07
of O 0 2.2008010969187808e-09
these O 0 1.69091549651057e-08
mutations O 0 3.09441293211421e-06
was O 0 2.6352572035648336e-07
observed O 0 6.501145577431089e-08
in O 0 2.312044333763197e-09
the O 0 1.840066943259444e-08
PTPase O 0 5.628029157378478e-06
core O 0 1.965235924217268e-06
motif O 0 2.7242842861596728e-06
. O 0 3.6345636544865556e-07

It O 0 7.643596973139211e-07
is O 0 3.512313284659285e-08
also O 0 8.017404518056992e-09
worthy O 0 2.7664700752438875e-08
of O 0 3.059177577924288e-09
note O 0 9.933503974934865e-08
that O 0 2.6483915060993013e-09
a O 0 1.7379585770527228e-08
single O 0 6.974550160521176e-06
nonsense O 0 2.027245727731497e-06
point O 0 1.4333127751342545e-07
mutation O 0 3.6188197327646776e-07
, O 0 7.157425319093136e-09
R233X O 0 1.5021259969216771e-07
, O 0 5.228101063181612e-09
was O 0 3.235016166058813e-08
observed O 0 1.9208519219660047e-08
in O 0 1.4691399208288658e-09
the O 0 8.182646560328521e-09
germline O 0 6.65204709093814e-07
DNA O 0 8.390384209633339e-08
from O 0 6.054324597215555e-09
two O 0 1.3385508701446724e-08
unrelated O 0 7.654203670881543e-08
CD B-Disease 0 1.607398644409841e-06
families O 0 8.951965924097749e-08
and O 0 3.09582404156572e-08
one O 0 8.124192873992797e-08
BZS B-Disease 0 4.3293886847095564e-05
family O 0 4.918389322483563e-07
. O 0 1.8148858771382947e-07

Genotype O 0 0.0024020997807383537
- O 0 0.0005980405840091407
phenotype O 0 4.4223292206879705e-05
studies O 0 1.117264559979958e-06
were O 0 2.5433600967517123e-06
not O 0 6.232754401480634e-08
performed O 0 6.699368668705574e-07
on O 0 1.4109843071707928e-08
this O 0 9.51942635829539e-10
small O 0 6.6327054959458565e-09
group O 0 2.254196118656182e-08
of O 0 2.7640265631845296e-09
BZS B-Disease 0 9.079799383471254e-06
families O 0 2.2368401175754116e-07
. O 0 1.8273296120696614e-07

However O 0 3.8566427065234166e-06
, O 0 2.95787998538799e-07
genotype O 0 1.7618074707570486e-05
- O 0 5.550558853428811e-06
phenotype O 0 5.888028681511059e-06
analysis O 0 4.9683802672007e-07
inthe O 0 8.398665158892982e-06
group O 0 1.3709502866277035e-07
of O 0 4.8203045999173355e-09
CD B-Disease 0 2.8386107260303106e-06
families O 0 1.2417389427810122e-07
revealed O 0 1.130070685917417e-07
two O 0 4.796513852767248e-09
possible O 0 1.3999238213102672e-08
associations O 0 4.445343648740163e-08
worthy O 0 3.4384058267278306e-08
of O 0 2.825690348373655e-09
follow O 0 1.6726899332297762e-07
- O 0 1.047459682013141e-05
up O 0 3.839757596324489e-07
in O 0 6.211247516318963e-09
independent O 0 4.856630653193861e-08
analyses O 0 1.6700644209777238e-06
. O 0 2.7625583243207075e-07

The O 0 1.3219292895882973e-06
first O 0 7.813047204763279e-07
was O 0 3.9433254528375983e-07
an O 0 1.0595394783763368e-08
association O 0 4.590322433273286e-08
noted O 0 2.5165991957010192e-08
in O 0 1.930109405634539e-09
the O 0 4.38442704364661e-09
group O 0 5.084540344313382e-09
of O 0 4.178392076781279e-10
CD B-Disease 0 4.916278726341261e-07
families O 0 6.667423946282725e-08
with O 0 1.0717171790020075e-06
breast B-Disease 1 0.9999977350234985
disease I-Disease 1 0.5998863577842712
. O 0 3.799328567311022e-07

A O 0 5.292342393659055e-06
correlation O 0 3.6823271329922136e-06
was O 0 8.063104814937105e-07
observed O 0 8.230077241933031e-08
between O 0 6.396702723066028e-09
the O 0 5.983287643118729e-09
presence O 0 6.602112989639863e-08
/ O 0 3.7925046854070388e-06
absence O 0 3.9788339734059264e-08
of O 0 1.651599967900097e-09
a O 0 2.0889064700213567e-08
PTEN O 0 6.2586323110735975e-06
mutation O 0 2.9785664423798153e-07
and O 0 6.1200391421323275e-09
the O 0 3.3619584893784804e-09
type O 0 5.922059358454135e-07
of O 0 1.3894164041516888e-08
breast O 1 0.7407485246658325
involvement O 0 4.359339982329402e-06
( O 0 3.9616597291569633e-07
unaffected O 0 1.4480343452305533e-05
versus O 0 5.3612919145962223e-05
benign O 0 0.012689922004938126
versus O 0 0.0004084391111973673
malignant O 0 0.013233763165771961
) O 0 2.3569141660573223e-07
. O 0 2.49477352554095e-07

Specifically O 0 4.8425563363707624e-06
and O 0 2.3004288607353374e-07
more O 0 7.359822085106771e-09
directly O 0 3.786505331504486e-08
, O 0 3.824245364825174e-09
an O 0 2.4476431992326297e-09
association O 0 1.0409786455056746e-07
was O 0 5.082352458884998e-07
also O 0 1.3471926685326707e-08
observed O 0 9.954325363992211e-09
between O 0 1.0055996035873704e-09
the O 0 1.3607032167683997e-09
presence O 0 2.039667545972179e-09
of O 0 2.9706875848134473e-10
a O 0 1.5016356158525923e-08
PTEN O 0 1.8153226847061887e-05
mutation O 0 6.064311492082197e-06
and O 0 5.599248197540874e-06
malignant B-Disease 1 0.9999959468841553
breast I-Disease 1 0.9999996423721313
disease I-Disease 1 0.997612476348877
. O 0 6.798965728194162e-07

Secondly O 0 0.00030998303554952145
, O 0 5.09679182414402e-07
there O 0 6.00107412651596e-08
appeared O 0 2.406436863111594e-07
to O 0 5.708552297534197e-09
be O 0 7.811540747582058e-09
an O 0 2.1406378891697386e-09
interdependent O 0 2.341172603337327e-06
association O 0 2.5231743805420592e-08
between O 0 1.2905069901592015e-08
mutations O 0 8.041403702918615e-07
upstream O 0 9.485759733252053e-08
and O 0 1.724229825583734e-08
within O 0 9.524734778665334e-09
the O 0 7.171336413591689e-09
PTPase O 0 5.304548267304199e-07
core O 0 1.6543538094992982e-07
motif O 0 5.454034024410248e-08
, O 0 3.955548777412332e-09
the O 0 2.4295683243025223e-09
core O 0 8.302682630301206e-08
motif O 0 2.9906512821753495e-08
containing O 0 7.608060847985598e-09
the O 0 1.7585851663781682e-09
majority O 0 3.092104794433226e-09
of O 0 7.964208181832078e-10
missense O 0 1.3050588449914358e-06
mutations O 0 9.601225201549823e-07
, O 0 7.548250025024572e-09
and O 0 5.942434988526202e-09
the O 0 3.7520671014590334e-09
involvement O 0 1.843168462301037e-08
of O 0 5.982052075914623e-10
all O 0 3.677663729106939e-09
major O 0 4.040982659603287e-08
organ O 0 2.0031288840982597e-06
systems O 0 1.0126891538675409e-06
( O 0 7.4340467115519004e-09
central O 0 1.6969348592965616e-08
nervous O 0 1.4313268366095144e-06
system O 0 9.322963023805642e-08
, O 0 2.546866362251876e-08
thyroid O 0 0.0009429065976291895
, O 0 4.124057184640151e-08
breast O 0 0.15246085822582245
, O 0 1.8986766292528046e-07
skin O 1 0.9879421591758728
and O 0 7.934742461657152e-05
gastrointestinal O 1 0.9995059967041016
tract O 0 0.40181678533554077
) O 0 4.645025342142617e-07
. O 0 3.719683263625484e-07

However O 0 3.3456788059993414e-06
, O 0 4.239398876393352e-08
these O 0 3.9011149866041706e-09
observations O 0 3.518488611575776e-08
would O 0 2.7889921483392754e-08
need O 0 1.6283008719142344e-08
to O 0 1.4280196580784832e-08
be O 0 1.4209939536158345e-07
confirmed O 0 2.9698973946779006e-08
by O 0 5.188590668225856e-10
studying O 0 1.7253212192258616e-09
a O 0 1.649443470697065e-09
larger O 0 2.5454374164013416e-09
number O 0 3.264032821803653e-09
of O 0 1.8453134575935337e-09
CD B-Disease 0 3.4081861031154403e-06
families O 0 3.653123599178798e-07
. O 0 1.620113749822849e-07

Molecular O 0 0.006217749323695898
defects O 1 0.9999232292175293
leading O 0 5.1566089496191125e-06
to O 0 6.610151359609517e-08
human O 0 1.4925558389222715e-07
complement B-Disease 0 7.397510671580676e-06
component I-Disease 1 0.8599593639373779
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.1296057301233304e-08
an O 0 1.6053940399274325e-08
African O 0 2.693434169032116e-07
- O 0 6.421915259124944e-06
American O 0 3.817339404577069e-07
family O 0 2.1267678107506072e-07
. O 0 1.6150787018887058e-07

Complement B-Disease 0 0.002571266610175371
component I-Disease 1 0.9966393709182739
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.8699836346058873e-06
C6D B-Disease 0 5.8209276176057756e-05
) O 0 1.2483192790568864e-07
was O 0 1.2269496437511407e-05
diagnosed O 0 0.0006829394260421395
in O 0 3.2568938657107083e-09
a O 0 1.7188316547844806e-08
16 O 0 4.5171134388510836e-08
- O 0 4.593081541770516e-07
year O 0 1.048366549127877e-08
- O 0 8.190752964765124e-07
old O 0 2.23344113692292e-06
African O 0 6.617670322839331e-08
- O 0 3.061911399981909e-07
American O 0 1.4763406852580374e-07
male O 0 1.5998269873307436e-06
with O 0 1.6792012047517346e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999998807907104
. O 0 1.4603424460801762e-06

The O 0 3.517573986755451e-06
patients O 0 0.00023022315872367471
father O 0 9.116631645156303e-07
and O 0 5.9432768040323936e-08
two O 0 1.981702268949448e-07
brothers O 0 7.96866079326719e-05
also O 0 7.083303898980375e-08
had O 0 8.542944556211296e-07
C6D B-Disease 0 2.7741109533963026e-06
, O 0 3.858049435478961e-09
but O 0 3.983463781054297e-09
gave O 0 1.7207243629968616e-08
no O 0 1.1156015666813346e-08
history O 0 1.2969819884744993e-08
of O 0 2.955510147728546e-08
meningitis B-Disease 1 0.9999998807907104
or O 0 9.494264645582007e-07
other O 0 1.0382243686990478e-07
neisserial B-Disease 0 0.07062084972858429
infection I-Disease 0 0.06568237394094467
. O 0 4.5668747361560236e-07

By O 0 4.1197731093234324e-07
using O 0 1.7061981338883925e-07
exon O 0 2.788013716781279e-06
- O 0 7.915480182418833e-07
specific O 0 1.1431071555989547e-07
polymerase O 0 1.6823413488964434e-06
chain O 0 2.5859926608973183e-06
reaction O 0 1.4065150821807038e-07
( O 0 1.3347190908064022e-08
PCR O 0 1.056566816259874e-06
) O 0 8.622476954656122e-09
/ O 0 3.450481926847715e-07
single O 0 7.350831765506882e-07
- O 0 5.45835234788683e-07
strand O 0 5.08429138790234e-07
conformation O 0 4.358058163234091e-07
polymorphism O 0 7.758325750728545e-07
as O 0 9.946506729363591e-09
a O 0 4.568161404705506e-09
screening O 0 8.400439810429816e-08
step O 0 4.934993569349899e-08
and O 0 7.079626662687133e-09
nucleotide O 0 9.114435073342975e-08
sequencing O 0 3.140716486882411e-08
of O 0 2.723874681365146e-09
target O 0 2.362634887731474e-07
exons O 0 3.5520017149792693e-07
, O 0 1.0445742049114415e-08
we O 0 2.224604855882717e-08
determined O 0 2.895560591298363e-08
that O 0 1.930396731353312e-09
the O 0 1.0333343070101364e-08
proband O 0 2.977878011733992e-06
was O 0 6.40776889326844e-08
a O 0 1.1151845669132854e-08
compound O 0 6.005035402267822e-08
heterozygote O 0 2.9250594479890424e-07
for O 0 3.497911071903559e-09
two O 0 2.648999242182981e-08
C6 O 0 1.1518980500113685e-05
gene O 0 5.094608695799252e-06
mutations O 0 1.757236896082759e-05
. O 0 8.485384341838653e-07

The O 0 9.057865781869623e-07
first O 0 1.9628069480859267e-07
, O 0 2.4000096132681392e-08
1195delC O 0 3.2119359616444854e-07
located O 0 2.9709511295550328e-08
in O 0 3.8374121658080185e-09
exon O 0 1.9788505767337483e-07
7 O 0 1.4986575536113378e-07
, O 0 4.88856111147129e-09
is O 0 1.4845846774136362e-09
a O 0 5.5883133676104535e-09
novel O 0 3.5445228974140264e-08
mutation O 0 1.043312209958458e-07
, O 0 3.87629750520091e-09
while O 0 6.438185096158122e-09
the O 0 3.856504449117892e-09
second O 0 2.5366767886225716e-07
, O 0 6.6001462073472794e-09
1936delG O 0 8.054008304725357e-08
in O 0 2.5018571658819155e-09
exon O 0 9.631536812548802e-08
12 O 0 3.8405190139201295e-08
, O 0 2.8614863811782243e-09
has O 0 6.327354196145052e-09
been O 0 1.5137247899588147e-08
described O 0 1.2404720806102887e-08
before O 0 5.039605621703913e-09
to O 0 5.6719660079807e-09
cause O 0 1.4470209919181798e-07
C6D B-Disease 0 3.127247964584967e-06
in O 0 2.9714086746679413e-09
an O 0 2.7912097078086617e-09
unrelated O 0 7.579414784686378e-08
African O 0 7.884081298925594e-08
- O 0 9.056760745806969e-07
American O 0 2.0546180223846022e-07
individual O 0 1.6714014350327489e-07
. O 0 2.354393586756487e-07

Both O 0 2.012368531723041e-05
mutations O 0 0.00031216134084388614
result O 0 8.501600632371265e-07
in O 0 1.2197857301998738e-07
premature O 0 2.7642747227218933e-05
termination O 0 6.23178357272991e-06
codons O 0 5.557597887673182e-06
and O 0 4.4678230892714055e-07
C6 O 0 0.00010400166502222419
null O 0 4.529110447037965e-05
alleles O 0 3.1956384191289544e-05
. O 0 1.2749037523462903e-06

Allele O 0 0.00015176275337580591
- O 0 1.3583564395958092e-05
specific O 0 2.216088859086085e-07
PCR O 0 4.3583008846326265e-06
indicated O 0 6.003162980050547e-07
that O 0 5.243680156752362e-09
the O 0 8.23104695513166e-09
probands O 0 1.1383773426132393e-06
two O 0 7.78355442321299e-08
brothers O 0 1.632590101507958e-05
also O 0 3.256317882005533e-08
inherited O 0 2.1853727503184928e-06
the O 0 6.553332099201725e-09
1195delC O 0 4.5294510186977277e-07
mutation O 0 1.060372838423973e-07
from O 0 8.086436409371345e-09
their O 0 5.102340949747486e-08
heterozygous O 0 9.51505353441462e-06
mother O 0 7.222450335575559e-07
and O 0 9.895187780273318e-09
the O 0 1.0600892608181312e-08
1936delG O 0 8.098825219349237e-07
mutation O 0 4.690323009981512e-07
from O 0 7.895875953067844e-09
their O 0 3.274647752959936e-08
homozygous O 0 9.957516340364236e-06
father O 0 2.4278378418784996e-07
. O 0 1.4656923674749578e-08
. O 0 7.675431845655112e-08

PAX6 O 0 0.06169866397976875
mutations O 0 0.004325398709625006
reviewed O 0 7.368972728727385e-05
. O 0 5.8728478506964166e-06

Mutations O 0 0.0007033515139482915
in O 0 2.2365136942426034e-07
PAX6 O 0 2.2208536393009126e-05
are O 0 3.729450881451157e-08
responsible O 0 8.07680606840222e-08
for O 0 4.213335014213726e-09
human O 0 7.548094771436809e-08
aniridia B-Disease 1 0.9999998807907104
and O 0 4.6982918888716085e-07
have O 0 2.5378770374118176e-07
also O 0 3.77312474597602e-08
been O 0 3.386531943760929e-08
found O 0 1.1837028246475256e-08
in O 0 3.197343501071259e-09
patients O 0 1.4837368667031114e-07
with O 0 3.545753202160995e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999994039535522
, O 0 2.794738520606188e-07
with O 0 1.10496021079598e-05
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9998780488967896
, O 0 3.347805588305164e-08
with O 0 7.911950206107576e-08
autosomal B-Disease 1 0.9653044939041138
dominant I-Disease 0 0.04035625979304314
keratitis I-Disease 0 0.016774050891399384
, O 0 1.5895781757535588e-07
and O 0 1.0461577204523564e-07
with O 0 4.795167569682235e-07
isolated B-Disease 1 0.5375615358352661
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 4.936654931952944e-06

No O 0 6.2223884924605954e-06
locus O 0 7.631042535649613e-06
other O 0 8.340489898728265e-08
than O 0 9.044696014370857e-08
chromosome O 0 4.76261593576055e-05
11p13 O 0 2.9204900329204975e-06
has O 0 7.231501086835124e-08
been O 0 7.109345290245983e-08
implicated O 0 8.488694334118918e-07
in O 0 4.88651288321762e-08
aniridia B-Disease 1 0.9999997615814209
, O 0 3.9455517963915554e-08
and O 0 3.0548818585884874e-08
PAX6 O 0 4.770295618072851e-06
is O 0 1.1803052757386467e-08
clearly O 0 4.198384218057072e-08
the O 0 1.6842872652134133e-09
major O 0 8.847888643970236e-09
, O 0 2.5133937153754005e-09
if O 0 3.564412098810976e-09
not O 0 5.244960465944359e-09
only O 0 4.962344313241829e-09
, O 0 4.159279143323147e-09
gene O 0 2.3833825935071218e-07
responsible O 0 7.294392503354175e-07
. O 0 2.4649511942698155e-07

Twenty O 0 0.00018377054948359728
- O 0 0.00010801432654261589
eight O 0 1.5719268731118063e-06
percent O 0 2.570473043306265e-07
of O 0 1.0557751117801217e-08
identified O 0 3.2918006809268263e-07
PAX6 O 0 6.41565975456615e-06
mutations O 0 1.3493729511537822e-06
are O 0 5.268967484539644e-08
C O 0 4.464678204385564e-05
- O 0 0.00016135135956574231
T O 0 2.574457903392613e-05
changes O 0 4.808112308296586e-08
at O 0 1.1304318547900039e-07
CpG O 0 1.1835039686047821e-06
dinucleotides O 0 9.637157063480117e-07
, O 0 5.434021677075407e-09
20 O 0 6.309181177499568e-09
% O 0 2.7015225612103677e-09
are O 0 9.47914968740804e-10
splicing O 0 1.8568601944934926e-07
errors O 0 2.3153875190473627e-06
, O 0 3.5857483648982225e-09
and O 0 3.6673177827850623e-09
more O 0 7.850341487980472e-10
than O 0 3.126322756230593e-09
30 O 0 1.4830770389551162e-08
% O 0 5.599484431684232e-09
are O 0 2.4429789302615745e-09
deletion O 0 4.095903705092496e-07
or O 0 8.177126886721453e-08
insertion O 0 8.46030275170051e-07
events O 0 9.142028716269124e-07
. O 0 7.266847887876793e-07

There O 0 5.01749991599354e-06
is O 0 7.902809784354758e-08
a O 0 5.7982305179393734e-08
noticeably O 0 1.2018479083053535e-06
elevated O 0 9.266822758036142e-07
level O 0 8.823993624673676e-08
of O 0 2.785210950762007e-09
mutation O 0 1.4258999669891637e-07
in O 0 3.4599825227132897e-09
the O 0 2.604319870869176e-09
paired O 0 2.0670528044774983e-07
domain O 0 4.008358089890862e-08
compared O 0 6.007063291235681e-08
with O 0 2.375977636859261e-09
the O 0 5.739985375896595e-09
rest O 0 4.792088059701882e-09
of O 0 5.71276470573423e-10
the O 0 7.426095738338745e-09
gene O 0 5.833861678183894e-07
. O 0 9.412838153366465e-08

Increased O 0 1.3119736649969127e-05
mutation O 0 4.621060725185089e-06
in O 0 2.8676618413214783e-08
the O 0 1.1689352596988556e-08
homeodomain O 0 9.414864621248853e-07
is O 0 9.521084365360366e-09
accounted O 0 2.2720543313425878e-07
for O 0 2.270098997669834e-09
by O 0 4.927128038900719e-09
the O 0 1.7590220835472792e-08
hypermutable O 0 8.699685167812277e-06
CpG O 0 3.874551111948676e-06
dinucleotide O 0 2.715561095101293e-06
in O 0 5.43555920273775e-08
codon O 0 2.7041744488087716e-06
240 O 0 1.2767617363351746e-06
. O 0 3.776436869884492e-07

Very O 0 8.094654731394257e-06
nearly O 0 8.355407885574095e-07
all O 0 3.212707255784153e-08
mutations O 0 5.2836509212284e-07
appear O 0 1.256251636050365e-07
to O 0 3.308663565348979e-08
cause O 0 3.1118731840251712e-06
loss O 0 2.4460393888148246e-07
of O 0 1.263963045339267e-09
function O 0 1.4476332133028791e-08
of O 0 1.2938728977118785e-09
the O 0 4.160564337496453e-09
mutant O 0 2.1740964939453988e-07
allele O 0 2.656386755006679e-07
, O 0 2.7832938176430844e-09
and O 0 1.5320349433523006e-09
more O 0 6.907635019537395e-10
than O 0 2.190916781330543e-09
80 O 0 6.8302359323979545e-09
% O 0 3.4251492753156754e-09
of O 0 1.525095938426091e-09
exonic O 0 1.9658282326417975e-06
substitutions O 0 9.193981327371148e-07
result O 0 1.9145393537201016e-07
in O 0 2.8160073384242423e-08
nonsense O 0 6.3537668211210985e-06
codons O 0 5.244641215540469e-06
. O 0 5.564028811022581e-07

In O 0 7.196399565145839e-07
a O 0 8.85120030602593e-08
gene O 0 1.9403132966999692e-07
with O 0 4.208211112910476e-09
such O 0 4.09724831840208e-09
extraordinarily O 0 5.408757033364964e-07
high O 0 4.074106030316216e-08
sequence O 0 1.4449629048840507e-08
conservation O 0 4.448216905927893e-09
throughout O 0 2.845463642486834e-09
evolution O 0 9.568453585018233e-09
, O 0 1.7413489539208626e-09
there O 0 2.9201177031978887e-09
are O 0 1.841885755027306e-08
presumed O 0 2.1744915557064814e-06
undiscovered O 0 1.4639513210568111e-06
missense O 0 2.9318978249648353e-06
mutations O 0 1.9544254428183194e-06
, O 0 2.979586799511935e-09
these O 0 1.1569745161921219e-09
are O 0 2.003752719303975e-09
hypothesized O 0 1.3660088171718598e-08
to O 0 3.8452374617747864e-09
exist O 0 2.5210432852418307e-08
in O 0 2.389439091032841e-09
as O 0 5.239164480030922e-08
- O 0 2.7520831281435676e-05
yet O 0 3.7614918824147026e-07
unidentified O 0 2.231857024526107e-06
phenotypes O 0 1.1874541314682574e-06
. O 0 2.5074529119706312e-08
. O 0 9.954366930742253e-08

Genetic O 0 0.0002859072119463235
heterogeneity O 0 2.1739071598858573e-05
and O 0 6.202087092788133e-07
penetrance O 0 1.7432626918889582e-05
analysis O 0 1.55328280015965e-07
of O 0 8.470133927573897e-09
the O 0 5.5322249892242326e-08
BRCA1 O 0 0.00017825614486355335
and O 0 3.895555948929541e-07
BRCA2 O 0 0.0005498721729964018
genes O 0 6.861079327791231e-06
in O 0 1.1168565379193751e-06
breast B-Disease 1 0.9999973773956299
cancer I-Disease 1 0.6560732126235962
families O 0 2.115106099154218e-06
. O 0 4.2721111981336435e-07

The O 0 0.008393572643399239
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0005955409724265337
Consortium O 0 3.121697227470577e-05
. O 0 1.5546922895737225e-06

The O 0 4.5591502839670284e-07
contribution O 0 1.8933894807560137e-07
of O 0 2.5147567583871933e-08
BRCA1 O 0 7.315424591070041e-05
and O 0 5.941366225670208e-07
BRCA2 O 0 0.13427333533763885
to O 0 7.040255150059238e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 7.222186468425207e-06
assessed O 0 1.9210503410249657e-07
by O 0 2.9714142257830645e-09
linkage O 0 1.4819283933320548e-06
and O 0 1.0615222123533385e-07
mutation O 0 3.6969717598367424e-07
analysis O 0 3.0599728972902085e-08
in O 0 4.6882009385740275e-09
237 O 0 5.044974926704526e-08
families O 0 5.6493060895945746e-08
, O 0 2.489191297527782e-09
each O 0 2.509422669660921e-09
with O 0 4.7157784344165066e-09
at O 0 1.131942113374862e-07
least O 0 2.365902140866183e-09
four O 0 3.331369846648613e-09
cases O 0 2.8672557661479914e-09
of O 0 2.740525850697395e-08
breast B-Disease 1 0.9999960660934448
cancer I-Disease 0 0.0014957735547795892
, O 0 6.73606326273557e-09
collected O 0 2.2334139870849867e-08
by O 0 1.2760123624389053e-08
the O 0 3.1086081435205415e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 7.304480095626786e-05
Consortium O 0 1.3192391634220257e-05
. O 0 1.163829438155517e-06

Families O 0 0.0001840560435084626
were O 0 1.4342564327307628e-06
included O 0 4.5418307337286024e-08
without O 0 1.368830826464773e-08
regard O 0 7.1751942165576565e-09
to O 0 1.4830846550850652e-09
the O 0 5.8076135012186114e-09
occurrence O 0 2.6428327259964135e-07
of O 0 3.523176062003586e-08
ovarian B-Disease 1 0.9882644414901733
or I-Disease 0 9.673215117800282e-07
other I-Disease 0 2.2277922084867896e-07
cancers I-Disease 1 0.9093863368034363
. O 0 4.744032082726335e-07

Overall O 0 0.0026712394319474697
, O 0 8.546427125111222e-06
disease O 0 0.10572486370801926
was O 0 2.3731443832275545e-07
linked O 0 7.803337211953476e-07
to O 0 2.5551576854354607e-08
BRCA1 O 0 4.241518035996705e-05
in O 0 4.159136146597575e-09
an O 0 2.397318121794001e-09
estimated O 0 1.849740449699766e-08
52 O 0 4.466361502863947e-08
% O 0 3.7037659605942963e-09
of O 0 1.0439999975631054e-09
families O 0 1.904649948869519e-08
, O 0 2.874121829421483e-09
to O 0 8.370240500710224e-09
BRCA2 O 0 6.130554993433179e-06
in O 0 3.7155114540610157e-09
32 O 0 3.6494842703405084e-08
% O 0 3.983008145524991e-09
of O 0 8.140704776948837e-10
families O 0 9.74460245828368e-09
, O 0 8.532768380753453e-10
and O 0 2.6995448099143005e-09
to O 0 5.776085387765306e-09
neither O 0 3.654248814655148e-08
gene O 0 2.6597017921403676e-08
in O 0 1.9912940185662364e-09
16 O 0 1.783073066974339e-08
% O 0 4.683347487599576e-09
( O 0 3.1164575364783786e-09
95 O 0 2.7664963653251107e-08
% O 0 5.390955237771777e-08
confidence O 0 3.4779131965478882e-06
interval O 0 6.961280178074958e-06
[ O 0 6.813374966441188e-07
CI O 0 4.546998297882965e-06
] O 0 1.9221278080294724e-07
6 O 0 9.795479627427994e-08
% O 0 4.441081458139706e-08
- O 0 2.468047341608326e-06
28 O 0 1.2631979018351558e-07
% O 0 1.412411343437725e-08
) O 0 1.7199064394901598e-09
, O 0 1.9620456370716965e-09
suggesting O 0 4.15656877805759e-08
other O 0 1.3752370797703861e-08
predisposition O 0 1.0953111996059306e-05
genes O 0 1.1724363275789074e-06
. O 0 3.085081914377952e-07

The O 0 2.5043252662726445e-06
majority O 0 8.590148468101688e-07
( O 0 1.0043506648571565e-07
81 O 0 1.7328387968973402e-07
% O 0 1.5224868477048403e-08
) O 0 1.6667234259415409e-09
of O 0 1.8533451440205795e-09
the O 0 2.5719541554281022e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.033278054928815e-07
were O 0 1.250106294037323e-07
due O 0 1.4737545406262598e-08
to O 0 1.0289975982402666e-08
BRCA1 O 0 0.0001182112391688861
, O 0 6.1174709742317646e-09
with O 0 1.7708572386254673e-09
most O 0 7.030833248933277e-09
others O 0 3.195649966869496e-08
( O 0 5.162463345698143e-09
14 O 0 3.949526927726765e-08
% O 0 1.8588581340850396e-08
) O 0 5.733497232540685e-09
due O 0 5.711147466058719e-08
to O 0 2.5107891588049824e-07
BRCA2 O 0 0.0009892989182844758
. O 0 4.785418354913418e-07

Conversely O 0 5.9301102737663314e-05
, O 0 2.067770452640616e-07
the O 0 9.841056858306274e-09
majority O 0 1.0590545329591805e-08
of O 0 1.0681464601702828e-09
families O 0 1.0635809566394983e-08
with O 0 2.0189101501699724e-09
male B-Disease 0 1.1516577842485276e-06
and I-Disease 0 1.9671807649501716e-07
female I-Disease 0 0.06466928869485855
breast I-Disease 1 0.9999935626983643
cancer I-Disease 0 0.0014564658049494028
were O 0 1.7284502007441915e-07
due O 0 3.0824960361997e-08
to O 0 5.91635824775949e-08
BRCA2 O 0 0.006518103182315826
( O 0 3.525085290334573e-08
76 O 0 4.487513081130601e-07
% O 0 7.576640115303235e-08
) O 0 3.84403655573351e-08
. O 0 1.8853874905744306e-07

The O 0 8.981482437775412e-07
largest O 0 5.532309046429873e-07
proportion O 0 3.972722595335654e-07
( O 0 3.917177693324447e-08
67 O 0 2.8387438533172826e-07
% O 0 2.1423788965080348e-08
) O 0 7.496079312829806e-10
of O 0 5.760371624141669e-10
families O 0 1.1876332806082246e-08
due O 0 7.750337260858942e-09
to O 0 2.5927024971394985e-09
other O 0 3.7394851659655615e-09
genes O 0 1.6329015295468707e-07
was O 0 1.704926262391382e-07
found O 0 5.753094445282159e-09
in O 0 1.2285944483991784e-09
families O 0 9.615399143569903e-09
with O 0 2.765692785899887e-09
four O 0 2.633121098938318e-08
or O 0 2.6250075890743574e-08
five O 0 4.491183869248516e-09
cases O 0 2.0163122282923496e-09
of O 0 6.217245385187198e-09
female O 1 0.7969121932983398
breast B-Disease 1 0.9999992847442627
cancer I-Disease 0 0.0020137333776801825
only O 0 1.1166792290850935e-07
. O 0 4.944957368024916e-07

These O 0 1.267577545149834e-06
estimates O 0 1.5055551330078742e-06
were O 0 3.332554001644894e-07
not O 0 1.8579967786536145e-08
substantially O 0 7.775007304644532e-08
affected O 0 1.7992221046370105e-08
either O 0 4.827001909291084e-09
by O 0 1.011173478282501e-09
changing O 0 1.8310622351691563e-08
the O 0 1.8745909269313188e-09
assumed O 0 7.213839836595071e-08
penetrance O 0 2.522053819120629e-07
model O 0 3.3817165956406825e-08
for O 0 6.247224515476546e-09
BRCA1 O 0 1.821716796257533e-05
or O 0 5.8847895445524045e-08
by O 0 3.758584554702793e-09
including O 0 1.904795432494666e-08
or O 0 1.45194491096845e-07
excluding O 0 2.4107650915539125e-06
BRCA1 O 0 0.0005648744408972561
mutation O 0 5.351571417122614e-06
data O 0 2.1713460682803998e-06
. O 0 6.78808703469258e-07

Among O 0 2.3769252948113717e-06
those O 0 3.35582313937266e-07
families O 0 1.913674054776493e-07
with O 0 1.285614672497104e-07
disease O 0 0.00014481750258710235
due O 0 5.193556518179321e-08
to O 0 2.9013156321866518e-08
BRCA1 O 0 0.0015215069288387895
that O 0 7.115666988966041e-08
were O 0 3.856753210129682e-06
tested O 0 1.6559195046284003e-06
by O 0 9.264936040587202e-10
one O 0 6.780945249751369e-10
of O 0 8.963349507062901e-11
the O 0 4.772602313352081e-10
standard O 0 1.4718275487268784e-08
screening O 0 2.6574857869832158e-08
methods O 0 1.0759727331333124e-07
, O 0 8.8245961649136e-09
mutations O 0 2.2434885238453717e-07
were O 0 5.764576016531464e-08
detected O 0 6.219026715825748e-08
in O 0 1.3569116941170023e-09
the O 0 1.9357353497895247e-09
coding O 0 1.6008571890324674e-07
sequence O 0 5.1347829099768205e-08
or O 0 2.2516092101909635e-08
splice O 0 4.103345872863429e-06
sites O 0 5.325568395164737e-07
in O 0 1.3333576909246858e-08
an O 0 7.423802017569869e-09
estimated O 0 6.824001275163027e-08
63 O 0 1.1151637835382644e-07
% O 0 1.3228906858842038e-08
( O 0 6.055710599639497e-09
95 O 0 6.05973369260937e-08
% O 0 1.4984031793119357e-07
CI O 0 1.3670100088347681e-05
51 O 0 7.846417133805517e-07
% O 0 1.4467892128777748e-07
- O 0 3.3828669074864592e-06
77 O 0 3.7382039863587124e-07
% O 0 4.698578592865488e-08
) O 0 2.33628032475508e-08
. O 0 7.675959068365046e-08

The O 0 1.2799949899999774e-06
estimated O 0 4.0475362084180233e-07
sensitivity O 0 4.340115538070677e-07
was O 0 5.252081223261484e-07
identical O 0 1.331403893800598e-07
for O 0 8.367234682893354e-10
direct O 0 5.4738324983816256e-09
sequencing O 0 9.658543120849572e-08
and O 0 2.1043183195956772e-08
other O 0 1.4073129328551204e-08
techniques O 0 4.362563231552485e-06
. O 0 8.273775620182278e-07

The O 0 2.691926965781022e-06
penetrance O 0 5.3362324251793325e-05
of O 0 2.781396233331179e-07
BRCA2 O 0 0.0003334364155307412
was O 0 5.739829020967591e-07
estimated O 0 4.2614338724433765e-08
by O 0 7.125986023481801e-09
maximizing O 0 1.8654080236046866e-07
the O 0 1.828130891112778e-08
LOD O 0 2.4567223590565845e-05
score O 0 2.5180959255521884e-06
in O 0 3.333608944444677e-08
BRCA2 O 0 0.000393932918086648
- O 0 5.53249583390425e-06
mutation O 0 2.6362854441686068e-06
families O 0 6.564118137930564e-08
, O 0 3.992652874984515e-09
over O 0 4.928387475899854e-09
all O 0 7.030537929608727e-09
possible O 0 7.881435237777623e-08
penetrance O 0 6.085184850235237e-06
functions O 0 5.471339932228148e-07
. O 0 4.092057679372374e-07

The O 0 1.0569940513960319e-06
estimated O 0 7.924725196062354e-07
cumulative O 0 1.0906028364843223e-06
risk O 0 1.557682708153152e-06
of O 0 4.9932989298895336e-08
breast B-Disease 1 0.9999845027923584
cancer I-Disease 0 0.07631384581327438
reached O 0 2.8286469841987127e-06
28 O 0 3.960722949614137e-07
% O 0 4.701501055137669e-08
( O 0 1.52334074243754e-08
95 O 0 1.1527133381150634e-07
% O 0 1.225635912760481e-07
CI O 0 9.294347364630084e-06
9 O 0 2.3914927282930876e-07
% O 0 9.434533865260164e-08
- O 0 1.2643732816286501e-06
44 O 0 7.773969201707587e-08
% O 0 1.9164129838600275e-08
) O 0 1.271007743497421e-09
by O 0 1.033018559581933e-09
age O 0 2.3011127225913697e-08
50 O 0 4.605579917438263e-09
years O 0 2.6114530538023928e-09
and O 0 4.618220472707435e-09
84 O 0 3.511522805865752e-08
% O 0 4.526305108498718e-09
( O 0 3.683300997536776e-09
95 O 0 2.027651824221266e-08
% O 0 4.0875715257016054e-08
CI O 0 1.8236682990391273e-06
43 O 0 1.0912857817402255e-07
% O 0 2.347724858964284e-08
- O 0 3.1254305099537305e-07
95 O 0 8.774618009965707e-08
% O 0 2.6076218517800953e-08
) O 0 1.6767482957646962e-09
by O 0 2.4686663824269317e-09
age O 0 8.297917020172463e-08
70 O 0 3.3286912781704814e-08
years O 0 4.724387636656502e-08
. O 0 1.071168824751112e-07

The O 0 2.072211282211356e-05
corresponding O 1 0.9980777502059937
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.05636347085237503
were O 0 9.692469120636815e-07
0 O 0 1.7065054862541729e-06
. O 0 4.974662601853197e-07

4 O 0 3.909357837983407e-05
% O 0 1.866211960077635e-06
( O 0 1.2720882125449862e-07
95 O 0 3.284926606283989e-07
% O 0 2.6863159519052715e-07
CI O 0 1.4474971976596862e-05
0 O 0 3.656072635749297e-07
% O 0 5.1759734276402014e-08
- O 0 4.035460960949422e-07
1 O 0 2.3001209825679325e-08
% O 0 1.0597719146687723e-08
) O 0 9.965299696546026e-10
by O 0 7.633435550324918e-10
age O 0 1.6888236586964922e-08
50 O 0 2.4926880559661413e-09
years O 0 2.0234474096270105e-09
and O 0 5.909318367969263e-09
27 O 0 4.776212847446004e-08
% O 0 4.702807920864416e-09
( O 0 1.6291140658708514e-09
95 O 0 1.7794038242868737e-08
% O 0 3.818110982933831e-08
CI O 0 2.743554887274513e-06
0 O 0 1.7149486097878253e-07
% O 0 5.473365760622073e-08
- O 0 8.653485679133155e-07
47 O 0 4.363240009297442e-07
% O 0 2.7456898976652155e-08
) O 0 2.0312933557420365e-09
by O 0 3.724842656538385e-09
age O 0 1.6997911700400437e-07
70 O 0 8.28477553227458e-08
years O 0 7.379237132454364e-08
. O 0 1.573023098444537e-07

The O 0 2.3513873657066142e-06
lifetime O 0 1.0385088899056427e-05
risk O 0 8.093466931313742e-06
of O 0 1.8334462481561786e-07
breast B-Disease 1 0.9999971389770508
cancer I-Disease 0 0.0061261337250471115
appears O 0 9.10857878011484e-08
similar O 0 6.3045257903127094e-09
to O 0 8.9595983965296e-09
the O 0 4.311271695200958e-08
risk O 0 7.408145847875858e-07
in O 0 3.756255750886339e-09
BRCA1 O 0 7.467697287211195e-06
carriers O 0 3.55232003812489e-07
, O 0 3.1916465026426977e-09
but O 0 2.475578853022853e-09
there O 0 3.538333404051741e-09
was O 0 1.2257395098913548e-08
some O 0 2.9387448030604446e-10
suggestion O 0 3.892939304250831e-09
of O 0 4.1128511707455573e-10
a O 0 2.0722945137663373e-08
lower O 0 3.194265900674509e-06
risk O 0 1.3014073374506552e-06
in O 0 7.639236798695492e-09
BRCA2 O 0 1.0077687875309493e-05
carriers O 0 2.880781266867416e-07
< O 0 3.1125330224313075e-07
50 O 0 2.8528230444635483e-08
years O 0 5.342627229509844e-09
of O 0 7.738136353907521e-09
age O 0 7.419989174195507e-07
. O 0 1.8044497096525447e-07

Eye B-Disease 1 0.999907374382019
movement I-Disease 0 0.0006866214680485427
abnormalities I-Disease 1 0.9622604846954346
correlate O 0 1.6233836504397914e-05
with O 0 1.4646269619333907e-07
genotype O 0 0.0010653168428689241
in O 0 1.6410193381943827e-07
autosomal O 1 0.9909572601318359
dominant O 0 0.1689157783985138
cerebellar B-Disease 0 0.030148131772875786
ataxia I-Disease 1 0.9999539852142334
type I-Disease 1 0.999880313873291
I I-Disease 0 0.28575506806373596
. O 0 1.0994417607435025e-06

We O 0 1.4102698514761869e-05
compared O 0 2.117041503879591e-06
horizontal O 0 0.0020392588339746
eye O 1 0.7427175045013428
movements O 0 2.7344820409780368e-05
( O 0 1.2608857957729924e-07
visually O 0 1.814676238609536e-06
guided O 0 3.609145778682432e-06
saccades O 0 0.0002787903940770775
, O 0 9.753978247317718e-08
antisaccades O 0 2.510401373001514e-06
, O 0 1.881867817132843e-08
and O 0 2.54048657666317e-08
smooth O 0 1.2132568372180685e-06
pursuit O 0 1.6295302884827834e-06
) O 0 8.114107608037102e-09
in O 0 3.741162046821955e-09
control O 0 6.969444257265422e-07
subjects O 0 1.7778503433873993e-06
( O 0 7.434446303022924e-08
n O 0 4.8375577534898184e-06
= O 0 1.1075618203904014e-05
14 O 0 7.697099846382116e-08
) O 0 4.108470452734991e-09
and O 0 4.871567327313642e-08
patients O 0 1.6847577910539258e-07
with O 0 1.3525782716072854e-09
three O 0 7.327437767656875e-09
forms O 0 3.1558062829617484e-08
of O 0 2.206804516902139e-08
autosomal O 0 0.3827345371246338
dominant O 0 0.0008696176228113472
cerebellar B-Disease 0 0.0003554299473762512
ataxias I-Disease 0 0.00035676374682225287
type I-Disease 0 0.22831788659095764
I I-Disease 0 0.004116538912057877
spinocerebellar B-Disease 0 0.0045993635430932045
ataxias I-Disease 0 7.405689393635839e-05
1 I-Disease 0 1.4533981129716267e-07
and I-Disease 0 5.687601500881101e-08
2 I-Disease 0 8.954099683933237e-08
( O 0 3.521993718891281e-08
SCA1 B-Disease 0 7.5637335612555034e-06
, O 0 2.173196378407738e-08
n O 0 4.70341683467268e-06
= O 0 7.596581326652085e-06
11 O 0 1.5817902010439866e-07
; O 0 2.6448693901670595e-08
SCA2 B-Disease 0 2.364700321777491e-06
, O 0 2.153941558447059e-08
n O 0 1.3876269804313779e-06
= O 0 2.6514057935855817e-06
10 O 0 2.307349156183136e-08
) O 0 6.806800456615747e-09
and O 0 1.5867928482293792e-07
SCA3 B-Disease 1 1.0
/ O 0 0.00011306270607747138
Machado B-Disease 0 1.7476339053246193e-05
- I-Disease 0 0.0001264271850232035
Joseph I-Disease 0 0.0001943878596648574
disease I-Disease 0 0.06719871610403061
( O 0 1.2535373627997615e-07
MJD B-Disease 1 0.9999998807907104
) O 0 6.382629180734511e-08
( O 0 4.97113816777528e-08
n O 0 2.8017195290885866e-05
= O 0 6.149400724098086e-05
16 O 0 5.05569630604441e-07
) O 0 5.913177147931492e-08
. O 0 1.4122826996754156e-07

In O 0 3.884377292706631e-06
SCA1 B-Disease 0 5.066331141279079e-05
, O 0 1.9124954064864141e-07
saccade O 0 5.92814467381686e-06
amplitude O 0 6.755338404218492e-07
was O 0 3.759031699246407e-07
significantly O 0 1.6916648348797025e-07
increased O 0 4.992803681602709e-08
, O 0 9.439785841891535e-09
resulting O 0 5.824945148447114e-08
in O 0 1.760314205512259e-08
hypermetria B-Disease 0 1.550605520606041e-05
. O 0 1.8501519605251815e-07

The O 0 3.427835508773569e-06
smooth O 0 1.2395066733006388e-05
pursuit O 0 1.2632411198865157e-05
gain O 0 1.789933958207257e-05
was O 0 7.663291398785077e-06
decreased O 0 1.0413542440801393e-05
. O 0 2.670147978278692e-07

In O 0 4.056601028423756e-06
SCA2 B-Disease 0 4.9659520300338045e-05
, O 0 1.3406273069449526e-07
saccade O 0 1.8641432689037174e-05
velocity O 0 5.064004199084593e-06
was O 0 1.9776741737587145e-06
markedly O 0 6.693303930660477e-06
decreased O 0 1.0003775059885811e-05
. O 0 5.349722300707072e-07

The O 0 1.1311030903016217e-06
percentage O 0 2.952579961856827e-06
of O 0 1.7568492438613248e-08
errors O 0 1.692883074611018e-06
in O 0 2.2861859960698894e-08
antisaccades O 0 4.454147074284265e-06
was O 0 2.1514946979550587e-07
greatly O 0 2.6912692518976655e-08
increased O 0 2.572625490415703e-08
and O 0 2.5800849456913966e-08
was O 0 5.041031414521058e-08
significantly O 0 6.81540370806033e-08
correlated O 0 1.2227569357037282e-07
with O 0 1.8592055894828263e-08
age O 0 1.3108416396789835e-06
at O 0 4.7547437134198844e-06
disease O 0 0.0008653037948533893
onset O 0 7.628295134054497e-05
. O 0 7.871847742535465e-07

In O 0 8.090195251497789e-07
addition O 0 1.3912361396251072e-07
, O 0 7.66951568920149e-09
a O 0 5.126657764975562e-09
correlation O 0 1.0998155630659312e-07
between O 0 1.8830276005132873e-08
smooth O 0 1.5258466419254546e-06
pursuit O 0 3.4113113542844076e-06
gain O 0 5.294705260894261e-06
and O 0 4.313072565764742e-08
the O 0 2.4983763946551107e-09
number O 0 5.352112530943032e-09
of O 0 7.783996558430317e-09
trinucleotide O 0 1.3346001651370898e-05
repeats O 0 2.6855163923755754e-06
was O 0 4.891580829280429e-07
found O 0 2.2290184631401644e-07
. O 0 1.7372931893078203e-07

In O 0 1.897346919577103e-05
SCA3 B-Disease 1 0.9999947547912598
, O 0 1.4735009017385892e-06
gaze B-Disease 0 0.0006576618179678917
- I-Disease 0 0.00015996773436199874
evoked I-Disease 0 2.489039434294682e-05
nystagmus I-Disease 0 0.0008035635692067444
was O 0 2.9510263175325235e-06
often O 0 2.081425947153548e-07
present O 0 2.654466690898971e-08
as O 0 1.731513066260959e-08
was O 0 7.216922170982798e-08
saccade O 0 2.944268317151e-06
hypometria O 0 3.2923485377978068e-06
and O 0 6.799990615036222e-08
smooth O 0 1.3011442661081674e-06
pursuit O 0 4.875405920756748e-06
gain O 0 1.6514626622665673e-05
was O 0 7.41549320082413e-06
markedly O 0 8.600168257544283e-06
decreased O 0 7.190334144979715e-06
. O 0 2.0102235964714055e-07

Three O 0 4.951407390763052e-06
major O 0 6.938546448509442e-07
criteria O 0 3.807272150879726e-07
, O 0 1.310829489398202e-08
saccade O 0 1.323092078564514e-06
amplitude O 0 2.0659020094626612e-07
, O 0 1.3543705712493193e-08
saccade O 0 1.727833591758099e-06
velocity O 0 6.107943022470863e-07
, O 0 8.162476028417132e-09
and O 0 6.712848499290658e-09
presence O 0 1.498082546902424e-08
of O 0 9.311248660992533e-09
gaze B-Disease 0 0.00020021438831463456
- I-Disease 0 1.8501377780921757e-05
evoked I-Disease 0 3.611008423831663e-06
nystagmus I-Disease 0 1.3150175618648063e-05
, O 0 1.0487025470240496e-08
permitted O 0 1.2998547127551774e-08
the O 0 5.1145567780963574e-09
correct O 0 2.629523407904344e-07
assignment O 0 5.70679183908851e-08
of O 0 1.7100539873027287e-09
90 O 0 1.4273633830441668e-08
% O 0 4.658553542924437e-09
of O 0 8.692055408765498e-10
the O 0 1.3432593704010287e-08
SCA1 B-Disease 0 2.370322135902825e-06
, O 0 3.883757759837181e-09
90 O 0 4.659326702238786e-09
% O 0 1.8334518347984385e-09
of O 0 4.265893749355598e-10
the O 0 5.676716874347676e-09
SCA2 B-Disease 0 2.8251583898963872e-06
, O 0 2.622604133861728e-09
and O 0 3.79585296528262e-09
93 O 0 1.2734228782562695e-08
% O 0 2.1027124486039384e-09
of O 0 4.777757078855416e-10
the O 0 2.9792362354896795e-08
patients O 0 1.8301724935554375e-07
with O 0 1.1268912025741429e-08
SCA3 B-Disease 1 0.9999997615814209
to O 0 4.0012693602875515e-08
their O 0 1.2410286842623464e-07
genetically O 0 2.3298152029838093e-07
confirmed O 0 2.2420897494157543e-07
patient O 0 2.38820632603165e-07
group O 0 1.039454389228922e-08
and O 0 5.9874203373055934e-09
, O 0 3.0211908530475284e-09
therefore O 0 7.1136829760121145e-09
, O 0 1.7477509439700611e-09
may O 0 2.040905933142767e-08
help O 0 1.9091091374434654e-08
orient O 0 9.4156007435231e-07
diagnoses O 0 4.249723588145571e-06
of O 0 7.835266657707507e-09
SCA1 B-Disease 0 1.1684486707963515e-05
, O 0 1.6667401681047522e-08
SCA2 B-Disease 0 2.1045889297965914e-06
, O 0 1.2671790727836196e-08
and O 0 8.381491056752566e-08
SCA3 B-Disease 1 0.9999994039535522
at O 0 3.091039673108753e-07
early O 0 6.328370716346399e-08
clinical O 0 6.301907546912844e-07
stages O 0 1.710421031475562e-07
of O 0 3.1163567282277427e-09
the O 0 2.0991154769944842e-07
diseases O 0 0.00010057703912025318
. O 0 1.4198175968260784e-08
. O 0 1.0774657965839651e-07

Genetic O 0 6.476065027527511e-05
basis O 0 6.299702022261044e-07
and O 0 8.937703199762836e-08
molecular O 0 1.0732475857366808e-05
mechanism O 0 7.036255556158721e-05
for O 0 3.63009276043158e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999997615814209
fibrillation I-Disease 1 1.0
. O 0 1.2791268090950325e-05

Ventricular B-Disease 1 0.9998258948326111
fibrillation I-Disease 1 0.9996217489242554
causes O 0 2.563071575423237e-05
more O 0 5.1715922211315046e-08
than O 0 1.269734006825729e-08
300 O 0 1.9783856330946037e-08
, O 0 5.887919485303428e-09
000 O 0 4.896514482766179e-08
sudden O 0 3.357814364335354e-07
deaths O 0 2.919412906976504e-07
each O 0 1.4861833541601754e-08
year O 0 1.1461773752330373e-08
in O 0 2.6069142400331202e-09
the O 0 2.5607294062979236e-08
USA O 0 5.270302153803641e-06
alone O 0 3.296387376394705e-07
. O 0 8.126765038696249e-08

In O 0 1.0356645816500532e-06
approximately O 0 3.450741985489003e-07
5 O 0 1.6815876335840585e-07
- O 0 1.0431804184918292e-06
12 O 0 4.9126608558935914e-08
% O 0 2.8418838393662327e-09
of O 0 1.2355592937662863e-10
these O 0 7.38755334683816e-10
cases O 0 1.5316081736216347e-09
, O 0 1.750840472602988e-09
there O 0 2.8745714697464564e-09
are O 0 1.1547968803427011e-08
no O 0 1.951302550651235e-07
demonstrable O 0 0.006145295687019825
cardiac O 0 0.0004636801313608885
or O 0 6.158581982163014e-06
non O 0 0.0015808090101927519
- O 1 0.5284456610679626
cardiac O 0 0.0028028306551277637
causes O 0 6.254869617805525e-07
to O 0 1.5870178060595208e-08
account O 0 8.817769270308418e-08
for O 0 1.5413084142323896e-09
the O 0 3.491445577097352e-09
episode O 0 2.6771903094413574e-07
, O 0 3.717219865251309e-09
which O 0 3.4157221495689782e-09
is O 0 2.4062052350615204e-09
therefore O 0 1.2283981831728852e-08
classified O 0 1.4789070519327652e-06
as O 0 1.557516043249052e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999971389770508
fibrillation I-Disease 1 1.0
( O 0 0.0001887008111225441
IVF B-Disease 1 1.0
) O 0 9.122790061155683e-07
. O 0 3.2597671406620066e-07

A O 0 4.2971200855390634e-06
distinct O 0 9.816910733206896e-07
group O 0 1.2578232144733192e-07
of O 0 2.1904916991388745e-08
IVF B-Disease 1 1.0
patients O 0 0.06180715560913086
has O 0 1.3106311769206513e-07
been O 0 7.494928411233559e-08
found O 0 7.959170211790934e-09
to O 0 2.261257403546324e-09
present O 0 7.268557755679694e-09
with O 0 7.865662787764904e-09
a O 0 7.636632659568932e-08
characteristic O 0 2.2327030819724314e-05
electrocardiographic O 0 4.2818541260203347e-05
pattern O 0 1.573660301801283e-05
. O 0 4.2031277303067327e-07

Because O 0 1.377410058012174e-06
of O 0 5.748038489628016e-09
the O 0 3.5974694334584e-09
small O 0 2.5646773593734906e-09
size O 0 1.0740757616645169e-08
of O 0 9.644341991688066e-10
most O 0 2.8648505789874434e-09
pedigrees O 0 7.1093444375947e-07
and O 0 2.2298513258078856e-08
the O 0 9.24541687652436e-09
high O 0 5.978590138511208e-07
incidence O 0 3.5582543205237016e-05
of O 0 8.45605807597849e-09
sudden B-Disease 0 1.951292915691738e-06
death I-Disease 0 1.5702413236340362e-07
, O 0 2.807317933672948e-09
however O 0 3.733719555754078e-09
, O 0 9.34243016281755e-10
molecular O 0 9.126351585564407e-08
genetic O 0 5.824055619996216e-07
studies O 0 5.630932164990554e-08
of O 0 2.5824284932696173e-08
IVF B-Disease 1 1.0
have O 0 6.974862571951235e-06
not O 0 1.0338059297509972e-07
yet O 0 1.3941101428827096e-07
been O 0 1.1133211330616177e-07
done O 0 5.430724172583723e-07
. O 0 1.5189357327471953e-07

Because O 0 0.00042025477159768343
IVF B-Disease 1 1.0
causes O 0 0.01251999568194151
cardiac O 1 0.5865397453308105
rhythm O 0 0.0005896989605389535
disturbance O 0 4.442425961315166e-06
, O 0 5.1293010727704313e-08
we O 0 5.329033214707124e-08
investigated O 0 1.417550663518341e-07
whether O 0 2.290686218486826e-08
malfunction O 0 1.3747409184361459e-06
of O 0 1.2462768594900808e-09
ion O 0 1.6188103302283707e-07
channels O 0 2.982914566018735e-06
could O 0 6.525770459120395e-06
cause O 0 5.18924935022369e-07
the O 0 3.289069994139027e-08
disorder O 0 2.5442057449254207e-05
by O 0 1.757471834729074e-09
studying O 0 9.394343081225998e-09
mutations O 0 1.6192178975416027e-07
in O 0 1.5480641213372337e-09
the O 0 1.15570033543122e-08
cardiac O 0 3.067276338697411e-06
sodium O 0 3.616004562445596e-07
channel O 0 6.449301054090029e-06
gene O 0 1.2482610145525541e-05
SCN5A O 0 6.399015546776354e-05
. O 0 1.1058436939492822e-06

We O 0 2.045491237367969e-05
have O 0 2.405941188499128e-07
now O 0 4.54963391405272e-08
identified O 0 5.8053352347542386e-08
a O 0 1.0607891454128549e-08
missense O 0 5.3026788009447046e-06
mutation O 0 1.045951762534969e-06
, O 0 2.9260276424025733e-09
a O 0 1.1528975996100144e-08
splice O 0 0.0016926941461861134
- O 0 0.00012951505777891725
donor O 0 5.416205226538295e-07
mutation O 0 3.2724367429182166e-06
, O 0 6.774213634486159e-09
and O 0 3.790969316241899e-09
a O 0 1.87437727561246e-08
frameshift O 0 2.5232588086510077e-05
mutation O 0 7.917390121292556e-07
in O 0 2.1123316429338956e-09
the O 0 3.607653065174077e-09
coding O 0 5.398877647166955e-07
region O 0 4.607629477959563e-08
of O 0 5.282348336521636e-09
SCN5A O 0 1.0222183846053667e-05
in O 0 1.7281939435065397e-08
three O 0 4.073663717463205e-07
IVF B-Disease 1 0.9999997615814209
families O 0 1.423912067366473e-06
. O 0 2.5705071493575815e-07

We O 0 6.487485279649263e-06
show O 0 5.041752615397854e-07
that O 0 1.0475150524769106e-08
sodium O 0 3.474195509056699e-08
channels O 0 3.686339056230281e-08
with O 0 5.455144336252715e-09
the O 0 1.3359492179176868e-08
missense O 0 4.97790233566775e-06
mutation O 0 1.771182837728702e-06
recover O 0 1.1016353482773411e-06
from O 0 8.83904949233738e-09
inactivation O 0 2.263300018512382e-07
more O 0 3.834083273090982e-09
rapidly O 0 5.2367667535691e-08
than O 0 2.4236717077741332e-09
normal O 0 2.0811672385434576e-08
and O 0 8.67283311833944e-09
that O 0 2.3594852738284544e-09
the O 0 1.4247169666248283e-08
frameshift O 0 2.222065450041555e-05
mutation O 0 1.7306188055954408e-06
causes O 0 5.898240829083079e-08
the O 0 5.0212509705716e-09
sodium O 0 5.686863602250014e-08
channel O 0 4.086796820956806e-07
to O 0 1.9782913085464315e-08
be O 0 7.908434440651035e-08
non O 0 5.562241085499409e-07
- O 0 3.07531945509254e-06
functional O 0 7.471942808479071e-06
. O 0 5.926985977566801e-07

Our O 0 1.6228821550612338e-05
results O 0 1.384047891406226e-06
indicate O 0 5.21241702244879e-07
that O 0 1.049717202050715e-08
mutations O 0 4.920547667097708e-07
in O 0 9.947170198643107e-09
cardiac O 0 8.971654210654378e-07
ion O 0 9.712001656225766e-07
- O 0 4.4494217945612036e-06
channel O 0 2.5044114408956375e-06
genes O 0 2.86110378056037e-07
contribute O 0 2.1271343797479858e-08
to O 0 5.34109911853875e-09
the O 0 1.1765000529351255e-08
risk O 0 1.1711708225448092e-07
of O 0 3.0826063923683478e-09
developing O 0 7.129027039809444e-07
IVF B-Disease 1 0.9999985694885254
. O 0 9.50004519495451e-08
. O 0 1.745204087910679e-07

Molecular O 0 3.768601163756102e-05
heterogeneity O 0 2.0235956981196068e-05
in O 0 4.869463623435877e-07
mucopolysaccharidosis B-Disease 0 3.0768351280130446e-05
IVA I-Disease 0 6.008470882079564e-05
in O 0 6.867625756967755e-08
Australia O 0 1.3600065074115264e-07
and O 0 1.753374512247774e-08
Northern O 0 7.245569122460438e-08
Ireland O 0 1.840479853854049e-06
: O 0 4.921830942805627e-09
nine O 0 1.536032456783687e-08
novel O 0 2.118760633607053e-08
mutations O 0 2.0272503320484248e-07
including O 0 7.2887154090039985e-09
T312S O 0 6.111549168963393e-07
, O 0 3.2216953549379923e-09
a O 0 3.973599227435898e-09
common O 0 2.1768885360984314e-08
allele O 0 1.5190386193353334e-07
that O 0 3.071566778700685e-09
confers O 0 8.816120811161454e-08
a O 0 1.296328377975442e-07
mild O 0 0.00024207998649217188
phenotype O 0 0.0003134158905595541
. O 0 6.657841709056811e-07

Mucopolysaccharidosis B-Disease 1 0.955072283744812
IVA I-Disease 1 0.9995038509368896
( O 0 0.014497623778879642
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.8167440291326784e-07
is O 0 2.3255037007174906e-08
an O 0 7.611460262069158e-08
autosomal B-Disease 1 0.9992411136627197
recessive I-Disease 1 0.9999939203262329
lysosomal I-Disease 1 0.9999768733978271
storage I-Disease 1 0.9999903440475464
disorder I-Disease 1 0.9999998807907104
caused O 0 2.7325217160978355e-05
by O 0 3.220947419890763e-08
a O 0 1.450224885957141e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.5977839495917578e-07
N O 0 0.0003832225629594177
- O 0 0.0002485830045770854
acetylgalactosamine O 0 0.0005987925687804818
- O 0 0.0002651031536515802
6 O 0 7.922701115603559e-06
- O 0 0.0009812981588765979
sulfate O 0 8.194096881197765e-05
sulfatase O 0 5.293612412060611e-05
( O 0 3.1505263109465886e-07
GALNS O 0 1.1075999282184057e-05
) O 0 9.379020582400699e-08
. O 0 1.6687384629676671e-07

Previous O 0 7.039180218271213e-06
studies O 0 4.3229562152191647e-07
of O 0 1.6702884408914542e-08
patients O 0 1.1790540384026826e-06
from O 0 4.522318519661894e-09
a O 0 4.936810427125238e-08
British O 0 1.5023601918073837e-05
- O 0 2.2463676941697486e-05
Irish O 0 1.5044240626593819e-06
population O 0 1.4277908633175684e-08
showed O 0 1.5281139553735557e-07
that O 0 1.2158916096183248e-09
the O 0 4.9686330605425155e-09
I113F O 0 3.942423063563183e-07
mutation O 0 1.6042623940393241e-07
is O 0 1.0236549385922444e-09
the O 0 5.304841010911332e-10
most O 0 6.96302071556687e-10
common O 0 1.0557590357507252e-08
single O 0 1.2499506283347728e-06
mutation O 0 2.6008870008809026e-06
among O 0 1.6550701786854916e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.10867131501436234
and O 0 1.9910640958187287e-07
produces O 0 2.1076367318073608e-07
a O 0 5.409082177720848e-07
severe O 0 0.18199042975902557
clinical O 0 0.0051137241534888744
phenotype O 0 0.0013326285406947136
. O 0 1.9991116460005287e-06

We O 0 1.2621827409020625e-05
studied O 0 4.266486484993948e-06
mutations O 0 7.981313501659315e-06
in O 0 2.242728491808066e-08
the O 0 1.2207581612244667e-08
GALNS O 0 2.0310619675001362e-06
gene O 0 1.5556327070953557e-07
from O 0 9.87542847497025e-09
23 O 0 3.389362390748829e-08
additional O 0 8.567039344598015e-08
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 0.0010341050801798701
( O 0 2.7442029093549536e-08
15 O 0 1.3842478274739278e-08
from O 0 4.748994975045662e-09
Australia O 0 4.488240534783472e-08
, O 0 4.82831863379829e-09
8 O 0 9.414145019093212e-09
from O 0 3.595562514391304e-09
Northern O 0 2.2994104398321724e-08
Ireland O 0 5.521508796846319e-07
) O 0 1.95020333215723e-09
, O 0 3.464596665114783e-10
with O 0 2.052435582600154e-10
various O 0 5.06686292922609e-09
clinical O 0 1.8472603187547065e-05
phenotypes O 0 4.202949276077561e-05
( O 0 1.3582838676029496e-07
severe O 0 9.877506090560928e-05
, O 0 8.64490612428881e-09
16 O 0 1.7430677345942058e-08
cases O 0 4.14339540455444e-09
; O 0 2.6373720984906868e-09
intermediate O 0 3.88418150976122e-08
, O 0 4.317564528122375e-09
4 O 0 2.6168391897840593e-08
cases O 0 1.289744133714521e-08
; O 0 3.2983678011078155e-08
mild O 0 3.074025153182447e-05
, O 0 3.872117204650749e-08
3 O 0 6.651863060369578e-08
cases O 0 2.0438745806927727e-08
) O 0 2.3533154092092445e-08
. O 0 1.067974153556861e-07

We O 0 1.207977402373217e-05
found O 0 1.309709034558182e-07
two O 0 1.1676406508343007e-08
common O 0 4.2355921436865174e-08
mutations O 0 4.842071916755231e-07
that O 0 3.3221567719010636e-09
together O 0 2.2581378544828112e-08
accounted O 0 3.032004940450861e-07
for O 0 1.9196020328848817e-09
32 O 0 4.890951288416545e-08
% O 0 3.6085543442254675e-09
of O 0 4.5447465235604056e-10
the O 0 6.15006534587792e-09
44 O 0 6.40856328004702e-08
unrelated O 0 3.354005073674671e-08
alleles O 0 8.169504184252219e-08
in O 0 3.837617335022969e-09
these O 0 2.1404430228244564e-08
patients O 0 7.375239761131525e-07
. O 0 1.7382842543156585e-07

One O 0 2.697714080568403e-06
is O 0 7.578461236334988e-08
the O 0 1.4624865762868922e-08
T312S O 0 1.0157231145058176e-06
mutation O 0 8.302633887069533e-07
, O 0 4.568370570723346e-09
a O 0 7.2154606733931814e-09
novel O 0 5.4351751543890714e-08
mutation O 0 4.019827599677228e-07
found O 0 1.1885260775557072e-08
exclusively O 0 2.4190178748995095e-08
in O 0 7.930560208535553e-09
milder O 0 1.8434713638271205e-05
patients O 0 1.4193746210366953e-05
. O 0 1.8882791152918799e-07

The O 0 1.2467719443520764e-06
other O 0 6.138067476513243e-08
is O 0 7.1275767510314836e-09
the O 0 4.73833638992005e-09
previously O 0 1.5952943499542016e-07
described O 0 5.990163742808363e-08
I113F O 0 2.4914163532230305e-07
that O 0 4.534912001474822e-09
produces O 0 6.066787960889997e-08
a O 0 1.9767831815897807e-07
severe O 0 0.0004398278542794287
phenotype O 0 9.058143041329458e-05
. O 0 4.2865463001362514e-07

The O 0 2.5467511477472726e-06
I113F O 0 8.858326509653125e-06
and O 0 1.1578386249766481e-07
T312S O 0 2.947589109680848e-06
mutations O 0 2.5375768473168137e-06
accounted O 0 6.555784466399928e-07
for O 0 8.47625880595615e-09
8 O 0 4.6333362035966275e-08
( O 0 6.326389190292048e-09
18 O 0 2.7679531555691028e-08
% O 0 6.346680958557727e-09
) O 0 1.743988065072699e-09
and O 0 1.3317006164470513e-08
6 O 0 6.408220798448383e-08
( O 0 5.376238121357346e-09
14 O 0 1.1486262607718345e-08
% O 0 2.3678614624600414e-09
) O 0 4.4521872299974063e-10
of O 0 6.38242847461612e-10
44 O 0 4.9824915748786225e-08
unrelated O 0 1.1513202480273321e-07
alleles O 0 3.4428330764058046e-07
, O 0 2.0772491282627925e-08
respectively O 0 6.238629453036992e-07
. O 0 1.8016230285411439e-07

The O 0 1.4331214970297879e-06
relatively O 0 1.3964549907541368e-06
high O 0 5.987851068312011e-07
residual O 0 7.676407221879344e-06
GALNS O 0 1.614480061107315e-05
activity O 0 5.62946013360488e-07
seen O 0 2.86336415911137e-07
when O 0 1.0720372145556212e-08
the O 0 3.4482423583170885e-09
T312S O 0 1.718508002568342e-07
mutant O 0 3.029583126590296e-07
cDNA O 0 1.662903343913058e-07
is O 0 9.258969591030564e-09
overexpressed O 0 3.6129847558186157e-07
in O 0 3.832277606363732e-09
mutant O 0 5.940443088547909e-07
cells O 0 4.4239524044087375e-08
provides O 0 3.786719826592844e-09
an O 0 1.3676088039815681e-09
explanation O 0 9.697525449325894e-09
for O 0 2.2840318525396697e-09
the O 0 2.5864506980610713e-08
mild O 0 0.00010143202962353826
phenotype O 0 5.4619893489871174e-05
in O 0 3.050095997991775e-08
patients O 0 3.810461635112006e-07
with O 0 3.935020753687013e-09
this O 0 6.71450006706209e-09
mutation O 0 4.375192474981304e-06
. O 0 2.267880603312733e-07

The O 0 2.997541628246836e-07
distribution O 0 4.798273067763148e-08
and O 0 7.634779919385437e-09
relative O 0 3.0265042028077005e-08
frequencies O 0 9.31604873244396e-08
of O 0 3.086707334176708e-09
the O 0 1.1619065709567167e-08
I113F O 0 3.8647908695566e-07
and O 0 2.426503620256426e-08
T312S O 0 4.672794773341593e-07
mutations O 0 2.570139372437552e-07
in O 0 3.642806278847388e-09
Australia O 0 1.096357227226008e-08
corresponded O 0 2.594039472114673e-08
to O 0 7.458091033640812e-09
those O 0 1.072683541991637e-08
observed O 0 2.1215994294720986e-08
in O 0 1.5015889642810976e-09
Northern O 0 1.2915461589102506e-08
Ireland O 0 2.891981978336844e-07
and O 0 1.6814441394785717e-08
are O 0 1.5202342718012574e-09
unique O 0 8.787204852644948e-10
to O 0 5.567957761520859e-10
these O 0 5.740650732555252e-10
two O 0 2.4193853587206604e-09
populations O 0 1.0364294311671074e-08
, O 0 5.365223265663133e-10
suggesting O 0 6.171215982675449e-09
that O 0 6.960683696100034e-10
both O 0 9.293647629249335e-09
mutations O 0 2.358287929382641e-07
were O 0 1.1254825693640669e-07
probably O 0 2.4991685165787203e-08
introduced O 0 7.52358442213108e-09
to O 0 7.002019852819785e-09
Australia O 0 5.590437979208218e-08
by O 0 5.648516765432987e-09
Irish O 0 9.647256860034759e-08
migrants O 0 1.4891542221562304e-08
during O 0 1.424803830474275e-08
the O 0 1.5823447441221106e-08
19th O 0 5.84238591727626e-07
century O 0 5.982645348012738e-07
. O 0 3.4519726455073396e-07

Haplotype O 0 0.0001855888549471274
analysis O 0 4.260119567334186e-06
using O 0 1.0217495400866028e-06
6 O 0 1.0076968237626716e-06
RFLPs O 0 1.0751753052318236e-06
provides O 0 8.377811333559748e-09
additional O 0 4.2757366536250174e-09
data O 0 1.025645417485066e-07
that O 0 2.322700698442759e-09
the O 0 6.97428248486176e-09
I113F O 0 4.249299934144801e-07
mutation O 0 2.6449760071045603e-07
originated O 0 5.447764905852637e-08
from O 0 4.312017853891348e-09
a O 0 1.515388703410281e-08
common O 0 1.0388404092509518e-07
ancestor O 0 1.3003577805648092e-06
. O 0 2.9064148066026974e-07

The O 0 1.157844621957338e-06
other O 0 8.565078246647317e-08
9 O 0 2.316316312089839e-07
novel O 0 1.1457035498096957e-07
mutations O 0 1.2525434840426897e-06
identified O 0 1.7374024707805802e-07
in O 0 2.035625668028729e-09
these O 0 1.244315583903699e-08
23 O 0 7.336236649280181e-07
patients O 0 2.3714905239557993e-07
were O 0 6.604379620966938e-08
each O 0 3.234230883109035e-09
limited O 0 8.832611975151394e-09
to O 0 1.1461380289290446e-08
a O 0 1.3624185157823376e-07
single O 0 2.8738944820361212e-05
family O 0 5.58838507913606e-07
. O 0 2.266340999312888e-07

These O 0 9.669710152593325e-07
data O 0 2.8277307251300954e-07
provide O 0 5.950888137817856e-08
further O 0 3.3752986183799294e-08
evidence O 0 2.530162213076892e-08
for O 0 2.8983604405397045e-09
extensive O 0 2.880031502172642e-07
allelic O 0 7.176084636739688e-06
heterogeneity O 0 3.3665112368908012e-06
in O 0 6.667652314717998e-07
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 0.9999971389770508
in O 0 1.461619945075654e-07
British O 0 0.00014070788165554404
- O 0 0.0008906297152861953
Irish O 0 6.577479325642344e-06
patients O 0 1.9982945786978235e-07
and O 0 1.6538159730572488e-09
provide O 0 5.634012367750074e-09
evidence O 0 9.109582421729101e-09
for O 0 2.4532658127185414e-09
their O 0 2.9867806006222963e-08
transmission O 0 2.4597268293291563e-06
to O 0 1.150487793921684e-08
Australia O 0 4.9876067720333594e-08
by O 0 3.99527344541184e-09
British O 0 1.2745451840601163e-06
- O 0 2.876627149817068e-06
Irish O 0 7.69727478200366e-07
migrants O 0 1.4110158019775554e-07
. O 0 1.457540843574634e-08
. O 0 8.747513646767402e-08

Identification O 0 1.2089662959624548e-05
of O 0 1.9766004299981432e-07
constitutional O 0 1.0274501391904778e-06
WT1 O 0 9.3315371486824e-05
mutations O 0 1.2983718079340179e-05
, O 0 1.9077113222465414e-08
in O 0 8.407681661992683e-09
patients O 0 6.001955625833943e-07
with O 0 1.7543914765383306e-08
isolated O 0 0.00011206865747226402
diffuse B-Disease 1 0.9160075187683105
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 8.810893348254467e-08
and O 0 4.0038936610642395e-09
analysis O 0 1.4709631734888262e-08
of O 0 1.1391594334497768e-08
genotype O 0 0.0006240882794372737
/ O 0 0.00012183872604509816
phenotype O 0 1.0453999493620358e-05
correlations O 0 7.633850032107148e-07
by O 0 4.76040362684671e-09
use O 0 1.0428780505833402e-08
of O 0 3.905984868879386e-09
a O 0 5.951920911684283e-08
computerized O 0 0.00045903693535365164
mutation O 0 4.050084316986613e-05
database O 0 3.570436547306599e-06
. O 0 6.897865318933327e-07

Constitutional O 0 9.500562555331271e-06
mutations O 0 6.481623131548986e-06
of O 0 1.3857852643184287e-08
the O 0 2.6927169827217767e-08
WT1 O 0 6.457431027229177e-06
gene O 0 4.066467340635427e-07
, O 0 4.2459107341130675e-09
encoding O 0 4.417089272124031e-08
a O 0 1.6780201406163542e-07
zinc O 0 0.004570281133055687
- O 0 1.3426797522697598e-05
finger O 0 3.2530570024391636e-05
transcription O 0 8.556324360142753e-07
factor O 0 7.176360838911933e-08
involved O 0 3.08487244637945e-08
in O 0 1.7956359954496293e-08
renal O 0 0.0001806821528589353
and O 0 1.5548806686638272e-07
gonadal O 0 0.00011114882363472134
development O 0 3.3697215684469484e-08
, O 0 6.797147733550446e-09
are O 0 2.179629587928389e-09
found O 0 4.473947434746606e-09
in O 0 5.889398968506043e-10
most O 0 7.179807859358789e-09
patients O 0 4.9799261603311606e-08
with O 0 2.7759366361124194e-08
Denys B-Disease 1 0.9999964237213135
- I-Disease 1 0.9999996423721313
Drash I-Disease 1 0.9999996423721313
syndrome I-Disease 1 1.0
( O 0 3.9383834860018396e-07
DDS B-Disease 1 0.9999998807907104
) O 0 1.1177191083788784e-07
, O 0 2.6328800473152114e-08
or O 0 8.619258551334497e-06
diffuse B-Disease 1 0.9995679259300232
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.0568151992629282e-05
DMS B-Disease 0 0.17163971066474915
) O 0 8.482036406576299e-08
associated O 0 2.5760337507563236e-07
with O 0 1.8645472721345868e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.8522085156291723e-05
/ O 0 0.041717611253261566
or O 0 0.00011248190276091918
Wilms B-Disease 1 0.9995612502098083
tumor I-Disease 0 0.24763868749141693
( O 0 2.702792244235752e-06
WT B-Disease 1 0.9999988079071045
) O 0 4.2165933678006695e-07
. O 0 2.842265587332804e-07

Most O 0 1.2688120477832854e-05
mutations O 0 0.0001683285372564569
in O 0 1.4332445061882026e-06
DDS B-Disease 1 1.0
patients O 1 0.9979368448257446
lie O 0 0.0001672180078458041
in O 0 1.9057473821249005e-08
exon O 0 7.403809831885155e-07
8 O 0 1.0161837593614109e-07
or O 0 3.940618142905805e-08
exon O 0 3.957653120778559e-07
9 O 0 1.8992886907653883e-07
, O 0 1.0166369968089839e-08
encoding O 0 4.747412560845987e-07
zinc O 0 0.0029567694291472435
finger O 0 0.012048838660120964
2 O 0 1.2345967661531176e-06
or O 0 8.763711775827687e-06
zinc O 0 0.02358062006533146
finger O 0 0.016135983169078827
3 O 0 5.474231556945597e-07
, O 0 1.960684770097032e-08
respectively O 0 4.53815061973728e-07
, O 0 4.6276285026181085e-09
with O 0 3.410175919427161e-09
a O 0 4.7283720050472766e-08
hot O 0 1.6225169019890018e-05
spot O 0 0.001306672114878893
( O 0 3.880604992900771e-08
R394W O 0 1.768654698253158e-07
) O 0 3.068445497689254e-09
in O 0 5.993658902525567e-09
exon O 0 1.8177038327849004e-06
9 O 0 1.5900527614576276e-06
. O 0 4.5967536266289244e-07

We O 0 9.779489118955098e-06
analyzed O 0 2.7405762921262067e-06
a O 0 4.0228876230230526e-08
series O 0 2.2725910042709074e-08
of O 0 2.935586884689201e-09
24 O 0 6.002115355840942e-07
patients O 0 4.2851030457313755e-07
, O 0 4.362513461586559e-09
10 O 0 5.658966184540759e-09
with O 0 1.60150399608483e-08
isolated B-Disease 0 4.8272071580868214e-05
DMS I-Disease 1 0.5232535004615784
( O 0 1.6960247251063265e-07
IDMS B-Disease 0 0.00018540401651989669
) O 0 2.3794619607997447e-08
, O 0 5.706788819281883e-09
10 O 0 1.3444152457964265e-08
with O 0 7.047134431559243e-08
DDS B-Disease 1 1.0
, O 0 2.4947163979049947e-07
and O 0 4.8762153426196164e-08
4 O 0 2.844992863515472e-08
with O 0 5.988496099007534e-08
urogenital B-Disease 0 0.12974382936954498
abnormalities I-Disease 1 0.9999699592590332
and O 0 9.818776561587583e-06
/ O 0 0.32696443796157837
or O 0 0.004148254636675119
WT B-Disease 1 1.0
. O 0 3.2229804673988838e-06

We O 0 2.4535847842344083e-05
report O 0 2.8144263524154667e-06
WT1 O 0 8.932565833674744e-05
heterozygous O 0 1.779259582690429e-05
mutations O 0 2.7227440568822203e-06
in O 0 1.2815538852350983e-08
16 O 0 1.645743026301716e-07
patients O 0 7.474626499970327e-07
, O 0 3.6289502514108563e-09
4 O 0 1.1329990279307367e-08
of O 0 5.5640323459726915e-09
whom O 0 6.659263931396708e-07
presented O 0 1.0094976943264555e-07
with O 0 3.396235399577563e-07
IDMS B-Disease 0 0.25693294405937195
. O 0 8.526657211405109e-07

One O 0 4.717319825431332e-06
male O 0 1.0676380043150857e-05
and O 0 4.345598725308264e-08
two O 0 1.1118760312456288e-07
female O 0 0.00015094548871275038
IDMS B-Disease 1 0.9990457892417908
patients O 0 0.00015818956308066845
with O 0 2.2920548303773103e-07
WT1 O 0 0.0026697563007473946
mutations O 0 0.0009708335855975747
underwent O 0 0.0001196704397443682
normal O 0 1.9677918317029253e-05
puberty O 0 0.0005928503233008087
. O 0 2.5895267299347324e-06

Two O 0 9.623816367820837e-06
mutations O 0 7.227735477499664e-05
associated O 0 4.654186511743319e-07
with O 0 2.8909139970778597e-08
IDMS B-Disease 0 0.01679166965186596
are O 0 3.209816412663713e-08
different O 0 5.769611011174902e-09
from O 0 1.1664319288229308e-08
those O 0 2.357336192915227e-08
described O 0 1.6026872629026911e-07
in O 0 1.2334052712503762e-07
DDS B-Disease 1 1.0
patients O 0 0.003293024841696024
. O 0 7.200539471341472e-07

No O 0 2.5843659386737272e-05
WT1 O 0 0.0004470796848181635
mutations O 0 0.00021752431348431855
were O 0 1.9413473637541756e-06
detected O 0 7.700556921008683e-07
in O 0 2.4830884015614174e-09
the O 0 2.8406375029987885e-09
six O 0 2.6371722583462542e-08
other O 0 1.303780461370252e-08
IDMS B-Disease 1 0.8572810292243958
patients O 0 4.477724360185675e-06
, O 0 5.440742079088068e-09
suggesting O 0 1.4406937509647832e-07
genetic O 0 5.638519269268727e-07
heterogeneity O 0 2.695728937851527e-07
of O 0 1.1023184143255094e-08
this O 0 1.086461267618688e-07
disease O 0 0.004863054025918245
. O 0 2.6749216885946225e-07

We O 0 5.601352768280776e-06
analyzed O 0 6.8169056248734705e-06
genotype O 0 7.742232264718041e-05
/ O 0 2.720208249229472e-05
phenotype O 0 9.262783351005055e-06
correlations O 0 2.5296542389696697e-06
, O 0 2.2487895989797835e-08
on O 0 5.3027395807703215e-09
the O 0 1.7106476235539958e-09
basis O 0 3.3870986015926974e-09
of O 0 1.0422650520425236e-09
the O 0 7.341147689743366e-09
constitution O 0 5.053928830989207e-09
of O 0 8.834864506646056e-10
a O 0 1.8507320120875193e-08
WT1 O 0 3.001935283464263e-06
mutation O 0 2.0112611309741624e-07
database O 0 2.5522643554154456e-08
of O 0 5.518511425606221e-09
84 O 0 4.652588927456236e-07
germ O 0 1.811253787309397e-05
- O 0 2.4954568289103918e-05
line O 0 1.4115171325101983e-05
mutations O 0 1.0416971463200753e-06
, O 0 1.5273577957941598e-09
to O 0 1.227203338949323e-09
compare O 0 3.423779304512209e-08
the O 0 1.6678937120317983e-09
distribution O 0 4.148464238795668e-09
and O 0 2.7916196021493533e-09
type O 0 1.3023057476857502e-07
of O 0 1.7653838391140653e-09
mutations O 0 9.767323945197859e-07
, O 0 2.1404256145274303e-09
according O 0 1.7645455097081708e-09
to O 0 2.2151702694372943e-09
the O 0 1.2504825619430449e-08
different O 0 2.065149402596944e-07
symptoms O 0 9.906625200528651e-05
. O 0 8.486308900046424e-08

This O 0 7.594434237034875e-07
demonstrated O 0 1.1621236808423419e-06
( O 0 4.667352015985671e-08
1 O 0 1.6950714609720308e-08
) O 0 2.3619526334783814e-09
the O 0 2.3841990604012153e-09
association O 0 1.4914851576008914e-08
between O 0 1.0362594338175768e-08
mutations O 0 2.3475419652640994e-07
in O 0 1.962165319113751e-09
exons O 0 2.866148065550078e-07
8 O 0 9.709930282042478e-08
and O 0 2.873290405602802e-08
9 O 0 1.0706848030395122e-07
and O 0 9.942223044845377e-08
DMS B-Disease 0 0.0027230121195316315
; O 0 2.206922466996275e-08
( O 0 4.7699653116239915e-09
2 O 0 6.5445879826597775e-09
) O 0 2.4777708773626728e-09
among O 0 7.000029889070447e-09
patients O 0 8.16459717611906e-08
with O 0 5.166363781228256e-09
DMS B-Disease 0 0.0008834779728204012
, O 0 4.290130473094678e-09
a O 0 2.627510875541361e-09
higher O 0 7.715013516929048e-09
frequency O 0 3.319282626534914e-08
of O 0 1.8100670962084564e-09
exon O 0 3.8155232573444664e-07
8 O 0 5.478942810555054e-08
mutations O 0 3.187034565144131e-07
among O 0 6.506452265853113e-09
46 O 0 1.0459741872637096e-07
, O 0 2.6805620834124966e-08
XY O 0 0.0070567927323281765
patients O 0 6.056129109310859e-07
with O 0 1.1987026482529473e-08
female O 0 9.780299023987027e-07
phenotype O 0 6.685046969323594e-07
than O 0 8.388683525595297e-09
among O 0 6.930178653163921e-09
46 O 0 1.1586339354607844e-07
, O 0 2.8261014861641343e-08
XY O 0 0.003928115125745535
patients O 0 7.590582526972867e-07
with O 0 1.1005915290240864e-08
sexual O 0 2.7851731942973856e-07
ambiguity O 0 2.823621230163553e-07
or O 0 2.8935678528796416e-06
male O 0 2.184037111874204e-05
phenotype O 0 3.7592931221297476e-06
; O 0 1.2910781777009106e-08
and O 0 9.397823674817118e-08
( O 0 1.687542194872549e-08
3 O 0 1.7042783184706423e-08
) O 0 5.611437536856556e-09
statistically O 0 2.0135027511969383e-07
significant O 0 1.8096329768013675e-08
evidence O 0 3.708482765318877e-08
that O 0 1.448287800798198e-08
mutations O 0 4.295110613838915e-07
in O 0 3.517011126774605e-09
exons O 0 6.563672627635242e-07
8 O 0 1.1270957855913366e-07
and O 0 2.4285872868290426e-08
9 O 0 5.505383171566791e-08
preferentially O 0 1.2743855393182457e-07
affect O 0 1.1981269665284344e-07
amino O 0 7.12946928160818e-08
acids O 0 7.1098029685856545e-09
with O 0 6.903183025208648e-10
different O 0 1.8891277431265507e-09
functions O 0 2.1193427457433245e-08
. O 0 1.5751240312056325e-08
. O 0 8.823993624673676e-08

The O 0 3.7812694699823624e-06
185delAG O 0 5.007118670619093e-05
BRCA1 O 0 0.00023326414520852268
mutation O 0 4.308124971430516e-06
originated O 0 2.5309714146715123e-07
before O 0 1.754893474981145e-08
the O 0 2.1080852619093093e-09
dispersion O 0 7.342942609511738e-08
of O 0 1.9141799256772174e-09
Jews O 0 4.503040429426619e-08
in O 0 1.5848510281912809e-09
the O 0 1.9242796245322324e-09
diaspora O 0 1.1240811836898956e-08
and O 0 7.311745875426823e-09
is O 0 1.9736734468978057e-09
not O 0 6.4694760659733674e-09
limited O 0 1.2284450789934453e-08
to O 0 2.990850944684098e-08
Ashkenazim O 0 9.689164289738983e-05
. O 0 2.969082686377078e-07

The O 0 2.907015641540056e-06
185delAG O 0 2.0866818886133842e-05
mutation O 0 4.083371095475741e-06
in O 0 2.6661115981596595e-08
BRCA1 O 0 3.892646782333031e-05
is O 0 1.704483132414225e-08
detected O 0 2.744863252246432e-07
in O 0 3.299876372153676e-09
Ashkenazi O 0 4.7879291287245e-07
Jews O 0 2.000370358246073e-08
both O 0 5.116820300798963e-09
in O 0 1.270252347751466e-08
familial B-Disease 1 0.9845247864723206
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999947547912598
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.84723875868076e-07
in O 0 4.425621646930722e-09
the O 0 8.061474154885673e-09
general O 0 2.0234329767276904e-08
population O 0 6.29893932568848e-08
. O 0 1.0944876294161077e-07

All O 0 4.244215233484283e-06
tested O 0 2.5938670660252683e-05
Ashkenazi O 0 2.971349204017315e-05
mutation O 0 5.437411346065346e-06
carriers O 0 7.00108671480848e-07
share O 0 9.033903580757396e-08
the O 0 8.370048654171569e-09
same O 0 2.2499952123666844e-08
allelic O 0 9.576945103617618e-07
pattern O 0 2.3184900328487856e-06
at O 0 1.8440604776515102e-07
the O 0 7.400873869300995e-08
BRCA1 O 0 0.0001597118389327079
locus O 0 4.4702512241201475e-05
. O 0 1.4088633406572626e-06

Our O 0 4.787011675944086e-06
previous O 0 1.3491426216205582e-06
study O 0 8.868234147030307e-08
showed O 0 4.879123025602894e-07
that O 0 1.6808725522565737e-09
this O 0 1.5400918318420054e-09
Ashkenazi O 0 1.6673957361490466e-06
mutation O 0 3.7185057522037823e-07
also O 0 2.273631594107428e-08
occurs O 0 8.452285094051604e-09
in O 0 2.20179607879345e-09
Iraqi O 0 5.165509833204851e-07
Jews O 0 1.0614752632420732e-08
with O 0 1.8012161762115397e-09
a O 0 8.156811226456284e-09
similar O 0 5.210483777773334e-08
allelic O 0 8.409187103097793e-06
pattern O 0 1.2109195267839823e-05
. O 0 3.6458183672039013e-07

We O 0 5.332802174962126e-06
extended O 0 2.806019665513304e-07
our O 0 5.320603690961434e-08
analysis O 0 1.0830160768193764e-08
to O 0 4.06831102139904e-09
other O 0 8.609560175898423e-09
non O 0 3.4891513678303454e-07
- O 0 5.618792329187272e-07
Ashkenazi O 0 1.5291242334569688e-06
subsets O 0 2.2513266628720885e-07
354 O 0 9.528282163273616e-08
of O 0 6.045416611755172e-09
Moroccan O 0 3.1785143050910847e-07
origin O 0 2.6884883652655844e-08
, O 0 3.7883669534721776e-09
200 O 0 7.110332322923796e-09
Yemenites O 0 4.197399334771035e-07
and O 0 1.0219269874767178e-08
150 O 0 2.1029540775430178e-08
Iranian O 0 1.123149431236925e-07
Jews O 0 1.8112046973328688e-07
. O 0 8.90831159949812e-08

Heteroduplex O 0 0.000299514940707013
analysis O 0 2.2955030090088258e-06
complemented O 0 2.7010246412828565e-06
by O 0 2.996320702663979e-08
direct O 0 7.34566043547602e-08
DNA O 0 2.017956859390324e-07
sequencing O 0 2.48443114969632e-07
of O 0 1.7347527858646572e-08
abnormally O 0 6.352906439133221e-06
migrating O 0 3.037431781649502e-07
bands O 0 8.527218824383453e-07
were O 0 4.035768768062553e-07
employed O 0 4.602522494678851e-06
. O 0 2.721088208090805e-07

Four O 0 6.2354456531465985e-06
of O 0 8.501959314344276e-08
Moroccan O 0 1.9983206129836617e-06
origin O 0 1.0763504576516425e-07
( O 0 1.6294379179271345e-08
1 O 0 5.165339267421132e-09
. O 0 9.224451202882733e-10
1 O 0 6.534135899016746e-09
% O 0 5.438522077128027e-09
) O 0 2.288523370808093e-09
and O 0 1.4062610631526695e-08
none O 0 3.355822641992745e-08
of O 0 7.045138916694782e-10
the O 0 7.298174953263015e-09
Yemenites O 0 3.961624770454364e-06
or O 0 1.3571560941727512e-07
Iranians O 0 4.72218921743206e-08
was O 0 2.6105478667659554e-08
a O 0 5.5142290733556365e-09
carrier O 0 6.241712213750361e-08
of O 0 1.4416696725305655e-09
the O 0 3.9424826070444396e-08
185delAG O 0 6.0762540670111775e-06
mutation O 0 4.076168806932401e-06
. O 0 3.2396968663306325e-07

BRCA1 O 0 0.003539350116625428
allelic O 0 6.341403059195727e-05
patterns O 0 7.404975622193888e-05
were O 0 6.878381100250408e-06
determined O 0 2.2460403670265805e-07
for O 0 6.706743604922849e-09
four O 0 2.0601563122113475e-08
of O 0 1.1564229573934881e-09
these O 0 5.43421885268458e-09
individuals O 0 4.7708565986681606e-09
and O 0 3.7822300846812595e-09
for O 0 1.1879996986152719e-09
12 O 0 1.1841454039540622e-08
additional O 0 2.8876721014370332e-09
non O 0 4.880113806393638e-07
- O 0 7.135957957871142e-07
Ashkenazi O 0 2.1354981072363444e-06
185delAG O 0 4.423438326739415e-07
mutation O 0 2.0717597237762675e-07
carriers O 0 2.376467023168516e-07
who O 0 2.932041240910621e-07
had O 0 0.00015381432604044676
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.6424247607792495e-06

Six O 0 4.4694756070384756e-05
non O 0 4.578306834446266e-05
- O 0 3.2560306863160804e-05
Ashkenazi O 0 3.667732744361274e-05
individuals O 0 1.2647046787606087e-07
shared O 0 3.938003345638208e-08
the O 0 1.1405770550254601e-08
common O 0 4.5938520543131744e-08
Ashkenazi O 0 3.0410828912863508e-06
haplotype O 0 9.633739637138206e-07
, O 0 1.7184710543460824e-08
four O 0 5.306627315349033e-08
had O 0 1.682397652302825e-07
a O 0 6.510064487486034e-09
closely O 0 5.44888720810377e-08
related O 0 1.5088389204720443e-08
pattern O 0 4.4979759650232154e-07
, O 0 3.872602682974957e-09
and O 0 8.73790462208035e-09
the O 0 1.2717165986941836e-08
rest O 0 7.393240508690724e-08
( O 0 1.574376007340561e-08
n O 0 5.02136299473932e-06
= O 0 4.279919448890723e-05
6 O 0 1.684921642208792e-07
) O 0 7.254098211006976e-09
displayed O 0 7.665424561764667e-08
a O 0 3.470208653766349e-08
distinct O 0 7.114546178854653e-07
BRCA1 O 0 0.00012710277223959565
allelic O 0 3.29737740685232e-05
pattern O 0 2.3891476303106174e-05
. O 0 1.375862325403432e-06

We O 0 8.54365589475492e-06
conclude O 0 3.710860880801192e-07
that O 0 6.601355018176491e-09
the O 0 2.225428374913463e-08
185delAG O 0 4.8536389840592165e-06
BRCA1 O 0 0.0001565184211358428
mutation O 0 1.857903043855913e-06
occurs O 0 2.946515564872243e-08
in O 0 1.4223267008617313e-09
some O 0 2.2023713963648106e-09
non O 0 2.1424406781989092e-07
- O 0 1.5357356915046694e-06
Ashkenazi O 0 5.335691639629658e-06
populations O 0 9.374907250503384e-08
at O 0 3.636296597164801e-08
rates O 0 9.419250091013964e-08
comparable O 0 4.1775038539526577e-08
with O 0 2.611233673732727e-09
that O 0 3.126322756230593e-09
of O 0 1.072869793006248e-08
Ashkenazim O 0 0.00010525668767513707
. O 0 2.6944385922433867e-07

The O 0 6.834186478954507e-07
majority O 0 2.9333781981222273e-07
of O 0 1.584428765966095e-08
Jewish O 0 6.790618840568641e-07
185delAG O 0 3.9687115531705786e-06
mutation O 0 2.3372911073238356e-06
carriers O 0 5.570421421907668e-07
have O 0 8.705332454894688e-09
a O 0 6.776384786633116e-09
common O 0 2.1354843227072706e-08
allelic O 0 1.5006642115622526e-06
pattern O 0 7.097622983565088e-06
, O 0 1.2520028569440456e-08
supporting O 0 4.889272631203312e-08
the O 0 8.424006381346771e-09
founder O 0 8.501505277536126e-08
effect O 0 1.4799799608056219e-08
notion O 0 1.4837391759670027e-08
, O 0 2.6519804130487046e-09
but O 0 3.4375386981366773e-09
dating O 0 5.437208017156081e-08
the O 0 7.291413250953838e-09
mutations O 0 1.8524065126257483e-07
origin O 0 6.211780867459993e-09
to O 0 2.0250225940543487e-09
an O 0 2.7642161892771355e-09
earlier O 0 2.1811734640664326e-08
date O 0 2.7802391500131307e-08
than O 0 5.536951341866825e-09
currently O 0 2.827476208722146e-08
estimated O 0 5.561000904208413e-08
. O 0 8.217842406565978e-08

However O 0 7.2420980359311216e-06
, O 0 6.342678204873664e-08
the O 0 7.068279739286254e-09
different O 0 1.0896568092277903e-08
allelic O 0 4.91988089379447e-07
pattern O 0 8.36211995647318e-07
at O 0 1.0162768404597955e-07
the O 0 2.0356887731054485e-08
BRCA1 O 0 1.489157057221746e-05
locus O 0 1.0181796596953063e-06
even O 0 4.707629841504968e-08
in O 0 2.0733215144730366e-09
some O 0 2.2230088880803578e-09
Jewish O 0 5.848244910566791e-08
mutation O 0 2.108080963125758e-07
carriers O 0 1.0461537414130362e-07
, O 0 4.9525294976149326e-09
might O 0 1.2123236636796264e-08
suggest O 0 2.3688295769375145e-08
that O 0 1.8547313684891265e-09
the O 0 7.582708683173678e-09
mutation O 0 7.000085702202341e-07
arose O 0 6.795180240715126e-08
independently O 0 3.014331753092847e-07
. O 0 2.319089809077468e-08
. O 0 1.1286275025668147e-07

Crystal O 0 0.00011828701826743782
structure O 0 2.422135366941802e-06
of O 0 5.6024358485728953e-08
the O 0 3.667243504423823e-07
hemochromatosis B-Disease 1 1.0
protein O 0 4.149719643464778e-06
HFE O 0 0.0001323524775216356
and O 0 8.584311927961608e-08
characterization O 0 2.9802765766362427e-07
of O 0 4.546378828962361e-09
its O 0 6.212930170335085e-09
interaction O 0 5.88307251803144e-08
with O 0 3.382045932198707e-08
transferrin O 0 8.888273441698402e-06
receptor O 0 5.440664153866237e-06
. O 0 5.107579568175424e-07

HFE O 0 0.007743495516479015
is O 0 5.249447667665663e-07
an O 0 6.97460436072106e-08
MHC O 0 9.331579349236563e-06
- O 0 2.3148929813032737e-06
related O 0 7.668378998459957e-08
protein O 0 4.0420541580488134e-08
that O 0 1.8319067374150677e-09
is O 0 1.8992547534679716e-09
mutated O 0 3.3509103047890676e-08
in O 0 2.2218984430111277e-09
the O 0 4.451546331551981e-08
iron B-Disease 1 0.997961163520813
- I-Disease 1 0.9999969005584717
overload I-Disease 1 0.9999938011169434
disease I-Disease 1 0.9999998807907104
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 2.2331523723551072e-05

HFE O 0 0.005846248473972082
binds O 0 3.4278167731827125e-05
to O 0 8.311863552989962e-07
transferrin O 0 1.5560892279609106e-05
receptor O 0 7.38527296562097e-06
( O 0 2.1672381933512952e-07
TfR O 0 5.015328042645706e-06
) O 0 2.1815271367131572e-08
and O 0 8.21161805220072e-09
reduces O 0 5.094930344284876e-08
its O 0 2.2449058167950398e-09
affinity O 0 2.1677069028669393e-08
for O 0 1.5282852317000106e-08
iron O 0 8.400388469453901e-05
- O 0 1.1536360943864565e-05
loaded O 0 2.384911113040289e-06
transferrin O 0 8.608617463323753e-07
, O 0 1.4811151416438406e-08
implicating O 0 3.2800444387248717e-06
HFE O 0 5.2732371841557324e-05
in O 0 1.5011838172540592e-07
iron O 0 7.199422543635592e-05
metabolism O 0 1.529738619865384e-05
. O 0 5.26217831975373e-07

The O 0 7.924801138869952e-06
2 O 0 8.543052899767645e-06
. O 0 1.2800962849723874e-06

6 O 0 0.0002231257822131738
A O 0 2.7732435228244867e-06
crystal O 0 4.595903646986699e-06
structure O 0 2.7067264340985275e-07
of O 0 1.2577399566282566e-08
HFE O 0 0.0001725804468151182
reveals O 0 3.3540155186528864e-07
the O 0 3.2940847827234165e-09
locations O 0 4.5975863116609617e-08
of O 0 3.613232379962028e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 0.005416670814156532
and O 0 8.95837075631789e-08
a O 0 7.346417163489605e-08
patch O 0 0.00023897401115391403
of O 0 4.963878197372651e-09
histidines O 0 1.57214424234553e-06
that O 0 4.650918317139485e-09
could O 0 4.0535191203616705e-08
be O 0 5.7615392456966674e-09
involved O 0 6.65792887488692e-09
in O 0 6.729911739000727e-09
pH O 0 5.704091745428741e-05
- O 0 5.9624471759889275e-06
dependent O 0 1.2672463753915508e-06
interactions O 0 8.148081178660505e-07
. O 0 2.9689354619222286e-07

We O 0 9.233405762643088e-06
also O 0 2.6110765816156345e-07
demonstrate O 0 3.279555187418737e-07
that O 0 2.6430740263094776e-08
soluble O 0 1.3345379556994885e-06
TfR O 0 1.23909176181769e-05
and O 0 9.041143300692056e-08
HFE O 0 3.648674828582443e-05
bind O 0 1.2069476724718697e-06
tightly O 0 1.6856463389558485e-06
at O 0 9.346732809945024e-08
the O 0 5.1982906867920065e-09
basic O 0 5.9392878171138364e-08
pH O 0 2.3911871949167107e-07
of O 0 1.0550297302458489e-09
the O 0 5.900735455810491e-09
cell O 0 1.271386054213508e-07
surface O 0 1.0629946700646542e-06
, O 0 8.459815958872241e-09
but O 0 4.259261832118e-09
not O 0 8.227969416907399e-09
at O 0 5.937928548860327e-08
the O 0 2.318364700215625e-08
acidic O 0 1.1007448392774677e-06
pH O 0 1.1115330380562227e-06
of O 0 7.421649961258936e-09
intracellular O 0 4.565883045870578e-06
vesicles O 0 9.033814421854913e-06
. O 0 8.092263215075945e-07

TfR O 1 0.7469019889831543
HFE O 0 0.013559973798692226
stoichiometry O 0 0.0001153932826127857
( O 0 4.2452229536138475e-06
2 O 0 3.53065729541413e-07
1 O 0 3.3270918464722854e-08
) O 0 6.721855516644837e-09
differs O 0 2.597733050890838e-08
from O 0 1.977306851586036e-08
TfR O 0 1.0570652193564456e-05
transferrin O 0 8.280034649033041e-07
stoichiometry O 0 2.9567857495749195e-07
( O 0 3.704933604353755e-08
2 O 0 3.4666825854401395e-08
2 O 0 3.364320733112436e-08
) O 0 5.155162074998998e-09
, O 0 2.2611106320624685e-09
implying O 0 2.6936930908050272e-08
a O 0 2.0324986138575696e-09
different O 0 1.5772576578143571e-09
mode O 0 3.256746339275196e-08
of O 0 1.9382477844942514e-09
binding O 0 3.066990217348575e-08
for O 0 6.65846178193874e-09
HFE O 0 1.361261365673272e-05
and O 0 5.276006831422819e-08
transferrin O 0 6.053980996512109e-07
to O 0 3.4587834818466945e-08
TfR O 0 6.656224741163896e-06
, O 0 1.5148742704695906e-08
consistent O 0 6.83511345300758e-08
with O 0 4.097639116906748e-09
our O 0 3.882996324477972e-08
demonstration O 0 4.539310438644861e-08
that O 0 8.855975508481606e-09
HFE O 0 5.353087544790469e-06
, O 0 1.5874658032544176e-08
transferrin O 0 1.722527827041631e-07
, O 0 1.0598487421020764e-08
and O 0 3.538375636935598e-08
TfR O 0 6.7395867517916486e-06
form O 0 3.913219615014896e-08
a O 0 7.163656334796542e-08
ternary O 0 2.656488049979089e-06
complex O 0 2.1038986233179457e-06
. O 0 6.637617957494513e-07

Identification O 0 8.190320841094945e-06
of O 0 1.4957133487314422e-07
three O 0 8.514211202736988e-08
novel O 0 1.5336237879637338e-07
mutations O 0 1.1401199344618362e-06
and O 0 1.1021670687227925e-08
a O 0 7.004116842068697e-09
high O 0 4.6887489446589825e-08
frequency O 0 1.25194119959815e-07
of O 0 2.456018721730402e-09
the O 0 1.2000339388862358e-08
Arg778Leu O 0 2.077066710626241e-06
mutation O 0 4.94439632348076e-07
in O 0 7.9484294701615e-09
Korean O 0 3.1295185181079432e-06
patients O 0 5.026734584134829e-07
with O 0 1.0060915656140423e-07
Wilson B-Disease 0 0.004116365686058998
disease I-Disease 0 0.0010687352623790503
. O 0 2.9019943781349866e-07

Four O 0 3.308508894406259e-05
mutations O 0 9.57374504650943e-05
- O 0 2.4441525965812616e-05
- O 0 1.0491352441022173e-05
R778L O 0 2.7266055440122727e-06
, O 0 1.7719697709139837e-08
A874V O 0 2.3595364950779185e-07
, O 0 4.862216851364565e-09
L1083F O 0 9.281889390422293e-08
, O 0 3.246201973894358e-09
and O 0 6.556307052818511e-09
2304delC O 0 5.907207878408371e-07
- O 0 1.2745475714837085e-06
- O 0 5.626540655612189e-07
in O 0 6.606140967591045e-09
the O 0 7.189798090223576e-09
copper O 0 3.412374098843429e-07
- O 0 1.205995801001336e-07
transporting O 0 8.480451185732818e-08
enzyme O 0 8.735209178212244e-08
, O 0 3.832321571195507e-09
P O 0 7.028535264907987e-07
- O 0 2.219735506514553e-07
type O 0 1.0439705420139944e-06
ATPase O 0 5.2268701438151766e-06
( O 0 6.738699909192292e-08
ATP7B O 0 2.036624664469855e-06
) O 0 6.429031085275483e-09
, O 0 2.16885975845571e-09
were O 0 1.932180460073596e-08
identified O 0 6.35040109386864e-08
in O 0 4.454856483704361e-09
Korean O 0 4.354329121269984e-06
Patients O 0 2.3354232325800695e-07
with O 0 4.60631106591336e-08
Wilson B-Disease 0 0.0008664077031426132
disease I-Disease 0 0.00012466275074984878
. O 0 1.8147510161270475e-07

Arg778Leu O 0 0.0004782258765771985
, O 0 7.95125117747375e-07
the O 0 2.1625531587687874e-08
most O 0 1.0505043945840953e-08
frequently O 0 4.3330436483302037e-07
reported O 0 1.8741724261417403e-07
mutation O 0 7.523129141873142e-08
of O 0 5.077240294859564e-10
this O 0 8.059501399593216e-10
enzyme O 0 7.208571872752145e-08
, O 0 9.040690862605061e-09
was O 0 7.0574380117705e-08
found O 0 1.0674850337011321e-08
in O 0 8.90069407066818e-10
six O 0 3.912725254906491e-09
of O 0 5.201253872044731e-10
eight O 0 3.5810685972137435e-08
unrelated O 0 2.0575338055550674e-07
patients O 0 8.935469963944342e-08
studied O 0 1.7898333481980444e-08
, O 0 1.1345143713370476e-09
an O 0 9.740583895023747e-10
allele O 0 9.128405054070754e-08
frequency O 0 1.7163819165944005e-07
of O 0 1.884464673196362e-08
37 O 0 1.111156848310202e-06
. O 0 4.567027360735665e-07

5 O 0 2.9613916922244243e-05
% O 0 2.246330495836446e-06
, O 0 2.0938687228522213e-08
which O 0 7.641597576935055e-09
is O 0 1.3034241463927287e-09
considerably O 0 1.4186212204947424e-08
higher O 0 7.22266202402011e-09
than O 0 1.549473216400088e-09
those O 0 1.8433539139550703e-09
in O 0 1.05684039297671e-09
other O 0 3.464770248484683e-09
Asian O 0 1.1011274381189651e-07
populations O 0 2.516792108053778e-07
. O 0 7.137523994060757e-08

The O 0 3.4625506941665662e-06
novel O 0 2.5638332772359718e-06
single O 0 1.6772116850916063e-06
nucleotide O 0 5.769878043793142e-06
deletion O 0 4.584574980981415e-06
, O 0 8.110428240115652e-08
2304delC O 0 1.518608314654557e-06
, O 0 2.3285661399086166e-08
was O 0 1.5395808361517993e-07
found O 0 1.8780847099719722e-08
in O 0 5.091100430121287e-09
one O 0 8.42855811811205e-08
patient O 0 2.249891622341238e-06
. O 0 1.473845259170048e-07

Since O 0 2.549305008869851e-06
a O 0 2.9930998834970524e-07
mutation O 0 2.1708201529690996e-06
at O 0 2.3133870286073943e-07
cDNA O 0 3.2045670650404645e-06
nucleotide O 0 1.696845720289275e-05
2302 O 0 5.257334851194173e-05
( O 0 1.5131712416405207e-07
2302insC O 0 1.0264649290547823e-06
) O 0 2.97394464610079e-08
had O 0 9.194085919261852e-07
been O 0 6.868398827464262e-08
previously O 0 8.213313407168243e-08
described O 0 2.056411041451156e-08
, O 0 5.561779925500332e-10
this O 0 1.0483135193251059e-10
region O 0 1.4899944611457272e-09
of O 0 5.056993157559475e-10
the O 0 1.0171976150274986e-08
ATP7B O 0 6.432193913497031e-06
gene O 0 2.613413130347908e-07
may O 0 2.705123058888148e-08
be O 0 4.3755132850265e-09
susceptible O 0 1.080305551681704e-07
to O 0 4.867719560763817e-09
gene O 0 2.1696673684346024e-06
rearrangements O 0 1.8095082850777544e-05
causing O 0 0.00015032925875857472
Wilson B-Disease 0 0.003870869055390358
disease I-Disease 0 0.009712062776088715
. O 0 5.078844083072909e-07

Disruption O 0 5.943040014244616e-05
of O 0 3.628779552400374e-07
splicing O 0 9.697983841761015e-06
regulated O 0 2.7912888072023634e-06
by O 0 3.019843930474053e-08
a O 0 5.747317644022587e-08
CUG O 0 1.487452391302213e-05
- O 0 9.201612556353211e-07
binding O 0 3.775680852413643e-07
protein O 0 6.47754177407478e-07
in O 0 2.2998322890543932e-07
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
. O 0 2.459696361256647e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9996076226234436
DM B-Disease 1 1.0
) O 0 1.5449091733898968e-05
is O 0 1.411990382393924e-07
caused O 0 3.6207632092555286e-07
by O 0 6.367548266439371e-09
a O 0 2.9538421486563493e-08
CTG O 0 1.4673702253276133e-06
expansion O 0 2.378119035029158e-08
in O 0 3.738857667912043e-09
the O 0 3.799033088114356e-09
3 O 0 3.4872410736852544e-08
untranslated O 0 1.0642230563462363e-06
region O 0 4.2910492936698574e-08
of O 0 1.1754727857749003e-08
the O 0 3.9133624341047835e-07
DM B-Disease 1 0.9999998807907104
gene O 0 1.504426199971931e-05
. O 0 7.403548352158396e-07

One O 0 1.3889866750105284e-06
model O 0 1.4764154911972582e-06
of O 0 2.3619092814897158e-07
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 7.774080586386845e-06
suggests O 0 2.0013709445265704e-07
that O 0 5.426233684602266e-09
RNAs O 0 2.3259967463218345e-07
from O 0 9.280787693910497e-09
the O 0 6.743917868590188e-09
expanded O 0 4.112925822141733e-08
allele O 0 1.6518816892130417e-07
create O 0 1.3992511149751863e-08
a O 0 9.130073586050003e-09
gain O 0 3.8213096331674024e-07
- O 0 1.0266821846016683e-06
of O 0 6.856968326474089e-09
- O 0 2.1273976926750038e-06
function O 0 3.7704626976164946e-08
mutation O 0 4.5768242529220515e-08
by O 0 8.500654069543145e-10
the O 0 1.8618058206243404e-09
inappropriate O 0 5.563844140965557e-08
binding O 0 2.0336512918106564e-08
of O 0 9.21330289838096e-10
proteins O 0 9.775206422091287e-09
to O 0 7.0356622750011866e-09
the O 0 7.395172474389256e-08
CUG O 0 5.320983109413646e-05
repeats O 0 4.896700374956708e-06
. O 0 3.596572923925123e-07

Data O 0 6.9288662416511215e-06
presented O 0 5.995799483571318e-07
here O 0 4.2696914448470125e-08
indicate O 0 7.928582590466249e-08
that O 0 2.7045079509235848e-09
the O 0 5.691569882060321e-09
conserved O 0 1.2544630578759097e-07
heterogeneous O 0 4.6957293875493633e-07
nuclear O 0 1.11717713480175e-06
ribonucleoprotein O 0 2.3015443275653524e-06
, O 0 3.2147667639037536e-08
CUG O 0 3.4655272429517936e-06
- O 0 6.781895081076073e-07
binding O 0 2.0413368417848687e-07
protein O 0 2.248249728609153e-07
( O 0 7.759732767453897e-08
CUG O 0 8.223443728638813e-06
- O 0 9.727121323521715e-06
BP O 0 4.247924152878113e-06
) O 0 5.090129651108555e-09
, O 0 1.9765402647919927e-09
may O 0 1.8434041848536253e-08
mediate O 0 2.512571199986269e-07
the O 0 3.1717554804799875e-08
trans O 0 7.991816914909577e-07
- O 0 4.848217031394597e-06
dominant O 0 9.79892433861096e-07
effect O 0 1.5276732767688372e-08
of O 0 1.154664142077877e-09
the O 0 1.1177292869035682e-08
RNA O 0 5.927314532527816e-07
. O 0 1.5970861966252414e-07

CUG O 0 0.2037803679704666
- O 0 0.0996965691447258
BP O 0 0.0004146677383687347
was O 0 5.646515432999877e-07
found O 0 3.8700424198623296e-08
to O 0 3.4935705439664844e-09
bind O 0 7.30589420072647e-08
to O 0 5.835183003455313e-09
the O 0 2.283749722664652e-08
human O 0 1.7034408017480018e-07
cardiac O 0 1.4919703062332701e-05
troponin O 0 2.570311880845111e-05
T O 0 4.28016392106656e-05
( O 0 4.9514365940694915e-08
cTNT O 0 4.3203760924370727e-07
) O 0 1.4981569762539948e-08
pre O 0 3.0914720809960272e-06
- O 0 3.479007773421472e-06
messenger O 0 3.355035858021438e-07
RNA O 0 1.7813979980019212e-07
and O 0 6.850955358572719e-09
regulate O 0 8.973095333431047e-08
its O 0 1.58819855045067e-08
alternative O 0 1.2776493463206862e-07
splicing O 0 3.341692718095146e-06
. O 0 4.2909223907372507e-07

Splicing O 0 0.00011031151370843872
of O 0 7.9724054558028e-07
cTNT O 0 3.622263830038719e-05
was O 0 2.004768475671881e-06
disrupted O 0 1.7964115613722242e-05
in O 0 3.712736997840693e-07
DM B-Disease 1 1.0
striated O 0 0.0008574720122851431
muscle O 0 7.651266059838235e-05
and O 0 1.0455075027948624e-07
in O 0 1.6429822835561936e-08
normal O 0 4.6971541678431095e-07
cells O 0 1.523988117924091e-07
expressing O 0 2.8444883781730823e-08
transcripts O 0 1.3782455710042996e-07
that O 0 1.4614157883841017e-08
contain O 0 8.250381711150112e-07
CUG O 0 0.00019899728067684919
repeats O 0 1.3839826351613738e-05
. O 0 6.214236805135442e-07

Altered O 0 7.138312503229827e-05
expression O 0 1.5459426094821538e-06
of O 0 7.345716568352145e-08
genes O 0 9.959768476619502e-07
regulated O 0 1.4352416428664583e-06
posttranscriptionally O 0 1.996023684114334e-06
by O 0 3.1097911801225564e-08
CUG O 0 8.00156340119429e-05
- O 0 4.1100654925685376e-05
BP O 0 1.2835563211410772e-05
therefore O 0 7.128707579795446e-08
may O 0 3.606347220852513e-08
contribute O 0 2.864819137471386e-08
to O 0 6.192099277768648e-08
DM B-Disease 1 1.0
pathogenesis O 0 1.0383475455455482e-05
. O 0 6.087653048325592e-08
. O 0 1.748260984868466e-07

Identification O 0 3.414341335883364e-06
of O 0 1.0292669117006881e-07
a O 0 1.67476500223529e-07
novel O 0 4.986584372090874e-07
nonsense O 0 4.371083832666045e-06
mutation O 0 7.61772639634728e-07
and O 0 1.013251260673087e-08
a O 0 8.215080171680711e-09
missense O 0 7.416650191771623e-07
substitution O 0 3.021699512828491e-08
in O 0 4.326500935292188e-09
the O 0 1.6213526521369204e-08
vasopressin O 0 4.7035641159709485e-07
- O 0 2.8970080165890977e-06
neurophysin O 0 3.4556624086690135e-06
II O 0 6.920802206877852e-07
gene O 0 1.491767420702672e-07
in O 0 8.966880571392721e-09
two O 0 3.9579205690642993e-08
Spanish O 0 2.0763754946528934e-06
kindreds O 0 1.4931373698345851e-05
with O 0 5.319309934748162e-07
familial B-Disease 1 0.9995623230934143
neurohypophyseal I-Disease 1 0.9999208450317383
diabetes I-Disease 1 0.9999991655349731
insipidus I-Disease 1 0.9966347813606262
. O 0 1.016126225295011e-05

Familial B-Disease 1 0.9999957084655762
neurohypophyseal I-Disease 1 0.9999951124191284
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999994039535522
( O 0 0.05225296691060066
FNDI B-Disease 1 1.0
) O 0 2.3945486304910446e-07
is O 0 1.6592480278632138e-08
an O 0 4.205934445167259e-08
autosomal B-Disease 1 0.9999945163726807
dominant I-Disease 1 0.9999979734420776
disease I-Disease 1 0.9999608993530273
caused O 0 1.1348608495609369e-05
by O 0 1.227557930860712e-07
deficiency O 0 0.008002767339348793
in O 0 7.655398093220356e-09
the O 0 7.09042708990637e-08
antidiuretic O 0 0.0002810205623973161
hormone O 0 1.0105038199981209e-05
arginine O 0 1.960800773304072e-06
vasopressin O 0 1.1541767435119255e-06
( O 0 3.137471082936827e-08
AVP O 0 5.308495474309893e-07
) O 0 4.472974879377034e-09
encoded O 0 1.3228754980332269e-08
by O 0 6.0256160061555875e-09
the O 0 1.7275546326800395e-08
AVP O 0 4.268676093488466e-06
- O 0 2.244895540570724e-06
neurophysin O 0 5.002439593226882e-06
II O 0 4.008074483863311e-06
( O 0 8.175037180535583e-08
AVP O 0 8.359756066056434e-06
- O 0 9.731390491651837e-06
NPII O 0 8.108106158033479e-06
) O 0 1.7255919360081862e-08
gene O 0 1.2972583363080048e-07
on O 0 5.535887837027076e-08
chromosome O 0 3.914931585313752e-05
20p13 O 0 1.047233945428161e-05
. O 0 6.560462111337984e-07

In O 0 7.1461192874267e-07
this O 0 1.3889024153002083e-08
study O 0 2.8953726527447543e-08
, O 0 6.880839453771159e-09
we O 0 1.2806204985338354e-08
analyzed O 0 3.548750626691799e-08
two O 0 1.6332029062482434e-08
families O 0 8.237898185825543e-08
with O 0 3.35657759364949e-08
FNDI B-Disease 1 0.9999958276748657
using O 0 3.442113438723027e-08
direct O 0 3.369997614299791e-08
automated O 0 5.937820333201671e-06
fluorescent O 0 1.382471509714378e-06
, O 0 1.2293217110936894e-08
solid O 0 2.8223101367075287e-07
phase O 0 8.408519391878144e-08
, O 0 2.6595698088272002e-08
single O 0 1.2213076843181625e-06
- O 0 1.468082587052777e-06
stranded O 0 2.776387475478259e-07
DNA O 0 6.856500789353959e-08
sequencing O 0 9.388005395294385e-08
of O 0 1.3272225096727652e-08
PCR O 0 7.704385097895283e-06
- O 0 4.047372840432217e-06
amplified O 0 1.4295138498710003e-05
AVP O 0 4.2537067201919854e-05
- O 0 1.528682878415566e-05
NPII O 0 4.5743701775791124e-05
DNA O 0 7.371572792180814e-06
. O 0 6.930537779226142e-07

In O 0 8.501697266183328e-07
one O 0 2.163007017941254e-08
of O 0 1.4775254353338596e-09
the O 0 7.426323112014188e-09
families O 0 2.585888481121401e-08
, O 0 4.634960415472733e-09
affected O 0 3.306386275880868e-08
individuals O 0 1.9253405536545642e-09
presented O 0 2.9357769548710166e-09
a O 0 9.571447634471042e-09
novel O 0 3.910630752557154e-08
nonsense O 0 4.221896858780383e-07
mutation O 0 1.1066374128176903e-07
in O 0 2.5169630823995703e-09
exon O 0 1.173039763102679e-07
3 O 0 1.4350697519205369e-08
of O 0 1.802797133798606e-09
the O 0 9.787183508080943e-09
gene O 0 1.6914776779231033e-07
, O 0 3.0722462351917557e-09
consisting O 0 5.893492360797836e-09
in O 0 1.6871423147435394e-09
a O 0 1.2068259280795246e-08
G O 0 7.065066824907262e-07
to O 0 1.945653060886343e-08
T O 0 7.0791020334581845e-06
transition O 0 9.509236065241566e-08
at O 0 7.79157502961425e-08
nucleotide O 0 7.95188839219918e-07
2101 O 0 1.0749620287242578e-06
, O 0 8.903550785532843e-09
which O 0 5.072190223387452e-09
produces O 0 6.748061220918089e-09
a O 0 2.414733968336691e-09
stop O 0 2.7775676869623567e-08
signal O 0 6.061178936533906e-08
in O 0 5.015154069809569e-09
codon O 0 4.050107804687286e-07
82 O 0 2.3729498366265034e-07
( O 0 3.2120212267727766e-08
Glu O 0 1.0297937478753738e-05
) O 0 1.960101414510973e-08
of O 0 2.7554374781857405e-08
NPII O 0 2.8305032174102962e-05
. O 0 3.1941243605615455e-07

The O 0 5.525235337699996e-06
premature O 0 2.5285875381086953e-05
termination O 0 2.3142044938140316e-06
eliminates O 0 1.1472006917756516e-06
part O 0 4.9887677988635915e-08
of O 0 5.369618083506111e-09
the O 0 5.0032802789701236e-08
C O 0 1.4475883290288039e-05
- O 0 1.581483957124874e-06
terminal O 0 1.8824427172603464e-07
domain O 0 2.5723213781247978e-08
of O 0 5.782986089997166e-09
NPII O 0 2.447874067001976e-06
, O 0 3.501489098667321e-09
including O 0 2.2802448818026733e-09
a O 0 5.792236468238343e-09
cysteine O 0 3.442159268729483e-08
residue O 0 1.253102226428382e-07
in O 0 4.081663895760812e-09
position O 0 1.9887943381036166e-07
85 O 0 2.4874603710145493e-08
, O 0 2.855282232872014e-09
which O 0 3.055241615257387e-09
could O 0 2.3305567253828485e-08
be O 0 2.239017415917033e-09
involved O 0 3.591964059523889e-09
in O 0 1.2228013046566844e-09
the O 0 5.876722219966268e-09
correct O 0 1.126716938415484e-06
folding O 0 8.952278562901483e-07
of O 0 8.945459484266394e-09
the O 0 1.1854260151267226e-07
prohormone O 0 6.97315190336667e-05
. O 0 5.960407065686013e-07

In O 0 1.1932322649954585e-06
the O 0 7.407567181871855e-08
second O 0 4.7339761977127637e-07
family O 0 6.087734050197469e-08
, O 0 1.949039374338213e-09
a O 0 4.6276285026181085e-09
G279A O 0 4.079409166024561e-08
substitution O 0 7.155241288359093e-09
at O 0 4.277778131722698e-08
position O 0 6.855206038380857e-07
- O 0 3.5156352851117845e-07
1 O 0 5.913038947369387e-09
of O 0 4.0710804172228165e-10
the O 0 2.1049755272173343e-09
signal O 0 1.6951985060131847e-07
peptide O 0 1.1023168156043539e-07
was O 0 3.0404191164734584e-08
observed O 0 7.599301632410516e-09
in O 0 7.235716470432862e-10
all O 0 4.080885851465155e-09
affected O 0 1.2705751828434586e-07
individuals O 0 3.154404026872726e-08
. O 0 8.797408668215212e-08

This O 0 2.4689772999408888e-06
missense O 0 7.955829642014578e-05
mutation O 0 1.838173375290353e-05
, O 0 9.041781368068769e-08
which O 0 5.9584859712913385e-08
replaces O 0 3.3838766739791026e-06
Ala O 0 1.063052059180336e-05
with O 0 4.1183895405083604e-08
Thr O 0 3.892264430760406e-05
, O 0 1.1107817776689899e-08
is O 0 1.3045832192304374e-09
frequent O 0 1.1019384515975617e-07
among O 0 3.376277675215533e-07
FNDI B-Disease 1 1.0
patients O 0 3.0023793442524038e-05
and O 0 1.540445104808441e-08
is O 0 2.7922586465223276e-09
thought O 0 1.1376222630588018e-08
to O 0 1.7667615148653226e-09
reduce O 0 5.501069111346624e-08
the O 0 2.215867489496759e-09
efficiency O 0 2.127877074542539e-08
of O 0 5.985772988381655e-10
cleavage O 0 8.332673360200715e-07
by O 0 1.3461653125546036e-08
signal O 0 9.642185432312544e-07
peptidases O 0 3.6164433367957827e-06
. O 0 3.6802902059207554e-08
. O 0 1.7063494794911094e-07

Genetic O 0 0.00017398021009285003
heterogeneity O 0 2.830530320352409e-05
of O 0 4.0499071474187076e-07
Saethre B-Disease 1 0.7984644770622253
- I-Disease 1 0.9999202489852905
Chotzen I-Disease 1 0.999988317489624
syndrome I-Disease 1 1.0
, O 0 3.136609549869718e-08
due O 0 6.069866742564045e-08
to O 0 2.3759881173646136e-08
TWIST O 0 5.807134130009217e-06
and O 0 1.5568377875752049e-06
FGFR O 0 0.0036607456859201193
mutations O 0 5.9713198425015435e-05
. O 0 4.1699738062561664e-07

Thirty O 0 0.00055144407087937
- O 0 0.0003200183855369687
two O 0 3.120605640560825e-07
unrelated O 0 1.5953979755067849e-06
patients O 0 1.7201685977852321e-06
with O 0 2.220656991624992e-09
features O 0 5.2846989007093725e-08
of O 0 4.469685066510465e-08
Saethre B-Disease 1 0.980878472328186
- I-Disease 1 0.9999673366546631
Chotzen I-Disease 1 0.9999285936355591
syndrome I-Disease 1 0.9999991655349731
, O 0 6.130437046891757e-09
a O 0 1.6000871738697242e-08
common O 0 2.4529545044060796e-06
autosomal B-Disease 1 0.9845987558364868
dominant I-Disease 0 0.37044984102249146
condition I-Disease 0 1.822858575906139e-05
of O 0 1.3802035958576653e-08
craniosynostosis B-Disease 0 0.12198935449123383
and O 0 2.3407551452692132e-06
limb B-Disease 0 0.20717021822929382
anomalies I-Disease 0 0.00023832368606235832
, O 0 7.093200338204042e-08
were O 0 1.4473094722688984e-07
screened O 0 4.2470716721254576e-07
for O 0 9.064069494968408e-09
mutations O 0 1.2146704193582991e-06
in O 0 7.572706905989435e-09
TWIST O 0 1.4760875046704314e-06
, O 0 7.040927840762379e-08
FGFR2 O 0 1.5935040210024454e-05
, O 0 3.596222697410667e-08
and O 0 1.6316842277319665e-07
FGFR3 O 0 5.650677121593617e-05
. O 0 2.7357324938748206e-07

Nine O 0 2.3814385713194497e-05
novel O 0 2.9493155579984887e-06
and O 0 1.849864474934293e-07
three O 0 3.2263216098726843e-07
recurrent O 0 0.00011040769459214061
TWIST O 0 4.6292996557895094e-05
mutations O 0 0.0013818519655615091
were O 0 2.925861736002844e-06
found O 0 6.836312138602807e-08
in O 0 1.5434626021715303e-08
12 O 0 1.6087575716028368e-07
families O 0 2.4007704269024543e-07
. O 0 2.180766500714526e-07

Seven O 0 3.165827365592122e-05
families O 0 3.1144263630267233e-06
were O 0 5.26769156294904e-07
found O 0 2.3251843117577664e-08
to O 0 7.066796925414565e-09
have O 0 3.775961232577174e-08
the O 0 1.4661592828701941e-08
FGFR3 O 0 6.8241515691624954e-06
P250R O 0 9.713761528473697e-07
mutation O 0 1.9642862980617792e-07
, O 0 1.7598198454038538e-09
and O 0 3.6081484466876645e-09
one O 0 6.575267441633059e-09
individual O 0 1.4186590568954216e-08
was O 0 1.9957273877935222e-07
found O 0 6.136180452642748e-09
to O 0 3.9210630298214255e-09
have O 0 4.2778921738317877e-08
an O 0 9.157664848657987e-09
FGFR2 O 0 3.0081055228947662e-05
VV269 O 0 2.2987321699474705e-06
- O 0 1.695312903393642e-06
270 O 0 7.902174843366083e-07
deletion O 0 1.4264851415646262e-05
. O 0 8.276481935354241e-07

To O 0 7.934510222185054e-07
date O 0 3.825554131253739e-07
, O 0 8.897234948790356e-09
our O 0 1.3031662859930293e-08
detection O 0 1.5832269184556935e-07
rate O 0 1.8238164045669691e-07
for O 0 2.6411224318678705e-09
TWIST O 0 1.0301562269887654e-06
or O 0 4.138817359944369e-07
FGFR O 0 2.5046452719834633e-05
mutations O 0 2.2423898826673394e-06
is O 0 4.5585437646877836e-09
68 O 0 4.9974723026480206e-08
% O 0 6.123261897528209e-09
in O 0 2.5431177164136898e-09
our O 0 3.646621848929499e-07
Saethre B-Disease 0 0.0003832463116850704
- I-Disease 1 0.7052212357521057
Chotzen I-Disease 1 0.9939285516738892
syndrome I-Disease 1 0.9999947547912598
patients O 0 9.743395139594213e-07
, O 0 1.0237681813407562e-09
including O 0 1.4635183065436763e-09
our O 0 4.900550720776664e-08
five O 0 9.831604330656774e-08
patients O 0 1.958629525233846e-07
elsewhere O 0 6.654528306171414e-08
reported O 0 9.29545933558984e-08
with O 0 1.2856180120479621e-08
TWIST O 0 2.0351399143692106e-05
mutations O 0 5.901975600863807e-05
. O 0 4.145473440075875e-07

More O 0 3.0756962132727494e-07
than O 0 5.060481456098387e-08
35 O 0 5.044821094202234e-08
different O 0 5.4435451701806414e-09
TWIST O 0 4.766675658629538e-07
mutations O 0 5.532917839445872e-06
are O 0 1.4360225897291912e-08
now O 0 1.6752018439092353e-08
known O 0 1.1543938249758412e-08
in O 0 2.0458976734971657e-09
the O 0 6.231253735222708e-09
literature O 0 3.707132023578197e-08
. O 0 7.910954025192041e-08

The O 0 4.3286655682095443e-07
most O 0 3.7857255108519894e-08
common O 0 1.9934118355990904e-08
phenotypic O 0 5.806497256344301e-07
features O 0 1.7806484038374037e-06
, O 0 2.8714440603039293e-08
present O 0 7.706365323656428e-09
in O 0 1.0390257543235748e-09
more O 0 8.125502493072645e-10
than O 0 1.4210631560374054e-09
a O 0 4.620246851771981e-09
third O 0 8.719511157551096e-08
of O 0 8.696035003197267e-10
our O 0 1.2682168915034708e-07
patients O 0 3.7690320198180416e-08
with O 0 2.8041444721793596e-09
TWIST O 0 2.927737341451575e-06
mutations O 0 1.5211872778309043e-05
, O 0 7.966931114822273e-09
are O 0 6.469933033770303e-09
coronal B-Disease 0 6.081123956391821e-06
synostosis I-Disease 0 2.347082227061037e-05
, O 0 1.8492499975764076e-08
brachycephaly B-Disease 0 3.035320105482242e-06
, O 0 5.591205720634207e-08
low B-Disease 0 0.00154147669672966
frontal I-Disease 1 0.9999998807907104
hairline I-Disease 1 1.0
, O 0 2.02134015125921e-06
facial B-Disease 1 0.8321316242218018
asymmetry I-Disease 0 9.75471775745973e-05
, O 0 1.9037335619032092e-07
ptosis B-Disease 0 0.06163856387138367
, O 0 6.107540428956781e-08
hypertelorism B-Disease 0 3.9808601286495104e-05
, O 0 2.83805015044436e-08
broad B-Disease 0 5.075372655483079e-07
great I-Disease 0 5.772926670033485e-07
toes I-Disease 1 0.5810922980308533
, O 0 4.077985593653466e-08
and O 0 1.4616952626056445e-07
clinodactyly B-Disease 0 1.1802796507254243e-05
. O 0 2.863738188807474e-07

Significant O 0 1.2253079148649704e-05
intra O 0 0.00015672855079174042
- O 0 0.0035363398492336273
and O 0 2.2457747661519534e-07
interfamilial O 0 4.165103291597916e-06
phenotypic O 0 6.537605713674566e-06
variability O 0 1.566207629366545e-06
is O 0 9.956604429817162e-09
present O 0 6.098376914565051e-09
for O 0 4.498608596747999e-09
either O 0 2.1179653231229167e-07
TWIST O 0 1.4388732779480051e-05
mutations O 0 8.43696398078464e-05
or O 0 8.80072946074506e-07
FGFR O 0 0.00029672952950932086
mutations O 0 2.5919733161572367e-05
. O 0 5.76819957132102e-07

The O 0 8.756032912060618e-07
overlap O 0 1.2340459534243564e-06
in O 0 3.587864227938553e-08
clinical O 0 4.1409884943277575e-07
features O 0 3.9869249235380266e-07
and O 0 1.1950551481731964e-07
the O 0 1.3566070045101242e-08
presence O 0 2.8823139430755873e-08
, O 0 1.4571786000061593e-09
in O 0 3.167157647254726e-10
the O 0 4.198491831974849e-10
same O 0 2.0775490217062043e-09
genes O 0 8.633882053743491e-09
, O 0 1.963482154643259e-10
of O 0 2.491531703174843e-10
mutations O 0 5.238324973788622e-08
for O 0 7.421787628913989e-10
more O 0 1.1536250843491302e-09
than O 0 5.4592663722985435e-09
one O 0 3.502385581555245e-08
craniosynostotic B-Disease 0 2.7390517061576247e-05
condition I-Disease 0 7.975690436978766e-07
- O 0 1.2418242079093034e-07
such O 0 6.653384065913315e-09
as O 0 3.171833995452289e-08
Saethre B-Disease 0 2.7401397346693557e-06
- I-Disease 0 9.881410960588255e-07
Chotzen I-Disease 0 7.712735055065423e-07
, I-Disease 0 4.999967551100326e-09
Crouzon I-Disease 0 2.612301841509179e-07
, I-Disease 0 4.425908528560285e-09
and I-Disease 0 3.450296759410776e-08
Pfeiffer I-Disease 0 5.663451520376839e-05
syndromes I-Disease 0 6.603627844015136e-05
- O 0 2.0803980760319973e-07
support O 0 1.055223552981488e-08
the O 0 2.828731915371918e-09
hypothesis O 0 2.4263187015094445e-08
that O 0 1.8572375859449153e-09
TWIST O 0 9.975997272704262e-08
and O 0 2.9195401651804787e-08
FGFRs O 0 8.493650511809392e-07
are O 0 5.107995360020823e-09
components O 0 4.5019756811370826e-08
of O 0 9.603462469698343e-10
the O 0 3.1902345209999794e-09
same O 0 9.535296108253988e-09
molecular O 0 5.343312992067695e-08
pathway O 0 3.49054154469286e-08
involved O 0 1.2963884188366137e-08
in O 0 6.998985280226577e-10
the O 0 9.68218061281334e-10
modulation O 0 6.427439558365222e-08
of O 0 7.507673593920572e-09
craniofacial O 0 5.316950773703866e-05
and O 0 3.2969910535030067e-07
limb O 0 5.766055983258411e-05
development O 0 2.474749294378853e-08
in O 0 1.0384042070654687e-08
humans O 0 6.69800215291616e-08
. O 0 1.1526402943218272e-08
. O 0 6.664067342398994e-08

Mutation O 0 9.107329969992861e-05
analysis O 0 7.280436875589658e-07
of O 0 2.2623525808285194e-07
UBE3A O 1 0.5025557279586792
in O 0 0.00020493885676842183
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9793753027915955
. O 0 2.3276395495486213e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9429649710655212
AS B-Disease 1 0.9999998807907104
) O 0 9.91614470535751e-08
is O 0 1.2978778052286088e-08
caused O 0 2.561985752436158e-07
by O 0 1.885996425698977e-08
chromosome O 0 9.030621004058048e-05
15q11 O 0 7.591316716570873e-06
- O 0 3.170517629769165e-06
q13 O 0 9.469532074035669e-07
deletions O 0 5.083156793261878e-07
of O 0 2.3801474569040693e-08
maternal O 0 2.7102185413241386e-05
origin O 0 1.6156947424406098e-07
, O 0 9.778077902922178e-09
by O 0 2.3793123915538672e-08
paternal O 0 0.000256882281973958
uniparental B-Disease 0 0.08263610303401947
disomy I-Disease 0 0.014328145422041416
( O 0 3.975067556893919e-06
UPD B-Disease 1 0.9999998807907104
) O 0 6.614502723323312e-08
15 O 0 2.897366968568349e-08
, O 0 2.6159945321069245e-09
by O 0 4.507489492766581e-09
imprinting O 0 0.00017738755559548736
defects O 1 0.9930214285850525
, O 0 7.236133470200912e-09
and O 0 3.318382235661943e-09
by O 0 3.7646548101122335e-09
mutations O 0 4.160888806836738e-07
in O 0 2.913008279037399e-09
the O 0 2.8127006501676988e-08
UBE3A O 0 1.9359715224709362e-05
gene O 0 1.892098453026847e-06
. O 0 2.029378123324932e-07

UBE3A O 0 0.0025150664150714874
encodes O 0 3.69208755728323e-05
a O 0 9.474816806687159e-07
ubiquitin O 0 5.267337655823212e-06
- O 0 1.3088055084153893e-06
protein O 0 3.054110209177452e-07
ligase O 0 1.83227157890542e-07
and O 0 3.4859642283890935e-08
shows O 0 1.4486532791124773e-06
brain O 0 0.0005298775504343212
- O 0 8.871202226146124e-06
specific O 0 1.0202869589193142e-06
imprinting O 0 8.063654968282208e-05
. O 0 1.4990349654908641e-06

Here O 0 3.3962853649427416e-06
we O 0 4.784327529705479e-07
describe O 0 9.301097065872455e-07
UBE3A O 0 2.5374283723067492e-05
coding O 0 1.5347872249549255e-05
- O 0 1.809724017221015e-05
region O 0 7.787746767462522e-07
mutations O 0 6.626197318837512e-06
detected O 0 4.7442989625778864e-07
by O 0 6.814399711174701e-09
SSCP O 0 9.86698523774976e-07
analysis O 0 6.853284162389173e-08
in O 0 1.426968676554452e-08
13 O 0 2.949457496015384e-07
AS B-Disease 1 0.9998170733451843
individuals O 0 6.31850483046037e-08
or O 0 2.279081314782161e-07
families O 0 2.500199229871214e-07
. O 0 9.82028467433338e-08

Two O 0 2.056091580016073e-05
identical O 0 0.00025929417461156845
de O 0 0.00016731416690163314
novo O 0 5.771798896603286e-06
5 O 0 2.711736328819825e-07
- O 0 1.7432244021620136e-06
bp O 0 1.6162740621439298e-06
duplications O 0 1.0979381386277964e-06
in O 0 1.951491768181768e-08
exon O 0 9.837698371484294e-07
16 O 0 3.235531664813607e-07
were O 0 1.3617156469081237e-07
found O 0 1.5198327218968188e-07
. O 0 1.5775208339618985e-07

Among O 0 1.62983633344993e-06
the O 0 5.346513987092294e-08
other O 0 6.193503043760984e-09
11 O 0 2.387599806752405e-08
unique O 0 1.1029913871141162e-08
mutations O 0 9.519758918941079e-07
, O 0 4.647149776104698e-09
8 O 0 1.0792136073689562e-08
were O 0 1.668645310815009e-08
small O 0 7.136133017837665e-09
deletions O 0 6.553347020599176e-07
or O 0 2.083624650595084e-07
insertions O 0 1.876874762274383e-06
predicted O 0 4.289668595447438e-06
to O 0 1.1217984052791508e-07
cause O 0 5.262507329462096e-06
frameshifts O 0 3.1297659006668255e-05
, O 0 2.8322531875346613e-08
1 O 0 3.2261674220990244e-08
was O 0 7.324646134065915e-08
a O 0 1.0591797661163582e-08
mutation O 0 1.2536114013528277e-07
to O 0 4.876175907497782e-09
a O 0 1.4617782539971813e-08
stop O 0 1.2060692711202137e-07
codon O 0 2.8925890660502773e-07
, O 0 9.951857116163865e-09
1 O 0 8.99401264575772e-09
was O 0 1.4158315408963063e-08
a O 0 6.948073227874829e-09
missense O 0 1.2138413012507954e-06
mutation O 0 4.771000021719374e-07
, O 0 5.922136114833165e-09
and O 0 9.661321520582078e-09
1 O 0 2.3988929953588922e-08
was O 0 1.7743785463153472e-07
predicted O 0 9.416214652446797e-08
to O 0 6.84565160113948e-09
cause O 0 7.432376492033654e-08
insertion O 0 6.001142338618592e-08
of O 0 4.600426262157953e-09
an O 0 3.1140174883148575e-08
isoleucine O 0 0.0005268568638712168
in O 0 8.045621058272445e-09
the O 0 4.638577522086962e-09
hect O 0 1.502286579579959e-07
domain O 0 8.23104695513166e-09
of O 0 7.021475068036409e-10
the O 0 5.468124619767423e-09
UBE3A O 0 1.9189387785445433e-06
protein O 0 3.43683232983949e-08
, O 0 2.0815116297256964e-09
which O 0 7.602066198764135e-10
functions O 0 7.143895697225844e-09
in O 0 1.5906048700387032e-09
E2 O 0 2.598724790914275e-07
binding O 0 1.267954417016881e-07
and O 0 2.64382524761686e-08
ubiquitin O 0 5.544964096770855e-07
transfer O 0 3.4565351825222024e-07
. O 0 2.0431248515251355e-07

Eight O 0 2.9118850761733484e-06
of O 0 1.753739198306903e-08
the O 0 1.1145806944057313e-08
cases O 0 2.3477920052528134e-08
were O 0 7.103936354724283e-07
familial O 0 5.694102219422348e-05
, O 0 1.8464803019924148e-07
and O 0 4.5109146640243125e-07
five O 0 2.3791632486336312e-07
were O 0 8.838697453938948e-07
sporadic O 0 8.811497536953539e-06
. O 0 3.7183639278737246e-07

In O 0 9.99007511381933e-07
two O 0 1.7618803838104213e-07
familial O 0 0.00019616357167251408
cases O 0 9.68693370850815e-07
and O 0 1.8345849639445078e-07
one O 0 7.089467146670358e-08
sporadic O 0 6.480300271505257e-06
case O 0 3.8994805606762384e-08
, O 0 6.243317418608285e-09
mosaicism O 0 1.186746544590278e-06
for O 0 2.1185586618344132e-08
UBE3A O 0 5.278736352920532e-05
mutations O 0 1.0828696758835576e-05
was O 0 2.1195413069108326e-07
detected O 0 2.3775163526806864e-07
in O 0 4.007928211535727e-09
the O 0 1.286201722905389e-08
mother O 0 1.3534830713979318e-06
of O 0 2.393882203577391e-09
three O 0 2.2117396270004974e-07
AS B-Disease 1 0.9999995231628418
sons O 0 0.00017699270392768085
, O 0 2.231752116443886e-09
in O 0 1.1318213033462143e-09
the O 0 4.590959168382369e-09
maternal O 0 4.279082077118801e-06
grandfather O 0 9.336930020253931e-07
of O 0 1.911983238400694e-09
two O 0 8.949763241616893e-08
AS B-Disease 1 0.9994145631790161
first O 0 1.5329278824083303e-07
cousins O 0 1.5006647117843386e-05
, O 0 8.597105249918968e-09
and O 0 4.9954493874793116e-09
in O 0 1.903225577137846e-09
the O 0 1.1919631504042627e-08
mother O 0 7.110870114956924e-07
of O 0 6.217064085767277e-10
an O 0 3.135831860845428e-08
AS B-Disease 1 0.999996542930603
daughter O 0 0.00010953667515423149
. O 0 1.3278661015192483e-07

The O 0 6.4542882682872e-07
frequencies O 0 3.839654993953445e-07
with O 0 1.870834331896276e-08
which O 0 1.5504022954360153e-08
we O 0 1.864600029932717e-08
detected O 0 1.4640697543200076e-07
mutations O 0 6.042318432264437e-07
were O 0 8.66281837375027e-08
5 O 0 8.056524336552684e-09
( O 0 4.010558551925669e-09
14 O 0 1.2769618251695647e-08
% O 0 6.0000640011992346e-09
) O 0 8.526244710260755e-10
of O 0 4.978857326420894e-10
35 O 0 2.78916232332449e-08
in O 0 2.4755033578571783e-09
sporadic O 0 8.691182529219077e-07
cases O 0 6.268999186431756e-08
and O 0 1.3220889627518773e-07
8 O 0 6.881866454477858e-08
( O 0 7.432784165928297e-09
80 O 0 1.075408118111909e-08
% O 0 5.181858053759925e-09
) O 0 8.826308572906783e-10
of O 0 4.682398913047336e-10
10 O 0 1.0388321314280802e-08
in O 0 4.9996051743050884e-09
familial O 0 6.535629654536024e-05
cases O 0 1.3477136917572352e-07
. O 0 2.18474180968542e-08
. O 0 1.219067087276926e-07

The O 0 4.042390355607495e-05
hemochromatosis B-Disease 1 0.9999798536300659
845 O 0 0.00019859203894156963
G O 0 0.000332141004037112
- O 0 6.400047277566046e-05
- O 0 7.628633738931967e-06
> O 0 4.2813863387891615e-07
A O 0 7.918169586673685e-08
and O 0 1.4947687532185228e-08
187 O 0 1.3392511277743324e-07
C O 0 1.8316231944481842e-06
- O 0 2.0983839021937456e-06
- O 0 3.6292199183662888e-06
> O 0 9.241944098903332e-07
G O 0 4.709372205979889e-06
mutations O 0 1.86245688382769e-06
: O 0 2.075118565869616e-08
prevalence O 0 2.0549562123051146e-06
in O 0 2.1403531391683828e-08
non O 0 5.357699137675809e-06
- O 0 8.921014523366466e-05
Caucasian O 0 6.381101411534473e-05
populations O 0 1.8403586636850378e-06
. O 0 2.7462198204375454e-07

Hemochromatosis B-Disease 1 0.9390244483947754
, O 0 6.800678420404438e-06
the O 0 5.761987722507911e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 4.17336245561728e-08
iron I-Disease 0 0.0028917717281728983
metabolism I-Disease 0 6.748353189323097e-05
, O 0 2.643114349609732e-08
leads O 0 9.987591909066396e-08
, O 0 1.1246988229629551e-08
if O 0 2.464071791052902e-08
untreated O 0 6.122287686594063e-06
, O 0 1.6108470113351814e-09
to O 0 9.04469299456423e-09
progressive O 0 5.7864366681315005e-05
iron B-Disease 1 0.9498315453529358
overload I-Disease 0 0.004563827533274889
and O 0 4.238948349666316e-06
premature B-Disease 0 4.009905023849569e-05
death I-Disease 0 9.1940336233165e-07
. O 0 2.0566076841532777e-07

The O 0 1.2556312867673114e-05
hemochromatosis B-Disease 1 0.9999961853027344
gene O 0 7.890271808719262e-05
, O 0 2.655723392308573e-07
HFE O 0 5.125354800838977e-05
, O 0 7.043828276209751e-08
recently O 0 1.982150195090071e-07
has O 0 1.7769957949553827e-08
been O 0 2.6079302273274152e-08
identified O 0 4.082335891553157e-08
, O 0 7.94757648581168e-10
and O 0 2.2333703775245795e-09
characterization O 0 2.7215236286792788e-08
of O 0 1.1845219249906336e-09
this O 0 1.183860232067957e-09
gene O 0 6.827933418662724e-08
has O 0 1.2608672328440207e-08
shown O 0 1.5375567485875763e-08
that O 0 1.0667334793268424e-09
it O 0 9.404647061117544e-10
contains O 0 1.8236930854342859e-09
two O 0 1.3769063222923705e-08
mutations O 0 5.04000240653113e-07
that O 0 3.8243475053434395e-09
result O 0 4.517269047710215e-08
in O 0 3.8761793774710895e-09
amino O 0 7.705737203878016e-08
acid O 0 3.972721884792918e-08
substitutions O 0 1.072708428750957e-07
- O 0 1.4108422874414828e-07
cDNA O 0 5.430765668279491e-07
nucleotides O 0 3.097345597780077e-07
845 O 0 5.036586117057595e-07
G O 0 1.6467602108605206e-06
- O 0 2.8599165489140432e-06
- O 0 5.122661150380736e-06
> O 0 7.517935500800377e-07
A O 0 2.482233298906067e-07
( O 0 2.3618548894432934e-08
C282Y O 0 1.9018389707525785e-07
) O 0 6.172440336627005e-09
and O 0 5.2275028750159436e-09
187 O 0 4.787577623233119e-08
C O 0 1.5928559378153295e-06
- O 0 2.8910715172969503e-06
- O 0 1.1489763892313931e-05
> O 0 2.492899739081622e-06
G O 0 1.6522846635780297e-05
( O 0 2.0653740762099915e-07
H63D O 0 1.5021309081930667e-05
) O 0 1.3926445774359308e-07
. O 0 1.871323718205531e-07

Although O 0 0.0004395872529130429
hemochromatosis B-Disease 1 1.0
is O 0 2.712289699502435e-07
common O 0 7.798087153787492e-08
in O 0 8.963221276303557e-09
Caucasians O 0 8.597721148362325e-07
, O 0 4.8459867230121745e-09
affecting O 0 1.0583865162061556e-07
> O 0 1.6365385135941324e-07
= O 0 1.1508968782436568e-06
1 O 0 4.43508803016357e-08
/ O 0 4.252413532412902e-07
300 O 0 1.8131018464373483e-08
individuals O 0 5.295158977958181e-09
of O 0 1.3420421440812902e-09
northern O 0 1.5944388920274832e-08
European O 0 2.582813181106758e-07
origin O 0 2.9561810777067876e-08
, O 0 2.2133330723761446e-09
it O 0 1.9782790960931607e-09
has O 0 1.279904981998925e-08
not O 0 6.881206715547705e-09
been O 0 1.0083965662488481e-08
recognized O 0 5.066398856001797e-09
in O 0 9.683528423565235e-10
other O 0 6.034817534583681e-09
populations O 0 1.3092132178371685e-07
. O 0 6.288723142233721e-08

The O 0 6.02112663727894e-07
present O 0 8.939510109939874e-08
study O 0 2.169067769841604e-08
used O 0 2.5895952049381776e-08
PCR O 0 1.4374702459463151e-06
and O 0 2.07726884582371e-08
restriction O 0 3.7977741840222734e-08
- O 0 1.7285573505887442e-07
enzyme O 0 2.613724632283265e-07
digestion O 0 1.3427475664684607e-07
to O 0 6.980217737151406e-09
analyze O 0 8.608775203811092e-08
the O 0 2.722793990272976e-09
frequency O 0 6.884255299155484e-08
of O 0 2.301414392391621e-09
the O 0 1.1461598781181692e-08
845 O 0 1.1450492820586078e-07
G O 0 8.842752663440478e-07
- O 0 8.858983733261994e-07
- O 0 1.0341693723603385e-06
> O 0 1.2019701500776137e-07
A O 0 5.162121397006558e-08
and O 0 1.7038363608889995e-08
187 O 0 6.459318768747835e-08
C O 0 1.0324064305677894e-06
- O 0 8.041173487072228e-07
- O 0 2.1192008716752753e-06
> O 0 5.394956019699748e-07
G O 0 1.5995294688764261e-06
mutations O 0 1.0302189821231877e-06
in O 0 2.301174184538013e-08
HLA O 0 1.6372191566915717e-06
- O 0 7.204048984021938e-07
typed O 0 7.899801630628644e-07
samples O 0 1.4367148537530738e-07
from O 0 1.571088326102199e-08
non O 0 3.65348626019113e-07
- O 0 1.4465246067629778e-06
Caucasian O 0 1.3280298389872769e-06
populations O 0 7.019700376531546e-08
, O 0 2.192806380918455e-09
comprising O 0 6.363785054475102e-09
Australian O 0 1.94938234443498e-08
Aboriginal O 0 1.627102541590375e-08
, O 0 1.3454201086560147e-09
Chinese O 0 1.1336360739022666e-09
, O 0 1.5412613407761455e-09
and O 0 7.05697722480636e-09
Pacific O 0 1.1729793669701394e-07
Islanders O 0 8.135478992699063e-07
. O 0 1.1591335180582973e-07

Results O 0 5.104122465127148e-05
showed O 0 3.423516545808525e-06
that O 0 8.21837176090412e-09
the O 0 1.2848727415359917e-08
845 O 0 2.3476806632061198e-07
G O 0 2.3148620584834134e-06
- O 0 8.922635061026085e-06
- O 0 8.33435569802532e-06
> O 0 2.813524986322591e-07
A O 0 8.488607505796608e-08
mutation O 0 1.3744000852966565e-06
was O 0 6.106864702815074e-08
present O 0 3.379742041786926e-09
in O 0 6.145207676055975e-10
these O 0 1.5424141963649163e-09
populations O 0 8.232946768771399e-09
( O 0 1.3600026660398612e-09
allele O 0 2.513433194906156e-08
frequency O 0 1.0168604802629488e-07
0 O 0 6.648388506391711e-08
. O 0 2.8157047804455715e-09
32 O 0 2.1781179526669803e-08
% O 0 7.100953602900972e-09
) O 0 1.3577271529285895e-09
, O 0 1.3708184587457595e-09
and O 0 9.369362174993512e-09
, O 0 2.161562484559454e-09
furthermore O 0 9.294799596659686e-09
, O 0 3.2257352344799983e-09
it O 0 6.657750351024561e-09
was O 0 4.111593341349362e-07
always O 0 8.760972036725434e-08
seen O 0 5.7697459254768546e-08
in O 0 1.6960085558181959e-09
conjunction O 0 8.963016107088606e-09
with O 0 1.3355950123639104e-08
HLA O 0 1.8628815041665803e-06
haplotypes O 0 2.4893310524021217e-07
common O 0 4.6288757715728934e-08
in O 0 4.918302209944159e-09
Caucasians O 0 1.3404982723841385e-07
, O 0 4.271245579445804e-09
suggesting O 0 1.916233927090616e-08
that O 0 2.7062674323730107e-09
845 O 0 1.1204619454474596e-07
G O 0 2.124435695805005e-06
- O 0 4.410625479067676e-06
- O 0 6.010065135342302e-06
> O 0 3.957200647164427e-07
A O 0 1.546479353464747e-07
may O 0 5.299754661791667e-07
have O 0 1.499986801434261e-08
been O 0 5.5628652795292055e-09
introduced O 0 2.941909382769836e-09
into O 0 1.5451703250235482e-09
these O 0 3.5788678687254105e-09
populations O 0 3.579319951541038e-08
by O 0 7.982978722509415e-09
Caucasian O 0 1.4239284382711048e-06
admixture O 0 6.950911938474746e-06
. O 0 9.506042601969966e-07

187 O 0 0.00012369580508675426
C O 0 0.00013593210314866155
- O 0 2.220480928372126e-05
- O 0 1.2428315130819101e-05
> O 0 2.5323190584458644e-06
G O 0 8.96308665687684e-06
was O 0 9.177986726172094e-08
present O 0 6.147883535589926e-09
at O 0 8.704835074979655e-09
an O 0 1.955406725429043e-09
allele O 0 6.695038479165305e-08
frequency O 0 6.941505859003883e-08
of O 0 8.230104597828358e-09
2 O 0 2.7963756110693794e-07
. O 0 2.217704206941562e-07

68 O 0 0.00044520950177684426
% O 0 2.3057734779285965e-06
in O 0 1.1449231784865788e-08
the O 0 4.226760719205913e-09
two O 0 9.318088523002643e-09
populations O 0 4.1834841368881825e-08
analyzed O 0 1.0240659520377449e-07
( O 0 7.102456844876315e-09
Australian O 0 3.011486882087411e-08
Aboriginal O 0 5.784776035966388e-08
and O 0 1.4118700875087598e-08
Chinese O 0 1.15607949879859e-08
) O 0 2.5865841024597103e-08
. O 0 9.835336811647721e-08

In O 0 1.1824457715192693e-06
the O 0 1.296481713097819e-07
Australian O 0 1.5052492585709842e-07
Aboriginal O 0 7.897565978964849e-08
samples O 0 4.215378979210982e-08
, O 0 2.9609592555601694e-09
187 O 0 3.5879875071032075e-08
C O 0 1.2743846582452534e-06
- O 0 1.3514336387743242e-06
- O 0 2.4781843421806116e-06
> O 0 6.645661869697506e-07
G O 0 5.464291916723596e-06
was O 0 1.9795263028754562e-07
found O 0 1.4961464955831616e-08
to O 0 3.972432160992412e-09
be O 0 1.140903371776858e-08
associated O 0 1.803231342023537e-08
with O 0 1.4246679391760608e-08
HLA O 0 3.5632153867481975e-06
haplotypes O 0 6.147024578240234e-07
common O 0 5.987376994198712e-08
in O 0 7.4115216186498856e-09
Caucasians O 0 3.284907847955765e-07
, O 0 5.518700607609617e-09
suggesting O 0 5.442613471018376e-08
that O 0 1.8592508643777705e-09
it O 0 3.114258850800411e-09
was O 0 2.571094981362876e-08
introduced O 0 1.1372793373709555e-08
by O 0 4.10758538293976e-09
recent O 0 5.5754235006588715e-08
admixture O 0 2.739813226071419e-06
. O 0 2.3012781014131178e-07

In O 0 7.233748533508333e-07
the O 0 5.484275078515566e-08
Chinese O 0 1.7794310025465165e-08
samples O 0 4.0591825012370464e-08
analyzed O 0 1.1770481478379224e-07
, O 0 4.743500259252187e-09
187 O 0 5.609482300883428e-08
C O 0 1.9667002106871223e-06
- O 0 1.7808795291784918e-06
- O 0 3.4364240946160862e-06
> O 0 6.912121648383618e-07
G O 0 5.917424005019711e-06
was O 0 1.346185030115521e-07
present O 0 7.743983232444407e-09
in O 0 2.6664459529257556e-09
association O 0 1.0094626468060142e-08
with O 0 1.0536220784729267e-09
a O 0 2.3892658962409996e-09
wide O 0 1.7967014542819015e-08
variety O 0 1.0421860707765518e-08
of O 0 2.7429563065339835e-09
HLA O 0 1.1191403928023647e-06
haplotypes O 0 4.7440906314477616e-07
, O 0 1.2806912863538855e-08
showing O 0 1.094539854307186e-07
this O 0 1.1602119265319288e-09
mutation O 0 2.863060188929012e-08
to O 0 1.2957992456819056e-09
be O 0 1.7838954757820602e-09
widespread O 0 5.5761222306216496e-09
and O 0 2.818285516070773e-08
likely O 0 3.953084615204716e-08
to O 0 4.814809440034651e-09
predate O 0 7.003256996540586e-07
the O 0 5.763143740011856e-09
more O 0 5.183498519301111e-09
genetically O 0 3.939122805718398e-08
restricted O 0 3.8401818613920113e-08
845 O 0 3.7675195585507026e-07
G O 0 6.074817520129727e-06
- O 0 1.610557228559628e-05
- O 0 2.439441414026078e-05
> O 0 2.3416930616804166e-06
A O 0 6.663634621872916e-07
mutation O 0 1.7126834791270085e-05
. O 0 7.402030064440623e-07

Genotype O 0 0.028882144019007683
- O 0 0.0024301635567098856
phenotype O 0 0.00031413353281095624
correlations O 0 0.0001371492980979383
in O 0 6.626809863519156e-06
attenuated B-Disease 1 0.9999182224273682
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999997615814209
. O 0 2.9884848117944784e-05

Germ O 0 0.014489328488707542
- O 0 0.0016478582983836532
line O 0 2.434739872114733e-05
mutations O 0 2.0434242742339848e-06
of O 0 1.060190424340135e-08
the O 0 7.195315987473805e-08
tumor B-Disease 0 9.235731340595521e-06
suppressor O 0 7.592047495563747e-06
APC O 0 3.1421925541508244e-06
are O 0 5.997721075345908e-08
implicated O 0 7.2898205871752e-06
in O 0 7.079480610627797e-07
attenuated B-Disease 1 0.9998904466629028
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.0007688785553909838
AAPC B-Disease 1 1.0
) O 0 1.2465269492167863e-06
, O 0 1.552793627013216e-08
a O 0 5.07210629052679e-08
variant O 0 0.00032861653016880155
of O 0 9.78710249910364e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0001774100528564304
FAP B-Disease 0 0.0001818198652472347
) O 0 1.0320579804101726e-06
. O 0 8.286093020615226e-07

AAPC B-Disease 1 0.9999979734420776
is O 0 4.970725058228709e-06
recognized O 0 4.1638460857029713e-07
by O 0 1.1989815362767331e-08
the O 0 7.39924654880042e-09
occurrence O 0 2.2671886767966498e-07
of O 0 1.3551096245123517e-08
< O 0 2.0743152617797023e-06
100 O 0 2.0739283002058073e-07
colonic B-Disease 0 1.1527244168973994e-05
adenomas I-Disease 0 6.369980837916955e-05
and O 0 3.6107248746475307e-08
a O 0 3.042159590904703e-08
later O 0 1.736474928293319e-07
onset O 0 0.00027132683317177
of O 0 5.345487079466693e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 6.331703161777114e-07
age O 0 7.233900305436691e-07
> O 0 5.240414111540304e-07
40 O 0 3.1899628538667457e-07
years O 0 6.760662785154636e-08
) O 0 4.474000903087472e-08
. O 0 8.590372146954905e-08

The O 0 9.228592148247117e-07
aim O 0 7.04180649790942e-07
of O 0 3.676443594002876e-09
this O 0 1.5562083843789765e-09
study O 0 7.072689101050855e-09
was O 0 3.8564326843015806e-08
to O 0 7.77234987481279e-09
assess O 0 1.0305894875273225e-06
genotype O 0 0.00022428203374147415
- O 0 6.088139707571827e-05
phenotype O 0 1.8816916053765453e-05
correlations O 0 8.753146175877191e-06
in O 0 5.906525757382042e-07
AAPC B-Disease 1 0.9999992847442627
families O 0 5.5963118938962e-06
. O 0 4.815317424800014e-07

By O 0 1.3703024706046563e-06
protein O 0 1.582105483066698e-06
- O 0 1.5822263321751961e-06
truncation O 0 5.199600309424568e-06
test O 0 7.329471827688394e-06
( O 0 5.727248364451043e-08
PTT O 0 9.907049616231234e-07
) O 0 3.697984807260468e-09
assay O 0 1.90385875953325e-07
, O 0 3.3258276133096842e-09
the O 0 2.528154130487792e-09
entire O 0 1.3278099508795549e-08
coding O 0 8.572172305321146e-08
region O 0 9.221042596152529e-09
of O 0 8.400176110257007e-10
the O 0 4.64409266598409e-09
APC B-Disease 0 8.986128818833095e-08
gene O 0 6.844897626478996e-08
was O 0 5.336549691037362e-08
screened O 0 1.4864477293485834e-07
in O 0 5.95893778765344e-09
affected O 0 8.260019512817962e-08
individuals O 0 8.273686624704624e-09
from O 0 8.601254819495807e-09
11 O 0 4.4543665467244864e-07
AAPC B-Disease 1 0.9999972581863403
kindreds O 0 1.3608160770672839e-05
, O 0 1.6929195822967813e-08
and O 0 9.246016396957657e-09
their O 0 1.6559884130629143e-08
phenotypic O 0 2.3257091470441082e-06
differences O 0 1.0827849109773524e-05
were O 0 3.698283990161144e-06
examined O 0 8.067634553299285e-06
. O 0 4.119376342259784e-07

Five O 0 2.299299740116112e-05
novel O 0 1.157939277618425e-05
germ O 0 0.0003107514639850706
- O 0 0.00031526703969575465
line O 0 8.42119479784742e-05
APC B-Disease 0 1.0121802006324288e-05
mutations O 0 5.3001158448751085e-06
were O 0 3.3014273981279985e-07
identified O 0 2.2938873200928356e-07
in O 0 2.0992350968640494e-08
seven O 0 2.977339761400799e-07
kindreds O 0 2.449601197440643e-05
. O 0 6.021344916007365e-07

Mutations O 0 0.0017651610542088747
were O 0 9.804348337638658e-06
located O 0 3.1294658242586593e-07
in O 0 1.020801043694064e-08
three O 0 4.3588870290989234e-09
different O 0 2.71745026481085e-09
regions O 0 1.515909175964225e-08
of O 0 2.2048176617772697e-09
the O 0 1.5384513218918983e-08
APC B-Disease 0 1.80464255095103e-07
gene O 0 5.499673960684959e-08
( O 0 4.09499856246498e-09
1 O 0 3.4673552917752204e-09
) O 0 2.196431259093856e-09
at O 0 3.3282912426102484e-08
the O 0 8.770029147342484e-09
5 O 0 2.2730549886773588e-08
end O 0 4.123852548332252e-08
spanning O 0 2.0569470393638767e-07
exons O 0 9.515557053418888e-07
4 O 0 1.299167422530445e-07
and O 0 3.766279377259707e-08
5 O 0 3.072763732347994e-08
, O 0 7.403891721935452e-09
( O 0 3.5136784592992854e-09
2 O 0 5.398299141035068e-09
) O 0 1.6720950180015848e-09
within O 0 2.306384416783658e-09
exon O 0 8.266292184089252e-08
9 O 0 6.367113769556454e-08
, O 0 4.502033412734363e-09
and O 0 1.878514765962791e-08
( O 0 4.769455497211084e-09
3 O 0 1.4334147202532677e-08
) O 0 1.5637778849608708e-09
at O 0 2.3526647296989722e-08
the O 0 3.0959999008928207e-09
3 O 0 1.2145687122711024e-08
distal O 0 1.243526099869996e-07
end O 0 3.419380689706486e-08
of O 0 2.0535018130374283e-09
the O 0 4.960700650258332e-08
gene O 0 2.0362633676995756e-06
. O 0 2.754119634573726e-07

Variability O 0 6.40741127426736e-05
in O 0 2.628615618505137e-07
the O 0 2.8479952618454263e-08
number O 0 5.8858560691987805e-08
of O 0 1.829109692152997e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.0014603001764044166
most O 0 2.249214325900084e-08
apparent O 0 1.126685305052888e-07
in O 0 4.389271612836865e-09
individuals O 0 1.1361779961305274e-08
with O 0 8.856651412258998e-09
mutations O 0 3.5616183140518842e-06
in O 0 3.620032495987857e-09
region O 0 3.2137368322082693e-08
1 O 0 2.668227949698121e-08
, O 0 3.3604452553959163e-09
and O 0 2.9179144434010595e-08
upper O 0 0.0032809614203870296
- O 1 0.620507538318634
gastrointestinal O 0 0.0019581071101129055
manifestations O 0 9.485910368312034e-07
were O 0 1.6862173879417242e-07
more O 0 4.097725270213459e-09
severe O 0 1.808017805160489e-05
in O 0 5.386779911020767e-09
them O 0 5.160418581340309e-08
. O 0 5.739364894452592e-08

In O 0 1.195677896248526e-06
individuals O 0 1.2824443729186896e-07
with O 0 1.515544845176464e-08
mutations O 0 1.829802272368397e-06
in O 0 8.774061477367923e-09
either O 0 9.454132054997899e-08
region O 0 6.816365072381814e-08
2 O 0 5.460706375970403e-08
or O 0 1.2027889795263036e-07
region O 0 4.539518272395071e-08
3 O 0 1.891955747623797e-08
, O 0 2.094378892536497e-09
the O 0 1.6333392416356673e-09
average O 0 3.992951747022744e-08
number O 0 2.5887689769632516e-09
of O 0 6.63231025654909e-10
adenomas B-Disease 0 5.317894533618528e-07
tended O 0 3.0554474506061524e-07
to O 0 6.643923633475879e-09
be O 0 2.1665000460302508e-08
lower O 0 4.6493862981833445e-08
than O 0 2.1247328341189586e-09
those O 0 1.6337473596195196e-09
in O 0 7.739371921111626e-10
individuals O 0 1.1634183616493488e-09
with O 0 9.729146377424058e-10
mutations O 0 1.454142619650156e-07
in O 0 7.399229007276631e-10
region O 0 7.61430385409767e-09
1 O 0 7.07954539436173e-09
, O 0 2.7490369980398555e-09
although O 0 9.128994449270067e-09
age O 0 2.480399530213617e-07
at O 0 3.345782602082181e-07
diagnosis O 0 0.0020581940189003944
was O 0 3.5988924196317384e-07
similar O 0 1.3481957239491749e-07
. O 0 2.0645843790134677e-07

In O 0 5.058887836639769e-06
all O 0 1.9510844140313566e-06
AAPC B-Disease 1 0.9999936819076538
kindreds O 0 7.554925105068833e-05
, O 0 4.986636525927679e-08
a O 0 2.1774450686962155e-08
predominance O 0 3.2962911973299924e-06
of O 0 1.3418795674624562e-07
right O 1 0.5363820195198059
- O 1 0.9999959468841553
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.008341866545379162
rectal B-Disease 1 0.999997615814209
polyp I-Disease 1 0.8766299486160278
sparing O 0 3.378668043296784e-05
was O 0 2.4094640593830263e-06
observed O 0 1.633187935112801e-06
. O 0 3.5057047398368013e-07

No O 0 0.0008209132356569171
desmoid B-Disease 1 0.9894056916236877
tumors I-Disease 1 1.0
were O 0 9.796535596251488e-05
found O 0 1.8002317858645256e-07
in O 0 2.142787458581097e-08
these O 0 1.1787230391746562e-07
kindreds O 0 3.1387484341394156e-05
. O 0 6.228820552678371e-07

Our O 0 6.215046141733183e-06
data O 0 5.626004053738143e-07
suggest O 0 2.598521575691848e-07
that O 0 8.70183036738581e-09
, O 0 5.1690451918773306e-09
in O 0 1.3298579126796994e-08
AAPC B-Disease 1 0.9999998807907104
families O 0 4.2408103695379396e-07
, O 0 1.6284616988215816e-09
the O 0 9.410443535529112e-10
location O 0 2.3039058660856426e-08
of O 0 1.8375478916254906e-09
the O 0 2.2657440368334392e-08
APC B-Disease 0 4.8959068408294115e-06
mutation O 0 5.504886303242529e-06
may O 0 4.0584708926871826e-07
partially O 0 1.6071089703473262e-06
predict O 0 1.8727983785993274e-07
specific O 0 1.0496635383105968e-07
phenotypic O 0 1.6231004337896593e-05
expression O 0 4.525411441136384e-06
. O 0 7.743778951407876e-07

This O 0 2.9168415949243354e-07
should O 0 4.2518937704016935e-08
help O 0 1.0518095727718446e-08
in O 0 1.3341711069259077e-09
the O 0 1.596763277156299e-09
design O 0 6.032126265154147e-08
of O 0 3.164683404222046e-09
tailored O 0 1.723748937365599e-05
clinical O 0 7.185752474470064e-05
- O 0 5.3260850108927116e-05
management O 0 7.574039528890353e-08
protocols O 0 2.3241645052962667e-08
in O 0 1.3945079535560012e-09
this O 0 6.862984625044533e-10
subset O 0 2.290411060812403e-08
of O 0 7.252714873118293e-09
FAP B-Disease 0 6.344139819702832e-06
patients O 0 1.8793372191794333e-06
. O 0 2.9256719713544044e-08
. O 0 1.7720923040087655e-07

Wilms B-Disease 1 0.5938158631324768
' I-Disease 0 0.001508247572928667
tumor I-Disease 0 0.0002806360716931522
1 O 0 1.103649083233904e-06
and O 0 2.4369566631321504e-07
Dax O 1 0.8476709723472595
- O 0 9.738148946780711e-06
1 O 0 1.3257910325137345e-07
modulate O 0 1.421338424734131e-06
the O 0 7.900022325202372e-08
orphan O 0 1.6079827673820546e-06
nuclear O 0 1.3679691619472578e-06
receptor O 0 1.4855039580652374e-06
SF O 0 4.005803566542454e-05
- O 0 2.0877885162917664e-06
1 O 0 3.57779121884505e-08
in O 0 6.604579105840003e-09
sex O 0 1.586381301876827e-07
- O 0 3.78770494080527e-07
specific O 0 9.018855706699469e-08
gene O 0 8.322785447489878e-07
expression O 0 5.425889071375423e-07
. O 0 2.4706983481337375e-07

Products O 0 1.1450079000496771e-05
of O 0 2.3968996742951276e-07
steroidogenic O 0 4.183411147096194e-05
factor O 0 1.1605862937358324e-06
1 O 0 2.8666894991147274e-07
( O 0 1.2395855719660176e-07
SF O 0 0.0034103423822671175
- O 0 2.490060251147952e-05
1 O 0 9.527300193212795e-08
) O 0 7.361562914809383e-09
and O 0 4.413998411223474e-08
Wilms B-Disease 0 0.0038535951171070337
tumor I-Disease 0 1.0912189281953033e-05
1 O 0 3.7742186265177224e-08
( O 0 2.6458382151872684e-08
WT1 O 0 2.101131258314126e-06
) O 0 6.7191376906805544e-09
genes O 0 1.9851214005939255e-08
are O 0 9.76364766813731e-10
essential O 0 3.0384579297049186e-09
for O 0 1.0533327543527093e-09
mammalian O 0 1.387295895938223e-07
gonadogenesis O 0 6.075334226807172e-07
prior O 0 3.7411350461979964e-08
to O 0 1.6460688812003355e-08
sexual O 0 3.7185378687354387e-07
differentiation O 0 1.8091278661813703e-06
. O 0 7.543560514022829e-07

In O 0 1.5139954712140025e-06
males O 0 3.966221811424475e-06
, O 0 6.36589945202104e-08
SF O 0 0.0002569037606008351
- O 0 6.285638846748043e-06
1 O 0 3.66562744602561e-08
participates O 0 3.098979206583863e-08
in O 0 3.327673914199636e-09
sexual O 0 4.252818897043653e-08
development O 0 2.3478130550813603e-09
by O 0 1.6707975003527054e-09
regulating O 0 3.3338888982825665e-08
expression O 0 1.6899901922329263e-08
of O 0 1.9457522260069027e-09
the O 0 4.021958943667414e-08
polypeptide O 0 1.8616490706335753e-05
hormone O 0 7.685563105042093e-06
Mullerian O 0 3.471851232461631e-05
inhibiting O 0 8.311036253871862e-06
substance O 0 3.882611053995788e-06
( O 0 3.270210413575114e-07
MIS O 0 0.0006197012844495475
) O 0 1.7541563579470676e-07
. O 0 1.445173012371015e-07

Here O 0 1.3494887980414205e-06
, O 0 7.264097945380854e-08
we O 0 4.4018332090445256e-08
show O 0 8.730595624228954e-08
that O 0 1.2824782125164802e-08
WT1 O 0 1.6805512132123113e-05
- O 0 2.864354883058695e-06
KTS O 0 1.3864952961739618e-05
isoforms O 0 5.284280746309378e-07
associate O 0 4.6217959948080534e-07
and O 0 5.684011483708673e-08
synergize O 0 1.349982812826056e-05
with O 0 2.799700382638548e-07
SF O 0 0.10138273239135742
- O 0 6.383540312526748e-05
1 O 0 1.0097577529677437e-07
to O 0 3.34836762760915e-08
promote O 0 1.6523054000572301e-06
MIS O 0 0.1998414248228073
expression O 0 3.4593949749250896e-06
. O 0 6.452368097598082e-07

In O 0 2.1618434402626008e-06
contrast O 0 2.0843033325945726e-06
, O 0 1.0321057430928704e-07
WT1 O 0 5.290387343848124e-05
missense O 0 2.3418639102601446e-05
mutations O 0 9.483925168751739e-06
, O 0 2.549709954280388e-08
associated O 0 9.928730548836029e-08
with O 0 8.88514790631234e-08
male B-Disease 0 0.006455199792981148
pseudohermaphroditism I-Disease 1 0.9999998807907104
in O 0 7.021467354206834e-07
Denys B-Disease 1 0.9999817609786987
- I-Disease 1 0.9999803304672241
Drash I-Disease 1 0.9998955726623535
syndrome I-Disease 1 0.999998927116394
, O 0 6.867127666509987e-08
fail O 0 1.6954843431449262e-06
to O 0 3.08888772337923e-08
synergize O 0 2.1888516130275093e-05
with O 0 7.810522220097482e-07
SF O 1 0.9907179474830627
- O 0 0.0004340549639891833
1 O 0 1.0141077382286312e-06
. O 0 4.2034042735394905e-07

Additionally O 0 1.4561185707862023e-05
, O 0 7.556349146398134e-08
the O 0 1.559513407300983e-08
X O 0 0.0001522400270914659
- O 0 4.704192906501703e-05
linked O 0 1.5687663108110428e-05
, O 0 7.53116591312164e-09
candidate O 0 4.5780204516177037e-08
dosage O 0 7.47932574540755e-07
- O 0 3.9828358922022744e-07
sensitive O 0 1.621575961507915e-06
sex O 0 8.426748081546975e-07
- O 0 5.347876026462473e-07
reversal O 0 2.7844615146932483e-07
gene O 0 4.923176106785832e-07
, O 0 3.2041519659742335e-08
Dax O 0 0.016104837879538536
- O 0 4.363333118817536e-06
1 O 0 4.879210990793581e-08
, O 0 5.680421466536245e-09
antagonizes O 0 6.157204666124017e-07
synergy O 0 1.7145301001164626e-07
between O 0 9.108786969136418e-08
SF O 0 0.0005196286947466433
- O 0 5.555176812777063e-06
1 O 0 2.476458504929724e-08
and O 0 1.5640083006474015e-08
WT1 O 0 1.721309217828093e-06
, O 0 5.076071563081541e-09
most O 0 2.095457585227223e-09
likely O 0 9.209301765622513e-09
through O 0 1.3638057350107147e-09
a O 0 1.7359004234052122e-09
direct O 0 4.617841664611433e-09
interaction O 0 4.2780555986610125e-08
with O 0 3.7988363033036876e-07
SF O 1 0.8869636058807373
- O 0 0.0002908779715653509
1 O 0 1.3025372709307703e-06
. O 0 3.3630252005423245e-07

We O 0 3.7640536447725026e-06
propose O 0 1.322252046520589e-06
that O 0 5.066614150450732e-08
WT1 O 0 8.814573448034935e-06
and O 0 1.8056307737879251e-07
Dax O 1 0.9939561486244202
- O 0 3.503284460748546e-05
1 O 0 7.740604957007235e-08
functionally O 0 2.8835907528446114e-07
oppose O 0 2.6125404062327107e-08
each O 0 4.8537849295371416e-09
other O 0 2.1138835126777167e-09
in O 0 3.5218978844397952e-09
testis O 0 9.512862106930697e-07
development O 0 1.2884163957949113e-08
by O 0 1.2088694489875706e-08
modulating O 0 3.7637196328432765e-06
SF O 0 0.0016310859937220812
- O 0 1.273121961276047e-05
1 O 0 3.4830472372959775e-07
- O 0 2.386676897003781e-06
mediated O 0 6.3128886722552124e-06
transactivation O 0 3.0678900657221675e-05
. O 0 1.441776902311176e-07
. O 0 3.717243544087978e-07

A O 0 8.366831025341526e-06
mouse O 0 2.6082641852553934e-05
model O 0 3.6072258353669895e-06
for O 0 1.1337748446749174e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 0 0.0120638906955719
- O 0 0.0023189799394458532
centre O 0 6.523884803755209e-05
mutations O 0 0.00016470665286760777
. O 0 1.2839720966439927e-06

Imprinting O 0 0.00012535306450445205
in O 0 8.61822798015055e-07
the O 0 1.4118248259364918e-07
15q11 O 0 4.7438329602300655e-06
- O 0 2.319834720765357e-06
q13 O 0 1.4535065702148131e-06
region O 0 7.01765188182435e-08
involves O 0 2.871942328397381e-08
an O 0 7.376278698956185e-09
imprinting O 0 2.2729154807166196e-06
centre O 0 1.2265718396520242e-06
( O 0 3.295689054994e-08
IC O 0 8.104689754873107e-07
) O 0 8.365196535464747e-09
, O 0 1.4003398440820547e-09
mapping O 0 5.001553304850859e-08
in O 0 2.7496818155725578e-09
part O 0 4.198582370662507e-09
to O 0 3.419815985949981e-09
the O 0 6.1614779944818565e-09
promoter O 0 1.877073714240396e-07
and O 0 1.4487602228996366e-08
first O 0 3.0177254473073845e-08
exon O 0 1.0276843340761843e-06
of O 0 7.128000589773364e-08
SNRPN O 0 6.875395047245547e-05
. O 0 8.91003310243832e-07

Deletion O 0 0.00019702997815329581
of O 0 2.147952073983106e-07
this O 0 3.92139369864708e-08
IC O 0 4.4461939978646114e-06
abolishes O 0 4.07073048336315e-06
local O 0 1.0883674406159116e-07
paternally O 0 6.137504897196777e-06
derived O 0 1.5522492446962133e-07
gene O 0 2.7910070343750704e-07
expression O 0 4.545808707234755e-08
and O 0 3.851302210478025e-08
results O 0 2.296915454280679e-06
in O 0 4.677030574384844e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.038393181981519e-05
PWS B-Disease 1 0.9999997615814209
) O 0 1.3927735835750354e-06
. O 0 7.421355121550732e-07

We O 0 1.687789881543722e-05
have O 0 9.409948376060129e-08
created O 0 4.203616654763209e-08
two O 0 1.1807713917733054e-08
deletion O 0 3.5813802696793573e-06
mutations O 0 2.286906919835019e-06
in O 0 9.19627751727603e-09
mice O 0 1.8740254290605662e-06
to O 0 2.3431661944073312e-08
understand O 0 4.703017566498602e-06
PWS B-Disease 1 1.0
and O 0 1.6643360822854447e-07
the O 0 1.0227772406778968e-08
mechanism O 0 6.935682250741593e-08
of O 0 2.284990419099131e-09
this O 0 9.021571045764176e-09
IC O 0 1.5795569197507575e-05
. O 0 5.832682177242532e-07

Mice O 1 0.8431954383850098
harbouring O 0 0.0010707316687330604
an O 0 2.835410839452379e-07
intragenic O 0 1.733185854391195e-05
deletion O 0 1.3097484043100849e-05
in O 0 8.478316715354595e-08
Snrpn O 0 5.6551070883870125e-06
are O 0 4.246625806558768e-08
phenotypically O 0 1.063597096617741e-06
normal O 0 1.0726020605034137e-07
, O 0 2.059958870148648e-09
suggesting O 0 2.1689229967591928e-08
that O 0 1.116878478590877e-09
mutations O 0 7.08804748228431e-08
of O 0 1.4410428406108622e-09
SNRPN O 0 4.5080519157636445e-06
are O 0 5.184111806499914e-09
not O 0 2.9353515174079803e-09
sufficient O 0 2.4809121867974682e-08
to O 0 6.688758702466657e-08
induce O 0 0.00022115073807071894
PWS B-Disease 1 0.9999998807907104
. O 0 1.993337491512648e-06

Mice O 0 0.2878056466579437
with O 0 3.488256368200382e-07
a O 0 6.311012867854515e-08
larger O 0 4.4217930650347625e-08
deletion O 0 1.574831799189269e-06
involving O 0 6.826540044357898e-08
both O 0 1.0458864352358432e-07
Snrpn O 0 1.3175191270420328e-05
and O 0 7.77170114929504e-08
the O 0 4.466514624823503e-08
putative O 0 9.570222027832642e-05
PWS O 1 0.9999998807907104
- O 0 3.203953747288324e-05
IC O 0 5.7261891015514266e-06
lack O 0 1.221296628273194e-07
expression O 0 2.4792470298962144e-08
of O 0 1.3674471555091827e-09
the O 0 1.795248927294324e-08
imprinted O 0 2.5612675926822703e-06
genes O 0 4.4552498934535834e-07
Zfp127 O 0 1.3216090337664355e-06
( O 0 1.9773368720166218e-08
mouse O 0 4.932805381940852e-07
homologue O 0 8.801955004855699e-07
of O 0 8.328897571630023e-09
ZNF127 O 0 8.136129508784506e-06
) O 0 2.8172589594532838e-08
, O 0 1.3783935770561584e-08
Ndn O 0 4.646284196496708e-06
and O 0 2.459981551794499e-08
Ipw O 0 3.628666036092909e-06
, O 0 2.376513741353392e-08
and O 0 1.9812178564393434e-08
manifest O 0 1.4261665626236208e-07
several O 0 1.3650347518989747e-08
phenotypes O 0 2.9785001061100047e-06
common O 0 2.5923338853317546e-07
to O 0 2.9642153549502837e-06
PWS B-Disease 1 1.0
infants O 1 0.98387211561203
. O 0 5.362441015677177e-07

These O 0 8.304090215460747e-07
data O 0 3.7424200627356186e-07
demonstrate O 0 8.393457306965502e-08
that O 0 3.7155682974798765e-09
both O 0 4.279620213765156e-09
the O 0 1.6475694142314978e-09
position O 0 1.60794456860458e-07
of O 0 3.768158562955648e-10
the O 0 1.7498457127729239e-09
IC O 0 3.7105778005752654e-07
and O 0 1.4739963027921021e-08
its O 0 3.368839429640502e-09
role O 0 1.1887301809565542e-08
in O 0 6.852075573604566e-10
the O 0 6.318137124594614e-10
coordinate O 0 6.304119182232171e-08
expression O 0 1.930044213338533e-08
of O 0 1.0367730007843079e-09
genes O 0 4.825734478686172e-08
is O 0 1.2795210446725491e-09
conserved O 0 6.1403486739664e-09
between O 0 5.136964631446972e-09
mouse O 0 7.330138487304794e-07
and O 0 2.9118099931224606e-08
human O 0 9.022413927084472e-09
, O 0 3.1844711312345453e-09
and O 0 1.085129230915527e-08
indicate O 0 7.399772528060566e-08
that O 0 1.5024856914180873e-09
the O 0 2.4092088324323413e-09
mouse O 0 2.2501525620555185e-07
is O 0 1.6343488784542615e-09
a O 0 1.6756740439660689e-09
suitable O 0 4.7941931313744135e-08
model O 0 7.29581230984877e-08
system O 0 2.0520461774253818e-08
in O 0 1.65822533482185e-09
which O 0 2.0294306235513204e-09
to O 0 2.2314117220645358e-09
investigate O 0 9.322587146698424e-09
the O 0 2.0335300110474464e-09
molecular O 0 6.534835961247154e-08
mechanisms O 0 6.612005165607115e-08
of O 0 2.095681628233592e-09
imprinting O 0 2.468178763592732e-07
in O 0 4.441163881097054e-09
this O 0 1.4333018105716633e-09
region O 0 6.378561678843653e-09
of O 0 1.0302244612958589e-09
the O 0 4.108345219577814e-09
genome O 0 4.9004757585180414e-08
. O 0 5.086684407018538e-09
. O 0 6.328298240987351e-08

Mutations O 0 0.00014248564548324794
of O 0 5.2852733745112346e-08
the O 0 2.5230781020013637e-08
ATM O 0 3.57184012500511e-06
gene O 0 8.431056812696625e-07
detected O 0 1.2751336271321634e-06
in O 0 2.681543875837633e-08
Japanese O 0 4.788409933098592e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9986661672592163
: O 0 3.300217699120367e-08
possible O 0 3.438274731593083e-08
preponderance O 0 2.902398534843087e-07
of O 0 1.5908444561674173e-09
the O 0 7.170187554805807e-09
two O 0 3.2496725310693364e-08
founder O 0 6.370090090968006e-07
mutations O 0 1.6823188389025745e-06
4612del165 O 0 1.011983385978965e-06
and O 0 8.097151038555239e-08
7883del5 O 0 7.66114317229949e-06
. O 0 3.265483030645555e-07

The O 0 6.760933956684312e-06
ATM O 0 5.14392668264918e-05
( O 0 5.63984440304921e-06
A O 1 0.9999829530715942
- O 1 0.9999877214431763
T O 1 1.0
, O 0 1.8639315868540507e-08
mutated O 0 2.3241274504925968e-07
) O 0 5.224103816203751e-09
gene O 0 7.116589273437057e-08
on O 0 2.4929128983330884e-08
human O 0 1.751126035287598e-07
chromosome O 0 3.214809839846566e-05
11q22 O 0 1.1447567885625176e-05
. O 0 5.12720816914225e-07

3 O 0 2.3541211703559384e-05
has O 0 3.247646986892505e-07
recently O 0 3.9143552044151875e-07
been O 0 5.690183968454221e-08
identified O 0 4.160741085001973e-08
as O 0 1.1562223400929383e-09
the O 0 1.1317521364517802e-09
gene O 0 6.724627610310563e-08
responsible O 0 3.206456966609039e-08
for O 0 1.3447095659202546e-09
the O 0 1.4561681638269874e-08
human O 0 1.4117509863353916e-06
recessive B-Disease 1 0.9999982118606567
disease I-Disease 1 0.9999957084655762
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.22666135430335999
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.597128852561582e-07
. O 0 1.8221160758002952e-07

In O 0 1.0989406291628256e-06
order O 0 1.750975684444711e-07
to O 0 1.8298717208153903e-08
define O 0 1.473516277883391e-07
the O 0 5.32818678067315e-09
types O 0 9.645490450793659e-08
of O 0 3.339514620392947e-08
disease O 0 0.20295946300029755
- O 0 3.9371672755805776e-05
causing O 0 1.7365225630783243e-06
ATM O 0 1.266798881260911e-05
mutations O 0 2.352114051973331e-06
in O 0 1.1303569635856547e-08
Japanese O 0 4.249058747518575e-06
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 5.903461897105444e-06
as O 0 4.495743333166047e-09
well O 0 5.808034497789549e-09
as O 0 3.57503382453217e-09
to O 0 2.519470188033779e-09
look O 0 6.73502498216294e-08
for O 0 2.3963397932647013e-09
possible O 0 2.4445370172543335e-08
mutational O 0 5.084110398456687e-06
hotspots O 0 3.101613174294471e-06
, O 0 3.6562845195931004e-08
reverse O 0 1.6843060848259483e-06
- O 0 3.961776201322209e-06
transcribed O 0 1.01985904166213e-06
RNA O 0 2.272552848125997e-07
derived O 0 3.3443082969597526e-08
from O 0 5.8510427614066884e-09
ten O 0 5.969724270471488e-08
patients O 0 5.404751490800663e-08
belonging O 0 3.241866153302908e-08
to O 0 5.964339244712846e-09
eight O 0 5.7495107341765106e-08
unrelated O 0 1.2554599493341811e-07
Japanese O 0 5.4641413953504525e-06
A B-Disease 1 0.9999978542327881
- I-Disease 1 0.999995231628418
T I-Disease 1 1.0
families O 0 1.4315422447452875e-07
was O 0 3.716952434729137e-08
analyzed O 0 3.0831547093157496e-08
for O 0 3.0235891568253237e-09
mutations O 0 9.47832603515053e-08
by O 0 1.024561213647246e-09
the O 0 3.1768998542958116e-09
restriction O 0 3.218736566168445e-08
endonuclease O 0 1.435468789168226e-06
fingerprinting O 0 9.318711704509042e-07
method O 0 1.3552487416745862e-06
. O 0 5.619885428131965e-07

As O 0 2.579824922577245e-06
has O 0 1.7141262276254565e-07
been O 0 5.390976198782482e-08
reported O 0 3.507399881641504e-08
by O 0 1.132395621716853e-09
others O 0 8.175407906207965e-09
, O 0 1.6935195468192887e-09
mutations O 0 4.663472097377053e-08
that O 0 1.2031871055029342e-09
lead O 0 1.4741201148638083e-08
to O 0 5.42536415792938e-09
exon O 0 5.879645073036954e-07
skipping O 0 2.369648655076162e-06
or O 0 7.506386623390426e-07
premature O 0 9.81243715614255e-07
protein O 0 6.7284254612332e-08
truncation O 0 7.203334462246858e-07
were O 0 8.261584980573389e-07
also O 0 2.1841751518536512e-08
predominant O 0 4.1544691953276924e-07
in O 0 7.596490547712165e-09
our O 0 9.680305623760432e-08
mutants O 0 1.4171440625432297e-06
. O 0 1.2914307490063948e-07

Six O 0 4.5860792852181476e-06
different O 0 2.1278350459397188e-07
mutations O 0 5.806635726912646e-06
were O 0 8.604407071288733e-07
identified O 0 1.7143779018624627e-07
on O 0 1.8347749985991868e-08
12 O 0 1.127637183628849e-08
of O 0 6.641588945477395e-10
the O 0 8.451059407832417e-09
16 O 0 1.3975632384699566e-07
alleles O 0 1.2269861144886818e-06
examined O 0 3.6358705983730033e-06
. O 0 3.378368376161234e-07

Four O 0 1.9437671653577127e-05
were O 0 8.364576729036344e-07
deletions O 0 1.2514474292402156e-06
involving O 0 3.075927850204607e-07
a O 0 2.0768317199326702e-07
loss O 0 5.487743806043e-07
of O 0 1.5195732450123955e-09
a O 0 2.1090034607595953e-08
single O 0 5.572796908381861e-07
exon O 0 4.895874781141174e-07
exon O 0 6.9628538312827e-07
7 O 0 8.613275781499397e-08
, O 0 4.392621821835974e-09
exon O 0 1.8712843541379698e-07
16 O 0 6.086816739525602e-08
, O 0 4.740488002141774e-09
exon O 0 5.563063609770325e-07
33 O 0 4.308333245717222e-07
or O 0 9.195983352583426e-08
exon O 0 3.989240212831646e-06
35 O 0 1.528389475424774e-06
. O 0 3.183343721957499e-07

The O 0 2.0194675016682595e-06
others O 0 1.2407593885654933e-06
were O 0 2.0226117669608357e-07
minute O 0 2.3899764300949755e-07
deletions O 0 1.3484557257470442e-06
, O 0 3.9395210649217915e-08
4649delA O 0 4.869560825682129e-07
in O 0 8.59490789650863e-09
exon O 0 4.5209020527181565e-07
33 O 0 3.886839010647236e-07
and O 0 2.5180829865689702e-08
7883del5 O 0 4.927065333504288e-07
in O 0 1.6603783237201242e-08
exon O 0 2.410358092674869e-06
55 O 0 1.4492102309304755e-06
. O 0 5.109654921398032e-07

The O 0 2.956930984510109e-06
mutations O 0 1.3635245522891637e-05
4612del165 O 0 2.0358963865874102e-06
and O 0 6.057584300833696e-08
7883del5 O 0 9.739205779624172e-07
were O 0 5.42638019851438e-07
found O 0 6.425745713301012e-09
in O 0 5.993175955509855e-10
more O 0 5.897852206615539e-10
than O 0 1.0627569935195424e-09
two O 0 5.787113011024303e-09
unrelated O 0 3.2688380002809936e-08
families O 0 1.9711199783500888e-08
; O 0 5.325078156204199e-09
44 O 0 2.718395286649411e-08
% O 0 9.680652723886851e-09
( O 0 2.66394484249588e-09
7 O 0 5.566048510985411e-09
of O 0 1.017961825944269e-09
16 O 0 1.7866067736349578e-08
) O 0 7.036678462135626e-10
of O 0 2.843389690365683e-10
the O 0 3.713881868705471e-09
mutant O 0 3.626378770604788e-07
alleles O 0 2.715439393341512e-07
had O 0 2.2076218897382205e-07
one O 0 2.8943774044165593e-09
of O 0 7.436665727666991e-10
the O 0 4.460748659340652e-09
two O 0 6.547212194618623e-08
mutations O 0 4.192513642919948e-06
. O 0 1.0044272613640715e-07

The O 0 2.193522277593729e-06
4612del165 O 0 1.6101224900921807e-05
mutations O 0 3.860197466565296e-06
in O 0 1.6924483148272884e-08
three O 0 7.777080313076112e-09
different O 0 5.16273868100825e-09
families O 0 3.8059248197441775e-08
were O 0 6.549235820330068e-08
all O 0 1.937700666587716e-09
ascribed O 0 2.5186979613067706e-08
to O 0 5.532707625377498e-09
the O 0 1.704548147074547e-08
same O 0 1.7813606234540202e-07
T O 0 1.4075730177864898e-05
- O 0 1.3270663430375862e-06
- O 0 3.567550095340266e-07
> O 0 2.9794406941618945e-08
A O 0 5.628706389870786e-09
substitution O 0 8.693104014412256e-09
at O 0 1.6013146364457498e-08
the O 0 1.3069548998601022e-08
splice O 0 8.673109732626472e-06
donor O 0 2.7872857799593476e-07
site O 0 3.0405675488509587e-07
in O 0 5.319111906487706e-08
intron O 0 5.474400313687511e-05
33 O 0 6.061090971343219e-06
. O 0 4.7444254391848517e-07

Microsatellite O 0 0.000829869881272316
genotyping O 0 9.826165478443727e-05
around O 0 3.6737160371558275e-06
the O 0 1.2832360596348735e-07
ATM O 0 6.112381470302353e-06
locus O 0 1.1634094335022382e-05
also O 0 2.0221179397594824e-07
indicated O 0 5.045884563514846e-07
that O 0 2.1906700897744713e-09
a O 0 7.821618908110395e-09
common O 0 4.4829018719383384e-08
haplotype O 0 1.588305167388171e-06
was O 0 4.923701908410294e-07
shared O 0 1.534249172152613e-08
by O 0 8.105596194241116e-10
the O 0 2.0039705450614065e-09
mutant O 0 2.677716395282914e-07
alleles O 0 1.7405486119059788e-07
in O 0 7.995413220385217e-09
both O 0 9.273077239413396e-08
mutations O 0 1.4483875929727219e-05
. O 0 3.7340421954468184e-07

This O 0 2.6613821546561667e-07
suggests O 0 2.813833646087005e-07
that O 0 4.7570813954678215e-09
these O 0 2.474766835902642e-09
two O 0 1.081542144731884e-08
founder O 0 2.7085260967396607e-07
mutations O 0 1.475179828958062e-06
may O 0 4.864018876560294e-08
be O 0 5.170642136675951e-09
predominant O 0 1.5064011904541985e-07
among O 0 2.3954273231652223e-08
Japanese O 0 2.9326315598154906e-07
ATM O 0 4.946669378114166e-06
mutant O 0 1.1257213373028208e-05
alleles O 0 9.543980922899209e-06
. O 0 6.870330366837152e-07

W474C O 0 0.0004504525277297944
amino O 0 1.346327735518571e-05
acid O 0 1.4353537380884518e-06
substitution O 0 1.5216367899029137e-07
affects O 0 1.0378739290217709e-07
early O 0 9.523300370517518e-09
processing O 0 1.4188051622454623e-08
of O 0 1.766249368984063e-09
the O 0 3.116065405706081e-09
alpha O 0 5.147802628613363e-09
- O 0 8.448867383492598e-09
subunit O 0 6.901712534812532e-09
of O 0 1.406668115322418e-09
beta O 0 3.8550943770587764e-08
- O 0 6.561375585079077e-07
hexosaminidase O 0 6.550122861881391e-07
A O 0 3.3399224719232734e-08
and O 0 9.643831511141343e-09
is O 0 1.691660034275344e-09
associated O 0 1.1310212322257485e-08
with O 0 3.330482201135965e-08
subacute O 0 0.0019200121751055121
G B-Disease 0 6.20449281996116e-05
( I-Disease 0 8.325946510012727e-08
M2 I-Disease 0 4.1734812839422375e-05
) I-Disease 0 1.462623941961283e-07
gangliosidosis I-Disease 0 2.0270761524443515e-05
. O 0 4.097751400422567e-07

Mutations O 0 0.00021891770302318037
in O 0 1.870461829867054e-07
the O 0 5.882780840238411e-08
HEXA O 0 3.189938433934003e-05
gene O 0 6.329619850475865e-07
, O 0 4.13936707133189e-09
encoding O 0 1.8237845011981335e-08
the O 0 4.52031745368231e-09
alpha O 0 1.4560515460004808e-08
- O 0 2.474494387172399e-08
subunit O 0 5.690856852424986e-08
of O 0 9.476514684081394e-09
beta O 0 1.651286538617569e-07
- O 0 3.1180102268990595e-06
hexosaminidase O 0 4.623873337550322e-06
A O 0 1.9671901441142836e-07
( O 0 1.3590439884580974e-08
Hex O 0 1.339814446055243e-07
A O 0 1.776894187344169e-08
) O 0 1.6787226053693871e-09
, O 0 1.0490961432907397e-09
that O 0 8.379756888388101e-10
abolish O 0 1.553997037717636e-07
Hex O 0 3.7526740470639197e-07
A O 0 1.960303208647929e-08
enzyme O 0 3.7123689367035695e-07
activity O 0 8.308811629831325e-07
cause O 0 0.00019634509226307273
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9967729449272156
( O 0 7.957261516366998e-08
TSD B-Disease 0 9.244392458640505e-06
) O 0 2.4111683316618837e-08
, O 0 5.913038947369387e-09
the O 0 3.558626104904761e-08
fatal O 0 0.00010732735245255753
infantile B-Disease 0 0.00012313411571085453
form I-Disease 0 4.08889036407345e-07
of I-Disease 0 4.654230778555757e-08
G I-Disease 0 3.289412779849954e-05
( I-Disease 0 4.400086695000027e-08
M2 I-Disease 0 3.484861008473672e-05
) I-Disease 0 2.9443526727845892e-08
gangliosidosis I-Disease 0 9.997852430387866e-07
, I-Disease 0 9.01018637478046e-09
Type I-Disease 0 8.682798693371296e-07
1 I-Disease 0 1.6670810509822331e-07
. O 0 1.3928982411925972e-07

Less O 0 9.16125500225462e-05
severe O 0 0.10961233079433441
, O 0 3.553567182734696e-07
subacute O 0 0.008522932417690754
( O 0 1.0408570005893125e-06
juvenile O 0 0.00016192083421628922
- O 0 0.08804264664649963
onset O 1 0.7799841165542603
) O 0 2.058493464573985e-07
and O 0 2.4347084490727866e-06
chronic O 1 0.9982894062995911
( O 0 8.508724391731448e-08
adult O 0 4.587003058986738e-05
- O 0 0.21640515327453613
onset O 0 0.031169645488262177
) O 0 1.0021152796468868e-08
variants O 0 2.2895075346696103e-07
are O 0 2.4709573054337852e-08
characterized O 0 4.931342800773564e-08
by O 0 1.8506463028700182e-09
a O 0 2.1633606017701368e-09
broad O 0 6.894084236819253e-08
spectrum O 0 7.306005755935985e-08
of O 0 2.998709058843474e-09
clinical O 0 1.0854211041078088e-06
manifestations O 0 2.487437313902774e-07
and O 0 4.100862582845366e-08
are O 0 1.0847959863724554e-08
associated O 0 1.7841276900298908e-08
with O 0 6.8149588194899025e-09
residual O 0 8.129755769914482e-06
levels O 0 8.737330858821224e-07
of O 0 2.527922537964855e-09
Hex O 0 3.8076316855040204e-07
A O 0 4.090363603381775e-08
enzyme O 0 2.794397460093023e-07
activity O 0 2.6107625217264285e-07
. O 0 1.352493086415052e-07

We O 0 1.8294766050530598e-05
identified O 0 1.6354729268641677e-06
a O 0 1.0713303311149502e-07
1422 O 0 9.769310963747557e-06
G O 0 1.887884172901977e-05
- O 0 1.2111159776395652e-05
- O 0 3.947675577364862e-05
> O 0 4.960699243383715e-06
C O 0 1.4180648577166721e-05
( O 0 4.671947806400567e-08
amino O 0 1.272002094765412e-07
acid O 0 7.592857542704223e-08
W474C O 0 5.986897377852074e-08
) O 0 1.1616489992150036e-09
substitution O 0 1.7710868327469598e-09
in O 0 1.29478638921654e-09
the O 0 1.902564994438194e-09
first O 0 1.2257769022028242e-08
position O 0 4.270139797313277e-08
of O 0 7.397450985102694e-10
exon O 0 9.63353983252091e-08
13 O 0 2.7735497454273172e-08
of O 0 2.701254775416828e-09
HEXA O 0 7.866347914387006e-06
of O 0 7.803738100164992e-09
a O 0 8.399575079920396e-08
non O 0 1.4544701798513415e-06
- O 0 3.032672566405381e-06
Jewish O 0 5.067396955382719e-07
proband O 0 6.344508619804401e-06
who O 0 2.0902500352804054e-07
manifested O 0 1.4051811092485877e-07
a O 0 4.209786652609182e-08
subacute O 0 2.7192563720745966e-05
variant O 0 6.750651664333418e-06
of O 0 9.310275572715909e-08
G B-Disease 0 7.002973143244162e-05
( I-Disease 0 2.617004781768628e-07
M2 I-Disease 0 0.00011230850941501558
) I-Disease 0 3.7774060501760687e-07
gangliosidosis I-Disease 0 4.289177741156891e-05
. O 0 9.053202347786282e-07

On O 0 1.3205860796006164e-06
the O 0 1.8291395065261895e-07
second O 0 6.070469567021064e-07
maternally O 0 2.510044396331068e-05
inherited O 0 8.135454663715791e-06
allele O 0 6.176859983497707e-07
, O 0 8.55815063260934e-09
we O 0 1.236866786769042e-08
identified O 0 3.555437544378037e-08
the O 0 7.434004078987755e-09
common O 0 2.5585384264559252e-06
infantile O 1 0.9996308088302612
disease O 1 0.9989110231399536
- O 0 0.0003240565420128405
causing O 0 2.3158572730608284e-05
4 O 0 3.303329378923081e-07
- O 0 8.276764674519654e-06
bp O 0 2.840877414200804e-06
insertion O 0 4.6613027393505035e-07
, O 0 3.4766284073839415e-08
+ O 0 5.359542001315276e-07
TATC O 0 4.812723545910558e-06
1278 O 0 2.3581962977914372e-06
, O 0 2.1222307466928214e-08
in O 0 1.1982020708956043e-08
exon O 0 3.820628080575261e-06
11 O 0 1.5147955991778872e-06
. O 0 7.369207537522016e-07

Pulse O 0 0.0007660131086595356
- O 0 0.0001312654057983309
chase O 0 7.56184408601257e-06
analysis O 0 1.3456600811423414e-07
using O 0 2.3436317064806644e-07
proband O 0 5.5848699958005454e-06
fibroblasts O 0 6.239653203010675e-07
revealed O 0 3.3949888234019454e-07
that O 0 4.071043502307248e-09
the O 0 9.121961852542881e-09
W474C O 0 3.0898135605639254e-07
- O 0 1.7262131279949244e-07
containing O 0 3.3690401579633544e-08
alpha O 0 4.888693894145035e-08
- O 0 6.326053636485085e-08
subunit O 0 9.024396518952926e-08
precursor O 0 6.905586502625738e-08
was O 0 7.333453311275662e-08
normally O 0 3.616403887463093e-08
synthesized O 0 4.5843204787843206e-08
, O 0 1.910087865653054e-09
but O 0 1.4516305935075025e-09
not O 0 7.624268993922101e-10
phosphorylated O 0 1.2794973969221246e-08
or O 0 1.8878321128568132e-08
secreted O 0 4.344115467347365e-08
, O 0 3.377357726819241e-09
and O 0 2.685145661374122e-09
the O 0 5.883989739885465e-09
mature O 0 4.395532116063805e-08
lysosomal O 0 2.269464260962195e-07
alpha O 0 2.9090344355608977e-08
- O 0 9.369114906121467e-08
subunit O 0 8.654478023117917e-08
was O 0 1.4226753819457372e-07
not O 0 3.1013559720349804e-08
detected O 0 2.2643869215244194e-06
. O 0 2.5161511985061225e-07

When O 0 4.313757472118596e-06
the O 0 1.6559179982778005e-07
W474C O 0 1.3733701962337364e-06
- O 0 3.729124102846981e-07
containing O 0 7.99367896320291e-08
alpha O 0 8.859240097081056e-08
- O 0 9.918074539427835e-08
subunit O 0 1.6451090800728707e-07
was O 0 2.2830013790553494e-07
transiently O 0 1.3751356391367153e-06
co O 0 4.993165703126579e-07
- O 0 2.261867138031448e-07
expressed O 0 7.293234904892643e-09
with O 0 3.483317190244861e-09
the O 0 3.738108933504236e-09
beta O 0 1.900672508270418e-08
- O 0 1.6759114984665757e-08
subunit O 0 3.967950945593657e-08
to O 0 8.402760265369125e-09
produce O 0 1.00831613281116e-07
Hex O 0 7.586472179355042e-07
A O 0 9.784349686015048e-08
( O 0 2.172458657412335e-08
alphabeta O 0 2.3352362177320174e-07
) O 0 2.94078739138115e-09
in O 0 9.49113054815598e-09
COS O 0 6.512759136967361e-05
- O 0 1.7074693232643767e-06
7 O 0 7.879496166651734e-08
cells O 0 2.8542816110643798e-08
, O 0 1.1949171652148038e-09
the O 0 1.996108389690221e-09
mature O 0 9.223329655583257e-09
alpha O 0 7.498686116491626e-09
- O 0 1.8047247252184206e-08
subunit O 0 2.954912581287772e-08
was O 0 4.646088669346682e-08
present O 0 4.434248523921269e-09
, O 0 1.342774447188333e-09
but O 0 1.3334333637260443e-09
its O 0 1.4322086849816174e-09
level O 0 2.5493061883707924e-08
was O 0 2.292377665469303e-08
much O 0 2.0791268706688015e-09
lower O 0 1.7478816616289805e-08
than O 0 9.998389893794979e-10
that O 0 7.571302473863284e-10
from O 0 1.2969144647101416e-09
normal O 0 7.896719722566559e-09
alpha O 0 7.744160868128347e-09
- O 0 3.4221276479229346e-08
subunit O 0 4.598077296691372e-08
transfections O 0 2.585598224413843e-07
, O 0 5.172891448523842e-09
although O 0 3.745045606962094e-09
higher O 0 8.80270878411693e-09
than O 0 2.7015949477515733e-09
in O 0 1.5730875491115626e-09
those O 0 1.4036777962189717e-08
cells O 0 3.116750590947959e-08
transfected O 0 2.6552115173217317e-07
with O 0 1.968290197496003e-09
an O 0 3.109617452423663e-09
alpha O 0 4.7101625710865846e-08
- O 0 1.2061532572715805e-07
subunit O 0 3.9050931377460074e-07
associated O 0 4.553653525363188e-07
with O 0 2.3768272683355463e-07
infantile O 0 0.08233869820833206
TSD B-Disease 0 0.0013520733918994665
. O 0 2.181761828978779e-06

Furthermore O 0 1.853775575000327e-05
, O 0 1.662017012904471e-07
the O 0 1.0151489426846183e-08
precursor O 0 9.021402291864433e-08
level O 0 3.6244834689114214e-08
of O 0 1.3811825017029378e-09
the O 0 4.030619837891436e-09
W474C O 0 1.1124021170871856e-07
alpha O 0 2.917113128830806e-08
- O 0 3.5385781416152895e-08
subunit O 0 5.048151052733374e-08
was O 0 5.81007597588723e-08
found O 0 6.714192757328874e-09
to O 0 4.58574334061268e-09
accumulate O 0 1.742569963880669e-07
in O 0 1.7935266605206834e-09
comparison O 0 2.34585364466966e-08
to O 0 7.165661841668225e-09
the O 0 1.6054094942319352e-08
normal O 0 7.062959639370092e-08
alpha O 0 6.189915069398921e-08
- O 0 1.8446462490828708e-07
subunit O 0 5.345469276107906e-07
precursor O 0 7.733357847428124e-07
levels O 0 2.1389794255810557e-06
. O 0 4.265020265847852e-07

We O 0 5.626859547191998e-06
conclude O 0 4.5927311020932393e-07
that O 0 7.596098861029077e-09
the O 0 7.493052400775468e-09
1422 O 0 1.0709028401834075e-06
G O 0 4.353590156824794e-06
- O 0 5.003604201192502e-06
- O 0 1.0963918612105772e-05
> O 0 1.915486791403964e-06
C O 0 1.4574189663107973e-05
mutation O 0 6.127271490186104e-07
is O 0 3.192827779940899e-09
the O 0 4.5534078729758676e-09
cause O 0 6.019851639393892e-08
of O 0 7.623254916211408e-09
Hex B-Disease 0 1.7481341274105944e-05
A I-Disease 0 0.0001571060565765947
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.6109860112578644e-08
the O 0 8.299848985870995e-08
proband O 0 1.6863741620909423e-05
. O 0 2.8253694495106174e-07

The O 0 3.181861302437028e-06
resulting O 0 2.4042856239248067e-06
W474C O 0 3.0085616344877053e-06
substitution O 0 2.947244581719133e-07
clearly O 0 2.4135661647051165e-07
interferes O 0 2.16576097500365e-07
with O 0 4.097967742922037e-09
alpha O 0 2.4888793248578622e-08
- O 0 1.9625554514846044e-08
subunit O 0 3.497605760571787e-08
processing O 0 3.076974763871476e-08
, O 0 5.586214157915492e-09
but O 0 2.4164801271098213e-09
because O 0 1.0715828224761026e-09
the O 0 8.401489504095139e-10
base O 0 1.294856311062631e-08
substitution O 0 1.3758195471780255e-08
falls O 0 5.471709982884931e-07
at O 0 1.3644100071985577e-08
the O 0 1.7374142124992886e-09
first O 0 4.399480779682108e-09
position O 0 1.9180220078851562e-08
of O 0 7.001615398571914e-10
exon O 0 1.6020914017644827e-07
13 O 0 2.853748171105508e-08
, O 0 2.1343593559208784e-09
aberrant O 0 1.727127028061659e-07
splicing O 0 6.816637778683798e-07
may O 0 3.0514027571371116e-07
also O 0 2.5699378625176905e-08
contribute O 0 2.1579467102128547e-08
to O 0 1.7674466334938188e-08
Hex B-Disease 0 9.921714990923647e-06
A I-Disease 0 4.464464382181177e-06
deficiency I-Disease 0 5.105485979584046e-05
in O 0 2.3803596871374566e-09
this O 0 2.948200572561177e-09
proband O 0 1.2038163959005033e-06
. O 0 1.7118889417133687e-08
. O 0 8.517768179672203e-08

Two O 0 6.883506557642249e-06
frequent O 0 8.236094436142594e-05
missense O 0 0.006337353494018316
mutations O 0 0.042156461626291275
in O 0 2.5934763471013866e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 6.010048309690319e-06

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.668947101687081e-05
an O 0 0.00015855408855713904
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.007426343858242035
by O 0 1.3220170558270183e-07
early O 0 1.822133708628826e-05
childhood O 1 0.9999810457229614
deafness B-Disease 1 1.0
and O 0 0.15925681591033936
goiter B-Disease 1 1.0
. O 0 8.832697858451866e-06

A O 0 6.925107300048694e-06
century O 0 9.502144848738681e-07
after O 0 3.0720663346528454e-08
its O 0 2.6306399281139647e-09
recognition O 0 5.654801515930785e-09
as O 0 1.5816628007314648e-08
a O 0 5.018467845729901e-07
syndrome O 1 0.7772884964942932
by O 0 4.214203208618983e-09
Vaughan O 0 5.550366495299386e-07
Pendred O 0 7.317517543015128e-07
, O 0 7.0193899581738606e-09
the O 0 3.839889117784878e-08
disease O 0 1.5195735613815486e-05
gene O 0 5.322044671629556e-07
( O 0 2.6616810089308274e-08
PDS O 0 9.559485079080332e-06
) O 0 1.948858141531673e-08
was O 0 7.529072121315039e-08
mapped O 0 9.366503945784643e-07
to O 0 1.106314542198561e-07
chromosome O 0 0.00025996402837336063
7q22 O 0 2.2334614186547697e-05
- O 0 1.7691652828943916e-05
q31 O 0 1.4147904948913492e-05
. O 0 3.87200714158098e-07

1 O 0 1.13102523755515e-05
and O 0 7.838496571821452e-07
, O 0 5.218101506443418e-08
recently O 0 2.1599402089123032e-07
, O 0 2.35717312335737e-09
found O 0 4.657105812100326e-09
to O 0 3.4822411620893945e-09
encode O 0 3.7750902492916794e-07
a O 0 2.4506252316314203e-07
putative O 0 3.4856882848544046e-05
sulfate O 0 2.374963332840707e-05
transporter O 0 9.551605035085231e-05
. O 0 1.2082653029210633e-06

We O 0 1.771079405443743e-05
performed O 0 4.2227447920595296e-06
mutation O 0 9.973635997084784e-07
analysis O 0 3.1094174346435466e-08
of O 0 2.905899743055329e-09
the O 0 1.9683248808632925e-08
PDS B-Disease 0 8.28163592814235e-06
gene O 0 4.230158765494707e-07
in O 0 2.0290366720132624e-08
patients O 0 1.6800601088107214e-07
from O 0 4.31254409960502e-09
14 O 0 3.386157487739183e-08
Pendred B-Disease 0 5.807699494653207e-07
families O 0 1.5329797875551776e-08
originating O 0 1.7256938988907677e-08
from O 0 4.6723198643405794e-09
seven O 0 8.65775984237871e-09
countries O 0 2.904990914487371e-09
and O 0 1.6905705280123584e-08
identified O 0 1.2942160765305744e-07
all O 0 1.6487648579754932e-08
mutations O 0 3.261311121605104e-06
. O 0 1.9870142864419904e-07

The O 0 1.9996282389911357e-06
mutations O 0 7.108264981070533e-06
include O 0 4.87303566387709e-08
three O 0 8.403741702522893e-08
single O 0 2.49517370320973e-06
base O 0 1.3915573049416707e-07
deletions O 0 5.973336101305904e-07
, O 0 9.560134905939321e-09
one O 0 1.624993650750639e-08
splice O 0 8.826889825286344e-05
site O 0 2.11749761547253e-06
mutation O 0 4.883661404164741e-06
and O 0 1.194699592588222e-07
10 O 0 2.619047165808297e-07
missense O 0 4.4967640860704705e-05
mutations O 0 2.3198048438644037e-05
. O 0 6.43511896214477e-07

One O 0 1.1531399650266394e-05
missense O 0 0.00021390752226579934
mutation O 0 2.866862269002013e-05
( O 0 2.153613252176001e-07
L236P O 0 1.5574970575471525e-06
) O 0 5.483919807147686e-08
was O 0 3.0574236120628484e-07
found O 0 2.6424791244039625e-08
in O 0 1.6332456498346914e-09
a O 0 1.7474251379212546e-08
homozygous O 0 3.5799666875391267e-06
state O 0 2.8770508198050493e-09
in O 0 1.6958080495399486e-09
two O 0 1.1018538081941642e-08
consanguineous O 0 2.1932692106929608e-05
families O 0 3.323217185879912e-07
and O 0 3.386131552929328e-08
in O 0 3.803310555383632e-09
a O 0 1.0989051446586018e-08
heterozygous O 0 3.759160733807221e-07
state O 0 1.8008725621854182e-09
in O 0 9.075309947981225e-10
five O 0 5.5760156492112856e-09
additional O 0 8.00852362203841e-09
non O 0 7.735475264780689e-07
- O 0 9.766516086529009e-06
consanguineous O 0 0.0001148836308857426
families O 0 7.281909120138153e-07
. O 0 2.417947939648002e-07

Another O 0 3.760703111765906e-05
missense O 0 0.00044655174133367836
mutation O 0 3.171227217535488e-05
( O 0 2.999094306233019e-07
T416P O 0 1.7927806084117037e-06
) O 0 3.661211422922861e-08
was O 0 3.0596231681556674e-07
found O 0 1.919903347413765e-08
in O 0 1.7145479480618064e-09
a O 0 1.0637716485462079e-08
homozygous O 0 5.059709451415983e-07
state O 0 1.6686001469423672e-09
in O 0 1.2433137852596587e-09
one O 0 1.7361164950102648e-08
family O 0 3.254740477132145e-08
and O 0 1.597221022109352e-08
in O 0 2.211429928067332e-09
a O 0 8.017373431812302e-09
heterozygous O 0 3.3099013307946734e-07
state O 0 1.8778476551517542e-09
in O 0 2.0957695578971425e-09
four O 0 4.372061823687545e-08
families O 0 1.0815260509389191e-07
. O 0 7.479234653828826e-08

Pendred B-Disease 0 0.03295329585671425
patients O 1 0.6885329484939575
in O 0 1.222000349798691e-07
three O 0 9.123636601771068e-08
non O 0 1.6815648677948047e-06
- O 0 5.314565441949526e-06
consanguineous O 0 3.168470357195474e-05
families O 0 2.3247061164965999e-07
were O 0 1.6918713185987144e-07
shown O 0 1.6903028310366608e-08
to O 0 8.99445851132441e-09
be O 0 2.4863693326437897e-08
compound O 0 6.192819768102709e-08
heterozygotes O 0 3.2478513389833097e-07
for O 0 9.275072265779727e-09
L236P O 0 8.897975476429565e-07
and O 0 6.529266727284266e-08
T416P O 0 5.601026714430191e-06
. O 0 3.3910507113432686e-07

In O 0 1.0581387641650508e-06
total O 0 2.3433567264419253e-07
, O 0 1.2225594758774605e-08
one O 0 3.821839289486206e-09
or O 0 1.0061295796504055e-08
both O 0 2.950158117798196e-09
of O 0 8.124665384912078e-10
these O 0 5.3886295425797925e-09
mutations O 0 9.593463801138569e-07
were O 0 3.0244851245697646e-07
found O 0 1.6709895689359655e-08
in O 0 1.7736696555914477e-09
nine O 0 2.2467487426069965e-08
of O 0 8.827992226123627e-10
the O 0 1.0103179626241854e-08
14 O 0 1.112970835492888e-07
families O 0 2.89341848258573e-08
analyzed O 0 6.017538680680445e-07
. O 0 2.0210691786815005e-07

The O 0 2.855001355328568e-07
identification O 0 2.021240703697913e-07
of O 0 7.828425019340557e-09
two O 0 2.3012399097410707e-08
frequent O 0 2.024291916313814e-06
PDS B-Disease 0 0.010580407455563545
mutations O 0 9.51046240516007e-06
will O 0 5.524714463689406e-09
facilitate O 0 1.5376446782511266e-08
the O 0 1.438185304181161e-08
molecular O 0 4.1626699385233223e-05
diagnosis O 1 0.991195559501648
of O 0 8.870651981851552e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.5308160022395896e-06

Insertional O 0 0.001125609502196312
mutation O 0 4.026731039630249e-05
by O 0 1.57484222995663e-07
transposable O 0 7.757402272545733e-06
element O 0 4.778345328304567e-07
, O 0 3.1491619978396557e-08
L1 O 0 1.554864320496563e-05
, O 0 1.2210912281318542e-08
in O 0 4.170797929248238e-09
the O 0 4.4193139814296956e-08
DMD B-Disease 1 0.9999996423721313
gene O 0 5.154062819201499e-06
results O 0 4.0280514213009155e-07
in O 0 6.254666118366004e-08
X B-Disease 1 0.999982476234436
- I-Disease 1 0.9999654293060303
linked I-Disease 1 0.9999701976776123
dilated I-Disease 1 0.9999814033508301
cardiomyopathy I-Disease 1 1.0
. O 0 4.140607416047715e-06

X B-Disease 1 0.9999853372573853
- I-Disease 1 0.9999935626983643
linked I-Disease 1 0.9999716281890869
dilated I-Disease 1 0.9999978542327881
cardiomyopathy I-Disease 1 1.0
( O 0 2.2199452359927818e-05
XLDCM B-Disease 0 0.0006389279733411968
) O 0 3.2335972122155e-08
is O 0 4.102871375977202e-09
a O 0 2.0356267782517534e-08
clinical O 0 1.5513198377448134e-05
phenotype O 0 5.400518602982629e-06
of O 0 9.769018483041236e-09
dystrophinopathy B-Disease 0 1.0646509508660529e-05
which O 0 9.623013497161992e-09
is O 0 1.864517429339685e-09
characterized O 0 2.3084760769620516e-08
by O 0 3.634089917881056e-09
preferential O 0 1.4477139302471187e-05
myocardial B-Disease 0 0.08714428544044495
involvement I-Disease 0 1.8278421975992387e-07
without O 0 1.638366420309012e-08
any O 0 5.865278041028432e-09
overt O 0 5.871274424862349e-06
clinical O 0 0.0008933613426052034
signs O 0 2.9278207875904627e-05
of O 0 1.2071894843757036e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 1.7242749891011044e-05

To O 0 1.1449939165686374e-06
date O 0 2.276613599860866e-07
, O 0 1.0611250544911854e-08
several O 0 9.79065628570197e-09
mutations O 0 5.008321863897436e-07
in O 0 5.0832409392853606e-09
the O 0 1.1009698397401735e-07
Duchenne B-Disease 1 0.9985211491584778
muscular I-Disease 0 0.13115249574184418
dystrophy I-Disease 1 0.6548046469688416
gene O 0 4.847102172789164e-05
, O 0 2.7485990017339645e-07
DMD O 1 0.9999998807907104
, O 0 1.791555348518159e-07
have O 0 1.1294899593394803e-07
been O 0 4.372245498984739e-08
identified O 0 6.93023451958652e-08
in O 0 5.048957252284936e-09
patients O 0 9.23947922615298e-08
with O 0 6.936764496145997e-09
XLDCM B-Disease 0 9.697788482299075e-05
, O 0 6.02092864454562e-09
but O 0 1.4307179885264532e-09
a O 0 1.2511690572480916e-09
pathogenic O 0 5.879953945964189e-08
correlation O 0 4.2892573048902705e-08
of O 0 1.4047376595271999e-09
these O 0 9.259816913242958e-09
cardiospecific O 0 1.0388011105533224e-05
mutations O 0 6.390360795194283e-06
in O 0 2.385651320935267e-08
DMD O 1 1.0
with O 0 6.676089725488055e-08
the O 0 7.075350794139013e-08
XLDCM B-Disease 0 0.00022961832291912287
phenotype O 0 1.5255965990945697e-05
has O 0 1.0485189250175608e-07
remained O 0 3.869622560159769e-07
to O 0 9.711834003667263e-09
be O 0 5.926952795221041e-08
elucidated O 0 5.000932560506044e-06
. O 0 2.422788440981094e-07

We O 0 2.6077466827700846e-05
report O 0 2.7460495743980573e-07
here O 0 4.512340723294983e-09
the O 0 1.84510229317425e-09
identification O 0 1.6393636670386513e-08
of O 0 2.6366175909231515e-09
a O 0 6.082255765704758e-08
unique O 0 3.428374100167275e-07
de O 0 3.458939681877382e-05
novo O 0 1.9529441033228068e-06
L1 O 0 3.929738340957556e-06
insertion O 0 5.367382414078747e-07
in O 0 2.566719459196065e-08
the O 0 1.441467034624111e-08
muscle O 0 4.1940504047488503e-07
exon O 0 4.2851766579588e-07
1 O 0 7.800526446999356e-08
in O 0 6.059918433720668e-08
DMD O 1 0.9999997615814209
in O 0 1.291598294983487e-07
three O 0 3.40833480549918e-07
XLDCM B-Disease 0 0.0006124647334218025
patients O 0 1.0055944130726857e-06
from O 0 3.35308891763475e-09
two O 0 1.0083542889560704e-08
unrelated O 0 1.313778454914427e-07
Japanese O 0 2.8112316385886515e-07
families O 0 2.2117838227586617e-07
. O 0 1.9209240065265476e-07

The O 0 1.066911977432028e-06
insertion O 0 4.077918674738612e-06
was O 0 7.054019306451664e-07
a O 0 2.1722845744420738e-08
5 O 0 2.522606479260503e-08
- O 0 1.6781224587703036e-07
truncated O 0 6.355890747045123e-08
form O 0 1.5727284363720173e-08
of O 0 1.6683709969100846e-09
human O 0 2.1632132529703085e-08
L1 O 0 1.6896345869099605e-06
inversely O 0 2.834061660905718e-07
integrated O 0 7.025633976809331e-07
in O 0 1.2552571426738268e-08
the O 0 1.8667636325631065e-08
5 O 0 6.172536615167701e-08
- O 0 6.407989303625072e-07
untranslated O 0 2.8904678401886486e-06
region O 0 1.1293833779291163e-07
in O 0 5.2005120210196765e-09
the O 0 5.270040404070642e-09
muscle O 0 1.0367343605821588e-07
exon O 0 5.51696679451652e-08
1 O 0 9.696045744078674e-09
, O 0 1.944587157964861e-09
which O 0 2.0990300608758616e-09
affected O 0 3.877406840047115e-09
the O 0 4.598529057542322e-10
transcription O 0 2.2782332464998944e-08
or O 0 2.6139261422031268e-08
the O 0 5.207956732533603e-09
stability O 0 3.293363803891225e-08
of O 0 5.858655227619636e-10
the O 0 3.4630724954354264e-09
muscle O 0 1.0143886441937866e-07
form O 0 5.712789352685377e-09
of O 0 1.421144424362808e-09
dystrophin O 0 2.542120682846871e-07
transcripts O 0 2.0930366417815094e-07
but O 0 1.3808671539550232e-08
not O 0 2.371594920447251e-09
that O 0 2.770601803536721e-10
of O 0 3.158085182253245e-10
the O 0 7.443907712456621e-09
brain O 0 8.184808393707499e-06
or O 0 1.2335875965163723e-07
Purkinje O 0 1.6157392792592873e-06
cell O 0 6.967788976908196e-07
form O 0 1.381625196472669e-07
, O 0 1.8685234692839003e-08
probably O 0 9.97751925524426e-08
due O 0 1.0718204990212143e-08
to O 0 3.046373375781286e-09
its O 0 2.9190374561949284e-09
unique O 0 4.221395233372505e-09
site O 0 3.6878578413279683e-08
of O 0 3.060315556524529e-09
integration O 0 3.4288970596207946e-07
. O 0 2.8261939633011934e-07

We O 0 5.5609220908081625e-06
speculate O 0 3.746397965187498e-07
that O 0 7.095930509848358e-09
this O 0 1.1518288545175892e-09
insertion O 0 4.510794227030601e-08
of O 0 3.1586171456154943e-09
an O 0 1.979140407115665e-08
L1 O 0 6.052463504602201e-05
sequence O 0 4.4288495359978697e-07
in O 0 1.1941459376885177e-07
DMD O 1 1.0
is O 0 6.841347044428403e-08
responsible O 0 6.016132658714923e-08
for O 0 6.826091358824726e-10
some O 0 2.60644533733867e-10
of O 0 2.0461191074794272e-10
the O 0 8.928068839786363e-10
population O 0 1.6256561652383539e-09
of O 0 3.4283831329418035e-10
Japanese O 0 2.9926147249170754e-07
patients O 0 1.5511778883592342e-07
with O 0 2.019080369564108e-08
XLDCM B-Disease 0 1.2869380043412093e-05
. O 0 3.308285201342187e-08
. O 0 1.1433044733166753e-07

Severe O 1 0.9278682470321655
early O 0 9.339051757706329e-05
- O 1 0.9720805287361145
onset O 1 0.9999862909317017
obesity B-Disease 1 1.0
, O 0 0.0005648044170811772
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 6.7920846049673855e-06
red O 0 2.566726107033901e-05
hair O 1 0.9903751015663147
pigmentation O 0 0.2597431242465973
caused O 0 6.682416824332904e-06
by O 0 7.299291837625788e-08
POMC O 0 0.00018094335973728448
mutations O 0 1.0066354661830701e-05
in O 0 4.6993672953021814e-08
humans O 0 7.128027164071682e-07
. O 0 3.2463648835800996e-07

Sequential O 0 4.388368324725889e-05
cleavage O 0 7.842024206183851e-05
of O 0 1.9483849200696568e-07
the O 0 5.786961310150218e-08
precursor O 0 6.315106588772323e-07
protein O 0 3.242033415062906e-07
pre O 0 1.678278567851521e-05
- O 0 2.614791810628958e-05
pro O 0 7.2954330789798405e-06
- O 0 4.072738374816254e-05
opiomelanocortin O 0 1.3615755051432643e-05
( O 0 7.476866414890537e-08
POMC O 0 6.8580961851694155e-06
) O 0 1.9225344871642847e-08
generates O 0 4.957182042630848e-08
the O 0 2.691125366993674e-08
melanocortin O 0 1.3823943845636677e-05
peptides O 0 1.0587656333882478e-06
adrenocorticotrophin O 0 4.1664220589154866e-06
( O 0 7.683048153239724e-08
ACTH O 0 7.728558557573706e-06
) O 0 1.603698684959909e-08
, O 0 1.4503915402030998e-08
melanocyte O 0 1.4332952559925616e-05
- O 0 1.5695146430516616e-05
stimulating O 0 1.6824164049467072e-05
hormones O 0 9.377878996019717e-06
( O 0 4.073842063689881e-08
MSH O 0 2.39981409322354e-06
) O 0 8.845256083134245e-09
alpha O 0 1.692067463920921e-08
, O 0 1.288683604272478e-09
beta O 0 3.719446750594102e-09
and O 0 1.32836652788626e-09
gamma O 0 1.3925391506575124e-08
as O 0 2.0698838198995873e-09
well O 0 2.9130748924188765e-09
as O 0 7.780756039466041e-10
the O 0 1.7283711128968093e-09
opioid O 0 2.3554845185458362e-08
- O 0 3.3252518960580346e-08
receptor O 0 1.1683717815458294e-07
ligand O 0 1.0121101468030247e-07
beta O 0 5.262118634163926e-07
- O 0 8.034726306505036e-06
endorphin O 0 0.00013663095887750387
. O 0 9.107698701882327e-07

While O 0 2.424136482659378e-06
a O 0 7.838215054789544e-08
few O 0 1.5960637256284826e-08
cases O 0 8.451075395043972e-09
of O 0 2.0724604254951373e-08
isolated O 0 0.028488866984844208
ACTH B-Disease 1 0.9999877214431763
deficiency I-Disease 1 0.918545126914978
have O 0 1.9425756647706294e-07
been O 0 5.028384748584358e-07
reported O 0 9.392928177476279e-07
( O 0 5.5098162476951984e-08
OMIM O 0 2.8581756851053797e-05
201400 O 0 1.3908622804592596e-06
) O 0 1.302699192962109e-08
, O 0 2.365667661763382e-09
an O 0 1.8456134398547874e-08
inherited O 0 0.15048812329769135
POMC O 0 0.004103184211999178
defect O 0 0.0005674533313140273
has O 0 1.834268346101453e-07
not O 0 5.276942971477183e-08
been O 0 4.8226976190335336e-08
described O 0 9.983611448660668e-08
so O 0 2.120644815306605e-08
far O 0 8.137794083040717e-08
. O 0 1.1556411294577629e-07

Recent O 0 3.1131287414609687e-06
studies O 0 8.039272074711334e-07
in O 0 3.389556013644324e-08
animal O 0 8.704606813125793e-08
models O 0 2.113566495154373e-07
elucidated O 0 5.723791218770202e-07
a O 0 1.2586134801040316e-08
central O 0 7.809231483690837e-09
role O 0 9.82993242359953e-09
of O 0 1.659361203998344e-09
alpha O 0 5.674457526083643e-08
- O 0 5.849282160852454e-07
MSH O 0 1.3001556453673402e-06
in O 0 2.972581958360365e-09
the O 0 4.086618599075109e-09
regulation O 0 1.4168742623610342e-08
of O 0 1.2963036200019928e-09
food O 0 5.3455528892243365e-09
intake O 0 6.671911911837469e-09
by O 0 3.9485745229050906e-10
activation O 0 8.144668939280564e-09
of O 0 1.2100729307462643e-09
the O 0 2.4580584678801642e-08
brain O 0 2.395785031694686e-06
melanocortin O 0 2.6490804430068238e-06
- O 0 7.021735655143857e-07
4 O 0 8.876899215692902e-08
- O 0 5.201646331443044e-07
receptor O 0 6.430983603422646e-07
( O 0 8.209303814510349e-08
MC4 O 0 1.2065715964126866e-05
- O 0 3.7833183341717813e-06
R O 0 8.623016583442222e-06
; O 0 3.630419698197329e-08
refs O 0 1.2920531844429206e-06
3 O 0 1.9069187828790746e-07
- O 0 6.74620366680756e-07
5 O 0 2.1386799886613517e-08
) O 0 2.2104937880129683e-09
and O 0 1.7296242216247038e-09
the O 0 2.193902393088365e-09
linkage O 0 2.246903676450529e-07
of O 0 8.354338554283913e-09
human O 0 3.7055207258163136e-07
obesity B-Disease 1 0.9999986886978149
to O 0 9.945560464075243e-08
chromosome O 0 9.110126848099753e-05
2 O 0 1.8135486357095942e-07
in O 0 1.2646293789941865e-08
close O 0 4.4393706843948166e-07
proximity O 0 2.2095618135153927e-07
to O 0 4.4212871586069014e-08
the O 0 8.147671337610518e-08
POMC O 0 1.0796224160003476e-05
locus O 0 1.0503158591745887e-06
, O 0 1.6634340127552605e-08
led O 0 6.3335603428527065e-09
to O 0 1.5059227198577219e-09
the O 0 3.6531178082555016e-09
proposal O 0 5.1118553834328395e-09
of O 0 5.662105229120584e-10
an O 0 2.6922022389186395e-09
association O 0 1.7675578334319653e-08
of O 0 7.448622607597599e-09
POMC O 0 1.5344372513936833e-05
with O 0 9.45835338939105e-08
human O 0 2.2222761799639557e-06
obesity B-Disease 1 0.9999996423721313
. O 0 8.573526315558411e-07

The O 0 6.078562364564277e-07
dual O 0 1.4278829212344135e-06
role O 0 1.8475512320037524e-07
of O 0 6.396861707003154e-09
alpha O 0 1.521288481853844e-07
- O 0 2.2676997559756273e-06
MSH O 0 7.695558451814577e-06
in O 0 6.1572249521191225e-09
regulating O 0 9.683759571998962e-08
food O 0 3.1849769044356435e-08
intake O 0 5.9330378832100905e-08
and O 0 1.3486324945688466e-08
influencing O 0 7.676352993257751e-07
hair O 0 0.00019805988995358348
pigmentation O 0 7.413153070956469e-06
predicts O 0 2.046820668510918e-07
that O 0 1.8340672314209883e-09
the O 0 5.383461676444767e-09
phenotype O 0 2.0461718577280408e-06
associated O 0 4.2360447594091966e-08
with O 0 1.2049123476742807e-08
a O 0 1.4105314960488613e-07
defect O 0 2.7280642825644463e-05
in O 0 9.608542406169818e-09
POMC O 0 5.07520144310547e-06
function O 0 6.854670431266641e-08
would O 0 1.9484010849168953e-08
include O 0 1.9895531977454084e-07
obesity B-Disease 1 1.0
, O 0 4.0141802770676804e-08
alteration O 0 4.4112255181971705e-07
in O 0 5.008503478620696e-08
pigmentation O 0 0.05339080095291138
and O 0 0.00023513045744039118
ACTH B-Disease 1 0.999991774559021
deficiency I-Disease 0 0.3008786737918854
. O 0 7.007132012404327e-07

The O 0 6.978721671657695e-07
observation O 0 1.1108262469861074e-06
of O 0 1.3961001243956161e-08
these O 0 1.350099978481012e-07
symptoms O 0 0.00011866671411553398
in O 0 4.501492512076766e-09
two O 0 1.0936463290533993e-08
probands O 0 1.0852947980311e-06
prompted O 0 2.1512972736559277e-08
us O 0 1.3220178729511645e-08
to O 0 2.456154613028616e-09
search O 0 2.9768163045673646e-08
for O 0 1.0989847254450069e-08
mutations O 0 1.3332887647266034e-06
within O 0 2.7976444272326262e-08
their O 0 1.2534727034108073e-07
POMC O 0 4.631852061720565e-05
genes O 0 4.0998020267579705e-06
. O 0 6.754031574018882e-07

Patient O 1 0.9592535495758057
1 O 0 5.765142759628361e-06
was O 0 7.617210826538212e-07
found O 0 3.8294153625884064e-08
to O 0 6.519719875086594e-09
be O 0 5.532961200316322e-09
a O 0 6.9989889439625586e-09
compound O 0 5.163372307492864e-08
heterozygote O 0 2.079319045833472e-07
for O 0 2.096097295734012e-09
two O 0 1.4216007038214684e-08
mutations O 0 1.4250382207592338e-07
in O 0 3.2804599037206117e-09
exon O 0 3.024779005045275e-07
3 O 0 8.493952208254996e-08
( O 0 1.896978396587201e-08
G7013T O 0 3.1116545073928137e-07
, O 0 9.655868105085119e-09
C7133delta O 0 3.047430254810024e-07
) O 0 1.8473311769184875e-09
which O 0 1.24376919874436e-09
interfere O 0 1.2392682435802271e-08
with O 0 1.547789563183244e-09
appropriate O 0 8.422063046964468e-09
synthesis O 0 1.9402349948904885e-08
of O 0 5.466372687834564e-09
ACTH O 0 1.2975214303878602e-05
and O 0 6.428223997545501e-08
alpha O 0 1.0354937103329576e-06
- O 0 2.1610008843708783e-05
MSH O 0 0.00015121817705221474
. O 0 1.0652973969627055e-06

Patient O 1 0.9800066351890564
2 O 0 1.17172594400472e-05
was O 0 1.2248674465809017e-06
homozygous O 0 1.2811611895813257e-06
for O 0 4.5235259982234766e-09
a O 0 1.4040259621594942e-08
mutation O 0 3.3486554684714065e-07
in O 0 5.781012113459383e-09
exon O 0 5.913515224165167e-07
2 O 0 2.0266935507606831e-07
( O 0 7.840442606266151e-08
C3804A O 0 1.6866031273821136e-06
) O 0 4.175145917884038e-08
which O 0 5.4069481336682657e-08
abolishes O 0 2.7005948140867986e-05
POMC O 0 0.00016056877211667597
translation O 0 5.069449798611458e-06
. O 0 1.4629603128923918e-06

These O 0 1.1240756521146977e-06
findings O 0 2.396259617398755e-07
represent O 0 2.7148043812985634e-08
the O 0 3.3174709646033307e-09
first O 0 2.734087178879463e-09
examples O 0 5.507438505247819e-09
of O 0 1.4288035199427895e-09
a O 0 1.2823616089008283e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999998807907104
within O 0 5.433123462239564e-08
the O 0 2.4312569735229772e-08
POMC O 0 6.976586064411094e-06
gene O 0 2.678329451555328e-07
and O 0 2.1525368154584612e-08
define O 0 2.6312065415368124e-07
a O 0 5.863401142391922e-08
new O 0 2.8726444156745856e-07
monogenic B-Disease 1 0.9964700937271118
endocrine I-Disease 1 0.9988476037979126
disorder I-Disease 0 0.05406977981328964
resulting O 0 1.8530798229221546e-07
in O 0 1.6322125873102777e-08
early O 0 9.736112360769766e-07
- O 1 0.9506565928459167
onset O 1 0.9999933242797852
obesity B-Disease 1 1.0
, O 0 0.0003522808838170022
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 4.133647962589748e-06
red O 0 1.0148188266612124e-05
hair O 0 0.028360500931739807
pigmentation O 0 0.00019271235214546323
. O 0 5.490471366442762e-08
. O 0 1.3572673651651712e-07

A O 0 9.2718864834751e-06
European O 0 3.1201223009702517e-06
multicenter O 0 4.817370427190326e-05
study O 0 7.397640615636192e-07
of O 0 2.584871026556357e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 5.8351197651518305e-08
classification O 0 1.6889903520223015e-07
of O 0 4.534687292334638e-09
105 O 0 1.2045865105392295e-07
mutations O 0 1.2998308420719695e-06
and O 0 6.9644721101269624e-09
a O 0 3.913591228865698e-09
general O 0 3.186512609332226e-09
system O 0 1.332554333544067e-08
for O 0 4.2114707277107755e-09
genotype O 0 3.379036343176267e-06
- O 0 1.2913166074213223e-06
based O 0 2.633402296225995e-08
prediction O 0 1.9545171880963608e-07
of O 0 1.93659310809835e-08
metabolic O 0 0.0005206703208386898
phenotype O 0 5.734065780416131e-05
. O 0 5.013970962863823e-07

Phenylketonuria B-Disease 1 0.999249279499054
( O 0 7.957065099617466e-05
PKU B-Disease 0 0.001177318743430078
) O 0 6.962554834899493e-07
and O 0 7.827097761037294e-07
mild B-Disease 1 0.9895738959312439
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.017181232571601868
MHP B-Disease 1 1.0
) O 0 1.179077173674159e-07
are O 0 5.2026383201564386e-08
allelic B-Disease 0 0.00027988682268187404
disorders I-Disease 1 0.9999085664749146
caused O 0 2.715415803322685e-06
by O 0 1.6992927953651815e-08
mutations O 0 1.2744696959998691e-06
in O 0 3.5318334923317707e-09
the O 0 1.9315024246679968e-08
gene O 0 1.3760499086856726e-06
encoding O 0 5.3512753765971866e-06
phenylalanine O 0 0.044821254909038544
hydroxylase O 0 0.019791254773736
( O 0 3.969366389355855e-06
PAH O 0 0.00035959036904387176
) O 0 3.289230789960129e-07
. O 0 2.710055753141205e-07

Previous O 0 7.109851594577776e-06
studies O 0 9.283780855184887e-07
have O 0 1.2328949594575533e-07
suggested O 0 6.082093761961005e-08
that O 0 1.6661259039096876e-09
the O 0 3.693177763608446e-09
highly O 0 9.094863884229198e-08
variable O 0 3.0601822800235823e-06
metabolic O 0 0.056763533502817154
phenotypes O 0 0.0010492246365174651
of O 0 2.0575466805894393e-06
PAH B-Disease 1 0.9999969005584717
deficiency I-Disease 1 0.9987313151359558
correlate O 0 0.00024117757857311517
with O 0 8.265192263934296e-06
PAH O 1 0.7102077007293701
genotypes O 0 0.000539750384632498
. O 0 1.6288279311993392e-06

We O 0 9.606228559277952e-06
identified O 0 1.7285503872699337e-06
both O 0 1.2808017402221594e-07
causative O 0 9.603645594324917e-06
mutations O 0 3.824565283139236e-06
in O 0 1.1874747407603081e-08
686 O 0 1.692225964688987e-06
patients O 0 7.3045252975134645e-06
from O 0 1.7404598651182823e-08
seven O 0 3.673360993161623e-08
European O 0 3.43414654935259e-07
centers O 0 3.9599447632099327e-07
. O 0 1.9901946757272526e-07

On O 0 1.2969444469490554e-06
the O 0 3.661672565158369e-08
basis O 0 1.4879163678926943e-08
of O 0 1.2188056119910584e-09
the O 0 4.284487875594323e-09
phenotypic O 0 4.579701453621965e-07
characteristics O 0 3.4947993299283553e-07
of O 0 8.30085866709851e-09
297 O 0 1.1220150781809934e-06
functionally O 0 8.336978680745233e-06
hemizygous O 0 9.183656402456108e-06
patients O 0 1.2907281643492752e-06
, O 0 2.317766423232115e-09
105 O 0 6.620116899114237e-09
of O 0 5.486717746805425e-10
the O 0 1.0190035482082749e-08
mutations O 0 1.1931126664421754e-06
were O 0 8.482230384743161e-08
assigned O 0 4.898737770986372e-08
to O 0 4.813413667648092e-09
one O 0 6.161383847569368e-09
of O 0 1.3648491226092574e-09
four O 0 2.8353447589779535e-08
arbitrary O 0 5.195171866034798e-07
phenotype O 0 1.167089976661373e-05
categories O 0 4.548810920823598e-06
. O 0 4.886531428383023e-07

We O 0 2.4192752334784018e-06
proposed O 0 1.0073262046716991e-07
and O 0 1.4710396101236256e-07
tested O 0 1.3741615703111165e-06
a O 0 7.983161687263873e-09
simple O 0 1.000293448072398e-08
model O 0 5.824500348694528e-08
for O 0 1.0586419518787693e-09
correlation O 0 1.5195254832178762e-07
between O 0 3.182833197001855e-08
genotype O 0 8.552721737942193e-06
and O 0 3.851331342730191e-08
phenotypic O 0 1.0725856554927304e-05
outcome O 0 3.0395956400752766e-06
. O 0 7.124113494683115e-07

The O 0 2.87996772385668e-06
observed O 0 4.5414681153488345e-06
phenotype O 0 6.645701432717033e-06
matched O 0 1.6936194242589409e-06
the O 0 3.221021316335282e-08
predicted O 0 3.507323356188863e-07
phenotype O 0 9.216797138833499e-07
in O 0 5.499901423178244e-09
79 O 0 1.0422322560543762e-07
% O 0 6.443615419016169e-09
of O 0 5.695846017061967e-10
the O 0 5.890974819067196e-09
cases O 0 9.20083920163961e-09
, O 0 4.360516836499073e-09
and O 0 1.613996936100648e-08
in O 0 1.0955142348834102e-09
only O 0 1.6772567779099745e-09
5 O 0 1.190669673967193e-09
of O 0 2.004516136411283e-10
184 O 0 2.2622636208780023e-08
patients O 0 1.7410000907602807e-07
was O 0 3.8089314813305464e-08
the O 0 3.8478051855861395e-09
observed O 0 2.3240758650899807e-08
phenotype O 0 3.5249303920181774e-08
more O 0 9.576007764522387e-10
than O 0 2.419404010467474e-09
one O 0 8.901325898591494e-09
category O 0 4.854259714193176e-07
away O 0 5.0407717111511374e-08
from O 0 6.695342946727578e-09
that O 0 6.70451827389229e-09
expected O 0 4.048944646228847e-08
. O 0 8.68863310188317e-08

Among O 0 4.144277681916719e-06
the O 0 1.439349262000178e-07
seven O 0 1.7900899251799274e-07
contributing O 0 1.0125948080030867e-07
centers O 0 3.6056871266509916e-08
, O 0 2.7051216822115975e-09
the O 0 2.5111845936010013e-09
proportion O 0 1.4224469602197587e-08
of O 0 1.3648153718293088e-09
patients O 0 4.8735934399246617e-08
for O 0 1.3833655332362582e-09
whom O 0 2.8795117401614334e-08
the O 0 2.7631936738714558e-09
observed O 0 6.987040279682333e-08
phenotype O 0 3.109489057351311e-07
did O 0 1.1376356923165076e-07
not O 0 1.3087359640451268e-08
match O 0 1.8340618623824412e-07
the O 0 1.4350861832213013e-08
predicted O 0 3.396374950170866e-07
phenotype O 0 8.825195436656941e-07
was O 0 6.504444627353223e-08
4 O 0 1.5788447882414403e-08
% O 0 2.4100648587932483e-08
- O 0 8.964983635451063e-07
23 O 0 2.183809186817598e-07
% O 0 2.315562852572839e-08
( O 0 2.6443446543567006e-08
P O 0 5.57215525986976e-06
< O 0 3.1640095699003723e-07
. O 0 6.861181400807936e-09
0001 O 0 4.253622023497883e-07
) O 0 2.5500341838124996e-09
, O 0 1.5619535664868067e-09
suggesting O 0 1.9723799482562754e-08
that O 0 8.420002473030763e-10
differences O 0 2.149738698165038e-08
in O 0 6.627112747459307e-10
methods O 0 1.5857802182495107e-08
used O 0 3.26509308479217e-08
for O 0 7.588727868323986e-09
mutation O 0 5.099611826153705e-07
detection O 0 1.470639858780487e-06
or O 0 9.174203796646907e-07
phenotype O 0 2.8168238713988103e-05
classification O 0 8.280119800474495e-06
may O 0 1.6413368939538486e-06
account O 0 7.38987111503775e-08
for O 0 1.830753881826297e-09
a O 0 8.078528956900755e-09
considerable O 0 5.7548426468656544e-08
proportion O 0 2.1586819798358192e-07
of O 0 1.391121529081829e-08
genotype O 0 0.0004994153277948499
- O 0 0.0003002190787810832
phenotype O 0 7.612823537783697e-05
inconsistencies O 0 1.6929565390455537e-05
. O 0 1.267737161469995e-06

Our O 0 4.7315525080193765e-06
data O 0 3.6007014614369837e-07
indicate O 0 2.995901127178513e-07
that O 0 5.6727342823137406e-09
the O 0 5.377666312256224e-08
PAH O 0 0.00014226272469386458
- O 0 3.5632626804726897e-06
mutation O 0 1.8283735698787495e-06
genotype O 0 1.5476877024411806e-06
is O 0 5.5127986620107094e-09
the O 0 2.2922279629966624e-09
main O 0 2.8544450358936047e-08
determinant O 0 2.9651440058842127e-07
of O 0 7.166236049016561e-09
metabolic O 0 0.0005769602139480412
phenotype O 0 8.634084224468097e-06
in O 0 1.0230386315868145e-08
most O 0 5.5246960783961185e-08
patients O 0 2.9984992579557e-05
with O 0 1.7570324416738003e-05
PAH B-Disease 1 0.9999908208847046
deficiency I-Disease 1 0.7047715187072754
. O 0 4.925171879222034e-07

In O 0 4.322922961819131e-07
the O 0 2.659975884000687e-08
present O 0 1.7793563955592617e-08
study O 0 9.136797984865552e-09
, O 0 1.7399146567953494e-09
the O 0 1.0856421317484433e-09
classification O 0 6.917952077856171e-08
of O 0 2.7154969384213246e-09
105 O 0 9.014510737870296e-07
PAH O 0 0.0001073349267244339
mutations O 0 4.597666247718735e-06
may O 0 2.691392353426636e-08
allow O 0 4.324965718893736e-09
the O 0 4.523647234577766e-09
prediction O 0 8.825643504906111e-08
of O 0 6.934485208276442e-10
the O 0 3.582433016902087e-09
biochemical O 0 1.5773855466250097e-06
phenotype O 0 1.3082438954370446e-06
in O 0 6.296606347433453e-09
> O 0 7.144415548054894e-08
10 O 0 1.2832856555178296e-08
, O 0 3.2677331951447286e-09
000 O 0 2.2421851042508933e-08
genotypes O 0 5.797710400656797e-07
, O 0 5.761362942280357e-09
which O 0 8.612254021045374e-09
may O 0 4.496217442806483e-08
be O 0 1.7491882386977409e-09
useful O 0 2.817451161263307e-09
for O 0 7.692131931413826e-10
the O 0 5.715024009589342e-09
management O 0 3.6826566685022044e-08
of O 0 1.1281579226363192e-08
hyperphenylalaninemia B-Disease 1 0.9999988079071045
in O 0 1.724309584005823e-07
newborns O 0 9.451379446545616e-05
. O 0 2.625148454171722e-07

Somatic O 0 0.0002653741976246238
instability O 0 2.0815439711441286e-05
of O 0 1.0075395096009743e-07
the O 0 1.3026300393903512e-07
CTG O 0 2.5251050828956068e-05
repeat O 0 1.7427938701075618e-06
in O 0 1.344769273714519e-08
mice O 0 8.294323379232083e-07
transgenic O 0 2.0303458825310372e-07
for O 0 6.180120859511362e-09
the O 0 2.866590875783004e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.5553440536896233e-06
is O 0 2.2756838191639872e-08
age O 0 4.6816083454359614e-08
dependent O 0 2.1375463177264464e-08
but O 0 2.343679028626866e-09
not O 0 2.9326709949373253e-09
correlated O 0 2.6193360369575203e-08
to O 0 2.3273749594210358e-09
the O 0 5.727616603223851e-09
relative O 0 2.3152828987349494e-07
intertissue O 0 2.2146828086988535e-06
transcription O 0 8.961761182035843e-07
levels O 0 9.135056870945846e-07
and O 0 2.0005579415283137e-07
proliferative O 0 0.00021172864944674075
capacities O 0 1.0093394848809112e-05
. O 0 4.0814023805069155e-07

A O 0 3.206903420505114e-05
( O 0 2.758874870778527e-06
CTG O 0 2.2954371161176823e-05
) O 0 5.856840346041281e-08
nexpansion O 0 1.0337798812543042e-06
in O 0 6.32173335901598e-09
the O 0 1.2651360847826254e-08
3 O 0 1.0528797389497413e-07
- O 0 3.902631306118565e-06
untranslated O 0 2.8295102310949005e-05
region O 0 6.629633730881324e-07
( O 0 2.5365306299818258e-08
UTR O 0 3.79776736281201e-07
) O 0 5.918319168074504e-09
of O 0 1.806321647812581e-09
the O 0 7.537045831895739e-08
DM O 1 0.9999998807907104
protein O 0 1.5234053307722206e-06
kinase O 0 1.759153019520454e-05
gene O 0 4.874499609286431e-06
( O 0 7.850708527712413e-08
DMPK O 0 3.5487178138282616e-06
) O 0 6.315321154914955e-09
is O 0 1.8722898786904807e-09
responsible O 0 6.768584626115626e-08
for O 0 3.685291360966403e-08
causing O 0 0.013256723992526531
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00033336266642436385
DM B-Disease 1 1.0
) O 0 8.772239539212023e-07
. O 0 2.677496695469017e-07

Major O 0 1.8851511413231492e-05
instability O 0 2.390599183854647e-05
, O 0 6.169405963873942e-08
with O 0 9.771515152579013e-09
very O 0 6.389984097410206e-09
large O 0 1.8162922277298321e-09
expansions O 0 3.0519466065470624e-08
between O 0 5.890693710597361e-09
generations O 0 1.0235305047956444e-08
and O 0 4.086976979067458e-09
high O 0 4.1583529508670836e-08
levels O 0 3.286010041847476e-08
of O 0 9.091179475895217e-10
somatic O 0 3.5486834804032696e-07
mosaicism O 0 2.802421931846766e-06
, O 0 1.067588950576237e-08
is O 0 6.66346755551217e-09
observed O 0 5.663568813929487e-08
in O 0 3.1539226341692483e-08
patients O 0 1.1159526138726505e-06
. O 0 2.1373183756168146e-07

There O 0 3.227391289328807e-06
is O 0 5.6380251578502794e-08
a O 0 2.5837390893457268e-08
good O 0 6.54743743666586e-08
correlation O 0 2.251743183023791e-07
between O 0 3.6627621824436574e-08
repeat O 0 1.968662672879873e-06
size O 0 2.4667150455570663e-07
( O 0 2.625017536672658e-08
at O 0 1.1392142340582723e-07
least O 0 1.0523934612649555e-08
in O 0 2.4398032483219367e-09
leucocytes O 0 7.138802970985125e-07
) O 0 2.9375246679563816e-09
, O 0 2.0329018468601134e-09
clinical O 0 2.0549649093482003e-07
severity O 0 4.61297668152838e-06
and O 0 1.143479977372408e-07
age O 0 3.133823440748529e-07
of O 0 1.828954054872156e-08
onset O 0 0.0002216504217358306
. O 0 6.968413686081476e-07

The O 0 8.913822966860607e-06
trinucleotide O 0 0.0008622560417279601
repeat O 0 5.661043178406544e-05
instability O 0 6.89989155944204e-06
mechanisms O 0 2.05044216272654e-06
involved O 0 3.572084779079887e-07
in O 0 7.923306100110494e-08
DM B-Disease 1 1.0
and O 0 1.4196420750067773e-07
other O 0 4.134019349066875e-08
human O 0 4.643857209885027e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.957095546207711e-07
unknown O 0 1.9801766484306427e-06
. O 0 2.4232713258243166e-07

We O 0 6.205629233591026e-06
studied O 0 1.2313114439166384e-06
somatic O 0 1.0272609870298766e-05
instability O 0 2.2923090909898747e-06
by O 0 4.2898381735767543e-08
measuring O 0 4.030492345918901e-05
the O 0 1.4495402922420908e-07
CTG O 0 1.1377260307199322e-05
repeat O 0 8.913628448681266e-07
length O 0 2.893461044095602e-07
at O 0 4.6259280850335927e-08
several O 0 4.13972234269977e-09
ages O 0 1.0905534253424776e-07
in O 0 1.261205695435308e-09
various O 0 6.827578502566212e-09
tissues O 0 2.6445772505212517e-07
of O 0 4.455111390910815e-09
transgenic O 0 1.1527466767802252e-06
mice O 0 4.493762389756739e-06
carrying O 0 1.5550023135801894e-07
a O 0 2.8092800974377496e-08
( O 0 3.199998843683716e-08
CTG O 0 2.1785058379464317e-06
) O 0 1.427137519272037e-08
55expansion O 0 5.545467161027773e-07
surrounded O 0 5.4799254911586104e-08
by O 0 1.6719643447515864e-09
45 O 0 3.950308968825311e-09
kb O 0 1.466214456513626e-07
of O 0 1.364378054979909e-09
the O 0 1.306386643307178e-08
human O 0 1.2508837698987918e-07
DM B-Disease 1 1.0
region O 0 2.420137263925426e-07
, O 0 3.739806242464283e-09
using O 0 2.6485899695671833e-08
small O 0 1.6950674819327105e-07
- O 0 1.638028334127739e-05
pool O 0 6.158217729534954e-06
PCR O 0 2.001344910240732e-05
. O 0 4.837705205318343e-07

These O 0 2.800682977976976e-06
mice O 0 5.3770982049172744e-05
have O 0 6.866368096325459e-08
been O 0 2.2685245681941524e-08
shown O 0 9.249014887302565e-09
to O 0 5.442112094300455e-09
reproduce O 0 2.408683030807879e-06
the O 0 4.567656031184697e-09
intergenerational O 0 1.5912814887997229e-07
and O 0 6.9858652196330695e-09
somatic O 0 3.7966955801493896e-07
instability O 0 2.6380382678325986e-07
of O 0 5.6382587487746605e-09
the O 0 3.361556011327593e-08
55 O 0 4.7386012624883733e-07
CTG O 0 3.6706478567793965e-06
repeat O 0 4.3481281863932963e-07
suggesting O 0 8.917830740529098e-08
that O 0 2.299865409227664e-09
surrounding O 0 9.039587745007793e-09
sequences O 0 2.952112865273193e-08
and O 0 5.27466603728044e-09
the O 0 2.0336543560262044e-09
chromatin O 0 4.626121707929087e-08
environment O 0 7.855337003093155e-08
are O 0 3.6017950844069446e-09
involved O 0 8.822542696407254e-09
in O 0 5.491012977643095e-09
instability O 0 7.746903065708466e-07
mechanisms O 0 2.0812642560485983e-06
. O 0 2.2393309961898922e-07

As O 0 1.7125132671935717e-06
observed O 0 2.8792709372282843e-07
in O 0 2.302586787905625e-09
some O 0 8.126897488303086e-10
of O 0 3.805703252535153e-10
the O 0 4.495143368643539e-09
tissues O 0 7.052660180306702e-07
of O 0 1.9404977180670357e-08
DM B-Disease 1 1.0
patients O 0 0.0004386859363876283
, O 0 4.1144145868088344e-09
there O 0 3.831561290468244e-09
is O 0 1.6148030690388282e-09
a O 0 5.3744337868977254e-09
tendency O 0 1.2538457383470814e-07
for O 0 6.146500641790453e-09
repeat O 0 5.759684427175671e-07
length O 0 1.4342164433855942e-07
and O 0 1.571361174512731e-08
somatic O 0 3.44840941579605e-07
mosaicism O 0 1.0204533964497386e-06
to O 0 1.5890773141791215e-08
increase O 0 1.2861084641713205e-08
with O 0 5.267015712462353e-09
the O 0 1.6104237943181943e-08
age O 0 3.5988986013535396e-08
of O 0 7.873344198827681e-10
the O 0 1.5491547600277045e-08
mouse O 0 3.4250906537636183e-06
. O 0 2.8818146802223055e-07

Furthermore O 0 3.5584333090810105e-05
, O 0 5.2820990958935e-07
we O 0 1.4187840235990734e-07
observed O 0 8.990173938627777e-08
no O 0 1.2764382439911515e-08
correlation O 0 1.0788146909135321e-07
between O 0 5.1822435231940744e-09
the O 0 4.0070027296224e-09
somatic O 0 7.598999332003586e-07
mutation O 0 1.238524873770075e-06
rate O 0 5.041675876782392e-07
and O 0 6.636226146383706e-08
tissue O 0 6.230283906916156e-05
proliferation O 0 6.55184339848347e-06
capacity O 0 3.198443607743684e-07
. O 0 1.6721396889352036e-07

The O 0 1.6519684322702233e-06
somatic O 0 1.3126958037901204e-05
mutation O 0 5.236614470049972e-06
rates O 0 1.0097102176587214e-06
in O 0 5.1577786486234345e-09
different O 0 8.203805634821038e-09
tissues O 0 1.731280690364656e-06
were O 0 3.037872033928579e-07
also O 0 4.568998068776864e-09
not O 0 2.241478558318022e-09
correlated O 0 1.901060464604143e-08
to O 0 2.4180846214250096e-09
the O 0 5.797995861200889e-09
relative O 0 2.573237054548372e-07
inter O 0 8.739224540477153e-06
- O 0 5.647142825182527e-05
tissue O 0 6.125348136265529e-06
difference O 0 6.685570497211302e-08
in O 0 1.9793509054011338e-09
transcriptional O 0 3.093799989528634e-07
levels O 0 1.1142942213382412e-07
of O 0 1.217539291609171e-09
the O 0 4.554641552800831e-09
three O 0 1.3898405093470956e-08
genes O 0 7.932045775760344e-08
( O 0 8.937136364295384e-09
DMAHP O 0 1.5116669374037883e-06
, O 0 1.1326942939149376e-08
DMPK O 0 1.2611651527549839e-06
and O 0 3.434630357901369e-08
59 O 0 1.2531477011634706e-07
) O 0 3.761797984225268e-09
surrounding O 0 1.2436702334639449e-08
the O 0 1.9698910946885917e-08
repeat O 0 7.407884368149098e-07
. O 0 1.657283910105889e-08
. O 0 1.0543749340286013e-07

A O 0 9.978230082197115e-06
novel O 0 4.586245722748572e-06
missense O 0 1.842095298343338e-05
mutation O 0 4.717990123026539e-06
in O 0 3.4251577574195835e-08
patients O 0 3.2493926482857205e-06
from O 0 1.54983759159677e-08
a O 0 8.947151286520239e-08
retinoblastoma B-Disease 0 7.818816811777651e-05
pedigree O 0 0.0009349954780191183
showing O 0 5.435878483694978e-05
only O 0 8.945121265924172e-08
mild O 0 7.336310318351025e-06
expression O 0 5.887607912313797e-08
of O 0 6.353972459294255e-09
the O 0 1.6129851587720623e-07
tumor B-Disease 0 2.0360581402201205e-05
phenotype O 0 1.0621602086757775e-05
. O 0 4.0217753394244937e-07

We O 0 1.1077414455940016e-05
have O 0 1.3754002736732218e-07
used O 0 1.7779593974864838e-07
single O 0 9.065281005860015e-07
strand O 0 5.549937327486987e-07
conformation O 0 5.747766635977314e-07
polymorphism O 0 5.374773763833218e-07
analysis O 0 3.0409992746172065e-08
to O 0 7.462644724398615e-09
study O 0 1.3332433823620704e-08
the O 0 5.120735391273001e-09
27 O 0 2.219578298934266e-08
exons O 0 9.509581389011146e-08
of O 0 1.6591744644856021e-09
the O 0 1.0161698149602216e-08
RB1 O 0 1.632804810469679e-06
gene O 0 1.0600209776612246e-07
in O 0 5.968424421354257e-09
individuals O 0 6.0889040476297396e-09
from O 0 3.9575263066637945e-09
a O 0 1.6413002512649655e-08
family O 0 1.533891378358021e-07
showing O 0 7.9783303590375e-06
mild O 0 1.6556539776502177e-05
expression O 0 7.05622653640603e-08
of O 0 4.487108462569722e-09
the O 0 5.919710943658174e-08
retinoblastoma B-Disease 0 1.7433541870559566e-05
phenotype O 0 2.5129282221314497e-05
. O 0 2.703849588669982e-07

In O 0 2.776212681965262e-07
this O 0 1.56606816403837e-08
family O 0 6.526801143991179e-08
affected O 0 7.88948142371737e-08
individuals O 0 6.139235786406516e-09
developed O 0 2.6240871875415905e-07
unilateral B-Disease 0 0.027059100568294525
tumors I-Disease 1 1.0
and O 0 1.049481852533063e-06
, O 0 5.814618564414786e-09
as O 0 3.0504203607506497e-09
a O 0 5.331358465809899e-09
result O 0 1.2369163471248612e-08
of O 0 5.682217474323181e-10
linkage O 0 6.203909492796811e-07
analysis O 0 1.1520561571387589e-07
, O 0 2.2398472410145587e-08
unaffected O 0 6.95863150212972e-07
mutation O 0 6.824287197559897e-07
carriers O 0 7.549447218480054e-07
were O 0 2.3081597078089544e-07
also O 0 2.046566116575832e-08
identified O 0 1.2760784784404677e-07
within O 0 1.6126554314155328e-08
the O 0 3.266114489974825e-08
pedigree O 0 3.3957749110413715e-05
. O 0 3.603638845106616e-07

A O 0 9.877955562842544e-06
single O 0 3.6482358609646326e-06
band O 0 6.30703027582058e-07
shift O 0 1.93192690289834e-07
using O 0 2.107238685766788e-07
SSCP O 0 1.4639185792475473e-05
was O 0 1.8526874612234678e-07
identified O 0 5.1721347205102575e-08
in O 0 3.902194123384106e-09
exon O 0 1.9116967564514198e-07
21 O 0 1.0030564823182431e-07
which O 0 8.019116926050174e-09
resulted O 0 2.7691042348010342e-08
in O 0 3.45907857912664e-09
a O 0 1.910478708566643e-08
missense O 0 4.872561476076953e-06
mutation O 0 8.077659003902227e-07
converting O 0 1.9615906410308526e-07
a O 0 1.4957961980144319e-07
cys O 0 0.00020983304420951754
- O 0 3.400944115128368e-05
- O 0 1.512510880274931e-05
> O 0 1.5323314528359333e-06
arg O 0 3.0449800760834478e-06
at O 0 8.48148644649882e-08
nucleotide O 0 6.434210604311374e-07
position O 0 7.526019771830761e-07
28 O 0 7.406183044622594e-08
in O 0 5.320773599493123e-09
the O 0 2.5437108419623655e-08
exon O 0 3.887012098857667e-06
. O 0 5.904712452320382e-07

The O 0 6.928046786924824e-06
mutation O 0 4.32251144957263e-05
destroyed O 0 6.4319183366023935e-06
an O 0 9.653736299242155e-08
NdeI O 0 3.844080765702529e-06
restriction O 0 2.2426478096804203e-07
enzyme O 0 8.57936640841217e-07
site O 0 9.840465509114438e-07
. O 0 2.2706939262207015e-07

Analysis O 0 1.7830546994446195e-06
of O 0 2.8905887461405655e-08
all O 0 4.117541152481863e-08
family O 0 4.645450601969969e-08
members O 0 7.064627105535237e-09
demonstrated O 0 1.9998593003833776e-08
that O 0 1.6805199454239528e-09
the O 0 5.208096176545496e-09
missense O 0 6.194029538164614e-06
mutation O 0 3.790815981119522e-06
co O 0 2.16384637496958e-06
- O 0 1.8850741980713792e-06
segregated O 0 2.3438378775608726e-06
with O 0 4.426687283398678e-08
patients O 0 3.81858080800157e-06
with O 0 6.371317908815399e-07
tumors B-Disease 1 1.0
or O 0 0.00012409761257003993
who O 0 2.0908848910039524e-06
, O 0 2.4624684513696593e-09
as O 0 1.7753077896642822e-09
a O 0 3.4643541368950537e-09
result O 0 7.46304262833064e-09
of O 0 5.197435815063045e-10
linkage O 0 3.289026722086419e-07
analysis O 0 2.1509409009468072e-07
had O 0 8.037454790610354e-06
been O 0 6.005745234460846e-08
predicted O 0 3.0661013283861394e-08
to O 0 2.00732186428354e-09
carry O 0 8.994067712819742e-08
the O 0 4.987264290434723e-08
predisposing O 0 1.7417505659977905e-05
mutation O 0 2.6333982532378286e-06
. O 0 2.2202351601663395e-07

These O 0 5.610519906440459e-07
observations O 0 1.24567600323644e-06
point O 0 2.978623285798676e-07
to O 0 1.7745064084806472e-08
another O 0 2.046370894959182e-08
region O 0 1.6764900578891684e-08
of O 0 1.2085276113182886e-09
the O 0 3.2285189632830225e-08
RB1 O 0 5.42469115316635e-06
gene O 0 2.1861221455310442e-07
where O 0 1.769943125395912e-08
mutations O 0 1.6678889380727924e-07
only O 0 3.945339166477879e-09
modify O 0 4.653786689345907e-08
the O 0 3.2000768701578863e-09
function O 0 6.077209402377548e-09
of O 0 5.221401644384116e-10
the O 0 2.230016171722582e-09
gene O 0 5.7700543010241745e-08
and O 0 3.86815157682463e-09
raise O 0 1.1055948156979412e-08
important O 0 2.5428072980560046e-09
questions O 0 1.2195828347216775e-08
for O 0 3.4488412126165713e-09
genetic O 0 1.41710063417122e-06
counseling O 0 3.4775709423229273e-07
in O 0 9.41249389541099e-09
families O 0 5.206638675758768e-08
with O 0 5.437277295072818e-09
these O 0 1.4272572457230126e-08
distinctive O 0 2.3432053239957895e-06
phenotypes O 0 6.08833124715602e-06
. O 0 2.1981927389447264e-08
. O 0 1.3888235628201073e-07

Maternal B-Disease 0 0.38583120703697205
disomy I-Disease 0 0.0457516610622406
and O 0 0.002469282830134034
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.00018194748554378748
with O 0 9.169868064873299e-08
gamete O 0 4.049990820931271e-06
complementation O 0 1.2053294994984753e-05
in O 0 1.178166275650483e-08
a O 0 6.7871468445446226e-09
case O 0 4.0483092433873935e-09
of O 0 3.160605777097203e-09
familial O 0 3.406179530429654e-05
translocation O 0 8.3626109699253e-06
( O 0 2.1346703249491839e-07
3 O 0 1.1358024920582466e-07
; O 0 1.7072064650847096e-08
15 O 0 3.286279692815697e-08
) O 0 7.374266974835564e-09
( O 0 9.120500799042475e-09
p25 O 0 2.3100183454971557e-07
; O 0 1.3176300939221619e-08
q11 O 0 3.628980493886047e-07
. O 0 4.225632732612894e-09
2 O 0 4.086589200369417e-08
) O 0 6.039702071802822e-08
. O 0 9.46143856594972e-08

Maternal B-Disease 1 0.9523946046829224
uniparental I-Disease 1 0.9888384342193604
disomy I-Disease 1 0.713676929473877
( I-Disease 0 0.00018857490795198828
UPD I-Disease 1 0.9999997615814209
) I-Disease 0 3.022864518698043e-07
for I-Disease 0 1.497939727812536e-08
chromosome I-Disease 0 0.00011709786485880613
15 I-Disease 0 8.433414677710971e-08
is O 0 4.7566279803845646e-09
responsible O 0 4.032920841723353e-08
for O 0 1.0320733156987671e-09
an O 0 2.7247579748035378e-09
estimated O 0 2.097030105119302e-08
30 O 0 4.217242555171197e-09
% O 0 1.5621501869844678e-09
of O 0 4.3472858646254053e-10
cases O 0 1.2932544812827018e-08
of O 0 6.760198516531091e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 7.08820516592823e-05
PWS B-Disease 1 0.9999998807907104
) O 0 1.1090056659668335e-06
. O 0 4.812259817299491e-07

We O 0 3.1384370231535286e-05
report O 0 2.708175088628195e-07
on O 0 1.1250034681609122e-08
an O 0 2.03427497069697e-09
unusual O 0 9.50943235267232e-09
case O 0 8.983863430955807e-09
of O 0 5.139159764411261e-09
maternal B-Disease 0 7.080099021550268e-05
disomy I-Disease 0 3.2303443731507286e-05
15 I-Disease 0 1.2931859316722694e-07
in O 0 4.565759681440795e-08
PWS B-Disease 1 0.9999998807907104
that O 0 1.765657486885175e-08
is O 0 3.3729414816718872e-09
most O 0 2.8343376534678555e-09
consistent O 0 7.721199324350891e-08
with O 0 5.523850266087038e-09
adjacent O 0 4.0956498992272827e-07
- O 0 2.607015858302475e-06
1 O 0 3.0498689795877e-08
segregation O 0 9.998818484291405e-08
of O 0 1.4321813734952116e-09
a O 0 2.7065786056823526e-08
paternal O 0 0.00029228985658846796
t O 0 1.2754892850352917e-05
( O 0 1.621581624533519e-08
3 O 0 2.1061653754372855e-08
; O 0 6.539497388047266e-09
15 O 0 1.4302249162767566e-08
) O 0 2.3274371319104148e-09
( O 0 3.269079673628994e-09
p25 O 0 1.330733709892229e-07
; O 0 1.243006320095219e-08
q11 O 0 1.6320265672220557e-07
. O 0 3.05421021806751e-09
2 O 0 1.359764834063526e-08
) O 0 2.201552495861847e-09
with O 0 2.917456720652467e-09
simultaneous O 0 2.2961621652939357e-06
maternal O 0 0.0016420745523646474
meiotic O 0 7.886359526310116e-05
nondisjunction O 0 4.755966801894829e-05
for O 0 5.917170753377832e-08
chromosome O 0 8.090997289400548e-05
15 O 0 5.084388021714403e-07
. O 0 2.547258191043511e-07

The O 0 3.6098620057600783e-06
patient O 0 8.788517152424902e-05
( O 0 3.283867897607706e-07
J O 0 0.00017610790382605046
. O 0 5.115437318181648e-08
B O 0 8.01398800831521e-06
. O 0 1.7964949527993213e-09
) O 0 2.4097648321230736e-09
, O 0 1.3297709600124108e-09
a O 0 1.091002399533636e-08
17 O 0 6.340840030816253e-08
- O 0 3.004688267083111e-07
year O 0 7.0102115223846795e-09
- O 0 3.4601961829139327e-07
old O 0 1.4562328942702152e-06
white O 0 1.5294114064090536e-07
male O 0 3.1705522474112513e-07
with O 0 4.370010842080774e-08
PWS B-Disease 1 0.9999998807907104
, O 0 3.515892643690677e-08
was O 0 7.634957910340745e-08
found O 0 5.141052028534432e-09
to O 0 1.9830506126083947e-09
have O 0 3.416238669728955e-08
47 O 0 1.027540790232706e-07
chromosomes O 0 2.596034960333782e-07
with O 0 6.998027934912443e-09
a O 0 4.738754810773571e-08
supernumerary O 0 1.548826003272552e-05
, O 0 5.2466241129423e-08
paternal O 0 0.0005387491546571255
der O 1 0.9357167482376099
( O 0 2.7783412903659155e-08
15 O 0 1.3550320865363119e-08
) O 0 1.6072684294599071e-09
consisting O 0 3.5929985653382346e-09
of O 0 1.174297992179163e-09
the O 0 2.3057697973172253e-08
short O 0 2.713112053243094e-06
arm O 0 0.0012609816621989012
and O 0 2.4341524351711996e-08
the O 0 1.0844795284015163e-08
proximal O 0 2.519775307519012e-06
long O 0 3.256024911024724e-06
arm O 0 2.5492159693385474e-05
of O 0 7.4470460909026315e-09
chromosome O 0 1.4499591088679153e-05
15 O 0 1.4643572399108962e-07
, O 0 9.123876765215755e-09
and O 0 1.0445108244994117e-07
distal O 0 0.00048656511353328824
chromosome O 1 0.5897692441940308
arm O 0 0.14438731968402863
3p O 0 0.001472797361202538
. O 0 4.807558070751838e-06

The O 0 4.34588309872197e-06
t O 0 2.5294075385318138e-05
( O 0 6.628054194379729e-08
3 O 0 1.9293301178890943e-08
; O 0 4.328828406841012e-09
15 O 0 1.0715220710721951e-08
) O 0 2.454463965406717e-09
was O 0 3.1569925340591e-08
present O 0 1.3931361619867744e-09
in O 0 7.757638975647296e-10
the O 0 1.935178017831163e-09
balanced O 0 1.4296111849887438e-08
state O 0 9.323969374364083e-10
in O 0 8.42080571938908e-10
the O 0 1.5704381794989786e-08
patients O 0 1.6086009679838753e-07
father O 0 7.039852789603174e-08
and O 0 1.3699042789028226e-08
a O 0 1.0366730407440627e-07
sister O 0 4.226381133776158e-05
. O 0 1.7618299352761824e-07

Fluorescent O 0 3.425722024985589e-05
in O 0 3.4163369377893105e-07
situ O 0 1.9852973309752997e-06
hybridization O 0 4.503753530116228e-07
analysis O 0 1.307873134237525e-07
demonstrated O 0 1.5019428190043982e-07
that O 0 7.404442392555666e-09
the O 0 7.513492761290763e-08
PWS B-Disease 1 0.9999997615814209
critical O 0 9.65115532380878e-07
region O 0 1.7371590388393088e-07
resided O 0 3.1549731716040696e-07
on O 0 2.0154443447495396e-08
the O 0 9.134149436818007e-09
derivative O 0 2.832821337506175e-07
chromosome O 0 1.4407545450012549e-06
3 O 0 1.7689778530893818e-08
and O 0 9.765813935302958e-09
that O 0 4.4272931987165975e-09
there O 0 1.3689978928255186e-08
was O 0 1.9590778777001105e-07
no O 0 1.2824977524417136e-08
deletion O 0 2.203673687972696e-07
of O 0 5.9459157597530066e-09
the O 0 2.567748254023172e-07
PWS B-Disease 1 1.0
region O 0 2.3759955070090655e-07
on O 0 3.244334223495571e-08
the O 0 1.4821099014739048e-08
normal O 0 5.996462704160876e-08
pair O 0 9.222910790640526e-08
of O 0 2.690918599057568e-09
15s O 0 4.506150617089588e-07
present O 0 4.143018017543909e-08
in O 0 7.833088488951034e-08
J O 0 0.0022457093000411987
. O 0 4.1699979647091823e-07

B O 0 0.02543957717716694
. O 0 1.542885001981631e-05

Methylation O 0 1.3867068446415942e-05
analysis O 0 7.840574767215003e-07
at O 0 1.4474930765118188e-07
exon O 0 3.2574797614870477e-07
alpha O 0 4.8050779355435225e-08
of O 0 1.8246534283505866e-09
the O 0 5.3228235152857906e-09
small O 0 4.6276223741870126e-08
nuclear O 0 1.925404376379447e-06
ribonucleoprotein O 0 6.748572104697814e-06
- O 0 6.077535090298625e-06
associated O 0 3.8370305333046417e-07
polypeptide O 0 2.8887041025882354e-06
N O 0 4.0726017687120475e-06
( O 0 3.290318772997125e-08
SNRPN O 0 1.2938115787619608e-06
) O 0 1.0050018595109123e-08
gene O 0 7.494685405617929e-08
showed O 0 1.1534797295098542e-07
a O 0 4.6655874719192525e-09
pattern O 0 1.3980299229388038e-07
characteristic O 0 5.8290126503379724e-08
of O 0 1.754052680880136e-09
only O 0 7.230863019458411e-09
the O 0 1.967600482544185e-08
maternal O 0 6.522143667098135e-05
chromosome O 0 7.984612602740526e-05
15 O 0 2.518840176435333e-07
in O 0 1.0519884341420038e-07
J O 0 0.0020271672401577234
. O 0 8.626870453554147e-07

B O 0 0.01588355377316475
. O 0 2.164771103707608e-05

Maternal B-Disease 0 0.24906083941459656
disomy I-Disease 0 0.0019976976327598095
was O 0 3.72508293366991e-06
confirmed O 0 1.4280229265750677e-07
by O 0 4.9629313991772506e-09
polymerase O 0 3.0468288514384767e-07
chain O 0 7.781414410601428e-07
reaction O 0 2.7841341676548836e-08
analysis O 0 2.5485867638508353e-08
of O 0 6.528305895869835e-09
microsatellite O 0 7.088721304171486e-06
repeats O 0 5.088781563244993e-06
at O 0 2.0757447316555044e-07
the O 0 3.790537306258557e-08
gamma O 0 1.0561495855654357e-06
- O 0 2.3607464754604734e-05
aminobutyric O 0 5.2327464800328016e-05
acid O 0 2.3678508114244323e-06
receptor O 0 7.256321623572148e-07
beta3 O 0 1.716393171591335e-06
subunit O 0 8.527193813279155e-07
( O 0 5.263955245027319e-07
GABRB3 O 0 2.5867380827548914e-05
) O 0 1.9093172909379064e-07
locus O 0 2.903591303038411e-05
. O 0 7.214726451820752e-07

A O 0 2.1476324036484584e-05
niece O 0 0.00015277780767064542
( O 0 6.020139267093327e-07
B O 0 2.3255419364431873e-05
. O 0 1.1582026893108832e-08
B O 0 1.006710363071761e-06
. O 0 9.670184653032265e-10
) O 0 7.361811715789202e-10
with O 0 1.4695490380134402e-09
45 O 0 1.3354448213931391e-08
chromosomes O 0 1.4212109533673356e-07
and O 0 1.1423361812035182e-08
the O 0 5.662551316731879e-09
derivative O 0 2.362035615988134e-07
3 O 0 3.283760818817427e-08
but O 0 1.4853814178650282e-08
without O 0 2.3256101044921706e-08
the O 0 2.135329602026559e-08
der O 0 0.015918832272291183
( O 0 4.85849982467812e-09
15 O 0 5.538123737380829e-09
) O 0 1.3393214315371438e-09
demonstrated O 0 7.448765160233961e-09
a O 0 1.2164698581784705e-08
phenotype O 0 1.2367179351713276e-06
consistent O 0 2.0828835545216862e-07
with O 0 7.305402949242534e-09
that O 0 6.664662599575877e-09
reported O 0 4.231925743169995e-08
for O 0 1.8153604175452642e-09
haploinsufficiency O 0 5.532034492716775e-07
of O 0 8.068334444999437e-09
distal O 0 1.1644472579064313e-05
3 O 0 1.4621764421463013e-06
p O 0 0.00013354502152651548
. O 0 4.806609013030538e-07

Uniparental B-Disease 1 0.9999990463256836
disomy I-Disease 1 0.999993085861206
associated O 0 2.667193803063128e-05
with O 0 1.8470473150955513e-07
unbalanced O 0 2.013591438299045e-05
segregation O 0 1.4800357348576654e-06
of O 0 1.2287169504077156e-08
non O 0 1.326435040027718e-06
- O 0 3.878743427776499e-06
Robertsonian O 0 2.0305215002736077e-06
translocations O 0 4.041440661239903e-06
has O 0 4.1919071236407035e-07
been O 0 5.308864956532489e-07
reported O 0 3.7332412716750696e-07
previously O 0 3.370840602201497e-07
but O 0 6.838344113191397e-09
has O 0 5.0284296726488265e-09
not O 0 3.9732506174061655e-09
, O 0 5.697193827813862e-10
to O 0 7.690444947527908e-10
our O 0 5.633443045383046e-09
knowledge O 0 2.851624714139689e-09
, O 0 2.2715282987917362e-09
been O 0 7.426549597511212e-09
observed O 0 6.833468013667243e-09
in O 0 3.7159564314492854e-10
a O 0 6.628885884651936e-09
case O 0 1.4496281508513675e-08
of O 0 4.746009452105682e-08
PWS B-Disease 1 0.9999991655349731
. O 0 1.0962359056065907e-06

Furthermore O 0 4.153811096330173e-05
, O 0 3.9937674500833964e-07
our O 0 1.8874419538406073e-07
findings O 0 9.892983854342674e-08
are O 0 6.610161751297028e-09
best O 0 4.914966211799765e-08
interpreted O 0 7.109399291493901e-08
as O 0 2.114602182246017e-08
true O 0 1.2195414456073195e-07
gamete O 0 1.0542719337536255e-06
complementation O 0 8.594158316554967e-06
resulting O 0 8.058123626142333e-07
in O 0 1.903390369761837e-07
maternal B-Disease 0 0.45229625701904297
UPD I-Disease 1 0.9999998807907104
15 I-Disease 0 4.2716255848063156e-05
and O 0 4.430628541740589e-05
PWS B-Disease 1 0.9999991655349731

Schwartz B-Disease 1 0.9388026595115662
- I-Disease 1 0.9985129237174988
Jampel I-Disease 1 0.9979639053344727
syndrome I-Disease 1 0.999998927116394
type I-Disease 0 5.980465721222572e-05
2 I-Disease 0 6.467394086939748e-07
and O 0 8.602347065789218e-07
Stuve B-Disease 1 0.9804465174674988
- I-Disease 1 0.9999972581863403
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
: O 0 1.5706808298432406e-08
a O 0 1.0144888484830972e-08
case O 0 1.0229820546214796e-08
for O 0 6.762621129752233e-09
" O 0 8.54950741313587e-08
lumping O 0 1.8320495200896403e-06
" O 0 3.09121645614141e-07
. O 0 1.292120828111365e-07

Recent O 0 9.54236020334065e-06
studies O 0 1.3435754908641684e-06
demonstrated O 0 4.158925150932191e-07
the O 0 8.02043231828975e-09
existence O 0 1.388319770256885e-08
of O 0 3.685660387997558e-10
a O 0 6.050215439756812e-09
genetically O 0 4.6024030808666794e-08
distinct O 0 1.273753191810556e-08
, O 0 2.3034829599311024e-09
usually O 0 9.571886394610374e-09
lethal O 0 2.655180431077042e-08
form O 0 4.680945409063497e-09
of O 0 1.7348246172943504e-09
the O 0 6.916949502056013e-08
Schwartz B-Disease 0 0.014649440534412861
- I-Disease 1 0.9772382378578186
Jampel I-Disease 1 0.9990612864494324
syndrome I-Disease 1 0.9999954700469971
( O 0 1.905358999465534e-07
SJS B-Disease 0 0.0013424487551674247
) O 0 8.098522741306624e-09
of O 0 5.494910748637949e-09
myotonia B-Disease 0 0.00032614212250337005
and O 0 6.950473903089005e-07
skeletal B-Disease 0 0.03343983739614487
dysplasia I-Disease 1 0.9311749935150146
, O 0 2.410441801714569e-08
which O 0 1.2664398418849032e-08
we O 0 4.0139433110653044e-08
called O 0 1.6425977378276002e-07
SJS B-Disease 0 0.48706620931625366
type I-Disease 0 1.5041407095850445e-05
2 I-Disease 0 7.593087616442062e-07
. O 0 3.9107879956645775e-07

This O 0 3.306280859760591e-06
disorder O 0 0.44636714458465576
is O 0 2.8120998862846136e-08
reminiscent O 0 1.7831368381848733e-07
of O 0 3.793255043404997e-09
another O 0 1.0240425041274648e-07
rare O 0 2.427208016797522e-07
condition O 0 3.6903952604916412e-06
, O 0 1.2516829350772696e-08
the O 0 7.706457694212077e-08
Stuve B-Disease 0 0.3106191158294678
- I-Disease 1 0.9997574687004089
Wiedemann I-Disease 1 0.9999957084655762
syndrome I-Disease 1 0.9999996423721313
( O 0 1.3851779101514694e-07
SWS B-Disease 0 0.00043379314593039453
) O 0 1.901724111519343e-08
, O 0 2.8575759536408896e-09
which O 0 2.031553147929799e-09
comprises O 0 1.6790437484814902e-08
campomelia B-Disease 0 1.4843470808045822e-06
at O 0 2.2959532941513316e-07
birth O 0 1.4482361621048767e-06
with O 0 5.96439804212423e-08
skeletal B-Disease 0 0.0017701757606118917
dysplasia I-Disease 0 0.2651464641094208
, O 0 8.641447379886813e-08
contractures B-Disease 0 8.261296170530841e-05
, O 0 4.2930629717830016e-08
and O 0 5.338117503583817e-08
early B-Disease 0 3.8822381043246423e-07
death I-Disease 0 4.982092605132493e-07
. O 0 1.3345947991183493e-07

To O 0 1.5680609521950828e-06
test O 0 1.3954046380604268e-06
for O 0 2.4641703788574887e-08
possible O 0 1.551139376942956e-07
nosologic O 0 2.7872481496160617e-06
identity O 0 1.863334944118833e-07
between O 0 2.832307188782579e-08
these O 0 1.0463693200790658e-07
disorders O 0 0.1419210284948349
, O 0 1.4478596987999026e-08
we O 0 7.345013042225901e-09
reviewed O 0 6.696594390120936e-09
the O 0 2.575009983019072e-09
literature O 0 3.0756879265680936e-09
and O 0 7.682400493536079e-09
obtained O 0 1.2991905329329256e-08
a O 0 5.8426783411391625e-09
follow O 0 3.080180377423858e-08
- O 0 2.1005544112995267e-06
up O 0 6.688861020620607e-08
of O 0 3.045221852460145e-10
the O 0 1.91445370667509e-09
only O 0 3.9068934754027396e-09
two O 0 1.3668114640097428e-08
surviving O 0 4.985979558114195e-06
patients O 0 9.093718489339153e-08
, O 0 1.0645139214560118e-09
one O 0 2.549197963830352e-09
with O 0 9.599310679675455e-09
SJS B-Disease 0 0.0009882621234282851
type I-Disease 0 3.3401440759917023e-06
2 I-Disease 0 4.465680092380353e-08
at O 0 1.5013641530003952e-07
age O 0 1.6340729303010448e-07
10 O 0 4.225309879757333e-09
years O 0 2.7603386243413297e-09
and O 0 3.7628744564699446e-09
another O 0 8.552390795557585e-09
with O 0 1.8942376556196905e-08
SWS B-Disease 0 0.028476042672991753
at O 0 1.2823689985452802e-06
age O 0 2.8903249926770513e-07
7 O 0 5.906256106413821e-08
years O 0 3.215797050870606e-08
. O 0 1.1421601442407336e-07

Patients O 1 0.9997578263282776
reported O 0 2.0508628949755803e-05
as O 0 6.4335232252688e-08
having O 0 5.524474318008288e-07
either O 0 6.348503120534588e-06
neonatal O 1 0.9999994039535522
SJS B-Disease 1 0.9999988079071045
or O 0 5.4972457292024046e-05
SWS B-Disease 0 0.06282943487167358
presented O 0 5.327579799541127e-08
a O 0 8.216725966292415e-09
combination O 0 2.3268080795446622e-08
of O 0 1.526885951008694e-09
a O 0 4.719793977869813e-08
severe O 0 5.3313953685574234e-05
, O 0 3.068821641249997e-08
prenatal O 1 0.9999974966049194
- O 1 0.9999942779541016
onset O 1 0.9999997615814209
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 0.9999980926513672
( O 0 3.003599431394832e-07
with O 0 4.827998623113672e-07
congenital B-Disease 1 0.9999998807907104
joint I-Disease 0 0.00227623013779521
contractures I-Disease 1 0.9998206496238708
, O 0 4.241378519509453e-06
respiratory O 1 0.9585713148117065
and O 0 3.343438095271267e-07
feeding O 0 1.0642327652021777e-05
difficulties O 0 2.05493847715843e-06
, O 0 9.725551919359532e-09
tendency O 0 1.4833010197889962e-07
to O 0 2.5745544363076078e-08
hyperthermia B-Disease 0 1.4322061360871885e-05
, O 0 2.1015026163695438e-08
and O 0 3.019625083311439e-08
frequent O 0 5.242221050139051e-06
death O 0 4.943123258271953e-06
in O 0 3.2984683429049255e-08
infancy O 0 0.0002490163897164166
) O 0 4.600847258728891e-09
with O 0 2.093508255640586e-09
a O 0 2.794700471042688e-08
distinct O 0 6.883506102894899e-07
campomelic B-Disease 0 0.0001891630672616884
- I-Disease 0 0.0013525227550417185
metaphyseal I-Disease 0 0.00036581134190782905
skeletal I-Disease 0 0.0009385549346916378
dysplasia I-Disease 0 0.14021356403827667
. O 0 2.385859716014238e-06

The O 0 3.146010669752286e-07
similarity O 0 2.0687606649971713e-07
of O 0 6.576070354924468e-09
the O 0 1.457090625933688e-08
clinical O 0 3.0283431442512665e-06
and O 0 7.575512483981584e-08
radiographic O 0 0.0018228533444926143
findings O 0 8.391606343138847e-07
is O 0 5.604420927340925e-09
so O 0 1.4332307562980873e-09
extensive O 0 9.51547463046154e-09
that O 0 6.985199085818294e-09
these O 0 1.1204426897393205e-07
disorders O 1 0.6849142909049988
appear O 0 4.036712084598548e-07
to O 0 2.2842247204835076e-08
be O 0 7.162371673530288e-08
a O 0 1.4247500246256095e-07
single O 0 1.6825608327053487e-05
entity O 0 3.7945087569823954e-06
. O 0 2.2171458624598017e-07

The O 0 1.1587327435336192e-06
follow O 0 5.369783480091428e-07
- O 0 3.959075456805294e-06
up O 0 1.0923729121259385e-07
observation O 0 3.2394558502346626e-07
of O 0 2.3112463054530963e-09
an O 0 5.423471005627789e-09
identical O 0 2.6632255867298227e-06
and O 0 8.040589527524844e-09
unique O 0 1.1604758043404217e-08
pattern O 0 2.179084646058982e-07
of O 0 6.9267560576236065e-09
progressive O 0 0.00020223393221385777
bone B-Disease 1 0.9287559986114502
dysplasia I-Disease 1 0.6834959983825684
in O 0 3.909459778128621e-08
the O 0 3.927059921693399e-08
two O 0 1.1196708555871737e-06
patients O 0 1.649572141104727e-06
( O 0 1.8995298667334737e-09
one O 0 3.233866952001563e-09
with O 0 3.0167182529794445e-08
SJS B-Disease 0 0.4345508813858032
type I-Disease 0 1.0687892427085899e-05
2 I-Disease 0 4.997815494789393e-08
, O 0 8.383741700868086e-09
one O 0 1.0416653317690816e-08
with O 0 4.2795573307330415e-08
SWS B-Disease 0 0.01155331265181303
) O 0 2.7121389578610433e-08
surviving O 0 3.496152771731431e-07
beyond O 0 1.7042857791693677e-07
infancy O 0 3.5370035220694263e-06
adds O 0 4.162916056316135e-08
to O 0 5.691591642431604e-09
the O 0 5.573357775290333e-09
evidence O 0 1.9689295527314243e-08
in O 0 2.8668400986475717e-09
favor O 0 2.2772383090341464e-08
of O 0 8.369952730902241e-09
identity O 0 1.1977356280112872e-06
. O 0 2.838844181951572e-07

The O 0 9.34835270527401e-07
hypothesis O 0 1.9293099740025355e-06
that O 0 5.352411491799103e-08
SWS B-Disease 0 0.00030952473753131926
and O 0 3.915157833489502e-07
SJS B-Disease 0 0.21167142689228058
type I-Disease 0 1.4777278011024464e-05
2 I-Disease 0 4.7734989294667685e-08
are O 0 4.246089257975427e-09
the O 0 5.512504230864579e-09
same O 0 5.20585444974131e-07
disorder O 0 0.0004261552821844816
should O 0 9.484653062941106e-09
be O 0 2.3136630389331003e-09
testable O 0 4.346469495430938e-08
by O 0 1.3116840946736374e-09
molecular O 0 5.492188748235094e-08
methods O 0 3.2147431738849264e-07
. O 0 2.778177154993955e-08
. O 0 1.3540714860482694e-07

A O 0 1.4804656530031934e-05
mouse O 0 2.7308076823828742e-05
model O 0 3.3405233352823416e-06
of O 0 5.706638717128953e-07
severe O 1 0.9999749660491943
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0010113914031535387
defects O 1 0.9999939203262329
in O 0 4.5530845227403915e-07
hemostasis O 1 0.9784162044525146
and O 0 4.0643113607075065e-05
thrombosis B-Disease 1 0.9687909483909607
. O 0 2.040688059423701e-06

von B-Disease 1 0.9994969367980957
Willebrand I-Disease 1 0.9956651329994202
factor I-Disease 0 0.00020305915677454323
( I-Disease 0 1.0560485861788038e-05
vWf I-Disease 0 0.0015523922629654408
) I-Disease 0 0.00010000943439081311
deficiency I-Disease 1 0.9999408721923828
causes O 0 0.0052985819056630135
severe O 1 0.9999986886978149
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 8.64720675508579e-07
humans O 0 8.407880159211345e-06
. O 0 5.114471832712297e-07

We O 0 7.435328370775096e-06
generated O 0 1.659948338783579e-07
a O 0 2.8009603525447346e-08
mouse O 0 4.241210831423814e-07
model O 0 1.4044309182281722e-07
for O 0 2.981900948384464e-09
this O 0 8.676556362274823e-09
disease O 0 2.384549588896334e-06
by O 0 1.3853195257595985e-09
using O 0 4.343187498534462e-08
gene O 0 1.0527267022553133e-06
targeting O 0 2.0404370388860116e-06
. O 0 4.484650730773865e-07

vWf B-Disease 0 0.016120417043566704
- I-Disease 1 0.9902563095092773
deficient I-Disease 0 0.4065696895122528
mice O 0 0.0003810847701970488
appeared O 0 3.193583779648179e-06
normal O 0 3.5364635664336674e-07
at O 0 1.1030423507918385e-07
birth O 0 1.0388062037236523e-06
; O 0 1.3007773524975619e-08
they O 0 4.481824333879558e-08
were O 0 2.3343611132986553e-07
viable O 0 2.9049380145806936e-07
and O 0 2.944173083108126e-08
fertile O 0 1.076060470950324e-06
. O 0 2.0718249515994103e-07

Neither O 0 0.00035243507591076195
vWf O 0 0.0013277927646413445
nor O 0 5.554472954827361e-05
vWf O 0 0.00034288951428607106
propolypeptide O 0 0.0004426855593919754
( O 0 2.56838507084467e-06
von B-Disease 0 0.07020571082830429
Willebrand I-Disease 0 0.010109632275998592
antigen O 0 0.00011760230700019747
II O 0 9.728984878165647e-05
) O 0 8.055697975350995e-08
were O 0 1.3257239572794788e-07
detectable O 0 1.4878092997605563e-06
in O 0 4.630427152818584e-09
plasma O 0 5.948754377982368e-08
, O 0 1.488032719265675e-08
platelets O 0 2.5019403437909205e-07
, O 0 6.261802631968294e-09
or O 0 5.0181991895215106e-08
endothelial O 0 1.608590309842839e-07
cells O 0 1.6517644141345045e-08
of O 0 7.749446084837075e-10
the O 0 2.065649162830141e-08
homozygous O 0 1.962991700565908e-05
mutant O 0 1.309619710809784e-05
mice O 0 2.179761213483289e-05
. O 0 6.180590048643353e-07

The O 0 4.27691156801302e-06
mutant O 0 0.0002008444134844467
mice O 0 0.011331038549542427
exhibited O 0 0.0013874976430088282
defects O 1 0.9992218017578125
in O 0 5.8332393138016414e-08
hemostasis O 0 0.0006146787200123072
with O 0 3.620420940819713e-08
a O 0 8.958678421322475e-08
highly O 0 3.282773150203866e-06
prolonged O 0 0.2124236524105072
bleeding O 1 0.8322170376777649
time O 0 1.2065984833498078e-07
and O 0 1.189187557315563e-07
spontaneous O 0 7.407051043628599e-07
bleeding O 0 0.0002586440823506564
events O 0 2.78609970649768e-08
in O 0 3.6811167447581283e-09
approximately O 0 7.1021317715747045e-09
10 O 0 5.906095612573381e-09
% O 0 5.093081512086428e-09
of O 0 7.9033490862912e-09
neonates O 0 1.2580449947563466e-05
. O 0 3.206476151262905e-07

As O 0 4.11404244005098e-06
in O 0 7.692168679795941e-08
the O 0 4.5852388552702905e-08
human O 0 2.519611541629274e-07
disease O 0 1.1624845683400054e-05
, O 0 1.4346009935550796e-09
the O 0 1.9320984812054576e-09
factor O 0 1.8589503270050045e-08
VIII O 0 6.53162771868665e-07
level O 0 1.6159798121861968e-07
in O 0 4.99098273820664e-09
these O 0 9.702835868097281e-09
mice O 0 3.5054918043897487e-06
was O 0 2.9281292768246203e-07
reduced O 0 1.20657279722991e-08
strongly O 0 1.2740715149561765e-08
as O 0 2.4000266218848765e-09
a O 0 3.1762215080277656e-09
result O 0 4.521542251723076e-09
of O 0 3.682751326117284e-10
the O 0 5.702425198705896e-09
lack O 0 2.9781906718540085e-08
of O 0 2.4069213289124036e-09
protection O 0 3.4778221191800185e-08
provided O 0 3.235522072486674e-08
by O 0 4.047369372983667e-08
vWf O 0 6.63637911202386e-06
. O 0 3.822126188879338e-07

Defective O 1 0.9454349279403687
thrombosis B-Disease 1 0.9367079138755798
in O 0 2.2528436147695174e-06
mutant O 0 4.248201730661094e-05
mice O 0 0.0014393109595403075
was O 0 8.483506803713681e-07
also O 0 3.188410957477572e-08
evident O 0 8.527131711844049e-08
in O 0 2.198501825034782e-09
an O 0 3.421199101794059e-09
in O 0 4.805011499797729e-09
vivo O 0 3.5325700764587964e-07
model O 0 4.509280415732064e-08
of O 0 3.5365136596965385e-08
vascular B-Disease 0 0.05186251550912857
injury I-Disease 0 0.29740968346595764
. O 0 7.947846825118177e-07

In O 0 3.780112365348032e-07
this O 0 1.270625471505582e-08
model O 0 1.0180364284906318e-07
, O 0 9.077980145377751e-09
the O 0 3.355540911798016e-08
exteriorized O 0 5.024797701480566e-06
mesentery O 0 3.733943958650343e-05
was O 0 5.150266133568948e-07
superfused O 0 1.2834419749196968e-06
with O 0 2.654674169377813e-08
ferric O 0 3.749758434423711e-06
chloride O 0 3.9903750348457834e-07
and O 0 3.463377851176119e-08
the O 0 1.1546536171636035e-08
accumulation O 0 4.541882958619681e-08
of O 0 6.408768626897654e-09
fluorescently O 0 3.200499850208871e-05
labeled O 0 1.662533759372309e-05
platelets O 0 5.503831289388472e-06
was O 0 1.8937976165034343e-07
observed O 0 6.46309032958925e-08
by O 0 8.523062255960667e-09
intravital O 0 1.2275349945412017e-06
microscopy O 0 1.9174497083440656e-06
. O 0 4.909625772597792e-07

We O 0 4.343699401943013e-06
conclude O 0 7.340253773691074e-07
that O 0 5.44283906833698e-09
these O 0 5.348673504101953e-09
mice O 0 6.027187851032068e-07
very O 0 1.637507374141478e-08
closely O 0 3.4108711588487495e-07
mimic O 0 0.0008508250466547906
severe O 0 0.014566607773303986
human O 0 2.1250649297144264e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 8.905555660021491e-06
will O 0 1.0434774111445222e-07
be O 0 2.4815131283162373e-08
very O 0 3.881861943000331e-09
useful O 0 7.430828397048117e-09
for O 0 1.4306306139744152e-09
investigating O 0 1.4824293792514709e-08
the O 0 1.5458305746562928e-09
role O 0 5.9196061386046495e-09
of O 0 8.037825405260435e-10
vWf O 0 1.507194440364401e-07
in O 0 4.595514635497011e-09
normal O 0 1.0772931346991754e-07
physiology O 0 1.238996958363714e-07
and O 0 1.0505568326379944e-07
in O 0 9.704875481020281e-08
disease O 0 5.472635893966071e-05
models O 0 4.1917192561413685e-07
. O 0 2.814364208347797e-08
. O 0 8.348958147053054e-08

Oral O 0 0.00044721030280925333
contraceptives O 0 0.48675864934921265
and O 0 7.472552852050285e-07
the O 0 1.3076261495825747e-07
risk O 0 8.30781846161699e-06
of O 0 5.584112159340293e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.268394155180431e-06

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999935626983643
Clinical O 0 0.0012787682935595512
Study O 0 2.5828871912381146e-06
Group O 0 4.563192760542734e-06
. O 0 3.9389956896229705e-07

BACKGROUND O 0 0.0004770119267050177
Women O 0 5.366699042497203e-05
with O 0 9.495914810031536e-08
mutations O 0 5.853160473634489e-06
in O 0 1.1754369033667444e-08
either O 0 4.479328907791569e-08
the O 0 2.0409371970231405e-08
BRCA1 O 0 0.00010208157618762925
or O 0 1.318928042337575e-07
the O 0 2.1869766442250693e-08
BRCA2 O 0 1.2100607818865683e-05
gene O 0 2.646237646786176e-07
have O 0 1.1304841507353558e-08
a O 0 6.494301540982406e-09
high O 0 8.705400773578731e-07
lifetime O 0 6.215757366589969e-06
risk O 0 8.287974924314767e-05
of O 0 6.841660706413677e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1048717851736e-06

Oral O 0 0.0009094380075111985
contraceptives O 1 0.9598824977874756
protect O 0 0.004638877231627703
against O 1 0.8112881183624268
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.009471877784108e-08
general O 0 7.624898046287854e-09
, O 0 6.115698170106043e-09
but O 0 6.034852173542049e-09
it O 0 1.7177000932733222e-09
is O 0 8.376017102129651e-10
not O 0 1.3652683428233559e-09
known O 0 2.8067506097073647e-09
whether O 0 2.060949189086614e-09
they O 0 6.661408757935305e-09
also O 0 4.430756650464218e-09
protect O 0 3.624123934287127e-08
against O 0 1.3178336644159572e-08
hereditary B-Disease 0 2.0959096218575723e-05
forms I-Disease 0 6.136803563094873e-07
of I-Disease 0 0.0005785506218671799
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.154432293849823e-07

METHODS O 0 2.0781284547410905e-05
We O 0 1.0122083722308162e-06
enrolled O 0 9.011631618704996e-07
207 O 0 1.734630700411799e-06
women O 0 1.5287538417396718e-06
with O 0 1.0634119462338276e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.4695756078708655e-07
161 O 0 6.851101375104918e-08
of O 0 3.867501874310619e-09
their O 0 5.507246214619954e-07
sisters O 0 9.817821592150722e-06
as O 0 1.4990799712677472e-08
controls O 0 8.123492989398073e-07
in O 0 4.4078043437423275e-09
a O 0 1.5603939473862738e-08
case O 0 3.4707845486536826e-08
- O 0 2.340351329621626e-06
control O 0 1.5578521015413571e-06
study O 0 2.594866543859098e-07
. O 0 1.5359071880993724e-07

All O 0 1.901312771224184e-06
the O 0 3.9958015918273304e-07
patients O 0 4.820260983251501e-06
carried O 0 2.0949477175236098e-07
a O 0 2.189865178081618e-08
pathogenic O 0 9.833945568971103e-07
mutation O 0 6.879778879920195e-07
in O 0 1.0557086760343282e-08
either O 0 2.1233894642591622e-07
BRCA1 O 0 2.658828452695161e-05
( O 0 4.212260407143731e-08
179 O 0 1.4789323188324488e-07
women O 0 7.672992978768889e-07
) O 0 1.2096928792004746e-08
or O 0 4.0258123590319883e-07
BRCA2 O 0 0.0015937202842906117
( O 0 1.035139760574566e-07
28 O 0 4.108073596853501e-07
women O 0 3.3597009974073444e-07
) O 0 3.475971865896099e-08
. O 0 1.0618219903335557e-07

The O 0 1.5610899026796687e-06
control O 0 6.2346844060812145e-06
women O 0 1.5002635791461216e-06
were O 0 8.595206679729017e-08
enrolled O 0 2.5199904385431182e-08
regardless O 0 9.765367181557849e-09
of O 0 4.784559970438806e-10
whether O 0 1.0390896143519512e-08
or O 0 1.7976070409986278e-07
not O 0 8.468038004139089e-08
they O 0 4.592573077388806e-08
had O 0 3.7886729842284694e-07
either O 0 3.1888100693322485e-07
mutation O 0 3.371520506334491e-06
. O 0 2.587736958048481e-07

Lifetime O 0 0.00011588552297325805
histories O 0 1.3376175957091618e-05
of O 0 1.5125523589176737e-07
oral O 0 5.404748208093224e-06
- O 0 3.927604848286137e-05
contraceptive O 0 0.00018618724425323308
use O 0 1.8455946246831445e-06
were O 0 2.3858028725953773e-06
obtained O 0 1.9619005087179175e-08
by O 0 2.8524733686197123e-09
interview O 0 5.50445861335902e-07
or O 0 5.1902489417443576e-08
by O 0 1.3130457832133402e-09
written O 0 4.834013189736197e-09
questionnaire O 0 7.004680924183049e-08
and O 0 2.0472219475209386e-08
were O 0 2.622816168695863e-07
compared O 0 3.095021483545679e-08
between O 0 1.6150563553196662e-08
patients O 0 1.017978235040573e-07
and O 0 1.0287249274654187e-08
control O 0 3.913671207556035e-06
women O 0 2.8468493837863207e-06
, O 0 5.828987070799485e-09
after O 0 7.47341299955906e-09
adjustment O 0 2.9405420320927078e-08
for O 0 9.939142842085857e-10
year O 0 7.411503633036887e-10
of O 0 1.0637628555798528e-09
birth O 0 1.1327147149131633e-06
and O 0 7.177086303045144e-08
parity O 0 1.2276121196919121e-05
. O 0 2.8675535190814117e-07

RESULTS O 0 3.095216379733756e-05
The O 0 4.6782525942035136e-07
adjusted O 0 0.00014128506882116199
odds O 0 5.2106570365140215e-05
ratio O 0 7.062486110953614e-05
for O 0 0.0012415904784575105
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.051026619184995e-07
with O 0 1.066469490496047e-08
any O 0 7.00967639488681e-09
past O 0 2.3003929428000447e-08
use O 0 6.313370271016083e-09
of O 0 3.33185301570893e-09
oral O 0 9.821012554311892e-07
contraceptives O 1 0.5660997033119202
was O 0 7.202055712696165e-06
0 O 0 8.121905352709291e-07
. O 0 2.397928540176508e-07

5 O 0 6.575033694389276e-06
( O 0 2.9656868605343334e-07
95 O 0 3.754972226488462e-07
percent O 0 1.0463447779329726e-06
confidence O 0 2.368710966038634e-06
interval O 0 4.7496499178123486e-07
, O 0 4.708085032945064e-09
0 O 0 2.157247180889499e-08
. O 0 7.94043997220939e-10
3 O 0 5.284383597370379e-09
to O 0 9.19911968821907e-09
0 O 0 2.891772510338342e-07
. O 0 3.7890899307058135e-09
8 O 0 6.176352229658733e-08
) O 0 2.2215520090185237e-08
. O 0 5.966036553672893e-08

The O 0 2.8132212719356176e-06
risk O 0 1.1737849490600638e-05
decreased O 0 4.1587028931644454e-07
with O 0 3.6431955230398216e-09
increasing O 0 8.601419132503452e-09
duration O 0 4.878224757476346e-08
of O 0 1.139158989360567e-09
use O 0 4.789988850006921e-08
( O 0 3.561654793315938e-08
P O 0 2.719951680774102e-06
for O 0 2.0673034395457535e-09
trend O 0 6.115151762742244e-08
, O 0 2.049643343937646e-09
< O 0 7.373567001422998e-08
0 O 0 2.8470827473370264e-08
. O 0 1.2649856717672492e-09
001 O 0 8.021781638944958e-08
) O 0 2.580575531041518e-09
; O 0 7.658490508433147e-10
use O 0 5.748279185979754e-09
for O 0 7.021023762376899e-09
six O 0 1.2261327242413245e-07
or O 0 5.3789381837532346e-08
more O 0 1.884722600209443e-09
years O 0 1.576079533549546e-08
was O 0 1.5362968497356633e-07
associated O 0 9.20196274734053e-09
with O 0 2.335000637287976e-09
a O 0 1.634249890969386e-08
60 O 0 5.262188196297757e-08
percent O 0 1.932170050622517e-07
reduction O 0 4.84532378663971e-08
in O 0 2.274043708894169e-08
risk O 0 2.0316372228990076e-06
. O 0 9.370080533699365e-08

Oral O 0 0.0005704222712665796
- O 0 0.000283127068541944
contraceptive O 0 0.00019806895579677075
use O 0 2.723518036873429e-06
protected O 0 0.00036468738107942045
against O 0 0.04264575242996216
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 3.4725260888990306e-08
for O 0 4.262472153016006e-09
carriers O 0 4.5167173112758974e-08
of O 0 1.82998938225154e-09
the O 0 2.1138845340828993e-08
BRCA1 O 0 0.00021121688769198954
mutation O 0 2.162988039344782e-06
( O 0 5.5213881466897874e-08
odds O 0 2.144353175026481e-06
ratio O 0 6.507634111585503e-07
, O 0 7.659926026803987e-09
0 O 0 2.6277026776710954e-08
. O 0 9.085597274527402e-10
5 O 0 7.335324792023812e-09
; O 0 3.0838473996652738e-09
95 O 0 4.041499224172185e-08
percent O 0 7.80448317527771e-07
confidence O 0 4.978111519449158e-06
interval O 0 1.3434741958917584e-06
, O 0 7.187097583738478e-09
0 O 0 1.8356221431758968e-08
. O 0 8.829170727864266e-10
3 O 0 4.601154568462107e-09
to O 0 4.5221457689592626e-09
0 O 0 6.555296749866102e-08
. O 0 1.444587449661583e-09
9 O 0 2.1449956477681553e-08
) O 0 8.450893873579446e-10
and O 0 2.9486844077553087e-09
for O 0 1.6174322992057455e-09
carriers O 0 2.6374941342055536e-08
of O 0 1.2404618443540016e-09
the O 0 2.4952486299412158e-08
BRCA2 O 0 4.796714711119421e-05
mutation O 0 7.606953431604779e-07
( O 0 1.6426689342097234e-08
odds O 0 1.0041013638328877e-06
ratio O 0 5.397899371928361e-07
, O 0 9.597406425143618e-09
0 O 0 1.771121738158854e-08
. O 0 1.344106936862488e-09
4 O 0 8.26736101799952e-09
; O 0 4.302405542944143e-09
95 O 0 4.870452485761234e-08
percent O 0 1.654105972193065e-06
confidence O 0 6.846556516393321e-06
interval O 0 1.6471827848363318e-06
, O 0 6.332280033660709e-09
0 O 0 1.843558905534337e-08
. O 0 6.923014383986015e-10
2 O 0 3.171481521846431e-09
to O 0 2.9110698296364035e-09
1 O 0 1.7608011049219385e-08
. O 0 1.930809068184658e-09
1 O 0 1.636651880687623e-08
) O 0 1.3644776863941388e-08
. O 0 6.601433000241741e-08

CONCLUSIONS O 0 7.11876928107813e-05
Oral O 0 8.910844917409122e-05
- O 0 4.8254994908347726e-05
contraceptive O 0 0.00012321678514126688
use O 0 3.3610695027164184e-07
may O 0 3.075737140534329e-07
reduce O 0 1.0724609467160917e-07
the O 0 1.89765145819365e-08
risk O 0 3.349627604620764e-06
of O 0 5.897418873246352e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.9395061556792825e-08
women O 0 1.8963964976137504e-07
with O 0 8.26241119966653e-09
pathogenic O 0 1.724554294924019e-06
mutations O 0 2.4356652374990517e-06
in O 0 8.940597595596955e-09
the O 0 6.591594114979671e-08
BRCA1 O 0 0.00034125696402043104
or O 0 6.142568508948898e-06
BRCA2 O 0 0.0027480870485305786
gene O 0 0.00011882614489877596

A O 0 9.502284228801727e-06
Japanese O 0 5.859801603946835e-06
family O 0 6.769978995180281e-07
with O 0 2.996709724811808e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.96618287873207e-07
a O 0 6.661411333652723e-08
codon O 0 2.627798721732688e-06
291 O 0 4.949836238665739e-07
deletion O 0 1.8229205807074322e-06
: O 0 2.4826539046785e-08
a O 0 2.9675758739244884e-08
clinical O 0 1.7949831089936197e-05
, O 0 2.0181486704018425e-08
biochemical O 0 2.037030526480521e-06
, O 0 1.2273912552984712e-08
pathological O 0 4.935897095492692e-07
, O 0 1.074481392748794e-08
and O 0 6.634821403395108e-08
genetic O 0 4.310619260650128e-05
report O 0 3.809992676906404e-07
. O 0 9.410612733518064e-08

We O 0 1.4748738976777531e-05
report O 0 5.244718295216444e-07
a O 0 6.825315779224184e-08
Japanese O 0 2.242057632884098e-07
family O 0 2.2957999590289546e-07
with O 0 9.64209334597399e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0007529835565946996
ALD B-Disease 1 1.0
) O 0 8.023037167959046e-08
with O 0 5.944702508031696e-09
a O 0 5.29051789044388e-08
three O 0 1.1085556650414219e-07
base O 0 5.845980695085018e-07
pair O 0 3.314678679089411e-06
deletion O 0 8.353867087862454e-06
( O 0 4.417367449605081e-08
delGAG O 0 3.828437229458359e-07
291 O 0 1.5204878422991897e-07
) O 0 6.23104012831277e-09
in O 0 3.505739254450191e-09
the O 0 2.636944032019528e-07
ALD B-Disease 1 0.9999997615814209
gene O 0 2.204777774750255e-05
. O 0 1.0101312000188045e-06

A O 0 1.9117928786727134e-06
variety O 0 1.596402512404893e-07
of O 0 2.5218175991881253e-08
phenotypes O 0 7.896074748714454e-06
were O 0 6.492242050626373e-07
observed O 0 1.010069752283016e-07
within O 0 6.9009882253112664e-09
this O 0 3.8055163464889574e-09
family O 0 1.9924317484765197e-07
. O 0 1.5030833822038403e-07

While O 0 8.157317097357009e-06
the O 0 2.6439369094077847e-07
proband O 0 1.2782547855749726e-05
( O 0 2.136112016160041e-07
patient O 0 3.49285755874007e-06
1 O 0 4.420637367275049e-08
) O 0 1.3109644925179964e-08
was O 0 2.644456174039078e-07
classified O 0 4.124836721075553e-07
as O 0 2.4839138745846867e-08
having O 0 7.728286277597363e-08
a O 0 3.6418754678635423e-09
rare O 0 4.59415661069329e-09
intermediate O 0 1.842131780449563e-08
type O 0 2.406693795364845e-07
of O 0 2.858480785405959e-09
adult O 0 4.216704382997705e-06
cerebral O 0 0.0003279858501628041
and O 0 4.5638532242264773e-07
cerebello O 0 0.0036647741217166185
- O 0 0.015203342773020267
brain O 0 0.0011154409730806947
stem O 0 2.846627467079088e-07
forms O 0 3.3911081942505916e-08
, O 0 6.992744161493647e-09
his O 0 6.09111410199148e-08
younger O 0 6.726840524606814e-07
brother O 0 7.355017714871792e-07
( O 0 3.120176472748426e-08
patient O 0 4.769540282723028e-07
2 O 0 1.7642435068410123e-08
) O 0 5.867191177344466e-09
and O 0 8.1743202429152e-08
nephew O 0 4.649736365536228e-05
( O 0 1.5246784812461556e-07
patient O 0 2.7013520593754947e-06
3 O 0 1.1845230574181187e-07
) O 0 2.080230565582042e-08
had O 0 8.30360704640043e-07
a O 0 7.366410841314064e-07
childhood O 1 0.8905198574066162
ALD B-Disease 1 1.0
type O 0 0.02367923967540264
. O 0 1.8767940446196008e-06

Another O 0 2.0596689864760265e-05
nephew O 0 7.216159428935498e-05
( O 0 7.099378080965835e-07
patient O 0 8.602539310231805e-06
4 O 0 3.191751574149748e-08
) O 0 3.044108076721841e-09
of O 0 2.5555071392346917e-09
patient O 0 1.0908953299804125e-05
1 O 0 5.139025560652044e-08
was O 0 7.880350381128665e-07
classified O 0 7.774916639391449e-07
as O 0 4.550059173880072e-08
having O 0 2.000340515451171e-07
an O 0 1.2273373428683954e-08
adolescent O 0 1.1762635040213354e-05
form O 0 7.947452900225471e-07
. O 0 7.184289643191732e-07

The O 0 9.069811426343222e-07
tau O 0 1.454894686503394e-06
level O 0 6.683644642180298e-07
in O 0 3.3913927666162635e-08
the O 0 1.573794321529931e-07
cerebrospinal O 1 0.7650058269500732
fluid O 0 0.00012405950110405684
( O 0 1.5260022792062955e-06
CSF O 0 0.04808254912495613
) O 0 1.0391531191089598e-08
in O 0 5.958426196883693e-09
patient O 0 9.482210998612572e-07
1 O 0 1.7946465646900833e-08
was O 0 2.508278669210995e-07
as O 0 1.8726897810239507e-09
high O 0 7.71168817692569e-09
as O 0 1.3687726507782827e-09
that O 0 4.524403907080199e-10
of O 0 1.8118148092938213e-09
patients O 0 2.704342421111505e-07
with O 0 4.895879328614683e-07
Alzheimers B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9705106616020203
( O 0 1.2073536481693736e-07
AD B-Disease 0 5.873492227692623e-06
) O 0 1.3911206053762726e-07
. O 0 1.8683705604871648e-07

His O 0 1.062747833202593e-05
brain O 0 3.6906370951328427e-05
magnetic O 0 1.1028294011339312e-06
resonance O 0 3.964898041886045e-06
image O 0 3.0224195143091492e-05
( O 0 1.28659237930151e-07
MRI O 0 0.0012333596823737025
) O 0 1.4551497429238225e-07
showed O 0 7.514716708101332e-05
abnormalities B-Disease 1 0.8759201169013977
in I-Disease 0 7.880830210638123e-09
the I-Disease 0 1.8104893584336423e-08
bilateral I-Disease 0 7.110253363862284e-07
cerebellar I-Disease 0 4.561919558909722e-05
hemispheres I-Disease 0 0.00018651683058124036
and O 0 1.7949585071619367e-06
brain O 0 0.0009937812574207783
stem O 0 8.856517297317623e-07
, O 0 5.57940982304217e-09
but O 0 2.9468907314367243e-09
not O 0 3.816478244544896e-09
in O 0 1.3908872942280937e-09
the O 0 1.515290470877062e-08
cerebral O 0 7.282544538611546e-05
white O 0 4.1002533635037253e-07
matter O 0 5.775798950224953e-09
, O 0 2.0994743721303166e-09
where O 0 4.176497814256663e-09
marked O 0 2.279593758203191e-08
reductions O 0 2.4153985478392315e-08
of O 0 8.086802893991774e-10
the O 0 1.3540760512853467e-08
cerebral O 0 0.0003166620444972068
blood O 0 4.104429990547942e-06
flow O 0 9.55091721266399e-08
and O 0 1.0647301706967482e-07
oxygen O 0 4.899485475107213e-07
metabolism O 0 6.522570856759558e-07
were O 0 1.1166536495466062e-07
clearly O 0 3.718597341162422e-08
demonstrated O 0 1.4598975361934663e-08
by O 0 3.4681491012378274e-09
positron O 0 1.1450529200374149e-06
emission O 0 1.3544877219828777e-06
tomography O 0 1.2244984645803925e-05
( O 0 1.9115564953153807e-07
PET O 0 7.437789463438094e-06
) O 0 1.0887411860949214e-07
. O 0 1.0764017588371644e-07

In O 0 2.6682439511205303e-06
patients O 0 0.00014653381367679685
2 O 0 2.1275245387641917e-07
and O 0 6.562340360005692e-08
3 O 0 7.297844462073044e-08
, O 0 6.303551902675508e-09
the O 0 1.8999115170004188e-08
autopsy O 0 1.7592587028048e-05
findings O 0 4.701689420016919e-07
showed O 0 4.221572908136295e-06
massive O 0 9.893198011923232e-07
demyelination B-Disease 1 0.9999862909317017
of I-Disease 0 2.8986772093730906e-08
the I-Disease 0 9.250852883724292e-08
cerebral I-Disease 0 0.016513735055923462
white I-Disease 0 4.998640292797063e-07
matter I-Disease 0 2.7062674323730107e-09
with O 0 1.7894365988979644e-09
sparing O 0 1.506932001404948e-08
of O 0 1.279235606332918e-09
the O 0 1.4620849420055038e-08
U O 0 8.006441021279898e-06
- O 0 6.582006608368829e-05
fibers O 0 1.3927329746366013e-05
, O 0 4.4139709665103055e-09
compatible O 0 2.1461007193579462e-08
with O 0 1.8975783167007876e-09
the O 0 2.710813573614246e-09
findings O 0 2.8705404275797264e-08
of O 0 1.3102445350909875e-08
childhood O 0 0.06235096603631973
ALD B-Disease 1 1.0
. O 0 2.0196675905026495e-06

Oleic O 0 0.014263498596847057
and O 0 1.3652887901116628e-05
erucic O 0 0.0011586302425712347
acids O 0 7.1922199822438415e-06
( O 0 1.718081819035433e-07
Lorenzos O 0 1.5699956747994293e-06
Oil O 0 1.6069587616129866e-07
) O 0 3.1394808974738453e-09
were O 0 1.014370809571119e-08
administered O 0 9.866504946387522e-09
to O 0 4.8180983647228e-09
patients O 0 1.1654671538963157e-07
1 O 0 6.278102482326631e-09
and O 0 1.6410812264666674e-08
4 O 0 2.946290855732059e-08
, O 0 3.980987983709383e-09
but O 0 2.2497879115235264e-09
sufficient O 0 2.758892492238374e-08
effectiveness O 0 4.334647201176267e-07
was O 0 2.1832136098964838e-07
not O 0 2.0437067149714494e-08
obtained O 0 1.5588091173412977e-07
. O 0 1.564877294413236e-07

The O 0 1.812816890378599e-06
findings O 0 6.774325242986379e-07
in O 0 1.0691437068999221e-08
this O 0 1.6834136307153358e-09
family O 0 2.089699258078781e-08
suggest O 0 3.083666655356865e-08
that O 0 2.1289923157752355e-09
delGAG291 O 0 1.1214048356578132e-07
is O 0 5.898155852612774e-10
part O 0 6.923938644654015e-10
of O 0 4.145606913308342e-10
the O 0 3.907415280224313e-09
cause O 0 4.0328515638066165e-08
of O 0 3.312949914402452e-09
Japanese O 0 1.8212511349702254e-05
ALD B-Disease 1 1.0
with O 0 3.818241722797211e-08
phenotypic O 0 1.1400122275517788e-05
variations O 0 1.2160300684627146e-05
. O 0 3.469673401923501e-07

Moreover O 0 3.14262360916473e-05
, O 0 2.8964592502234154e-07
although O 0 2.0542158196690252e-08
the O 0 2.535354148847091e-09
scale O 0 1.0785122839251926e-07
of O 0 2.4621396033097653e-09
the O 0 4.118230645389076e-09
study O 0 8.23987367226664e-09
is O 0 2.0871528949584217e-09
limited O 0 4.542252796113644e-09
, O 0 2.379451746747918e-09
there O 0 2.3651982594685705e-09
is O 0 6.3462785027113e-10
a O 0 1.73600311903499e-09
possibility O 0 6.5536065463334126e-09
that O 0 1.3056535852484785e-09
PET O 0 9.833242984313983e-07
can O 0 6.305791089289414e-08
detect O 0 0.00035664677852764726
an O 0 5.53534924563337e-08
insidious B-Disease 0 3.8271056837402284e-05
lesion I-Disease 0 0.0060933674685657024
which O 0 1.0159939023424158e-07
is O 0 5.562230853684014e-08
undetectable O 0 3.036492671526503e-06
by O 0 5.632948774092483e-09
computed O 0 6.55078508771112e-07
tomogram O 0 3.156892489641905e-06
( O 0 2.2830398904716276e-08
CT O 0 2.326429239474237e-05
) O 0 1.5361964145199636e-08
or O 0 2.287389833099951e-08
MRI O 0 2.24813061322493e-06
analysis O 0 1.699167029300952e-07
, O 0 9.829650871040485e-09
and O 0 9.873695638873414e-09
that O 0 9.35528654544271e-10
the O 0 1.2169611984802486e-09
higher O 0 9.777816778466786e-09
level O 0 1.4423305216837434e-08
of O 0 5.623306265079009e-10
tau O 0 1.1588169535059478e-08
reflects O 0 3.560192585183586e-09
the O 0 1.2915108982269885e-09
process O 0 2.5871105258090665e-09
of O 0 2.6023734278624033e-09
neuronal B-Disease 0 2.5488307073828764e-06
degeneration I-Disease 0 0.00013095235044602305
in O 0 8.646093760944495e-07
ALD B-Disease 1 1.0
. O 0 4.071417606610339e-06

Lorenzos O 0 0.0006058132275938988
Oil O 0 8.072352102317382e-06
should O 0 1.46935832390227e-07
be O 0 6.407925301488149e-09
given O 0 7.648972566443035e-10
in O 0 5.789074775108816e-10
the O 0 1.8310508664853842e-09
early O 0 4.5496253875398907e-08
stage O 0 1.8957215388581972e-06
. O 0 1.6588842299825046e-08
. O 0 1.0331988420375637e-07

Nonsense O 0 0.0002884749264921993
mutation O 0 1.0149814443138894e-05
in O 0 6.439710631411799e-08
exon O 0 1.1395569572414388e-06
4 O 0 1.0647890036352692e-07
of O 0 3.331840359166449e-09
human O 0 2.6543348852214876e-08
complement O 0 1.8877030072417256e-07
C9 O 0 8.112027899187524e-06
gene O 0 6.506926411020686e-07
is O 0 4.933391029027234e-09
the O 0 4.441434331425853e-09
major O 0 2.499302276248727e-08
cause O 0 4.669667319490145e-08
of O 0 5.920871348763512e-09
Japanese O 0 3.6676945001090644e-06
complement B-Disease 0 8.722881466383114e-05
C9 I-Disease 1 0.9133859872817993
deficiency I-Disease 0 0.011087553575634956
. O 0 7.119875249372853e-07

Deficiency B-Disease 1 0.9993975162506104
of I-Disease 0 1.0256727733803928e-07
the I-Disease 0 1.0132439598464771e-07
ninth I-Disease 0 6.252525395211705e-07
component I-Disease 0 7.971540583184833e-08
of I-Disease 0 2.2080162143112148e-09
human I-Disease 0 1.9445474563895004e-08
complement I-Disease 0 1.4585175733827782e-07
( O 0 2.207612759264066e-08
C9 O 0 1.5273767530743498e-06
) O 0 2.9671101131611977e-09
is O 0 5.16551412754751e-10
the O 0 5.363565702687367e-10
most O 0 3.3781306640889852e-09
common O 0 7.638146257704648e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 5.863487917423527e-09
Japan O 0 3.139527962048305e-07
but O 0 4.6191193092681715e-09
is O 0 4.378491735845813e-10
rare O 0 6.161721133324249e-10
in O 0 4.1184797239246507e-10
other O 0 2.152412692524308e-09
countries O 0 1.0646018289151016e-08
. O 0 8.250083993743829e-08

We O 0 4.369288035377394e-06
studied O 0 1.9570761367049272e-07
the O 0 1.6691865667439743e-08
molecular O 0 1.3661552600297e-07
basis O 0 4.28017763454136e-08
of O 0 3.1138867484514776e-08
C9 B-Disease 1 0.9959955215454102
deficiency I-Disease 0 0.3170008957386017
in O 0 7.636177912218045e-09
four O 0 4.563809241631134e-08
Japanese O 0 8.026539717320702e-07
C9 B-Disease 0 0.00017416942864656448
- I-Disease 0 0.0007910278509370983
deficient I-Disease 0 0.0004222694842610508
patients O 0 4.310599251766689e-06
who O 0 5.286503323986835e-07
had O 0 1.973890721274074e-05
suffered O 1 0.9895025491714478
from O 0 1.349302056041779e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 2.616890014905948e-06

Direct O 0 5.717987278330838e-06
sequencing O 0 3.4047748158627655e-06
of O 0 1.321110971730377e-07
amplified O 0 4.839422217628453e-06
C9 O 0 1.669062658038456e-05
cDNA O 0 1.7124968962889398e-06
and O 0 1.3694646838757762e-07
DNA O 0 6.816741802140314e-07
revealed O 0 2.9612215257657226e-07
a O 0 2.448214075911892e-08
nonsense O 0 3.0724859811925853e-07
substitution O 0 5.67764040226848e-08
( O 0 3.4859908737416845e-08
CGA O 0 1.3043446642768686e-06
- O 0 2.9368227842496708e-05
- O 0 1.1212010576855391e-05
> O 0 1.09124164282548e-06
TGA O 0 5.071915893495316e-06
) O 0 2.057537074051652e-08
at O 0 4.9879016472687e-08
codon O 0 1.501649080637435e-07
95 O 0 2.3645322144716374e-08
in O 0 1.63646374229387e-09
exon O 0 8.155414121802096e-08
4 O 0 1.8440582394418925e-08
in O 0 3.068240994608118e-09
the O 0 1.1939518707038133e-08
four O 0 3.1156571367318975e-07
C9 B-Disease 0 0.0006623463123105466
- I-Disease 0 0.006049388088285923
deficient I-Disease 0 0.00011867610010085627
individuals O 0 2.2956206180424488e-07
. O 0 1.8011316171850922e-07

An O 0 2.448186933179386e-06
allele O 0 2.146549195458647e-05
- O 0 3.2047778404376004e-06
specific O 0 1.5095966432454588e-07
polymerase O 0 1.3360495358938351e-06
chain O 0 1.9917338249797467e-06
reaction O 0 1.0000096750673038e-07
system O 0 5.68679894286106e-08
designed O 0 2.4822048771966365e-07
to O 0 1.2879151967126745e-08
detect O 0 2.67434588749893e-05
exclusively O 0 1.0421705809449122e-07
only O 0 6.409416553054825e-09
one O 0 2.057186643256159e-09
of O 0 2.0790466570552724e-10
the O 0 1.7356455161987583e-09
normal O 0 1.3172958723828287e-08
and O 0 5.512420298003917e-09
mutant O 0 1.686304216264034e-07
alleles O 0 1.0111241266486104e-07
indicated O 0 4.834431166500508e-08
that O 0 9.950807955405594e-10
all O 0 1.8582581029491507e-09
the O 0 4.015793919620592e-09
four O 0 8.610845014800361e-08
patients O 0 1.1200067717709317e-07
were O 0 4.634308936601883e-08
homozygous O 0 1.893855454682125e-07
for O 0 1.255951009859757e-09
the O 0 3.039037688168378e-09
mutation O 0 4.246569318411275e-08
in O 0 9.369268694214838e-10
exon O 0 6.561788978842742e-08
4 O 0 2.2843249070092497e-08
and O 0 7.516871569634986e-09
that O 0 9.027642522418944e-10
the O 0 2.4999586845098065e-09
parents O 0 4.728047287017034e-08
of O 0 2.0200348060939177e-09
patient O 0 4.0261352296511177e-07
2 O 0 5.5510710694761656e-08
were O 0 3.482469139726163e-07
heterozygous O 0 9.933550245477818e-06
. O 0 2.1364583346894506e-07

The O 0 1.1254509217906161e-06
common O 0 7.514889261983626e-07
mutation O 0 2.150129830624792e-06
at O 0 6.574091315769692e-08
codon O 0 3.1666598943047575e-07
95 O 0 7.77487372261021e-08
in O 0 3.2580929065773034e-09
exon O 0 2.097302598258466e-07
4 O 0 8.427368669572388e-08
might O 0 4.858928193129941e-08
be O 0 2.561353129593158e-09
responsible O 0 1.0183157428400591e-08
for O 0 7.301429461037401e-10
most O 0 8.924224914608203e-09
Japanese O 0 5.312913799571106e-06
C9 B-Disease 1 0.5438830256462097
deficiency I-Disease 0 0.0003567477688193321
. O 0 3.654541558262281e-08
. O 0 1.2484775879784138e-07

BRCA1 O 0 0.0022348365746438503
required O 0 3.998243300884496e-06
for O 0 5.4143882266544097e-08
transcription O 0 3.3688752409943845e-06
- O 0 0.00010478580952621996
coupled O 0 1.4537751667376142e-05
repair O 0 0.0002105712192133069
of O 0 9.151138158358663e-08
oxidative O 0 0.00017718908202368766
DNA O 0 6.313141057034954e-05
damage O 0 0.00020983105059713125
. O 0 1.025345682137413e-06

The O 0 3.225250111427158e-05
breast B-Disease 1 0.9999994039535522
and I-Disease 1 0.9998987913131714
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.0031217485666275024
gene O 0 7.344481855398044e-05
BRCA1 O 0 0.0009591285488568246
encodes O 0 4.397089469421189e-06
a O 0 1.2705500012089033e-06
zinc O 0 0.39442548155784607
finger O 0 0.0011496207443997264
protein O 0 3.6794693869524053e-07
of O 0 2.2133130883617014e-08
unknown O 0 6.150220315248589e-07
function O 0 5.233990805209032e-07
. O 0 2.2830600698853232e-07

Association O 0 8.107975190796424e-06
of O 0 4.7543444736675156e-08
the O 0 6.997068879854851e-08
BRCA1 O 0 1.2464908650144935e-05
protein O 0 9.842393211556555e-08
with O 0 8.820792984920445e-09
the O 0 1.3271237442324946e-08
DNA O 0 5.441419261842384e-07
repair O 0 9.079435585590545e-06
protein O 0 2.587524647879036e-07
Rad51 O 0 3.3351245747326175e-06
and O 0 2.167334933744769e-08
changes O 0 1.2601244492316255e-08
in O 0 1.4652612456700354e-09
the O 0 1.5939607411752377e-09
phosphorylation O 0 1.6375512501554113e-08
and O 0 9.233080966453144e-09
cellular O 0 7.532518964126211e-08
localization O 0 1.2559952722313028e-07
of O 0 1.3882184290991972e-09
the O 0 2.014152178375639e-09
protein O 0 2.977173885199136e-08
after O 0 3.1151103030424565e-08
exposure O 0 3.5365141570764536e-07
to O 0 1.1156058299377491e-08
DNA O 0 1.498566234658938e-06
- O 0 1.853724279499147e-05
damaging O 0 7.725942850811407e-06
agents O 0 2.6884174531005556e-07
are O 0 2.0969540770465755e-08
consistent O 0 9.194668137979534e-08
with O 0 1.2519878467287526e-09
a O 0 5.193682373061392e-09
role O 0 2.1858838294974703e-08
for O 0 4.131321507117036e-09
BRCA1 O 0 5.624246568913804e-06
in O 0 1.8033688320429064e-08
DNA O 0 2.011302512983093e-06
repair O 0 0.000196848573978059
. O 0 1.3253476254249108e-06

Here O 0 2.8115048280596966e-06
, O 0 4.7379778322920174e-08
it O 0 3.4017177963363565e-09
is O 0 1.7252289596925152e-09
shown O 0 5.672182723515107e-09
that O 0 2.890581773939971e-09
mouse O 0 1.5709348417658475e-06
embryonic O 0 1.624803417143994e-06
stem O 0 1.156211510533467e-06
cells O 0 4.0763180209069105e-07
deficient B-Disease 0 6.277266493270872e-07
in I-Disease 0 3.492431233098614e-09
BRCA1 I-Disease 0 6.425394985853927e-06
are O 0 1.9001433315679606e-08
defective O 0 1.4277180753197172e-06
in O 0 2.5463890995780503e-09
the O 0 4.299239186877912e-09
ability O 0 3.932449388344139e-08
to O 0 5.126207902605984e-09
carry O 0 4.471586834142727e-08
out O 0 3.298984552202455e-08
transcription O 0 4.1404751982554444e-07
- O 0 4.067792815476423e-06
coupled O 0 2.1913269847573247e-06
repair O 0 1.950117075466551e-05
of O 0 1.1128685528660753e-08
oxidative O 0 9.150907317234669e-06
DNA O 0 7.32042553863721e-06
damage O 0 2.2159540094435215e-05
, O 0 1.3814730692729427e-08
and O 0 8.931376527243629e-09
are O 0 9.395597189154614e-09
hypersensitive O 0 1.4503439160762355e-06
to O 0 4.620971694180298e-08
ionizing O 0 0.0007967720739543438
radiation O 0 0.013071706518530846
and O 0 6.070284257475578e-07
hydrogen O 0 1.9039219978367328e-06
peroxide O 0 0.00011021560931112617
. O 0 6.978183364481083e-07

These O 0 1.262847604266426e-06
results O 0 4.5618341459885414e-07
suggest O 0 8.890894775959168e-08
that O 0 2.6364666005918025e-09
BRCA1 O 0 3.3478872865089215e-06
participates O 0 5.589243912140773e-08
, O 0 2.891778372315912e-09
directly O 0 2.0061859729025855e-08
or O 0 4.779092321882672e-08
indirectly O 0 1.321128593190224e-07
, O 0 1.028626295251911e-09
in O 0 7.490691400491301e-10
transcription O 0 3.6922503454661637e-07
- O 0 8.805457582639065e-06
coupled O 0 1.988901658478426e-06
repair O 0 2.587066228443291e-05
of O 0 1.851748976378076e-08
oxidative O 0 3.0355568014783785e-05
DNA O 0 1.7499070963822305e-05
damage O 0 2.8776408726116642e-05
. O 0 4.6317726543065874e-08
. O 0 2.0652834109569085e-07

Truncation O 0 0.0005054669454693794
mutations O 0 0.0005865627317689359
in O 0 1.6670905722548923e-07
the O 0 3.160649342248689e-08
transactivation O 0 5.012067049392499e-06
region O 0 1.6443294725831947e-07
of O 0 1.777694080828951e-08
PAX6 O 0 1.7151336578535847e-05
result O 0 2.0316726079272485e-07
in O 0 2.6910946360203525e-08
dominant O 0 9.794273864827119e-06
- O 0 1.3746695913141593e-05
negative O 0 5.764614797953982e-06
mutants O 0 6.7803894125972874e-06
. O 0 6.109900141382241e-07

PAX6 O 0 0.001436506980098784
is O 0 4.3616091716103256e-07
a O 0 2.5683746684990183e-08
transcription O 0 1.557486655201501e-07
factor O 0 4.773462691787245e-08
with O 0 2.7303035388115404e-09
two O 0 1.3293608880360352e-08
DNA O 0 6.389791451510973e-07
- O 0 1.0895299737967434e-06
binding O 0 2.391898590303754e-07
domains O 0 6.12779160746868e-07
( O 0 4.361317706980117e-08
paired O 0 1.5598277514072834e-06
box O 0 1.1764976761696744e-06
and O 0 1.3244792285149742e-07
homeobox O 0 7.53832466671156e-07
) O 0 9.993209815206683e-09
and O 0 5.619052778627065e-09
a O 0 1.6915832290465005e-08
proline O 0 1.670535993980593e-06
- O 0 1.585854874974757e-06
serine O 0 2.851708131856867e-06
- O 0 1.9914848508051364e-06
threonine O 0 3.147558118143934e-06
( O 0 8.171139853629938e-08
PST O 0 2.3283855625777505e-06
) O 0 5.716923467957713e-08
- O 0 8.177250379048928e-07
rich O 0 1.9766419256939116e-07
transactivation O 0 1.623936441319529e-05
domain O 0 1.8120941831512027e-06
. O 0 5.725565301872848e-07

PAX6 O 0 0.0040038228034973145
regulates O 0 8.512760541634634e-05
eye O 0 0.005076664034277201
development O 0 2.4773615336926014e-07
in O 0 1.9922600458244233e-08
animals O 0 1.795447523988969e-08
ranging O 0 2.2206370076105486e-08
from O 0 6.616254655256171e-09
jellyfish O 0 1.8877456042787344e-08
to O 0 2.188310643802538e-09
Drosophila O 0 7.258128675857733e-08
to O 0 1.718425046703942e-08
humans O 0 3.743119521004701e-07
. O 0 9.796301014830533e-08

Heterozygous O 0 0.002054588170722127
mutations O 0 9.04418557183817e-05
in O 0 7.384629441276047e-08
the O 0 3.561056871603796e-08
human O 0 4.628540040130247e-08
PAX6 O 0 4.3738655222114176e-06
gene O 0 5.928139898969675e-07
result O 0 2.991626857351548e-08
in O 0 9.621869967446628e-10
various O 0 4.842845235941695e-09
phenotypes O 0 2.5936121801350964e-06
, O 0 6.100576044332229e-09
including O 0 7.678623603624146e-08
aniridia B-Disease 1 1.0
, O 0 1.824849505283055e-06
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999953508377075
, O 0 3.0185492505552247e-07
autosomal B-Disease 0 0.15586522221565247
dominant I-Disease 0 0.0026448883581906557
keratitis I-Disease 0 0.01069521065801382
, O 0 2.2283596479155676e-07
and O 0 7.876067797951691e-07
familial B-Disease 1 0.9878522157669067
foveal I-Disease 1 0.7419875860214233
dysplasia I-Disease 1 0.9997974038124084
. O 0 7.663547876290977e-06

It O 0 1.046282932293252e-06
is O 0 3.193170172721693e-08
believed O 0 3.6855091423149133e-08
that O 0 6.029453047950994e-10
the O 0 1.7704485655301028e-09
mutated O 0 1.4678835213999264e-07
allele O 0 1.6516439416136564e-07
of O 0 5.620285126184399e-09
PAX6 O 0 7.435151474055601e-06
produces O 0 7.48061808053535e-08
an O 0 8.195486067563706e-09
inactive O 0 4.499739532093372e-07
protein O 0 1.1892544904412716e-07
and O 0 4.307975416395493e-07
aniridia B-Disease 1 1.0
is O 0 1.1154828172266207e-07
caused O 0 6.131591590019525e-07
due O 0 8.039611287813386e-08
to O 0 5.578114681270563e-08
genetic O 0 0.00010393048432888463
haploinsufficiency O 0 0.00011499146785354242
. O 0 4.202045431611623e-07

However O 0 5.550738933379762e-06
, O 0 5.305463801619226e-08
several O 0 7.88161180764746e-09
truncation O 0 1.0847338671737816e-06
mutations O 0 6.144543476693798e-06
have O 0 1.5132289377106645e-07
been O 0 6.124548690422671e-08
found O 0 1.4145035365231706e-08
to O 0 3.6509795187100735e-09
occur O 0 2.041474544967059e-08
in O 0 2.1110668768642427e-09
the O 0 2.255081987811991e-08
C O 0 3.0190205507096834e-05
- O 0 3.5287962418806273e-06
terminal O 0 4.014996193291154e-07
half O 0 2.3104540503027238e-08
of O 0 3.8047907047200624e-09
PAX6 O 0 1.5953446563798934e-06
in O 0 1.8864390938233555e-08
patients O 0 4.319906281580188e-07
with O 0 5.017433579723729e-08
Aniridia B-Disease 1 0.9999988079071045
resulting O 0 4.572396221647068e-07
in O 0 6.314671008311734e-09
mutant O 0 2.1339415923193883e-07
proteins O 0 2.098330398325743e-08
that O 0 2.8913980099076753e-09
retain O 0 9.584604043766376e-08
the O 0 5.404336533842979e-09
DNA O 0 1.1364862473328685e-07
- O 0 8.132766282642478e-08
binding O 0 2.1677152517440845e-08
domains O 0 7.279174241148212e-08
but O 0 3.6195096697611007e-08
have O 0 4.7193708496706677e-08
lost O 0 1.417108819623536e-06
most O 0 1.2412973982023345e-09
of O 0 1.0525895710600253e-09
the O 0 2.5249605073440762e-08
transactivation O 0 7.773310244374443e-06
domain O 0 1.5157030475165811e-06
. O 0 3.511724742111255e-07

It O 0 1.073501152859535e-06
is O 0 4.447489487802159e-08
not O 0 7.698476522932651e-09
clear O 0 1.5740669212505054e-08
whether O 0 2.1383035342381618e-09
such O 0 1.8426404846394462e-09
mutants O 0 4.945244995724352e-07
really O 0 1.0701458563744382e-07
behave O 0 2.799315268475766e-08
as O 0 7.290078318789028e-09
loss O 0 3.635728162976193e-08
- O 0 1.3549473010243673e-07
of O 0 1.7445003219762611e-09
- O 0 8.638907047497923e-07
function O 0 9.851501658886264e-08
mutants O 0 2.2271592570177745e-07
as O 0 2.369787566181003e-08
predicted O 0 1.36987864607363e-07
by O 0 1.3410807575553463e-08
haploinsufficiency O 0 5.104509909870103e-06
. O 0 1.46838331716026e-07

Contrary O 0 1.2802226592611987e-05
to O 0 6.496954796375576e-08
this O 0 1.9920463056877225e-09
theory O 0 5.781177314645447e-09
, O 0 1.7977153099479892e-09
our O 0 4.505486650430157e-09
data O 0 2.8021517550769204e-08
showed O 0 3.7269305153131427e-07
that O 0 5.440531913869506e-10
these O 0 5.149518589320223e-10
mutants O 0 3.322791641835465e-08
are O 0 3.2784959191900498e-09
dominant O 0 4.0023499536800955e-07
- O 0 9.71516101344605e-07
negative O 0 2.305436339611333e-07
in O 0 3.5054117386579264e-09
transient O 0 2.1836966368482535e-07
transfection O 0 1.6527499155927217e-06
assays O 0 2.566113153079641e-06
when O 0 1.728105587517348e-07
they O 0 1.965289975203177e-08
are O 0 3.3051172909637216e-09
coexpressed O 0 1.6722847817618458e-07
with O 0 8.02860533610783e-09
wild O 0 2.3616053113073576e-07
- O 0 3.3227208859898383e-06
type O 0 3.9860951801529154e-05
PAX6 O 0 0.00017960433615371585
. O 0 7.326497666326759e-07

We O 0 1.161464024335146e-05
found O 0 1.2049311237660731e-07
that O 0 3.6515714896268037e-09
the O 0 7.961645565046638e-09
dominant O 0 1.5335185707954224e-06
- O 0 3.4907461667899042e-06
negative O 0 1.8736769789029495e-06
effects O 0 3.857304818666307e-06
result O 0 5.951353188038411e-08
from O 0 2.041193214452619e-09
the O 0 2.2221484652362733e-09
enhanced O 0 4.270001241479804e-08
DNA O 0 1.035358963008548e-07
binding O 0 3.77972249054892e-08
ability O 0 3.151794203404279e-08
of O 0 1.4973333684054069e-09
these O 0 1.0456166599226435e-08
mutants O 0 1.060810291164671e-06
. O 0 1.5519829332788504e-07

Kinetic O 0 1.66006684594322e-05
studies O 0 1.410615141139715e-06
of O 0 2.3043892127816434e-08
binding O 0 4.4356548301038856e-07
and O 0 2.1993758991811774e-07
dissociation O 0 4.515556156547973e-06
revealed O 0 2.9352057140386023e-07
that O 0 8.695736908315155e-10
various O 0 2.2212034433977124e-09
truncation O 0 2.731086965468421e-07
mutants O 0 5.267983169687795e-07
have O 0 2.522760489398479e-08
3 O 0 3.494984923690936e-08
- O 0 8.754538498578768e-07
5 O 0 5.534124625228287e-08
- O 0 3.4929334447042493e-07
fold O 0 1.2277311611796904e-07
higher O 0 1.041909847288025e-08
affinity O 0 1.0437656072781465e-08
to O 0 1.5569506794932408e-09
various O 0 2.2538897415103065e-09
DNA O 0 4.8536946906097e-08
- O 0 4.2919822362819104e-08
binding O 0 1.5298514455253098e-08
sites O 0 3.5295588673989187e-08
when O 0 1.4699254258232486e-08
compared O 0 7.039339777747955e-09
with O 0 9.69402669248609e-10
the O 0 6.2083813645585906e-09
wild O 0 7.398332968477916e-08
- O 0 1.8617234900375479e-06
type O 0 1.8000882846536115e-05
PAX6 O 0 0.00011744956282200292
. O 0 9.14464408197091e-07

These O 0 1.769075993252045e-06
results O 0 4.997768314751738e-07
provide O 0 4.788892837837011e-08
a O 0 1.1809268229967529e-08
new O 0 2.9481050933810593e-09
insight O 0 1.4266584358324508e-08
into O 0 3.1417330959016e-09
the O 0 1.4034789996841823e-09
role O 0 1.0226445468219936e-08
of O 0 2.4950472798934697e-09
mutant O 0 1.2534600273284013e-06
PAX6 O 0 6.582456080650445e-06
in O 0 5.997137719759849e-08
causing O 0 6.755739377695136e-06
aniridia B-Disease 1 0.9999924898147583
. O 0 9.274668855141499e-08
. O 0 3.202869720553281e-07

Reversal O 0 5.486676673172042e-05
of O 0 1.5062214515637606e-06
severe O 1 0.9998230338096619
hypertrophic B-Disease 1 0.9999994039535522
cardiomyopathy I-Disease 1 1.0
and O 0 1.4428210306505207e-05
excellent O 0 3.374894004082307e-05
neuropsychologic O 0 6.951362593099475e-05
outcome O 0 2.5537013925713836e-07
in O 0 1.4670628267765551e-08
very B-Disease 0 2.0286155688609142e-07
- I-Disease 0 6.318272789940238e-05
long I-Disease 0 9.49250261328416e-06
- I-Disease 0 2.330472671019379e-05
chain I-Disease 0 1.433908983017318e-05
acyl I-Disease 0 4.626431746146409e-06
- I-Disease 0 5.163843070477014e-06
coenzyme I-Disease 0 5.1587239795480855e-06
A I-Disease 0 2.27875602831773e-06
dehydrogenase I-Disease 0 0.0035803092177957296
deficiency I-Disease 0 0.006497515831142664
. O 0 6.725269372509501e-07

Very B-Disease 0 4.466978134587407e-05
- I-Disease 0 0.00019679265096783638
long I-Disease 0 1.5899458958301693e-05
- I-Disease 0 3.970214311266318e-05
chain I-Disease 0 1.0357710380048957e-05
acyl I-Disease 0 4.6602899601566605e-06
- I-Disease 0 1.5465973319805926e-06
coenzyme I-Disease 0 7.229783136608603e-07
A I-Disease 0 9.100347142521059e-08
dehydrogenase I-Disease 0 5.876472641830333e-06
( I-Disease 0 1.8280130120729154e-07
VLCAD I-Disease 0 0.000210877216886729
) I-Disease 0 3.133864936444297e-07
deficiency I-Disease 0 5.16263535246253e-05
is O 0 4.0463334904927706e-09
a O 0 5.813955894495848e-08
disorder O 0 0.005684175994247198
of O 0 1.1131190191804308e-08
fatty O 0 4.938086476613535e-06
acid O 0 3.163496842262248e-07
beta O 0 2.643739449581517e-08
oxidation O 0 3.320232622172625e-08
that O 0 1.1678120692693028e-08
reportedly O 0 2.3733910836654104e-07
has O 0 6.1410978524634174e-09
high O 0 5.121646395878088e-08
rates O 0 4.203648700240592e-07
of O 0 7.162560322626632e-09
morbidity O 0 4.95188869535923e-05
and O 0 1.0284550171490991e-06
mortality O 0 0.0002782672527246177
. O 0 3.717172489814402e-07

We O 0 3.17796116178215e-06
describe O 0 4.3998105070386373e-07
the O 0 9.800895206524274e-09
outcome O 0 2.1863842292191293e-08
of O 0 7.858970696439371e-10
a O 0 2.0374834264202946e-08
5 O 0 5.216987375433746e-08
- O 0 1.1932834240724333e-06
year O 0 2.565040801982832e-08
- O 0 1.6577477026658016e-06
old O 0 7.402746632578783e-06
girl O 0 1.687062467681244e-05
with O 0 5.110503025207436e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.3871996316083823e-06
was O 0 1.612939115602785e-07
first O 0 3.2848443964894614e-08
seen O 0 3.243898447635729e-07
at O 0 3.392298708604358e-08
5 O 0 7.752081643275233e-09
months O 0 5.620799825578615e-09
of O 0 1.4305788775814676e-09
age O 0 2.708719932797976e-07
with O 0 3.083684703142353e-07
severe O 1 0.9999691247940063
hypertrophic B-Disease 1 0.9999997615814209
cardiomyopathy I-Disease 1 1.0
, O 0 7.90467020124197e-05
hepatomegaly B-Disease 1 1.0
, O 0 3.203877349733375e-05
encephalopathy B-Disease 1 0.9909070730209351
, O 0 6.094588655969346e-08
and O 0 3.493326516945672e-07
hypotonia B-Disease 0 0.0017894896445795894
. O 0 1.1245056157349609e-06

Biochemical O 0 0.0004535923944786191
studies O 0 0.00021156316506676376
indicated O 1 0.999382495880127
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 7.237964746309444e-05
by O 0 3.2106061809145103e-08
a O 0 1.3551746746998106e-07
stable O 0 1.9496019376674667e-05
yet O 0 2.099139493338953e-07
inactive O 0 1.7979617723540287e-06
enzyme O 0 1.9355243239260744e-06
. O 0 1.9052700395150168e-07

Molecular O 0 5.942881034570746e-05
genetic O 0 1.5658430129406042e-05
analysis O 0 4.42810204503985e-07
of O 0 4.0393796751914124e-08
her O 0 7.558159722975688e-06
VLCAD O 0 0.0007474343292415142
gene O 0 8.072806849668268e-06
revealed O 0 2.137091314580175e-06
a O 0 1.207568942618309e-07
T1372C O 0 4.8982983571477234e-06
( O 0 6.77284717198745e-08
F458L O 0 1.6549580550417886e-06
) O 0 4.179783275048976e-08
missense O 0 8.685119610163383e-06
mutation O 0 7.818258382030763e-06
and O 0 2.529654068439413e-07
a O 0 7.507847499255149e-07
1668 O 0 0.0007533947937190533
ACAG O 0 0.0004314375401008874
1669 O 0 3.12115516862832e-05
splice O 0 0.000459653208963573
site O 0 1.7982729332288727e-05
mutation O 0 6.251465674722567e-05
. O 0 1.8075551224683295e-06

After O 0 4.5043389036436565e-06
initial O 0 1.4657296105724527e-06
treatment O 0 1.4570372286470956e-06
with O 0 4.037931589095933e-08
intravenous O 0 4.096374595974339e-06
glucose O 0 4.427562453201972e-05
and O 0 1.196324177499264e-07
carnitine O 0 3.3533835903654108e-06
, O 0 2.368377849393255e-08
the O 0 1.573499552876001e-08
patient O 0 7.7495559480667e-07
has O 0 1.950167138886627e-08
thrived O 0 1.7086601644678012e-07
on O 0 1.15162510638811e-08
a O 0 3.2674229544227273e-08
low O 0 2.5207071303157136e-05
- O 0 1.9485705706756562e-05
fat O 0 9.602058526070323e-07
diet O 0 1.155268734009951e-07
supplemented O 0 7.090034870316231e-08
with O 0 1.8752141173195014e-08
medium O 0 3.0085300295468187e-06
- O 0 1.0653862773324363e-05
chain O 0 3.752606062334962e-06
triglyceride O 0 1.9612907635746524e-06
oil O 0 2.0785576282378315e-07
and O 0 1.1937697053099328e-08
carnitine O 0 9.349395782010106e-07
and O 0 2.1334974675824014e-08
avoidance O 0 1.670150481913879e-06
of O 0 7.488369391239758e-08
fasting O 0 8.041411092563067e-06
. O 0 4.286268335818022e-07

Her O 0 0.00267382082529366
ventricular O 0 0.06396030634641647
hypertrophy O 0 0.0006785955047234893
resolved O 0 4.327883289079182e-06
significantly O 0 6.815480446675792e-07
over O 0 3.638863788069102e-08
1 O 0 3.2838549657299154e-08
year O 0 6.5163381357535854e-09
, O 0 3.3190405979155457e-09
and O 0 4.051292989970534e-08
cognitively O 0 1.2616303138202056e-05
, O 0 1.0989260168514647e-08
she O 0 1.0784896886661954e-07
is O 0 1.294065521406651e-09
in O 0 6.04409911009185e-10
the O 0 2.4447035507080273e-09
superior O 0 4.8784571049509395e-08
range O 0 7.602088203384483e-08
for O 0 2.0644280951387373e-08
age O 0 9.004742196339066e-07
. O 0 1.057984917451904e-07

Clinical O 0 0.0013817243743687868
recognition O 0 3.5376581308810273e-06
of O 0 1.3427463272819296e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.806109833386472e-08
important O 0 1.9955765040435836e-08
because O 0 1.3064514803318161e-08
it O 0 1.3837455625775874e-09
is O 0 3.6465305774946444e-10
one O 0 2.9147967373077677e-10
of O 0 1.0302907832437924e-10
the O 0 2.268756960077667e-09
few O 0 4.999016667284195e-08
directly O 0 5.391610102378763e-06
treatable O 0 0.0078268488869071
causes O 0 1.5167427136475453e-07
of O 0 2.5353843469133608e-08
cardiomyopathy B-Disease 1 1.0
in O 0 4.695160953360755e-07
children O 0 3.6242356600268977e-06
. O 0 2.3629180390116744e-08
. O 0 1.309612969180307e-07

Cloning O 0 2.6998637622455135e-05
of O 0 8.268878559647419e-08
a O 0 6.099984517504708e-08
novel O 0 5.084659093768096e-08
member O 0 1.0297418029381333e-08
of O 0 1.2003859017895024e-09
the O 0 1.182105346941853e-08
low O 0 7.315187394851819e-05
- O 0 5.165689071873203e-05
density O 0 8.876608603713976e-07
lipoprotein O 0 0.0006433151429519057
receptor O 0 1.2133286872995086e-05
family O 0 1.0483374808245571e-06
. O 0 2.651744637205411e-07

A O 0 5.04907484355499e-06
gene O 0 2.975099050672725e-06
encoding O 0 5.731805003961199e-07
a O 0 1.427561358013918e-07
novel O 0 1.9896802427865623e-07
transmembrane O 0 7.477514714082645e-07
protein O 0 4.238687836277677e-07
was O 0 3.0960609365138225e-07
identified O 0 7.332823770411778e-08
by O 0 2.4257436059826887e-09
DNA O 0 6.611021774460824e-08
sequence O 0 2.6237461980826993e-08
analysis O 0 3.160450745554044e-08
within O 0 1.8280019276062376e-08
the O 0 5.789831547531321e-08
insulin B-Disease 1 0.8565399646759033
- I-Disease 1 0.9991412162780762
dependent I-Disease 1 0.9998025298118591
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.394226976321079e-05
IDDM B-Disease 0 0.0005648561054840684
) O 0 1.199325083689473e-07
locus O 0 1.629215148568619e-05
IDDM4 O 0 3.7134537706151605e-05
on O 0 5.913560130466067e-07
chromosome O 0 0.00022366999473888427
11q13 O 0 3.12528973154258e-05
. O 0 6.899845743646438e-07

Based O 0 7.707735107942426e-07
on O 0 8.175972965318579e-08
its O 0 2.335469417857894e-08
chromosomal O 0 4.956499469699338e-05
position O 0 3.544652145137661e-06
, O 0 4.020246802127758e-09
this O 0 7.048741035298178e-10
gene O 0 3.213761701204021e-08
is O 0 1.0803293815087045e-09
a O 0 2.3568673679363883e-09
candidate O 0 3.61777026114396e-08
for O 0 3.256962255449025e-09
conferring O 0 4.223261669267231e-07
susceptibility O 0 1.3409983694145922e-05
to O 0 7.868853231229878e-07
diabetes B-Disease 1 0.9931564927101135
. O 0 3.458164030689659e-07

The O 0 1.3231601769803092e-06
gene O 0 4.010410521004815e-06
, O 0 5.0613980562275174e-08
termed O 0 5.862506213816232e-07
low O 0 3.8865120586706325e-05
- O 0 8.769354280957486e-06
density O 0 1.0635990292939823e-06
lipoprotein O 0 0.0001608697639312595
receptor O 0 4.0291761251864955e-06
related O 0 1.9106468585050607e-07
protein O 0 3.088691187258519e-07
5 O 0 8.562367526110393e-08
( O 0 3.351351196556607e-08
LRP5 O 0 3.8124096590763656e-06
) O 0 7.550611691442555e-09
, O 0 1.0071640188513697e-09
encodes O 0 3.040917917473962e-08
a O 0 7.790249334505006e-09
protein O 0 3.116732827379565e-08
of O 0 3.8918179789959595e-09
1615 O 0 1.3251908512756927e-06
amino O 0 3.170437139488058e-07
acids O 0 2.5040069573378787e-08
that O 0 6.205229108324772e-10
contains O 0 9.703682302131256e-10
conserved O 0 5.99649485621967e-09
modules O 0 1.0369078928817999e-08
which O 0 3.0058211475392227e-09
are O 0 1.385160985911682e-09
characteristic O 0 1.4717601359848231e-08
of O 0 1.3418477440296783e-09
the O 0 1.9236640724784593e-08
low O 0 0.0005775195313617587
- O 0 0.001298697548918426
density O 0 2.2129556782601867e-06
lipoprotein O 0 0.0021803914569318295
( O 0 5.089947876513179e-07
LDL O 0 0.00011452071339590475
) O 0 8.240318294383542e-08
receptor O 0 2.128122105204966e-06
family O 0 1.0347218903916655e-06
. O 0 2.979396072078089e-07

These O 0 5.583723350355285e-07
modules O 0 6.685531843686476e-07
include O 0 5.5572048296426146e-08
a O 0 6.083903514308986e-08
putative O 0 1.152913796431676e-06
signal O 0 4.3759874301940727e-07
peptide O 0 8.487182867611409e-08
for O 0 1.832570761806096e-09
protein O 0 1.4030059780623105e-08
export O 0 1.9413862517581038e-08
, O 0 1.9527344186087703e-09
four O 0 7.888169228920106e-09
epidermal O 0 2.2005635003097268e-07
growth O 0 1.0233278402438373e-07
factor O 0 1.256234867241801e-07
( O 0 3.108166524157241e-08
EGF O 0 2.8942413337063044e-06
) O 0 1.4014414517760088e-08
repeats O 0 2.411946411484678e-07
with O 0 1.1416652512252767e-08
associated O 0 1.3261096398764494e-07
spacer O 0 3.2158759495359845e-06
domains O 0 3.05467165162554e-06
, O 0 5.2629410163262946e-08
three O 0 1.0768699354457567e-07
LDL O 0 9.799964755075052e-05
- O 0 2.0390018107718788e-05
receptor O 0 1.3715679187953356e-06
( O 0 3.5107461826555664e-08
LDLR O 0 2.09027075470658e-06
) O 0 7.98770116716696e-09
repeats O 0 1.0976276598739787e-07
, O 0 3.960161532035045e-09
a O 0 7.605783558517487e-09
single O 0 5.91734021782031e-07
transmembrane O 0 4.010480552096851e-07
spanning O 0 2.9310768923096475e-07
domain O 0 3.261418157762819e-07
, O 0 2.4484753780029678e-08
and O 0 1.9260504302565096e-08
a O 0 3.916938595693864e-08
cytoplasmic O 0 3.658639570858213e-06
domain O 0 1.8405816035738098e-06
. O 0 5.391098625295854e-07

The O 0 4.405554534514522e-07
encoded O 0 6.174975055728282e-07
protein O 0 1.7275388586313056e-07
has O 0 6.880905178974217e-09
a O 0 4.357864291648639e-09
unique O 0 4.399900443985416e-09
organization O 0 5.211543641081562e-09
of O 0 2.5002258041695313e-09
EGF O 0 4.965157586411806e-06
and O 0 1.1778454478417189e-07
LDLR O 0 2.209446392953396e-05
repeats O 0 1.1945792266487842e-06
; O 0 1.934872528863707e-08
therefore O 0 3.527405567638198e-08
, O 0 8.446208177304015e-09
LRP5 O 0 3.5102286801702576e-06
likely O 0 8.171139853629938e-08
represents O 0 7.148693637049064e-09
a O 0 2.7648703326832447e-09
new O 0 3.812359761212747e-09
category O 0 1.4223715538719262e-07
of O 0 2.3074668842326673e-09
the O 0 4.2254090004689715e-08
LDLR O 0 5.582122321357019e-05
family O 0 3.400059540581424e-07
. O 0 2.3608757260262792e-07

Both O 0 7.1134595600597095e-06
human O 0 1.5549355794064468e-06
and O 0 1.783213292583241e-07
mouse O 0 1.4812480003456585e-05
LRP5 O 0 4.608584276866168e-05
cDNAs O 0 3.876483788189944e-06
have O 0 1.8516647060096147e-07
been O 0 5.99512475218944e-08
isolated O 0 1.8785296163059684e-07
and O 0 5.06591568694148e-09
the O 0 1.125990412020883e-09
encoded O 0 3.2749603917636705e-08
mature O 0 1.8221225417391906e-08
proteins O 0 7.663111922795451e-09
are O 0 3.431891437699619e-09
95 O 0 1.7151899456280262e-08
% O 0 3.477788723671438e-08
identical O 0 1.920084741868777e-06
, O 0 1.2648126990200126e-08
indicating O 0 5.076044828911108e-08
a O 0 4.930371222400254e-09
high O 0 4.123058161553672e-08
degree O 0 1.3760767636483706e-08
of O 0 1.1497720553421686e-09
evolutionary O 0 8.669744744338459e-08
conservation O 0 2.8444176791708742e-08
. O 0 1.3202187787442199e-08
. O 0 1.3048979496943502e-07

The O 0 5.565405444940552e-06
APC B-Disease 0 1.6925287127378397e-05
variants O 0 2.8532258511404507e-06
I1307K O 0 4.320616881159367e-06
and O 0 5.670324654261094e-08
E1317Q O 0 6.476738576566277e-07
are O 0 3.034590889683386e-08
associated O 0 3.915075694749248e-07
with O 1 0.6980674266815186
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 9.419728485227097e-06
but O 0 7.974825422252252e-08
not O 0 6.183778822332897e-08
always O 0 1.0287959639754263e-07
with O 0 3.965195283228695e-09
a O 0 4.3919289538507655e-08
family O 0 1.823082413920929e-07
history O 0 2.772825666852441e-07
. O 0 1.8989717887052393e-07

Classical O 1 0.8981974124908447
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.05544552206993103
FAP B-Disease 0 0.0007694066152907908
) O 0 4.402139666126459e-07
is O 0 1.6956827053604684e-08
a O 0 2.5139799575413235e-08
high O 0 2.154424146283418e-05
- O 1 0.9505689144134521
penetrance O 1 0.9132269620895386
autosomal B-Disease 1 0.9990673661231995
dominant I-Disease 1 0.6652334928512573
disease I-Disease 0 0.020667172968387604
that O 0 4.9555537451340115e-09
predisposes O 0 8.886196383173228e-07
to O 0 1.4032548456555105e-08
hundreds O 0 3.285634164740259e-08
or O 0 5.5136638366093393e-08
thousands O 0 3.3449335745672215e-08
of O 0 7.569460080958379e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.6901715397834778
carcinoma I-Disease 1 1.0
and O 0 4.351132702140603e-06
that O 0 3.093463263326157e-08
results O 0 2.1472045830250863e-07
from O 0 1.2406778715501332e-08
truncating O 0 1.344517386314692e-06
mutations O 0 9.886737188935513e-07
in O 0 9.338319451046573e-09
the O 0 3.8117800471582086e-08
APC B-Disease 0 1.8003672721533803e-06
gene O 0 1.4870531686028698e-06
. O 0 3.044182790290506e-07

A O 0 7.195423222583486e-06
variant O 0 1.3698301700060256e-05
of O 0 1.6522851353784063e-07
FAP B-Disease 0 4.1331808461109176e-05
is O 0 1.0779184549392085e-06
attenuated B-Disease 1 0.7967863082885742
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999988079071045
coli I-Disease 1 1.0
, O 0 5.119342176840291e-07
which O 0 3.7027579224968576e-08
results O 0 1.0706234832014161e-07
from O 0 2.3469414855981086e-08
germ O 0 3.7559930206043646e-05
- O 0 1.1835078112198971e-05
line O 0 1.75415952980984e-05
mutations O 0 3.099712557741441e-07
in O 0 3.3583564817973866e-09
the O 0 3.0319511346021955e-09
5 O 0 9.324294225621088e-09
and O 0 6.5892908907017045e-09
3 O 0 6.967621146714009e-09
regions O 0 7.749036079474081e-09
of O 0 1.991635967257821e-09
the O 0 3.3388651843324624e-08
APC B-Disease 0 1.06238462649344e-06
gene O 0 2.040370645772782e-06
. O 0 4.1240423342969734e-07

Attenuated B-Disease 1 0.9999737739562988
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.9999996423721313
have O 0 1.570968743180856e-05
" O 0 1.5464070202142466e-06
multiple O 0 0.00010151137394132093
" O 1 0.8282402157783508
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 6.584946277143899e-07
typically O 0 5.084261829324532e-07
fewer O 0 6.228262350305158e-08
than O 0 5.237652533907067e-09
100 O 0 9.663404298976275e-09
) O 0 2.0833266223263536e-09
without O 0 1.0542899886445412e-08
the O 0 7.0246000127838215e-09
florid O 0 7.859659490350168e-06
phenotype O 0 1.8242493524667225e-06
of O 0 1.3250144093035487e-08
classical O 0 9.127427915700537e-07
FAP B-Disease 0 2.562988447607495e-05
. O 0 6.60693729059858e-07

Another O 0 8.410671398451086e-06
group O 0 3.9327045442405506e-07
of O 0 2.16338644776215e-08
patients O 0 8.378547704523953e-07
with O 0 1.5688035759353625e-08
multiple O 0 1.631768282095436e-05
adenomas B-Disease 0 0.001310199499130249
has O 0 2.442701543259318e-07
no O 0 1.213232110330864e-07
mutations O 0 4.351007021341502e-07
in O 0 1.8677350777096535e-09
the O 0 3.353645361414692e-09
APC B-Disease 0 9.64837951755726e-08
gene O 0 1.0544513173726955e-07
, O 0 3.2496463298059552e-09
and O 0 3.932687064889251e-09
their O 0 4.1903202685489305e-08
phenotype O 0 2.6503489607421216e-06
probably O 0 1.9972411280377855e-07
results O 0 2.7832900428848006e-08
from O 0 3.8412570901869e-09
variation O 0 8.162572839864879e-08
at O 0 2.216435603941136e-07
a O 0 2.0652038301705034e-08
locus O 0 2.4911460059229285e-06
, O 0 1.0513942605427928e-08
or O 0 2.3267059390263967e-08
loci O 0 8.301890375150833e-08
, O 0 5.604698927186291e-09
elsewhere O 0 2.7023279614013518e-08
in O 0 3.4841078910829992e-09
the O 0 1.828800400005548e-08
genome O 0 4.120759626857762e-07
. O 0 1.7310121336322482e-07

Recently O 0 5.85951711400412e-05
, O 0 1.8332818285671237e-07
however O 0 3.248495161756182e-08
, O 0 4.843768941498183e-09
a O 0 1.1446502412582049e-08
missense O 0 1.1538719490999938e-06
variant O 0 1.1611687114054803e-06
of O 0 1.3258865116938523e-08
APC B-Disease 0 1.0221257298326236e-06
( O 0 2.229583451196504e-08
I1307K O 0 2.6908796257885115e-07
) O 0 5.6973266104876075e-09
was O 0 3.239029311430386e-08
described O 0 1.6014674031339382e-08
that O 0 7.964602866117332e-10
confers O 0 1.5687437127098747e-08
an O 0 3.3317957282008592e-09
increased O 0 2.1842132014171511e-07
risk O 0 4.0158938645618036e-05
of O 0 1.6311165381921455e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 5.455916607388644e-07
including O 0 2.729378145716055e-08
multiple O 0 1.7375848983647302e-05
adenomas B-Disease 0 0.0017219636356458068
, O 0 6.452054179817424e-08
in O 0 9.941312839600869e-08
Ashkenazim O 0 0.0003909669176209718
. O 0 7.04317017152789e-07

We O 0 3.9133337850216776e-05
have O 0 9.420292457207324e-08
studied O 0 6.323472234726069e-08
a O 0 1.022270090800248e-08
set O 0 2.094879292258156e-08
of O 0 1.1635116203834173e-09
164 O 0 5.80274445383111e-07
patients O 0 1.5032338751552743e-06
with O 0 1.1728619142559182e-07
multiple O 1 0.9999864101409912
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.011260418221354485
/ I-Disease 1 0.998801589012146
or I-Disease 1 0.939791202545166
carcinoma I-Disease 1 1.0
and O 0 7.765381269564386e-06
analyzed O 0 8.53089750307845e-06
codons O 0 3.3613880532357143e-06
1263 O 0 8.051348231674638e-06
- O 0 2.3066465928422986e-06
1377 O 0 2.124784032275784e-06
( O 0 5.521472701275343e-08
exon O 0 8.609216592958546e-07
15G O 0 3.470276169537101e-06
) O 0 1.0372085412768683e-08
of O 0 1.4468651832189039e-09
the O 0 8.314755106653138e-09
APC B-Disease 0 2.085757841996383e-07
gene O 0 1.61170888191009e-07
for O 0 2.8229875326246656e-08
germ O 0 2.04473253688775e-05
- O 0 1.2814294677809812e-05
line O 0 8.597650776209775e-06
variants O 0 6.175720955070574e-06
. O 0 6.517763608826499e-07

Three O 0 3.184443266945891e-05
patients O 0 0.00028461316833272576
with O 0 1.8624035647007986e-08
the O 0 1.690151485433944e-08
I1307K O 0 5.695796971849632e-07
allele O 0 5.433039973468112e-07
were O 0 1.3092321182739397e-07
detected O 0 3.761570894766919e-07
, O 0 3.001392911983203e-09
each O 0 2.0765507091624613e-09
of O 0 6.003338270943459e-09
Ashkenazi O 0 1.8291748347110115e-05
descent O 0 2.6912261091638356e-05
. O 0 4.909719564238912e-07

Four O 0 8.117706602206454e-05
patients O 0 0.013022156432271004
had O 0 1.2390836445774767e-06
a O 0 2.0684174728557991e-07
germ O 0 0.0008441113168373704
- O 0 8.568712655687705e-05
line O 0 1.5025693755887914e-05
E1317Q O 0 1.945321173479897e-06
missense O 0 1.7137302847913816e-06
variant O 0 5.970488246020977e-07
of O 0 1.0733876010249332e-08
APC O 0 3.675306459172134e-07
that O 0 5.678514991558359e-09
was O 0 1.2759069534240552e-07
not O 0 6.218716208650221e-09
present O 0 3.4170775098374406e-09
in O 0 2.086778749799123e-09
controls O 0 1.98894736058719e-06
; O 0 7.680319491498722e-09
one O 0 2.4787822905381063e-09
of O 0 3.171915508026757e-10
these O 0 2.959716915995614e-09
individuals O 0 1.2199318888406196e-08
had O 0 2.0335160400009045e-07
an O 0 9.769832720607496e-10
unusually O 0 4.676387987956332e-08
large O 0 3.928848357759307e-09
number O 0 6.229756710496304e-09
of O 0 4.218867477590038e-09
metaplastic B-Disease 0 3.2268559152726084e-05
polyps I-Disease 0 6.475160262198187e-06
of I-Disease 0 8.545200103071693e-09
the I-Disease 0 1.225182444386519e-07
colorectum I-Disease 0 1.8033118976745754e-05
. O 0 3.856823127534881e-07

There O 0 1.4566343224942102e-06
is O 0 1.4637200784761717e-08
increasing O 0 1.1272458522171291e-08
evidence O 0 1.0285208240645716e-08
that O 0 2.6124491459000865e-09
there O 0 6.689419684846598e-09
exist O 0 7.345254005031165e-08
germ O 0 5.061870069766883e-06
- O 0 3.593697101678117e-06
line O 0 1.3431206298264442e-06
variants O 0 6.98139146493304e-08
of O 0 1.1168017621798754e-09
the O 0 5.99720362259859e-09
APC B-Disease 0 1.556444289008141e-07
gene O 0 5.883745757273573e-08
that O 0 1.766727764085374e-09
predispose O 0 5.342100095617752e-08
to O 0 2.415323496762767e-09
the O 0 2.7428201931911644e-09
development O 0 4.091204264256021e-09
of O 0 1.0295845953578464e-08
multiple O 1 0.9987534284591675
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9819897413253784
carcinoma I-Disease 1 1.0
, O 0 9.298355507780798e-07
but O 0 3.192561237597147e-08
without O 0 2.0828272440098772e-08
the O 0 5.172496653216285e-09
florid O 0 2.3525042252003914e-06
phenotype O 0 5.954293555987533e-07
of O 0 1.2946778094047318e-09
classical O 0 5.8175945838456755e-08
FAP B-Disease 0 5.516466217159177e-07
, O 0 5.036502326305481e-09
and O 0 3.173617368901205e-09
possibly O 0 1.7528661189203376e-08
with O 0 2.4910105089759327e-09
importance O 0 1.1833578383857457e-07
for O 0 0.001791511196643114
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0003804988809861243
in O 0 2.94659296962152e-09
the O 0 4.076218029780421e-09
general O 0 1.1371102281998446e-08
population O 0 1.0369118896846885e-08
. O 0 4.506286011007887e-09
. O 0 6.001062047289452e-08

Genomic O 0 3.052431929972954e-05
structure O 0 8.673132469994016e-07
of O 0 8.975025167501371e-09
the O 0 8.962438613480117e-08
human O 0 1.7831631339504384e-05
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999972581863403
diarrhea I-Disease 1 1.0
( O 0 2.9912365789641626e-05
CLD B-Disease 0 0.42544808983802795
) O 0 5.154147970642953e-07
gene O 0 7.989104233274702e-06
. O 0 5.82534426030179e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999998807907104
diarrhea I-Disease 1 1.0
( O 0 0.008230612613260746
CLD B-Disease 1 0.9969694018363953
) O 0 6.705338932988525e-07
is O 0 2.9088790043374502e-08
caused O 0 1.238342548504079e-07
by O 0 9.874637996176716e-09
mutations O 0 1.6786935930213076e-06
in O 0 4.010711318613858e-09
a O 0 1.5757670723814954e-08
gene O 0 2.54704218605184e-07
which O 0 1.09206839127296e-08
encodes O 0 4.3183575826333254e-07
an O 0 1.2981443830994976e-07
intestinal O 0 0.00010707016917876899
anion O 0 1.6102254448924214e-05
transporter O 0 0.00011053399794036523
. O 0 1.695545734037296e-06

We O 0 2.1431247660075314e-05
report O 0 2.5609841713958303e-07
here O 0 6.661282192510498e-09
the O 0 2.455526892930493e-09
complete O 0 1.031229679426815e-08
genomic O 0 2.0891040719561715e-07
organization O 0 1.3720982572351659e-08
of O 0 9.62956381300728e-10
the O 0 1.1134800637080389e-08
human O 0 6.864587476229644e-08
CLD B-Disease 0 1.8843817088054493e-05
gene O 0 3.910280668151245e-07
which O 0 1.1738349847689733e-08
spans O 0 3.584383136967517e-07
approximately O 0 6.090138526815281e-08
39kb O 0 3.546261268638773e-06
, O 0 1.8747993379975014e-08
and O 0 1.88129014588867e-08
comprises O 0 9.208181239728219e-08
21 O 0 3.0069415402067534e-07
exons O 0 5.543724000744987e-06
. O 0 7.205863425951975e-07

All O 0 4.841623649554094e-06
exon O 0 7.66315424698405e-05
/ O 0 4.620249819708988e-05
intron O 0 0.00014511497283820063
boundaries O 0 9.213280463882256e-06
conform O 0 2.420793862256687e-06
to O 0 6.547449515892367e-08
the O 0 5.8333277763722435e-08
GT O 0 1.1517574421304744e-05
/ O 0 0.00016684801084920764
AG O 0 0.37982916831970215
rule O 0 2.522169779695105e-06
. O 0 4.007877123513026e-07

An O 0 2.629019490996143e-07
analysis O 0 9.657345856339816e-08
of O 0 8.934886608358283e-09
the O 0 9.69007363238461e-09
putative O 0 5.933014790571178e-07
promoter O 0 8.976344361144584e-07
region O 0 1.0294829166923591e-07
sequence O 0 9.402197775898458e-08
shows O 0 1.7442258126720844e-07
a O 0 4.989414748024501e-08
putative O 0 3.5076586755167227e-06
TATA O 0 5.7348729569639545e-06
box O 0 2.7137848519487306e-06
and O 0 7.341906638203e-08
predicts O 0 6.63918740428926e-07
multiple O 0 4.767457539855968e-07
transcription O 0 1.0301336033080588e-06
factor O 0 2.7158978355146246e-07
binding O 0 3.0439505849244597e-07
sites O 0 1.1330765801176312e-06
. O 0 4.3581084696597827e-07

The O 0 9.54691586230183e-07
genomic O 0 4.589806394506013e-06
structure O 0 1.6237531781371217e-06
was O 0 3.2141329597834556e-07
determined O 0 1.0033109987261923e-07
using O 0 2.5411214465975718e-08
DNA O 0 1.1808078426156499e-07
from O 0 3.2619231760122602e-09
several O 0 2.8556090825304636e-09
sources O 0 6.704927280054562e-09
including O 0 4.383766682991563e-09
multiple O 0 1.4608144738303963e-07
large O 0 9.677075496483667e-08
- O 0 4.775809429702349e-05
insert O 0 1.867205173766706e-05
libaries O 0 3.361875315022189e-06
and O 0 1.6965463700557848e-08
genomic O 0 6.021700755809434e-07
DNA O 0 8.24651920083852e-07
from O 0 4.155633348545962e-08
Finnish O 0 0.00019852387777063996
CLD B-Disease 1 0.8853378295898438
patients O 0 4.5845587010262534e-05
and O 0 8.769448101020316e-08
controls O 0 1.4562700016540475e-05
. O 0 8.46328816805908e-07

Exon O 0 0.00013832739205099642
- O 0 3.021509292011615e-05
specific O 0 5.560098657042545e-07
primers O 0 8.452772817690857e-06
developed O 0 5.921731940361497e-07
in O 0 3.2832143670447067e-09
this O 0 3.9742184543278825e-10
study O 0 2.7566662286204746e-09
will O 0 1.2286273110007073e-09
facilitate O 0 1.1536740451845162e-08
mutation O 0 1.1046930126212828e-07
screening O 0 3.9150265251919336e-08
studies O 0 1.501876312204331e-08
of O 0 7.659166634255143e-09
patients O 0 1.0962693295368808e-06
with O 0 3.301565243418736e-08
the O 0 1.735295882099308e-06
disease O 0 0.008148213848471642
. O 0 2.7389955903345253e-07

Genomic O 0 5.017983858124353e-05
sequencing O 0 6.5090007410617545e-06
of O 0 2.0296761249483097e-07
a O 0 8.517822607245762e-07
BAC O 0 0.001101915491744876
clone O 0 0.0001195032600662671
H O 1 0.9999998807907104
_ O 0 4.2672212430261425e-07
RG364P16 O 0 1.2982599173483322e-06
revealed O 0 2.26803194891545e-07
the O 0 2.9320950112321498e-09
presence O 0 5.207142717011948e-09
of O 0 6.578024236425506e-10
another O 0 5.08475395122332e-09
, O 0 1.0099224789783534e-09
highly O 0 5.739493325052081e-09
homologous O 0 5.3176311354263817e-08
gene O 0 5.3441691960642856e-08
3 O 0 7.460139173076641e-09
of O 0 8.958260799829532e-10
the O 0 2.8130331841680345e-08
CLD B-Disease 0 0.00015001824067439884
gene O 0 6.052711114534759e-07
, O 0 3.339462040230501e-09
with O 0 8.589839950445821e-10
a O 0 4.303406964112355e-09
similar O 0 7.706777438443169e-09
genomic O 0 2.9452158400999906e-07
structure O 0 3.946899767015566e-07
, O 0 7.261296453009436e-09
recently O 0 6.549934994382056e-08
identified O 0 5.799635260927971e-08
as O 0 1.3613685290181365e-08
the O 0 7.478205930055992e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 9.305637831857894e-06
( O 0 1.7952410757970938e-07
PDS B-Disease 0 1.6740856153774075e-05
) O 0 4.354966876007893e-08
. O 0 2.4508956641966506e-08
. O 0 1.1674283939555608e-07

The O 0 2.45194655690284e-06
APCI1307K O 0 6.749240856152028e-05
allele O 0 2.2131956939119846e-05
and O 0 1.0208622370555531e-05
cancer B-Disease 0 0.27005302906036377
risk O 0 1.0647840099409223e-05
in O 0 4.216116344935017e-09
a O 0 1.571807750622156e-08
community O 0 2.2359115448011835e-08
- O 0 1.1342701782268705e-06
based O 0 8.312138533028701e-09
study O 0 7.970290205605579e-09
of O 0 4.321486279934561e-09
Ashkenazi O 0 5.273740953271044e-06
Jews O 0 4.1697589381328726e-07
. O 0 8.260492023737243e-08

Mutations O 0 0.0011049859458580613
in O 0 3.253040574691113e-07
APC O 0 5.734829301218269e-06
are O 0 6.813233000002583e-08
classically O 0 0.00016243671416305006
associated O 0 2.225058324256679e-06
with O 0 7.527878187829629e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0001492971641710028
FAP B-Disease 0 9.234376921085641e-05
) O 0 5.444669781695666e-08
, O 0 6.4548828504484845e-09
a O 0 7.125716905420632e-08
highly O 0 0.00012299868103582412
penetrant O 1 0.9999877214431763
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999998807907104
disorder I-Disease 1 1.0
characterized O 0 1.67694415722508e-05
by O 0 3.331219033952948e-08
multiple O 0 0.00029791099950671196
intestinal O 0 0.07950647920370102
polyps B-Disease 0 0.010630185715854168
and O 0 5.0472461765593835e-08
, O 0 7.0370043125933535e-09
without O 0 2.181685232471864e-08
surgical O 0 4.908024038741132e-06
intervention O 0 8.114390226410251e-08
, O 0 2.1390542670474133e-09
the O 0 2.600185400325472e-09
development O 0 6.948870634460036e-08
of O 0 0.00010407776426291093
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.357514858886134e-06
CRC B-Disease 0 3.944074342143722e-05
) O 0 2.5094414013437927e-07
. O 0 2.521135229471838e-07

APC B-Disease 0 0.0002929178299382329
is O 0 7.04568208220735e-07
a O 0 6.597215929105005e-07
tumour O 1 0.9999942779541016
- O 0 3.993822701886529e-06
suppressor O 0 2.452449280099245e-06
gene O 0 3.976023492668901e-07
, O 0 7.411832037007571e-09
and O 0 1.03005994844807e-08
somatic O 0 3.4073966617143014e-06
loss O 0 2.1819221274199663e-06
occurs O 0 2.8782110916836245e-07
in O 0 2.736943258696556e-07
tumours B-Disease 1 1.0
. O 0 1.0788564850372495e-06

The O 0 3.459962499618996e-06
germline O 0 7.906133396318182e-05
T O 0 4.6857425331836566e-05
- O 0 1.1607855867623584e-06
to O 0 6.839964328264614e-08
- O 0 3.5331131584825926e-06
A O 0 9.851802929006226e-08
transversion O 0 9.371024702886643e-07
responsible O 0 4.2792876797648205e-08
for O 0 1.0522002158452892e-09
the O 0 5.563151717069559e-09
APC O 0 2.1005291728215525e-07
I1307K O 0 1.0481690537744726e-07
allele O 0 1.0856224008648496e-07
converts O 0 2.3978042662520238e-08
the O 0 5.433772987117891e-09
wild O 0 2.802686260849896e-08
- O 0 1.1474432426439307e-07
type O 0 2.760980635230226e-07
sequence O 0 6.890167014717008e-08
to O 0 2.7512678357766163e-08
a O 0 4.4474137439465267e-07
homopolymer O 0 0.006590589415282011
tract O 0 0.0002683510538190603
( O 0 3.457635600057074e-08
A8 O 0 7.166428076743614e-06
) O 0 5.680973913513299e-09
that O 0 1.4656078572983233e-09
is O 0 2.6571955746845788e-09
genetically O 0 7.071613339348914e-08
unstable O 0 1.4649749573436566e-06
and O 0 2.0226263330869187e-08
prone O 0 1.0139810001419391e-05
to O 0 3.5203481019152605e-08
somatic O 0 1.4354372979141772e-05
mutation O 0 3.3074051316361874e-05
. O 0 4.06151031029367e-07

The O 0 7.444140919687925e-06
I1307K O 0 3.600807394832373e-05
allele O 0 6.37983248452656e-06
was O 0 4.4767114104615757e-07
found O 0 5.611665443439051e-08
in O 0 8.654111205430581e-09
6 O 0 2.837807357991551e-07
. O 0 1.433148781870841e-07

1 O 0 9.36269589146832e-06
% O 0 5.081600988887658e-07
of O 0 1.7091549509018478e-08
unselected O 0 7.5411676334624644e-06
Ashkenazi O 0 1.007063747238135e-05
Jews O 0 3.319349843877717e-07
and O 0 1.851508635297705e-08
higher O 0 5.5971806744992136e-08
proportions O 0 2.017793292452552e-07
of O 0 3.773417578400995e-09
Ashkenazim O 0 1.4238458788895514e-05
with O 0 2.628364370593772e-08
family O 0 1.2439292618182662e-07
or O 0 1.9253457139711827e-07
personal O 0 1.484163021814311e-06
histories O 0 1.8315064153284766e-05
of O 0 3.652144542343194e-08
CRC B-Disease 0 8.03375878604129e-05
( O 0 1.32423792820191e-07
ref O 0 0.00013480521738529205
. O 0 3.0643590775980556e-08
2 O 0 1.0047798326695556e-07
) O 0 7.433496307385212e-08
. O 0 1.0338710154655928e-07

To O 0 1.3379136589719565e-06
evaluate O 0 1.3586185332314926e-06
the O 0 1.645089575674774e-08
role O 0 3.336318599167498e-08
of O 0 2.8879696412076328e-09
I1307K O 0 2.693151657240378e-07
in O 0 1.821233119869703e-08
cancer B-Disease 0 3.709980092025944e-06
, O 0 4.975613254742939e-09
we O 0 1.392759596541282e-08
genotyped O 0 7.976169626999763e-07
5 O 0 3.5598617387222475e-08
, O 0 1.7444877542516224e-08
081 O 0 4.043441549583804e-06
Ashkenazi O 0 4.120356607018039e-06
volunteers O 0 3.6096855637879344e-07
in O 0 7.558276671204567e-09
a O 0 2.990126191093623e-08
community O 0 4.4707082480499594e-08
survey O 0 3.849954737233929e-06
. O 0 2.1833218966094137e-07

Risk O 0 0.00035945503623224795
of O 0 1.6962269455689238e-07
developing O 0 9.603645594324917e-06
colorectal B-Disease 1 1.0
, I-Disease 0 1.2791931567335268e-06
breast I-Disease 1 0.5000637769699097
and I-Disease 0 4.928446628582606e-07
other I-Disease 0 3.049038070912502e-07
cancers I-Disease 1 0.9762192368507385
were O 0 1.0427506822452415e-06
compared O 0 4.297733013913785e-08
between O 0 5.058522489775896e-08
genotyped O 0 6.928959010110702e-06
I1307K O 0 1.3722285530093359e-06
carriers O 0 2.7372459499019897e-07
and O 0 3.433680717535026e-08
non O 0 4.6545326881641813e-07
- O 0 1.7221975667780498e-06
carriers O 0 1.6751674536408245e-07
and O 0 4.2951247003486515e-09
their O 0 4.925004848388426e-09
first O 0 2.6286651078066825e-08
- O 0 4.3299166918586707e-07
degree O 0 1.0739756817201851e-07
relatives O 0 6.311699394245807e-07
. O 0 1.2252550618541136e-07

Sperm O 0 0.0002579151769168675
DNA O 0 1.2096962564100977e-05
analysis O 0 5.159532747711637e-07
in O 0 6.120087903127569e-08
a O 0 4.4689355149785115e-07
Friedreich B-Disease 0 0.043077390640974045
ataxia I-Disease 1 0.9965349435806274
premutation O 0 0.002731826389208436
carrier O 0 2.836015119100921e-05
suggests O 0 3.051132182463334e-07
both O 0 4.814095433403054e-08
meiotic O 0 2.0052236777701182e-06
and O 0 5.8380699385907064e-08
mitotic O 0 1.1784447906393325e-06
expansion O 0 6.039402222768331e-08
in O 0 1.0563512731209812e-08
the O 0 3.750551869075025e-08
FRDA B-Disease 0 1.1674428606056608e-05
gene O 0 2.172634367525461e-06
. O 0 4.989833541912958e-07

Friedreich B-Disease 1 0.9961458444595337
ataxia I-Disease 1 0.9999808073043823
is O 0 1.4843362805549987e-05
usually O 0 8.937666279962286e-06
caused O 0 6.851662988083262e-07
by O 0 3.6814327142309367e-09
an O 0 2.5943647230519673e-09
expansion O 0 1.2366780488548557e-08
of O 0 4.7909911593535526e-09
a O 0 1.46809640000356e-07
GAA O 0 7.480511703761294e-05
trinucleotide O 0 2.729250627453439e-05
repeat O 0 2.3909256015031133e-06
in O 0 2.0502934461319455e-08
intron O 0 7.061435553623596e-06
1 O 0 4.16259844371325e-08
of O 0 5.459349861069995e-09
the O 0 4.548896370693001e-08
FRDA B-Disease 0 2.022785338340327e-05
gene O 0 1.6319064570780029e-06
. O 0 2.751530985278805e-07

Occasionally O 0 0.0005142549052834511
, O 0 3.5817893717648985e-07
a O 0 3.329758158088225e-08
fully O 0 7.951101821390694e-08
expanded O 0 3.172965534758987e-08
allele O 0 2.2335913740789692e-07
has O 0 6.344441860761663e-09
been O 0 7.241449218042817e-09
found O 0 3.698633843640664e-09
to O 0 1.9125778738526833e-09
arise O 0 1.1054725135295485e-08
from O 0 1.148982908816265e-09
a O 0 5.6715112606298135e-09
premutation O 0 2.5848981977105723e-07
of O 0 1.3133464316084087e-09
100 O 0 1.8380044153332165e-08
or O 0 3.326837827444251e-08
less O 0 7.57045697241665e-08
triplet O 0 0.00018374915816821158
repeats O 0 8.898374289856292e-06
. O 0 5.422893423201458e-07

We O 0 9.645335012464784e-06
have O 0 2.2693345158586453e-07
examined O 0 5.399032261266257e-07
the O 0 2.595811388061975e-08
sperm O 0 4.4559342882166675e-07
DNA O 0 1.828912701284935e-07
of O 0 8.231863191099364e-09
a O 0 1.7174232880279305e-07
premutation O 0 7.858299068175256e-05
carrier O 0 4.238008477841504e-05
. O 0 7.908304269221844e-07

This O 0 5.676481578120729e-07
mans O 0 3.755430589080788e-05
leucocyte O 0 3.0119290386210196e-05
DNA O 0 1.6901116168810404e-06
showed O 0 7.371344281636993e-07
one O 0 1.7843625244040595e-08
normal O 0 8.957789532360039e-08
allele O 0 2.278190436300065e-07
and O 0 1.7182939515691942e-08
one O 0 6.762233883961244e-09
allele O 0 6.104046690325049e-08
of O 0 1.7356124315526245e-09
approximately O 0 2.280254562947448e-08
100 O 0 3.7565154542562595e-08
repeats O 0 1.7474371816206258e-06
. O 0 2.6060808977490524e-07

His O 0 2.466165642545093e-05
sperm O 0 1.853645153460093e-05
showed O 0 3.6970882320019882e-06
an O 0 1.632262502937465e-08
expanded O 0 2.5471294406997913e-07
allele O 0 8.120193797367392e-07
in O 0 1.6351664910985164e-08
a O 0 2.9795884870509326e-08
tight O 0 7.046044743219682e-07
range O 0 1.0953146301062588e-07
centering O 0 2.807504984048137e-07
on O 0 4.630447492104395e-08
a O 0 5.811502834518478e-09
size O 0 1.202728761029448e-08
of O 0 3.84176246370771e-09
approximately O 0 6.452583534155565e-08
320 O 0 7.616266088916746e-07
trinucleotide O 0 6.882769230287522e-05
repeats O 0 1.8972656107507646e-05
. O 0 1.2853307680416037e-06

His O 0 2.7132517061545514e-05
affected O 0 2.1693611415685154e-05
son O 0 1.2602113201864995e-05
has O 0 1.0086047552704258e-07
repeat O 0 5.608096103060234e-07
sizes O 0 4.978164724889211e-07
of O 0 3.050334385079623e-08
1040 O 0 1.4292575087893056e-06
and O 0 9.46575227089852e-08
540 O 0 1.968401647900464e-06
. O 0 3.1350458584711305e-07

These O 0 1.019448632177955e-06
data O 0 5.435558136923646e-07
suggest O 0 2.180747742386302e-07
that O 0 5.053263585352852e-09
expansion O 0 9.815936508061895e-09
occurs O 0 6.352069981119257e-09
in O 0 1.0243971226842064e-09
two O 0 6.6228573736282215e-09
stages O 0 6.55131600524328e-07
, O 0 3.7224274773706156e-09
the O 0 2.0338637440886487e-09
first O 0 9.945784640308375e-09
during O 0 2.69514224271461e-08
meiosis O 0 1.1394620003102318e-07
followed O 0 2.60509640526152e-08
by O 0 2.8341538005349776e-09
a O 0 1.182579012493079e-08
second O 0 1.2123865644753096e-07
mitotic O 0 3.7987306313880254e-06
expansion O 0 1.0617465022733086e-06
. O 0 5.252191499494074e-07

We O 0 1.5809178876224905e-05
also O 0 1.376762526206221e-07
show O 0 2.065110038529383e-07
that O 0 2.937754484122479e-09
in O 0 1.0673073536082711e-09
all O 0 1.768083013331534e-09
informative O 0 8.04562532152886e-08
carrier O 0 9.584821327734971e-07
father O 0 5.930673552256849e-08
to O 0 4.155045196796436e-09
affected O 0 4.8309836131466e-08
child O 0 1.0083027746077278e-07
transmissions O 0 3.5189495974918827e-06
, O 0 7.207098029482495e-09
with O 0 1.5633007111048869e-09
the O 0 2.2800272780898467e-09
notable O 0 1.0489506152566719e-08
exception O 0 9.060940442395804e-09
of O 0 1.430213170117156e-09
the O 0 1.5767110284059527e-08
premutation O 0 2.4295106868521543e-06
carrier O 0 4.36524601354904e-07
, O 0 3.2615934397739466e-09
the O 0 2.3674280313912277e-09
expansion O 0 2.602285498198853e-08
size O 0 1.0931065475006108e-07
decreases O 0 6.660178542006179e-07
. O 0 2.5034719186578513e-08
. O 0 1.3155626277239207e-07

The O 0 2.519241661502747e-06
R496H O 0 9.616422175895423e-06
mutation O 0 1.4336752656163299e-06
of O 0 1.9918534377438846e-08
arylsulfatase O 0 5.800116014142986e-06
A O 0 2.781268904072931e-07
does O 0 3.1451287441086606e-07
not O 0 5.372929194891185e-07
cause O 0 8.033874473767355e-05
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 0.9999997615814209
. O 0 3.63942649528326e-06

Deficiency B-Disease 1 0.9999593496322632
of I-Disease 0 8.89353032107465e-07
arylsulfatase I-Disease 0 7.897753675933927e-05
A I-Disease 0 1.1369170351827051e-06
( O 0 1.8178758409703732e-07
ARSA O 0 0.00032139854738488793
) O 0 5.098449307183728e-08
enzyme O 0 2.7955779842159245e-06
activity O 0 5.3409967222251e-06
causes O 0 0.00016034982400014997
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
( O 0 0.00014299766917247325
MLD B-Disease 1 0.9999996423721313
) O 0 1.0612120604491793e-06
. O 0 7.719291374996828e-07

A O 0 3.5541636407288024e-06
number O 0 2.2135628796604578e-07
of O 0 5.827989468798478e-08
ARSA O 0 0.0008803185191936791
gene O 0 1.256730956811225e-05
mutations O 0 1.1134437954751775e-05
responsible O 0 1.1022510761904414e-06
for O 0 1.6763917187745392e-07
MLD B-Disease 1 1.0
have O 0 5.857929409103235e-06
been O 0 8.480691917611693e-07
identified O 0 2.5075325993384467e-06
. O 0 2.1664324378889432e-07

Recently O 0 1.699021777312737e-05
, O 0 1.1646827857703101e-07
the O 0 3.567161499518079e-08
R496H O 0 1.4882293726259377e-06
mutation O 0 7.549274414486717e-07
of O 0 1.6549842385416014e-08
ARSA O 0 0.00017855897021945566
was O 0 2.2288865864084073e-07
proposed O 0 7.472814367304181e-09
to O 0 1.1062740057354858e-08
be O 0 1.2455551257062325e-08
a O 0 1.5873688141709863e-08
cause O 0 2.1593140786535514e-07
of O 0 4.029668332350411e-08
MLD B-Disease 1 0.9999998807907104
( O 0 4.806379934052529e-07
Draghia O 0 2.0603487428161316e-05
et O 0 0.00012309630983509123
al O 0 0.0005825406406074762
. O 0 1.3056618008988607e-08
, O 0 7.778430344274057e-09
1997 O 0 3.189335728848164e-08
) O 0 1.863800136447935e-08
. O 0 5.215077081288655e-08

We O 0 7.002996426308528e-06
have O 0 1.0942955697146317e-07
investigated O 0 1.8870082385546993e-07
the O 0 1.7622022951968574e-08
R496H O 0 6.506119802907051e-07
mutation O 0 4.153288841735048e-07
and O 0 2.521952247036552e-08
found O 0 2.6508995887297715e-08
this O 0 2.2548229949848064e-09
mutation O 0 2.1533709571031068e-07
at O 0 3.5167911249800454e-08
a O 0 1.1632170782149842e-08
relatively O 0 4.46374670559635e-08
high O 0 2.8476096147755925e-08
frequency O 0 1.3762610251433216e-07
in O 0 4.2229091334888835e-09
an O 0 4.614672199920733e-09
African O 0 1.2739890031809864e-08
American O 0 2.7473610941797233e-08
population O 0 5.878941777837099e-09
( O 0 6.709942379501399e-09
f O 0 6.268664378694666e-07
= O 0 1.4333676290334552e-06
0 O 0 8.551121766231518e-08
. O 0 5.835572469692352e-09
09 O 0 1.0013922064899816e-06
, O 0 1.956038175876529e-08
n O 0 3.2613390885671834e-06
= O 0 1.0127962013939396e-05
61 O 0 6.985068239373504e-07
subjects O 0 1.3972330634715036e-06
) O 0 9.8182802332758e-08
. O 0 1.5320391355544416e-07

The O 0 7.884967999416403e-06
ARSA O 0 0.0004846293886657804
enzyme O 0 4.488935246627079e-06
activity O 0 5.184080578146677e-07
in O 0 1.8081426134131107e-08
subjects O 0 2.5914783918778994e-07
with O 0 2.8211037061964817e-08
and O 0 1.80313563191703e-07
without O 0 3.2962169882466696e-08
the O 0 5.653377765924006e-09
R496H O 0 3.429041157687607e-07
mutation O 0 2.6186222612523125e-07
was O 0 5.7273680909020186e-08
determined O 0 5.252501722452507e-08
and O 0 9.586319293930501e-09
found O 0 1.8186851136192672e-08
to O 0 9.974890247121948e-09
be O 0 6.588426515463652e-08
normal O 0 3.1580617587678717e-07
. O 0 9.11295785499533e-08

It O 0 8.408100597989687e-07
is O 0 5.912590594903122e-08
therefore O 0 2.8229013793179547e-08
concluded O 0 1.0617688062097841e-08
that O 0 9.007793955184695e-10
the O 0 2.5462822961230813e-09
R496H O 0 2.358056292450783e-07
mutation O 0 1.1218839546245363e-07
of O 0 3.6336047504192948e-09
ARSA O 0 2.4366145225940272e-05
does O 0 3.076059229556449e-08
not O 0 8.442842869271772e-09
negatively O 0 2.22347651401833e-08
influence O 0 5.828464821888701e-09
the O 0 2.470418536404395e-09
activity O 0 1.5231519157055118e-08
of O 0 1.6003000036235449e-09
ARSA O 0 4.48347745987121e-05
and O 0 3.257268232914612e-08
is O 0 3.962730588114027e-09
not O 0 5.035714512047207e-09
a O 0 1.6934103896915076e-08
cause O 0 4.278096241705498e-07
of O 0 2.861025052425248e-07
MLD B-Disease 1 0.9999994039535522

Down O 0 0.000455528381280601
- O 0 9.895406947180163e-06
regulation O 0 4.2172447933808144e-07
of O 0 3.0010564699978204e-08
transmembrane O 0 3.372327455508639e-06
carbonic O 0 9.19782087294152e-06
anhydrases O 0 9.937074537447188e-06
in O 0 2.2339513350289053e-07
renal B-Disease 1 0.9996134638786316
cell I-Disease 1 0.9997010827064514
carcinoma I-Disease 1 1.0
cell O 0 0.01358945295214653
lines O 0 2.5827497665886767e-05
by O 0 3.1311280679346964e-08
wild O 0 2.996644070663024e-07
- O 0 3.674367326311767e-05
type O 0 0.03245595842599869
von B-Disease 1 0.9997528195381165
Hippel I-Disease 1 0.9998724460601807
- I-Disease 1 0.936825156211853
Lindau I-Disease 1 0.9726396203041077
transgenes O 0 0.0013112194137647748
. O 0 7.495123099943157e-06

To O 0 3.493120630082558e-06
discover O 0 1.121061995945638e-05
genes O 0 4.944094143866096e-06
involved O 0 5.083360861135588e-07
in O 0 2.536135070840828e-07
von B-Disease 1 0.9959912896156311
Hippel I-Disease 1 0.9999897480010986
- I-Disease 1 0.9997522234916687
Lindau I-Disease 1 0.9999470710754395
( O 0 4.106348569621332e-06
VHL B-Disease 0 0.0005854277405887842
) O 0 2.3514718350270414e-07
- O 0 3.389574203538359e-06
mediated O 0 5.796699497295776e-06
carcinogenesis O 0 1.5503333997912705e-05
, O 0 4.450867052696594e-08
we O 0 7.754983499808077e-08
used O 0 8.102671927190386e-06
renal B-Disease 1 0.999946117401123
cell I-Disease 1 0.9996119141578674
carcinoma I-Disease 1 1.0
cell O 0 0.045649487525224686
lines O 0 0.0007918589981272817
stably O 0 7.366604404523969e-05
transfected O 0 1.9286077076685615e-05
with O 0 9.069952966456185e-08
wild O 0 7.66576022215304e-07
- O 0 9.255756594939157e-05
type O 0 0.01150353904813528
VHL O 0 0.16151787340641022
- O 0 0.0002559227286837995
expressing O 0 7.889428161433898e-06
transgenes O 0 8.74737961567007e-05
. O 0 1.8911458710135776e-06

Large O 0 8.416512173425872e-06
- O 0 1.4004740478412714e-05
scale O 0 3.05288631352596e-06
RNA O 0 8.526112651452422e-07
differential O 0 5.524158268599422e-07
display O 0 1.453995679412401e-07
technology O 0 4.1478887879975446e-08
applied O 0 1.8858886008388254e-08
to O 0 5.207102304893851e-09
these O 0 1.3669835929874807e-08
cell O 0 8.349720133082883e-07
lines O 0 5.489347586262738e-06
identified O 0 7.852445804701347e-08
several O 0 4.322162183711953e-09
differentially O 0 2.2601250293519115e-07
expressed O 0 5.420523585542014e-09
genes O 0 5.014276638348747e-08
, O 0 1.0223554225419207e-09
including O 0 1.1876257755005781e-09
an O 0 2.7747122377519418e-09
alpha O 0 1.6672606761858333e-07
carbonic O 0 2.123082595062442e-06
anhydrase O 0 1.6655220633765566e-06
gene O 0 5.202023203310091e-07
, O 0 4.1185938215448914e-08
termed O 0 3.6953153994545573e-06
CA12 O 0 6.732502515660599e-05
. O 0 7.240830086630012e-07

The O 0 8.079454119069851e-07
deduced O 0 2.752774889813736e-06
protein O 0 3.1443070724890276e-07
sequence O 0 1.3293308143147442e-07
was O 0 1.14317799670971e-07
classified O 0 2.2144030253912206e-07
as O 0 1.0430491137469744e-08
a O 0 2.4973434875619205e-08
one O 0 2.160119407790262e-07
- O 0 1.0979477337969001e-05
pass O 0 3.7035283639852423e-06
transmembrane O 0 2.2549529603566043e-05
CA O 0 3.5865334211848676e-05
possessing O 0 1.7906876337292488e-07
an O 0 1.3327424497333595e-08
apparently O 0 5.165366587789322e-07
intact O 0 1.7068215640847484e-07
catalytic O 0 7.135237467537081e-08
domain O 0 5.4417828465602724e-08
in O 0 8.44343794881297e-09
the O 0 2.204389915050342e-08
extracellular O 0 3.4386532661301317e-06
CA O 0 0.00014464717241935432
module O 0 5.412671271187719e-06
. O 0 7.098593073351367e-07

Reintroduced O 0 0.0001646448072278872
wild O 0 1.087242617359152e-05
- O 0 4.033129880554043e-05
type O 0 9.350047912448645e-05
VHL B-Disease 0 0.00032091079629026353
strongly O 0 9.873112958302954e-07
inhibited O 0 5.40536916560086e-07
the O 0 5.968925353982968e-09
overexpression O 0 1.3136532572843862e-07
of O 0 4.351709659289327e-09
the O 0 1.725657838846928e-08
CA12 O 0 2.0038778529851697e-06
gene O 0 1.1794325160963126e-07
in O 0 4.566358402513515e-09
the O 0 1.800399473950165e-08
parental O 0 0.04302849620580673
renal B-Disease 1 0.9999947547912598
cell I-Disease 1 0.9999843835830688
carcinoma I-Disease 1 1.0
cell O 0 0.1630622297525406
lines O 0 0.002943769795820117
. O 0 2.7153278097102884e-06

Similar O 0 9.318337106378749e-06
results O 0 8.765106940700207e-06
were O 0 4.42413863765978e-07
obtained O 0 3.8062296425778186e-08
with O 0 2.1453804066595694e-08
CA9 O 0 9.48442320805043e-05
, O 0 7.746923103013614e-09
encoding O 0 7.228908316392335e-08
another O 0 1.151278539168743e-07
transmembrane O 0 2.2771464500692673e-05
CA O 0 0.0010933533776551485
with O 0 1.4047169649700209e-08
an O 0 2.2175386860112667e-08
intact O 0 1.1625570550677367e-06
catalytic O 0 5.42881821274932e-07
domain O 0 1.9916121800633846e-06
. O 0 5.339400672710326e-07

Although O 0 2.424691501801135e-06
both O 0 4.571912270989742e-08
domains O 0 1.5992884527804563e-07
of O 0 6.231372751130948e-09
the O 0 3.754989563731215e-08
VHL B-Disease 0 1.1124790034955367e-05
protein O 0 7.173692040396418e-08
contribute O 0 1.9499886150242673e-08
to O 0 4.413668097669188e-09
regulation O 0 6.759915294196617e-08
of O 0 4.318421176208176e-09
CA12 O 0 7.602835921716178e-06
expression O 0 6.641303684773447e-08
, O 0 5.344981790500469e-09
the O 0 5.653874257660618e-09
elongin O 0 5.361648618418258e-07
binding O 0 3.871430465096637e-08
domain O 0 1.1767821916919274e-07
alone O 0 2.8226438075762417e-07
could O 0 8.333429235563017e-08
effectively O 0 7.273899313986476e-07
regulate O 0 4.149988853896502e-06
CA9 O 0 0.00010136415949091315
expression O 0 2.3023214907880174e-06
. O 0 4.6563798150600633e-07

We O 0 2.7876634703716263e-05
mapped O 0 0.0001093743703677319
CA12 O 0 0.0003732645127456635
and O 0 1.3322032828000374e-06
CA9 O 0 0.00025898858439177275
loci O 0 5.607605999102816e-06
to O 0 7.633880727553333e-08
chromosome O 0 3.3097330742748454e-05
bands O 0 4.331161562731722e-06
15q22 O 0 7.908834049885627e-06
and O 0 2.4977086354738276e-07
17q21 O 0 1.4070375073060859e-05
. O 0 7.673820618947502e-07

2 O 0 2.086948552459944e-05
respectively O 0 3.0825663088762667e-06
, O 0 3.1096725194856845e-08
regions O 0 1.2940149929363542e-07
prone O 0 5.407550270319916e-05
to O 0 1.9062055045537818e-08
amplification O 0 5.757905228165328e-07
in O 0 5.559566140789229e-09
some O 0 1.7373487537497567e-08
human O 0 6.475991085608257e-07
cancers B-Disease 0 0.008881439454853535
. O 0 2.8746887892339146e-07

Additional O 0 2.978147904286743e-06
experiments O 0 1.6045102029238478e-06
are O 0 5.919642731555541e-08
needed O 0 3.2657219151133177e-08
to O 0 8.093396175468115e-09
define O 0 2.4717024871279136e-07
the O 0 6.7524639213445425e-09
role O 0 3.3178267244693416e-08
of O 0 1.1924293552567633e-08
CA O 0 1.0824762284755707e-05
IX O 0 1.5918431017780676e-06
and O 0 3.5302332435094286e-07
CA O 0 1.6508014596183784e-05
XII O 0 2.965459543702309e-06
enzymes O 0 2.479198144555994e-07
in O 0 5.546316295124143e-09
the O 0 5.0227932923974095e-09
regulation O 0 2.6176479650530382e-08
of O 0 2.035000612465865e-09
pH O 0 9.77750005404232e-07
in O 0 2.14476547633069e-09
the O 0 2.2200767890723228e-09
extracellular O 0 6.92753800990431e-08
microenvironment O 0 3.765296128221962e-07
and O 0 8.526086503479746e-09
its O 0 2.7303452831972663e-09
potential O 0 1.1988856130074055e-08
impact O 0 2.447961833240697e-08
on O 0 9.190862471086803e-08
cancer B-Disease 0 4.649050424632151e-06
cell O 0 8.341101533915207e-07
growth O 0 3.7825358845111623e-07
. O 0 8.932113360060612e-08

A O 0 2.3318389139603823e-06
gene O 0 2.016663302129018e-06
encoding O 0 6.218160706339404e-07
a O 0 9.502038267328317e-08
transmembrane O 0 1.0303585895599099e-06
protein O 0 1.8700391990478238e-07
is O 0 8.852936161929392e-09
mutated O 0 3.990714105839288e-07
in O 0 1.3488202554867712e-08
patients O 0 5.8457021623326e-06
with O 0 9.920390766637865e-06
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.04125641658902168
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999990463256836
( O 0 0.17506815493106842
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.1515051028254675e-06
. O 0 4.4463533299676783e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.001453996286727488
WFS B-Disease 1 0.8034356236457825
; O 0 1.0718125849962234e-05
OMIM O 0 0.00759529834613204
222300 O 0 2.5593906684662215e-05
) O 0 7.50584305819757e-08
is O 0 1.283545092434224e-08
an O 0 1.1488918971735984e-07
autosomal B-Disease 1 0.9999982118606567
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 0.9999971389770508
disorder I-Disease 1 0.9998786449432373
defined O 0 1.5042262475617463e-06
by O 0 2.0852995774589544e-08
young O 0 2.277360522384697e-07
- O 0 7.66977700550342e-06
onset O 0 0.0005685192882083356
non O 0 0.000449300860054791
- O 0 0.4675899147987366
immune O 0 0.11911491304636002
insulin B-Disease 0 0.3222905993461609
- I-Disease 0 0.3553737699985504
dependent I-Disease 1 0.8997378945350647
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 2.3194399545900524e-05
progressive O 0 0.010356860235333443
optic B-Disease 1 0.9999991655349731
atrophy I-Disease 1 0.5821742415428162
. O 0 2.256314246551483e-06

Linkage O 0 6.243898678803816e-05
to O 0 1.5652071851945948e-06
markers O 0 3.028599894605577e-05
on O 0 1.3053949032837409e-06
chromosome O 0 0.07376376539468765
4p O 0 0.0011357740731909871
was O 0 6.252541879803175e-06
confirmed O 0 3.599870694870333e-07
in O 0 9.096039477185514e-09
five O 0 7.358645603972036e-08
families O 0 2.1763038660083112e-07
. O 0 1.1025796453623116e-07

On O 0 9.299251928496233e-07
the O 0 2.182401281913826e-08
basis O 0 1.590050580091429e-08
of O 0 6.325689305697324e-09
meiotic O 0 8.81174946698593e-06
recombinants O 0 0.00022363352763932198
and O 0 1.7710186511976644e-05
disease O 0 0.397818922996521
- O 0 1.87330151675269e-05
associated O 0 3.9468770296480216e-07
haplotypes O 0 1.6843109733599704e-06
, O 0 9.337749240501125e-09
the O 0 1.1210878447798223e-08
WFS B-Disease 0 1.9189523300155997e-05
gene O 0 5.170256258679728e-07
was O 0 7.565289195099467e-08
localized O 0 3.915983199931361e-07
to O 0 3.725391195530392e-08
a O 0 2.2363346374731918e-07
BAC O 0 4.122092650504783e-05
/ O 0 2.7057169518229784e-06
P1 O 0 8.55260714160977e-06
contig O 0 2.523728880987619e-06
of O 0 7.954162661860664e-09
less O 0 2.8747045632826485e-08
than O 0 1.3109294982882602e-08
250 O 0 9.249000498812165e-08
kb O 0 2.1218285837676376e-05
. O 0 6.548111741722096e-07

Mutations O 0 0.0006369552575051785
in O 0 1.3824885058966174e-07
a O 0 7.869267903970467e-08
novel O 0 2.996446823999577e-07
gene O 0 1.7253044006793061e-06
( O 0 1.0712853537597766e-07
WFS1 O 0 2.3228144527820405e-06
) O 0 5.741616959653584e-09
encoding O 0 3.7060786439724325e-08
a O 0 2.8479627545152653e-08
putative O 0 7.335760869864316e-07
transmembrane O 0 5.08625987549749e-07
protein O 0 2.019119591523122e-07
were O 0 2.994709973336285e-07
found O 0 9.106698506400335e-09
in O 0 9.737463058101525e-10
all O 0 2.959784639600116e-09
affected O 0 3.6131776681713745e-08
individuals O 0 2.9830897751992325e-09
in O 0 1.7786156991661528e-09
six O 0 3.748620613919229e-08
WFS B-Disease 0 5.194881396164419e-06
families O 0 2.6088356364084575e-08
, O 0 6.074911129694271e-10
and O 0 6.897866167143718e-10
these O 0 1.4342917964427215e-09
mutations O 0 3.1161627589426644e-07
were O 0 3.0497933067863414e-08
associated O 0 1.4511662982386042e-08
with O 0 8.218323799269456e-09
the O 0 5.48989987692039e-07
disease O 0 0.00041426238021813333
phenotype O 0 1.690828321443405e-05
. O 0 2.598160051547893e-07

WFS1 O 0 0.0006085417699068785
appears O 0 2.554617594796582e-06
to O 0 4.116222029892924e-08
function O 0 9.480242368908876e-08
in O 0 1.1718641168556587e-08
survival O 0 8.541958322894061e-07
of O 0 4.5575960783139635e-09
islet O 0 3.472093794698594e-06
beta O 0 2.807014993777557e-07
- O 0 1.8462405932950787e-05
cells O 0 2.0399416200689302e-07
and O 0 1.805754301642537e-08
neurons O 0 1.5998895719349093e-07
. O 0 1.04460209371382e-08
. O 0 7.204104690572422e-08

Stable O 0 8.404154505115002e-05
interaction O 0 2.0892734653443767e-07
between O 0 6.069264912866856e-08
the O 0 6.731696089445904e-09
products O 0 1.3562318379456428e-08
of O 0 1.0301733910367261e-09
the O 0 1.2375934943520406e-08
BRCA1 O 0 2.2896281734574586e-05
and O 0 4.730505338557123e-07
BRCA2 O 0 0.0007994964253157377
tumor B-Disease 0 6.551624665007694e-06
suppressor O 0 2.0584202502504922e-06
genes O 0 7.251562124110933e-07
in O 0 2.4814420740426613e-08
mitotic O 0 2.093702505590045e-06
and O 0 5.704043246623769e-07
meiotic O 0 0.0001431556884199381
cells O 0 7.919822564872447e-06
. O 0 4.259313186594227e-07

BRCA1 O 0 0.19607625901699066
and O 0 9.876005606201943e-06
BRCA2 O 0 0.0006616191822104156
account O 0 7.007560043348349e-07
for O 0 6.009432951259441e-09
most O 0 4.495460448339372e-09
cases O 0 4.348681414967359e-09
of O 0 9.207049567194758e-10
familial O 0 2.163543103961274e-05
, O 0 1.631534018997627e-08
early O 0 2.0268250011667988e-07
onset O 0 0.0038240766152739525
breast B-Disease 1 0.9699786305427551
and I-Disease 0 2.1263704184093513e-05
/ I-Disease 1 0.9999827146530151
or I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.872599758063643e-08
encode O 0 2.3252292180586664e-07
products O 0 3.7905016370132216e-07
that O 0 2.506127083634624e-09
each O 0 6.883491110443174e-09
interact O 0 5.571638794776845e-08
with O 0 3.094360323530054e-08
hRAD51 O 0 9.466360097576398e-06
. O 0 2.4424778644061007e-07

Results O 0 1.4368368283612654e-05
presented O 0 5.671644203175674e-07
here O 0 3.291687278306199e-08
show O 0 1.630865824608918e-07
that O 0 4.983002011016424e-09
BRCA1 O 0 2.2135332983452827e-05
and O 0 5.199790962251427e-07
BRCA2 O 0 0.0006544719799421728
coexist O 0 1.083270035451278e-06
in O 0 6.726523782418781e-09
a O 0 1.761637591357612e-08
biochemical O 0 6.718615281897655e-07
complex O 0 8.836777709575472e-08
and O 0 5.6714604568242066e-08
colocalize O 0 1.202883368023322e-06
in O 0 7.0718528810687076e-09
subnuclear O 0 5.054963594375295e-07
foci O 0 4.627357554909395e-07
in O 0 8.469423384838137e-09
somatic O 0 3.8720440898032393e-07
cells O 0 1.6982744455162901e-07
and O 0 1.0129246774681633e-08
on O 0 1.085679901535741e-08
the O 0 2.0449184567894463e-09
axial O 0 3.523868485899584e-08
elements O 0 2.6846196377050546e-08
of O 0 1.2453365449971443e-08
developing O 0 5.100025077808823e-07
synaptonemal O 0 3.7968507058394607e-06
complexes O 0 1.3995095287100412e-06
. O 0 2.91846106392768e-07

Like O 0 2.311792559339665e-05
BRCA1 O 0 0.000902327592484653
and O 0 1.2779750022673397e-06
RAD51 O 0 0.0002541455323807895
, O 0 6.492682018688356e-07
BRCA2 O 0 5.915634392295033e-05
relocates O 0 4.0606455513625406e-06
to O 0 2.0583422610798152e-07
PCNA O 0 3.028186984010972e-05
+ O 0 1.1816848655143986e-06
replication O 0 4.407974927289615e-07
sites O 0 1.9018081331978465e-07
following O 0 7.93740397853071e-08
exposure O 0 1.4094183597990195e-06
of O 0 8.669458928523e-09
S O 0 2.900236950154067e-06
phase O 0 2.4852391788954264e-07
cells O 0 1.88446890092564e-07
to O 0 4.144322218735397e-08
hydroxyurea O 0 1.1771478966693394e-05
or O 0 1.0263787544317893e-06
UV O 0 0.0003974545979872346
irradiation O 0 1.1145774806209374e-05
. O 0 6.876833253954828e-07

Thus O 0 1.1419959264458157e-05
, O 0 2.1370209424276254e-07
BRCA1 O 0 1.2238901945238467e-05
and O 0 1.1405143851561661e-07
BRCA2 O 0 2.1866862880415283e-05
participate O 0 9.561835412341679e-08
, O 0 1.1189216664320156e-08
together O 0 1.5127895380828704e-08
, O 0 2.285500455556644e-09
in O 0 1.2428965634470046e-09
a O 0 1.3895171235844828e-08
pathway O 0 1.355999614816028e-07
( O 0 1.0145817519457978e-08
s O 0 8.462739060632885e-07
) O 0 2.4567730072533323e-09
associated O 0 1.0055789978480334e-08
with O 0 1.3916409136172092e-09
the O 0 3.6127483227232915e-09
activation O 0 3.48470123867628e-08
of O 0 5.550803372500468e-09
double O 0 8.309117220051121e-06
- O 0 2.4495382604072802e-05
strand O 0 7.284330877155298e-06
break O 0 2.060079714283347e-05
repair O 0 0.0001792919065337628
and O 0 4.691548554092151e-07
/ O 0 8.91883155418327e-06
or O 0 3.5797066288978385e-07
homologous O 0 4.7059024836926255e-06
recombination O 0 1.027563848765567e-05
. O 0 1.4806711305936915e-06

Dysfunction O 0 0.31256598234176636
of O 0 1.330080294792424e-07
this O 0 2.2008439515275313e-08
pathway O 0 8.908733093448973e-07
may O 0 6.348644774334389e-07
be O 0 4.038561041141975e-09
a O 0 2.0187982396890902e-09
general O 0 1.3939415177688375e-09
phenomenon O 0 1.1081641382304497e-08
in O 0 2.761063877532166e-10
the O 0 6.95711321885284e-10
majority O 0 1.3016427935497177e-09
of O 0 2.5280758042534046e-10
cases O 0 1.3142285038014734e-09
of O 0 2.2220085771351705e-09
hereditary B-Disease 1 0.9900139570236206
breast I-Disease 1 0.9992045760154724
and I-Disease 0 0.0018948086071759462
/ I-Disease 1 0.9999997615814209
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0493012325696327e-07
. O 0 2.1904838831687812e-07

A O 0 1.1005370652128477e-05
novel O 0 4.377136974653695e-06
Arg362Ser O 0 1.844790494942572e-05
mutation O 0 3.145112714264542e-06
in O 0 2.5170695749920924e-08
the O 0 2.1290219365255325e-08
sterol O 0 7.895976523286663e-06
27 O 0 7.201026619441109e-07
- O 0 2.063796273432672e-06
hydroxylase O 0 6.262273927859496e-06
gene O 0 1.0428382211102871e-06
( O 0 2.7953028336469288e-08
CYP27 O 0 1.277051524084527e-06
) O 0 3.807310022807542e-09
: O 0 1.3897973882848191e-09
its O 0 3.050327102016581e-09
effects O 0 2.5679028681224736e-07
on O 0 2.7298884930360146e-08
pre O 0 1.3864960237697233e-06
- O 0 2.3231213219787605e-07
mRNA O 0 1.2087153322681843e-07
splicing O 0 5.075484068584046e-07
and O 0 5.1411625179298426e-08
enzyme O 0 6.204453484315309e-07
activity O 0 6.544515258610772e-07
. O 0 2.0657955701608444e-07

A O 0 9.899843462335411e-06
novel O 0 3.115359277217067e-06
C O 0 6.717719315929571e-06
to O 0 2.631213291692802e-08
A O 0 1.2567524265705288e-07
mutation O 0 6.125349045760231e-07
in O 0 3.3393476872589645e-09
the O 0 1.5122413543622315e-08
sterol O 0 3.953955456381664e-06
27 O 0 5.300821044329496e-07
- O 0 1.5859592394917854e-06
hydroxylase O 0 5.682164101017406e-06
gene O 0 9.488498449172766e-07
( O 0 4.306939871412396e-08
CYP27 O 0 3.708246595124365e-06
) O 0 1.4238802137356288e-08
was O 0 3.531781445076376e-08
identified O 0 3.3006333666207865e-08
by O 0 2.107828134256806e-09
sequencing O 0 8.76593659882019e-08
amplified O 0 9.000088425636932e-07
CYP27 O 0 2.6352824988862267e-06
gene O 0 3.229381775327056e-07
products O 0 9.879087059516678e-08
from O 0 1.2411962124758702e-08
a O 0 8.431661768781851e-08
patient O 0 3.4366796626272844e-06
with O 0 5.190798333387647e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 0.9999998807907104
( O 0 2.1737739643867826e-06
CTX B-Disease 0 0.0004425488878041506
) O 0 3.8629448795290955e-07
. O 0 2.750187775291124e-07

The O 0 3.499953209029627e-06
mutation O 0 1.2052225429215468e-05
changed O 0 4.28884817438302e-07
the O 0 1.4931588410149743e-08
adrenodoxin O 0 1.1819158771686489e-06
cofactor O 0 8.303868526127189e-07
binding O 0 1.0539803270148695e-06
residue O 0 5.441987013909966e-06
362Arg O 0 3.466631369519746e-06
to O 0 9.334581818620791e-08
362Ser O 0 1.0578771252767183e-05
( O 0 1.446105102331785e-07
CGT O 0 1.3339143151824828e-05
362Arg O 0 2.0223853880452225e-06
to O 0 7.74374981915571e-08
AGT O 0 3.183359149261378e-05
362Ser O 0 5.630745818052674e-06
) O 0 2.6933745900237227e-08
, O 0 3.7625871307511716e-09
and O 0 1.1527765408914092e-08
was O 0 2.3129832982249354e-07
responsible O 0 2.298849750559384e-07
for O 0 2.6667372310384962e-08
deficiency O 0 9.208194569509942e-06
in O 0 1.7912463734504058e-09
the O 0 6.845691569168366e-09
sterol O 0 1.9125131984765176e-06
27 O 0 1.4143435578262142e-07
- O 0 2.245823935709268e-07
hydroxylase O 0 5.622281946671137e-07
activity O 0 6.870062918551412e-08
, O 0 2.015339450878173e-09
as O 0 1.989832298932015e-09
confirmed O 0 1.0963550955978008e-08
by O 0 8.846769983250624e-10
expression O 0 4.561579114437109e-09
of O 0 2.26945817694002e-09
mutant O 0 1.8222098674414156e-07
cDNA O 0 2.7162604965269566e-07
into O 0 1.1357494855701589e-07
COS O 0 7.436273881467059e-05
- O 0 3.933435436920263e-06
1 O 0 3.0517841764776676e-07
cells O 0 7.313059313673875e-07
. O 0 1.8511138932808535e-07

Quantitative O 0 1.7010986994137056e-05
analysis O 0 2.018262193814735e-06
showed O 0 3.3883138712553773e-06
that O 0 3.0461411171245345e-09
the O 0 3.940240134170381e-09
expression O 0 1.0382140480658109e-08
of O 0 2.2100847818506963e-09
CYP27 O 0 1.1725861668310245e-06
gene O 0 1.5581329648739484e-07
mRNA O 0 8.658506800429677e-08
in O 0 6.947118880162861e-09
the O 0 1.813475414280674e-08
patient O 0 5.3455045190276e-07
represented O 0 1.4241589951780043e-07
52 O 0 8.184326247828722e-07
. O 0 2.503496432382235e-07

5 O 0 1.0714201380324084e-05
% O 0 7.0306003863152e-07
of O 0 1.8857232220170772e-08
the O 0 5.202281272431719e-08
normal O 0 1.0815275572895189e-06
level O 0 2.195018623751821e-06
. O 0 3.2044613362813834e-07

As O 0 3.3759827147150645e-06
the O 0 1.2544533944947034e-07
mutation O 0 1.421930960532336e-06
occurred O 0 2.9536766987803276e-07
at O 0 6.697734278304779e-08
the O 0 9.006819290391377e-09
penultimate O 0 3.9862752032604476e-07
nucleotide O 0 1.8853839378607518e-07
of O 0 2.6273052622372006e-09
exon O 0 3.770754517518071e-07
6 O 0 1.4458665020811168e-07
( O 0 2.4703965095795866e-08
- O 0 2.857142078482866e-07
2 O 0 1.771168989250782e-08
position O 0 5.986372286770347e-08
of O 0 1.2077049360570413e-09
exon O 0 3.196327327259496e-07
6 O 0 2.971323453948571e-07
- O 0 1.4856810821584077e-06
intron O 0 1.1770232958951965e-05
6 O 0 2.1576219921826123e-07
splice O 0 5.479023002408212e-06
site O 0 2.411997002127464e-07
) O 0 3.7953391540668235e-09
of O 0 5.840024019931889e-10
the O 0 3.0736295730804386e-09
gene O 0 8.710884458196233e-08
, O 0 4.655604790571033e-09
we O 0 5.904743805018597e-09
hypothesized O 0 1.6073183672915548e-08
that O 0 7.486348763130479e-10
the O 0 1.0480866841078296e-08
mutation O 0 2.2169183466758113e-06
may O 0 1.6737047303649888e-07
partially O 0 5.965217724224203e-07
affect O 0 2.575016111450168e-08
the O 0 4.315366286533617e-09
normal O 0 1.5131272235180404e-08
splicing O 0 1.3023282008362003e-07
efficiency O 0 6.46755466959803e-08
in O 0 2.5224127231382454e-09
exon O 0 1.1677724387482158e-07
6 O 0 5.208685394109125e-08
and O 0 2.3149093308916235e-08
cause O 0 7.281632008471206e-08
alternative O 0 4.189488933548091e-08
splicing O 0 7.787465392539161e-07
elsewhere O 0 4.22610639816412e-07
, O 0 6.5549068395398535e-09
which O 0 4.2404075806246055e-09
resulted O 0 6.250182593703357e-08
in O 0 8.271303642004568e-09
decreased O 0 6.638383638346568e-07
transcript O 0 1.787342114312196e-07
in O 0 9.447134630136134e-09
the O 0 5.026552329923106e-08
patient O 0 2.3686320673732553e-06
. O 0 2.0140808487667528e-07

Transfection O 0 0.00033149344380944967
of O 0 4.664442201374186e-07
constructed O 0 5.8564546634443104e-06
minigenes O 0 9.1646716100513e-06
, O 0 2.3307968888275354e-08
with O 0 5.543757009007777e-09
or O 0 2.0988352389395004e-07
without O 0 2.0848700543751875e-08
the O 0 3.350307808958064e-09
mutation O 0 1.1039011127422782e-07
, O 0 2.1812265327270097e-09
into O 0 1.3113696795130636e-08
COS O 0 4.64571567135863e-05
- O 0 1.0938674677163363e-06
1 O 0 4.99196559644588e-08
cells O 0 4.6197115466384275e-08
confirmed O 0 1.8428556458616185e-08
that O 0 6.787712614197972e-10
the O 0 1.5000660713582192e-09
mutant O 0 2.88762208811022e-07
minigene O 0 7.407905968648265e-07
was O 0 6.05056342806165e-08
responsible O 0 4.016868615508429e-08
for O 0 1.1900089802452385e-09
a O 0 5.436095573685407e-09
mRNA O 0 7.994288608870193e-08
species O 0 8.396527917398089e-09
alternatively O 0 6.959162845987521e-08
spliced O 0 1.6749197584431386e-06
at O 0 1.5246450857375748e-07
an O 0 1.7191988277431847e-08
activated O 0 1.3878717481929925e-06
cryptic O 0 8.75860507676407e-07
5 O 0 8.208380108953861e-08
splice O 0 9.418803529115394e-06
site O 0 1.74874230651767e-06
88 O 0 5.58280248696974e-07
bp O 0 1.7514211094749044e-06
upstream O 0 1.2532719040336815e-07
from O 0 1.0988379983700725e-08
the O 0 6.848459577213362e-09
3 O 0 1.0630252234022919e-08
end O 0 1.2131887494604143e-08
of O 0 3.2686369166867735e-09
exon O 0 1.343935423392395e-06
6 O 0 5.560634122048214e-07
. O 0 1.9718632415788306e-07

Our O 0 5.9599119595077354e-06
data O 0 4.849812853535695e-07
suggest O 0 1.4071872556087328e-07
that O 0 4.155424893070858e-09
the O 0 4.833119238156769e-09
C O 0 4.1143624684991664e-07
to O 0 6.263641605386283e-09
A O 0 4.401245234930684e-08
mutation O 0 3.662112817437446e-07
at O 0 3.1283644119639575e-08
the O 0 9.712315396370741e-09
penultimate O 0 3.839153634999093e-07
nucleotide O 0 1.2963381834651955e-07
of O 0 1.82703541184992e-09
exon O 0 1.6879131692348892e-07
6 O 0 3.823999605856443e-08
of O 0 1.4523091618201533e-09
the O 0 1.1727272486439233e-08
CYP27 O 0 1.5116726217456744e-06
gene O 0 1.7905628624248493e-07
not O 0 1.1340087091582518e-08
only O 0 7.179260297363044e-09
causes O 0 8.395794992566152e-08
the O 0 2.519169299830537e-07
deficiency B-Disease 0 6.571169797098264e-05
in I-Disease 0 1.8105194010686887e-09
the I-Disease 0 1.5866545410858635e-08
sterol I-Disease 0 3.6881858704873594e-06
27 I-Disease 0 6.453826699726051e-07
- I-Disease 0 5.924640618104604e-07
hydroxylase I-Disease 0 1.7067023918571067e-06
activity I-Disease 0 2.5917157131516433e-07
, O 0 1.586146147758427e-08
but O 0 1.2910043700742335e-08
also O 0 1.9019200436787287e-08
partially O 0 7.150045462367416e-07
leads O 0 2.067698900987125e-08
to O 0 9.318640081801277e-09
alternative O 0 5.765037869309708e-08
pre O 0 1.0513882671148167e-06
- O 0 1.4295831363142497e-07
mRNA O 0 6.610782321558872e-08
splicing O 0 1.7022779275066569e-07
of O 0 4.763946126473684e-09
the O 0 2.66647770530426e-08
gene O 0 1.0786537814055919e-06
. O 0 2.1304930442056502e-07

To O 0 1.5822263321751961e-06
our O 0 2.413948152479861e-07
knowledge O 0 3.0876744716579196e-08
, O 0 4.081702975611279e-09
this O 0 5.654518520081808e-10
is O 0 5.952119352947705e-10
the O 0 7.193429185647915e-10
first O 0 8.166400000675367e-09
report O 0 5.34175104149881e-09
regarding O 0 6.7788925584011395e-09
effects O 0 1.443864334760292e-07
on O 0 1.760287382523984e-08
pre O 0 1.304332272411557e-06
- O 0 9.989706484248018e-08
mRNA O 0 4.415050725015135e-08
splicing O 0 9.970632675049274e-08
of O 0 2.441665314378838e-09
a O 0 1.0377982917475492e-08
mutation O 0 1.8943214286082366e-07
at O 0 3.919584301570467e-08
the O 0 1.3692798894737734e-08
- O 0 2.9384027584455907e-06
2 O 0 6.399951502089607e-08
position O 0 2.8422547870832204e-07
of O 0 2.700976553526857e-09
a O 0 3.0198787470681054e-08
5 O 0 6.807828611954392e-08
splice O 0 5.042794509790838e-05
site O 0 7.3694991442607716e-06
. O 0 6.847965892120556e-07

ATM O 0 0.002908275928348303
germline O 0 0.002411414636299014
mutations O 0 0.0001801894250093028
in O 0 3.781392479140777e-07
classical O 0 6.897946877870709e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999071359634399
in O 0 3.3066196891695654e-08
the O 0 4.296929745351008e-08
Dutch O 0 4.514108877629042e-05
population O 0 1.329180037146216e-07
. O 0 1.637117748032324e-07

Germline O 0 0.00499320775270462
mutations O 0 0.0003243687388021499
in O 0 1.328945415934868e-07
the O 0 1.5333393221794722e-08
ATM O 0 9.440083772460639e-07
gene O 0 3.784592195188452e-07
are O 0 5.720160345390468e-09
responsible O 0 3.726549735461049e-08
for O 0 9.804747236330513e-09
the O 0 0.0002830976736731827
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.4282955825328827
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.5584648710719193e-07
. O 0 1.576289321292279e-07

In O 0 1.229631152455113e-06
our O 0 2.487031736109202e-07
study O 0 2.5247437918096693e-08
, O 0 6.491180926104789e-09
we O 0 7.247100697327369e-09
have O 0 4.3416283901365205e-09
determined O 0 1.4911153201069283e-08
the O 0 2.1571717745416663e-09
ATM O 0 7.326567015297769e-07
mutation O 0 1.4011986593231995e-07
spectrum O 0 2.8721835576561716e-08
in O 0 4.117751473131648e-09
19 O 0 2.469157500684105e-08
classical O 0 2.497375248822209e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.113881459488766e-06
, O 0 4.2327127913743823e-10
including O 0 2.6697524746488455e-10
some O 0 9.593301708576973e-10
immigrant O 0 6.127984164550071e-08
populations O 0 1.7716690337010732e-08
, O 0 9.019674451771209e-10
as O 0 2.0596051530930026e-09
well O 0 5.200571973063006e-09
as O 0 7.383471167798916e-09
12 O 0 9.879723705807919e-09
of O 0 1.4559174976724876e-09
Dutch O 0 5.891331056773197e-06
ethnic O 0 8.720792976646408e-08
origin O 0 3.704344351262989e-07
. O 0 2.2654207043615315e-07

Both O 0 2.1381513306550914e-06
the O 0 1.0792716409468994e-07
protein O 0 4.006493554697954e-07
truncation O 0 2.38549137066002e-06
test O 0 7.580355941172456e-06
( O 0 5.972640337859048e-08
PTT O 0 1.391590672028542e-06
) O 0 3.5841278833714796e-09
and O 0 1.6290644389016506e-09
the O 0 2.989491765248431e-09
restriction O 0 3.934662373694664e-08
endonuclease O 0 1.1694435215758858e-06
fingerprinting O 0 9.298311738348275e-07
( O 0 5.6010577509368886e-08
REF O 0 5.233659067016561e-06
) O 0 6.51594023182156e-09
method O 0 3.93406978105304e-08
were O 0 1.3445517765831028e-07
used O 0 8.431372577888396e-08
and O 0 4.871065328870827e-08
compared O 0 2.3291436335171056e-08
for O 0 1.1460324911283237e-09
their O 0 4.714483026191374e-09
detection O 0 8.787966976342432e-08
efficiency O 0 1.0232225378103976e-07
, O 0 5.321260765356328e-09
identifying O 0 1.31909544620612e-07
76 O 0 5.516324819154761e-08
% O 0 1.1692318224731935e-08
and O 0 6.386425610571678e-09
60 O 0 1.4781744717140555e-08
% O 0 3.5568736844737714e-09
of O 0 1.4263692449389964e-09
the O 0 3.5185358626677044e-08
mutations O 0 2.1281443878251594e-06
, O 0 3.10142134196667e-08
respectively O 0 1.262291448256292e-06
. O 0 2.3602160581503995e-07

Most O 0 1.0491103239473887e-05
patients O 0 0.0006557918968610466
were O 0 5.707656214326562e-07
found O 0 4.359928595931706e-08
to O 0 1.71863820952467e-08
be O 0 9.069329820476923e-08
compound O 0 1.0590929377940483e-06
heterozygote O 0 1.3477007996698376e-05
. O 0 2.2717293290952512e-07

Seventeen O 0 0.00012742435501422733
mutations O 0 0.00015659960627090186
were O 0 1.0271239716530545e-06
distinct O 0 1.2421783424088062e-07
, O 0 7.2990937738381945e-09
of O 0 1.6519305923168304e-09
which O 0 3.125435910078522e-08
10 O 0 2.396414444660877e-08
were O 0 4.6772487394264317e-07
not O 0 5.67505296089621e-08
reported O 0 5.116750116940239e-07
previously O 0 4.029811293548846e-07
. O 0 1.4440117013236886e-07

Mutations O 0 0.0006207887199707329
are O 0 1.2998775389405637e-07
small O 0 6.00987064558467e-08
deletions O 0 2.669104105734732e-06
or O 0 2.8780596039723605e-06
point O 0 2.982538944706903e-06
mutations O 0 8.168289059540257e-05
frequently O 0 3.6519991226668935e-06
affecting O 0 2.7142611997987842e-06
splice O 0 0.00020910169405397028
sites O 0 1.2624655937543139e-05
. O 0 2.637253601278644e-06

Moreover O 0 5.1607898058136925e-05
, O 0 6.715847575833322e-07
a O 0 4.3171965558030934e-07
16 O 0 7.382403737210552e-07
. O 0 3.244545041525271e-07

7 O 0 6.906669295858592e-05
- O 0 1.8168087990488857e-05
kb O 0 8.248207450378686e-06
genomic O 0 1.4270307246988523e-06
deletion O 0 3.363433734193677e-06
of O 0 1.1891065909708232e-08
the O 0 1.0545514683713009e-08
3 O 0 1.2074177213605708e-08
end O 0 4.599530978310895e-09
of O 0 1.8610381291583877e-10
the O 0 1.6608336927959044e-09
gene O 0 4.289265476131732e-08
, O 0 1.5475947190424222e-09
most O 0 1.5038648104592767e-09
likely O 0 1.8804863444188413e-08
a O 0 5.816615189502272e-09
result O 0 7.348684771812941e-09
of O 0 6.186274270625347e-10
recombination O 0 2.8496689452595092e-08
between O 0 1.9023048025701428e-08
two O 0 2.208885376830949e-07
LINE O 0 0.00010969556751661003
elements O 0 1.7170695798540692e-07
, O 0 2.1727032617491204e-08
was O 0 3.1472953310185403e-07
identified O 0 6.334438467092696e-07
. O 0 1.2305255836508877e-07

The O 0 8.504422339683515e-07
most O 0 8.096610315533326e-08
frequently O 0 9.110208907259221e-07
found O 0 1.0586227716657959e-07
mutation O 0 4.970228815182054e-07
, O 0 7.52921280877672e-09
identified O 0 1.3325077929948748e-07
in O 0 1.9533825668105465e-09
three O 0 2.101671014997919e-08
unrelated O 0 1.9481377933061594e-07
Turkish O 0 5.971785867586732e-06
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999957084655762
T I-Disease 1 1.0
individuals O 0 9.48778620113444e-08
, O 0 5.068157893362013e-09
was O 0 9.544397272520655e-08
previously O 0 7.59930500748851e-08
described O 0 1.5863307112340408e-08
to O 0 6.295525878385888e-09
be O 0 2.5248979795833293e-08
a O 0 2.7655994827568975e-08
Turkish O 0 8.513359716744162e-06
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999861717224121
T I-Disease 1 0.9999995231628418
founder O 0 2.2005058326612925e-06
mutation O 0 2.3909051378723234e-06
. O 0 3.550227063442435e-07

The O 0 4.3760667267633835e-07
presence O 0 9.127534639219448e-08
of O 0 5.733431507337627e-09
a O 0 1.3859914993474831e-08
founder O 0 1.692918800699772e-07
mutation O 0 3.726944726167858e-07
among O 0 8.947506735523802e-09
relatively O 0 2.0100621611618408e-08
small O 0 9.989169491575467e-09
ethnic O 0 1.3944581489511165e-08
population O 0 1.4624168542809457e-08
groups O 0 3.819186744635772e-09
in O 0 1.4018737282128768e-09
Western O 0 2.0444320014689765e-08
Europe O 0 7.585263688270061e-07
could O 0 1.7113086414610734e-07
indicate O 0 1.0343444500904297e-07
a O 0 1.030696683557153e-08
high O 0 7.825637027281118e-08
carrier O 0 1.5071108805386757e-07
frequency O 0 5.9173515865040827e-08
in O 0 3.9455723133130505e-09
such O 0 1.116005954315824e-08
communities O 0 3.2460087595609366e-07
. O 0 1.9062677836245712e-07

In O 0 5.002463694836479e-06
patients O 0 0.00012857862748205662
of O 0 2.6631637339846748e-08
Dutch O 0 8.772994078753982e-06
ethnic O 0 5.3334765937052e-08
origin O 0 7.966646364820917e-08
, O 0 1.1419484025054771e-08
however O 0 8.156857411734109e-09
, O 0 1.8284647129718223e-09
no O 0 7.974061411175626e-09
significant O 0 5.6927533798045715e-09
founder O 0 8.71831389304134e-08
effect O 0 3.612157684074191e-08
could O 0 5.6608044474160124e-08
be O 0 1.7480651592904906e-08
identified O 0 4.3513927039384726e-07
. O 0 7.155080083975918e-08

The O 0 2.0485597360675456e-06
observed O 0 1.8375385479885153e-06
genetic O 0 1.5842570064705797e-06
heterogeneity O 0 4.2890610529866535e-07
including O 0 2.0545682488659622e-08
the O 0 1.0773420378029641e-08
relative O 0 2.418136944015714e-07
high O 0 9.065436188393505e-07
percentage O 0 1.6316606661348487e-06
of O 0 3.8002290203564826e-09
splice O 0 0.0012801605043932796
- O 0 0.00011689035454764962
site O 0 1.6096918216135236e-06
mutations O 0 2.3944279746501707e-05
had O 0 4.6748272097829613e-07
no O 0 2.8331390566904702e-08
reflection O 0 4.012419907439835e-08
on O 0 7.679502544988281e-08
the O 0 8.624372327403762e-08
phenotype O 0 1.1664412340905983e-05
. O 0 2.488856409854634e-07

All O 0 2.2647629521088675e-05
patients O 0 0.00021239345369394869
manifested O 0 5.529414920601994e-06
classical O 0 1.7936955600816873e-06
A B-Disease 1 0.9999971389770508
- I-Disease 1 0.9999814033508301
T I-Disease 1 1.0
and O 0 5.276188375091806e-08
increased O 0 6.832740950812877e-08
cellular O 0 1.10123721697164e-06
radioresistant O 0 2.598348373794579e-06
DNA O 0 6.55973678931332e-07
synthesis O 0 7.722155714873224e-07
. O 0 6.779560521863459e-07

Determination O 0 9.141739610640798e-06
of O 0 3.1848554016278285e-08
the O 0 1.0135005723554968e-08
genomic O 0 1.240394453816407e-07
structure O 0 6.82372771620976e-08
of O 0 1.4568174444562487e-09
the O 0 8.120455419202699e-09
COL4A4 O 0 1.8953003291244386e-06
gene O 0 5.8845767370030444e-08
and O 0 5.633292943230117e-09
of O 0 3.5724705416129154e-09
novel O 0 1.407913714501774e-06
mutations O 0 0.005287158768624067
causing O 0 0.00033347710268571973
autosomal B-Disease 1 0.9999964237213135
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.931599950301461e-06

Autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.960558612765453e-07
a O 0 3.9728627143631456e-07
progressive O 0 0.0004326813796069473
hematuric B-Disease 1 0.9633607268333435
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.00021308919531293213
by O 0 1.2381961767005123e-07
glomerular B-Disease 0 0.0008735266164876521
basement I-Disease 0 0.307962030172348
membrane I-Disease 0 0.027471594512462616
abnormalities I-Disease 1 0.9999786615371704
and O 0 2.5465658382017864e-07
associated O 0 1.4557994632014015e-07
with O 0 1.584715825231342e-08
mutations O 0 4.947838988300646e-06
in O 0 4.754342253221466e-09
either O 0 3.888132482643414e-08
the O 0 1.750741063233363e-08
COL4A3 O 0 1.3393969311437104e-05
or O 0 2.889855643672945e-08
the O 0 6.5287539818825735e-09
COL4A4 O 0 1.1628120546447462e-06
gene O 0 9.159170133443695e-08
, O 0 1.1908172226071656e-09
which O 0 8.302374343571728e-10
encode O 0 5.331259700369628e-08
the O 0 1.0552637874639004e-08
alpha3 O 0 7.935055350571929e-07
and O 0 2.843186486245486e-08
alpha4 O 0 1.8310678342459141e-06
type O 0 8.022905603866093e-06
IV O 0 4.351944153313525e-05
collagen O 0 6.4266391746059526e-06
chains O 0 2.4169841708499007e-05
, O 0 1.2727483067465073e-07
respectively O 0 1.255685447176802e-06
. O 0 1.6611249975539977e-07

To O 0 2.006842123591923e-06
date O 0 4.791505716639222e-07
, O 0 2.2068887162163264e-08
mutation O 0 1.6043526329667657e-07
screening O 0 8.286150432468276e-08
in O 0 6.023352483452982e-09
the O 0 8.173692833679524e-09
two O 0 1.7356265757939582e-08
genes O 0 3.204809502221906e-07
has O 0 3.9393107442720066e-08
been O 0 6.324702184201669e-08
hampered O 0 1.3929051192462794e-06
by O 0 2.8055515688407695e-09
the O 0 2.967902590356175e-09
lack O 0 1.2338177590720534e-08
of O 0 1.4494809796872232e-09
genomic O 0 3.56923095523598e-07
structure O 0 3.763701954540011e-07
information O 0 1.632434276643835e-07
. O 0 2.0427584956905775e-07

We O 0 1.868846084107645e-05
report O 0 2.7760486887018487e-07
here O 0 8.457896605307269e-09
the O 0 1.2595637866041898e-09
complete O 0 1.155475448655352e-08
characterization O 0 5.333965091836035e-08
of O 0 1.345438205291316e-09
the O 0 5.413435477663597e-09
48 O 0 4.468167702498249e-08
exons O 0 1.1111763598137259e-07
of O 0 4.137306941487395e-09
the O 0 2.587763248129704e-08
COL4A4 O 0 3.1801682780496776e-06
gene O 0 1.8392867673355795e-07
, O 0 5.405758951582129e-09
a O 0 5.460349505881368e-09
comprehensive O 0 1.26339429584732e-07
gene O 0 1.7352498105083214e-07
screen O 0 8.024244380067103e-06
, O 0 2.0706586667529336e-08
and O 0 7.305723581652046e-09
the O 0 1.5446516288264434e-09
subsequent O 0 9.408150702938656e-09
detection O 0 6.559061205280159e-08
of O 0 1.6600925079046647e-09
10 O 0 5.483550946649984e-09
novel O 0 2.2052308423781142e-08
mutations O 0 2.414652726656641e-07
in O 0 6.887404424560373e-09
eight O 0 3.088993707933696e-06
patients O 0 0.0004919969360344112
diagnosed O 0 0.2919095456600189
with O 0 2.6576713025860954e-06
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.009556950128172e-06

Furthermore O 0 2.738788134593051e-05
, O 0 3.567890303202148e-07
we O 0 8.290260211651912e-08
identified O 0 7.987033967538082e-08
a O 0 8.557873520942394e-09
glycine O 0 2.9628628794853284e-07
to O 0 1.1395376198208851e-08
alanine O 0 5.639229243570298e-07
substitution O 0 3.373522261540529e-08
in O 0 4.1313770182682674e-09
the O 0 4.586119484173423e-09
collagenous O 0 3.878685390645842e-07
domain O 0 3.2117515758045556e-08
that O 0 3.743110710274777e-09
is O 0 8.145740970633142e-09
apparently O 0 1.5582206458475412e-07
silent O 0 2.018545757209722e-07
in O 0 1.6442448513842578e-09
the O 0 5.350163423401e-09
heterozygous O 0 8.922626761886931e-07
carriers O 0 1.0120521665157867e-07
, O 0 4.367767036939085e-09
in O 0 9.451568416807277e-09
11 O 0 1.6633855182135449e-07
. O 0 9.535572331742515e-08

5 O 0 1.0221306183666456e-05
% O 0 3.3058697113119706e-07
of O 0 5.097863464698094e-09
all O 0 9.172453019345994e-09
control O 0 2.872310176371684e-07
individuals O 0 1.0715751841416932e-08
, O 0 2.144724620123384e-09
and O 0 4.978783607612058e-09
in O 0 1.352500889062469e-09
one O 0 4.9948396529941874e-09
control O 0 1.5503614747558458e-07
individual O 0 1.480290467981149e-08
homozygous O 0 5.052563665230991e-07
for O 0 8.765075332206607e-10
this O 0 8.714033383760977e-10
glycine O 0 1.89729917110526e-07
substitution O 0 1.5669606057144847e-07
. O 0 3.1365053132503817e-07

There O 0 5.530543603526894e-06
has O 0 3.669685213480989e-07
been O 0 1.369822513197505e-07
no O 0 3.0936284645122214e-08
previous O 0 6.882365255478362e-08
finding O 0 1.2964279427762904e-08
of O 0 5.982371265034203e-10
a O 0 2.747731819852106e-09
glycine O 0 6.016385611928854e-08
substitution O 0 1.013257033832815e-08
that O 0 1.4257655056582053e-09
is O 0 1.5476537829073322e-09
not O 0 3.9507761506740735e-09
associated O 0 8.912555138351763e-09
with O 0 4.202003189845982e-09
any O 0 3.0665926686879175e-08
obvious O 0 7.899740808170463e-07
phenotype O 0 2.920879751400207e-06
in O 0 1.7623063897076463e-08
homozygous O 0 1.552558569528628e-05
individuals O 0 1.5039307754705078e-07
. O 0 1.8372864474258677e-07

Founder O 0 0.00011854660260723904
BRCA1 O 0 0.0022217638324946165
and O 0 2.5473389086982934e-06
BRCA2 O 0 0.0010175789939239621
mutations O 0 9.56445455813082e-06
in O 0 5.3432717805890206e-08
French O 0 8.6304944488802e-06
Canadian O 0 0.0001858372997958213
breast B-Disease 1 0.9999997615814209
and I-Disease 1 0.9999693632125854
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.464179816452088e-06
. O 0 5.86795465551404e-07

We O 0 1.610581784916576e-05
have O 0 1.4613355858728028e-07
identified O 0 1.641542155539355e-07
four O 0 2.41977442527741e-08
mutations O 0 2.6443152023603034e-07
in O 0 1.025274865007475e-09
each O 0 1.1210915529247245e-09
of O 0 6.418919284989499e-10
the O 0 6.834590635662607e-07
breast B-Disease 1 0.9999972581863403
cancer I-Disease 0 0.005307082552462816
- O 0 7.76625529397279e-06
susceptibility O 0 1.803504528652411e-05
genes O 0 1.4217180250852834e-06
, O 0 1.3166855161728108e-08
BRCA1 O 0 9.709078767627943e-06
and O 0 4.9628962273118304e-08
BRCA2 O 0 4.499754140852019e-05
, O 0 7.571435922670844e-09
in O 0 5.376125322698044e-09
French O 0 2.224873696832219e-06
Canadian O 0 2.7893334845430218e-05
breast B-Disease 1 0.9997808337211609
cancer I-Disease 0 0.0045432765036821365
and O 0 3.109437966486439e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.493851404025918e-06
from O 0 2.814665549522033e-07
Quebec O 0 7.269445177371381e-06
. O 0 4.4128540821475326e-07

To O 0 1.5465384421986528e-06
identify O 0 5.662322564603528e-06
founder O 0 9.239423661711044e-07
effects O 0 2.51355413638521e-06
, O 0 2.4552376132191966e-08
we O 0 3.90901249147646e-08
examined O 0 5.415503210315364e-07
independently O 0 8.70314295298158e-07
ascertained O 0 1.8054565771308262e-06
French O 0 2.7611595214693807e-06
Canadian O 0 3.090131031058263e-06
cancer B-Disease 0 1.941847767739091e-05
families O 0 1.393846549291311e-08
for O 0 6.616768799538875e-10
the O 0 1.1653016329660204e-09
distribution O 0 4.143497989161915e-09
of O 0 7.845775695791701e-10
these O 0 3.5163738587584703e-09
eight O 0 4.937743014465923e-08
mutations O 0 2.57844499174098e-06
. O 0 1.0305575415259227e-07

Mutations O 0 0.0013679808471351862
were O 0 6.592564204765949e-06
found O 0 1.1536943134160538e-07
in O 0 5.784817513898588e-09
41 O 0 9.322785388121702e-08
of O 0 9.357968622225599e-09
97 O 0 8.687396189088759e-07
families O 0 5.772343456555973e-07
. O 0 3.052823274174443e-07

Six O 0 7.766396265651565e-06
of O 0 5.341132336411647e-08
eight O 0 2.8303341537139204e-07
mutations O 0 2.3557238364446675e-06
were O 0 1.8272513102601806e-07
observed O 0 1.0658964555432249e-07
at O 0 1.2792222037205647e-07
least O 0 7.26063476008676e-08
twice O 0 1.1412665799070965e-06
. O 0 1.5846953260734153e-07

The O 0 6.51867321721511e-06
BRCA1 O 0 0.001239350182004273
C4446T O 0 1.807993794500362e-05
mutation O 0 1.1059691132686567e-05
was O 0 1.2422886186413962e-07
the O 0 2.60488630665634e-09
most O 0 2.4366966222544306e-09
common O 0 2.5397888236966537e-08
mutation O 0 7.270015771609906e-07
found O 0 5.823389770398535e-08
, O 0 2.8910558391714858e-09
followed O 0 9.33986843421053e-09
by O 0 6.1930065520243716e-09
the O 0 8.899581871446571e-08
BRCA2 O 0 0.00044085452100262046
8765delAG O 0 1.0563084288151003e-05
mutation O 0 6.8199619818187784e-06
. O 0 5.564055527429446e-07

Together O 0 3.4803683774953242e-06
, O 0 4.244213158699495e-08
these O 0 1.0947795558990947e-08
mutations O 0 5.097730308989412e-07
were O 0 1.754104488327357e-07
found O 0 1.508418812079526e-08
in O 0 1.246039271762811e-09
28 O 0 9.952541013547034e-09
of O 0 4.991922986086195e-10
41 O 0 7.817759950512482e-08
families O 0 1.8626378661679155e-08
identified O 0 5.6575874651798586e-08
to O 0 3.6741654163563453e-09
have O 0 5.912117018169738e-08
a O 0 1.4058875308364804e-07
mutation O 0 4.946414719597669e-06
. O 0 2.529130540551705e-07

The O 0 1.9489420992613304e-06
odds O 0 3.1936019695422146e-06
of O 0 6.097016225226071e-09
detection O 0 2.0891818053314637e-07
of O 0 2.9743969509610224e-09
any O 0 5.728993279774386e-09
of O 0 1.0397275262974404e-09
the O 0 1.027693308230937e-08
four O 0 2.064629569531462e-07
BRCA1 O 0 0.0010767647763714194
mutations O 0 9.037606105266605e-06
was O 0 6.526235551973514e-07
18 O 0 2.9653531896656204e-07
. O 0 1.4049908259039512e-07

7x O 0 0.00041550680180080235
greater O 0 2.4679086436663056e-06
if O 0 1.463343863861155e-07
one O 0 8.661145578514606e-09
or O 0 8.70360672422521e-09
more O 0 8.373589044374796e-10
cases O 0 2.0479797413486267e-08
of O 0 1.544400947750546e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.408411273790989e-05
also O 0 3.9483296632170095e-08
present O 0 6.523725115670231e-09
in O 0 3.0958935415270616e-09
the O 0 2.8859778566925343e-08
family O 0 3.130035963749833e-07
. O 0 1.810750518416171e-07

The O 0 1.6154189097505878e-06
odds O 0 2.9471982543327613e-06
of O 0 6.156496645814968e-09
detection O 0 1.6662258417454723e-07
of O 0 1.8329132656091929e-09
any O 0 3.745488363904315e-09
of O 0 9.687260993374025e-10
the O 0 1.624255929755236e-08
four O 0 5.983461051073391e-07
BRCA2 O 0 0.013512533158063889
mutations O 0 7.383751835732255e-06
was O 0 2.172877771045023e-07
5 O 0 1.2824015982459969e-07
. O 0 1.5104347994565614e-07

3x O 0 0.00029893641476519406
greater O 0 1.8530793113313848e-06
if O 0 2.832448444678448e-07
there O 0 3.0109813309309175e-08
were O 0 1.3652200436808926e-07
at O 0 2.1973542985165295e-08
least O 0 3.712869123262408e-09
five O 0 1.901549140370662e-09
cases O 0 2.0998747185529965e-09
of O 0 2.1772788016960476e-08
breast B-Disease 1 0.9999994039535522
cancer I-Disease 0 0.1408209204673767
in O 0 1.2324935738661225e-08
the O 0 6.839768218469544e-08
family O 0 9.451100027035864e-07
. O 0 3.1675722311774734e-07

Interestingly O 0 5.9563790273386985e-05
, O 0 1.4958361305161816e-07
the O 0 1.0325424071311318e-08
presence O 0 1.909669933297664e-08
of O 0 4.604376435679569e-09
a O 0 7.460404845005542e-07
breast B-Disease 1 0.9998362064361572
cancer I-Disease 0 7.023404032224789e-05
case O 0 1.8109657773379695e-08
< O 0 3.1422268875758164e-07
36 O 0 5.8391833590576425e-08
years O 0 4.455995572527627e-09
of O 0 1.6633474597682607e-09
age O 0 2.9874959750486596e-07
was O 0 6.647792361036409e-08
strongly O 0 1.6616517939382902e-08
predictive O 0 5.038157269154908e-08
of O 0 8.491999881066192e-10
the O 0 2.6478155223941258e-09
presence O 0 4.0125631706189324e-09
of O 0 1.960301365677708e-10
any O 0 1.7968857513039893e-09
of O 0 9.020224567279911e-10
the O 0 1.658175641239268e-08
eight O 0 2.417671396415244e-07
mutations O 0 3.4390075143164722e-06
screened O 0 6.152042260509916e-06
. O 0 5.297894745126541e-07

Carriers O 0 3.5534962080419064e-05
of O 0 4.868353542519799e-08
the O 0 2.4891592786957517e-08
same O 0 1.9650839178098067e-08
mutation O 0 1.5469292691250303e-07
, O 0 2.218218497773705e-09
from O 0 1.4928049907325658e-09
different O 0 5.257741353403844e-09
families O 0 2.7110580447242683e-08
, O 0 2.350358130343011e-09
shared O 0 8.29206037167296e-09
similar O 0 6.581339917488549e-09
haplotypes O 0 3.423169800953474e-07
, O 0 5.999240215714963e-09
indicating O 0 3.0004670747985074e-08
that O 0 8.493393210962097e-10
the O 0 2.302551704858047e-09
mutant O 0 1.867985730541477e-07
alleles O 0 1.3087912975606741e-07
were O 0 1.2298147566980333e-07
likely O 0 2.8599984602806217e-08
to O 0 4.378017948170054e-09
be O 0 2.4344586790903122e-08
identical O 0 3.945033313357271e-07
by O 0 3.020943273313037e-09
descent O 0 1.7794251050418097e-07
for O 0 2.81673084856493e-09
a O 0 2.3808874871633634e-08
mutation O 0 2.8815509267587913e-07
in O 0 4.713745838103023e-09
the O 0 1.778562186416366e-08
founder O 0 3.38781177333658e-07
population O 0 3.174890750301529e-08
. O 0 6.234002825067364e-08

The O 0 1.8604140450406703e-07
identification O 0 1.1896901241925661e-07
of O 0 5.302254191263955e-09
common O 0 1.6460506913063e-07
BRCA1 O 0 0.000600320054218173
and O 0 7.571857167931739e-07
BRCA2 O 0 0.0017898303922265768
mutations O 0 5.043607870902633e-06
will O 0 1.0134484362822604e-08
facilitate O 0 4.929029628897297e-08
carrier O 0 9.546215551381465e-07
detection O 0 8.205387871385028e-07
in O 0 1.9044611221374907e-08
French O 0 1.1061474651796743e-05
Canadian O 0 0.00010511175059946254
breast B-Disease 1 0.9999762773513794
cancer I-Disease 1 0.5316427946090698
and O 0 0.0007160555687732995
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0134860531252343e-05
. O 0 8.941561873143655e-07

Are O 0 1.371074358758051e-05
Dp71 O 0 8.724787039682269e-05
and O 0 6.657593871750578e-07
Dp140 O 0 2.612423850223422e-05
brain O 0 7.25251593394205e-05
dystrophin O 0 1.0980231309076771e-05
isoforms O 0 1.0053930736830807e-06
related O 0 2.2237506414057862e-07
to O 0 8.881810487082475e-08
cognitive B-Disease 0 0.002257945016026497
impairment I-Disease 0 0.0015398500254377723
in O 0 1.0660423868102953e-06
Duchenne B-Disease 1 0.9999974966049194
muscular I-Disease 1 0.9999691247940063
dystrophy I-Disease 1 0.9999833106994629
? O 0 0.00013364832557272166

Molecular O 0 1.012825123325456e-05
study O 0 1.7821741948864656e-06
and O 0 2.2555086331976781e-07
neuropsychological O 0 1.7090664186980575e-05
analysis O 0 3.4415887739669415e-07
were O 0 9.277779327021562e-07
performed O 0 6.687432119178993e-07
concurrently O 0 7.075714592019722e-08
on O 0 1.0866063604453302e-07
49 O 0 5.468243671202799e-06
patients O 0 5.057133307673212e-07
with O 0 2.511289665108052e-07
Duchenne B-Disease 1 0.9999935626983643
muscular I-Disease 1 0.9998537302017212
dystrophy I-Disease 1 0.9999916553497314
( O 0 2.495413900760468e-05
DMD B-Disease 1 1.0
) O 0 2.396213858446572e-07
in O 0 7.3932651112329495e-09
order O 0 7.294654214007323e-09
to O 0 4.50793624651169e-09
find O 0 2.5805080738905417e-08
a O 0 3.1990696758299464e-09
molecular O 0 7.653722633449433e-08
explanation O 0 6.021962484226151e-09
for O 0 1.6333827623782327e-09
the O 0 1.6441736860883793e-08
cognitive B-Disease 0 6.377632962539792e-05
impairment I-Disease 0 5.182798304304015e-06
observed O 0 1.2688848016750853e-07
in O 0 7.481870234471444e-09
most O 0 3.321258930100157e-07
DMD B-Disease 1 1.0
patients O 0 0.0010227711172774434
. O 0 4.2900427388303797e-07

Complete O 0 3.826936790574109e-06
analysis O 0 4.6897505967535835e-07
of O 0 1.612556843610946e-08
the O 0 3.0654344840286285e-08
dystrophin O 0 2.2060296487325104e-06
gene O 0 1.1059892131015658e-06
was O 0 2.4152356559170585e-07
performed O 0 1.7782646466457663e-07
to O 0 5.351367349248903e-09
define O 0 2.1638575731230958e-07
the O 0 4.039270251610105e-09
localization O 0 1.235243871633429e-07
of O 0 1.6240540023915173e-09
deletions O 0 2.777028385025915e-07
and O 0 5.472989883514856e-08
duplications O 0 2.7237388167122845e-06
in O 0 1.7367126403655675e-08
relation O 0 7.877858365645807e-08
to O 0 1.1224250862085228e-08
the O 0 2.1874022593237896e-08
different O 0 6.123859748186078e-07
DMD B-Disease 1 0.9999994039535522
promoters O 0 1.531447924207896e-05
. O 0 4.925402095068421e-07

Qualitative O 0 2.5165014449157752e-05
analysis O 0 9.762881063579698e-07
of O 0 3.25209690288375e-08
the O 0 2.504331497732437e-08
Dp71 O 0 1.6870036461114069e-06
transcript O 0 2.826132003974635e-07
and O 0 4.848152812542139e-08
testing O 0 1.751901095303765e-07
for O 0 8.458634903618645e-10
the O 0 6.277249275932206e-10
specific O 0 2.6594975111038366e-09
first O 0 4.740578596340583e-09
exon O 0 8.644414606351347e-08
of O 0 6.544862429791465e-09
Dp140 O 0 9.857880058916635e-07
were O 0 6.260902978283411e-07
also O 0 5.050973328479813e-08
carried O 0 5.353187475520826e-07
out O 0 4.063653022967628e-07
. O 0 1.771149555906959e-07

Neuropsychological O 0 0.0003993223363067955
analysis O 0 2.7790945296146674e-06
assessed O 0 4.699860710388748e-06
verbal O 0 2.434310590615496e-05
and O 0 4.2318129089835566e-07
visuospatial O 0 0.00021481336443684995
intelligence O 0 2.620880513859447e-05
, O 0 2.6307716893825273e-08
verbal O 0 1.0260293493047357e-05
memory O 0 0.00010740137804532424
, O 0 4.0526302313992346e-08
and O 0 2.492076056626047e-08
reading O 0 5.020367098040879e-06
skills O 0 5.842850805493072e-05
. O 0 4.372529076590581e-07

Comparison O 0 1.6578773056608043e-06
of O 0 3.993736541474391e-08
molecular O 0 5.906684350520663e-07
and O 0 5.185044216204915e-08
psychometric O 0 5.3247291361913085e-05
findings O 0 5.036120569457125e-07
demonstrated O 0 1.0743915623834255e-07
that O 0 2.2806798671837214e-09
deletions O 0 2.2330057447561558e-07
and O 0 1.8798910872419583e-08
duplications O 0 1.952383627212839e-06
that O 0 3.038993057202788e-08
were O 0 2.2435806101839262e-07
localized O 0 3.3775594943108445e-07
in O 0 9.875616768795226e-09
the O 0 7.714719529872127e-09
distal O 0 4.375495166186738e-07
part O 0 1.295691376412833e-08
of O 0 1.9302053289038668e-09
the O 0 6.6352612293485436e-09
gene O 0 2.144985984386949e-07
seemed O 0 5.6873627585218856e-08
to O 0 3.9010705776831855e-09
be O 0 6.222477200168441e-09
preferentially O 0 4.60573126304098e-08
associated O 0 2.9340768037400267e-08
with O 0 2.7968974691816584e-08
cognitive B-Disease 0 0.0002349072601646185
impairment I-Disease 0 7.747460767859593e-05
. O 0 4.486520310820197e-07

Two O 0 1.0055646271212026e-05
altered O 0 1.3326414773473516e-05
Dp71 O 0 9.378389222547412e-06
transcripts O 0 1.5607311070198193e-06
and O 0 1.4161872741169645e-07
two O 0 2.135512744416701e-08
deleted O 0 2.3742859411868267e-06
Dp140 O 0 6.450147225223191e-07
DNA O 0 1.6584355932991457e-07
sequences O 0 1.7800223872654897e-07
were O 0 1.5643492190520192e-07
found O 0 2.215576877517833e-08
in O 0 2.1595554233755365e-09
four O 0 9.950532131597356e-08
patients O 0 1.71954548022768e-06
with O 0 2.1260682103729778e-07
severe O 1 0.998417854309082
cerebral B-Disease 1 0.999984622001648
dysfunction I-Disease 1 0.5478073358535767
. O 0 7.819294296496082e-07

These O 0 6.674542305518116e-07
findings O 0 1.972222634094578e-07
suggest O 0 8.852146038407227e-08
that O 0 2.219483929977173e-09
some O 0 8.885021052229547e-10
sequences O 0 2.5348573018391107e-08
located O 0 3.098045198157706e-08
in O 0 1.985783315561207e-09
the O 0 4.974853862194095e-09
distal O 0 3.5884769999938726e-07
part O 0 5.602561081730073e-09
of O 0 8.659571948399503e-10
the O 0 4.8900719029632e-09
gene O 0 6.874624602914992e-08
and O 0 1.61996176473167e-08
, O 0 9.009048507202522e-10
in O 0 2.2685006650924322e-10
particular O 0 2.9954794200648394e-09
, O 0 6.679714004143023e-10
some O 0 1.5812789966318519e-09
DMD B-Disease 1 0.989995002746582
isoforms O 0 6.310001765541529e-08
expressed O 0 9.845299686617182e-09
in O 0 3.1552089829745e-09
the O 0 1.7845223965196055e-08
brain O 0 2.9219188945717178e-05
may O 0 8.341683610524342e-08
be O 0 1.5032367572942462e-09
related O 0 2.391892017783448e-09
to O 0 2.1945134598411187e-09
the O 0 3.286969274540752e-08
cognitive B-Disease 0 0.0009119127062149346
impairment I-Disease 0 2.440428033878561e-05
associated O 0 3.820500751317013e-07
with O 0 5.712192319151654e-07
DMD B-Disease 1 1.0
. O 0 2.01069340732829e-07
. O 0 2.4410923060713685e-07

I1307K O 0 0.0006134963477961719
APC O 0 7.95581509009935e-05
and O 0 5.911231824029528e-07
hMLH1 O 0 5.009118467569351e-06
mutations O 0 3.4063143630191917e-06
in O 0 1.193860832415794e-08
a O 0 3.732631981279155e-08
non O 0 7.104057999640645e-07
- O 0 2.2323465600493364e-06
Jewish O 0 1.198817471959046e-07
family O 0 1.3862425873867323e-08
with O 0 2.366914664264641e-08
hereditary B-Disease 1 0.987059473991394
non I-Disease 1 0.9924433827400208
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.0542958029400324e-06

We O 0 8.904571586754173e-06
describe O 0 1.9768822312471457e-06
a O 0 2.0212890206039447e-07
French O 0 1.0545601071498822e-05
Canadian O 0 8.593495294917375e-06
hereditary B-Disease 1 0.9984999895095825
non I-Disease 1 0.9978827834129333
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.343543256865814e-05
HNPCC B-Disease 1 0.9689908623695374
) O 0 3.704383289004909e-07
kindred O 0 4.562570666166721e-06
which O 0 2.002340160345284e-08
carries O 0 9.986811022599795e-08
a O 0 6.981378675163796e-08
novel O 0 2.1412765249806398e-07
truncating O 0 3.3014005111908773e-06
mutation O 0 4.8977376536640804e-06
in O 0 1.340968793783759e-07
hMLH1 O 0 2.1237154214759357e-05
. O 0 6.545377004840702e-07

Interestingly O 0 6.552990089403465e-05
, O 0 2.8824689479733934e-07
the O 0 5.246544176884527e-08
I1307K O 0 1.403704118274618e-06
APC O 0 5.213515805735369e-07
polymorphism O 0 8.87935129867401e-07
, O 0 7.556316461432289e-09
associated O 0 8.090139225203075e-09
with O 0 1.2838407004167607e-09
an O 0 1.8412806834788853e-09
increased O 0 1.6236683109127625e-07
risk O 0 3.524754720274359e-05
of O 0 4.218264621158596e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.250781663969974e-08
is O 0 2.5986137686118127e-09
also O 0 1.1266010346844268e-08
present O 0 7.899130238797625e-09
in O 0 1.8837882365119185e-09
this O 0 5.352684517845319e-09
family O 0 2.6111038664566877e-07
. O 0 1.3147987942829786e-07

The O 0 1.8068501503876178e-06
I1307K O 0 4.5040424083708785e-06
polymorphism O 0 8.504166544298641e-06
has O 0 2.6145474407712754e-07
previously O 0 4.752694735543628e-07
only O 0 1.2481616629145265e-08
been O 0 2.4751129146238782e-08
identified O 0 1.869300447765454e-08
in O 0 5.523974055954284e-10
individuals O 0 2.38234898475298e-09
of O 0 2.6757231985641283e-09
self O 0 1.2115780009480659e-05
- O 0 0.0001265286118723452
reported O 0 2.609846660561743e-06
Ashkenazi O 0 1.0945834219455719e-05
Jewish O 0 6.408685635506117e-07
origins O 0 1.4769492509003612e-06
. O 0 3.308490477138548e-07

In O 0 4.2214861650791136e-07
addition O 0 8.877254487060782e-08
, O 0 9.62947677152215e-09
in O 0 1.5438504918918738e-09
this O 0 1.2207459487711958e-09
family O 0 1.035429608720051e-08
, O 0 1.5440890788198658e-09
there O 0 2.202606763646031e-09
appears O 0 1.009880623570325e-08
to O 0 2.4133111065083312e-09
be O 0 2.2303405344814564e-08
no O 0 1.0126754546035954e-08
relationship O 0 1.2133924975898935e-08
between O 0 2.863080661441586e-09
the O 0 2.9611062490886297e-09
I1307K O 0 1.029469203217559e-07
polymorphism O 0 1.9140428264563525e-07
and O 0 9.584527838057966e-09
the O 0 2.336662419111235e-09
presence O 0 1.3353759875656124e-08
or O 0 4.5385313285351e-08
absence O 0 6.871006519304501e-08
of O 0 1.906103719306884e-08
cancer B-Disease 0 8.217893082473893e-06
. O 0 1.4397524061848799e-08
. O 0 9.005448475818412e-08

Identification O 0 4.708034339273581e-06
of O 0 1.4086225519349682e-07
a O 0 9.783025234355591e-08
novel O 0 1.5606551073688024e-07
mutation O 0 2.912866250426305e-07
of O 0 2.7547004677330733e-09
the O 0 1.3474419802150805e-08
CPO O 0 2.465671286699944e-06
gene O 0 1.6125883917084138e-07
in O 0 4.533554420760311e-09
a O 0 4.696419253491513e-08
Japanese O 0 4.494075255934149e-06
hereditary B-Disease 0 0.030672922730445862
coproporphyria I-Disease 0 6.34788884781301e-05
family O 0 1.3577921436080942e-06
. O 0 3.793572034282988e-07

Hereditary B-Disease 1 0.9999922513961792
coproporphyria I-Disease 1 0.911164402961731
( O 0 1.8345308490097523e-05
HCP B-Disease 0 0.00025541448849253356
) O 0 8.131324591431621e-08
is O 0 7.96676502545779e-09
an O 0 2.437450952186282e-08
autosomal B-Disease 1 0.9999332427978516
dominant I-Disease 1 0.9999035596847534
disease I-Disease 1 0.9948065876960754
characterized O 0 6.927313052074169e-07
by O 0 1.4473515719259922e-08
a O 0 8.006539928828715e-07
deficiency B-Disease 0 0.012014077976346016
of I-Disease 0 6.267717456154287e-09
coproporphyrinogen I-Disease 0 1.380289268126944e-05
oxidase I-Disease 0 8.262339179054834e-06
( O 0 1.216657210534322e-07
CPO O 0 5.095833330415189e-06
) O 0 9.376584841902513e-09
caused O 0 4.471032255537466e-08
by O 0 1.7247026029565404e-09
a O 0 9.637395770312196e-09
mutation O 0 3.098598426731769e-07
in O 0 3.0090390179537962e-09
the O 0 2.4486624283781566e-08
CPO O 0 4.957965757057536e-06
gene O 0 8.810831673145003e-07
. O 0 1.3881826532724517e-07

Only O 0 2.2028029889042955e-06
11 O 0 3.5897605243917496e-07
mutations O 0 4.0847470472726854e-07
of O 0 2.820574884765392e-09
the O 0 6.213143777245023e-09
gene O 0 1.6596064256191312e-07
have O 0 6.048301770533726e-08
been O 0 7.180126004868725e-08
reported O 0 2.34329860404614e-07
in O 0 3.7100534200362745e-08
HCP B-Disease 0 0.0005589515785686672
patients O 0 1.1593735507631209e-05
. O 0 2.9040930371593277e-07

We O 0 2.9108801754773594e-05
report O 0 4.0424481539957924e-07
another O 0 5.214241483031401e-08
mutation O 0 3.7052561197015166e-07
in O 0 5.569936067928438e-09
a O 0 2.6317753309967884e-08
Japanese O 0 8.311649253300857e-07
family O 0 3.7690682574975654e-07
. O 0 1.3453238523197797e-07

Polymerase O 0 0.0003616365429479629
chain O 0 8.380322833545506e-05
reaction O 0 3.634844915723079e-06
- O 0 7.88915713201277e-06
single O 0 7.772677577122522e-07
strand O 0 2.849748454991641e-07
conformational O 0 6.085191728288919e-08
polymorphism O 0 5.710449499929382e-07
and O 0 1.790755277397693e-08
direct O 0 6.223915960390514e-08
sequence O 0 1.977684576104366e-07
analyses O 0 1.3172967783248168e-06
demonstrated O 0 1.8759516251520836e-07
a O 0 6.229260662848901e-08
C O 0 8.828957902551338e-07
to O 0 1.229926915868873e-08
T O 0 3.783488295994175e-07
substitution O 0 9.026665637179576e-09
in O 0 1.580100161824305e-09
exon O 0 5.461654239979907e-08
1 O 0 7.1376029531222684e-09
of O 0 1.5012167065009407e-09
the O 0 1.412470673756161e-08
CPO O 0 1.0447573686178657e-06
gene O 0 9.180998716828981e-08
at O 0 2.5874722808794104e-08
nucleotide O 0 2.068107818331555e-07
position O 0 4.16056735730308e-07
85 O 0 6.218078141273509e-08
, O 0 4.190493729794298e-09
which O 0 6.2814442536307524e-09
lies O 0 7.334963925131888e-08
in O 0 2.6745701209307526e-09
the O 0 6.204581293189904e-09
putative O 0 3.6787608337363054e-07
presequence O 0 6.957118898753833e-07
for O 0 4.431940148208469e-09
targeting O 0 2.6386746299067454e-07
to O 0 6.658819984295405e-08
mitochondria O 0 3.618499476942816e-06
. O 0 5.631425779029087e-07

This O 0 8.071406227827538e-07
mutation O 0 1.9711103504960192e-06
changes O 0 6.316142986406703e-08
the O 0 5.569234406976875e-09
codon O 0 1.5053470292514248e-07
for O 0 1.983659458915099e-09
glutamine O 0 3.243257751250894e-08
to O 0 4.570654077440395e-09
a O 0 2.9050090333271328e-08
termination O 0 7.525223395532521e-07
codon O 0 1.1663516943372088e-06
at O 0 2.0267322042855085e-07
amino O 0 7.008809461694909e-07
acid O 0 2.166174084550221e-07
position O 0 5.908419211664295e-07
29 O 0 5.233151796346647e-07
. O 0 1.4053124175461562e-07

MaeI O 0 0.00021680847567040473
restriction O 0 2.0412096546351677e-06
analysis O 0 3.5385923524700047e-07
showed O 0 9.34893250814639e-07
two O 0 9.867464179080798e-09
other O 0 5.793872492887431e-09
carriers O 0 9.023587921319631e-08
in O 0 2.9980229410142556e-09
the O 0 7.328556428376487e-09
family O 0 1.2317465802880179e-07
. O 0 7.868157325674474e-08

The O 0 8.600522050983272e-06
C O 0 0.0020834209863096476
- O 0 0.007243666332215071
T O 0 0.0003030225052498281
mutation O 0 9.903856152959634e-07
is O 0 7.426351089634409e-09
located O 0 2.9412262847472448e-08
within O 0 7.415027702961652e-09
a O 0 9.17175402292969e-09
recently O 0 6.112924211265636e-08
proposed O 0 2.0336745620852525e-08
putative O 0 2.2004732613822853e-07
alternative O 0 6.436100363771402e-08
translation O 0 7.027564663530939e-08
initiation O 0 9.087338526114763e-08
codon O 0 5.407761136666522e-07
( O 0 3.760924371931651e-08
TIC O 0 1.2502199524533353e-06
- O 0 7.721080805822567e-07
1 O 0 2.2734104376809228e-08
) O 0 3.3706006874467676e-09
, O 0 1.455339848632775e-09
supporting O 0 1.2044780284270473e-08
that O 0 2.846799018740853e-09
TIC O 0 8.393647590310138e-07
- O 0 3.7767037497360434e-07
1 O 0 8.803246132060849e-09
is O 0 1.4178089813299266e-09
the O 0 4.840277956219552e-09
real O 0 2.5904827793965524e-07
TIC O 0 9.71898771240376e-07
rather O 0 3.429027373158533e-08
than O 0 1.6843973327240747e-08
TIC O 0 2.310261379534495e-06
- O 0 1.6406389704570756e-06
2 O 0 9.611405715759247e-08
. O 0 1.734077770265685e-08
. O 0 1.3520997299565352e-07

Human B-Disease 0 5.9913341829087585e-05
complement I-Disease 0 8.469480962958187e-05
factor I-Disease 0 0.0018369550816714764
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999898672103882
associated O 0 5.082779534859583e-05
with O 0 0.0005299962940625846
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.007826540444512e-05

This O 0 2.451315026519296e-07
study O 0 8.620705216344504e-08
reports O 0 5.579944684086513e-08
on O 0 8.2351920838164e-09
six O 0 2.204381388537513e-08
cases O 0 4.510258388989996e-09
of O 0 1.4233262568552618e-08
deficiency B-Disease 0 0.00039014522917568684
in I-Disease 0 8.501107595648705e-10
the I-Disease 0 2.497937856560384e-09
human I-Disease 0 4.256095031962559e-09
complement I-Disease 0 2.0765478225825973e-08
regulatory I-Disease 0 9.680859847094325e-08
protein I-Disease 0 1.4453162577865442e-07
Factor I-Disease 0 8.049767075135605e-07
H I-Disease 1 0.9999998807907104
( O 0 2.7586463602347067e-07
FH O 0 3.170976196997799e-05
) O 0 6.092505611121624e-09
in O 0 9.814995483026223e-10
the O 0 1.0472948064332854e-09
context O 0 1.2235508606295298e-08
of O 0 2.9739204432388533e-09
an O 0 4.71546672997647e-06
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.4185900403826963e-06

Five O 0 1.6950640429058694e-06
of O 0 1.7628543957926013e-08
the O 0 1.777270419722754e-08
cases O 0 1.818650297025215e-08
were O 0 1.0035081032810922e-07
observed O 0 5.946066394812988e-08
in O 0 3.3869824722643216e-09
children O 0 1.2095664203570777e-07
presenting O 0 2.042557980530546e-07
with O 0 3.047280370083172e-05
idiopathic O 1 0.9999997615814209
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.710367309395224e-05
HUS B-Disease 1 0.9999343156814575
) O 0 1.1282556897640461e-06
. O 0 5.406884611147689e-07

Two O 0 3.9793809492039145e-07
of O 0 2.0513027720880928e-08
the O 0 2.941288101965256e-08
children O 0 2.728366723658837e-07
exhibited O 0 1.087978716896032e-06
a O 0 4.1869648725878506e-07
homozygous O 1 0.9983086585998535
deficiency O 0 0.0001588937157066539
characterized O 0 5.2136449824047304e-08
by O 0 1.9033270515222966e-09
the O 0 2.322771752716335e-09
absence O 0 1.0664675365035237e-08
of O 0 3.5616104510083346e-10
the O 0 1.4998028374790806e-09
150 O 0 4.43273462380489e-09
- O 0 2.7493685550439295e-08
kD O 0 8.581577759514403e-08
form O 0 6.142000241737833e-09
of O 0 1.9111703331020635e-09
Factor O 0 9.064453365681402e-08
H O 1 0.9999997615814209
and O 0 4.6913786633240306e-08
the O 0 4.620705151836546e-09
presence O 0 1.2611944377738382e-08
, O 0 1.6310292005883298e-09
upon O 0 1.9808239493102064e-09
immunoblotting O 0 7.887585695698363e-08
, O 0 7.809093927058086e-10
of O 0 3.378477220206122e-10
the O 0 3.943864346211967e-09
42 O 0 1.228909667361222e-07
- O 0 8.907461790386151e-08
kD O 0 1.178920342681522e-06
Factor O 0 5.227226438364596e-07
H O 1 0.9999520778656006
- O 0 1.882846163425711e-06
like O 0 6.45180833203085e-08
protein O 0 7.069711216445285e-08
1 O 0 3.713777374514393e-08
( O 0 1.4007679460803502e-08
FHL O 0 1.4322525885290815e-06
- O 0 4.829711883758137e-07
1 O 0 1.0044537646081153e-08
) O 0 1.74381498130316e-09
and O 0 4.331801584100958e-09
other O 0 1.0679555018100473e-08
FH O 0 0.00013554429460782558
- O 0 2.322471118532121e-06
related O 0 1.1148957668183357e-07
protein O 0 2.479287957157794e-07
( O 0 4.864176261776265e-08
FHR O 0 5.340762527339393e-06
) O 0 5.850342077451387e-08
bands O 0 1.3939708196630818e-06
. O 0 2.3187099884580675e-07

Southern O 0 3.495638520689681e-05
blot O 0 0.0001743591856211424
and O 0 3.7904584360148874e-07
PCR O 0 2.9262441785249393e-06
analysis O 0 9.158331693015498e-08
of O 0 2.1564479091296107e-09
DNA O 0 4.370069106585106e-08
of O 0 2.0040202830529097e-09
one O 0 5.7367163464050464e-08
patient O 0 1.3789242530037882e-06
with O 0 8.84348807517199e-08
homozygous O 1 0.9968991279602051
deficiency O 0 0.000927419459912926
ruled O 0 7.256731038296493e-08
out O 0 9.650658050475158e-09
the O 0 3.2133307126258615e-09
presence O 0 4.037513878785148e-09
of O 0 2.2218972495213762e-10
a O 0 1.0268952355119154e-09
large O 0 1.2911267610604682e-09
deletion O 0 6.49430447197119e-08
of O 0 6.210996161826188e-10
the O 0 7.066998986005046e-09
FH O 0 7.1510330599267036e-06
gene O 0 7.65270087299541e-08
as O 0 3.572320883549196e-09
the O 0 8.526720662871412e-09
underlying O 0 1.3334387176655582e-06
defect O 0 2.496104343663319e-06
for O 0 1.1293807666845623e-08
the O 0 3.9921184225022444e-07
deficiency O 0 0.0003592747962102294
. O 0 1.150695680962599e-07

The O 0 4.1428924646425003e-07
other O 0 1.725953957532056e-08
four O 0 3.531047454430336e-08
children O 0 9.315764515349656e-08
presented O 0 1.4589983443613619e-08
with O 0 5.140731218489236e-08
heterozygous O 1 0.9437034130096436
deficiency O 0 0.0006359111284837127
and O 0 1.5341292680659535e-08
exhibited O 0 4.0478954588252236e-07
a O 0 3.1847520176597754e-08
normal O 0 2.5859461061372713e-07
immunoblotting O 0 1.000788870442193e-06
pattern O 0 1.040333543755878e-07
of O 0 1.1096674690236341e-09
proteins O 0 7.452317873912762e-09
of O 0 2.9557172265270992e-09
the O 0 1.547668517787315e-07
FH O 0 0.009619676508009434
family O 0 1.276712964681792e-06
. O 0 3.7432695876304933e-07

Factor B-Disease 1 0.9675052165985107
H I-Disease 1 1.0
deficiency I-Disease 1 0.9998674392700195
is O 0 3.741905629794928e-08
the O 0 2.1313255160748668e-08
only O 0 4.651763561014377e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 6.106218961576815e-07
with O 0 2.57101220313416e-07
HUS B-Disease 1 0.9989356398582458
. O 0 1.4850918432784965e-06

These O 0 1.5840078049222939e-06
observations O 0 2.9425614229694474e-06
suggest O 0 6.145741622276546e-07
a O 0 5.258696589294232e-08
role O 0 1.094830111014744e-07
for O 0 1.3944608134863756e-08
FH O 0 4.727438499685377e-05
and O 0 1.8477801688732143e-07
/ O 0 1.2323675946390722e-05
or O 0 6.678872068732744e-07
FH O 0 6.32444498478435e-05
receptors O 0 3.2552409834352147e-07
in O 0 6.1204121770686015e-09
the O 0 1.9745330703813124e-08
pathogenesis O 0 9.185296221403405e-07
of O 0 4.161844202599241e-08
idiopathic O 0 0.00028715861844830215
HUS B-Disease 1 0.9550398588180542
. O 0 3.913552575340873e-07
. O 0 4.80262258406583e-07

Further O 0 1.9836772935377667e-06
evidence O 0 1.6642852074255643e-07
for O 0 7.918877109602818e-09
a O 0 1.2284357531200385e-08
major O 0 4.767984762565902e-08
ancient O 0 1.2396162674122024e-07
mutation O 0 0.0006675294716842473
underlying O 0 0.00020706551731564105
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 4.294946904792596e-07
linkage O 0 2.3851909645600244e-05
disequilibrium O 0 3.469084549578838e-05
studies O 0 6.147745921225578e-07
in O 0 1.9806055462368022e-08
the O 0 1.667659077497774e-08
Japanese O 0 5.190466936255689e-07
population O 0 6.597694124366171e-08
. O 0 7.563933479559637e-08

The O 0 0.00011874402844114229
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.5961824655532837
DM B-Disease 1 1.0
) O 0 3.477375912552816e-06
mutation O 0 1.250396053364966e-05
is O 0 3.4358883738150325e-08
an O 0 2.0068672057504955e-08
unstable O 0 0.00011529010953381658
( O 0 1.0166994712790256e-07
CTG O 0 2.6132115635846276e-06
) O 0 1.523666171010518e-08
n O 0 5.495939490174351e-07
repeat O 0 7.691800760767364e-07
, O 0 1.1445083991645788e-08
present O 0 8.300842679886955e-09
at O 0 3.21007327386269e-08
a O 0 2.907934559814862e-09
copy O 0 2.7584349027165445e-08
number O 0 2.1730708343881133e-09
of O 0 9.981526716273947e-10
5 O 0 3.247727065058825e-08
- O 0 1.5000274515841738e-06
37 O 0 1.523445973816706e-07
repeats O 0 1.800616473701666e-07
on O 0 3.103569312656873e-08
normal O 0 1.0265809180509677e-07
chromosomes O 0 1.8752504615804355e-07
but O 0 4.9357065101673925e-09
amplified O 0 1.0120965754367717e-07
to O 0 2.311300306701014e-08
50 O 0 4.967441924463856e-08
- O 0 2.5225398303518887e-07
3000 O 0 1.638598519093648e-07
copies O 0 8.769782766648859e-08
on O 0 1.935838099598186e-06
DM B-Disease 1 0.9999997615814209
chromosomes O 0 4.204865763313137e-05
. O 0 1.2206951396365184e-06

Previous O 0 2.565707836765796e-05
findings O 0 1.3225596831034636e-06
in O 0 4.5506059365152396e-08
Caucasian O 0 5.427909854915924e-06
populations O 0 2.174324720272125e-07
of O 0 9.13132769397862e-09
a O 0 1.8161081243306398e-06
DM B-Disease 1 1.0
founder O 0 3.5397943065618165e-06
chromosome O 0 1.3619637684314512e-05
raise O 0 1.565444591733467e-07
a O 0 1.6261067159462073e-08
question O 0 2.0059333749600228e-08
about O 0 1.7962278331395964e-09
the O 0 1.3714277491416738e-09
molecular O 0 6.422562393026965e-08
events O 0 3.440367279949896e-08
involved O 0 3.712007057288247e-08
in O 0 4.34636771018404e-09
the O 0 1.0269956440822625e-08
expansion O 0 1.7465195867316652e-07
mutation O 0 3.4758675155899255e-06
. O 0 3.2853151310519024e-07

To O 0 7.775991548442107e-07
investigate O 0 7.725573709649325e-07
whether O 0 7.825740766520539e-08
a O 0 2.6203455405493514e-08
founder O 0 1.7654663508892554e-07
chromosome O 0 3.955049123760546e-06
for O 0 1.7609757207992516e-08
the O 0 3.0394454597626464e-07
DM B-Disease 1 1.0
mutation O 0 1.2628100193978753e-05
exists O 0 5.598675656415253e-08
in O 0 2.4527464503876217e-09
the O 0 2.1283588225173844e-09
Japanese O 0 9.113096410828803e-08
population O 0 8.575111287711934e-09
, O 0 4.052806090726335e-09
we O 0 1.0311844711452522e-08
genotyped O 0 2.1347192102894041e-07
families O 0 1.2500628088218946e-08
using O 0 2.9976586546354156e-08
polymorphic O 0 1.4698183576911106e-06
markers O 0 1.1230791642447002e-05
near O 0 2.9873415314796148e-06
the O 0 5.707967432044825e-08
( O 0 8.286340147378723e-08
CTG O 0 2.137003548341454e-06
) O 0 1.64892206555578e-08
n O 0 9.972266070690239e-07
repeat O 0 1.6710299632904935e-06
region O 0 3.057213859847252e-07
and O 0 1.1210882178147585e-07
constructed O 0 4.4124849409854505e-06
haplotypes O 0 1.4481903235719074e-05
. O 0 5.133647391630802e-07

Six O 0 3.1518625291937497e-06
different O 0 2.1482000533978862e-07
haplotypes O 0 2.9494590307876933e-06
were O 0 1.25611666135228e-06
found O 0 1.0343819667468779e-07
and O 0 1.4763859326194506e-06
DM B-Disease 1 1.0
alleles O 0 4.6651392040075734e-05
were O 0 2.2671504211757565e-06
always O 0 4.771223416355497e-07
haplotype O 0 3.0461012556770584e-06
A O 0 1.0699177437345497e-06
. O 0 4.797349220098113e-07

To O 0 1.3005970913582132e-06
find O 0 4.736789378512185e-07
an O 0 9.498954511855118e-09
origin O 0 1.9229524639285955e-08
of O 0 1.6362328159047479e-09
the O 0 1.7193562129591555e-08
( O 0 4.4136363896996045e-08
CTG O 0 1.2800046533811837e-06
) O 0 6.468587887553667e-09
n O 0 3.376599977400474e-07
repeat O 0 3.374198627170699e-07
mutation O 0 2.7682233394443756e-07
and O 0 7.41683869875942e-09
to O 0 3.786734481536769e-09
investigate O 0 2.9865638850878895e-08
the O 0 2.4455151237390282e-09
mechanism O 0 5.58509505310667e-09
of O 0 4.172522882761598e-10
the O 0 9.784901777720734e-10
expansion O 0 7.468539564570165e-09
mutation O 0 5.087181520480044e-08
in O 0 1.241013292130333e-09
the O 0 2.8035991306296637e-09
Japanese O 0 4.6509295970054154e-08
population O 0 4.011798004910361e-09
we O 0 2.935586884689201e-09
have O 0 1.3344408911208916e-09
studied O 0 2.0664213451482283e-08
90 O 0 2.8497831650042826e-08
Japanese O 0 8.744382853365096e-07
DM B-Disease 1 0.9999996423721313
families O 0 2.3609388222212147e-07
comprising O 0 2.3662284576175807e-08
190 O 0 4.88717475377598e-08
affected O 0 6.504023275510917e-08
and O 0 1.4571961415299484e-08
130 O 0 1.1363377439010947e-07
unaffected O 0 1.1944754305659444e-06
members O 0 6.138512276265828e-08
. O 0 1.0588448873249945e-07

The O 0 2.1306402686604997e-06
results O 0 8.692550181876868e-07
suggest O 0 1.2075217625806545e-07
that O 0 3.6255189961309497e-09
a O 0 5.656937140940954e-09
few O 0 5.468041130995971e-09
common O 0 1.55316079997192e-08
ancestral O 0 1.7073799085665087e-07
mutations O 0 8.335717325280712e-07
in O 0 1.5486458782021373e-09
both O 0 1.0411886464112285e-08
Caucasian O 0 3.1440433190255135e-07
and O 0 1.536902871634993e-08
Japanese O 0 9.228682529283105e-08
populations O 0 2.004655819121126e-08
have O 0 2.7658935142227392e-09
originated O 0 2.541503008046675e-09
by O 0 5.457597707092532e-10
expansion O 0 1.0304879172196024e-09
of O 0 5.686890403033829e-10
an O 0 4.04491373728888e-09
ancestral O 0 5.477887157212535e-07
n O 0 5.346623311197618e-06
= O 0 4.29808778790175e-06
5 O 0 5.656551849142488e-08
repeat O 0 4.5586895680571615e-07
to O 0 1.0321863896933792e-07
n O 0 7.119856309145689e-05
= O 0 5.132078877068125e-05
19 O 0 9.978944035538007e-07
- O 0 2.3069678718457e-06
37 O 0 5.140176995155343e-07
copies O 0 3.8945606206652883e-07
. O 0 2.6905280492428574e-07

These O 0 5.405235015132348e-07
data O 0 2.3164335516412393e-07
support O 0 6.941426278217477e-08
multistep O 0 6.436911235141451e-07
models O 0 2.4819161126288236e-07
of O 0 9.286914348649589e-09
triplet O 0 1.5349261957453564e-05
repeat O 0 3.999957414180244e-07
expansion O 0 3.2728870280607225e-08
that O 0 6.7568444173105036e-09
have O 0 1.1283299627962151e-08
been O 0 3.1527664923203247e-09
proposed O 0 1.5780942108634122e-09
for O 0 2.4089055195020137e-09
both O 0 9.139535563917889e-07
DM B-Disease 1 1.0
and O 0 2.265378270749352e-06
Friedreichs B-Disease 0 0.00015267498383764178
ataxia I-Disease 0 0.004221125040203333
. O 0 1.6815523906643648e-07
. O 0 2.8892640102640144e-07

The O 0 7.124235139599477e-07
molecular O 0 1.2612276805157308e-06
basis O 0 2.161733050343173e-07
of O 0 6.065284310352581e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.4853955399019014e-08
the O 0 5.5106541552163435e-09
western O 0 4.378537710181263e-08
Cape O 0 5.269711778055353e-07
, O 0 1.3722866398779843e-08
South O 0 6.344711067640674e-08
Africa O 0 1.34118479877543e-07
. O 0 5.6757350819225394e-08

Deficiency B-Disease 1 0.9998072981834412
of I-Disease 0 7.560731773992302e-08
the I-Disease 0 4.8383331119339346e-08
sixth I-Disease 0 1.2064965630997904e-06
component I-Disease 0 1.924325090385537e-07
of I-Disease 0 3.219551514277441e-09
human I-Disease 0 1.020324091882685e-08
complement I-Disease 0 1.2266626470136544e-07
( O 0 1.9251984895163332e-08
C6 O 0 9.505843081569765e-07
) O 0 5.8412745751468265e-09
has O 0 1.592129272864895e-08
been O 0 1.3813762222980586e-07
reported O 0 6.80192329127749e-08
in O 0 7.206599206277531e-10
a O 0 1.32767763449948e-09
number O 0 2.800493836829787e-09
of O 0 1.261393434148772e-09
families O 0 1.3896125139467586e-08
from O 0 1.98065008838455e-09
the O 0 2.572889012952828e-09
western O 0 1.217268241759939e-08
Cape O 0 1.423576492243228e-07
, O 0 8.389292815991212e-09
South O 0 5.48071987793719e-08
Africa O 0 1.1038379454930691e-07
. O 0 8.581660182471751e-08

Meningococcal B-Disease 1 0.9999740123748779
disease I-Disease 1 0.9999929666519165
is O 0 5.210245035414118e-07
endemic O 0 2.0962868063634232e-07
in O 0 6.841200939078362e-09
the O 0 9.094131669939998e-09
Cape O 0 2.2781685515838035e-07
and O 0 1.664294124736898e-08
almost O 0 2.4254211083984956e-08
all O 0 1.6411775272118234e-09
pedigrees O 0 2.0111556864321756e-07
of O 0 6.194707857787307e-09
total O 0 0.0009333444177173078
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.559814333835675e-07
C6Q0 O 0 1.2118230188207235e-05
) O 0 1.265756299773102e-08
have O 0 2.701338530641806e-08
been O 0 4.678350506992501e-08
ascertained O 0 4.2513511289143935e-07
because O 0 8.254928296480557e-09
of O 0 2.396332021703529e-08
recurrent O 1 0.9707720279693604
disease O 1 0.62589031457901
. O 0 5.539594098991074e-07

We O 0 1.254541984962998e-05
have O 0 8.772995130357231e-08
sequenced O 0 2.2337894733936992e-07
the O 0 4.13163681045603e-09
expressed O 0 3.6074669917951496e-09
exons O 0 6.753007397719557e-08
of O 0 1.7424053311287935e-09
the O 0 1.010961714342784e-08
C6 O 0 1.1152334309372236e-06
gene O 0 8.391760530912507e-08
from O 0 2.799052101210009e-09
selected O 0 1.0829044327920201e-08
cases O 0 3.3250979747379006e-09
and O 0 1.553193484937765e-08
have O 0 9.723422067509091e-08
found O 0 4.011945264892347e-08
three O 0 3.1555835278140876e-08
molecular O 0 7.243550498969853e-05
defects O 1 0.9897280335426331
leading O 0 6.743598532921169e-07
to O 0 4.3806092975273714e-08
total O 0 1.5076391719048843e-05
deficiency O 0 0.007286703679710627
879delG O 0 4.076306368006044e-07
, O 0 3.145426585859923e-09
which O 0 1.9696608788422054e-09
is O 0 8.002977169851988e-10
the O 0 3.2861087184699045e-09
common O 0 1.0949303685947598e-07
defect O 0 3.231992877772427e-06
in O 0 3.666912329336469e-09
the O 0 9.94644899776631e-09
Cape O 0 1.1124084409175339e-07
and O 0 1.7191069900945877e-08
hitherto O 0 6.150619356048992e-07
unreported O 0 1.4395388348020788e-07
, O 0 6.452938183798551e-09
and O 0 8.49417514103834e-09
1195delC O 0 2.8595354706340004e-07
and O 0 2.1201513433766195e-08
1936delG O 0 1.9176275145582622e-07
, O 0 2.330866832878087e-09
which O 0 2.7179789530151766e-09
have O 0 3.4229763912208e-08
been O 0 6.021895870844673e-08
previously O 0 2.4205388626796775e-07
reported O 0 8.746579283069877e-08
in O 0 3.4469536114301036e-09
African O 0 7.301324700392797e-08
- O 0 2.407066176601802e-06
Americans O 0 5.213202598497446e-07
. O 0 1.0110219506032081e-07

We O 0 9.807387868931983e-06
also O 0 1.6429062554834672e-07
show O 0 1.1642485731044871e-07
that O 0 3.201096276939097e-09
the O 0 4.638259110123499e-09
879delG O 0 7.628427738382015e-07
and O 0 1.0845647580026707e-07
1195delC O 0 4.2721472709672526e-05
defects O 0 0.18658773601055145
are O 0 1.1884172756992939e-08
associated O 0 3.2053989684754924e-08
with O 0 2.9608814955395246e-08
characteristic O 0 5.2548188250511885e-05
C6 O 0 0.0006589693948626518
/ O 0 0.00013400524039752781
C7 O 0 0.0002028056769631803
region O 0 1.1700370805556304e-06
DNA O 0 1.7799320630729198e-06
marker O 0 3.785050466831308e-06
haplotypes O 0 1.6183239495148882e-06
, O 0 1.5848215184632863e-08
although O 0 3.881062138333391e-09
small O 0 7.740823093627114e-09
variations O 0 7.891435984674899e-07
were O 0 1.8602611362439347e-06
observed O 0 6.399145604518708e-07
. O 0 7.093146336956124e-08

The O 0 3.746945139937452e-06
1936delG O 0 7.517734047723934e-05
defect O 0 0.00020887171558570117
was O 0 5.863378760295745e-07
observed O 0 6.256432527607103e-08
only O 0 9.935887668177656e-09
once O 0 5.1424866143179315e-08
in O 0 1.7438749333464898e-09
the O 0 4.238903450470843e-09
Cape O 0 9.581697923977117e-08
, O 0 3.258757930169054e-09
but O 0 1.3629526396385927e-09
its O 0 9.893333929866799e-10
associated O 0 1.6942763636507152e-08
haplotype O 0 3.3485565609225887e-07
could O 0 1.5525068874922e-07
be O 0 3.3693808632051514e-08
deduced O 0 6.85944371525693e-07
. O 0 1.5743647452381992e-07

The O 0 7.398501224997744e-07
data O 0 2.810132855302072e-07
from O 0 8.402439632959613e-09
the O 0 5.440036865422826e-09
haplotypes O 0 1.1416776857231525e-07
indicate O 0 5.4603418675469584e-08
that O 0 9.390487276661474e-10
these O 0 1.6165533356371498e-09
three O 0 1.686831119229737e-08
molecular O 0 1.3988387763674837e-05
defects O 1 0.8124449849128723
account O 0 6.80855620771581e-08
for O 0 6.505645355758816e-09
the O 0 2.933663836302003e-07
defects O 1 0.916660726070404
in O 0 4.237222128722351e-09
all O 0 4.2021794932622925e-09
the O 0 5.44180123185356e-09
38 O 0 1.1406449118567252e-07
unrelated O 0 7.721111927594393e-08
C6Q0 O 0 1.1279823866061633e-06
individuals O 0 1.6303831174013794e-08
we O 0 1.4643426915483815e-08
have O 0 4.218642324360644e-09
studied O 0 3.960548511372508e-08
from O 0 5.910197220515556e-09
the O 0 1.735494059573739e-08
Cape O 0 1.3958012914372375e-06
. O 0 1.4705457829222723e-07

We O 0 2.6031750167021528e-05
have O 0 2.9444265692291083e-07
also O 0 5.1202793116544854e-08
observed O 0 1.0786214232894054e-07
the O 0 1.5659695762337833e-08
879delG O 0 4.565861217997735e-06
defect O 0 4.859132332057925e-06
in O 0 1.190279785845405e-08
two O 0 3.555916237019119e-07
Dutch O 1 0.9988929629325867
C6 B-Disease 1 1.0
- I-Disease 1 0.9993975162506104
deficient I-Disease 1 0.9999996423721313
kindreds O 0 1.8516715499572456e-05
, O 0 2.4564977607610672e-08
but O 0 1.076992806048338e-08
the O 0 9.26048837612825e-09
879delG O 0 1.1784503612943809e-06
defect O 0 9.60566580943123e-07
in O 0 3.785463498218178e-09
the O 0 5.495088384321889e-09
Cape O 0 2.7312563588566263e-07
probably O 0 9.082798158033256e-08
did O 0 3.1615780216043277e-08
not O 0 6.690530351960433e-09
come O 0 4.334934189387241e-09
from O 0 2.5240682877125664e-09
The O 0 7.730966089525282e-09
Netherlands O 0 9.357379440189106e-07
. O 0 1.281788630791425e-08
. O 0 6.090323978469314e-08

Complement B-Disease 1 0.9983855485916138
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 8.905506092560245e-07
seven O 0 2.0178086401756445e-07
further O 0 1.621457101919077e-07
molecular O 0 0.00016690182383172214
defects O 1 0.9998589754104614
and O 0 2.957955871352169e-07
their O 0 6.534543217640021e-07
associated O 0 3.824444775091251e-06
marker O 0 6.589196709683165e-05
haplotypes O 0 3.0881023121764883e-05
. O 0 1.420037733623758e-06

Seven O 0 8.627845090813935e-06
further O 0 4.728908891138417e-07
molecular O 0 2.1489081518666353e-06
bases O 0 5.497808615473332e-06
of O 0 4.167530732956948e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.4211355998413637e-07
described O 0 1.5240781294778571e-06
. O 0 2.7749052833314636e-07

All O 0 4.756476243983343e-07
these O 0 3.119414770935691e-08
new O 0 3.100398160427176e-08
molecular O 0 9.338496965938248e-06
defects O 0 0.3365233540534973
involve O 0 3.783170541282743e-07
single O 0 9.273354407923762e-06
- O 0 2.4149069304257864e-06
nucleotide O 0 7.664912118343636e-07
events O 0 6.909169769642176e-08
, O 0 6.115931316941214e-09
deletions O 0 1.2670733440245385e-07
and O 0 3.336293374900379e-08
substitutions O 0 1.082657092865702e-07
, O 0 3.701753348295256e-09
some O 0 2.555876343901531e-10
of O 0 4.0562375680508467e-10
which O 0 4.75436046087907e-09
alter O 0 2.892713268920488e-07
splice O 0 3.949560777982697e-06
sites O 0 3.1821235779716517e-07
, O 0 1.8481076224929893e-08
and O 0 1.9487764291170606e-08
others O 0 1.2294323425976472e-07
codons O 0 1.151239416685712e-06
. O 0 1.0133251038269009e-07

They O 0 8.488131243211683e-06
are O 0 5.165460237321895e-08
distributed O 0 1.1049412051988838e-08
along O 0 1.9996837963276448e-08
the O 0 4.646556028831128e-09
C7 O 0 2.501518338249298e-06
gene O 0 2.3413664962390612e-07
, O 0 5.5535354093194655e-09
but O 0 3.0641937875941494e-09
predominantly O 0 9.654911536927102e-09
towards O 0 1.3193225179009005e-08
the O 0 9.730932504226075e-09
3 O 0 4.4532363574489864e-08
end O 0 3.322453494547517e-07
. O 0 1.281576373912685e-07

All O 0 4.8137335397768766e-06
were O 0 2.2323060875351075e-06
found O 0 1.5595452396155451e-07
in O 0 1.5978821821249767e-08
compound O 0 5.907360218770918e-07
heterozygous O 0 6.489192855951842e-06
individuals O 0 1.709100132529784e-07
. O 0 1.9455792710232345e-07

The O 0 1.9130815417156555e-05
C6 O 0 0.0026248290669173002
/ O 0 0.0007663607248105109
C7 O 0 0.0009329155436716974
marker O 0 7.025903323665261e-05
haplotypes O 0 2.667015724000521e-05
associated O 0 1.4092865967541002e-06
with O 0 1.0788352966528691e-07
most O 0 1.0190209422944463e-06
C7 B-Disease 1 0.99997878074646
defects I-Disease 1 0.9999983310699463
are O 0 7.479882242478197e-07
tabulated O 0 0.0011805631220340729
. O 0 4.3779280645139806e-08
. O 0 2.0510100284809596e-07

A O 0 8.207179234887008e-06
genome O 0 5.273067017697031e-06
- O 0 1.5937951047817478e-06
wide O 0 1.9398470385567634e-07
search O 0 1.355959398097184e-07
for O 0 2.3717861452610123e-08
chromosomal O 0 0.0005018602823838592
loci O 0 5.731144483434036e-06
linked O 0 5.400409918365767e-06
to O 0 7.458478279431802e-08
mental O 0 0.008963821455836296
health O 0 1.7518422055218252e-06
wellness O 0 2.0687382402684307e-06
in O 0 1.1915495257142084e-08
relatives O 0 1.2205818222810194e-07
at O 0 6.97660027526581e-08
high O 0 1.325336143054301e-06
risk O 0 1.0955002835544292e-05
for O 0 4.088265370683075e-08
bipolar B-Disease 1 0.9999525547027588
affective I-Disease 1 0.9907177090644836
disorder I-Disease 1 0.9926619529724121
among O 0 4.879285597780836e-08
the O 0 2.324696524169667e-08
Old O 0 1.471255700380425e-06
Order O 0 5.319030549344461e-08
Amish O 0 4.255100975569803e-06
. O 0 2.8213787572894944e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 0.9999995231628418
disorder I-Disease 1 1.0
( O 0 0.005777996964752674
BPAD B-Disease 1 1.0
; O 0 0.0005253426497802138
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9999850988388062
) O 0 4.4344279359620487e-08
is O 0 5.707398109677797e-09
characterized O 0 4.05494198219003e-08
by O 0 3.0709574883047708e-09
episodes O 0 1.043328126115739e-07
of O 0 4.6711439161128965e-09
mania B-Disease 0 9.177299943985417e-06
and O 0 5.045100124334567e-07
/ O 0 0.00019087012333329767
or O 0 1.7089827224481269e-06
hypomania B-Disease 0 0.0005273542483337224
interspersed O 0 4.1852031245070975e-06
with O 0 3.6516428991717476e-08
periods O 0 5.35503602350218e-07
of O 0 4.5327524844651634e-08
depression B-Disease 0 0.0006603646324947476
. O 0 3.5011075283364335e-07

Compelling O 0 9.84657890512608e-06
evidence O 0 3.374803441147378e-07
supports O 0 1.455841101005717e-07
a O 0 1.615142686262061e-08
significant O 0 2.8849651556583922e-08
genetic O 0 6.232516511772701e-07
component O 0 1.6068210584307963e-07
in O 0 3.932882020052375e-09
the O 0 9.779010490262863e-09
susceptibility O 0 1.553173319734924e-06
to O 0 1.96642488958787e-07
develop O 0 0.0002268726093461737
BPAD B-Disease 1 0.9999998807907104
. O 0 1.7851916709332727e-06

To O 0 1.352209665128612e-06
date O 0 9.631644388718996e-07
, O 0 2.8919894035084326e-08
however O 0 1.6157958526719085e-08
, O 0 4.172644452182794e-09
linkage O 0 2.1550103213030525e-07
studies O 0 4.272885334444254e-08
have O 0 3.491959787993437e-08
attempted O 0 2.009058448493306e-07
only O 0 6.1006923957052095e-09
to O 0 6.433790389337446e-09
identify O 0 1.1046420240745647e-06
chromosomal O 0 5.326278187567368e-05
loci O 0 4.0603947581985267e-07
that O 0 6.455055157061906e-09
cause O 0 6.073387481819736e-08
or O 0 2.919840902393389e-08
increase O 0 1.1718953807360322e-08
the O 0 3.72830584183248e-08
risk O 0 1.1653421552182408e-06
of O 0 6.188779266835809e-09
developing O 0 3.6924864161846926e-06
BPAD B-Disease 1 0.9999994039535522
. O 0 7.171386187110329e-07

To O 0 1.3075778042548336e-06
determine O 0 4.586795512295794e-07
whether O 0 3.29845590840705e-08
there O 0 8.000875517666373e-09
could O 0 2.337278637298823e-08
be O 0 5.4208957322998685e-09
protective O 0 1.6145334313932835e-07
alleles O 0 8.560832753801151e-08
that O 0 2.3846584706888052e-09
prevent O 0 8.595354472618055e-08
or O 0 3.345699184365003e-08
reduce O 0 6.82258303186245e-08
the O 0 1.0705782926834218e-08
risk O 0 9.702876724304588e-08
of O 0 1.4542715920384808e-09
developing O 0 4.522398171502573e-07
BPAD B-Disease 1 0.9999997615814209
, O 0 3.817074656353725e-09
similar O 0 1.8488469644140082e-09
to O 0 2.3828716777529735e-09
what O 0 1.593921217235561e-09
is O 0 8.919762151116117e-10
observed O 0 1.1167000657508197e-08
in O 0 1.330988985692727e-09
other O 0 5.790626644852637e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.3195843528990281e-08
we O 0 2.264737553048235e-08
used O 0 8.288788535537606e-07
mental O 0 0.048399392515420914
health O 0 2.7034059257857734e-06
wellness O 0 3.104664074271568e-06
( O 0 1.8285005509710572e-08
absence O 0 1.8837891246903382e-08
of O 0 2.064675097557256e-09
any O 0 9.975119610317051e-07
psychiatric B-Disease 1 0.9785289764404297
disorder I-Disease 0 0.08794617652893066
) O 0 9.052753213723008e-09
as O 0 6.3365694913386506e-09
the O 0 1.1999790494598983e-08
phenotype O 0 4.618372599907161e-07
in O 0 4.798234254366207e-09
our O 0 2.2601890137252667e-08
genome O 0 9.561671276969719e-08
- O 0 2.5097190814449277e-07
wide O 0 2.8836291221523425e-07
linkage O 0 2.385313791819499e-06
scan O 0 2.845426024578046e-05
of O 0 8.235003789991424e-09
several O 0 1.1868270810566628e-08
large O 0 4.998816294232711e-08
multigeneration O 0 4.2269189179933164e-06
Old O 0 5.463023740048811e-07
Order O 0 2.541334431782616e-08
Amish O 0 8.43896486912854e-07
pedigrees O 0 2.3994982711883495e-06
exhibiting O 0 3.070950924666249e-07
an O 0 8.732938816535807e-09
extremely O 0 4.236565871451603e-07
high O 0 2.8029567147314083e-06
incidence O 0 0.007779785897582769
of O 0 7.914197226455144e-07
BPAD B-Disease 1 1.0
. O 0 2.5678709789644927e-06

We O 0 2.048206442850642e-05
have O 0 1.4365818401529395e-07
found O 0 3.291988548426161e-08
strong O 0 2.4139476195728093e-08
evidence O 0 1.343492428418358e-08
for O 0 3.607866227994805e-09
a O 0 2.3569226570430146e-08
locus O 0 9.530846909910906e-06
on O 0 1.034362753671303e-06
chromosome O 0 0.0005582529120147228
4p O 0 8.78399150678888e-05
at O 0 8.008479426280246e-07
D4S2949 O 0 3.1773247428645846e-06
( O 0 5.1343420182092814e-08
maximum O 0 1.6238044509009342e-07
GENEHUNTER O 0 2.5851104510365985e-05
- O 0 2.3526029053755337e-06
PLUS O 0 4.7485897880505945e-07
nonparametric O 0 4.876550519838929e-06
linkage O 0 6.167515948618529e-06
score O 0 1.1100182746304199e-05
= O 0 2.661585313035175e-06
4 O 0 6.806232022427139e-08
. O 0 7.161358173135568e-09
05 O 0 2.5702352104417514e-06
, O 0 3.7331943758545094e-08
P O 0 8.794522727839649e-06
= O 0 5.184288056625519e-07
5 O 0 9.813558854432358e-09
. O 0 2.4585402602639306e-09
22 O 0 1.922761683204044e-08
x O 0 4.2862640725616075e-07
10 O 0 5.22457490603756e-08
( O 0 2.6608992342858073e-08
- O 0 6.140099344520422e-07
4 O 0 5.5055508596524305e-08
) O 0 6.066878110999596e-09
; O 0 6.081255943257702e-09
SIBPAL O 0 1.2653526937356219e-06
Pempirical O 0 5.344648457139556e-07
value O 0 1.1260553378633631e-08
< O 0 1.3753661676219053e-07
3 O 0 3.221156319455076e-08
x O 0 1.065830929292133e-06
10 O 0 8.71341043762186e-08
( O 0 3.207674126315396e-08
- O 0 1.677498062235827e-06
5 O 0 2.27603109692609e-08
) O 0 2.4474002824348418e-09
) O 0 9.533472900002948e-10
and O 0 7.078208685840082e-09
suggestive O 0 1.440670712327119e-05
evidence O 0 3.452838015505222e-08
for O 0 2.9995212980082897e-09
a O 0 2.254918562982766e-08
locus O 0 5.137897005624836e-06
on O 0 1.391309297105181e-06
chromosome O 0 0.005373834166675806
4q O 0 0.00027020054403692484
at O 0 5.449140871860436e-07
D4S397 O 0 1.404295858264959e-06
( O 0 2.346744309988935e-08
maximum O 0 1.228220583016082e-07
GENEHUNTER O 0 1.2995187717024237e-05
- O 0 3.4062916256516473e-06
PLUS O 0 5.304927412908e-07
nonparametric O 0 4.395069026941201e-06
linkage O 0 6.597344508918468e-06
score O 0 1.791749309631996e-05
= O 0 3.833292339550098e-06
3 O 0 7.895232556620613e-08
. O 0 6.195984170176416e-09
29 O 0 1.0862768817787583e-07
, O 0 7.452246819639186e-09
P O 0 5.076910383650102e-06
= O 0 4.423876873715926e-07
2 O 0 1.0000931638387556e-08
. O 0 2.516933994556325e-09
57 O 0 3.875929976970838e-08
x O 0 4.351380198386323e-07
10 O 0 5.346075226952962e-08
( O 0 2.640735985437459e-08
- O 0 1.2778336895280518e-06
3 O 0 5.8029218763522294e-08
) O 0 4.815691401205413e-09
; O 0 4.566680811279866e-09
SIBPAL O 0 1.1744035646188422e-06
Pempirical O 0 6.406754664567416e-07
value O 0 1.6421864756921423e-08
< O 0 1.459257816804893e-07
1 O 0 2.4814800880790244e-08
x O 0 2.3926088488224195e-06
10 O 0 1.37009820377898e-07
( O 0 4.406057740879987e-08
- O 0 4.2990304791601375e-06
3 O 0 4.635608519265588e-08
) O 0 1.7948305064408032e-09
) O 0 6.546732045364934e-10
that O 0 7.830571746580972e-10
are O 0 2.1285659901337795e-09
linked O 0 3.1133464517552056e-07
to O 0 3.290174532821766e-08
mental O 0 0.03903723880648613
health O 0 6.420556019293144e-06
wellness O 0 2.6285397325409576e-05
. O 0 4.890797526968527e-07

These O 0 1.0480985110916663e-06
findings O 0 6.175999942570343e-07
are O 0 7.435495774643641e-08
consistent O 0 2.1977655251248507e-07
with O 0 2.1043613518401116e-09
the O 0 1.5130197095203357e-09
hypothesis O 0 1.6070607955498417e-08
that O 0 8.135893070360112e-10
certain O 0 1.9006318741077166e-09
alleles O 0 6.755507087063961e-08
could O 0 7.819265590569557e-08
prevent O 0 1.6770344757333078e-07
or O 0 1.9763039205145105e-08
modify O 0 8.49029149208036e-08
the O 0 1.0241319792214654e-08
clinical O 0 6.534561975968245e-07
manifestations O 0 3.0895427016730537e-07
of O 0 2.6571514766260407e-08
BPAD B-Disease 1 1.0
and O 0 1.729234924141565e-07
perhaps O 0 5.403102321110964e-08
other O 0 1.3119800357230815e-08
related O 0 2.5708800421853084e-06
affective B-Disease 1 0.9858241081237793
disorders I-Disease 1 0.9998555183410645
. O 0 9.778628964340896e-07

Segregation O 0 0.0039408705197274685
distortion O 0 0.0033616642467677593
in O 0 2.064983345917426e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.2831634194299113e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999762237071991
DM B-Disease 1 1.0
) O 0 8.31168051718123e-07
is O 0 2.376069652143542e-08
an O 0 2.1214457746054904e-08
autosomal B-Disease 1 0.9975179433822632
dominant I-Disease 1 0.9993976354598999
disease I-Disease 1 0.995711088180542
which O 0 6.06694996463375e-08
, O 0 4.540122056084783e-09
in O 0 9.360641151090476e-10
the O 0 4.148432708461769e-09
typical O 0 1.9424572883508517e-07
pedigree O 0 2.544639937696047e-05
, O 0 7.510337241001253e-09
shows O 0 3.0448763510548815e-08
a O 0 1.1575821190490387e-08
three O 0 2.639809260074344e-08
generation O 0 1.9507442061694746e-07
anticipation O 0 1.328560301772086e-07
cascade O 0 2.4179489628295414e-06
. O 0 3.23655939382661e-07

This O 0 1.2040391084156e-06
results O 0 1.5063277487570303e-06
in O 0 1.7691675679998298e-07
infertility B-Disease 1 0.9989961981773376
and O 0 0.0050353845581412315
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.1415580956963822e-05
CDM B-Disease 0 6.207641854416579e-05
) O 0 2.6573946598773546e-08
with O 0 4.585900992282177e-09
the O 0 6.808254848778006e-09
disappearance O 0 2.424602882911131e-07
of O 0 1.7541305297186227e-08
DM B-Disease 1 1.0
in O 0 5.69007525541565e-08
that O 0 6.132871277486629e-08
pedigree O 0 6.582816422451288e-05
. O 0 5.95620178955869e-07

The O 0 3.457214461377589e-07
concept O 0 8.714290800071467e-08
of O 0 7.153194925280104e-09
segregation O 0 7.775984158797655e-07
distortion O 0 1.68944450251729e-06
, O 0 8.972047105260117e-09
where O 0 3.29260840814527e-09
there O 0 5.406571301769247e-10
is O 0 3.33804678342986e-10
preferential O 0 1.5995198054952198e-08
transmission O 0 3.0853968269184406e-07
of O 0 8.54452730791877e-10
the O 0 2.971912937965726e-09
larger O 0 1.2707102925446634e-08
allele O 0 2.1615804257635318e-07
at O 0 8.546834351363941e-08
the O 0 5.299163063909873e-08
DM B-Disease 1 0.9999991655349731
locus O 0 1.0443646715430077e-05
, O 0 4.171158352050952e-08
has O 0 1.800767002180237e-08
been O 0 2.5335280540161875e-08
put O 0 2.822083011722043e-08
forward O 0 1.609373612154741e-08
to O 0 8.010143659475943e-09
explain O 0 2.449964142670069e-07
partially O 0 1.947455757544958e-06
the O 0 4.723880397961011e-09
maintenance O 0 9.139674830294098e-07
of O 0 2.023070244661085e-08
DM B-Disease 1 1.0
in O 0 4.7802959812770496e-08
the O 0 4.856185853441275e-08
population O 0 1.247646821411763e-07
. O 0 1.7594155110600695e-07

In O 0 1.2339835393504472e-06
a O 0 1.831834879340022e-07
survey O 0 2.1848995856998954e-06
of O 0 7.56569420445885e-08
DM B-Disease 1 1.0
in O 0 1.2819737094105221e-07
Northern O 0 6.995867920522869e-07
Ireland O 0 4.4822613745054696e-06
, O 0 2.8416684116905344e-08
59 O 0 4.212397470837459e-07
pedigrees O 0 8.706408152647782e-06
were O 0 1.426856442776625e-06
ascertained O 0 5.266845164442202e-06
. O 0 1.7029178422944824e-07

Sibships O 0 0.0002870179305318743
where O 0 9.112911243391864e-07
the O 0 2.3821867145557007e-08
status O 0 1.3669314569142443e-08
of O 0 1.0424797691754861e-09
all O 0 3.4210296817605013e-09
the O 0 3.7750949033465986e-09
members O 0 4.2844798819885455e-09
had O 0 2.693937801723223e-07
been O 0 1.8227272136073225e-08
identified O 0 1.8462472439750854e-08
were O 0 9.176233106700238e-09
examined O 0 1.245885350442677e-08
to O 0 2.0586901072761066e-09
determine O 0 4.4041254199100877e-08
the O 0 3.104816848065184e-09
transmission O 0 7.388362632809731e-07
of O 0 8.292277420274274e-10
the O 0 1.6009359171675897e-08
DM B-Disease 1 0.9999967813491821
expansion O 0 4.496139993648285e-08
from O 0 1.3401244558508552e-08
affected O 0 6.475207214862166e-08
parents O 0 3.7430478272426626e-08
to O 0 1.0517513082675123e-08
their O 0 4.6590182023464877e-07
offspring O 0 3.2929106055235025e-06
. O 0 1.72248846297407e-07

Where O 0 2.273218797199661e-06
the O 0 1.3482522831509414e-07
transmitting O 0 0.00011545611778274179
parent O 0 3.5258628940937342e-06
was O 0 1.7936444862698409e-07
male O 0 1.4409341986265645e-07
, O 0 1.1163487023679863e-08
58 O 0 3.219093400730344e-07
. O 0 1.0114887061263289e-07

3 O 0 1.0068256415252108e-05
% O 0 3.5461835068417713e-07
of O 0 3.6761560462394982e-09
the O 0 1.2477474164995783e-08
offspring O 0 9.672006626715302e-07
were O 0 4.645654598789406e-07
affected O 0 3.631687306437925e-08
, O 0 1.6232054589337963e-09
and O 0 4.921736795893139e-09
in O 0 7.980600624790668e-10
the O 0 1.3553519417897064e-09
case O 0 8.308362331455044e-10
of O 0 1.3003841059511245e-10
a O 0 9.568453585018233e-09
female O 0 1.2198432841614704e-06
transmitting O 0 0.00037545611849054694
parent O 0 1.6053993476816686e-06
, O 0 1.7503939631069443e-08
68 O 0 3.4271059234924905e-07
. O 0 1.1620510775856019e-07

7 O 0 5.632804095512256e-05
% O 0 2.1767323232779745e-06
were O 0 1.1890122095792321e-06
affected O 0 1.5904576002867543e-06
. O 0 5.223578796176298e-07

Studies O 0 1.609846185601782e-05
on O 0 8.047356914175907e-07
meiotic O 0 7.282643309736159e-06
drive O 0 2.392296210018685e-06
in O 0 9.704671555255118e-08
DM B-Disease 1 1.0
have O 0 2.946921426882909e-07
shown O 0 3.9323740708141486e-08
increased O 0 1.481999589714178e-08
transmission O 0 3.466729765477794e-07
of O 0 1.5428966992914184e-09
the O 0 3.125810055237821e-09
larger O 0 1.339971067437773e-08
allele O 0 4.1450425669609103e-07
at O 0 9.921082266828307e-08
the O 0 7.886066555329307e-08
DM B-Disease 1 0.9999973773956299
locus O 0 1.3531548574974295e-05
in O 0 2.2545621902736457e-07
non O 0 3.2262316381093115e-05
- O 0 0.13644501566886902
DM O 1 1.0
heterozygotes O 0 4.1745006456039846e-05
for O 0 1.0833966257450811e-07
CTGn O 0 1.918621092045214e-05
. O 0 6.234294005480479e-07

This O 0 8.304678544845956e-08
study O 0 3.22167856836586e-08
provides O 0 1.3492525319236393e-08
further O 0 8.77990391501271e-09
evidence O 0 1.4832694184008233e-08
that O 0 5.401348257549898e-09
the O 0 2.4926370301159295e-08
DM B-Disease 1 0.9999984502792358
expansion O 0 6.873444391430894e-08
tends O 0 2.891102326429973e-07
to O 0 1.4910414236624092e-08
be O 0 3.696661110552668e-08
transmitted O 0 2.71286376118951e-06
preferentially O 0 2.5657998321548803e-06
. O 0 2.3270482074622123e-07

Diagnosis O 1 0.9999033212661743
of O 0 2.445406607876066e-05
hemochromatosis B-Disease 1 1.0
. O 0 3.351346094859764e-05

If O 0 0.000100048360764049
untreated O 0 0.17866244912147522
, O 0 9.604173101251945e-07
hemochromatosis B-Disease 1 1.0
can O 0 0.0016414852580055594
cause O 0 0.0036053855437785387
serious O 0 0.1236213818192482
illness O 0 0.3693813979625702
and O 0 8.241450188961608e-08
early B-Disease 0 3.296267720998003e-07
death I-Disease 0 1.9866901368459366e-07
, O 0 3.7189504809020946e-09
but O 0 4.353054361416753e-09
the O 0 5.012268289306121e-08
disease O 0 2.5768600607989356e-05
is O 0 2.4491981776009197e-09
still O 0 4.231360861695066e-08
substantially O 0 3.735794678050297e-07
under O 0 4.2992252247131546e-07
- O 1 0.6574486494064331
diagnosed O 0 0.013986492529511452
. O 0 2.3263471859991114e-07

The O 0 6.765557714061288e-07
cornerstone O 0 7.32618275378627e-07
of O 0 4.372175954614477e-09
screening O 0 5.292324800620918e-08
and O 0 1.4767147504812783e-08
case O 0 7.2661729966227995e-09
detection O 0 1.303557155551971e-07
is O 0 3.0644042858796183e-09
the O 0 2.365487139499578e-09
measurement O 0 8.408725875597156e-07
of O 0 1.5616565818277195e-08
serum O 0 2.3699922166997567e-06
transferrin O 0 2.1524626845348394e-06
saturation O 0 1.4393249330169056e-06
and O 0 6.041972255843575e-08
the O 0 4.8036024935527166e-08
serum O 0 5.251196853350848e-06
ferritin O 0 3.80318051611539e-05
level O 0 7.608899522892898e-06
. O 0 6.219572696863906e-07

Once O 0 2.9625976821989752e-05
the O 0 2.736024669047765e-07
diagnosis O 0 0.0009800274856388569
is O 0 3.429347827932361e-08
suspected O 0 3.481118710624287e-06
, O 0 1.301239027640122e-08
physicians O 0 1.2415850392244465e-07
must O 0 2.428846634927595e-08
use O 0 1.242589462435717e-07
serum O 0 2.8761072826455347e-05
ferritin O 0 0.00027498090639710426
levels O 0 6.2243350839708e-05
and O 0 8.572120009375794e-07
hepatic O 0 0.00020705186761915684
iron O 0 9.305935964221135e-05
stores O 0 2.558567530286382e-06
on O 0 3.9171411003735557e-07
liver O 0 5.885024802410044e-05
biopsy O 0 0.00012630523997358978
specimens O 0 1.5263429986589472e-07
to O 0 1.843597630113436e-08
assess O 0 5.0035660024150275e-06
patients O 0 1.619037107047916e-06
for O 0 1.1821363887776215e-09
the O 0 7.11873227032811e-09
presence O 0 3.1833067737352394e-08
of O 0 1.0914061654432317e-08
iron B-Disease 0 0.013631857931613922
overload I-Disease 0 0.0001481246144976467
. O 0 7.155857701945934e-07

Liver O 1 0.9999411106109619
biopsy O 1 0.9984733462333679
is O 0 3.754402655431477e-07
also O 0 3.447586394145219e-08
used O 0 2.976719848390985e-08
to O 0 1.1146104483827912e-08
establish O 0 1.468093557832617e-07
the O 0 8.441393362090821e-09
presence O 0 3.996715847165433e-08
or O 0 5.98261635786912e-08
absence O 0 7.172898364160574e-08
of O 0 1.2272413307812258e-08
cirrhosis B-Disease 0 5.435131970443763e-05
, O 0 8.194579237397193e-09
which O 0 9.511572862663797e-09
can O 0 1.9366288483979588e-07
affect O 0 3.916807600035099e-06
prognosis O 0 0.00018318866204936057
and O 0 1.25151856877892e-07
management O 0 5.76405852825701e-07
. O 0 2.660940481291618e-07

A O 0 1.2745203093800228e-05
DNA O 0 6.033310910424916e-06
- O 0 4.673080638895044e-06
based O 0 4.887948534815223e-08
test O 0 6.641417371611169e-08
for O 0 1.7122014916992612e-09
the O 0 1.3233702134129999e-08
HFE O 0 9.825557754084002e-06
gene O 0 2.374473240251973e-07
is O 0 2.438407697979983e-09
commercially O 0 2.3078245092733596e-08
available O 0 5.149521697944692e-09
, O 0 2.339449522992254e-09
but O 0 1.547937222845519e-09
its O 0 1.089907830653658e-09
place O 0 8.736404488729477e-09
in O 0 7.841930993457424e-10
the O 0 7.493481390952184e-09
diagnosis O 0 0.00012096273712813854
of O 0 3.7008092590440356e-08
hemochromatosis B-Disease 1 1.0
is O 0 4.90844627165643e-07
still O 0 6.10747065366013e-07
being O 0 2.751866645667178e-07
evaluated O 0 5.986977384964121e-07
. O 0 1.494455830197694e-07

Currently O 0 2.0486382709350437e-05
, O 0 6.499831073369933e-08
the O 0 5.3661879384492295e-09
most O 0 3.130750103608193e-09
useful O 0 1.0543986128652705e-08
role O 0 1.683311801059517e-08
for O 0 1.4506895684718302e-09
this O 0 1.0282927842553136e-09
test O 0 1.191522684962365e-07
is O 0 6.798078211467384e-10
in O 0 3.209053855979249e-10
the O 0 8.5320356335572e-10
detection O 0 8.098896131514266e-08
of O 0 9.92965532020662e-09
hemochromatosis B-Disease 1 1.0
in O 0 1.6904674993156732e-08
the O 0 6.536628571751635e-09
family O 0 1.661880055792153e-08
members O 0 1.4075752785558393e-09
of O 0 1.3887322403149938e-09
patients O 0 8.629078251942701e-08
with O 0 1.476905486796909e-09
a O 0 2.1636424207827076e-08
proven O 0 8.297417366520676e-07
case O 0 2.5281587934244953e-09
of O 0 7.667201318284356e-10
the O 0 2.4501204620719363e-07
disease O 0 5.7510100305080414e-05
. O 0 9.897947705894694e-08

It O 0 9.268511576010496e-07
is O 0 6.99533444503686e-08
crucial O 0 5.485215979206259e-07
to O 0 1.0646950840964564e-06
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 0 0.04034559056162834
hepatic B-Disease 1 0.999995231628418
cirrhosis I-Disease 1 0.9999376535415649
develops O 0 3.690035009640269e-05
because O 0 3.792049199091707e-07
phlebotomy O 0 0.001917446032166481
therapy O 0 0.0014056807849556208
can O 0 8.212158718379214e-06
avert O 1 0.7994698286056519
serious O 1 0.9970694184303284
chronic O 1 1.0
disease O 1 0.9994542002677917
and O 0 2.1473580602560105e-07
can O 0 3.117717142231413e-07
even O 0 2.6980643497154233e-07
lead O 0 1.287936925109534e-06
to O 0 3.111114210696542e-08
normal O 0 2.614574896142585e-06
life O 0 1.9326989786350168e-07
expectancy O 0 1.43196575663751e-06
. O 0 2.1308620645754672e-08
. O 0 1.391950092965999e-07

Prevalence O 0 0.0034686513245105743
of O 0 2.0334967132384918e-07
the O 0 8.962318531757774e-08
I1307K O 0 2.7709565983968787e-06
APC B-Disease 0 1.482963170928997e-06
gene O 0 3.794335441398289e-07
variant O 0 5.082333132122585e-07
in O 0 8.114046323726143e-09
Israeli O 0 6.070550284675846e-07
Jews O 0 2.515927377544358e-08
of O 0 6.897840076902639e-10
differing O 0 1.848594166631301e-08
ethnic O 0 2.4191423975139514e-08
origin O 0 6.945081310050227e-08
and O 0 1.7571316845987894e-07
risk O 0 7.647793972864747e-05
for O 0 2.895251782319974e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3053501106696785e-06

BACKGROUND O 0 0.0004405123763717711
& O 0 0.00015203199291136116
AIMS O 0 1.0199211828876287e-05
Israeli O 0 2.7484545626066392e-06
Jews O 0 1.1228644325456116e-07
of O 0 3.2862841337077953e-09
European O 0 4.234711923345458e-07
birth O 0 1.0539528375375085e-05
, O 0 1.5565149169560755e-08
i O 0 1.9076645685345284e-07
. O 0 4.3706233077145384e-10
e O 0 5.5199983250986406e-08
. O 0 1.0298158992227968e-09
, O 0 8.187888145272382e-10
Ashkenazim O 0 2.9650252031387936e-07
, O 0 2.351685512991253e-09
have O 0 8.89177353968762e-09
the O 0 6.550534692451038e-08
highest O 1 0.9987672567367554
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.03857947140932083
of O 0 1.1987483894415618e-08
any O 0 7.275579605448002e-08
Israeli O 0 3.42085404554382e-05
ethnic O 0 3.074452479268075e-07
group O 0 5.930293696110311e-07
. O 0 1.1034337887849688e-07

The O 0 3.2446084787807195e-06
I1307K O 0 2.6907462597591802e-05
APC B-Disease 0 6.761766144336434e-06
gene O 0 1.9983092442998895e-06
variant O 0 6.984374522289727e-06
was O 0 9.70401174527069e-07
found O 0 5.108300271672306e-08
in O 0 1.387970272048733e-08
6 O 0 4.145793752741156e-07
. O 0 2.551332727307454e-07

1 O 0 9.253036296286155e-06
% O 0 4.919318143947748e-07
of O 0 1.0704209962852929e-08
American O 0 6.488930637260637e-08
Jews O 0 6.439906741206869e-08
, O 0 5.456008089765874e-09
28 O 0 1.3951417798807597e-08
% O 0 3.114158042549775e-09
of O 0 2.333905291251881e-09
their O 0 4.025985981570557e-05
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 6.939393642824143e-06
, O 0 2.0564502989373068e-08
but O 0 1.3137929855133734e-08
not O 0 9.021398739150754e-09
in O 0 4.9036148475067876e-09
non O 0 9.682730706117582e-07
- O 0 4.90680713483016e-06
Jews O 0 3.0073829293542076e-07
. O 0 7.565274984244752e-08

We O 0 1.0889018994930666e-05
assessed O 0 3.1162148843577597e-06
the O 0 7.332111096047811e-08
I1307K O 0 1.8234526351079694e-06
prevalence O 0 3.6198835005052388e-06
in O 0 7.686005609741642e-09
Israeli O 0 3.758809441478661e-07
Jews O 0 1.9955686880734902e-08
of O 0 7.50520645631525e-10
differing O 0 2.4632962336568198e-08
ethnic O 0 1.6236860744811565e-08
origin O 0 5.096641331192586e-08
and O 0 1.1874570304826193e-07
risk O 0 5.720881017623469e-05
for O 0 3.2176616514334455e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.4609080380978412e-06

METHODS O 0 2.9072793040541e-05
DNA O 0 4.927816462441115e-06
samples O 0 5.388271233641717e-07
from O 0 1.630899326698909e-08
500 O 0 2.699252732440982e-08
unrelated O 0 3.829035222224775e-08
Jews O 0 2.0291606617206526e-08
of O 0 1.7776933258772942e-09
European O 0 3.79464324851142e-07
or O 0 5.336855224413739e-07
non O 0 2.4676849079696694e-06
- O 0 2.1843393369636033e-06
European O 0 2.7003838454220386e-07
origin O 0 1.868879806465884e-08
, O 0 2.4175865753761627e-09
with O 0 4.076124771046352e-09
or O 0 1.0950472528747923e-07
without O 0 1.1102353703051904e-08
a O 0 2.568770085531469e-09
personal O 0 6.364297178151901e-07
and O 0 1.21634195693332e-06
/ O 0 1.7223128452314995e-05
or O 0 7.705442044425581e-07
family O 0 3.406491799751166e-08
history O 0 1.2595020137950996e-08
of O 0 4.913651263649399e-09
neoplasia B-Disease 0 3.0539486033376306e-05
, O 0 2.5680071402689464e-08
were O 0 2.629375615015306e-07
examined O 0 1.8450369054789917e-07
for O 0 2.898836060083454e-09
the O 0 6.7328387309828486e-09
I1307K O 0 2.907102327753819e-07
variant O 0 1.3686994293493626e-07
by O 0 3.7845464539998375e-09
the O 0 6.489546677812541e-09
allele O 0 3.8713685057700786e-07
- O 0 1.5140140874336794e-07
specific O 0 2.4776587892461066e-08
oligonucleotide O 0 2.5537749479553895e-06
( O 0 1.0448993492673253e-07
ASO O 0 3.249661676818505e-05
) O 0 1.8308806915001696e-08
method O 0 2.6882736392508377e-07
. O 0 1.748039295534909e-07

RESULTS O 0 8.01386559032835e-05
In O 0 8.389231709315936e-08
persons O 0 1.6569322269788245e-07
at O 0 7.148164371528765e-08
average O 0 5.036355105403345e-06
risk O 0 4.9953479901887476e-05
for O 0 1.5797617379575968e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.1954444662242167e-07
I1307K O 0 3.1576423680235166e-06
was O 0 9.998339010053314e-07
found O 0 5.8020805937530895e-08
in O 0 1.1975302527389431e-08
5 O 0 1.3724206837650854e-07
. O 0 2.0496000274761172e-07

0 O 0 3.6017107049701735e-05
% O 0 8.611474413555698e-07
of O 0 1.163490015443358e-08
120 O 0 4.546294363194647e-08
European O 0 3.9281690078496467e-07
and O 0 1.226842840651443e-07
1 O 0 2.1891868584589247e-07
. O 0 1.5940108255563246e-07

6 O 0 2.657439654285554e-05
% O 0 4.7396000013577577e-07
of O 0 1.3904186246804784e-08
188 O 0 1.3917934893470374e-07
non O 0 5.627662176266313e-07
- O 0 1.6275049574687728e-06
European O 0 2.626894115564937e-07
Jews O 0 1.9014164820418955e-07
( O 0 4.158392385988918e-08
P O 0 4.6518118324456736e-05
= O 0 4.9320387915940955e-06
0 O 0 1.2359993206700892e-07
. O 0 1.2125457082845514e-08
08 O 0 4.5219454136713466e-07
) O 0 7.538095303516457e-08
. O 0 1.4153810923289711e-07

It O 0 4.087235993210925e-06
occurred O 0 1.5026648725324776e-06
in O 0 6.83597320971785e-08
15 O 0 3.1754694873598055e-07
. O 0 1.6962624727057118e-07

4 O 0 1.4329193618323188e-05
% O 0 7.143515858842875e-07
of O 0 2.1604092736993152e-08
52 O 0 6.677618102912675e-07
Ashkenazi O 0 7.491778433177387e-06
Israelis O 0 2.032660404438502e-06
with O 0 1.5451112744813145e-07
familial O 1 0.99899822473526
cancer B-Disease 1 0.8258474469184875
( O 0 3.1017381729725457e-07
P O 0 0.002888440852984786
= O 0 2.5200510208378546e-05
0 O 0 1.8432903914344934e-07
. O 0 1.049791276130918e-08
02 O 0 1.3436510926112533e-06
) O 0 6.735446422823088e-09
and O 0 2.586283187611116e-08
was O 0 4.4128034915047465e-07
not O 0 9.849468796119254e-09
detected O 0 1.084562697428737e-07
in O 0 1.8262724665873975e-09
51 O 0 1.3765786377462064e-07
non O 0 7.694076487041457e-08
- O 0 1.4253724600621354e-07
European O 0 4.257720931377662e-08
Jews O 0 4.78271253712137e-08
at O 0 1.4334439413232758e-07
increased O 0 2.5818405902100494e-06
cancer B-Disease 0 0.00020472756295930594
risk O 0 4.395944870339008e-06
. O 0 1.297373444231198e-07

Colorectal B-Disease 1 0.9999527931213379
neoplasia I-Disease 1 0.8460577726364136
occurred O 0 0.00010109599679708481
personally O 0 5.6534259783802554e-05
or O 0 1.0455448773427634e-06
in O 0 9.059506034247988e-09
the O 0 5.9827285348035275e-09
families O 0 1.477850197773023e-08
of O 0 3.160700590143506e-10
13 O 0 9.529550482056948e-09
of O 0 9.222551056176087e-10
20 O 0 1.8225883025024814e-08
Ashkenazi O 0 6.745463565493992e-07
I1307K O 0 2.29579569577254e-07
carriers O 0 5.378241141329454e-08
, O 0 1.3535073062342917e-09
8 O 0 3.848950047569133e-09
of O 0 9.376152076967514e-10
whom O 0 1.021970277292894e-07
also O 0 7.990447414840673e-08
had O 0 4.0454406757817196e-07
a O 0 7.366520726748149e-09
personal O 0 1.7716101865516976e-06
or O 0 1.8358325633016648e-06
family O 0 6.686769182806529e-08
history O 0 4.927732177861799e-08
of O 0 4.1572189246608104e-08
noncolonic O 0 0.0004554293991532177
neoplasia B-Disease 0 0.002538087544962764
. O 0 1.2168966350145638e-06

CONCLUSIONS O 0 5.6378019507974386e-05
The O 0 9.349796528113075e-07
I1307K O 0 1.3572880561696365e-05
APC O 0 6.052040134818526e-06
variant O 0 7.37281743568019e-06
may O 0 3.2728252108427114e-07
represent O 0 2.6327995783503866e-08
a O 0 1.4823049454548709e-08
susceptibility O 0 3.1173208299151156e-06
gene O 0 2.3399472866003634e-06
for O 0 1.4671837789137498e-07
colorectal B-Disease 1 1.0
, I-Disease 0 1.3813814803143032e-07
or I-Disease 0 9.392142885644716e-08
other I-Disease 0 1.5691567156750352e-08
, I-Disease 0 2.969665047203307e-08
cancers I-Disease 0 0.002161215990781784
in O 0 4.3582883968440456e-09
Ashkenazi O 0 2.1121047666383674e-06
Jews O 0 8.941266571582673e-08
, O 0 4.657611629710345e-09
and O 0 1.7838623023180844e-08
partially O 0 2.122244723068434e-06
explains O 0 2.8137202789935145e-08
the O 0 3.0573283904544724e-09
higher O 0 1.0920166459982283e-07
incidence O 0 0.001207177061587572
of O 0 3.04531986330403e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.646393467870439e-08
European O 0 6.847444183222251e-06
Israelis O 0 2.1958054276183248e-05
. O 0 3.3528417020534107e-07

Systematic O 0 9.86774011835223e-06
analysis O 0 1.389108547300566e-06
of O 0 2.0219309249114303e-07
coproporphyrinogen O 0 0.0002376955671934411
oxidase O 0 0.00040225122938863933
gene O 0 0.0012443808373063803
defects O 1 0.9765241146087646
in O 0 1.3196010684168868e-07
hereditary B-Disease 1 0.7455618381500244
coproporphyria I-Disease 0 0.0004415939620230347
and O 0 7.353685305133695e-07
mutation O 0 6.661919178441167e-05
update O 0 7.393356554530328e-06
. O 0 8.377222115996119e-07

Hereditary B-Disease 1 0.9999752044677734
coproporphyria I-Disease 1 0.7986269593238831
( O 0 3.603613731684163e-05
HC B-Disease 0 0.2992197871208191
) O 0 3.22315429457376e-07
is O 0 5.610541364831079e-08
an O 0 4.575741741064121e-07
acute O 1 0.9999690055847168
hepatic B-Disease 1 0.9999972581863403
porphyria I-Disease 1 0.9999992847442627
with O 0 4.5318115553527605e-06
autosomal O 1 0.9998307228088379
dominant O 0 0.12948189675807953
inheritance O 0 9.980984032154083e-05
caused O 0 5.1209417506470345e-06
by O 0 2.5708203565955046e-08
deficient B-Disease 0 5.076353772892617e-06
activity I-Disease 0 6.86589700649165e-08
of I-Disease 0 1.5253032614737094e-08
coproporphyrinogen I-Disease 0 1.4255331734602805e-05
III I-Disease 0 7.5725092756329104e-06
oxidase I-Disease 0 1.0207055311184376e-05
( O 0 3.491501274766051e-07
CPO O 0 9.849387424765155e-06
) O 0 9.148206459030916e-08
. O 0 1.2497700652147614e-07

Clinical O 0 0.009683377109467983
manifestations O 0 1.7219630535691977e-05
of O 0 4.703958822460663e-08
the O 0 7.030646997918666e-07
disease O 0 0.09529180824756622
are O 0 1.3387347230775504e-08
characterized O 0 3.15923642801863e-07
by O 0 1.670377791640476e-08
acute O 0 0.0034480071626603603
attacks O 0 2.953041075670626e-05
of O 0 3.8603855045948876e-07
neurological B-Disease 1 0.9999997615814209
dysfunction I-Disease 0 0.4445880651473999
often O 0 7.412138529616641e-07
precipitated O 0 2.9111058097441855e-07
by O 0 4.382002316560829e-09
drugs O 0 2.8201837309893563e-08
, O 0 3.7247713802202043e-09
fasting O 0 7.47897743735848e-08
, O 0 3.769569101308434e-09
cyclical O 0 6.736393515893724e-06
hormonal O 0 1.0313385246263351e-05
changes O 0 2.6601735925169123e-08
, O 0 1.3681834332146536e-08
or O 0 2.2425033421313856e-06
infectious B-Disease 0 0.0009379006805829704
diseases I-Disease 0 0.0004693118971772492
. O 0 3.6376707157614874e-07

Skin O 1 0.9999996423721313
photosensitivity O 1 0.9998273253440857
may O 0 0.013723880983889103
also O 0 4.0167503811971983e-07
be O 0 4.411801413084504e-08
present O 0 9.785357946157092e-08
. O 0 1.6627114973744028e-07

The O 0 1.826073344091128e-06
seven O 0 5.404513672147004e-07
exons O 0 1.7411707631254103e-06
, O 0 3.7806454855626725e-08
the O 0 1.5444550527377032e-08
exon O 0 1.482821858189709e-06
/ O 0 2.947836264866055e-06
intron O 0 2.209454760304652e-05
boundaries O 0 1.0087447662954219e-05
and O 0 7.038027405315006e-08
part O 0 7.306824922892474e-09
of O 0 2.2529658139092135e-09
3 O 0 1.6890943754788168e-08
noncoding O 0 2.821992381996097e-07
sequence O 0 3.9328092782398016e-08
of O 0 3.7476182157547555e-09
the O 0 1.633826052227505e-08
CPO O 0 2.7169287477590842e-06
gene O 0 2.904743894305284e-07
were O 0 1.265304234721043e-07
systematically O 0 5.02609282193589e-07
analyzed O 0 3.081379418290453e-08
by O 0 9.111767451663866e-10
an O 0 1.0614504830641636e-09
exon O 0 1.7267728935621562e-07
- O 0 3.0600608624808956e-07
by O 0 1.4528279912440212e-08
- O 0 8.285081776193692e-07
exon O 0 5.235076514509274e-06
denaturing O 0 6.862150621600449e-05
gradient O 0 3.1169704016065225e-05
gel O 0 0.0006527216173708439
electrophoresis O 0 3.6411354813026264e-05
( O 0 3.606949974255258e-07
DGGE O 0 4.335062840254977e-06
) O 0 1.5643186301872447e-08
strategy O 0 2.5702320272102952e-08
followed O 0 6.681972752886622e-09
by O 0 6.331865587405616e-10
direct O 0 3.4392175773945155e-09
sequencing O 0 6.033323529663903e-08
in O 0 9.142271828466164e-09
seven O 0 5.012822867911382e-08
unrelated O 0 1.3948682919817657e-07
heterozygous O 0 7.711514626862481e-06
HC B-Disease 0 9.248918649973348e-05
patients O 0 9.674483408161905e-06
from O 0 4.25178043883534e-08
France O 0 4.2421856051078066e-05
, O 0 4.01883077927323e-08
Holland O 0 9.759067324921489e-06
, O 0 2.431757906151688e-08
and O 0 9.246918608596388e-08
Czech O 0 2.1289673895807937e-05
Republic O 0 1.0430121619720012e-06
. O 0 3.2960102203105635e-07

Seven O 0 1.4984823792474344e-05
novel O 0 3.2624338928144425e-06
mutations O 0 6.546452823386062e-06
and O 0 4.005071829737972e-08
two O 0 1.8224248776732566e-08
new O 0 6.712120637075714e-08
polymorphisms O 0 0.0007084915414452553
were O 0 2.198127276642481e-06
detected O 0 9.486838280281518e-06
. O 0 2.906844542849285e-07

Among O 0 1.9377405351406196e-06
these O 0 1.2730895093682193e-07
mutations O 0 1.6454399656140595e-06
two O 0 5.184866580520975e-08
are O 0 5.4899686574572115e-08
missense O 0 4.99933503306238e-06
( O 0 7.899073040107396e-08
G197W O 0 1.2576891776916455e-06
, O 0 1.4778079204802452e-08
W427R O 0 3.389728249203472e-07
) O 0 4.5110244428769875e-09
, O 0 1.3141382426695714e-09
two O 0 4.942469988833409e-09
are O 0 3.3613570593615805e-08
nonsense O 0 6.513799917229335e-07
( O 0 1.120155879164031e-08
Q306X O 0 2.6974316824635025e-07
, O 0 5.174933814799942e-09
Q385X O 0 8.788286010030788e-08
) O 0 1.9554999841631115e-09
, O 0 6.823748233131255e-10
two O 0 1.8426510317581801e-09
are O 0 3.106594093083004e-09
small O 0 1.2498626134060942e-08
deletions O 0 1.3149233382137027e-06
( O 0 9.699101610749494e-08
662de14bp O 0 7.78439073201298e-07
; O 0 2.6290260635164486e-08
1168del3bp O 0 5.528638098439842e-07
removing O 0 1.2873644550381869e-07
a O 0 6.008997299744578e-09
glycine O 0 1.8946792579299654e-07
at O 0 8.363413428469357e-08
position O 0 1.3270508247842372e-07
390 O 0 1.2913490721189191e-08
) O 0 2.579443769690215e-09
, O 0 1.7078830572003767e-09
and O 0 5.243620204709032e-09
one O 0 4.6989434565603005e-09
is O 0 1.1277270228760017e-09
a O 0 7.071178753648155e-09
splicing O 0 1.9173326109012123e-06
mutation O 0 2.3120114747143816e-06
( O 0 8.88679210220289e-08
IVS1 O 0 3.789731636061333e-06
- O 0 1.4919709201421938e-06
15c O 0 4.570343662635423e-06
- O 0 6.522317562485114e-06
- O 0 3.5243501770310104e-06
> O 0 6.060647024241916e-07
g O 0 6.595341233150975e-07
) O 0 3.1974227709952174e-09
which O 0 2.007597421638252e-09
creates O 0 1.6261592961086535e-08
a O 0 3.0304190268282127e-09
new O 0 6.046408262960767e-09
acceptor O 0 3.848857090815727e-07
splice O 0 4.9737151130102575e-05
site O 0 6.1205364545458e-06
. O 0 1.4973347788327374e-06

The O 0 5.680753929482307e-07
pathological O 0 1.0711490858739126e-06
significance O 0 5.959236659691669e-08
of O 0 5.2027542274402094e-09
the O 0 9.496871733460921e-09
point O 0 2.24762814582391e-07
mutations O 0 1.2252378382981988e-06
G197W O 0 2.951646536075714e-07
, O 0 7.339355345692411e-09
W427R O 0 1.3225883321865695e-07
, O 0 4.001923681329345e-09
and O 0 4.994153979254179e-09
the O 0 7.092723741664031e-09
in O 0 8.524509098606359e-09
- O 0 4.026494934805669e-06
frame O 0 2.9925005947006866e-05
deletion O 0 9.812205462367274e-06
390delGly O 0 2.5360552626807475e-06
were O 0 9.136871170767336e-08
assessed O 0 2.0319415483527337e-08
by O 0 1.2205596533476637e-09
their O 0 5.4535531646138224e-09
respective O 0 4.3846551278647894e-08
expression O 0 1.1482736539392135e-08
in O 0 1.0327959598654957e-09
a O 0 2.41374387144333e-09
prokaryotic O 0 1.1794388576902293e-08
system O 0 8.735637990753276e-09
using O 0 1.9995693989471874e-08
site O 0 4.057650357935927e-07
- O 0 1.862583076217561e-06
directed O 0 6.596624757548852e-07
mutagenesis O 0 1.6032030544010922e-05
. O 0 4.4508163909995346e-07

These O 0 1.97482472685806e-06
mutations O 0 2.3046211936161853e-05
resulted O 0 1.696712246257448e-07
in O 0 9.257839828080705e-09
the O 0 1.0241671510868855e-08
absence O 0 2.06074460606942e-07
or O 0 5.214022635868787e-08
a O 0 1.3925151698401805e-08
dramatic O 0 1.2799434045973612e-07
decrease O 0 3.581369298899517e-07
of O 0 1.540838923119736e-08
CPO O 0 6.9813640948268585e-06
activity O 0 1.195437334899907e-06
. O 0 4.2874495420619496e-07

The O 0 1.5769478522997815e-06
two O 0 2.3207054766771762e-07
polymorphisms O 0 6.280212255660444e-05
were O 0 5.318939884091378e-07
localized O 0 5.130505087436177e-07
in O 0 1.0015879681191109e-08
noncoding O 0 3.802718140377692e-07
part O 0 1.626717782698961e-08
of O 0 1.88579774018649e-09
the O 0 3.4521909775264703e-09
gene O 0 4.037808309931279e-08
1 O 0 8.253306482686185e-09
) O 0 3.5656495533942234e-09
a O 0 1.3207173132911976e-08
C O 0 2.6752761641546385e-06
/ O 0 1.2814190313292784e-06
G O 0 7.559424943792692e-07
polymorphism O 0 1.096020582735946e-06
in O 0 1.3845277813118173e-08
the O 0 1.1162741841985735e-08
promotor O 0 1.991260887734825e-06
region O 0 1.1908365848967151e-07
, O 0 7.3431922764655155e-09
142 O 0 3.3687381773006564e-08
bp O 0 3.455585897427227e-07
upstream O 0 4.7261899283057573e-08
from O 0 2.3188275743990516e-09
the O 0 1.9357946356990396e-09
transcriptional O 0 8.560326136830554e-08
initiation O 0 4.026203370699477e-08
site O 0 1.7176984101752168e-07
( O 0 5.321608043118431e-08
- O 0 7.948506208776962e-07
142C O 0 1.7654102748565492e-06
/ O 0 1.2752502698276658e-06
G O 0 1.0919766282313503e-06
) O 0 6.124429408060905e-09
, O 0 3.2627258672590642e-09
and O 0 8.019850561424846e-09
2 O 0 7.4080444001367596e-09
) O 0 1.2683294414728152e-09
a O 0 5.948014081269548e-09
6 O 0 6.195714519208195e-08
bp O 0 4.0712288296163024e-07
deletion O 0 3.744762011592684e-07
polymorphism O 0 6.853323384348187e-07
in O 0 6.855242151715402e-09
the O 0 7.1902372944521176e-09
3 O 0 1.4407634196800245e-08
noncoding O 0 1.5849975909532077e-07
part O 0 1.5001985431695175e-08
of O 0 2.8288233977491473e-09
the O 0 1.0799054983579026e-08
CPO O 0 9.672522764958558e-07
gene O 0 1.5322642354931304e-07
, O 0 6.6260796849348935e-09
574 O 0 1.049293132382445e-07
bp O 0 2.8398946483321197e-07
downstream O 0 2.4695813394259858e-08
of O 0 1.6202080788119133e-09
the O 0 5.334776176368905e-09
last O 0 1.0596607147306258e-08
base O 0 1.2917924507860334e-08
of O 0 1.4115919544366307e-09
the O 0 1.2531591764286532e-08
normal O 0 2.548069630847749e-07
termination O 0 6.751326964149484e-07
codon O 0 1.922506953633274e-06
( O 0 8.228899872619877e-08
+ O 0 9.044572948369023e-07
574 O 0 1.7996479755311157e-06
delATTCTT O 0 3.072974095630343e-06
) O 0 7.904543508630013e-08
. O 0 1.3347118965612026e-07

Five O 0 1.6697902537998743e-05
intragenic O 0 4.613988858181983e-05
dimorphisms O 0 3.0288254492916167e-05
are O 0 1.7996653411955776e-07
now O 0 6.615424297251593e-08
well O 0 2.9840698800853716e-08
characterized O 0 1.6167152239177085e-07
and O 0 2.7360915311192002e-08
the O 0 7.0378898264777945e-09
high O 0 7.405349577993547e-08
degree O 0 9.61451895875598e-09
of O 0 3.056687125635449e-09
allelic O 0 7.473814207514806e-07
heterogeneity O 0 4.1805370187830704e-07
in O 0 3.1098679187380185e-08
HC B-Disease 0 0.0011179018765687943
is O 0 4.991242263940876e-08
demonstrated O 0 2.200927973206035e-08
with O 0 1.6137068348243133e-09
seven O 0 3.5565750344801472e-09
new O 0 8.215984559356571e-10
different O 0 2.384440200842164e-09
mutations O 0 1.6980138184408133e-07
making O 0 6.1146248064858355e-09
a O 0 5.160139870952207e-09
total O 0 4.233554395938199e-09
of O 0 1.2876321120458556e-09
nineteen O 0 1.3608540712084505e-06
CPO O 0 0.00010795799607876688
gene B-Disease 0 6.452891830122098e-05
defects I-Disease 0 0.4541407823562622
reported O 0 1.0591262480375008e-06
so O 0 4.776559237029687e-08
far O 0 6.856959089418524e-08
. O 0 1.51286752014812e-08
. O 0 1.0986644838339998e-07

Coincidence O 0 1.5011713912826963e-05
of O 0 1.3783349572804582e-07
two O 0 2.108985910354022e-07
novel O 0 5.034679588789004e-07
arylsulfatase O 0 2.6872303351410665e-06
A O 0 1.1550572054375152e-07
alleles O 0 8.783942462287087e-07
and O 0 9.362095454434893e-08
mutation O 0 6.120302714407444e-06
459 O 0 1.895548052743834e-06
+ O 0 2.362752638873644e-06
1G O 0 4.531028389465064e-05
> O 0 3.39923690262367e-06
A O 0 2.7415671866037883e-07
within O 0 4.18321306483449e-08
a O 0 6.65371615582444e-08
family O 0 3.088172775278508e-07
with O 0 1.0149533409276046e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 3.210753263260813e-08
molecular O 0 1.5828042876364634e-07
basis O 0 8.091362246887002e-08
of O 0 1.4840928486137273e-08
phenotypic O 0 4.050447387271561e-05
heterogeneity O 0 5.182133463677019e-05
. O 0 2.1607922917610267e-06

In O 0 1.5457982271982473e-06
a O 0 2.2340515215546475e-07
family O 0 8.895254666185792e-08
with O 0 9.256356570119806e-09
three O 0 6.482856207412624e-08
siblings O 0 1.5648429325665347e-05
, O 0 3.340940191165487e-09
one O 0 2.9216220553962557e-09
developed O 0 6.956774711852631e-08
classical O 0 3.334630207518785e-07
late O 0 2.1975001800456084e-05
infantile O 1 0.9998773336410522
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 3.263758844695985e-05
MLD B-Disease 1 0.9999985694885254
) O 0 1.8829203440873243e-07
, O 0 2.6847065015545013e-08
fatal O 0 1.62984142662026e-05
at O 0 5.565859737544088e-07
age O 0 7.615902859470225e-07
5 O 0 1.6580585793235514e-08
years O 0 1.3289196409971282e-08
, O 0 5.610281572643316e-09
with O 0 3.534921688697068e-08
deficient O 0 0.00012635259190574288
arylsulfatase O 0 3.96565474147792e-06
A O 0 1.6169309446922853e-07
( O 0 4.717400159393037e-08
ARSA O 0 9.004784260469023e-06
) O 0 9.15623221686701e-09
activity O 0 5.123053270494893e-08
and O 0 1.0978744136025398e-08
increased O 0 1.598678665004627e-07
galactosylsulfatide O 0 3.753629789571278e-05
( O 0 6.143467317087925e-07
GS O 1 0.9999990463256836
) O 0 1.6996922624912258e-07
excretion O 0 2.4091839350148803e-06
. O 0 5.472571729114861e-07

The O 0 8.895897281036014e-07
two O 0 1.038412520415477e-07
other O 0 2.4263833608983987e-08
siblings O 0 7.681415809202008e-06
, O 0 4.2849805481637304e-08
apparently O 0 1.993292016777559e-06
healthy O 0 1.7043865341292985e-07
at O 0 2.550784827803909e-08
12 O 0 1.866454013565999e-08
( O 0 2.2428001678065357e-09
1 O 0 7.650639233247603e-09
/ O 0 1.7464462587213347e-07
2 O 0 2.3069311794188252e-08
) O 0 2.3264872250905455e-09
and O 0 1.426465257026166e-08
15 O 0 1.8136343982178005e-08
years O 0 3.198691533867759e-09
, O 0 1.3944813082034102e-09
respectively O 0 3.340521104178151e-08
, O 0 8.517224148185676e-10
and O 0 5.51934276060706e-09
their O 0 5.578316475407519e-08
father O 0 2.641882588250155e-07
, O 0 6.304333499684844e-09
apparently O 0 2.1194038879457366e-07
healthy O 0 1.651887515663475e-08
as O 0 2.5533342107308954e-09
well O 0 6.37996100394389e-09
, O 0 2.81843459681852e-09
presented O 0 4.8920519191142375e-08
ARSA O 0 5.8061970776179805e-05
and O 0 1.5263938166754087e-06
GS O 1 0.9999982118606567
values O 0 2.1138083639016259e-07
within O 0 6.9970669258623275e-09
the O 0 4.6438359824207964e-09
range O 0 1.279727257497143e-07
of O 0 7.36181888782994e-08
MLD B-Disease 1 0.9999998807907104
patients O 0 4.0246537537314e-05
. O 0 2.6921219387077144e-07

Mutation O 0 7.645753066753969e-05
screening O 0 4.6009072320885025e-06
and O 0 1.7423190001863986e-07
sequence O 0 2.538232592996792e-07
analysis O 0 1.6177639849956904e-07
disclosed O 0 5.481680886987306e-07
the O 0 6.7852958807179675e-09
involvement O 0 2.143883293115323e-08
of O 0 1.5074372861079155e-09
three O 0 1.0250739812533993e-08
different O 0 3.957746841365406e-08
ARSA O 0 0.0013060842175036669
mutations O 0 7.471558546967572e-06
being O 0 4.228117589377689e-08
the O 0 2.774198870625355e-09
molecular O 0 5.721505402789262e-08
basis O 0 3.960208516673447e-08
of O 0 2.2166338098372762e-08
intrafamilial O 0 1.4768923392693978e-05
phenotypic O 0 6.386201857822016e-05
heterogeneity O 0 7.732758967904374e-05
. O 0 4.1026496546692215e-06

The O 0 2.711242132136249e-06
late O 0 5.272469024930615e-06
infantile O 1 0.8475102186203003
patient O 0 0.03605760261416435
inherited O 0 0.00132983666844666
from O 0 7.200725349321146e-08
his O 0 9.024454357131617e-07
mother O 0 5.0215016926813405e-06
the O 0 1.7969448151688994e-08
frequent O 0 1.3012000863454887e-06
0 O 0 3.716860874192207e-06
- O 0 1.1836364137707278e-05
type O 0 5.624248296953738e-05
mutation O 0 4.155858277954394e-06
459 O 0 9.402858722751262e-07
+ O 0 5.953623940513353e-07
1G O 0 3.904209734173492e-06
> O 0 5.232772650742845e-07
A O 0 2.261668754499624e-07
, O 0 1.4154966976320793e-08
and O 0 1.952765238399934e-08
from O 0 9.552989510552834e-09
his O 0 1.9156826169819396e-07
father O 0 9.671869065641658e-07
a O 0 1.1749483164180674e-08
novel O 0 2.303237955914028e-08
, O 0 5.966102722965161e-09
single O 0 2.615976484321436e-07
basepair O 0 1.659538270359917e-06
microdeletion O 0 4.566652478388278e-07
of O 0 2.6684607856708453e-09
guanine O 0 1.0997442245752609e-07
at O 0 5.133832914339109e-08
nucleotide O 0 3.1917642218104447e-07
7 O 0 2.767831652761288e-08
in O 0 3.0287377050797204e-09
exon O 0 3.8167425486790307e-07
1 O 0 9.713319570892054e-08
( O 0 5.251359525004773e-08
7delG O 0 2.6213808723696275e-06
) O 0 1.0252111337649694e-07
. O 0 1.9658679661915812e-07

The O 0 2.7511239295563428e-06
two O 0 9.438193160349329e-07
clinically O 0 0.004791848361492157
unaffected O 0 1.2811899978260044e-05
siblings O 0 3.783549118452356e-06
carried O 0 3.5495432371135394e-07
the O 0 3.5173950863054415e-08
maternal O 0 2.3044827685225755e-05
mutation O 0 2.7123360268888064e-06
459 O 0 7.750819008833787e-07
+ O 0 1.1716593917299178e-06
1G O 0 1.019056981022004e-05
> O 0 8.244930427281361e-07
A O 0 2.3319580577663146e-07
and O 0 8.525829997552137e-08
, O 0 3.1245344089825267e-09
on O 0 8.080300872848056e-09
their O 0 3.593041242311301e-08
paternal O 0 3.609042551033781e-06
allele O 0 6.326886250462849e-07
, O 0 5.955756332554074e-09
a O 0 9.630744202127062e-09
novel O 0 3.082625710248976e-08
cytosine O 0 1.1923025056148617e-07
to O 0 4.980949430688497e-09
thymidine O 0 7.337580427702051e-07
transition O 0 1.794012121081323e-07
at O 0 1.513015348564295e-07
nucleotide O 0 1.4803816839048523e-06
2435 O 0 2.8582751383510185e-06
in O 0 1.750347244922068e-08
exon O 0 4.1320060972793726e-07
8 O 0 1.222256713617753e-07
, O 0 6.631314164451396e-09
resulting O 0 1.3659879449789969e-08
in O 0 1.6834457161607475e-09
substitution O 0 1.2410826144559906e-08
of O 0 5.743336917163333e-09
alanine O 0 7.448359156114748e-06
464 O 0 7.875842698013003e-07
by O 0 9.79443299797822e-08
valine O 0 5.767771654063836e-05
( O 0 1.5051016077904933e-07
A464V O 0 2.328114533156622e-06
) O 0 1.5839337663692277e-07
. O 0 9.738585760032947e-08

The O 0 4.571294084598776e-06
fathers O 0 3.628453123383224e-05
genotype O 0 4.0332492062589154e-05
thus O 0 1.006475145004515e-06
was O 0 5.981167987556546e-07
7delG O 0 1.0425545951875392e-05
/ O 0 1.7247963114641607e-05
A464V O 0 3.85391540476121e-05
. O 0 8.789389198682329e-07

Mutation O 0 0.00045355738257057965
A464V O 0 0.00010668554023141041
was O 0 4.214043201500317e-06
not O 0 7.818460545649941e-08
found O 0 3.210159249533717e-08
in O 0 4.822566346263102e-09
18 O 0 1.4130128533906827e-07
unrelated O 0 2.884769855882041e-06
MLD B-Disease 1 0.9999998807907104
patients O 0 0.00020251622481737286
and O 0 8.780142479736242e-08
50 O 0 1.1989340009677107e-07
controls O 0 1.0134348485735245e-05
. O 0 6.332348903015372e-07

A464V O 0 0.0001375341962557286
, O 0 5.070230031378742e-07
although O 0 7.849300942552873e-08
clearly O 0 2.71243465022053e-07
modifying O 0 1.0552415687925532e-06
ARSA O 0 0.00020499205857049674
and O 0 3.431731101954938e-06
GS O 1 1.0
levels O 0 7.159985398175195e-05
, O 0 2.1380110126756335e-08
apparently O 0 9.834605663172624e-08
bears O 0 3.379433977102053e-08
little O 0 3.3354263795359884e-09
significance O 0 9.157769653711512e-09
for O 0 4.517430429729075e-09
clinical O 0 2.6517900550970808e-06
manifestation O 0 6.37388211544021e-07
of O 0 6.535633900739413e-08
MLD B-Disease 1 0.9999997615814209
, O 0 1.5532178565536015e-07
mimicking O 0 7.932626431284007e-06
the O 0 1.9762667591294303e-07
frequent O 0 1.810538742574863e-05
ARSA O 0 0.07823656499385834
pseudodeficiency O 0 0.00015949711087159812
allele O 0 3.402553193154745e-05
. O 0 1.1806811244241544e-06

Our O 0 1.846763552748598e-05
results O 0 1.4537199604092166e-06
demonstrate O 0 2.248277723992942e-07
that O 0 4.445858792223589e-09
in O 0 2.402930743272691e-09
certain O 0 2.4928274555691132e-08
genetic O 0 4.860348781221546e-05
conditions O 0 0.0001095598709071055
MLD B-Disease 1 0.9999996423721313
- O 0 0.00019693061767611653
like O 0 1.86572970051202e-06
ARSA O 0 0.0017118711257353425
and O 0 3.280535565863829e-06
GS O 1 0.9999984502792358
values O 0 5.090918762107322e-07
need O 0 7.887285136121136e-08
not O 0 7.636585586112687e-09
be O 0 2.838790313930417e-09
paralleled O 0 2.556454248292539e-08
by O 0 7.592260153899133e-09
clinical O 0 0.0020699165761470795
disease O 0 0.008029484190046787
, O 0 1.9952708374404438e-09
a O 0 5.594317453727626e-09
finding O 0 4.290345501090087e-08
with O 0 2.6466757674370456e-08
serious O 0 1.9816181975329528e-06
diagnostic O 0 5.046806836617179e-05
and O 0 7.588758990095812e-07
prognostic O 0 0.001018308219499886
implications O 0 1.2891810911241919e-05
. O 0 6.993479928496527e-07

Moreover O 0 3.7629193684551865e-05
, O 0 3.6026904126629233e-07
further O 0 4.883443125436315e-07
ARSA O 0 0.00047783865011297166
alleles O 0 5.901598797208862e-06
functionally O 0 2.4290520741487853e-06
similar O 0 3.520589686445419e-08
to O 0 2.16466595759357e-08
A464V O 0 1.4453758012678009e-06
might O 0 2.6841033218261146e-07
exist O 0 6.073850755683452e-08
which O 0 5.5009925503668455e-09
, O 0 2.2240607133738877e-09
together O 0 8.665821837894327e-09
with O 0 9.871474304645744e-09
0 O 0 1.002058979793219e-06
- O 0 6.375830253091408e-06
type O 0 0.0006325226277112961
mutations O 0 2.844916161848232e-05
, O 0 3.501423861962394e-08
may O 0 2.0883470597254927e-07
cause O 0 3.8691277381985856e-07
pathological O 0 4.337767222750699e-06
ARSA O 0 0.0456099733710289
and O 0 2.090430280077271e-05
GS O 1 1.0
levels O 0 4.891405478701927e-05
, O 0 1.2011102334952284e-08
but O 0 4.112374885067993e-09
not O 0 1.318613129797086e-08
clinical O 0 8.08603772384231e-07
outbreak O 0 2.52568383984908e-07
of O 0 2.0787382926101827e-09
the O 0 4.1345447243656963e-07
disease O 0 0.00014942804409656674
. O 0 1.9044684052005323e-08
. O 0 1.4212379539912945e-07

Human O 0 0.001036767615005374
MLH1 O 1 0.999671459197998
deficiency O 1 0.9946250319480896
predisposes O 0 0.00015179647016339004
to O 0 2.818280563587905e-06
hematological B-Disease 1 0.9993395209312439
malignancy I-Disease 1 0.9992407560348511
and O 0 8.220165909733623e-06
neurofibromatosis B-Disease 1 0.9999486207962036
type I-Disease 0 0.004893953446298838
1 I-Disease 0 2.0103725546505302e-06
. O 0 5.222572667662462e-07

Heterozygous O 0 0.0016931761056184769
germ O 0 0.0015074119437485933
- O 0 0.00023721467005088925
line O 0 2.419417432975024e-05
mutations O 0 4.231314960634336e-06
in O 0 1.388820258796386e-08
the O 0 1.2734642673706276e-08
DNA O 0 8.903858770281659e-07
mismatch O 0 4.827671727980487e-05
repair O 0 0.00037961790803819895
genes O 0 1.4558770089934114e-05
lead O 0 3.132558276774944e-06
to O 0 1.9453748336673016e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.65350546821719e-06

The O 0 9.452187441638671e-06
disease O 0 0.0020378015469759703
susceptibility O 0 2.7747116746468237e-06
of O 0 1.7988925904433017e-08
individuals O 0 1.7774880234355805e-07
who O 0 6.075711098674219e-07
constitutionally O 0 7.648885912203696e-06
lack O 0 4.829140820561406e-08
both O 0 1.606588817537613e-08
wild O 0 7.505457233492052e-08
- O 0 4.375617663754383e-06
type O 0 4.3476968130562454e-05
alleles O 0 2.5606229883123888e-06
is O 0 3.4423035089048426e-08
unknown O 0 2.968374985812261e-07
. O 0 9.605559370129413e-08

We O 0 1.628502104722429e-05
have O 0 1.9021148034426005e-07
identified O 0 2.2002653565778019e-07
three O 0 2.6495902361034496e-08
offspring O 0 3.364683891504683e-07
in O 0 7.220526843099151e-09
a O 0 3.86277150710157e-07
hereditary B-Disease 1 0.9999998807907104
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 6.517026122310199e-06
who O 0 7.027389301583753e-07
developed O 0 7.842184459150303e-06
hematological B-Disease 1 0.9866727590560913
malignancy I-Disease 0 0.37250521779060364
at O 0 4.146576486618869e-07
a O 0 2.3173919672103693e-08
very O 0 2.363639417524155e-08
early O 0 7.106877575324688e-08
age O 0 5.880256139789708e-07
, O 0 2.428521383990301e-09
and O 0 1.7220047610067013e-08
at O 0 1.532647218027705e-07
least O 0 3.353446853537889e-09
two O 0 5.994181817570166e-10
of O 0 3.3425640033613035e-10
them O 0 4.568902145507536e-09
displayed O 0 2.313060605274586e-07
signs O 0 4.4008763211422774e-07
of O 0 1.0396804306367358e-08
neurofibromatosis B-Disease 0 0.10256850719451904
type I-Disease 0 5.2398867410374805e-05
1 I-Disease 0 2.6205236736132065e-07
( O 0 1.8575367732864834e-07
NF1 B-Disease 0 2.1805803044117056e-05
) O 0 1.2639510771350615e-07
. O 0 2.2494894835745072e-07

DNA O 0 1.2322863767622039e-05
sequence O 0 6.500023346234229e-07
analysis O 0 2.1744345701790735e-07
and O 0 2.8217062464364062e-08
allele O 0 1.0112829613717622e-06
- O 0 3.50462499909554e-07
specific O 0 3.548635518768606e-08
amplification O 0 2.6831460786524985e-07
in O 0 6.600121338351528e-09
two O 0 2.552391009658095e-08
siblings O 0 1.0698355254135095e-05
revealed O 0 5.095917572361941e-07
a O 0 7.356148046255839e-08
homozygous O 0 0.0001560548262204975
MLH1 O 0 0.00016780034638941288
mutation O 0 5.853261427546386e-06
( O 0 1.313372735012308e-07
C676T O 0 3.119036364296335e-06
- O 0 3.555459261406213e-05
- O 0 8.264392818091437e-05
> O 0 7.859801371523645e-06
Arg226Stop O 0 2.3496129870181903e-05
) O 0 1.712528074904185e-07
. O 0 2.5519923951833334e-07

Thus O 0 2.237938497273717e-05
, O 0 3.6347438481243444e-07
a O 0 2.917130927926337e-07
homozygous O 0 6.981995102250949e-05
germ O 0 0.00019185066048521549
- O 0 7.692366489209235e-05
line O 0 4.710944995167665e-05
MLH1 O 0 0.0008907157462090254
mutation O 0 7.37048321752809e-06
and O 0 1.3216678951266658e-07
consequent O 0 3.550545807229355e-05
mismatch O 1 0.996330201625824
repair O 1 0.9999996423721313
deficiency O 1 0.9999977350234985
results O 0 2.11841074815311e-06
in O 0 1.3078751415207535e-08
a O 0 7.284118908046366e-08
mutator O 0 0.00042408480658195913
phenotype O 0 6.946928624529392e-05
characterized O 0 7.795453029757482e-07
by O 0 5.694722204907521e-08
leukemia B-Disease 0 0.33277076482772827
and O 0 1.2113872571717366e-06
/ O 1 0.999316930770874
or O 1 0.9999570846557617
lymphoma B-Disease 1 1.0
associated O 0 3.700706292875111e-05
with O 0 6.658374900325725e-07
neurofibromatosis B-Disease 1 0.9999325275421143
type I-Disease 0 0.003638068912550807
1 I-Disease 0 2.9714735205743636e-07
. O 0 5.5644385099640203e-08
. O 0 2.8503762905529584e-07

Missense O 0 0.001682792790234089
mutations O 0 0.0004707927873823792
in O 0 1.0139670081343866e-07
the O 0 1.0983812082088207e-08
most O 0 2.7117443845980915e-09
ancient O 0 3.951635463295133e-09
residues O 0 7.501235188556166e-08
of O 0 1.8173941240817726e-09
the O 0 3.400279169341047e-08
PAX6 O 0 1.3991349987918511e-05
paired O 0 1.200750375573989e-06
domain O 0 1.6170389471881208e-07
underlie O 0 4.893881282441725e-07
a O 0 1.2075973110370342e-08
spectrum O 0 1.4303017792371975e-07
of O 0 2.3635312373926354e-08
human O 0 2.5077571990550496e-05
congenital B-Disease 1 0.9999998807907104
eye I-Disease 1 0.9999631643295288
malformations I-Disease 1 0.9909040331840515
. O 0 1.7935109326572274e-06

Mutations O 0 0.00016494539158884436
of O 0 8.532662576499206e-08
the O 0 8.361499936881955e-08
human O 0 2.0396790034737933e-07
PAX6 O 0 0.00016228282765951008
gene O 0 8.655393321532756e-05
underlie O 0 0.14942452311515808
aniridia B-Disease 1 1.0
( O 0 0.0009927459759637713
congenital B-Disease 1 0.9999995231628418
absence I-Disease 0 1.4938160575184156e-06
of I-Disease 0 4.5422270389394725e-09
the I-Disease 0 2.9639556586857907e-08
iris I-Disease 0 4.9694122026267e-06
) O 0 9.027388614413212e-09
, O 0 1.5166342626216078e-09
a O 0 8.764995840238043e-09
rare O 0 2.4196779691010306e-07
dominant O 0 0.07829443365335464
malformation B-Disease 0 0.1877223402261734
of I-Disease 0 1.3204150661749736e-08
the I-Disease 0 1.753131186887913e-07
eye I-Disease 0 0.37443166971206665
. O 0 8.080162956503045e-07

The O 0 1.36027028929675e-06
spectrum O 0 1.7436051393815433e-06
of O 0 9.989630456175291e-08
PAX6 O 0 0.00018219366029370576
mutations O 0 3.68057080777362e-05
in O 0 2.76749460681458e-07
aniridia B-Disease 1 1.0
patients O 0 0.0013014823198318481
is O 0 5.891401588797862e-09
highly O 0 2.3224894007967123e-08
biased O 0 6.211486720530957e-07
, O 0 8.91929019530835e-09
with O 0 5.8149733916934565e-09
92 O 0 7.141609614791378e-08
% O 0 4.367275430183781e-09
of O 0 6.896589965776911e-10
all O 0 7.675018842689951e-09
reported O 0 1.9764476633099548e-07
mutations O 0 3.773477601498598e-07
leading O 0 7.043533400974411e-08
to O 0 2.121882758387983e-08
premature O 0 4.09646986554435e-07
truncation O 0 2.2598793236738857e-07
of O 0 6.683999576040378e-09
the O 0 2.544953225935842e-08
protein O 0 1.3519269259631983e-07
( O 0 2.505009888409404e-08
nonsense O 0 4.487367277761223e-07
, O 0 4.508383444346009e-09
splicing O 0 1.607659356750446e-07
, O 0 6.526189366695689e-09
insertions O 0 1.8320653794035024e-07
and O 0 2.9658838940349597e-08
deletions O 0 3.2010251516112476e-07
) O 0 2.0465114047851785e-08
and O 0 6.080318826207076e-08
just O 0 1.0607652711769333e-07
2 O 0 3.110218216306748e-08
% O 0 1.7213283243222577e-08
leading O 0 2.6040284595296725e-08
to O 0 2.6165485333962124e-09
substitution O 0 6.031112498305902e-09
of O 0 2.6431936639426112e-09
one O 0 3.07502681096139e-08
amino O 0 1.8948996682865982e-07
acid O 0 8.069353185646833e-08
by O 0 2.149335820433862e-09
another O 0 1.1987940418123344e-08
( O 0 9.795848576743538e-09
missense O 0 1.3489484445017297e-06
) O 0 3.6420438220829965e-08
. O 0 8.469168477631683e-08

The O 0 9.610120059733163e-07
extraordinary O 0 3.061739164422761e-07
conservation O 0 4.817833954007256e-08
of O 0 1.8776755705829373e-09
the O 0 8.401525697365742e-09
PAX6 O 0 3.7651200273103314e-06
protein O 0 9.974341708129941e-08
at O 0 7.696689152680847e-08
the O 0 1.2306355046121098e-08
amino O 0 1.1673905930820183e-07
acid O 0 4.8111580497334216e-08
level O 0 2.614324934313572e-08
amongst O 0 1.880357380912301e-08
vertebrates O 0 3.222901767685471e-08
predicts O 0 8.04047033398092e-08
that O 0 3.0199462930369236e-09
pathological O 0 5.552701054511999e-07
missense O 0 1.2505916856753174e-05
mutations O 0 1.635039552638773e-05
should O 0 8.428719411313068e-08
in O 0 3.81542974992044e-09
fact O 0 7.72383312863667e-09
be O 0 3.8760905596291195e-09
common O 0 4.760603466991142e-09
even O 0 1.7486852854631252e-08
though O 0 1.1250421039221692e-08
they O 0 1.4269713410897111e-08
are O 0 4.4172554503063566e-09
hardly O 0 5.584150386539477e-08
ever O 0 1.9134623130412365e-07
seen O 0 4.1065146660912433e-07
in O 0 7.951571490139031e-08
aniridia B-Disease 1 1.0
patients O 0 2.2961487047723494e-05
. O 0 2.902600613197137e-07

This O 0 4.38496471133476e-07
indicates O 0 5.062644277131767e-07
that O 0 7.343401886572565e-09
there O 0 5.546020087621173e-09
is O 0 1.4711419860091723e-09
a O 0 3.789711211510394e-09
heavy O 0 2.492467274350929e-06
ascertainment O 0 2.1565578208537772e-05
bias O 0 3.644316848294693e-07
in O 0 9.251568400259202e-10
the O 0 5.291663218720544e-10
selection O 0 1.688764905694029e-09
of O 0 2.0003008138758105e-09
patients O 0 9.076910600924748e-08
for O 0 3.079650312542981e-09
PAX6 O 0 8.666718713357113e-06
mutation O 0 7.802481718499621e-07
analysis O 0 4.3871313692989133e-08
and O 0 3.75954023468239e-08
that O 0 8.05280642168782e-09
the O 0 2.935817811078323e-08
missing O 0 2.485962568243849e-06
PAX6 O 0 9.672705346019939e-05
missense O 0 9.737393702380359e-05
mutations O 0 8.085799345280975e-05
frequently O 0 1.2192350368422922e-05
may O 0 2.1534644929488422e-06
underlie O 0 4.654509757529013e-05
phenotypes O 0 3.089740130235441e-05
distinct O 0 6.492929287560401e-07
from O 0 1.7807337826525327e-07
textbook O 0 0.00037817901466041803
aniridia B-Disease 1 0.9999997615814209
. O 0 3.52638403455785e-06

Here O 0 3.669108082249295e-06
we O 0 2.6836170263777603e-07
present O 0 3.239659207565637e-08
four O 0 4.7322874507926826e-08
novel O 0 3.7911379990873684e-07
PAX6 O 0 2.6161113055422902e-05
missense O 0 1.7402762750862166e-05
mutations O 0 1.2748375411320012e-05
, O 0 2.2774814922854603e-08
two O 0 1.1026044077766528e-08
in O 0 3.953346539020686e-09
association O 0 3.293816419613904e-08
with O 0 1.8453883754432354e-08
atypical O 0 6.846426003903616e-06
phenotypes O 0 5.258031887933612e-05
ectopia B-Disease 0 3.05256835417822e-05
pupillae I-Disease 0 1.8843458747141995e-05
( O 0 5.304502437297742e-08
displaced B-Disease 0 1.4926669678061444e-07
pupils I-Disease 0 1.1382275033611222e-06
) O 0 6.348657421995085e-08
and O 0 2.304065446878667e-06
congenital B-Disease 1 0.9999992847442627
nystagmus I-Disease 0 0.0037204427644610405
( O 0 6.83602507933756e-08
searching B-Disease 0 5.013329769099073e-07
gaze I-Disease 0 2.1063813619548455e-05
) O 0 1.5368119221648158e-08
, O 0 4.471917058879171e-09
and O 0 1.2750537514705229e-08
two O 0 2.166152945903832e-08
in O 0 7.986177941177175e-09
association O 0 2.6314642909142094e-08
with O 0 3.5738065840007494e-09
more O 0 1.4233778600214464e-08
recognizable O 0 3.6635767173720524e-05
aniridia B-Disease 1 0.999994158744812
phenotypes O 0 5.5330139730358496e-05
. O 0 5.92908975249884e-07

Strikingly O 0 0.00020446168491616845
, O 0 3.8726349771422974e-07
all O 0 2.156284395482544e-08
four O 0 2.5928621028015186e-08
mutations O 0 3.7119369267202273e-07
are O 0 3.5887524063582532e-09
located O 0 1.528906246051065e-08
within O 0 7.454763029102196e-09
the O 0 1.238519242718894e-08
PAX6 O 0 4.729896772914799e-06
paired O 0 4.6021094135539897e-07
domain O 0 8.83854767153025e-08
and O 0 5.382222667549286e-08
affect O 0 1.6432871063898347e-07
amino O 0 7.459772888296357e-08
acids O 0 1.7974418398125636e-08
which O 0 7.245742894568252e-10
are O 0 5.601212271777456e-10
highly O 0 3.775656676197059e-09
conserved O 0 5.438605121810269e-09
in O 0 7.102372578948746e-10
all O 0 1.909202795857823e-09
known O 0 1.9911052362431292e-08
paired O 0 1.401800062694747e-07
domain O 0 1.0752074786068988e-07
proteins O 0 1.963097133739211e-07
. O 0 1.3997988901337521e-07

Our O 0 2.211750324931927e-05
results O 0 1.1764348073484143e-06
support O 0 4.035660339241076e-08
the O 0 7.093549303505142e-09
hypothesis O 0 2.8462357803960003e-08
that O 0 8.066391998795552e-10
the O 0 2.8046633904210694e-09
under O 0 4.647841223004434e-09
- O 0 3.232018386256641e-08
representation O 0 1.3225550432593991e-08
of O 0 3.150223859549328e-09
missense O 0 9.144024261331651e-06
mutations O 0 4.004059064754983e-06
is O 0 7.297186854771098e-09
caused O 0 4.551066012936644e-08
by O 0 7.581349770191537e-09
ascertainment O 0 3.7146994600334438e-06
bias O 0 1.3605400681626634e-06
and O 0 8.916997984442787e-08
suggest O 0 9.278543444679599e-08
that O 0 1.9555745911503664e-09
a O 0 4.6914117035612435e-09
substantial O 0 1.761089940544025e-08
burden O 0 3.153445220505091e-07
of O 0 4.22958335022372e-09
PAX6 B-Disease 0 9.194416634272784e-05
- I-Disease 0 0.0020415636245161295
related I-Disease 0 2.1846810341230594e-05
disease I-Disease 0 0.016766833141446114
remains O 0 4.7956564941387114e-08
to O 0 8.687633723525323e-09
be O 0 3.8424825987704025e-08
uncovered O 0 1.561333988320257e-06
. O 0 2.4435767187469537e-08
. O 0 2.1091931046157697e-07

The O 0 1.3841126929037273e-06
chromosomal O 0 5.526970562641509e-05
order O 0 1.6617316589417896e-07
of O 0 1.8611748586749854e-08
genes O 0 8.651884968458035e-07
controlling O 0 1.575303485878976e-06
the O 0 2.087966244346262e-08
major O 0 5.959838844660226e-08
histocompatibility O 0 2.7658850285661174e-06
complex O 0 1.2560023776586604e-07
, O 0 8.504971837908215e-09
properdin O 0 6.379854085025727e-07
factor O 0 1.5370046924090275e-07
B O 0 5.871397206647089e-06
, O 0 1.0711827869158697e-08
and O 0 3.919166147170472e-07
deficiency B-Disease 0 7.2459602051822e-06
of I-Disease 0 1.2760675849321501e-09
the I-Disease 0 5.263088631579649e-09
second I-Disease 0 9.051323246467291e-08
component I-Disease 0 8.544388663267455e-08
of I-Disease 0 4.476200743397385e-09
complement I-Disease 0 6.785188020330679e-07
. O 0 1.9931880501644628e-07

The O 0 5.754347967013018e-07
relationship O 0 2.2388014997432037e-07
of O 0 3.859477182288629e-09
the O 0 4.60576465854956e-09
genes O 0 4.457043090155821e-08
coding O 0 1.3471444049173442e-07
for O 0 9.645376941591621e-09
HLA O 0 4.699564613019902e-07
to O 0 7.37913508075394e-09
those O 0 1.1606175576162059e-08
coding O 0 2.527461901991046e-07
for O 0 1.1289737145148138e-08
properdin O 0 2.0120010049140546e-06
Factor O 0 2.5662208713583823e-07
B O 0 2.17273372982163e-06
allotypes O 0 4.846987735618313e-07
and O 0 2.6399904484719627e-08
for O 0 4.152155241854416e-08
deficiency B-Disease 0 5.77654600419919e-06
of I-Disease 0 4.4834616574895847e-10
the I-Disease 0 3.2528770788076145e-09
second I-Disease 0 6.865988666504563e-08
component I-Disease 0 5.93161182393942e-08
of I-Disease 0 1.292839391098255e-09
complement I-Disease 0 1.0462454724802228e-07
( O 0 5.449905771115482e-08
C2 O 0 3.558084790711291e-05
) O 0 1.5356400595578634e-08
was O 0 2.846159752323274e-08
studied O 0 2.08915729160708e-08
in O 0 1.3147499755561398e-09
families O 0 7.062552320746818e-09
of O 0 2.821188171964195e-09
patients O 0 7.693913062212232e-07
with O 0 1.8212611507806287e-07
connective O 1 0.9995324611663818
tissue O 1 0.9999648332595825
disorders O 1 0.999984622001648
. O 0 1.0210364962404128e-06

Patients O 1 0.9976611137390137
were O 0 3.2902107705012895e-06
selected O 0 1.7570226873431238e-07
because O 0 2.4391811237478578e-08
they O 0 2.4943160426005306e-08
were O 0 6.920684114675169e-08
heterozygous O 0 1.2101553465981851e-06
or O 0 1.2356528600321326e-07
homozygous O 0 9.686938574304804e-05
for O 0 7.800631465215702e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.9660096591615e-07

12 O 0 3.3945867471629754e-05
families O 0 1.5614203903169255e-06
with O 0 3.251092550726753e-08
15 O 0 1.1441355241004203e-07
matings O 0 4.943203293805709e-06
informative O 0 2.0806468455702998e-05
for O 0 0.004719726275652647
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 6.159844815556426e-06
found O 0 3.828952230833238e-07
. O 0 2.597971331397275e-07

Of O 0 1.924389152918593e-06
57 O 0 4.8524170779273845e-06
informative O 0 3.608340421124012e-06
meioses O 0 2.573411984485574e-05
, O 0 2.8038304122901536e-08
two O 0 8.015477170886243e-09
crossovers O 0 5.326335212885169e-07
were O 0 3.126950787191163e-07
noted O 0 1.720015596617941e-08
between O 0 1.353058998176948e-08
the O 0 6.634449164266698e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999955892562866
gene O 0 2.469494972956454e-07
and O 0 1.009027617016045e-08
the O 0 2.1086655976887414e-08
HLA O 0 2.105948169628391e-06
- O 0 7.520878625655314e-06
B O 0 1.2512226930994075e-05
gene O 0 1.5354868310168968e-07
, O 0 2.0570221082039097e-09
with O 0 7.884163877314165e-10
a O 0 3.1734965766361256e-09
recombinant O 0 2.7107736499942803e-08
fraction O 0 2.3928881986989836e-08
of O 0 3.566690498502112e-09
0 O 0 5.269752136882744e-07
. O 0 2.421529359253327e-07

035 O 0 0.0382918082177639
. O 0 0.00019820916349999607

A O 0 5.519175829249434e-05
lod O 0 0.0006215186440385878
score O 0 1.3381712960836012e-05
of O 0 3.093876443927002e-08
13 O 0 2.127922158479123e-07
was O 0 2.5079359033952642e-08
calculated O 0 5.040607931050545e-08
for O 0 5.325869967265362e-09
linkage O 0 2.585108086350374e-05
between O 0 0.0001844748912844807
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 4.1544299733686785e-07
HLA O 0 4.154324869887205e-06
- O 0 1.9067647372139618e-05
B O 0 2.111236062773969e-05
at O 0 2.93273387796944e-08
a O 0 6.50640252786161e-09
maximum O 0 9.919187249352035e-09
likelihood O 0 1.7161847054580903e-08
value O 0 1.1863466875539075e-09
of O 0 2.625996364802319e-10
the O 0 1.043241604214984e-09
recombinant O 0 1.1991782677966967e-08
fraction O 0 2.5233186207174185e-08
of O 0 9.341579065846872e-09
0 O 0 1.2334882057984942e-06
. O 0 2.589292193988513e-07

04 O 0 0.02834639698266983
. O 0 6.031088560121134e-05

18 O 0 8.116537355817854e-05
families O 0 1.3923181541031227e-06
with O 0 3.948186844127122e-08
21 O 0 7.878729491039849e-08
informative O 0 1.2352981570984412e-07
matings O 0 2.3444840735464823e-06
for O 0 1.8462049666823077e-08
both O 0 6.594788004576912e-08
properdin O 0 5.368450729292817e-06
Factor O 0 3.5537703979571234e-07
B O 0 1.9430924567132024e-06
allotype O 0 1.0023313734563999e-06
and O 0 1.0553124951684367e-07
HLA O 0 5.459067779156612e-06
- O 0 7.294736133189872e-05
B O 0 0.00021376479708123952
were O 0 4.821400807486498e-07
found O 0 1.4770830603083596e-07
. O 0 2.196629935724559e-07

Of O 0 2.7212022359890398e-06
72 O 0 1.656120002735406e-05
informative O 0 8.292019629152492e-06
meioses O 0 3.404191738809459e-05
, O 0 1.1458750748261082e-07
three O 0 6.913915484574318e-08
recombinants O 0 5.004530066798907e-06
were O 0 1.4381640767169301e-06
found O 0 5.78985357435613e-08
, O 0 3.8222620624139836e-09
giving O 0 4.047807866669473e-09
a O 0 2.0642378917301585e-09
recombinant O 0 2.0500159791936312e-08
fraction O 0 2.76211498118073e-08
of O 0 4.8802135665937385e-09
0 O 0 5.428554459285806e-07
. O 0 2.056772530067974e-07

042 O 0 0.00941026397049427
. O 0 0.00011788603296736255

A O 0 9.637749826651998e-06
lod O 0 0.0001570661988807842
score O 0 3.3281980904575903e-06
of O 0 2.1362664526236586e-08
16 O 0 1.0535627126273539e-07
between O 0 3.4655187164389645e-08
HLA O 0 3.760325853363611e-06
- O 0 1.4362288311531302e-05
B O 0 1.1783069567172788e-05
and O 0 3.4939255044719175e-08
Factor O 0 9.910699105830645e-08
B O 0 1.6228042341026594e-06
allotypes O 0 4.6803407371953654e-07
was O 0 9.389044208774067e-08
calculated O 0 5.3794721566191583e-08
at O 0 1.526388793138267e-08
a O 0 1.7730878987265442e-09
maximum O 0 1.145606898234064e-08
likelihood O 0 1.982949271450707e-08
value O 0 1.8489386688358422e-09
of O 0 2.023886336299796e-10
the O 0 6.195201018854846e-10
recombinant O 0 3.884735644277271e-09
fraction O 0 1.2503203805636076e-08
of O 0 3.779922153057669e-09
0 O 0 6.569703714376374e-07
. O 0 1.5641879258510016e-07

04 O 0 0.025986438617110252
. O 0 4.057499245391227e-05

A O 0 2.275364067827468e-06
crossover O 0 1.805696001611068e-06
was O 0 8.363108463527169e-07
shown O 0 8.075327428969103e-08
to O 0 6.911249794683272e-09
have O 0 2.0824021618182087e-08
occurred O 0 2.681185939934494e-08
between O 0 4.6780983531391485e-09
genes O 0 3.328392850221462e-08
for O 0 1.7876216062973072e-09
Factor O 0 3.5263695963294595e-08
B O 0 6.689550104965747e-07
and O 0 1.7829641763000836e-08
HLA O 0 6.891670523145876e-07
- O 0 7.190793439804111e-06
D O 0 3.527505396050401e-05
, O 0 4.202307390954729e-09
in O 0 1.3012382282795443e-09
which O 0 8.177623023186698e-09
HLA O 0 5.010156201024074e-07
- O 0 2.4240951006504474e-06
D O 0 6.7831770138582215e-06
segregared O 0 8.749997846280166e-07
with O 0 2.493050743623826e-08
HLA O 0 1.6762187442509457e-06
- O 0 1.0878584362217225e-06
A O 0 1.7732011770021927e-07
and O 0 1.0726348165235322e-07
B O 0 1.895722743938677e-05
. O 0 1.437574184137702e-07

These O 0 1.2254985222170944e-06
studies O 0 2.6011426257355197e-07
suggest O 0 1.1525264653755585e-07
that O 0 2.394320519627513e-09
the O 0 3.7619773962660474e-09
genes O 0 4.4944766131038705e-08
for O 0 6.338177094278308e-09
Factor O 0 3.0127998229545483e-07
B O 0 0.007260196376591921
and O 0 0.0002345091343158856
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.7038754407394663e-08
located O 0 1.730885657025283e-08
outside O 0 1.4415275195744925e-08
those O 0 1.8875501162085584e-09
for O 0 2.1154886731267197e-09
HLA O 0 2.3414870042870461e-07
, O 0 2.4009056964757747e-09
that O 0 5.554613435876377e-10
the O 0 8.401890849718541e-10
order O 0 1.434144025758144e-09
of O 0 5.454434126583863e-10
genese O 0 2.896743751534814e-07
is O 0 3.77245346072641e-09
HLA O 0 1.6729116225633334e-07
- O 0 1.878646145314633e-07
A O 0 8.130547968221435e-08
, O 0 7.549574299048345e-09
- O 0 2.92581802341374e-07
B O 0 1.6539529497094918e-06
, O 0 8.026431075336404e-09
- O 0 1.9992229738363676e-07
D O 0 1.0398033509773086e-06
, O 0 3.6024201399698086e-09
Factor O 0 4.820536858574087e-08
B O 0 2.4389917143707862e-06
allotype O 0 4.687953605753137e-06
, O 0 2.1686475975002395e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 4.023629873728396e-09
that O 0 3.87551213343329e-10
the O 0 1.6987670159451795e-09
genes O 0 4.6842615120112896e-08
coding O 0 1.090317937268992e-06
for O 0 1.3328641443877132e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 8.111604898886071e-08
Factor O 0 2.0301445147197228e-07
B O 0 4.435749815456802e-06
allotypes O 0 4.895417191619345e-07
are O 0 8.37937719211368e-09
approximately O 0 2.3964965123468573e-08
3 O 0 3.498072942420549e-08
- O 0 4.776937316819385e-07
- O 0 7.584902164126106e-07
5 O 0 2.72192313133246e-08
centimorgans O 0 1.0854401466531272e-07
from O 0 3.5077991622500804e-09
the O 0 4.095841887874485e-09
HLA O 0 1.7436087773603504e-07
- O 0 9.813955870185964e-08
A O 0 3.3853179814968826e-08
and O 0 2.0090350716372996e-08
HLA O 0 6.80379741879733e-07
- O 0 9.494164601164812e-07
B O 0 7.397189278890437e-07
loci O 0 5.153533066959426e-08
, O 0 2.074611149538441e-09
and O 0 1.8743693264156036e-09
that O 0 8.749441171573835e-10
the O 0 2.1897217372668365e-09
apparent O 0 3.596243303150004e-08
lack O 0 1.4750257015805346e-08
of O 0 1.6592409668447772e-09
recombinants O 0 2.918029622378526e-07
between O 0 6.926161422171617e-09
the O 0 7.886033159820727e-09
Factor O 0 8.356111180773951e-08
B O 0 3.0534279176208656e-06
gene O 0 1.3922954167355783e-06
and O 0 0.0001370979007333517
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 1.1315972869851976e-06
suggests O 0 5.3789797505032766e-08
that O 0 1.4056302788389985e-09
these O 0 2.224077588763862e-09
two O 0 2.0235564335280287e-08
genes O 0 5.625381618301617e-07
lie O 0 3.4715508263616357e-06
in O 0 8.553711516867679e-09
close O 0 4.815280476577755e-07
proximity O 0 3.0780788051743e-07
to O 0 6.498516569308777e-08
one O 0 6.805582586366654e-08
another O 0 3.361226390552474e-07
. O 0 2.3809425897525216e-07

Distribution O 0 1.6409173895226559e-06
of O 0 1.057845651075695e-07
emerin O 0 7.130507583497092e-06
and O 0 1.4697563699428429e-07
lamins O 0 1.519124361948343e-05
in O 0 1.619591039059287e-08
the O 0 4.097243078149404e-08
heart O 0 1.7141520629593288e-06
and O 0 2.1123771176689843e-08
implications O 0 2.2932266574571258e-07
for O 0 3.828947825468276e-08
Emery B-Disease 0 0.0013012889539822936
- I-Disease 0 0.44701099395751953
Dreifuss I-Disease 1 0.9997465014457703
muscular I-Disease 1 0.9987086057662964
dystrophy I-Disease 1 0.9913071990013123
. O 0 4.271999387128744e-06

Emerin O 0 0.0008444543927907944
is O 0 4.7287824145314516e-07
a O 0 5.787932622070002e-08
nuclear O 0 5.093006620882079e-07
membrane O 0 1.371010540651696e-07
protein O 0 8.570749088221419e-08
which O 0 1.1468815230841756e-08
is O 0 5.694762883479143e-09
missing O 0 2.964974044061819e-07
or O 0 1.4629237909957737e-07
defective O 0 7.696871762163937e-06
in O 0 3.3488849027207834e-08
Emery B-Disease 0 0.0019932836294174194
- I-Disease 1 0.8568463325500488
Dreifuss I-Disease 1 0.9999483823776245
muscular I-Disease 1 0.9999210834503174
dystrophy I-Disease 1 0.9999769926071167
( O 0 1.654443440202158e-05
EDMD B-Disease 1 0.9999997615814209
) O 0 7.400449248962104e-07
. O 0 4.479982749217015e-07

It O 0 1.8694521486395388e-06
is O 0 3.301074258388326e-08
one O 0 4.125620733930191e-09
member O 0 1.8435156734497582e-09
of O 0 3.130247450133794e-10
a O 0 4.8394470653079225e-09
family O 0 1.9372100368286738e-08
of O 0 2.5165693973150383e-09
lamina O 0 2.1998218926455593e-06
- O 0 9.794151992537081e-06
associated O 0 9.459110117404634e-08
proteins O 0 1.3483804295333357e-08
which O 0 2.3661639314553895e-09
includes O 0 8.805814744050622e-09
LAP1 O 0 3.535172481861082e-06
, O 0 1.4195956410389954e-08
LAP2 O 0 2.8503186513262335e-06
and O 0 1.0605629796600624e-07
lamin O 0 0.00012645323295146227
B O 0 0.0016692755743861198
receptor O 0 5.921770934946835e-06
( O 0 4.043242256557278e-07
LBR O 0 0.00020501138351392
) O 0 3.7223020399324014e-07
. O 0 3.649234088243247e-07

A O 0 5.703348051611101e-06
panel O 0 7.763920848447015e-07
of O 0 3.989548957861189e-08
16 O 0 2.744753544448031e-07
monoclonal O 0 2.039485707427957e-06
antibodies O 0 2.239208015453187e-06
( O 0 4.2274081124560325e-08
mAbs O 0 8.602765433352033e-07
) O 0 1.4248473512168403e-08
has O 0 1.437189833808361e-08
been O 0 7.379866939771773e-09
mapped O 0 1.6274942993277364e-07
to O 0 8.256676231610527e-09
six O 0 1.2357206813362609e-08
specific O 0 5.554001702989808e-09
sites O 0 4.6075587789573547e-08
throughout O 0 1.2812654937022216e-08
the O 0 5.549914305902348e-09
emerin O 0 2.713288438371819e-07
molecule O 0 2.529969123088449e-08
using O 0 2.5269889292189873e-08
phage O 0 2.271891901273193e-07
- O 0 3.334938583066105e-07
displayed O 0 1.0850551745988923e-07
peptide O 0 1.6972778738022498e-08
libraries O 0 5.350346832244668e-09
and O 0 6.1075846602420825e-09
has O 0 4.116078589078143e-09
been O 0 6.76816913625089e-09
used O 0 4.312626700198052e-09
to O 0 4.2552019685615505e-09
localize O 0 4.477792572288308e-06
emerin O 0 6.702444807160646e-06
in O 0 1.440625929660655e-08
human O 0 4.1344925705288915e-08
and O 0 2.5189939378833515e-07
rabbit O 0 0.0002291151467943564
heart O 0 3.991503763245419e-05
. O 0 3.4720764574558416e-07

Several O 0 8.159417120623402e-06
mAbs O 0 9.56295189098455e-05
against O 0 7.365076157839212e-07
different O 0 2.0573415326907707e-07
emerin O 0 5.848227829119423e-06
epitopes O 0 4.73236468678806e-06
did O 0 2.729936170453584e-07
not O 0 2.2544970335047765e-08
recognize O 0 3.887286936787859e-08
intercalated O 0 1.3475644777827256e-07
discs O 0 2.809875240927795e-06
in O 0 1.1406683597670053e-08
the O 0 5.1911499099333014e-08
heart O 0 1.5549562704109121e-06
, O 0 5.202357655775813e-09
though O 0 9.480275231510404e-09
they O 0 9.943661005706872e-09
recognized O 0 1.2682527028573531e-08
cardiomyocyte O 0 2.801457981149724e-07
nuclei O 0 6.039932287649208e-08
strongly O 0 6.161597099207938e-08
, O 0 6.636666327608509e-09
both O 0 1.0966395791456307e-08
at O 0 1.5270067876826943e-07
the O 0 1.0427586794037325e-08
rim O 0 1.1699617630256398e-07
and O 0 2.124097875366715e-08
in O 0 6.251563267056781e-09
intranuclear O 0 8.613487239017559e-07
spots O 0 8.007929750419862e-07
or O 0 7.847444294384331e-08
channels O 0 9.525299446977442e-07
. O 0 1.9551546870388847e-07

A O 0 4.1598126699682325e-05
polyclonal O 0 0.00037548475665971637
rabbit O 0 0.00016587041318416595
antiserum O 0 0.00010412054689368233
against O 0 1.0324419008611585e-06
emerin O 0 1.0562842362560332e-05
did O 0 3.4792361702784547e-07
recognize O 0 1.7894411996621784e-07
both O 0 2.795233555730192e-08
nuclear O 0 1.0167591426579747e-06
membrane O 0 1.4727352493082435e-07
and O 0 1.9131332962274428e-08
intercalated O 0 2.1890345180963777e-07
discs O 0 2.5336692033306463e-06
but O 0 3.8833444904184944e-08
, O 0 2.415986966042283e-09
after O 0 3.895033628964484e-09
affinity O 0 2.12770263630091e-08
purification O 0 3.340750609481802e-08
against O 0 1.465507892817186e-08
a O 0 1.9416010132999872e-08
pure O 0 1.059919867429926e-07
- O 0 6.1253713283804245e-06
emerin O 0 3.4507361306168605e-06
band O 0 2.048205089977273e-07
on O 0 1.5189105084800758e-08
a O 0 1.4087900623849237e-08
western O 0 3.212633714611002e-08
blot O 0 5.2997285820310935e-05
, O 0 4.087166161070854e-08
it O 0 1.875721977739886e-08
stained O 0 3.265639315941371e-05
only O 0 1.4780729529206837e-08
the O 0 1.5940285535975818e-08
nuclear O 0 1.14047452370869e-06
membrane O 0 9.219725143339019e-07
. O 0 2.280829392020678e-07

These O 0 2.3411034817399923e-06
results O 0 5.40243661362183e-07
would O 0 5.307396833131861e-08
not O 0 7.84657316899029e-09
be O 0 5.209993325649975e-09
expected O 0 7.517976463589093e-09
if O 0 6.235415295208213e-09
immunostaining O 0 3.5010742749364e-07
at O 0 4.155474897515887e-08
intercalated O 0 2.2016926948253968e-07
discs O 0 5.3103094614925794e-06
were O 0 1.412955157320539e-06
due O 0 1.5636295813692414e-08
to O 0 2.569583656963914e-09
a O 0 6.6469278969805146e-09
product O 0 1.348972045178698e-08
of O 0 5.061914221116126e-10
the O 0 2.256281383949954e-09
emerin O 0 1.3465317749705719e-07
gene O 0 4.764621053254814e-08
and O 0 9.238612541651037e-09
, O 0 2.362700479707769e-09
therefore O 0 7.267115798015311e-09
, O 0 8.560643860455741e-10
cast O 0 1.3015045929876123e-08
some O 0 2.6213438086841734e-09
doubt O 0 1.4889327992761991e-08
upon O 0 8.773002879713943e-10
the O 0 2.274372246091616e-09
hypothesis O 0 3.903246081904399e-08
that O 0 2.2679579103623837e-08
cardiac B-Disease 0 0.0012064276961609721
defects I-Disease 1 0.9944307208061218
in O 0 2.1230046343134745e-07
EDMD B-Disease 1 1.0
are O 0 1.0510794936635648e-06
caused O 0 4.1877154899339075e-07
by O 0 6.718138489958392e-09
absence O 0 6.843266220357691e-08
of O 0 4.9105781663172365e-09
emerin O 0 7.103155439835973e-06
from O 0 5.303146721757912e-08
intercalated O 0 3.5679759093909524e-06
discs O 0 2.0771933122887276e-05
. O 0 6.398371397153824e-07

Although O 0 6.584753919014474e-06
emerin O 0 1.9123481251881458e-05
was O 0 4.447532546691946e-07
abundant O 0 3.294155348498862e-08
in O 0 6.975213295845606e-09
the O 0 6.563113608137883e-09
membranes O 0 5.114725354360417e-07
of O 0 5.887537568582957e-09
cardiomyocyte O 0 2.4230896542576374e-06
nuclei O 0 1.861801877112157e-07
, O 0 1.1548188183496677e-08
it O 0 8.146953334176033e-09
was O 0 1.9897429126558563e-07
absent O 0 3.44803368079738e-08
from O 0 1.7573780208834933e-09
many O 0 4.0512295740313675e-09
non O 0 2.389962787674449e-07
- O 0 2.683168759176624e-06
myocyte O 0 4.404430001159199e-06
cells O 0 1.3506678442354314e-07
in O 0 9.656385024925385e-09
the O 0 7.896361609027736e-08
heart O 0 3.441363105594064e-06
. O 0 1.9628069480859267e-07

This O 0 2.1870106081678387e-07
distribution O 0 8.475502966120985e-08
of O 0 5.886684029121625e-09
emerin O 0 2.995800741700805e-06
was O 0 9.850450055637339e-08
similar O 0 2.7571078753396705e-09
to O 0 3.74858322160776e-09
that O 0 1.962277673683843e-09
of O 0 1.7075183489367873e-09
lamin O 0 1.6294089846269344e-06
A O 0 8.623895553228067e-08
, O 0 2.6364870286954556e-09
a O 0 4.279130383366692e-09
candidate O 0 1.8304966431514913e-08
gene O 0 2.5434392370016212e-08
for O 0 1.0966766383901927e-09
an O 0 7.113411193415686e-09
autosomal O 0 1.9667111700982787e-05
form O 0 7.066866487548396e-07
of O 0 4.929922852170421e-07
EDMD B-Disease 1 1.0
. O 0 1.9156839243805734e-06

In O 0 8.375336619792506e-07
contrast O 0 7.768454111101164e-07
, O 0 1.0273801365201507e-07
lamin O 0 0.0002784309908747673
B1 O 1 0.7727749943733215
was O 0 1.4788844282520586e-06
absent O 0 2.6472974923308357e-07
from O 0 1.1664319288229308e-08
cardiomyocyte O 0 7.952980354275496e-07
nuclei O 0 1.5158231292389246e-07
, O 0 9.53102308187681e-09
showing O 0 2.414459459032514e-07
that O 0 1.1013832512674071e-08
lamin O 0 2.7602363843470812e-05
B1 O 0 0.00043589455890469253
is O 0 8.28951396414368e-09
not O 0 3.0578766185840323e-09
essential O 0 3.042981866485661e-09
for O 0 7.258856293823612e-10
localization O 0 6.640252081524523e-08
of O 0 3.4953300254159103e-09
emerin O 0 9.533114280202426e-07
to O 0 1.1690779011530594e-08
the O 0 3.3545745736773824e-08
nuclear O 0 7.59509612180409e-06
lamina O 0 7.249118880281458e-06
. O 0 3.509842940729868e-07

Lamin O 1 0.5636911988258362
B1 O 1 0.9995864033699036
is O 0 1.9031358533538878e-06
also O 0 2.3703940144059743e-07
almost O 0 1.7828631371230586e-07
completely O 0 1.4336807225845405e-06
absent O 0 2.9762438202851627e-07
from O 0 3.170067941482557e-08
skeletal O 0 6.802444841014221e-05
muscle O 0 2.5752606234163977e-05
nuclei O 0 9.433393643121235e-06
. O 0 5.915517249377444e-07

In O 0 1.732688360789325e-05
EDMD B-Disease 1 0.9999991655349731
, O 0 4.9811799129884093e-08
the O 0 4.870189584949003e-09
additional O 0 8.466547463115148e-09
absence O 0 5.115730417060149e-08
of O 0 1.0601802991061504e-08
lamin O 0 0.00012067633360857144
B1 O 0 0.012753896415233612
from O 0 5.16118596749493e-08
heart O 0 1.8313245391254895e-06
and O 0 7.023463410860131e-08
skeletal O 0 0.00010750936780823395
muscle O 0 1.3251201380626298e-05
nuclei O 0 6.155243568173319e-07
which O 0 6.47760316496715e-08
already O 0 5.877396915821009e-07
lack O 0 2.874321580748074e-07
emerin O 0 9.576411684975028e-06
may O 0 1.522886776683663e-07
offer O 0 7.744662688935477e-09
an O 0 2.5238275913608277e-09
alternative O 0 1.3770691253967016e-08
explanation O 0 7.009181679507037e-09
of O 0 1.3164713763558211e-09
why O 0 1.7094222926061775e-08
these O 0 3.3053124681714507e-09
tissues O 0 2.881594696191314e-07
are O 0 7.867238416281452e-09
particularly O 0 2.9596733952530485e-08
affected O 0 1.8437914661717514e-07
. O 0 1.3924940311937917e-08
. O 0 6.929705875791115e-08

Genetic O 0 4.904642628389411e-05
mapping O 0 4.524888936430216e-06
of O 0 9.00240877399483e-08
the O 0 1.968531933016493e-07
copper B-Disease 0 5.608042556559667e-05
toxicosis I-Disease 0 0.0002592501987237483
locus O 0 8.714207979210187e-06
in O 0 7.06139644535142e-08
Bedlington O 0 1.3621988728118595e-05
terriers O 0 1.758076723490376e-05
to O 0 1.1413282408057057e-07
dog O 0 0.00010293334344169125
chromosome O 0 0.00037196159246377647
10 O 0 1.6660257529110822e-07
, O 0 1.021227546971204e-08
in O 0 3.285431704469488e-09
a O 0 4.470051706562117e-08
region O 0 3.386096807389549e-07
syntenic O 0 3.7480242554011056e-06
to O 0 1.6588462159461415e-08
human O 0 6.793171536401132e-08
chromosome O 0 2.9843356969649903e-05
region O 0 7.15170983767166e-07
2p13 O 0 1.8386625015409663e-05
- O 0 2.0226194465067238e-05
p16 O 0 2.089965892082546e-05
. O 0 8.952458188105084e-07

Abnormal O 1 0.9998327493667603
hepatic B-Disease 1 0.9998763799667358
copper I-Disease 0 0.0023233017418533564
accumulation I-Disease 0 4.777780304721091e-06
is O 0 1.991162257297674e-08
recognized O 0 3.382684354846788e-08
as O 0 2.5686929916446388e-08
an O 0 6.865915906928421e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 8.539761608972185e-08
man O 0 2.2012907265889226e-06
, O 0 7.020326986406644e-09
mouse O 0 1.950414571183501e-06
, O 0 3.5037352574818215e-08
rat O 0 8.759852789808065e-06
and O 0 1.944347616245068e-07
dog O 0 0.00019204814452677965
. O 0 8.323365250362258e-07

The O 0 1.206098545480927e-06
major O 0 5.522715014194546e-07
cause O 0 1.1586312211875338e-06
of O 0 7.262213586045618e-08
hepatic B-Disease 0 0.060168005526065826
copper I-Disease 0 0.0018103955080732703
accumulation I-Disease 0 4.0704430830373894e-06
in O 0 5.137476932759455e-08
man O 0 1.985388280445477e-06
is O 0 5.215034626360193e-09
a O 0 2.4608263871073177e-08
dysfunctional O 0 7.928436389192939e-06
ATP7B O 0 6.076961199141806e-06
gene O 0 7.208880106190918e-07
, O 0 5.2678821305107704e-08
causing O 0 7.996444765012711e-06
Wilson B-Disease 0 0.0014807293191552162
disease I-Disease 0 0.0851195678114891
( O 0 1.7832422827268601e-07
WD B-Disease 0 0.0015796339139342308
) O 0 1.6672909453063767e-07
. O 0 2.851937210834876e-07

Mutations O 0 0.0005636067944578826
in O 0 3.017219398770976e-07
the O 0 5.614995046698823e-08
ATP7B O 0 5.271207101031905e-06
genes O 0 6.408978947547439e-07
have O 0 3.366515599623199e-08
also O 0 1.8057610517985268e-08
been O 0 4.754018334551802e-08
demonstrated O 0 1.026698015493821e-08
in O 0 2.1057948718095076e-09
mouse O 0 1.1495948228912312e-06
and O 0 1.617544853615982e-07
rat O 0 3.754553108592518e-05
. O 0 3.7054644508316414e-07

The O 0 1.6666803048792644e-06
ATP7B O 0 3.590609776438214e-05
gene O 0 2.5828921934589744e-06
has O 0 5.471715880389638e-08
been O 0 2.7751744013926327e-08
excluded O 0 3.315416918781011e-08
in O 0 5.366512789706235e-10
the O 0 6.429063947877012e-10
much O 0 4.221073268695363e-09
rarer O 0 3.3330405813103425e-07
human O 0 1.1784904074829683e-07
copper B-Disease 0 7.680668932152912e-05
overload I-Disease 0 0.027489129453897476
disease O 0 0.004709604196250439
non B-Disease 0 1.2517446066340199e-06
- I-Disease 0 6.50638230581535e-06
Indian I-Disease 0 2.2930824172817665e-07
childhood I-Disease 0 0.03433375060558319
cirrhosis I-Disease 0 0.1682504564523697
, O 0 2.5041405393722016e-08
indicating O 0 1.0859553185582627e-06
genetic O 0 9.407555808138568e-06
heterogeneity O 0 8.738399628782645e-06
. O 0 7.205402425825014e-07

By O 0 5.356088195185293e-07
investigating O 0 6.949247790544177e-07
the O 0 8.185272548644207e-08
common O 0 9.6237852176273e-07
autosomal O 1 0.8115713000297546
recessive O 1 0.999523401260376
copper B-Disease 0 0.01440276950597763
toxicosis I-Disease 0 0.0546812005341053
( O 0 4.6027588496144745e-07
CT B-Disease 0 0.00011211387027287856
) O 0 4.736802949878438e-08
in O 0 8.608049384406513e-09
Bedlington O 0 8.701734259375371e-06
terriers O 0 6.19883940089494e-05
, O 0 2.9410466950707814e-08
we O 0 2.250304120821056e-08
have O 0 7.117781475329821e-09
identified O 0 1.363541102250565e-08
a O 0 1.4531181813381977e-09
new O 0 1.7584577127749412e-09
locus O 0 4.877927040070063e-07
involved O 0 9.149497515181793e-08
in O 0 9.650882759615342e-08
progressive O 1 0.996708869934082
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.112809268823185e-07

We O 0 1.598398739588447e-05
examined O 0 6.203263183124363e-06
whether O 0 1.834838485592627e-07
the O 0 7.289858672265837e-08
WD B-Disease 0 0.000408435967983678
gene O 0 8.155667273967993e-06
ATP7B O 0 6.501428288174793e-05
was O 0 4.537042741503683e-07
also O 0 2.232613205421785e-08
causative O 0 6.754823971277801e-07
for O 0 8.58054338692682e-09
CT B-Disease 0 4.8944704758469015e-05
by O 0 1.9132464501581126e-08
investigating O 0 1.0253030779949768e-07
the O 0 1.6863516805187828e-08
chromosomal O 0 8.075981168076396e-05
co O 0 1.586870894243475e-05
- O 0 1.0582185723251314e-06
localization O 0 8.779906011113781e-07
of O 0 8.03565303186815e-09
ATP7B O 0 5.035409230913501e-06
and O 0 2.4006688192912407e-08
C04107 O 0 1.7920372386015515e-07
, O 0 2.5328648067812765e-09
using O 0 7.473526686396781e-09
fluorescence O 0 7.653824241060647e-08
in O 0 9.918959875676592e-09
situ O 0 6.980200168982265e-07
hybridization O 0 3.3084307915487443e-07
( O 0 9.173681547736123e-08
FISH O 0 3.302132824956061e-07
) O 0 8.046391997140745e-08
. O 0 1.8913898713890376e-07

C04107 O 0 0.0008139713318087161
is O 0 1.0142169912796817e-06
an O 0 1.034117502740628e-07
anonymous O 0 1.6568056935284403e-06
microsatellite O 0 3.9426489820471033e-05
marker O 0 2.0212271920172498e-05
closely O 0 3.1347160529549e-06
linked O 0 1.1794031706813257e-05
to O 0 1.850111317480696e-07
CT B-Disease 0 0.08933081477880478
. O 0 1.8969984694194864e-06

However O 0 2.1167274098843336e-05
, O 0 7.887222750468936e-07
BAC O 0 0.0001154531491920352
clones O 0 5.6578587646072265e-06
containing O 0 4.798872623723582e-07
ATP7B O 0 1.8473378077032976e-05
and O 0 5.6729533071120386e-08
C04107 O 0 6.97620009759703e-07
mapped O 0 1.0997741810570005e-06
to O 0 2.2976216484948964e-08
the O 0 3.189177633089457e-08
canine O 0 0.00020385783864185214
chromosome O 0 0.00048429914750158787
regions O 0 1.376859927404439e-06
CFA22q11 O 0 1.3707918697036803e-05
and O 0 2.066301902914347e-07
CFA10q26 O 0 4.579374945024028e-06
, O 0 2.1292532181860224e-08
respectively O 0 1.7412922659332253e-07
, O 0 5.3846638259358315e-09
demonstrating O 0 2.4440335977260474e-08
that O 0 6.402232077817871e-09
WD B-Disease 0 7.938005001051351e-05
cannot O 0 2.520793884741579e-07
be O 0 1.2402425753066382e-08
homologous O 0 2.715273694775533e-07
to O 0 1.345121205531541e-07
CT B-Disease 0 0.009356061927974224
. O 0 1.0762678357423283e-06

The O 0 4.031374373880681e-06
copper O 0 8.732160495128483e-06
transport O 0 1.1021460295523866e-06
genes O 0 1.45049887123605e-06
CTR1 O 0 5.385325493989512e-06
and O 0 1.0468404099128747e-07
CTR2 O 0 2.2509544578497298e-05
were O 0 5.481493303705065e-07
also O 0 1.0034101549649677e-08
excluded O 0 5.5443305058133774e-08
as O 0 2.870111925901142e-09
candidate O 0 2.2418944922719675e-08
genes O 0 3.3120162612476634e-08
for O 0 4.009227616563749e-09
CT B-Disease 0 0.0002566846669651568
since O 0 3.2399071869804175e-07
they O 0 3.5617635063545094e-08
both O 0 7.3785297871609146e-09
mapped O 0 1.6300244851663592e-06
to O 0 9.571323289492284e-08
canine O 0 0.003696317784488201
chromosome O 0 0.006862074136734009
region O 0 6.682600997010013e-06
CFA11q22 O 0 0.00012530178355518728
. O 0 6.397004312930221e-07

2 O 0 0.00012301746755838394
- O 0 0.0003053122491110116
22 O 0 1.135449838329805e-05
. O 0 7.644209176760342e-07

5 O 0 0.0001506226835772395
. O 0 9.625468919693958e-06

A O 0 1.0466957974131219e-05
transcribed O 0 8.063049790507648e-06
sequence O 0 9.017064712679712e-07
identified O 0 3.5997027225675993e-07
from O 0 1.2955677419768108e-08
the O 0 2.283562494653779e-08
C04107 O 0 2.0886766378680477e-06
- O 0 4.679314770328347e-06
containing O 0 6.732738597747812e-07
BAC O 0 2.4550290618208237e-05
was O 0 1.7869331259134924e-07
found O 0 1.2785849712315667e-08
to O 0 3.4079588040469844e-09
be O 0 4.720404067626305e-09
homologous O 0 4.059895175601014e-08
to O 0 3.3943809985004236e-09
a O 0 1.1017131207324837e-08
gene O 0 1.1681846245892302e-07
expressed O 0 5.795529833818591e-09
from O 0 5.804535074815931e-09
human O 0 2.950075383978401e-08
chromosome O 0 4.64410504719126e-06
2p13 O 0 2.4009998469409766e-06
- O 0 2.229121264463174e-06
p16 O 0 9.387680393047049e-07
, O 0 6.585747946985521e-09
a O 0 7.09065428594613e-09
region O 0 3.288580785465456e-08
devoid O 0 1.2732726872854983e-07
of O 0 1.5171897072008278e-09
any O 0 1.0577424269797575e-08
positional O 0 4.2262818169547245e-06
candidate O 0 4.37196376879001e-06
genes O 0 5.399143446993548e-06
. O 0 5.827633344779315e-07

Molecular O 0 7.703297342231963e-06
analysis O 0 3.877324559198314e-07
of O 0 3.418565697188569e-08
the O 0 3.681631000063135e-08
APC B-Disease 0 5.636965738631261e-07
gene O 0 1.6022548265937075e-07
in O 0 4.7594865826283694e-09
205 O 0 1.0345062406713623e-07
families O 0 2.4249862562442104e-08
: O 0 7.608177199358579e-09
extended O 0 8.408134277715362e-08
genotype O 0 4.239872214384377e-05
- O 0 8.169601642293856e-06
phenotype O 0 1.4556899259332567e-06
correlations O 0 3.5318495861247357e-07
in O 0 1.0550905926720588e-08
FAP B-Disease 0 2.481717444879905e-07
and O 0 1.2688914807768015e-08
evidence O 0 7.325859030515858e-09
for O 0 1.2247619585181724e-09
the O 0 3.0587050670050075e-09
role O 0 1.6317892814754487e-08
of O 0 2.938791210382874e-09
APC B-Disease 0 6.507925718324259e-07
amino O 0 1.5400580366531358e-07
acid O 0 9.686474555792302e-08
changes O 0 4.6183902924212816e-08
in O 0 7.000158348091645e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.12916627526283264
. O 0 1.5740660046503763e-06

BACKGROUND O 0 0.00036718937917612493
/ O 0 0.00013606174616143107
AIMS O 0 3.366504870427889e-06
The O 0 1.9483303859146872e-08
development O 0 2.8317346689732403e-08
of O 0 6.122246759332484e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.609225605165193e-08
a O 0 1.3251483466092395e-08
variable O 0 1.8155940040287533e-07
range O 0 2.4943403786892304e-07
of O 0 1.2090032086575775e-08
extracolonic O 0 6.421939906431362e-05
manifestations O 0 1.4061791262065526e-05
in O 0 3.350167844473617e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 3.958913657697849e-05
FAP B-Disease 0 2.5068462491617538e-05
) O 0 7.103814425590826e-08
is O 0 4.1615724200028126e-09
the O 0 3.6402223457798755e-09
result O 0 8.572331289258273e-09
of O 0 1.2328362775093638e-09
the O 0 2.157699796612178e-08
dominant O 0 3.937441579182632e-05
inheritance O 0 1.1726930097211152e-05
of O 0 3.904202458215877e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999998807907104
( O 0 3.876920345646795e-06
APC B-Disease 0 1.4202330021362286e-05
) O 0 2.3860548026277684e-07
gene O 0 1.0614614438964054e-05
mutations O 0 2.5973127776524052e-05
. O 0 1.2120541441618116e-06

In O 0 3.930394996132236e-07
this O 0 1.8891142872234923e-08
study O 0 1.1474197592065138e-08
, O 0 2.1711856756923e-09
direct O 0 1.3957380140539044e-08
mutation O 0 1.4689940996959194e-07
analysis O 0 1.746618671916167e-08
of O 0 1.5902226202513248e-09
the O 0 1.0143089923531079e-08
APC B-Disease 0 4.865336791226582e-07
gene O 0 1.3127151987646357e-07
was O 0 4.858353719328079e-08
performed O 0 7.113793998314577e-08
to O 0 7.22286852550269e-09
determine O 0 3.108567057097389e-07
genotype O 0 4.806917058886029e-05
- O 0 4.616339083440835e-06
phenotype O 0 1.3669271083927015e-06
correlations O 0 2.1774081915282295e-07
for O 0 9.540608303382214e-09
nine O 0 1.4340140808144497e-07
extracolonic O 0 1.155741870206839e-06
manifestations O 0 1.3223474581991468e-07
and O 0 9.750272589315045e-09
to O 0 4.445545265241435e-09
investigate O 0 1.0443037012919376e-07
the O 0 2.2436182689489215e-08
incidence O 0 1.3210269571573008e-05
of O 0 8.665507422733754e-09
APC B-Disease 0 8.654203611513367e-07
mutations O 0 1.350873048977519e-06
in O 0 2.4933884290589958e-08
non O 0 8.801608782960102e-05
- O 1 0.9996294975280762
FAP O 1 0.9999443292617798
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.2208967038750416e-06

METHODS O 0 1.6571990272495896e-05
The O 0 4.6814346887913416e-07
APC B-Disease 0 3.5264949929114664e-06
gene O 0 1.0704566193453502e-06
was O 0 1.2712138186543598e-07
analysed O 0 1.389806669749305e-07
in O 0 5.452294615793107e-09
190 O 0 3.933551795398671e-08
unrelated O 0 8.031473441860726e-08
FAP B-Disease 0 5.140162784300628e-07
and O 0 3.0695421315840576e-08
15 O 0 1.436565497670017e-07
non O 0 4.798736335942522e-05
- O 1 0.9993529915809631
FAP O 1 0.9998100399971008
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00014320921036414802
using O 0 5.414026418293361e-07
denaturing O 0 0.0005000969977118075
gradient O 0 4.0305232687387615e-05
gel O 0 0.0009874419774860144
electrophoresis O 0 9.954772394848987e-06
, O 0 1.184533982012681e-08
the O 0 3.4066784948549866e-09
protein O 0 2.4427102118806943e-08
truncation O 0 2.5218832888640463e-07
test O 0 1.2976050811630557e-06
, O 0 6.420600051626479e-09
and O 0 3.0829652164499066e-09
direct O 0 6.558698828484921e-08
sequencing O 0 3.1235581445798744e-06
. O 0 7.035529847598809e-07

RESULTS O 0 0.00011514958896441385
Chain O 0 1.489927035436267e-05
terminating O 0 2.31484227697365e-06
signals O 0 1.1565269915081444e-06
were O 0 1.1166579128030207e-07
only O 0 4.93331597795077e-09
identified O 0 6.146643016791131e-08
in O 0 2.624866102252099e-09
patients O 0 5.909974731821421e-08
belonging O 0 2.5182220753094953e-08
to O 0 5.222778654001559e-09
the O 0 1.6427192051082784e-08
FAP B-Disease 0 6.038101787453343e-07
group O 0 4.018523824811382e-08
( O 0 8.452606614639535e-09
105 O 0 1.6053826357165235e-07
patients O 0 1.1317570169921964e-06
) O 0 4.414891208170957e-08
. O 0 1.340329447430122e-07

Amino O 0 5.819384750793688e-05
acid O 0 4.188892489764839e-06
changes O 0 1.581811233108965e-07
were O 0 1.619736877955802e-07
identified O 0 4.8965329568773086e-08
in O 0 2.102511942325691e-09
four O 0 8.427657860465843e-08
patients O 0 2.065933557560129e-07
, O 0 1.3231877815655935e-09
three O 0 1.989562958826241e-09
of O 0 1.236094893108941e-09
whom O 0 1.2930773607422452e-07
belonged O 0 6.985707301510047e-08
to O 0 3.32597349661512e-09
the O 0 1.797105753098549e-08
non O 0 7.585863954773231e-07
- O 0 3.8986995605228e-06
FAP O 0 1.3723908978136024e-06
group O 0 2.0964345992524613e-07
of O 0 1.3931414741819026e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0028427084907889366
. O 0 5.350431706574454e-07

Genotype O 0 0.015623563900589943
- O 0 0.001736049889586866
phenotype O 0 8.797001646598801e-05
correlations O 0 1.488095131207956e-05
identified O 0 4.073308900842676e-06
significant O 0 8.396627748652463e-08
differences O 0 5.322318656908465e-07
in O 0 5.697054827891179e-09
the O 0 2.8958464515227433e-09
nature O 0 3.526441583190376e-09
of O 0 4.836409051023338e-10
certain O 0 1.7332048685148038e-08
extracolonic O 0 5.264485025691101e-06
manifestations O 0 3.4782638635988405e-07
in O 0 2.1689684714942814e-08
FAP B-Disease 0 2.2450112737715244e-06
patients O 0 8.192650966520887e-07
belonging O 0 1.5123229957225703e-07
to O 0 1.91138251892653e-08
three O 0 1.904047479683868e-07
mutation O 0 9.70049950410612e-06
subgroups O 0 3.5696707527677063e-06
. O 0 6.496144351331168e-07

CONCLUSIONS O 0 5.471221811603755e-05
Extended O 0 1.4620740330428816e-05
genotype O 0 0.0003790113260038197
- O 0 4.152813198743388e-05
phenotype O 0 1.0119436410604976e-05
correlations O 0 2.0355819287942722e-06
made O 0 9.892777086406568e-08
in O 0 3.6686609306002538e-09
this O 0 9.237162701403179e-10
study O 0 7.765549092653146e-09
may O 0 2.769205309505196e-07
have O 0 1.4820533245085699e-08
the O 0 1.3451738611891528e-09
potential O 0 3.0074212009623125e-09
to O 0 2.302059876058138e-09
determine O 0 2.525485420790119e-08
the O 0 1.1136153110768987e-09
most O 0 8.237544535383279e-10
appropriate O 0 3.0893223534889103e-09
surveillance O 0 9.935076406009102e-08
and O 0 1.0951847428941619e-08
prophylactic O 0 2.2712795271218056e-06
treatment O 0 3.331302309561579e-07
regimens O 0 2.8340642188595666e-07
for O 0 3.0527367300692276e-09
those O 0 3.4909010793171547e-08
patients O 0 7.341486707446165e-08
with O 0 6.957966203202659e-09
mutations O 0 1.23089930639253e-05
associated O 0 1.0844344444649323e-07
with O 0 3.9193448486685156e-08
life O 0 9.91646402326296e-07
threatening O 0 0.00018814779468812048
conditions O 0 1.3493895494320896e-05
. O 0 1.819244062062353e-07

This O 0 2.034812069950931e-07
study O 0 1.1771717112196711e-07
also O 0 2.6090845040016575e-08
provided O 0 2.040882662868171e-08
evidence O 0 7.3193642258218006e-09
for O 0 9.801002232023848e-10
the O 0 6.561811982663812e-09
pathological O 0 2.7975892180620576e-07
nature O 0 1.9373024073843226e-08
of O 0 3.964378603171781e-09
amino O 0 2.3267621429567953e-07
acid O 0 5.741817332705068e-08
changes O 0 1.0008240458603268e-08
in O 0 4.634244099577245e-09
APC O 0 1.5102158101854002e-07
associated O 0 1.7450801692575624e-08
with O 0 2.5931969904746666e-09
both O 0 2.743805183058612e-08
FAP B-Disease 0 8.948778713602223e-07
and O 0 1.5828314303689694e-07
non O 0 0.00013244993169791996
- O 1 0.9996656179428101
FAP O 1 0.9999479055404663
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.012004182673990726
. O 0 9.109377430149834e-08
. O 0 1.7660271112163173e-07

Inherited B-Disease 1 0.9999971389770508
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999992847442627
and O 0 0.12558288872241974
cancer B-Disease 1 0.9998953342437744
risk O 0 6.134364957688376e-05
of O 0 1.7023129572635298e-08
the O 0 1.1237258235041736e-07
APC O 0 6.095453954912955e-06
I1307K O 0 1.047082150762435e-05
polymorphism O 0 6.043847315595485e-05
. O 0 1.9247891032136977e-06

Germ O 0 0.006639810279011726
- O 0 0.0012016532709822059
line O 0 6.662530722678639e-06
and O 0 1.8467721574211282e-08
somatic O 0 9.211498763761483e-07
truncating O 0 1.619801537344756e-06
mutations O 0 9.014416377794987e-07
of O 0 2.9668385526093743e-09
the O 0 8.535393725139784e-09
APC B-Disease 0 2.0554332991196134e-07
gene O 0 6.566534693774884e-08
are O 0 7.557844128314173e-09
thought O 0 2.4823794575468128e-08
to O 0 1.7036349220234115e-08
initiate O 0 0.00020036601927131414
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9073489308357239
formation O 0 7.953276508487761e-06
in O 0 4.245648142386926e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 2.999700518557802e-05
sporadic O 1 0.9987909197807312
colorectal O 1 1.0
carcinogenesis O 1 0.9750112891197205
, O 0 1.850476223808073e-06
respectively O 0 5.885199243493844e-06
. O 0 1.1236662658120622e-06

Recently O 0 6.185635720612481e-05
, O 0 1.608739097491707e-07
an O 0 7.532634072049404e-08
isoleucine O 0 0.0012033781968057156
- O 0 9.264631808036938e-05
- O 0 2.3426457119057886e-05
> O 0 1.3812775705446256e-06
lysine O 0 1.8495198901291587e-06
polymorphism O 0 5.316948318068171e-06
at O 0 3.067915486099082e-07
codon O 0 1.513729785074247e-06
1307 O 0 1.709342882350029e-06
( O 0 3.011710703049175e-08
I1307K O 0 1.4826915162302612e-07
) O 0 2.3099062662623737e-09
of O 0 4.3869513577377006e-10
the O 0 6.367755212011161e-09
APC B-Disease 0 1.5645998985291953e-07
gene O 0 1.177000967800268e-07
has O 0 1.0650059500960651e-08
been O 0 2.2169636793023528e-08
identified O 0 2.8997609646808087e-08
in O 0 8.990235222938736e-10
6 O 0 2.9001316903531915e-08
% O 0 2.7556056991784317e-08
- O 0 5.45219791092677e-07
7 O 0 6.584707534784684e-08
% O 0 8.29807245139591e-09
of O 0 7.819855318835778e-10
the O 0 6.538399155431307e-09
Ashkenazi O 0 1.9774706743191928e-06
Jewish O 0 1.922721963865115e-07
population O 0 4.691128197009675e-08
. O 0 1.0948154738343874e-07

To O 0 1.6733454231143696e-06
assess O 0 4.218156391289085e-06
the O 0 8.095715031686268e-08
risk O 0 3.67716836535692e-07
of O 0 9.561079705733277e-10
this O 0 2.3017261430169356e-09
common O 0 4.109162077270412e-08
APC B-Disease 0 5.119625257066218e-07
allelic O 0 1.5785877849339158e-06
variant O 0 4.274689490557648e-05
in O 0 1.5383023992399103e-06
colorectal O 1 1.0
carcinogenesis O 0 0.03420455753803253
, O 0 4.2578508896440326e-07
we O 0 1.7564514109835727e-07
have O 0 1.2582078490197546e-08
analyzed O 0 4.564854094724069e-08
a O 0 1.7572573396407165e-09
large O 0 4.110743745400214e-09
cohort O 0 1.7545697517107328e-07
of O 0 5.7957509902450965e-09
unselected O 0 8.676352990732994e-06
Ashkenazi O 0 4.7049916247488e-06
Jewish O 0 3.572030493614875e-07
subjects O 0 4.749405491111247e-07
with O 0 9.060131844762509e-08
adenomatous B-Disease 0 0.000995983718894422
polyps I-Disease 0 0.00021942028251942247
and O 0 1.6207226849473955e-07
. O 0 7.698744042272665e-08
or O 1 0.9987874627113342
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.608810672517393e-08
for O 0 3.872787424086255e-09
the O 0 5.074312525721325e-08
APC O 0 2.707152134462376e-06
I1307K O 0 2.7862888600793667e-06
polymorphism O 0 1.1665858437481802e-05
. O 0 8.349385893779981e-07

The O 0 5.524207608686993e-06
APC O 0 1.850291300797835e-05
I1307K O 0 7.076685051288223e-06
allele O 0 3.3737426292645978e-06
was O 0 4.584696284837264e-07
identified O 0 1.7530142315536068e-07
in O 0 3.5788405572390047e-09
48 O 0 5.034209138443657e-08
( O 0 2.2603430238632427e-09
10 O 0 2.2032453639297955e-09
. O 0 4.893885852119695e-10
1 O 0 3.233490586396215e-09
% O 0 2.6161091071230658e-09
) O 0 7.157039405569776e-10
of O 0 1.5933194763562142e-09
476 O 0 6.079287118154753e-07
patients O 0 1.6592216525168624e-06
. O 0 1.9797791139808396e-07

Compared O 0 3.393469887669198e-05
with O 0 6.722486745047718e-08
the O 0 1.3846386259785959e-08
frequency O 0 1.2624198575394985e-07
in O 0 3.085188771123626e-09
two O 0 6.866012203232685e-09
separate O 0 2.7037717842404163e-08
population O 0 8.582179411575908e-09
control O 0 8.581103827509651e-08
groups O 0 7.3449428761307445e-09
, O 0 1.7270463947838266e-09
the O 0 6.202558022749827e-09
APC O 0 1.7911247596202884e-07
I1307K O 0 1.9014200347555743e-07
allele O 0 1.352405263332912e-07
is O 0 2.6230941863047974e-09
associated O 0 6.3179483866804276e-09
with O 0 1.2432143092766523e-09
an O 0 5.4490301160114996e-09
estimated O 0 4.1847929566074527e-08
relative O 0 5.32243063844362e-07
risk O 0 8.229062018472177e-07
of O 0 5.011606685201286e-09
1 O 0 1.429887248605155e-07
. O 0 1.8705010518260679e-07

5 O 0 5.600575968855992e-05
- O 0 0.00012162640632595867
1 O 0 1.9700128177646548e-06
. O 0 8.365477697225288e-07

7 O 0 6.364333967212588e-05
for O 0 4.972261194780003e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.95819091796875
( O 0 1.6278340808639769e-06
both O 0 2.4277364900626708e-06
P O 0 0.44216790795326233
= O 0 0.00028400085284374654
. O 0 1.5475222880922956e-07
01 O 0 5.1736704335780814e-05
) O 0 2.5481548959760403e-07
. O 0 3.45510471788657e-07

Furthermore O 0 3.241339436499402e-05
, O 0 4.20392922251267e-07
compared O 0 2.5358662014696165e-07
with O 0 2.765731288434381e-08
noncarriers O 0 3.2736791126808384e-06
, O 0 1.124915538497362e-08
APC O 0 4.487273201903008e-07
I1307K O 0 7.29604835214559e-07
carriers O 0 3.641936814346991e-07
had O 0 3.7832638355439485e-08
increased O 0 6.348170433767564e-09
numbers O 0 1.911758218398063e-08
of O 0 3.5803633391395806e-09
adenomas B-Disease 0 2.3068902009981684e-05
and O 0 4.446264210855588e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.999997615814209
per O 0 7.906457540229894e-06
patient O 0 0.00010508367995498702
( O 0 2.1782140890991286e-07
P O 0 0.001593724824488163
= O 0 1.983257243409753e-05
. O 0 7.4266628402597235e-09
03 O 0 3.4707561553659616e-06
) O 0 4.2798324884074646e-09
, O 0 8.279507635045036e-10
as O 0 2.8211453173554446e-09
well O 0 4.6370383088856215e-09
as O 0 2.6941746611441886e-09
a O 0 8.690435926439477e-09
younger O 0 3.1934754929352493e-07
age O 0 1.2556311901334993e-07
at O 0 2.0489316909788613e-07
diagnosis O 0 0.0001907660480355844
. O 0 1.9704890519278706e-07

We O 0 5.300697011989541e-06
conclude O 0 4.779566893375886e-07
that O 0 9.968537106885833e-09
the O 0 1.0843017150818923e-08
APC O 0 5.572190957536804e-07
I1307K O 0 5.352973175831721e-07
variant O 0 8.583106136939023e-07
leads O 0 1.634521851201498e-07
to O 0 3.929359948529054e-08
increased O 0 1.684339440544136e-05
adenoma B-Disease 1 1.0
formation O 0 8.037776524361107e-07
and O 0 3.119521707617423e-08
directly O 0 2.182217961888e-08
contributes O 0 2.3229590695450497e-08
to O 0 3.165021578155347e-09
3 O 0 5.142790726608837e-08
% O 0 2.3315836372717058e-08
- O 0 1.8716058036716277e-07
4 O 0 1.649588909913291e-08
% O 0 2.617441818841826e-09
of O 0 7.438411553373214e-10
all O 0 3.5041228585441786e-08
Ashkenazi O 0 0.0013191596372053027
Jewish O 0 0.3737197518348694
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.46471381867741e-06

The O 0 1.7669093494987465e-06
estimated O 0 7.243108939292142e-07
relative O 0 4.198536487365345e-07
risk O 0 7.064427336445078e-07
for O 0 5.059716201571973e-09
carriers O 0 8.142775982378225e-07
may O 0 4.9921467848434986e-08
justify O 0 6.90541526182642e-08
specific O 0 1.1229690066727471e-08
clinical O 0 6.912755168286822e-08
screening O 0 3.8458114914874386e-08
for O 0 1.3501837425877738e-09
the O 0 1.3493521855423296e-09
360 O 0 7.802040791204945e-09
, O 0 1.3168807155850004e-09
000 O 0 4.833358602240878e-09
Americans O 0 4.886687499094933e-09
expected O 0 2.481516547803153e-09
to O 0 3.763678257939773e-09
harbor O 0 7.712324645581248e-08
this O 0 6.623776527270309e-10
allele O 0 4.6679751619649323e-08
, O 0 1.4795360492314558e-09
and O 0 3.858976693749128e-09
genetic O 0 2.8192596346343635e-07
testing O 0 2.8548652153403964e-07
in O 0 3.741375653731893e-09
the O 0 7.347044750360965e-09
setting O 0 3.451942376386796e-08
of O 0 2.2967618917846266e-09
long O 0 3.399057675324002e-07
- O 0 8.242758667620365e-06
term O 0 1.5119522913664696e-06
- O 0 3.7299525956768775e-07
outcome O 0 2.1379213066552438e-08
studies O 0 2.0699401304113962e-08
may O 0 1.4649182311643472e-08
impact O 0 5.5528396103454725e-08
significantly O 0 2.118940074069542e-06
on O 0 0.20527364313602448
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.706737202766817e-05
in O 0 7.96904409128274e-09
this O 0 3.6004212944362735e-09
population O 0 3.7725776280694845e-08
. O 0 8.010834307015102e-08

Localization O 0 2.1760515664936975e-05
of O 0 2.211826171105713e-07
human O 0 3.193591169292631e-07
BRCA1 O 0 5.06335127283819e-05
and O 0 1.726237854882129e-07
its O 0 4.514374651876096e-08
loss O 0 1.4366175093982747e-07
in O 0 4.082076454636763e-09
high O 0 1.0000960628531175e-06
- O 0 2.41646575886989e-05
grade O 0 2.877964470826555e-05
, O 0 2.722286751577485e-08
non B-Disease 0 5.338705250323983e-06
- I-Disease 0 0.2726324200630188
inherited I-Disease 1 0.9988715052604675
breast I-Disease 1 0.9999738931655884
carcinomas I-Disease 1 0.9999998807907104
. O 0 4.59626335214125e-06

Although O 0 2.5452454792684875e-06
the O 0 1.0382660065033633e-07
link O 0 5.675041734320985e-07
between O 0 5.276087478023328e-08
the O 0 1.3925635755640542e-07
BRCA1 O 1 0.9081873893737793
tumour B-Disease 1 0.9999990463256836
- O 0 1.2706686902674846e-06
suppressor O 0 1.7403871197529952e-06
gene O 0 7.308583462872775e-07
and O 0 1.5024541255570512e-07
hereditary B-Disease 1 0.9999738931655884
breast I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 4.320384050515713e-08
established O 0 2.5433518402451227e-08
, O 0 2.83734502559696e-09
the O 0 1.712061048486646e-09
role O 0 1.4228973554963886e-08
, O 0 2.2171948721450008e-09
if O 0 6.30918983723916e-10
any O 0 4.519297991389948e-10
, O 0 5.66750757435841e-10
of O 0 7.761131737282767e-10
BRCA1 O 0 7.217773145384854e-06
in O 0 2.5442444595569214e-08
non B-Disease 0 1.894262823043391e-05
- I-Disease 0 0.11832829564809799
familial I-Disease 1 0.9998399019241333
cancers I-Disease 1 0.9999933242797852
is O 0 1.910854621200997e-07
unclear O 0 7.085126867423241e-07
. O 0 3.8200272456379025e-07

BRCA1 O 1 0.8616401553153992
mutations O 0 0.0008090633200481534
are O 0 1.8406396407044667e-07
rare O 0 5.140868353237238e-08
in O 0 2.0541765621828745e-08
sporadic B-Disease 0 0.0054499804973602295
cancers I-Disease 1 0.9999948740005493
, O 0 4.274091480738207e-08
but O 0 2.223221962083244e-08
loss O 0 4.736983783004689e-08
of O 0 2.897260653611511e-09
BRCA1 O 0 8.971380157163367e-05
resulting O 0 1.0456231791522441e-07
from O 0 1.3089506367691683e-08
reduced O 0 1.3683562372079905e-07
expression O 0 1.2106765723274293e-07
or O 0 1.397817896986453e-07
incorrect O 0 2.6032046207546955e-06
subcellular O 0 8.187891580746509e-06
localization O 0 2.575220833023195e-06
is O 0 1.0924808613310688e-08
postulated O 0 6.082127868012321e-08
to O 0 4.851980150988311e-09
be O 0 4.754850291277535e-09
important O 0 2.7642161892771355e-09
in O 0 2.7370508082213973e-09
non B-Disease 0 1.528132997918874e-06
- I-Disease 0 0.004320242907851934
familial I-Disease 1 0.9998492002487183
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999274015426636
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 2.708159172470914e-06

Epigenetic O 0 0.00013724586460739374
loss O 0 0.0001421510096406564
, O 0 1.759885321916954e-07
however O 0 3.9597857437456696e-08
, O 0 4.489042915167829e-09
has O 0 7.14977099747216e-09
not O 0 2.7321427342741345e-09
received O 0 2.026069756411175e-09
general O 0 3.153716621184799e-09
acceptance O 0 1.541520866510382e-08
due O 0 2.0753956775365623e-08
to O 0 2.5655579882766233e-09
controversy O 0 1.2396961679428387e-08
regarding O 0 9.667699529813945e-09
the O 0 7.842982263639442e-09
subcellular O 0 1.4086873534324695e-06
localization O 0 3.276941527019517e-07
of O 0 1.923590886576676e-08
BRCA1 O 0 7.830644790374208e-06
proteins O 0 7.271555801935392e-08
, O 0 6.701117438723259e-09
reports O 0 1.999813470376921e-08
of O 0 1.0736572741976147e-09
which O 0 1.2754720835062017e-08
have O 0 1.974555452477489e-08
ranged O 0 1.357992545081288e-07
from O 0 4.6005665943482654e-09
exclusively O 0 2.5978717843599952e-08
nuclear O 0 1.4252610469611682e-07
, O 0 1.36153144314477e-09
to O 0 2.1000430283635296e-09
conditionally O 0 7.028582871271283e-08
nuclear O 0 6.102719396494649e-08
, O 0 1.7098779059310232e-09
to O 0 1.8374777255303343e-09
the O 0 1.4311608786954366e-08
ER O 0 1.5894396710791625e-05
/ O 0 7.917835773696424e-07
golgi O 0 2.185954144806601e-06
, O 0 1.54750985359442e-08
to O 0 5.6889652988445505e-09
cytoplasmic O 0 1.0294667163179838e-06
invaginations O 0 1.7577746120878146e-06
into O 0 2.772803853190453e-08
the O 0 4.810864595583553e-08
nucleus O 0 7.476915016013663e-07
. O 0 2.0322346472312347e-07

In O 0 9.17949932954798e-07
an O 0 3.942069071172227e-08
attempt O 0 2.2737796712135605e-07
to O 0 3.495244982332224e-08
resolve O 0 4.423809514264576e-07
this O 0 1.203343091837894e-09
issue O 0 4.424439925543311e-09
, O 0 3.032165185601343e-09
we O 0 1.0926975768654756e-08
have O 0 1.491675760689759e-08
comprehensively O 0 2.302246912222472e-06
characterized O 0 2.861106622731313e-07
19 O 0 2.770193248124997e-07
anti O 0 1.8389428078080527e-06
- O 0 7.114480104064569e-05
BRCA1 O 0 0.00043993809958919883
antibodies O 0 1.1913223715964705e-05
. O 0 5.251640686765313e-07

These O 0 3.822311555268243e-06
reagents O 0 7.536840257671429e-06
detect O 0 3.051765088457614e-05
a O 0 1.9582186894240294e-07
220 O 0 3.228482512440678e-07
- O 0 2.038381126112654e-06
kD O 0 4.951988103130134e-06
protein O 0 2.5790990321183926e-07
localized O 0 4.640071153971803e-07
in O 0 1.1412342182381963e-08
discrete O 0 3.109317106009257e-07
nuclear O 0 2.211649871242116e-06
foci O 0 2.3265208710654406e-06
in O 0 1.6196837648863038e-08
all O 0 1.546173322708455e-08
epithelial O 0 4.742209114283469e-07
cell O 0 2.9136990633560345e-06
lines O 0 9.979011338145938e-06
, O 0 4.079266702206041e-09
including O 0 2.042840563376558e-09
those O 0 7.546838709515669e-09
derived O 0 4.505359996187508e-08
from O 0 4.018707855379944e-08
breast B-Disease 0 0.04809333384037018
malignancies I-Disease 0 0.00032596898381598294
. O 0 9.625473467167467e-07

Immunohistochemical O 0 0.0015357864322140813
staining O 0 0.00023150094784796238
of O 0 6.17852094819682e-07
human O 0 1.5542030951110064e-06
breast O 0 0.12516871094703674
specimens O 0 1.443224391550757e-06
also O 0 2.7230612431594636e-07
revealed O 0 8.905437425710261e-06
BRCA1 O 0 0.0009444845491088927
nuclear O 0 5.201098247198388e-06
foci O 0 2.0904442862956785e-05
in O 0 1.1706715952186642e-07
benign O 0 0.20877127349376678
breast O 1 0.9626579284667969
, O 0 1.2082369948984706e-07
invasive B-Disease 0 0.0004582074179779738
lobular I-Disease 1 0.9997791647911072
cancers I-Disease 1 0.9999988079071045
and O 0 2.2486797206511255e-06
low B-Disease 1 0.8378204107284546
- I-Disease 1 0.9932016730308533
grade I-Disease 1 0.9936554431915283
ductal I-Disease 1 0.999279797077179
carcinomas I-Disease 1 1.0
. O 0 1.5248808267642744e-05

Conversely O 0 0.0001661461719777435
, O 0 1.8194103859059396e-06
BRCA1 O 0 7.201770495157689e-05
expression O 0 1.3364088999878732e-06
was O 0 8.687801482665236e-07
reduced O 0 1.7225738702109084e-07
or O 0 4.7548073212055897e-07
undetectable O 0 6.626431058975868e-06
in O 0 2.4452353475368227e-09
the O 0 2.075921212707499e-09
majority O 0 4.635340111747155e-09
of O 0 8.288356112551298e-10
high O 0 1.6205478914343985e-06
- O 0 0.0006550080724991858
grade O 0 0.00025861250469461083
, O 0 1.0444132669817918e-07
ductal B-Disease 0 0.0001802102051442489
carcinomas I-Disease 1 0.9999997615814209
, O 0 4.239132067596074e-08
suggesting O 0 8.78972699069891e-08
that O 0 3.2591060961095764e-09
absence O 0 2.773295726399283e-08
of O 0 2.1786568105142123e-09
BRCA1 O 0 4.6882232709322125e-05
may O 0 6.89675445642024e-08
contribute O 0 8.623842084887201e-09
to O 0 1.9484482915999024e-09
the O 0 4.20363832631665e-09
pathogenesis O 0 3.029472850357706e-08
of O 0 3.812954396664736e-10
a O 0 2.2591966075680148e-09
significant O 0 6.332738777814484e-09
percentage O 0 1.2597367060607212e-07
of O 0 8.739871049101566e-09
sporadic B-Disease 0 0.3696834146976471
breast I-Disease 1 0.9999998807907104
cancers I-Disease 1 0.9999614953994751
. O 0 6.291446652539889e-08
. O 0 2.992814245317277e-07

